

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 July 2002 (25.07.2002)

PCT

(10) International Publication Number
WO 02/056905 A2

(51) International Patent Classification⁷: **A61K 39/00**

(21) International Application Number: PCT/IB02/00166

(22) International Filing Date: 21 January 2002 (21.01.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/262,379 19 January 2001 (19.01.2001) US
60/288,549 4 May 2001 (04.05.2001) US
60/326,998 5 October 2001 (05.10.2001) US
60/331,045 7 November 2001 (07.11.2001) US

(71) Applicant (for all designated States except US): **CYTOS BIOTECHNOLOGY AG** [CH/CH]; Wagistrasse 25, CH-8952 Zürich-Schlieren (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **RENNER, Wolfgang, A.** [CH/CH]; Weinbergstrasse 64, CH-8006 Zürich (CH). **BACHMANN, Martin** [CH/CH]; Tachlisbrunnstrasse 30, CH-8400 Winterthur (CH). **TISSOT, Alain** [CH/CH]; Brauerstrasse 78, CH-8004 Zürich (CH). **MAURER, Patrick** [DE/CH]; Richenbergstrasse 38, CH-8400 Winterthur (CH). **LECHNER, Franziska** [CH/CH];

Froschaugasse 12, CH-8001 Zürich (CH). **SEBBEL, Peter** [DE/CH]; Schulstrasse 36, CH-8050 Zürich (CH). **PIOSSEK, Christine** [DE/CH]; Eichbühl 14, CH-8405 Winterthur (CH).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: MOLECULAR ANTIGEN ARRAY

(57) Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.

WO 02/056905 A2

Molecular Antigen Array

BACKGROUND OF THE INVENTION

Field of the Invention

The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.

Background Art

WO 00/3227 describes compositions and processes for the production of ordered and repetitive antigen or antigenic determinant arrays. The compositions are useful for the production of vaccines for the prevention of infectious diseases, the treatment of allergies and the treatment of cancers. The compositions comprise a core particle, such as a virus or a virus-like particle, to which at least one antigen or one antigenic determinant, is associated by way of at least one non-peptide bond leading to the ordered and repetitive antigen array.

Virus-like particles (VLPs) are being exploited in the area of vaccine production because of both their structural properties and their non-infectious nature. VLPs are supermolecular structures built in a symmetric manner from many protein molecules of one or more types. They lack the viral genome and, therefore, are noninfectious. VLPs can often be produced in large quantities by heterologous expression and can be easily be purified.

-2-

Examples of VLPs include the capsid proteins of Hepatitis B virus (Ulrich, *et al.*, *Virus Res.* 50:141-182 (1998)), measles virus (Warnes, *et al.*, *Gene* 160:173-178 (1995)), Sindbis virus, rotavirus (US 5,071,651 and US 5,374,426), foot-and-mouth-disease virus (Twomey, *et al.*, *Vaccine* 13:1603-1610, (1995)), Norwalk virus (Jiang, X., *et al.*, *Science* 250:1580-1583 (1990); Matsui, S.M., *et al.*, *J. Clin. Invest.* 87:1456-1461 (1991)), the retroviral GAG protein (WO 96/30523), the retrotransposon Ty protein p1, the surface protein of Hepatitis B virus (WO 92/11291) and human papilloma virus (WO 98/15631).

It is generally difficult to induce immune responses against self-molecules due to immunological tolerance. Specifically, lymphocytes with a specificity for self-molecules are usually hypo- or even unresponsive if triggered by conventional vaccination strategies.

The amyloid B peptide ($A\beta_{1-42}$) has a central role in the neuropathology of Alzheimers disease. Region specific, extracellular accumulation of $A\beta$ peptide is accompanied by microgliosis, cytoskeletal changes, dystrophic neuritis and synaptic loss. These pathological alterations are thought to be linked to the cognitive decline that defines the disease.

In a mouse model of Alzheimer disease, transgenic animals engineered to produce $A\beta_{1-42}$ (PDAPP-mice), develop plaques and neuron damage in their brains. Recent work has shown immunization of young PDAPP-mice, using $A\beta_{1-42}$, resulted in inhibition of plaque formation and associated dystrophic neuritis (Schenk, D. *et al.*, *Nature* 400:173-77 (1999)).

Furthermore immunization of older PDAPP mice that had already developed AD-like neuropathologies, reduced the extent and progression of the neuropathologies. The immunization protocol for these studies was as follows; peptide was dissolved in aqueous buffer and mixed 1:1 with complete Freund's adjuvant (for primary dose) to give a peptide concentration of 100 μ g/dose. Subsequent boosts used incomplete Freund's adjuvant. Mice received 11 immunizations over an 11 month period. Antibodies titres greater than 1:10 000 were achieved and maintained. Hence, immunization may be an effective prophylactic and therapeutic action against Alzheimer disease.

In another study, peripherally administered antibodies raised against $A\beta_{1-42}$, were able to cross the blood-brain barrier, bind $A\beta$ peptide, and induce clearance of pre-existing amyloid (Bard, F. *et al.*, *Nature Medicine* 6:916-19 (2000)). This study utilized either polyclonal antibodies raised against $A\beta_{1-42}$, or monoclonal antibodies raised against synthetic fragments derived from different regions of $A\beta$. Thus induction of antibodies can be considered as a potential therapeutic treatment for Alzheimer disease.

It is well established that the administration of purified proteins alone is usually not sufficient to elicit a strong immune response; isolated antigen generally

-3-

must be given together with helper substances called adjuvants. Within these adjuvants, the administered antigen is protected against rapid degradation, and the adjuvant provides an extended release of a low level of antigen.

As indicated, one of the key events in Alzheimer's Disease (AD) is the deposition of amyloid as insoluble fibrous masses (amyloidogenesis) resulting in extracellular neuritic plaques and deposits around the walls of cerebral blood vessels (for review see Selkoe, D. J. (1999) *Nature*. 399, A23-31). The major constituent of the neuritic plaques and congophilic angiopathy is amyloid β ($A\beta$), although these deposits also contain other proteins such as glycosaminoglycans and apolipoproteins. $A\beta$ is proteolytically cleaved from a much larger glycoprotein known as Amyloid Precursor Proteins (APPs), which comprises isoforms of 695-770 amino acids with a single hydrophobic transmembrane region. $A\beta$ forms a group of peptides up to 43 amino acids in length showing considerable amino- and carboxy-terminal heterogeneity (truncation) as well as modifications (Roher, A. E., Palmer, K. C., Chau, V., & Ball, M. J. (1988) *J. Cell Biol.* 107, 2703-2716. Roher, A. E., Palmer, K. C., Yurewicz, E. C., Ball, M. J., & Greenberg, B. D. (1993) *J. Neurochem.* 61, 1916-1926). Prominent isoforms are $A\beta$ 1-40 and 1-42. It has a high propensity to form β -sheets aggregating into fibrils, which ultimately leads to the amyloid. Recent studies demonstrated that a vaccination-induced reduction in brain amyloid deposits resulted in cognitive improvements (Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) *Nature*. 400, 173-177).

We have surprisingly found that self-molecules or self-antigens presented in a highly ordered and repetitive array were able to efficiently induce self-specific immune responses, in particular antibody responses. Moreover, such responses could even be induced in the absence of adjuvants that otherwise non-specifically activate antigen presenting cells and other immune cells.

BRIEF SUMMARY OF THE INVENTION

The present invention provides compositions, which comprises highly ordered and repetitive antigen or antigenic determinant arrays, as well as the processes for their production and their uses. Thus, the compositions of the invention are useful for the production of vaccines for the prevention of infectious diseases, the treatment of allergies and cancers, and to efficiently induce self-specific immune responses, in particular antibody responses.

In a first aspect, the present invention provides a novel composition comprising, or alternatively consisting of, (A) a non-natural molecular scaffold and (B) an antigen or antigenic determinant. The non-natural molecular scaffold comprises, or alternatively consists of, (i) a core particle selected from the group consisting of (1) a core particle of non-natural origin and (2) a core particle of natural origin; and (ii) an organizer comprising at least one first attachment site, wherein said organizer is connected to said core particle by at least one covalent bond. The antigen or antigenic determinant is a self antigen or a fragment thereof and has at least one second attachment site which is selected from the group consisting of (i) an attachment site not naturally occurring with said antigen or antigenic determinant; and (ii) an attachment site naturally occurring with said antigen or antigenic determinant. The invention provides for an ordered and repetitive self antigen array through an association of the second attachment site to the first attachment site by way of at least one non-peptide bond. Thus, the self antigen or self antigenic determinant and the non-natural molecular scaffold are brought together through this association of the first and the second attachment site to form an ordered and repetitive antigen array.

In a second aspect, the present invention provides a novel composition comprising, or alternatively consisting of, (A) a non-natural molecular scaffold and (B) an antigen or antigenic determinant. The non-natural molecular scaffold comprises, or alternatively consists of, (i) a core particle and (ii) an organizer comprising at least one first attachment site, wherein said core particle is a virus-like particle comprising recombinant proteins, or fragments thereof, of a bacteriophage, and wherein said

-5-

organizer is connected to said core particle by at least one covalent bond. The antigen or antigenic determinant has at least one second attachment site which is selected from the group consisting of (i) an attachment site not naturally occurring with said antigen or antigenic determinant; and (ii) an attachment site naturally occurring with said antigen or antigenic determinant. The invention provides for an ordered and repetitive antigen array through an association of the second attachment site to the first attachment site by way of at least one non-peptide bond.

In a third aspect, the present invention provides a novel composition comprising, or alternatively consisting of, (A) a non-natural molecular scaffold and (B) an antigen or antigenic determinant. The non-natural molecular scaffold comprises, or alternatively consists of, (i) a core particle selected from the group consisting of (1) a core particle of non-natural origin and (2) a core particle of natural origin; and (ii) an organizer comprising at least one first attachment site, wherein said organizer is connected to said core particle by at least one covalent bond. The antigen or antigenic determinant is an amyloid beta peptide ($A\beta_{1-42}$) or a fragment thereof, and has at least one second attachment site which is selected from the group consisting of (i) an attachment site not naturally occurring with said antigen or antigenic determinant; and (ii) an attachment site naturally occurring with said antigen or antigenic determinant. The invention provides for an ordered and repetitive antigen array through an association of the second attachment site to the first attachment site by way of at least one non-peptide bond.

In a fourth aspect, the present invention provides a novel composition comprising, or alternatively consisting of, (A) a non-natural molecular scaffold and (B) an antigen or antigenic determinant. The non-natural molecular scaffold comprises, or alternatively consists of, (i) a core particle selected from the group consisting of (1) a core particle of non-natural origin and (2) a core particle of natural origin; and (ii) an organizer comprising at least one first attachment site, wherein said organizer is connected to said core particle by at least one covalent bond. The antigen or antigenic determinant is an anti-idiotypic antibody or an anti-idiotypic antibody fragment and has at least one second attachment site which is selected from the group consisting of (i) an attachment site not naturally occurring with said antigen or antigenic determinant; and (ii) an attachment site naturally occurring with said antigen or antigenic determinant. The invention provides for an ordered and repetitive antigen

-6-

array through an association of the second attachment site to the first attachment site by way of at least one non-peptide bond.

Further aspects as well as preferred embodiments and advantages of the present invention will become apparent in the following as well as, in particular, in the light of the detailed description, the examples and the accompanying claims.

In a preferred embodiment of the present invention, the core particle is a virus-like particle comprising recombinant proteins of a RNA-phage, preferably selected from the group consisting of a) bacteriophage Q β ; b) bacteriophage R17; c) bacteriophage fr; d) bacteriophage GA; e) bacteriophage SP; f) bacteriophage MS2; g) bacteriophage M11; h) bacteriophage MX1; i) bacteriophage NL95; k) bacteriophage f2; and l) bacteriophage PP7. Most preferred are bacteriophage Q β and bacteriophage fr.

In another preferred embodiment of the invention, the recombinant proteins of the RNA-phages comprise wild type coat proteins.

In further preferred embodiment of the invention, the recombinant proteins of the RNA-phages comprise mutant coat proteins.

In yet another embodiment, the core particle comprises, or alternatively consists of, one or more different Hepatitis core (capsid) proteins (HBcAgs). In a related embodiment, one or more cysteine residues of these HBcAgs are either deleted or substituted with another amino acid residue (*e.g.*, a serine residue). In a specific embodiment, the cysteine residues of the HBcAg used to prepare compositions of the invention which correspond to amino acid residues 48 and 107 in SEQ ID NO:134 are either deleted or substituted with another amino acid residue (*e.g.*, a serine residue).

Further, the HBcAg variants used to prepare compositions of the invention will generally be variants which retain the ability to associate with other HBcAgs to form dimeric or multimeric structures that present ordered and repetitive antigen or antigenic determinant arrays.

In another embodiment, the non-natural molecular scaffold comprises, or alternatively consists of, pili or pilus-like structures that have been either produced from pilin proteins or harvested from bacteria. When pili or pilus-like structures are used to prepare compositions of the invention, they may be formed from products of pilin genes which are naturally resident in the bacterial cells but have been modified

-7-

by genetically engineered (*e.g.*, by homologous recombination) or pilin genes which have been introduced into these cells.

In a related embodiment, the core particle comprises, or alternatively consists of, pili or pilus-like structures that have been either prepared from pilin proteins or harvested from bacteria. These core particles may be formed from products of pilin genes naturally resident in the bacterial cells.

In a particular embodiment, the organizer may comprise at least one first attachment site. The first and the second attachment sites are particularly important elements of compositions of the invention. In various embodiments of the invention, the first and/or the second attachment site may be an antigen and an antibody or antibody fragment thereto; biotin and avidin; streptavidin and biotin; a receptor and its ligand; a ligand-binding protein and its ligand; interacting leucine zipper polypeptides; an amino group and a chemical group reactive thereto; a carboxyl group and a chemical group reactive thereto; a sulfhydryl group and a chemical group reactive thereto; or a combination thereof.

In a further preferred embodiment, the composition further comprises an amino acid linker. Preferably the amino acid linker comprises, or alternatively consists of, the second attachment site. The second attachment site mediates a directed and ordered association and binding, respectively, of the antigen to the core particle. An important function of the amino acid linker is to further ensure proper display and accessibility of the second attachment site, and thus to facilitate the binding of the antigen to the core particle, in particular by way of chemical cross-linking. Another important property of the amino acid linker is to further ensure optimal accessibility and, in particular, reactivity of the second attachment site. These properties of the amino acid linker are of even more importance for protein antigens.

In another preferred embodiment, the amino acid linker is selected from the group consisting of (a) CGG; (b) N-terminal gamma 1-linker; (c) N-terminal gamma 3-linker; (d) Ig hinge regions; (e) N-terminal glycine linkers; (f) $(G)_kC(G)_n$ with $n=0-12$ and $k=0-5$; (g) N-terminal glycine-serine linkers; (h) $(G)_kC(G)_m(S)_l(GGGGS)_n$ with $n=0-3$, $k=0-5$, $m=0-10$, $l=0-2$; (i) GGC; (k) GGC-NH₂; (l) C-terminal gamma 1-linker; (m) C-terminal gamma 3-linker; (n) C-terminal glycine linkers; (o) $(G)_nC(G)_k$ with $n=0-12$ and $k=0-5$; (p) C-terminal glycine-serine linkers; (q) $(G)_m(S)_l(GGGGS)_n(G)_oC(G)_k$ with $n=0-3$, $k=0-5$, $m=0-10$, $l=0-2$, and $o=0-8$.

An important property of glycine and glycine serine linkers is their flexibility, in particular their structural flexibility, allowing a wide range of conformations and disfavoring folding into structures precluding accessibility of the second attachment

-8-

site. As glycine and glycine serine linkers contain either no or a limited amount of side chain residues, they have limited tendency for engagement into extensive interactions with the antigen, thus, further ensuring accessibility of the second attachment site. Serine residues within the glycine serine linkers confer improved solubility properties to these linkers. Accordingly, the insertion of one or two amino acids either in tandem or isolation, and in particular of polar or charged amino acid residues, in the glycine or glycine serine amino acid linker, is also encompassed by the teaching of the invention.

In a further preferred embodiment, the amino acid linker is either GGC-NH₂, GGC-NMe, GGC-N(Me)₂, GGC-NHET or GGC-N(Et)₂, in which the C-terminus of the cysteine residue of GGC is amidated. These amino acid linkers are preferred in particular for peptide antigens, and in particular for embodiments, in which the antigen or antigenic determinant with said second attachment site comprises A β peptides or fragments thereof. Particular preferred is GGC-NH₂. In another embodiment, the amino acid linker is an Immunoglobulin (Ig) hinge region. Fragments of Ig hinge regions are also within the scope of the invention, as well as Ig hinge regions modified with glycine residues. Preferably, the Ig hinge regions contain only one cysteine residue. It is to be understood, that the single cysteine residue of the Ig hinge region amino acid linker can be located at several positions within the linker sequence, and a man skilled in the art would know how to select them with the guidance of the teachings of this invention.

In one embodiment, the invention provides the coupling of almost any antigen of choice to the surface of a virus, bacterial pilus, structure formed from bacterial pilin, bacteriophage, virus-like particle or viral capsid particle. By bringing an antigen into a quasi-crystalline 'virus-like' structure, the invention exploits the strong antiviral immune reaction of a host for the production of a highly efficient immune response, i.e., a vaccination, against the displayed antigen.

In yet another embodiment, the antigen may be selected from the group consisting of: (1) a protein suited to induce an immune response against cancer cells; (2) a protein suited to induce an immune response against infectious diseases; (3) a protein suited to induce an immune response against allergens; (4) a protein suited to induce an improved response against self-antigens; and (5) a protein suited to induce an immune response in farm animals or pets. In another embodiment, the first attachment site and/or the second attachment site are selected from the group comprising: (1) a genetically engineered lysine residue and (2) a genetically engineered cysteine residue, two residues that may be chemically linked together.

-9-

In a yet further preferred embodiment, first attachment site comprises or is an amino group and said second attachment site comprises or is a sulfhydryl group. Preferably, the first attachment site comprises or is a lysine residue and said second attachment site comprises or is a cysteine residue.

The invention also includes embodiments where the organizer particle has only a single first attachment site and the antigen or antigenic determinant has only a single second attachment site. Thus, when an ordered and repetitive antigen array is prepared using such embodiments, each organizer will be bound to a single antigen or antigenic determinant.

In a further aspect, the invention provides compositions comprising, or alternatively consisting of, (a) a non-natural molecular scaffold comprising (i) a core particle selected from the group consisting of a core particle of non-natural origin and a core particle of natural origin, and (ii) an organizer comprising at least one first attachment site, wherein the core particle comprises, or alternatively consists of, a virus-like particle, a bacterial pilus, a pilus-like structure, or a modified HBcAg, or fragment thereof, and wherein the organizer is connected to the core particle by at least one covalent bond, and (b) an antigen or antigenic determinant with at least one second attachment site, the second attachment site being selected from the group consisting of (i) an attachment site not naturally occurring with the antigen or antigenic determinant and (ii) an attachment site naturally occurring with the antigen or antigenic determinant, wherein the second attachment site is capable of association through at least one non-peptide bond to the first attachment site, and wherein the antigen or antigenic determinant and the scaffold interact through the association to form an ordered and repetitive antigen array.

Other embodiments of the invention include processes for the production of compositions of the invention and a methods of medical treatment using vaccine compositions described herein.

It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are intended to provide further explanation of the invention as claimed.

In a still further aspect, the present invention provides a composition comprising a bacteriophage Q β coat protein attached by a covalent bond to phospholipase A₂ protein, or a fragment thereof. In a preferred embodiment, the phospholipase A₂ protein, or a fragment thereof, and the bacteriophage Q β coat protein interact through the covalent bond to form an ordered and repetitive antigen array. In another preferred embodiment, the covalent bond is not a peptide bond. In another preferred embodiment, the phospholipase A₂ protein includes an amino acid selected from the group consisting of the amino acid sequence of SEQ ID NO:168, the amino acid sequence of SEQ ID NO:169, the amino acid sequence of SEQ ID NO:170, the amino acid sequence of SEQ ID NO:171, the amino acid sequence of SEQ ID

-10-

NO:172, the amino acid sequence of SEQ ID NO:173, the amino acid sequence of SEQ ID NO:174, and the amino acid sequence of SEQ ID NO:175.

The present invention also provides a method of making the composition comprising combining the bacteriophage Q β coat protein and the phospholipase A₂ protein, wherein the bacteriophage Q β coat protein and the phospholipase A₂ protein interact to form an antigen array.

In another aspect, the present invention also provides a composition comprising a non-natural molecular scaffold comprising a bacteriophage Q β coat protein, and an organizer comprising at least one first attachment site, wherein the organizer is connected to the bacteriophage Q β coat protein by at least one covalent bond; and phospholipase A₂ protein, or a fragment thereof, or a variant thereof with at least one second attachment site, the second attachment site being selected from the group consisting of: an attachment site not naturally occurring with the a phospholipase A₂ protein, or a fragment thereof; and an attachment site naturally occurring with the a phospholipase A₂ protein, or a fragment thereof, wherein the second attachment site associates through at least one non-peptide bond to the first attachment site, and wherein the antigen or antigenic determinant and the scaffold interact through the association to form an ordered and repetitive antigen array. In a preferred embodiment, the phospholipase A₂ protein includes an amino acid selected from the group consisting of the amino acid sequence of SEQ ID NO:168, the amino acid sequence of SEQ ID NO:169, the amino acid sequence of SEQ ID NO:170, the amino acid sequence of SEQ ID NO:171, the amino acid sequence of SEQ ID NO:172, the amino acid sequence of SEQ ID NO:173, the amino acid sequence of SEQ ID NO:174, and the amino acid sequence of SEQ ID NO:175.

The present invention also provides a method of making the composition comprising combining the bacteriophage Q β coat protein and the phospholipase A₂ protein, wherein the bacteriophage Q β coat protein and the phospholipase A₂ protein interact to form an antigen array. Preferably, the antigen array is ordered and/or repetitive.

The present invention also provides a pharmaceutical composition comprising a phospholipase A₂ protein, and a pharmaceutically acceptable carrier. The present invention also provides a vaccine composition comprising a phospholipase A₂ protein. In a preferred embodiment, the vaccine composition of claim 31, further comprising at least one adjuvant.

The present invention also provides a method of treating an allergy to bee venom, comprising administering the pharmaceutical composition or the vaccine composition to a subject. As a result of such administration the subject exhibits a decreased immune response to the venom.

The invention also relates to a vaccine for the prevention of prion-mediated diseases by induction of anti-lymphotoxin β , anti-lymphotoxin α or anti-

-11-

lymphotoxin β -receptor antibodies. The vaccine contains protein carries foreign to the immunized human or animal coupled to lymphotoxin β or fragments thereof, lymphotoxin α or fragments thereof or the lymphotoxin β receptor or fragments thereof. The vaccine is injected in humans or animals in order to induce antibodies specific for endogenous lymphotoxin β , lymphotoxin α or lymphotoxin β receptor. These induced anti-lymphotoxin β , lymphotoxin α or anti-lymphotoxin β receptor antibodies reduce or eliminate the pool of follicular dendritic cells present in lymphoid organs. Since prion-replication in lymphoid organs and transport to the central nervous system are impaired in the absence of follicular dendritic cells, this treatment inhibits progression of prion-mediated disease. In addition, blocking lymphotoxin β is beneficial for patients with autoimmune diseases such as diabetes type I.

BRIEF DESCRIPTION OF THE FIGURES

- FIG. 1A-1C Modular eukaryotic expression vectors for expression of antigens according to the invention;
- FIG. 2A-2C Cloning, expression and coupling of resistin to Q β capsid protein;
- FIG. 3A-3B Cloning and expression of lymphotoxin- β constructs for coupling to virus-like particles and pili.
- FIG. 4A-4B Cloning, expression and coupling of MIF constructs to Q β capsid protein.
- FIG. 4C ELISA analysis of IgG antibodies specific for MIF in sera of mice immunized against MIF proteins coupled to Q β capsid protein.
- FIG. 5 Coupling of MIF constructs to fr capsid protein and to HBcAg-lys-2cys-Mut capsid protein analyzed by SDS-Page.
- FIG. 6 Cloning and expression of human-C-RANKL.
- FIG. 7 Cloning and expression of prion protein.
- FIG. 8A. ELISA analysis of IgG antibodies specific for "Angio I" in sera of mice immunized against angiotensin peptides coupled to Q β capsid protein.
- FIG. 8B. ELISA analysis of IgG antibodies specific for "Angio II" in sera of mice immunized against angiotensin peptides coupled to Q β capsid protein.

- FIG. 8C. ELISA analysis of IgG antibodies specific for "Angio III" in sera of mice immunized against angiotensin peptides coupled to Q β capsid protein.
- FIG. 8D. ELISA analysis of IgG antibodies specific for "Angio IV" in sera of mice immunized against angiotensin peptides coupled to Q β capsid protein.
- FIG. 9A. ELISA analysis of IgG antibodies specific for "Der p I p52" in sera of mice immunized against Der p I peptides coupled to Q β capsid protein.
- FIG. 9B. ELISA analysis of IgG antibodies specific for "Der p I p117" in sera of mice immunized against Der p I peptides coupled to Q β capsid protein.
- FIG. 10A. ELISA analysis of IgG antibodies specific for human VEGFR II peptide in sera of mice immunized against human VEGFR II peptide and the extracellular domain of human VEGFR II both coupled to Type-1 pili protein.
- FIG. 10B. ELISA analysis of IgG antibodies specific for the extracellular domain of human VEGFR II in sera of mice immunized against human VEGFR II peptide and extracellular domain of human VEGFR II both coupled to Type-1 pili protein.
- FIG. 11. ELISA analysis of IgG antibodies specific for anti-TNF α protein in sera of mice immunized against full length HBc-TNF.
- FIG. 12. ELISA analysis of IgG antibodies specific for anti-TNF α protein in sera of mice immunized against 2cysLys-mut HBcAg1-149 coupled to the 3'TNF II peptide
- FIG. 13A. SDS-PAGE analysis of coupling of "A β 1-15" to Q β capsid protein using the cross-linker SMPH.
- FIG. 13B. SDS-PAGE analysis of coupling of "A β 33-42" to Q β capsid protein using the cross-linker SMPH.
- FIG. 13C. SDS-PAGE analysis of coupling of "A β 1-27" to Q β capsid protein using the cross-linker SMPH.
- FIG. 13D. SDS-PAGE analysis of coupling of "A β 1-15" to Q β capsid protein using the cross-linker Sulfo-GMBS.
- FIG. 13E. SDS-PAGE analysis of coupling of "A β 1-15" to Q β capsid protein using the cross-linker Sulfo-MBS.

-13-

- FIG. 14A. ELISA analysis of IgG antibodies specific for "A β 1-15" in sera of mice immunized against "A β 1-15" coupled to Q β capsid protein.
- FIG. 14B. ELISA analysis of IgG antibodies specific for "A β 1-27" in sera of mice immunized against "A β 1-27" coupled to Q β capsid protein.
- FIG. 14C. ELISA analysis of IgG antibodies specific for "A β 33-42" in sera of mice immunized against "A β 33-42" coupled to Q β capsid protein.
- FIG. 15A. SDS-PAGE analysis of coupling of pCC2 to Q β capsid protein.
- FIG. 15B. SDS-PAGE analysis of coupling of pCA2 to Q β capsid protein.
- FIG. 15C. SDS-PAGE analysis of coupling of pCB2 to Q β capsid protein.
- FIG. 16. Coupling of prion peptides to Q β capsid protein; SDS-Page analysis.
- FIG. 17 A. SDS-PAGE analysis of expression of IL-5 in bacteria
- FIG. 17 B. Western-Blot analysis of expression of IL-5 and IL-13 in eukaryotic cells
- FIG. 18 A. SDS-PAGE analysis of coupling of murine VEGFR-2 peptide to Pili.
- FIG. 18 B. SDS-PAGE analysis of coupling of murine VEGFR-2 peptide to Q β capsid protein.
- FIG. 18 C. SDS-PAGE analysis of coupling of murine VEGFR-2 peptide to HBcAg-lys-2cys-Mut.
- FIG 18 D. ELISA analysis of IgG antibodies specific for murine VEGFR-2 peptide in sera of mice immunized against murine VEGFR-2 peptide coupled to Pili.
- FIG 18 E. ELISA analysis of IgG antibodies specific for murine VEGFR-2 peptide in sera of mice immunized against murine VEGFR-2 peptide coupled to Q β capsid protein.
- FIG 18 F. ELISA analysis of IgG antibodies specific for murine VEGFR-2 peptide in sera of mice immunized against murine VEGFR-2 peptide coupled to HBcAg-lys-2cys-Mut.
- FIG.19 A. SDS-PAGE analysis of coupling of A β 1-15 peptide to HBcAg-lys-2cys-Mut and fr capsid protein.

-14-

- FIG.19 B. ELISA analysis of IgG antibodies specific for A β 1-15 peptide in sera of mice immunized against A β 1-15 peptide coupled to HBcAg-lys-2cys-Mut or fr capsid protein.
- FIG.20 ELISA analysis of IgG antibodies specific for human A β in sera of transgenic APP23 mice immunized with human A β peptides coupled to Q β capsid protein.
- FIG. 21 SDS-PAGE analysis of coupling of an Fab antibody fragment to Q β capsid protein.
- FIG. 22 A. SDS-PAGE analysis of coupling of flag peptide coupled to mutant Q β capsid protein with cross-linker sulfo GMBS
- FIG. 22 B. SDS-PAGE analysis of coupling of flag peptide coupled to mutant Q β capsid protein with cross-linker sulfo MBS
- FIG. 22 C. SDS-PAGE analysis of coupling of flag peptide coupled to mutant Q β capsid protein with cross-linker SMPH
- FIG. 22 D. SDS-PAGE analysis of coupling of PLA₂-cys protein coupled to mutant Q β capsid protein with cross-linker SMPH
- FIG.23 ELISA analysis of immunization with M2 peptide coupled to mutant Q β capsid protein and fr capsid
- FIG. 24 SDS-PAGE analysis of coupling of DER p1,2 peptide coupled to mutant Q β capsid protein
- FIG. 25 A Desensitization of allergic mice with PLA₂ coupled to Q β capsid protein: temperature measurements
- FIG. 25 B Desensitization of allergic mice with PLA₂-cys coupled to Q β capsid protein: IgG 2A and Ig E titers
- FIG. 26 SDS-PAGE Analysis and Western-blot analysis of coupling of PLA₂-cys to Q β capsid protein
- FIG. 27 A ELISA analysis of IgG antibodies specific for M2 peptide in sera of mice immunized against M2 peptide coupled to HBcAg-lys-2cys-Mut, Q β capsid protein, fr capsid protein, HBcAg-lys-1-183 and M2 peptide fused to HBcAg 1-183

-15-

FIG. 28 A SDS-PAGE Analysis of coupling of anti-idiotypic IgE mimobody VAE051 to Q β capsid protein

FIG. 28 B. ELISA analysis of IgG antibodies specific for anti-idiotypic antibody VAE051 and Human IgE in sera of mice immunized against VAE051 coupled to Q β capsid protein

DETAILED DESCRIPTION OF THE INVENTION

1. Definitions

Alphavirus: As used herein, the term "alphavirus" refers to any of the RNA viruses included within the genus *Alphavirus*. Descriptions of the members of this genus are contained in Strauss and Strauss, *Microbiol. Rev.*, 58:491-562 (1994). Examples of alphaviruses include Aura virus, Bebaru virus, Cabassou virus, Chikungunya virus, Easter equine encephalomyelitis virus, Fort morgan virus, Getah virus, Kyzylagach virus, Mayoaro virus, Middleburg virus, Mucambo virus, Ndumu virus, Pixuna virus, Tonate virus, Trinita virus, Una virus, Western equine encephalomyelitis virus, Whataroa virus, Sindbis virus (SIN), Semliki forest virus (SFV), Venezuelan equine encephalomyelitis virus (VEE), and Ross River virus.

Antigen: As used herein, the term "antigen" is a molecule capable of being bound by an antibody. An antigen is additionally capable of inducing a humoral immune response and/or cellular immune response leading to the production of B- and/or T-lymphocytes. An antigen may have one or more epitopes (B- and T-epitopes). The specific reaction referred to above is meant to indicate that the antigen will react, in a highly selective manner, with its corresponding antibody and not with the multitude of other antibodies which may be evoked by other antigens.

Antigenic determinant: As used herein, the term "antigenic determinant" is meant to refer to that portion of an antigen that is specifically recognized by either B- or T-lymphocytes. B-lymphocytes respond to foreign antigenic determinants via antibody production, whereas T-lymphocytes are the mediator of cellular immunity. Thus, antigenic determinants or epitopes are those parts of an antigen that are recognized by antibodies, or in the context of an MHC, by T-cell receptors.

Association: As used herein, the term "association" as it applies to the first and second attachment sites, refers to at least one non-peptide bond. The nature of the association may be covalent, ionic, hydrophobic, polar or any combination thereof.

Attachment Site, First: As used herein, the phrase "first attachment site" refers to an element of the "organizer", itself bound to the core particle in a non-random fashion, to which the second attachment site located on the antigen or antigenic determinant may associate. The first attachment site may be a protein, a polypeptide, an amino acid, a peptide, a sugar, a polynucleotide, a natural or synthetic polymer, a secondary metabolite or compound (biotin, fluorescein, retinol, digoxigenin, metal ions, phenylmethylsulfonylfluoride), or a combination thereof, or a chemically reactive group thereof. Multiple first attachment sites are present on the surface of the non-natural molecular scaffold in a repetitive configuration.

Attachment Site, Second: As used herein, the phrase "second attachment site" refers to an element associated with the antigen or antigenic determinant to which the first attachment site of the "organizer" located on the surface of the non-natural molecular scaffold may associate. The second attachment site of the antigen or antigenic determinant may be a protein, a polypeptide, a peptide, a sugar, a polynucleotide, a natural or synthetic polymer, a secondary metabolite or compound (biotin, fluorescein, retinol, digoxigenin, metal ions, phenylmethylsulfonylfluoride), or a combination thereof, or a chemically reactive group thereof. At least one second attachment site is present on the antigen or antigenic determinant. The term "antigen or antigenic determinant with at least one second attachment site" refers, therefore, to an antigen or antigenic construct comprising at least the antigen or antigenic determinant and the second attachment site. However, in particular for a second attachment site, which is not naturally occurring within the antigen or antigenic determinant, these antigen or antigenic constructs comprise an "amino acid linker". Such an amino acid linker, or also just termed "linker" within this specification, either associates the antigen or antigenic determinant with the second attachment site, or more preferably, already comprises or contains the second attachment site, typically - but not necessarily - as one amino acid residue, preferably as a cysteine residue. The term "amino acid linker" as used herein, however, does not intend to imply that such an amino acid linker consists exclusively of amino acid residues, even if an amino acid linker consisting of amino acid residues is a preferred embodiment of the present invention. The amino acid residues of the amino acid linker is, preferably, composed of naturally occurring amino acids or unnatural amino acids known in the art, all-L or all-D or mixtures thereof. However, an amino acid linker comprising a molecule with a sulfhydryl group or cysteine residue is also encompassed within the invention. Such a molecule comprise preferably a C1-C6 alkyl-, cycloalkyl (C5,C6), aryl or heteroaryl moiety. Association between the antigen or antigenic determinant or optionally the

-17-

second attachment site and the amino acid linker is preferably by way of at least one covalent bond, more preferably by way of at least one peptide bond.

Bound: As used herein, the term "bound" refers to binding or attachment that may be covalent, *e.g.*, by chemically coupling, or non-covalent, *e.g.*, ionic interactions, hydrophobic interactions, hydrogen bonds, etc. Covalent bonds can be, for example, ester, ether, phosphoester, amide, peptide, imide, carbon-sulfur bonds, carbon-phosphorus bonds, and the like. The term "bound" is broader than and includes terms such as "coupled," "fused" and "attached".

Core particle: As used herein, the term "core particle" refers to a rigid structure with an inherent repetitive organization that provides a foundation for attachment of an "organizer". A core particle as used herein may be the product of a synthetic process or the product of a biological process.

Coat protein(s): As used herein, the term "coat protein(s)" refers to the protein(s) of a bacteriophage or a RNA-phage capable of being incorporated within the capsid assembly of the bacteriophage or the RNA-phage. However, when referring to the specific gene product of the coat protein gene of RNA-phages the term "CP" is used. For example, the specific gene product of the coat protein gene of RNA-phage Q β is referred to as "Q β CP", whereas the "coat proteins" of bacteriophage Q β comprise the "Q β CP" as well as the A1 protein.

Cis-acting: As used herein, the phrase "cis-acting" sequence refers to nucleic acid sequences to which a replicase binds to catalyze the RNA-dependent replication of RNA molecules. These replication events result in the replication of the full-length and partial RNA molecules and, thus, the alphavirus subgenomic promoter is also a "cis-acting" sequence. Cis-acting sequences may be located at or near the 5' end, 3' end, or both ends of a nucleic acid molecule, as well as internally.

Fusion: As used herein, the term "fusion" refers to the combination of amino acid sequences of different origin in one polypeptide chain by in-frame combination of their coding nucleotide sequences. The term "fusion" explicitly encompasses internal fusions, *i.e.*, insertion of sequences of different origin within a polypeptide chain, in addition to fusion to one of its termini.

Heterologous sequence: As used herein, the term "heterologous sequence" refers to a second nucleotide sequence present in a vector of the invention. The term "heterologous sequence" also refers to any amino acid or RNA sequence encoded by a heterologous DNA sequence contained in a vector of the invention. Heterologous nucleotide sequences can encode proteins or RNA molecules normally expressed in the cell type in which they are present or molecules not normally expressed therein (*e.g.*, Sindbis structural proteins).

Isolated: As used herein, when the term "isolated" is used in reference to a molecule, the term means that the molecule has been removed from its native environment. For example, a polynucleotide or a polypeptide naturally present in a living animal is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated." Further, recombinant DNA molecules contained in a vector are considered isolated for the purposes of the present invention. Isolated RNA molecules include *in vivo* or *in vitro* RNA replication products of DNA and RNA molecules. Isolated nucleic acid molecules further include synthetically produced molecules. Additionally, vector molecules contained in recombinant host cells are also isolated. Thus, not all "isolated" molecules need be "purified."

Immunotherapeutic: As used herein, the term "immunotherapeutic" is a composition for the treatment of diseases or disorders. More specifically, the term is used to refer to a method of treatment for allergies or a method of treatment for cancer.

Individual: As used herein, the term "individual" refers to multicellular organisms and includes both plants and animals. Preferred multicellular organisms are animals, more preferred are vertebrates, even more preferred are mammals, and most preferred are humans.

Low or undetectable: As used herein, the phrase "low or undetectable," when used in reference to gene expression level, refers to a level of expression which is either significantly lower than that seen when the gene is maximally induced (*e.g.*, at least five fold lower) or is not readily detectable by the methods used in the following examples section.

Lectin: As used herein, proteins obtained particularly from the seeds of leguminous plants, but also from many other plant and animal sources, that have binding sites for specific mono- or oligosaccharides. Examples include concanavalin A and wheat-germ agglutinin, which are widely used as analytical and preparative agents in the study of glycoprotein.

Mimotope: As used herein, the term "mimotope" refers to a substance which induces an immune response to an antigen or antigenic determinant. Generally, the term mimotope will be used with reference to a particular antigen. For example, a peptide which elicits the production of antibodies to a phospholipase A₂ (PLA₂) is a mimotope of the antigenic determinant to which the antibodies bind. A mimotope may or may not have substantial structural similarity to or share structural properties with an antigen or antigenic determinant to which it induces an immune response. Methods for generating and identifying mimotopes which induce immune responses to particular antigens or antigenic determinants are known in the art and are described elsewhere herein.

-19-

Natural origin: As used herein, the term "natural origin" means that the whole or parts thereof are not synthetic and exist or are produced in nature.

Non-natural: As used herein, the term generally means not from nature, more specifically, the term means from the hand of man.

Non-natural origin: As used herein, the term "non-natural origin" generally means synthetic or not from nature; more specifically, the term means from the hand of man.

Non-natural molecular scaffold: As used herein, the phrase "non-natural molecular scaffold" refers to any product made by the hand of man that may serve to provide a rigid and repetitive array of first attachment sites. Ideally but not necessarily, these first attachment sites are in a geometric order. The non-natural molecular scaffold may be organic or non-organic and may be synthesized chemically or through a biological process, in part or in whole. The non-natural molecular scaffold is comprised of: (a) a core particle, either of natural or non-natural origin; and (b) an organizer, which itself comprises at least one first attachment site and is connected to a core particle by at least one covalent bond. In a particular embodiment, the non-natural molecular scaffold may be a virus, virus-like particle, a bacterial pilus, a virus capsid particle, a phage, a recombinant form thereof, or synthetic particle.

Ordered and repetitive antigen or antigenic determinant array: As used herein, the term "ordered and repetitive antigen or antigenic determinant array" generally refers to a repeating pattern of antigen or antigenic determinant, characterized by a uniform spatial arrangement of the antigens or antigenic determinants with respect to the non-natural molecular scaffold. In one embodiment of the invention, the repeating pattern may be a geometric pattern. Examples of suitable ordered and repetitive antigen or antigenic determinant arrays are those which possess strictly repetitive paracrystalline orders of antigens or antigenic determinants with spacings of 5 to 15 nanometers.

Organizer: As used herein, the term "organizer" is used to refer to an element bound to a core particle in a non-random fashion that provides a nucleation site for creating an ordered and repetitive antigen array. An organizer is any element comprising at least one first attachment site that is bound to a core particle by at least one covalent bond. An organizer may be a protein, a polypeptide, a peptide, an amino acid (*i.e.*, a residue of a protein, a polypeptide or peptide), a sugar, a polynucleotide, a natural or synthetic polymer, a secondary metabolite or compound (biotin, fluorescein, retinol, digoxigenin, metal ions, phenylmethylsulfonylfluoride), or a combination thereof, or a chemically reactive group thereof. Therefore, the organizer further ensures formation of an ordered and repetitive antigen array in

-20-

accordance with the present invention. In typical embodiments of the invention, the core particle is modified, e.g. by way of genetic engineering or chemical reaction, so as to generate a non-natural molecular scaffold comprising the core particle and the organizer, the latter being connected to the core particle by at least one covalent bond. In certain embodiments of the invention, however, the organizer is selected as being part of the core particle. Therefore, for those embodiments modification of the core particle is not necessarily needed to generate a non-natural molecular scaffold comprising the core particle and the organizer and to ensure the formation of an ordered and repetitive antigen array.

Permissive temperature: As used herein, the phrase "permissive temperature" refers to temperatures at which an enzyme has relatively high levels of catalytic activity.

Pili: As used herein, the term "pili" (singular being "pilus") refers to extracellular structures of bacterial cells composed of protein monomers (e.g., pilin monomers) which are organized into ordered and repetitive patterns. Further, pili are structures which are involved in processes such as the attachment of bacterial cells to host cell surface receptors, inter-cellular genetic exchanges, and cell-cell recognition. Examples of pili include Type-1 pili, P-pili, F1C pili, S-pili, and 987P-pili. Additional examples of pili are set out below.

Pilus-like structure: As used herein, the phrase "pilus-like structure" refers to structures having characteristics similar to that of pili and composed of protein monomers. One example of a "pilus-like structure" is a structure formed by a bacterial cell which expresses modified pilin proteins that do not form ordered and repetitive arrays that are essentially identical to those of natural pili.

Polypeptide: As used herein the term "polypeptide" refers to a polymer composed of amino acid residues, generally natural amino acid residues, linked together through peptide bonds. Although a polypeptide may not necessarily be limited in size, the term polypeptide is often used in conjunction with peptide of a size of about ten to about 50 amino acids.

Protein: As used herein, the term protein refers to a polypeptide generally of a size of above 20, more particularly of above 50 amino acid residues. Proteins generally have a defined three dimensional structure although they do not necessarily need to, and are often referred to as folded, in opposition to peptides and polypeptides which often do not possess a defined three-dimensional structure, but rather can adopt a large number of different conformations, and are referred to as unfolded. The defined three-dimensional structures of proteins is especially important for the association between the core particle and the antigen, mediated by the second

attachment site, and in particular by way of chemical cross-linking between the first and second attachment site using a chemical cross-linker. The amino acid linker is also intimately related to the structural properties of proteins in some aspects of the invention.

Purified: As used herein, when the term "purified" is used in reference to a molecule, it means that the concentration of the molecule being purified has been increased relative to molecules associated with it in its natural environment. Naturally associated molecules include proteins, nucleic acids, lipids and sugars but generally do not include water, buffers, and reagents added to maintain the integrity or facilitate the purification of the molecule being purified. For example, even if mRNA is diluted with an aqueous solvent during oligo dT column chromatography, mRNA molecules are purified by this chromatography if naturally associated nucleic acids and other biological molecules do not bind to the column and are separated from the subject mRNA molecules.

Receptor: As used herein, the term "receptor" refers to proteins or glycoproteins or fragments thereof capable of interacting with another molecule, called the ligand. The ligand may belong to any class of biochemical or chemical compounds. The receptor need not necessarily be a membrane-bound protein. Soluble protein, like *e.g.*, maltose binding protein or retinol binding protein are receptors as well.

Residue: As used herein, the term "residue" is meant to mean a specific amino acid in a polypeptide backbone or side chain.

Recombinant host cell: As used herein, the term "recombinant host cell" refers to a host cell into which one or more nucleic acid molecules of the invention have been introduced.

Recombinant virus: As used herein, the phrase "recombinant virus" refers to a virus that is genetically modified by the hand of man. The phrase covers any virus known in the art. More specifically, the phrase refers to an alphavirus genetically modified by the hand of man, and most specifically, the phrase refers to a Sinbis virus genetically modified by the hand of man.

Restrictive temperature: As used herein, the phrase "restrictive temperature" refers to temperatures at which an enzyme has low or undetectable levels of catalytic activity. Both "hot" and "cold" sensitive mutants are known and, thus, a restrictive temperature may be higher or lower than a permissive temperature.

RNA-dependent RNA replication event: As used herein, the phrase "RNA-dependent RNA replication event" refers to processes which result in the formation of an RNA molecule using an RNA molecule as a template.

RNA-Dependent RNA polymerase: As used herein, the phrase "RNA-Dependent RNA polymerase" refers to a polymerase which catalyzes the production of an RNA molecule from another RNA molecule. This term is used herein synonymously with the term "replicase."

RNA-phage: As used herein, the term "RNA-phage" refers to RNA viruses infecting bacteria, preferably to single-stranded positive-sense RNA viruses infecting bacteria.

Self antigen : As used herein, the tem "self antigen" refers to proteins encoded by the host's DNA and products generated by proteins or RNA encoded by the host's DNA are defined as self. In addition, proteins that result from a combination of two or several self-molecules or that represent a fraction of a self-molecule and proteins that have a high homology two self-molecules as defined above (>95%) may also be considered self.

Temperature-sensitive: As used herein, the phrase "temperature-sensitive" refers to an enzyme which readily catalyzes a reaction at one temperature but catalyzes the same reaction slowly or not at all at another temperature. An example of a temperature-sensitive enzyme is the replicase protein encoded by the pCYTts vector, which has readily detectable replicase activity at temperatures below 34°C and has low or undetectable activity at 37°C.

Transcription: As used herein, the term "transcription" refers to the production of RNA molecules from DNA templates catalyzed by RNA polymerase.

Untranslated RNA: As used herein, the phrase "untranslated RNA" refers to an RNA sequence or molecule which does not encode an open reading frame or encodes an open reading frame, or portion thereof, but in a format in which an amino acid sequence will not be produced (*e.g.*, no initiation codon is present). Examples of such molecules are tRNA molecules, rRNA molecules, and ribozymes.

Vector: As used herein, the term "vector" refers to an agent (*e.g.*, a plasmid or virus) used to transmit genetic material to a host cell. A vector may be composed of either DNA or RNA.

Virus-like particle: As used herein, the term "virus-like particle" refers to a structure resembling a virus particle. Moreover, a virus-like particle in accordance with the invention is non replicative and noninfectious since it lacks all or part of the viral genome, in particular the replicative and infectious components of the viral genome. A virus-like particle in accordance with the invention may contain nucleic acid distinct from their genome.

-23-

Virus-like particle of a bacteriophage: As used herein, the term "virus-like particle of a bacteriophage" refers to a virus-like particle resembling the structure of a bacteriophage, being non replicative and noninfectious, and lacking at least the gene or genes encoding for the replication machinery of the bacteriophage, and typically also lacking the gene or genes encoding the protein or proteins responsible for viral attachment to or entry into the host. This definition should, however, also encompass virus-like particles of bacteriophages, in which the aforementioned gene or genes are still present but inactive, and, therefore, also leading to non-replicative and noninfectious virus-like particles of a bacteriophage.

Virus particle: The term "virus particle" as used herein refers to the morphological form of a virus. In some virus types it comprises a genome surrounded by a protein capsid; others have additional structures (*e.g.*, envelopes, tails, etc.).

one, a, or an: When the terms "one," "a," or "an" are used in this disclosure, they mean "at least one" or "one or more," unless otherwise indicated.

2. Compositions of Ordered and Repetitive Antigen or Antigenic Determinant Arrays and Methods to Make the Same

The disclosed invention provides compositions comprising an ordered and repetitive antigen or antigenic determinant array. Furthermore, the invention conveniently enables the practitioner to construct ordered and repetitive antigen or antigenic determinant arrays for various treatment purposes, which includes the prevention of infectious diseases, the treatment of allergies and the treatment of cancers.

Compositions of the invention essentially comprise, or alternatively consist of, two elements: (1) a non-natural molecular scaffold; and (2) an antigen or antigenic determinant with at least one second attachment site capable of association through at least one non-peptide bond to said first attachment site.

Compositions of the invention also comprise, or alternatively consist of, bacterial pilus proteins to which antigens or antigenic determinants are directly linked.

The non-natural molecular scaffold comprises, or alternatively consists of: (a) a core particle selected from the group consisting of (1) a core particle of non-natural origin and (2) a core particle of natural origin; and (b) an organizer comprising at

least one first attachment site, wherein said organizer is connected to said core particle by at least one covalent bond.

Compositions of the invention also comprise, or alternatively consist of, core particles to which antigens or antigenic determinants are directly linked.

The antigen or antigenic determinant has at least one second attachment site which is selected from the group consisting of (a) an attachment site not naturally occurring with said antigen or antigenic determinant; and (b) an attachment site naturally occurring with said antigen or antigenic determinant.

The invention provides for an ordered and repetitive antigen array through an association of the second attachment site to the first attachment site by way of at least one non-peptide bond. Thus, the antigen or antigenic determinant and the non-natural molecular scaffold are brought together through this association of the first and the second attachment site to form an ordered and repetitive antigen array.

The practitioner may specifically design the antigen or antigenic determinant and the second attachment site such that the arrangement of all the antigens or antigenic determinants bound to the non-natural molecular scaffold or, in certain embodiments, the core particle will be uniform. For example, one may place a single second attachment site on the antigen or antigenic determinant at the carboxyl or amino terminus, thereby ensuring through design that all antigen or antigenic determinant molecules that are attached to the non-natural molecular scaffold are positioned in a uniform way. Thus, the invention provides a convenient means of placing any antigen or antigenic determinant onto a non-natural molecular scaffold in a defined order and in a manner which forms a repetitive pattern.

As will be clear to those skilled in the art, certain embodiments of the invention involve the use of recombinant nucleic acid technologies such as cloning, polymerase chain reaction, the purification of DNA and RNA, the expression of recombinant proteins in prokaryotic and eukaryotic cells, etc. Such methodologies are well known to those skilled in the art and may be conveniently found in published laboratory methods manuals (e.g., Sambrook, J. *et al.*, eds., *MOLECULAR CLONING, A LABORATORY MANUAL*, 2nd. edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989); Ausubel, F. *et al.*, eds., *CURRENT PROTOCOLS IN MOLECULAR BIOLOGY*, John H. Wiley & Sons, Inc. (1997)). Fundamental laboratory techniques for working with tissue culture cell lines (Celis, J., ed., *CELL BIOLOGY*, Academic Press, 2nd edition, (1998)) and antibody-based technologies (Harlow, E. and Lane, D., "Antibodies: A Laboratory Manual," Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1988); Deutscher, M.P., "Guide to Protein Purification," *Meth. Enzymol.* 128, Academic Press San Diego (1990); Scopes, R.K., "Protein Purification Principles and Practice," 3rd ed., Springer-Verlag, New York (1994)) are

-25-

also adequately described in the literature, all of which are incorporated herein by reference.

A. Core Particles and Non-Natural Molecular Scaffolds

One element in certain compositions of the invention is a non-natural molecular scaffold comprising, or alternatively consisting of, a core particle and an organizer. As used herein, the phrase "non-natural molecular scaffold" refers to any product made by the hand of man that may serve to provide a rigid and repetitive array of first attachment sites. More specifically, the non-natural molecular scaffold comprises, or alternatively consists of, (a) a core particle selected from the group consisting of (1) a core particle of non-natural origin and (2) a core particle of natural origin; and (b) an organizer comprising at least one first attachment site, wherein said organizer is connected to said core particle by at least one covalent bond.

As will be readily apparent to those skilled in the art, the core particle of the non-natural molecular scaffold of the invention is not limited to any specific form. The core particle may be organic or non-organic and may be synthesized chemically or through a biological process.

In one embodiment, a non-natural core particle may be a synthetic polymer, a lipid micelle or a metal. Such core particles are known in the art, providing a basis from which to build the novel non-natural molecular scaffold of the invention. By way of example, synthetic polymer or metal core particles are described in U.S. Patent No. 5,770,380, which discloses the use of a calixarene organic scaffold to which is attached a plurality of peptide loops in the creation of an 'antibody mimic', and U.S. Patent No. 5,334,394 describes nanocrystalline particles used as a viral decoy that are composed of a wide variety of inorganic materials, including metals or ceramics. Suitable metals include chromium, rubidium, iron, zinc, selenium, nickel, gold, silver, platinum. Suitable ceramic materials in this embodiment include silicon dioxide, titanium dioxide, aluminum oxide, ruthenium oxide and tin oxide. The core particles of this embodiment may be made from organic materials including carbon (diamond). Suitable polymers include polystyrene, nylon and nitrocellulose. For this type of nanocrystalline particle, particles made from tin oxide, titanium dioxide or carbon (diamond) are may also be used. A lipid micelle may be prepared by any means known in the art. For example micelles may be prepared according to the procedure of Baiselle and Millar (*Biophys. Chem.* 4:355-361 (1975)) or Corti *et al.* (*Chem. Phys. Lipids* 38:197-214 (1981)) or Lopez *et al.* (*FEBS Lett.* 426:314-318 (1998)) or Topchieva and Karezin (*J. Colloid Interface Sci.* 213:29-35 (1999)) or

Morein *et al.*, (*Nature* 308:457-460 (1984)), which are all incorporated herein by reference.

The core particle may also be produced through a biological process, which may be natural or non-natural. By way of example, this type of embodiment may include a core particle comprising, or alternatively consisting of, a virus, virus-like particle, a bacterial pilus, a phage, a viral capsid particle or a recombinant form thereof. In a more specific embodiment, the core particle may comprise, or alternatively consist of, recombinant proteins of Rotavirus, recombinant proteins of Norwalk virus, recombinant proteins of Alphavirus, recombinant proteins which form bacterial pili or pilus-like structures, recombinant proteins of Foot and Mouth Disease virus, recombinant proteins of Retrovirus, recombinant proteins of Hepatitis B virus (*e.g.*, a HBcAg), recombinant proteins of Tobacco mosaic virus, recombinant proteins of Flock House Virus, and recombinant proteins of human Papillomavirus. The core particle may further comprise, or alternatively consist of, one or more fragments of such proteins, as well as variants of such proteins which retain the ability to associate with each other to form ordered and repetitive antigen or antigenic determinant arrays.

As explained in more below, variants of proteins which retain the ability to associate with each other to form ordered and repetitive antigen or antigenic determinant arrays may share, for example, at least 80%, 85%, 90%, 95%, 97%, or 99% identity at the amino acid level with their wild-type counterparts. Using the HBcAg having the amino acid sequence shown in SEQ ID NO:89 for illustration, the invention includes vaccine compositions comprising HBcAg polypeptides comprising, or alternatively consisting of, amino acid sequences which are at least 80%, 85%, 90%, 95%, 97%, or 99% identical to the amino acid sequence shown in SEQ ID NO:89, and forms of this protein which have been processed, where appropriate, to remove N-terminal leader sequence. These variants will generally be capable of associating to form dimeric or multimeric structures. Methods which can be used to determine whether proteins form such structures comprise gel filtration, agarose gel electrophoresis, sucrose gradient centrifugation and electron microscopy (*e.g.*, Koschel, M. *et al.*, *J. Virol* 73: 2153-2160 (1999)).

Fragments of proteins which retain the ability to associate with each other to form ordered and repetitive antigen or antigenic determinant arrays may comprise, or alternatively consist of, polypeptides which are 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, or 200 amino acids in length. Examples of such protein fragments include fragments of proteins discussed herein which are suitable for the preparation of core particles and/or non-natural molecular scaffolds.

Whether natural or non-natural, the core particle of the invention will generally have an organizer that is attached to the natural or non-natural core particle by at least one covalent bond. The organizer is an element bound to a core particle in a non-random fashion that provides a nucleation site for creating an ordered and repetitive antigen array. Ideally, but not necessarily, the organizer is associated with the core particle in a geometric order. Minimally, the organizer comprises a first attachment site.

In some embodiments of the invention, the ordered and repetitive array is formed by association between (1) either core particles or non-natural molecular scaffolds and (2) either (a) an antigen or antigenic determinant or (b) one or more antigens or antigenic determinants. For example, bacterial pili or pilus-like structures are formed from proteins which are organized into ordered and repetitive structures. Thus, in many instances, it will be possible to form ordered arrays of antigens or antigenic determinants by linking these constituents to bacterial pili or pilus-like structures either directly or through an organizer.

As previously stated, the organizer may be any element comprising at least one first attachment site that is bound to a core particle by at least one covalent bond. An organizer may be a protein, a polypeptide, a peptide, an amino acid (*i.e.*, a residue of a protein, a polypeptide or peptide), a sugar, a polynucleotide, a natural or synthetic polymer, a secondary metabolite or compound (biotin, fluorescein, retinol, digoxigenin, metal ions, phenylmethylsulfonylfluoride), or a combination thereof, or a chemically reactive group thereof. In a more specific embodiment, the organizer may comprise a first attachment site comprising an antigen, an antibody or antibody fragment, biotin, avidin, streptavidin, a receptor, a receptor ligand, a ligand, a ligand-binding protein, an interacting leucine zipper polypeptide, an amino group, a chemical group reactive to an amino group; a carboxyl group, chemical group reactive to a carboxyl group, a sulfhydryl group, a chemical group reactive to a sulfhydryl group, or a combination thereof.

In one embodiment, the core particle of the non-natural molecular scaffold comprises a virus, a bacterial pilus, a structure formed from bacterial pilin, a bacteriophage, a virus-like particle, a viral capsid particle or a recombinant form thereof. Any virus known in the art having an ordered and repetitive coat and/or core protein structure may be selected as a non-natural molecular scaffold of the invention; examples of suitable viruses include sindbis and other alphaviruses, rhabdoviruses (*e.g.* vesicular stomatitis virus), picornaviruses (*e.g.*, human rhino virus, Aichi virus), togaviruses (*e.g.*, rubella virus), orthomyxoviruses (*e.g.*, Thogoto virus, Batken virus, fowl plague virus), polyomaviruses (*e.g.*, polyomavirus BK, polyomavirus JC, avian polyomavirus BFDV), parvoviruses, rotaviruses, bacteriophage Q β , bacteriophage R17, bacteriophage M11, bacteriophage MX1, bacteriophage NL95, bacteriophage fr,

-28-

bacteriophage GA, bacteriophage SP, bacteriophage MS2, bacteriophage f2, bacteriophage PP7, Norwalk virus, foot and mouth disease virus, a retrovirus, Hepatitis B virus, Tobacco mosaic virus, Flock House Virus, and human Papillomavirus (for example, *see* Table 1 in Bachman, M.F. and Zinkernagel, R.M., *Immunol. Today* 17:553-558 (1996)).

In one embodiment, the invention utilizes genetic engineering of a virus to create a fusion between an ordered and repetitive viral envelope protein and an organizer comprising a heterologous protein, peptide, antigenic determinant or a reactive amino acid residue of choice. Other genetic manipulations known to those in the art may be included in the construction of the non-natural molecular scaffold; for example, it may be desirable to restrict the replication ability of the recombinant virus through genetic mutation. The viral protein selected for fusion to the organizer (*i.e.*, first attachment site) protein should have an organized and repetitive structure. Such an organized and repetitive structure include paracrystalline organizations with a spacing of 5-15 nm on the surface of the virus. The creation of this type of fusion protein will result in multiple, ordered and repetitive organizers on the surface of the virus. Thus, the ordered and repetitive organization of the first attachment sites resulting therefrom will reflect the normal organization of the native viral protein.

As will be discussed in more detail herein, in another embodiment of the invention, the non-natural molecular scaffold is a recombinant alphavirus, and more specifically, a recombinant Sindbis virus. Alphaviruses are positive stranded RNA viruses that replicate their genomic RNA entirely in the cytoplasm of the infected cell and without a DNA intermediate (Strauss, J. and Strauss, E., *Microbiol. Rev.* 58:491-562 (1994)). Several members of the alphavirus family, Sindbis (Xiong, C. *et al.*, *Science* 243:1188-1191 (1989); Schlesinger, S., *Trends Biotechnol.* 11:18-22 (1993)), Semliki Forest Virus (SFV) (Liljeström, P. & Garoff, H., *Bio/Technology* 9:1356-1361 (1991)) and others (Davis, N.L. *et al.*, *Virology* 171:189-204 (1989)), have received considerable attention for use as virus-based expression vectors for a variety of different proteins (Lundstrom, K., *Curr. Opin. Biotechnol.* 8:578-582 (1997); Liljeström, P., *Curr. Opin. Biotechnol.* 5:495-500 (1994)) and as candidates for vaccine development. Recently, a number of patents have issued directed to the use of alphaviruses for the expression of heterologous proteins and the development of vaccines (*see* U.S. Patent Nos. 5,766,602; 5,792,462; 5,739,026; 5,789,245 and 5,814,482). The construction of the alphaviral scaffold of the invention may be done by means generally known in the art of recombinant DNA technology, as described by the aforementioned articles, which are incorporated herein by reference.

A variety of different recombinant host cells can be utilized to produce a viral-based core particle for antigen or antigenic determinant attachment. For example,

Alphaviruses are known to have a wide host range; Sindbis virus infects cultured mammalian, reptilian, and amphibian cells, as well as some insect cells (Clark, H., *J. Natl. Cancer Inst.* 51:645 (1973); Leake, C., *J. Gen. Virol.* 35:335 (1977); Stollar, V. in *THE TOGAVIRUSES*, R.W. Schlesinger, Ed., Academic Press, (1980), pp.583-621). Thus, numerous recombinant host cells can be used in the practice of the invention. BHK, COS, Vero, HeLa and CHO cells are particularly suitable for the production of heterologous proteins because they have the potential to glycosylate heterologous proteins in a manner similar to human cells (Watson, E. *et al.*, *Glycobiology* 4:227, (1994)) and can be selected (Zang, M. *et al.*, *Bio/Technology* 13:389 (1995)) or genetically engineered (Renner W. *et al.*, *Biotech. Bioeng.* 4:476 (1995); Lee K. *et al.* *Biotech. Bioeng.* 50:336 (1996)) to grow in serum-free medium, as well as in suspension.

Introduction of the polynucleotide vectors into host cells can be effected by methods described in standard laboratory manuals (*see, e.g.*, Sambrook, J. *et al.*, eds., *MOLECULAR CLONING, A LABORATORY MANUAL*, 2nd. edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989), Chapter 9; Ausubel, F. *et al.*, eds., *CURRENT PROTOCOLS IN MOLECULAR BIOLOGY*, John H. Wiley & Sons, Inc. (1997), Chapter 16), including methods such as electroporation, DEAE-dextran mediated transfection, transfection, microinjection, cationic lipid-mediated transfection, transduction, scrape loading, ballistic introduction, and infection. Methods for the introduction of exogenous DNA sequences into host cells are discussed in Felgner, P. *et al.*, U.S. Patent No. 5,580,859.

Packaged RNA sequences can also be used to infect host cells. These packaged RNA sequences can be introduced to host cells by adding them to the culture medium. For example, the preparation of non-infective alphaviral particles is described in a number of sources, including "Sindbis Expression System", Version C (*Invitrogen* Catalog No. K750-1).

When mammalian cells are used as recombinant host cells for the production of viral-based core particles, these cells will generally be grown in tissue culture. Methods for growing cells in culture are well known in the art (*see, e.g.*, Celis, J., ed., *CELL BIOLOGY*, Academic Press, 2nd edition, (1998); Sambrook, J. *et al.*, eds., *MOLECULAR CLONING, A LABORATORY MANUAL*, 2nd. edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989); Ausubel, F. *et al.*, eds., *CURRENT PROTOCOLS IN MOLECULAR BIOLOGY*, John H. Wiley & Sons, Inc. (1997); Freshney, R., *CULTURE OF ANIMAL CELLS*, Alan R. Liss, Inc. (1983)).

As will be understood by those in the art, the first attachment site may be or be a part of any suitable protein, polypeptide, sugar, polynucleotide, peptide (amino acid), natural or synthetic polymer, a secondary metabolite or combination thereof

-30-

that may serve to specifically attach the antigen or antigenic determinant of choice to the non-natural molecular scaffold. In one embodiment, the attachment site is a protein or peptide that may be selected from those known in the art. For example, the first attachment site may be selected from the following group: a ligand, a receptor, a lectin, avidin, streptavidin, biotin, an epitope such as an HA or T7 tag, Myc, Max, immunoglobulin domains and any other amino acid sequence known in the art that would be useful as a first attachment site.

It should be further understood by those in the art that with another embodiment of the invention, the first attachment site may be created secondarily to the organizer (*i.e.*, protein or polypeptide) utilized in constructing the in-frame fusion to the capsid protein. For example, a protein may be utilized for fusion to the envelope protein with an amino acid sequence known to be glycosylated in a specific fashion, and the sugar moiety added as a result may then serve as the first attachment site of the viral scaffold by way of binding to a lectin serving as the secondary attachment site of an antigen. Alternatively, the organizer sequence may be biotinylated *in vivo* and the biotin moiety may serve as the first attachment site of the invention, or the organizer sequence may be subjected to chemical modification of distinct amino acid residues *in vitro*, the modification serving as the first attachment site.

In another embodiment of the invention, the first attachment site is selected to be the *JUN-FOS* leucine zipper protein domain that is fused in frame to the Hepatitis B capsid (core) protein (HBcAg). However, it will be clear to all individuals in the art that other viral capsid proteins may be utilized in the fusion protein construct for locating the first attachment site in the non-natural molecular scaffold of the invention.

In another embodiment of the invention, the first attachment site is selected to be a lysine or cysteine residue that is fused in frame to the HBcAg. However, it will be clear to all individuals in the art that other viral capsid or virus-like particles may be utilized in the fusion protein construct for locating the first attachment in the non-natural molecular scaffold of the invention.

The *JUN* amino acid sequence utilized for the first attachment site is the following:

CGGRIARLEEKVKTLKAQNSELASTANMLREQVAQLKQKVMNHVGC
(SEQ ID NO:59)

In this instance, the anticipated second attachment site on the antigen would be the *FOS* leucine zipper protein domain and the amino acid sequence would be the following:

CGGLTDTLQAETDQVEDEKSALQTEIANLLKEKEKLEFILAAHGGC
(SEQ ID NO:60)

These sequences are derived from the transcription factors *JUN* and *FOS*, each flanked with a short sequence containing a cysteine residue on both sides. These sequences are known to interact with each other. The original hypothetical structure proposed for the *JUN-FOS* dimer assumed that the hydrophobic side chains of one monomer interdigitate with the respective side chains of the other monomer in a zipper-like manner (Landschulz *et al.*, *Science* 240:1759-1764 (1988)). However, this hypothesis proved to be wrong, and these proteins are known to form an α -helical coiled coil (O'Shea *et al.*, *Science* 243:538-542 (1989); O'Shea *et al.*, *Cell* 68:699-708 (1992); Cohen & Parry, *Trends Biochem. Sci.* 11:245-248 (1986)). Thus, the term "leucine zipper" is frequently used to refer to these protein domains for more historical than structural reasons. Throughout this patent, the term "leucine zipper" is used to refer to the sequences depicted above or sequences essentially similar to the ones depicted above. The terms *JUN* and *FOS* are used for the respective leucine zipper domains rather than the entire *JUN* and *FOS* proteins.

As previously stated, the invention includes viral-based core particles which comprise, or alternatively consist of, a virus, virus-like particle, a phage, a viral capsid particle or a recombinant form thereof. Skilled artisans have the knowledge to produce such core particles and attach organizers thereto. The production of Hepatitis B virus-like particles and measles viral capsid particles as core particles is disclosed in Examples 17 to 22 of WO 00/32227, which is explicitly incorporated by reference. In such embodiments, the *JUN* leucine zipper protein domain or *FOS* leucine zipper protein domain may be used as an organizer, and hence as a first attachment site, for the non-natural molecular scaffold of the invention.

Examples 23-29 provide details of the production of Hepatitis B core particles carrying an in-frame fused peptide with a reactive lysine residue and antigens carrying a genetically fused cysteine residue, as first and second attachment site, respectively.

1. In other embodiments, the core particles used in compositions of the invention are composed of a Hepatitis B capsid (core) protein (HBcAg), a fragment of a HBcAg, or other protein or peptide which can form ordered arrays, which have been modified to either eliminate or reduce the number of free cysteine residues. Zhou *et al.* (*J. Virol.* 66:5393-5398 (1992)) demonstrated that HBcAgs which have been modified to remove the naturally resident cysteine residues retain the ability to associate and form multimeric structures. Thus, core particles suitable for use in compositions of the invention include those comprising modified HBcAgs, or

-32-

fragments thereof, in which one or more of the naturally resident cysteine residues have been either deleted or substituted with another amino acid residue (*e.g.*, a serine residue).

2 The HBcAg is a protein generated by the processing of a Hepatitis B core antigen precursor protein. A number of isotypes of the HBcAg have been identified. For example, the HBcAg protein having the amino acid sequence shown in SEQ ID NO:132 is 183 amino acids in length and is generated by the processing of a 212 amino acid Hepatitis B core antigen precursor protein. This processing results in the removal of 29 amino acids from the N-terminus of the Hepatitis B core antigen precursor protein. Similarly, the HBcAg protein having the amino acid sequence shown in SEQ ID NO:134 is 185 amino acids in length and is generated by the processing of a 214 amino acid Hepatitis B core antigen precursor protein. The amino acid sequence shown in SEQ ID NO:134, as compared to the amino acid sequence shown in SEQ ID NO:132, contains a two amino acid insert at positions 152 and 153 in SEQ ID NO:134.

In most instances, vaccine compositions of the invention will be prepared using the processed form of a HBcAg (*i.e.*, a HBcAg from which the N-terminal leader sequence (*e.g.*, the first 29 amino acid residues shown in SEQ ID NO:134) of the Hepatitis B core antigen precursor protein have been removed).

Further, when HBcAgS are produced under conditions where processing will not occur, the HBcAgS will generally be expressed in "processed" form. For example, bacterial systems, such as *E. coli*, generally do not remove the leader sequences, also referred to as "signal peptides," of proteins which are normally expressed in eukaryotic cells. Thus, when an *E. coli* expression system is used to produce HBcAgS of the invention, these proteins will generally be expressed such that the N-terminal leader sequence of the Hepatitis B core antigen precursor protein is not present.

In one embodiment of the invention, a modified HBcAg comprising the amino acid sequence shown in SEQ ID NO:134, or subportion thereof, is used to prepare non-natural molecular scaffolds. In particular, modified HBcAgS suitable for use in the practice of the invention include proteins in which one or more of the cysteine residues at positions corresponding to positions 48, 61, 107 and 185 of a protein having the amino acid sequence shown in SEQ ID NO:134 have been either deleted or substituted with other amino acid residues (*e.g.*, a serine residue). As one skilled in the art would recognize, cysteine residues at similar locations in HBcAg variants having amino acids sequences which differ from that shown in SEQ ID NO:134 could also be deleted or substituted with

-33-

other amino acid residues. The modified HBcAg variants can then be used to prepare vaccine compositions of the invention.

The present invention also includes HBcAg variants which have been modified to delete or substitute one or more additional cysteine residues which are not found in polypeptides having the amino acid sequence shown in SEQ ID NO:134. Examples of such HBcAg variants have the amino acid sequences shown in SEQ ID NOs:90 and 132. These variant contain cysteines residues at a position corresponding to amino acid residue 147 in SEQ ID NO:134. Thus, the vaccine compositions of the invention include compositions comprising HBcAg in which cysteine residues not present in the amino acid sequence shown in SEQ ID NO:134 have been deleted.

Under certain circumstances (*e.g.*, when a heterobifunctional cross-linking reagent is used to attach antigens or antigenic determinants to the non-natural molecular scaffold), the presence of free cysteine residues in the HBcAg is believed to lead to covalent coupling of toxic components to core particles, as well as the cross-linking of monomers to form undefined species.

Further, in many instances, these toxic components may not be detectable with assays performed on compositions of the invention. This is so because covalent coupling of toxic components to the non-natural molecular scaffold would result in the formation of a population of diverse species in which toxic components are linked to different cysteine residues, or in some cases no cysteine residues, of the HBcAg. In other words, each free cysteine residue of each HBcAg will not be covalently linked to toxic components. Further, in many instances, none of the cysteine residues of particular HBcAg will be linked to toxic components. Thus, the presence of these toxic components may be difficult to detect because they would be present in a mixed population of molecules. The administration to an individual of HBcAg species containing toxic components, however, could lead to a potentially serious adverse reaction.

It is well known in the art that free cysteine residues can be involved in a number of chemical side reactions. These side reactions include disulfide exchanges, reaction with chemical substances or metabolites that are, for example, injected or formed in a combination therapy with other substances, or direct oxidation and reaction with nucleotides upon exposure to UV light. Toxic adducts could thus be generated, especially considering the fact that HBcAg have a strong tendency to bind nucleic acids. Detection of such toxic products in antigen-capsid conjugates would be difficult using capsids prepared using HBcAg containing free cysteines and heterobifunctional cross-linkers, since a distribution of products with a broad range of molecular weight would be

-34-

generated. The toxic adducts would thus be distributed between a multiplicity of species, which individually may each be present at low concentration, but reach toxic levels when together.

In view of the above, one advantage to the use of HBcAgs in vaccine compositions which have been modified to remove naturally resident cysteine residues is that sites to which toxic species can bind when antigens or antigenic determinants are attached to the non-natural molecular scaffold would be reduced in number or eliminated altogether. Further, a high concentration of cross-linker can be used to produce highly decorated particles without the drawback of generating a plurality of undefined cross-linked species of HBcAg monomers (*i.e.*, a diverse mixture of cross-linked monomeric HBcAgs).

A number of naturally occurring HBcAg variants suitable for use in the practice of the present invention have been identified. Yuan *et al.*, (*J. Virol.* 73:10122-10128 (1999)), for example, describe variants in which the isoleucine residue at position corresponding to position 97 in SEQ ID NO:134 is replaced with either a leucine residue or a phenylalanine residue. The amino acid sequences of a number of HBcAg variants, as well as several Hepatitis B core antigen precursor variants, are disclosed in GenBank reports AAF121240 (SEQ ID NO:89), AF121239 (SEQ ID NO:90), X85297 (SEQ ID NO:91), X02496 (SEQ ID NO:92), X85305 (SEQ ID NO:93), X85303 (SEQ ID NO:94), AF151735 (SEQ ID NO:95), X85259 (SEQ ID NO:96), X85286 (SEQ ID NO:97), X85260 (SEQ ID NO:98), X85317 (SEQ ID NO:99), X85298 (SEQ ID NO:100), AF043593 (SEQ ID NO:101), M20706 (SEQ ID NO:102), X85295 (SEQ ID NO:103), X80925 (SEQ ID NO:104), X85284 (SEQ ID NO:105), X85275 (SEQ ID NO:106), X72702 (SEQ ID NO:107), X85291 (SEQ ID NO:108), X65258 (SEQ ID NO:109), X85302 (SEQ ID NO:110), M32138 (SEQ ID NO:111), X85293 (SEQ ID NO:112), X85315 (SEQ ID NO:113), U95551 (SEQ ID NO:114), X85256 (SEQ ID NO:115), X85316 (SEQ ID NO:116), X85296 (SEQ ID NO:117), AB033559 (SEQ ID NO:118), X59795 (SEQ ID NO:119), X85299 (SEQ ID NO:120), X85307 (SEQ ID NO:121), X65257 (SEQ ID NO:122), X85311 (SEQ ID NO:123), X85301 (SEQ ID NO:124), X85314 (SEQ ID NO:125), X85287 (SEQ ID NO:126), X85272 (SEQ ID NO:127), X85319 (SEQ ID NO:128), AB010289 (SEQ ID NO:129), X85285 (SEQ ID NO:130), AB010289 (SEQ ID NO:131), AF121242 (SEQ ID NO:132), M90520 (SEQ ID NO:135), P03153 (SEQ ID NO:136), AF110999 (SEQ ID NO:137), and M95589 (SEQ ID NO:138), the disclosures of each of which are incorporated herein by reference. These HBcAg variants differ in amino acid sequence at a number of positions, including amino acid residues which corresponds to the

-35-

amino acid residues located at positions 12, 13, 21, 22, 24, 29, 32, 33, 35, 38, 40, 42, 44, 45, 49, 51, 57, 58, 59, 64, 66, 67, 69, 74, 77, 80, 81, 87, 92, 93, 97, 98, 100, 103, 105, 106, 109, 113, 116, 121, 126, 130, 133, 135, 141, 147, 149, 157, 176, 178, 182 and 183 in SEQ ID NO:134.

HBcAgs suitable for use in the present invention may be derived from any organism so long as they are able to associate to form an ordered and repetitive antigen array.

As noted above, generally processed HBcAgs (*i.e.*, those which lack leader sequences) will be used in the vaccine compositions of the invention. Thus, when HBcAgs having amino acid sequence shown in SEQ ID NOs:136, 137, or 138 are used to prepare vaccine compositions of the invention, generally 30, 35-43, or 35-43 amino acid residues at the N-terminus, respectively, of each of these proteins will be omitted.

The present invention includes vaccine compositions, as well as methods for using these compositions, which employ the above described variant HBcAgs for the preparation of non-natural molecular scaffolds.

Further included within the scope of the invention are additional HBcAg variants which are capable of associating to form dimeric or multimeric structures. Thus, the invention further includes vaccine compositions comprising HBcAg polypeptides comprising, or alternatively consisting of, amino acid sequences which are at least 80%, 85%, 90%, 95%, 97%, or 99% identical to any of the amino acid sequences shown in SEQ ID NOs:89-132 and 134-138, and forms of these proteins which have been processed, where appropriate, to remove the N-terminal leader sequence.

Whether the amino acid sequence of a polypeptide has an amino acid sequence that is at least 80%, 85%, 90%, 95%, 97%, or 99% identical to one of the amino acid sequences shown in SEQ ID NOs:89-132 and 134-138, or a subportion thereof, can be determined conventionally using known computer programs such as the Bestfit program. When using Bestfit or any other sequence alignment program to determine whether a particular sequence is, for instance, 95% identical to a reference amino acid sequence according to the present invention, the parameters are set such that the percentage of identity is calculated over the full length of the reference amino acid sequence and that gaps in homology of up to 5% of the total number of amino acid residues in the reference sequence are allowed.

The HBcAg variants and precursors having the amino acid sequences set out in SEQ ID NOs:89-132 and 134-136 are relatively similar to each other. Thus, reference to an amino acid residue of a HBcAg variant located at a position

-36-

which corresponds to a particular position in SEQ ID NO:134, refers to the amino acid residue which is present at that position in the amino acid sequence shown in SEQ ID NO:134. The homology between these HBcAg variants is for the most part high enough among Hepatitis B viruses that infect mammals so that one skilled in the art would have little difficulty reviewing both the amino acid sequence shown in SEQ ID NO:134 and that of a particular HBcAg variant and identifying "corresponding" amino acid residues. For example, the HBcAg amino acid sequence shown in SEQ ID NO:135, which shows the amino acid sequence of a HBcAg derived from a virus which infect woodchucks, has enough homology to the HBcAg having the amino acid sequence shown in SEQ ID NO:134 that it is readily apparent that a three amino acid residue insert is present in SEQ ID NO:135 between amino acid residues 155 and 156 of SEQ ID NO:134.

The HBcAgs of Hepatitis B viruses which infect snow geese and ducks differ enough from the amino acid sequences of HBcAgs of Hepatitis B viruses which infect mammals that alignment of these forms of this protein with the amino acid sequence shown in SEQ ID NO:134 is difficult. However, the invention includes vaccine compositions which comprise HBcAg variants of Hepatitis B viruses which infect birds, as well as vaccine compositions which comprise fragments of these HBcAg variants. HBcAg fragments suitable for use in preparing vaccine compositions of the invention include compositions which contain polypeptide fragments comprising, or alternatively consisting of, amino acid residues selected from the group consisting of 36-240, 36-269, 44-240, 44-269, 36-305, and 44-305 of SEQ ID NO:137 or 36-240, 36-269, 44-240, 44-269, 36-305, and 44-305 of SEQ ID NO:138. As one skilled in the art would recognize, one, two, three or more of the cysteine residues naturally present in these polypeptides (*e.g.*, the cysteine residues at position 153 in SEQ ID NO:137 or positions 34, 43, and 196 in SEQ ID NO:138) could be either substituted with another amino acid residue or deleted prior to their inclusion in vaccine compositions of the invention.

In one embodiment, the cysteine residues at positions 48 and 107 of a protein having the amino acid sequence shown in SEQ ID NO:134 are deleted or substituted with another amino acid residue but the cysteine at position 61 is left in place. Further, the modified polypeptide is then used to prepare vaccine compositions of the invention.

As set out below in Example 31, the cysteine residues at positions 48 and 107, which are accessible to solvent, may be removed, for example, by site-directed mutagenesis. Further, the inventors have found that the Cys-48-Ser,

-37-

Cys-107-Ser HBcAg double mutant constructed as described in Example 31 can be expressed in *E. coli*.

As discussed above, the elimination of free cysteine residues reduces the number of sites where toxic components can bind to the HBcAg, and also eliminates sites where cross-linking of lysine and cysteine residues of the same or of neighboring HBcAg molecules can occur. The cysteine at position 61, which is involved in dimer formation and forms a disulfide bridge with the cysteine at position 61 of another HBcAg, will normally be left intact for stabilization of HBcAg dimers and multimers of the invention.

As shown in Example 32, cross-linking experiments performed with (1) HBcAgs containing free cysteine residues and (2) HBcAgs whose free cysteine residues have been made unreactive with iodacetamide, indicate that free cysteine residues of the HBcAg are responsible for cross-linking between HBcAgs through reactions between heterobifunctional cross-linker derivatized lysine side chains, and free cysteine residues. Example 32 also indicates that cross-linking of HBcAg subunits leads to the formation of high molecular weight species of undefined size which cannot be resolved by SDS-polyacrylamide gel electrophoresis.

When an antigen or antigenic determinant is linked to the non-natural molecular scaffold through a lysine residue, it may be advantageous to either substitute or delete one or both of the naturally resident lysine residues located at positions corresponding to positions 7 and 96 in SEQ ID NO:134, as well as other lysine residues present in HBcAg variants. The elimination of these lysine residues results in the removal of binding sites for antigens or antigenic determinants which could disrupt the ordered array and should improve the quality and uniformity of the final vaccine composition.

In many instances, when both of the naturally resident lysine residues at positions corresponding to positions 7 and 96 in SEQ ID NO:134 are eliminated, another lysine will be introduced into the HBcAg as an attachment site for an antigen or antigenic determinant. Methods for inserting such a lysine residue are set out, for example, in Example 23 below. It will often be advantageous to introduce a lysine residue into the HBcAg when, for example, both of the naturally resident lysine residues at positions corresponding to positions 7 and 96 in SEQ ID NO:134 are altered and one seeks to attach the antigen or antigenic determinant to the non-natural molecular scaffold using a heterobifunctional cross-linking agent.

The C-terminus of the HBcAg has been shown to direct nuclear localization of this protein. (Eckhardt *et al.*, *J. Virol.* 65:575-582 (1991).)

-38-

Further, this region of the protein is also believed to confer upon the HBcAg the ability to bind nucleic acids.

In some embodiments, vaccine compositions of the invention will contain HBcAgs which have nucleic acid binding activity (*e.g.*, which contain a naturally resident HBcAg nucleic acid binding domain). HBcAgs containing one or more nucleic acid binding domains are useful for preparing vaccine compositions which exhibit enhanced T-cell stimulatory activity. Thus, the vaccine compositions of the invention include compositions which contain HBcAgs having nucleic acid binding activity. Further included are vaccine compositions, as well as the use of such compositions in vaccination protocols, where HBcAgs are bound to nucleic acids. These HBcAgs may bind to the nucleic acids prior to administration to an individual or may bind the nucleic acids after administration.

In other embodiments, vaccine compositions of the invention will contain HBcAgs from which the C-terminal region (*e.g.*, amino acid residues 145-185 or 150-185 of SEQ ID NO:134) has been removed and do not bind nucleic acids. Thus, additional modified HBcAgs suitable for use in the practice of the present invention include C-terminal truncation mutants. Suitable truncation mutants include HBcAgs where 1, 5, 10, 15, 20, 25, 30, 34, 35, 36, 37, 38, 39, 40, 41, 42 or 48 amino acids have been removed from the C-terminus.

HBcAgs suitable for use in the practice of the present invention also include N-terminal truncation mutants. Suitable truncation mutants include modified HBcAgs where 1, 2, 5, 7, 9, 10, 12, 14, 15, or 17 amino acids have been removed from the N-terminus.

Further HBcAgs suitable for use in the practice of the present invention include N- and C-terminal truncation mutants. Suitable truncation mutants include HBcAgs where 1, 2, 5, 7, 9, 10, 12, 14, 15, and 17 amino acids have been removed from the N-terminus and 1, 5, 10, 15, 20, 25, 30, 34, 35, 36, 37, 38, 39, 40, 41, 42 or 48 amino acids have been removed from the C-terminus.

The invention further includes vaccine compositions comprising HBcAg polypeptides comprising, or alternatively consisting of, amino acid sequences which are at least 80%, 85%, 90%, 95%, 97%, or 99% identical to the above described truncation mutants.

As discussed above, in certain embodiments of the invention, a lysine residue is introduced as a first attachment site into a polypeptide which forms the non-natural molecular scaffold. In preferred embodiments, vaccine compositions of the invention are prepared using a HBcAg comprising, or alternatively consisting of, amino acids 1-144 or amino acids 1-149 of SEQ ID NO:134 which

-39-

is modified so that the amino acids corresponding to positions 79 and 80 are replaced with a peptide having the amino acid sequence of Gly-Gly-Lys-Gly-Gly (SEQ ID NO:158) and the cysteine residues at positions 48 and 107 are either deleted or substituted with another amino acid residue, while the cysteine at position 61 is left in place. The invention further includes vaccine compositions comprising corresponding fragments of polypeptides having amino acid sequences shown in any of SEQ ID NOs:89-132 and 135-136 which also have the above noted amino acid alterations.

The invention further includes vaccine compositions comprising fragments of a HBcAg comprising, or alternatively consisting of, an amino acid sequence other than that shown in SEQ ID NO:134 from which a cysteine residue not present at corresponding location in SEQ ID NO:134 has been deleted. One example of such a fragment would be a polypeptide comprising, or alternatively consisting of, amino acids 1-149 of SEQ ID NO:132 where the cysteine residue at position 147 has been either substituted with another amino acid residue or deleted.

The invention further includes vaccine compositions comprising HBcAg polypeptides comprising, or alternatively consisting of, amino acid sequences which are at least 80%, 85%, 90%, 95%, 97%, or 99% identical to amino acids 1-144 or 1-149 of SEQ ID NO:134 and corresponding subportions of a polypeptide comprising an amino acid sequence shown in any of SEQ ID NOs:89-132 or 134-136, as well as to amino acids 1-147 or 1-152 of SEQ ID NO:158.

The invention also includes vaccine compositions comprising HBcAg polypeptides comprising, or alternatively consisting of, amino acid sequences which are at least 80%, 85%, 90%, 95%, 97%, or 99% identical to amino acids 36-240, 36-269, 44-240, 44-269, 36-305, and 44-305 of SEQ ID NO:137 or 36-240, 36-269, 44-240, 44-269, 36-305, and 44-305 of SEQ ID NO:138.

Vaccine compositions of the invention may comprise mixtures of different HBcAgs. Thus, these vaccine compositions may be composed of HBcAgs which differ in amino acid sequence. For example, vaccine compositions could be prepared comprising a "wild-type" HBcAg and a modified HBcAg in which one or more amino acid residues have been altered (*e.g.*, deleted, inserted or substituted). In most applications, however, only one type of a HBcAg, or at least HBcAgs having essentially equivalent first attachment sites, will be used because vaccines prepared using such HBcAgs will present highly ordered and repetitive arrays of antigens or antigenic determinants. Further,

-40-

preferred vaccine compositions of the invention are those which present highly ordered and repetitive antigen array

The invention further includes vaccine compositions where the non-natural molecular scaffold is prepared using a HBcAg fused to another protein. As discussed above, one example of such a fusion protein is a HBcAg/*FOS* fusion. Other examples of HBcAg fusion proteins suitable for use in vaccine compositions of the invention include fusion proteins where an amino acid sequence has been added which aids in the formation and/or stabilization of HBcAg dimers and multimers. This additional amino acid sequence may be fused to either the N- or C-terminus of the HBcAg. One example, of such a fusion protein is a fusion of a HBcAg with the GCN4 helix region of *Saccharomyces cerevisiae* (GenBank Accession No. P03069 (SEQ ID NO:154)).

The helix domain of the GCN4 protein forms homodimers via non-covalent interactions which can be used to prepare and stabilize HBcAg dimers and multimers.

In one embodiment, the invention provides vaccine compositions prepared using HBcAg fusion proteins comprising a HBcAg, or fragment thereof, with a GCN4 polypeptide having the sequence of amino acid residues 227 to 276 in SEQ ID NO:154 fused to the C-terminus. This GCN4 polypeptide may also be fused to the N-terminus of the HBcAg.

HBcAg/*src* homology 3 (SH3) domain fusion proteins could also be used to prepare vaccine compositions of the invention. SH3 domains are relatively small domains found in a number of proteins which confer the ability to interact with specific proline-rich sequences in protein binding partners (see McPherson, *Cell Signal* 11:229-238 (1999)). HBcAg/SH3 fusion proteins could be used in several ways. First, the SH3 domain could form a first attachment site which interacts with a second attachment site of the antigen or antigenic determinant. Similarly, a proline rich amino acid sequence could be added to the HBcAg and used as a first attachment site for an SH3 domain second-attachment site of an antigen or antigenic determinant. Second, the SH3 domain could associate with proline rich regions introduced into HBcAg. Thus, SH3 domains and proline rich SH3 interaction sites could be inserted into either the same or different HBcAg and used to form and stabilize dimers and multimers of the invention.

In other embodiments, a bacterial pilin, a subportion of a bacterial pilin, or a fusion protein which contains either a bacterial pilin or subportion thereof is used to prepare vaccine compositions of the invention. Examples of pilin proteins include pilins produced by *Escherichia coli*, *Haemophilus*

influenzae, *Neisseria meningitidis*, *Neisseria gonorrhoeae*, *Caulobacter crescentus*, *Pseudomonas stutzeri*, and *Pseudomonas aeruginosa*. The amino acid sequences of pilin proteins suitable for use with the present invention include those set out in GenBank reports AJ000636 (SEQ ID NO:139), AJ132364 (SEQ ID NO:140), AF229646 (SEQ ID NO:141), AF051814 (SEQ ID NO:142), AF051815 (SEQ ID NO:143), and X00981 (SEQ ID NO:155), the entire disclosures of which are incorporated herein by reference.

Bacterial pilin proteins are generally processed to remove N-terminal leader sequences prior to export of the proteins into the bacterial periplasm. Further, as one skilled in the art would recognize, bacterial pilin proteins used to prepare vaccine compositions of the invention will generally not have the naturally present leader sequence.

One specific example of a pilin protein suitable for use in the present invention is the P-pilin of *E. coli* (GenBank report AF237482 (SEQ ID NO:144)). An example of a Type-1 *E. coli* pilin suitable for use with the invention is a pilin having the amino acid sequence set out in GenBank report P04128 (SEQ ID NO:146), which is encoded by nucleic acid having the nucleotide sequence set out in GenBank report M27603 (SEQ ID NO:145). The entire disclosures of these GenBank reports are incorporated herein by reference. Again, the mature form of the above referenced protein would generally be used to prepare vaccine compositions of the invention.

Bacterial pilins or pilin subportions suitable for use in the practice of the present invention will generally be able to associate to form non-natural molecular scaffolds.

Methods for preparing pili and pilus-like structures *in vitro* are known in the art. Bullitt *et al.*, *Proc. Natl. Acad. Sci. USA* 93:12890-12895 (1996), for example, describe the *in vitro* reconstitution of *E. coli* P-pili subunits. Further, Eshdat *et al.*, *J. Bacteriol.* 148:308-314 (1981) describe methods suitable for dissociating Type-1 pili of *E. coli* and the reconstitution of pili. In brief, these methods are as follows: pili are dissociated by incubation at 37°C in saturated guanidine hydrochloride. Pilin proteins are then purified by chromatography, after which pilin dimers are formed by dialysis against 5 mM tris(hydroxymethyl) aminomethane hydrochloride (pH 8.0). Eshdat *et al.* also found that pilin dimers reassemble to form pili upon dialysis against the 5 mM tris(hydroxymethyl) aminomethane (pH 8.0) containing 5 mM MgCl₂.

Further, using, for example, conventional genetic engineering and protein modification methods, pilin proteins may be modified to contain a first attachment site to which an antigen or antigenic determinant is linked through a

second attachment site. Alternatively, antigens or antigenic determinants can be directly linked through a second attachment site to amino acid residues which are naturally resident in these proteins. These modified pilin proteins may then be used in vaccine compositions of the invention.

Bacterial pilin proteins used to prepare vaccine compositions of the invention may be modified in a manner similar to that described herein for HBcAg. For example, cysteine and lysine residues may be either deleted or substituted with other amino acid residues and first attachment sites may be added to these proteins. Further, pilin proteins may either be expressed in modified form or may be chemically modified after expression. Similarly, intact pili may be harvested from bacteria and then modified chemically.

In another embodiment, pili or pilus-like structures are harvested from bacteria (e.g., *E. coli*) and used to form vaccine compositions of the invention. One example of pili suitable for preparing vaccine compositions is the Type-1 pilus of *E. coli*, which is formed from pilin monomers having the amino acid sequence set out in SEQ ID NO:146.

A number of methods for harvesting bacterial pili are known in the art. Bullitt and Makowski (*Biophys. J.* 74:623-632 (1998)), for example, describe a pilus purification method for harvesting P-pili from *E. coli*. According to this method, pili are sheared from hyperpilated *E. coli* containing a P-pilus plasmid and purified by cycles of solubilization and $MgCl_2$ (1.0 M) precipitation. A similar purification method is set out below in Example 33.

Once harvested, pili or pilus-like structures may be modified in a variety of ways. For example, a first attachment site can be added to the pili to which antigens or antigen determinants may be attached through a second attachment site. In other words, bacterial pili or pilus-like structures can be harvested and modified to form non-natural molecular scaffolds.

Pili or pilus-like structures may also be modified by the attachment of antigens or antigenic determinants in the absence of a non-natural organizer. For example, antigens or antigenic determinants could be linked to naturally occurring cysteine residues or lysine residues. In such instances, the high order and repetitiveness of a naturally occurring amino acid residue would guide the coupling of the antigens or antigenic determinants to the pili or pilus-like structures. For example, the pili or pilus-like structures could be linked to the second attachment sites of the antigens or antigenic determinants using a heterobifunctional cross-linking agent.

When structures which are naturally synthesized by organisms (e.g., pili) are used to prepare vaccine compositions of the invention, it will often be

advantageous to genetically engineer these organisms so that they produce structures having desirable characteristics. For example, when Type-1 pili of *E. coli* are used, the *E. coli* from which these pili are harvested may be modified so as to produce structures with specific characteristics. Examples of possible modifications of pilin proteins include the insertion of one or more lysine residues, the deletion or substitution of one or more of the naturally resident lysine residues, and the deletion or substitution of one or more naturally resident cysteine residues (*e.g.*, the cysteine residues at positions 44 and 84 in SEQ ID NO:146).

Further, additional modifications can be made to pilin genes which result in the expression products containing a first attachment site other than a lysine residue (*e.g.*, a *FOS* or *JUN* domain). Of course, suitable first attachment sites will generally be limited to those which do not prevent pilin proteins from forming pili or pilus-like structures suitable for use in vaccine compositions of the invention.

Pilin genes which naturally reside in bacterial cells can be modified *in vivo* (*e.g.*, by homologous recombination) or pilin genes with particular characteristics can be inserted into these cells. For examples, pilin genes could be introduced into bacterial cells as a component of either a replicable cloning vector or a vector which inserts into the bacterial chromosome. The inserted pilin genes may also be linked to expression regulatory control sequences (*e.g.*, a *lac* operator).

In most instances, the pili or pilus-like structures used in vaccine compositions of the invention will be composed of single type of a pilin subunit. Pili or pilus-like structures composed of identical subunits will generally be used because they are expected to form structures which present highly ordered and repetitive antigen arrays.

However, the compositions of the invention also include vaccines comprising pili or pilus-like structures formed from heterogenous pilin subunits. The pilin subunits which form these pili or pilus-like structures can be expressed from genes naturally resident in the bacterial cell or may be introduced into the cells. When a naturally resident pilin gene and an introduced gene are both expressed in a cell which forms pili or pilus-like structures, the result will generally be structures formed from a mixture of these pilin proteins. Further, when two or more pilin genes are expressed in a bacterial cell, the relative expression of each pilin gene will typically be the factor which determines the ratio of the different pilin subunits in the pili or pilus-like structures.

When pili or pilus-like structures having a particular composition of mixed pilin subunits is desired, the expression of at least one of the pilin genes can be regulated by a heterologous, inducible promoter. Such promoters, as well as other genetic elements, can be used to regulate the relative amounts of different pilin subunits produced in the bacterial cell and, hence, the composition of the pili or pilus-like structures.

In addition, while in most instances the antigen or antigenic determinant will be linked to bacterial pili or pilus-like structures by a bond which is not a peptide bond, bacterial cells which produce pili or pilus-like structures used in the compositions of the invention can be genetically engineered to generate pilin proteins which are fused to an antigen or antigenic determinant. Such fusion proteins which form pili or pilus-like structures are suitable for use in vaccine compositions of the invention.

As already discussed, viral capsids may be used for (1) the presentation of antigen or antigenic determinants and (2) the preparation of vaccine compositions of the invention. Particularly, useful in the practice of the invention are viral capsid proteins, also referred to herein as "coat proteins," which upon expression form capsids or capsid-like structures. Thus, these capsid proteins can form core particles and non-natural molecular scaffolds. Generally, these capsids or capsid-like structures form ordered and repetitive arrays which can be used for the presentation of antigens or antigenic determinants and the preparation of vaccine compositions of the invention.

One or more (*e.g.*, one, two, three, four, five, etc.) antigens or antigenic determinants may be attached by any number of means to one or more (*e.g.*, one, two, three, four, five, etc.) proteins which form viral capsids or capsid-like structures (*e.g.*, bacteriophage coat proteins), as well as other proteins. For example, antigens or antigenic determinants may be attached to core particles using first and second attachment sites. Further, one or more (*e.g.*, one, two, three, four, five, etc.) heterobifunctional crosslinkers can be used to attach antigens or antigenic determinants to one or more proteins which form viral capsids or capsid-like structures.

Viral capsid proteins, or fragments thereof may be used, for example, to prepare core particles and vaccine compositions of the invention. Bacteriophage Q β coat proteins, for example, can be expressed recombinantly in *E. coli*. Further, upon such expression these proteins spontaneously form capsids. Additionally, these capsids form ordered and repetitive antigen or antigenic determinant arrays which can be used for antigen presentation and the preparation of vaccine compositions. As described below in Example 38, bacteriophage Q β

coat proteins can be used to prepare vaccine compositions which elicit immunological responses to antigenic determinants.

Specific examples of bacteriophage coat proteins which can be used to prepare compositions of the invention include the coat proteins of RNA bacteriophages such as bacteriophage Q β (SEQ ID NO:159; PIR Database, Accession No. VCBPQ β referring to Q β CP and SEQ ID NO: 217; Accession No. AAA16663 referring to Q β A1 protein), bacteriophage R17 (SEQ ID NO:160; PIR Accession No. VCBPR7), bacteriophage fr (SEQ ID NO:161; PIR Accession No. VCBPFR), bacteriophage GA (SEQ ID NO:162; GenBank Accession No. NP-040754), bacteriophage SP (SEQ ID NO:163; GenBank Accession No. CAA30374 referring to SP CP and SEQ ID NO: 254; Accession No. referring to SP A1 protein), bacteriophage MS2 (SEQ ID NO:164; PIR Accession No. VCBPM2), bacteriophage M11 (SEQ ID NO:165; GenBank Accession No. AAC06250), bacteriophage MX1 (SEQ ID NO:166; GenBank Accession No. AAC14699), bacteriophage NL95 (SEQ ID NO:167; GenBank Accession No. AAC14704), bacteriophage f2 (SEQ ID NO: 215; GenBank Accession No. P03611), bacteriophage PP7 (SEQ ID NO: 253). As one skilled in the art would recognize, any protein which forms capsids or capsid-like structures can be used for the preparation of vaccine compositions of the invention. Furthermore, the A1 protein of bacteriophage Q β or C-terminal truncated forms missing as much as 100, 150 or 180 amino acids from its C-terminus may be incorporated in a capsid assembly of Q β coat proteins. The A1 protein may also be fused to an organizer and hence a first attachment site, for attachment of Antigens containing a second attachment site. Generally, the percentage of A1 protein relative to Q β CP in the capsid assembly will be limited, in order to insure capsid formation. A1 protein accession No. AAA16663 (SEQ ID NO: 217).

Q β coat protein has also been found to self-assemble into capsids when expressed in *E. coli* (Kozłowska TM. *et al.*, *GENE* 137: 133-137 (1993)). The obtained capsids or virus-like particles showed an icosahedral phage-like capsid structure with a diameter of 25 nm and T=3 quasi symmetry. Further, the crystal structure of phage Q β has been solved. The capsid contains 180 copies of the coat protein, which are linked in covalent pentamers and hexamers by disulfide bridges (Golmohammadi, R. *et al.*, *Structure* 4: 543-5554 (1996)). Other RNA phage coat proteins have also been shown to self-assemble upon expression in a bacterial host (Kastelein, RA. *et al.*, *Gene* 23: 245-254 (1983), Kozlovskaya, TM. *et al.*, *Dokl. Akad. Nauk SSSR* 287: 452-455 (1986), Adhin, MR. *et al.*, *Virology* 170: 238-242

-46-

(1989), Ni, CZ., *et al.*, *Protein Sci.* 5: 2485-2493 (1996), Priano, C. *et al.*, *J. Mol. Biol.* 249: 283-297 (1995)). The Q β phage capsid contains, in addition to the coat protein, the so called read-through protein A1 and the maturation protein A2. A1 is generated by suppression at the UGA stop codon and has a length of 329 aa. The capsid of phage Q β recombinant coat protein used in the invention is devoid of the A2 lysis protein, and contains RNA from the host. The coat protein of RNA phages is an RNA binding protein, and interacts with the stem loop of the ribosomal binding site of the replicase gene acting as a translational repressor during the life cycle of the virus. The sequence and structural elements of the interaction are known (Witherell, GW. & Uhlenbeck, OC. *Biochemistry* 28: 71-76 (1989); Lim F. *et al.*, *J. Biol. Chem.* 271: 31839-31845 (1996)). The stem loop and RNA in general are known to be involved in the virus assembly (Golmohammadi, R. *et al.*, *Structure* 4: 543-5554 (1996))

Proteins or protein domains may affect the structure and assembly of the particle even more than a short peptide. As an example, proper folding of antigens comprising disulfide bridges will generally not be possible in the cytoplasm of *E. coli*, where the Q β particles are expressed. Likewise, glycosylation is generally not possible in prokaryotic expression systems. It is therefore an advantage of the contemplated invention described here to attach the antigen to the particle by starting with the already assembled particle and the isolated antigen. This allows expression of both the particle and the antigen in an expression host guaranteeing proper folding of the antigen, and proper folding and assembly of the particle.

It is a finding of this invention, that one or several several antigen molecules may be attached to one subunit of the capsid of RNA phages coat proteins. A specific feature of the capsid of the coat protein of RNA phages and in particular of Q β capsid is thus the possibility to couple several antigens per subunit. This allows for the generation of a dense antigen array. Other viral capsids used for covalent attachment of antigens by way of chemical cross-linking, such for example a HBcAg modified with a lysine residue in its major immunodominant region (MIR; WO 00/32227), show coupling density of maximally 0.5 antigens per subunit. The distance between the spikes (corresponding to the MIR) of HBcAg is 50 Å (Wynne, SA. *et al.*, *Mol. Cell* 3: 771-780 (1999)), and therefore an antigen array with distances shorter than 50 Å cannot be generated

-47-

Capsids of Q β coat protein display a defined number of lysine residues on their surface, with a defined topology with three lysine residues pointing towards the interior of the capsid and interacting with the RNA, and four other lysine residues exposed to the exterior of the capsid. These defined properties favor the attachment of antigens to the exterior of the particle, and not to the interior where the lysine residues interact with RNA. Capsids of other RNA phage coat proteins also have a defined number of lysine residues on their surface and a defined topology of these lysine residues. Another advantage of the capsids derived from RNA phages is their high expression yield in bacteria, that allows to produce large quantities of material at affordable cost.

Another feature of the capsid of Q β coat protein is its stability. Q β subunits are bound via disulfide bridges to each other, covalently linking the subunits. Q β capsid protein also shows unusual resistance to organic solvents and denaturing agents. Surprisingly, we have observed that DMSO and acetonitrile concentrations as high as 30%, and Guanidinium concentrations as high as 1 M could be used without affecting the stability or the ability to form antigen arrays of the capsid. Thus, these organic solvents may be used to couple hydrophobic peptides. The high stability of the capsid of Q β coat protein is an important feature pertaining to its use for immunization and vaccination of mammals and humans in particular. The resistance of the capsid to organic solvent allows the coupling of antigens not soluble in aqueous buffers.

Insertion of a cysteine residue into the N-terminal β -hairpin of the coat protein of the RNA phage MS-2 has been described in the patent application US/5,698,424. We note however, that the presence of an exposed free cysteine residue in the capsid may lead to oligomerization of capsids by way of disulfide bridge formation. Other attachments contemplated in patent application US/5,698,424 involve the formation of disulfide bridges between the antigen and the Q β particle. Such attachments are labile to sulfhydryl-moiety containing molecules.

The reaction between an initial disulfide bridge formed with a cys-residue on Q β , and the antigen containing a free sulfhydryl residue releases sulfhydryl containing species other than the antigen. These newly formed sulfhydryl containing species can react again with other disulfide bridges present on the particle, thus establishing an equilibrium. Upon reaction with the disulfide bridge formed on the

-48-

particle, the antigen may either form a disulfide bridge with the cys-residue from the particle, or with the cys-residue of the leaving group molecule which was forming the initial disulfide bridge on the particle. Moreover, the other method of attachment described, using a hetero-bifunctional cross-linker reacting with a cysteine on the Q β particle on one side, and with a lysine residue on the antigen on the other side, leads to a random orientation of the antigens on the particle.

We further note that, in contrast to the capsid of the Q β and Fr coat proteins, recombinant MS-2 described in patent application US/5,698,424 is essentially free of nucleic acids, while RNA is packaged inside the two capsids mentioned above.

We describe new and inventive compositions allowing the formation of robust antigen arrays with variable antigen density. We show that much higher epitope density can be achieved than usually obtained with other VLPs. We also disclose compositions with simultaneous display of several antigens with appropriate spacing, and compositions wherein the addition of accessory molecules, enhancing solubility or modifying the capsid in a suitable and desired way.

The preparation of compositions of capsids of RNA phage coat proteins with a high epitope density is disclosed in this application. As a skilled artisan in the Art would know, the conditions for the assembly of the ordered and repetitive antigen array depend for a good part on the antigen and on the selection of a second attachment site on the antigen. In the case of the absence of a useful second attachment site, such a second attachment has to be engineered to the antigen.

A prerequisite in designing a second attachment site, is the choice of the position at which it should be fused, inserted or generally engineered. A skilled artisan would know how to find guidance in selecting the position of the second attachment site. A crystal structure of the antigen may provide information on the availability of the C- or N-termini of the molecule (determined for example from their accessibility to solvent), or on the exposure to solvent of residues suitable for use as second attachment sites, such as cysteine residues. Exposed disulfide bridges, as is the case for Fab fragments, may also be a source of a second attachment site, since they can be generally converted to single cysteine residues through mild reduction. In general, in the case where immunization with a self-antigen is aiming at inhibiting the interaction of this self-antigen with its natural ligands, the second attachment site will

-49-

be added such that it allows generation of antibodies against the site of interaction with the natural ligands. Thus, the location of the second attachment site will be selected such, that steric hindrance from the second attachment site or any amino acid linker containing it, is avoided. In further embodiments, an antibody response directed at a site distinct from the interaction site of the self-antigen with its natural ligand is desired. In such embodiments, the second attachment site may be selected such that it prevents generation of antibodies against the interaction site of the self-antigen with its natural ligands.

Other criteria in selecting the position of the second attachment site include the oligomerization state of the antigen, the site of oligomerization, the presence of a cofactor, and the availability of experimental evidence disclosing sites in the antigen structure and sequence where modification of the antigen is compatible with the function of the self-antigen, or with the generation of antibodies recognizing the self-antigen.

In some embodiments, engineering of a second attachment site onto the antigen requires the fusion of an amino acid linker containing an amino acid suitable as second attachment site according to the disclosures of this invention. In a preferred embodiment, the amino acid is cysteine. The selection of the amino acid linker will be dependent on the nature of the self-antigen, on its biochemical properties, such as pI, charge distribution, glycosylation. In general, flexible amino acid linkers are favored. Examples of amino acid linkers are the hinge region of Immunoglobulins, glycine serine linkers (GGGGS)_n, and glycine linkers (G)_n all further containing a cysteine residue as second attachment site and optionally further glycine residues. (In the following are examples of said amino acid linkers :

N-terminal gamma1: CGDKTHTSPP

C-terminal gamma 1: DKTHTSPPCG

N-terminal gamma 3: CGGPKPSTPPGSSGGAP

C-terminal gamma 3: PKPSTPPGSSGGAPGGCG

N-terminal glycine linker: GCGGGG

C-terminal glycine linker: GGGGCG)

-50-

For peptides, GGCG linkers at the C-terminus of the peptide, or CGG at its N-terminus have shown to be useful. In general, glycine residues will be inserted between bulky amino acids and the cysteine to be used as second attachment site.

A particularly favored method of attachment of antigens to VLPs, and in particular to capsids of RNA phage coat proteins is the linking of a lysine residue on the surface of the capsid of RNA phage coat proteins with a cysteine residue on the antigen. To be effective as second attachment site, a sulfhydryl group must be available for coupling. Thus, a cysteine residue has to be in its reduced state, that is a free cysteine or a cysteine residue with a free sulfhydryl group has to be available. In the instant where the cysteine residue to function as second attachment site is in an oxidized form, for example if it is forming a disulfide bridge, reduction of this disulfide bridge with *e.g.* DTT, TCEP or β -mercaptoethanol is required.

It is a finding of this application that epitope density on the capsid of RNA phage coat proteins can be modulated by the choice of cross-linker and other reaction conditions. For example, the cross-linkers Sulfo-GMBS and SMPH allow reaching higher epitope density than the cross-linker Sulfo-MBS under the same reaction conditions. Derivatization is positively influenced by high concentration of reactands, and manipulation of the reaction conditions can be used to control the number of antigens coupled to RNA phages capsid proteins, and in particular to Q β capsid protein.

From theoretical calculation, the maximally achievable number of globular protein antigens of a size of 17 kDa does not exceed 0.5. Thus, several of the lysine residues of the capsid of Q β coat protein will be derivatized with a cross-linker molecule, yet be devoid of antigen. This leads to the disappearance of a positive charge, which may be detrimental to the solubility and stability of the conjugate. By replacing some of the lysine residues with arginines, such is the case in the disclosed Q β coat protein mutant, we prevent the excessive disappearance of positive charges since the arginine residues do not react with the cross-linker.

In further embodiments, we disclose a Q β mutant coat protein with additional lysine residues, suitable for obtaining high density arrays of antigens.

The crystal structure of several RNA bacteriophages has been determined (Golmohammadi, R. *et al.*, *Structure* 4:543-554 (1996)). Using such

-51-

information, one skilled in the art could readily identify surface exposed residues and modify bacteriophage coat proteins such that one or more reactive amino acid residues can be inserted. Thus, one skilled in the art could readily generate and identify modified forms of bacteriophage coat proteins which can be used in the practice of the invention. Thus, variants of proteins which form capsids or capsid-like structures (*e.g.*, coat proteins of bacteriophage Q β , bacteriophage R17, bacteriophage fr, bacteriophage GA, bacteriophage SP, and bacteriophage MS2) can also be used to prepare vaccine compositions of the invention.

Although the sequence of the variants proteins discussed above will differ from their wild-type counterparts, these variant proteins will generally retain the ability to form capsids or capsid-like structures. Thus, the invention further includes vaccine compositions which contain variants of proteins which form capsids or capsid-like structures, as well as methods for preparing such vaccine compositions, individual protein subunits used to prepare such vaccine compositions, and nucleic acid molecules which encode these protein subunits. Thus, included within the scope of the invention are variant forms of wild-type proteins which form ordered and repetitive antigen arrays (*e.g.*, variants of proteins which form capsids or capsid-like structures) and retain the ability to associate and form capsids or capsid-like structures.

As a result, the invention further includes vaccine compositions comprising proteins comprising, or alternatively consisting of, amino acid sequences which are at least 80%, 85%, 90%, 95%, 97%, or 99% identical to wild-type proteins which form ordered arrays. In many instances, these proteins will be processed to remove signal peptides (*e.g.*, heterologous signal peptides).

Further included within the scope of the invention are nucleic acid molecules which encode proteins used to prepare vaccine compositions of the invention.

In particular embodiments, the invention further includes vaccine compositions comprising proteins comprising, or alternatively consisting of, amino acid sequences which are at least 80%, 85%, 90%, 95%, 97%, or 99% identical to any of the amino acid sequences shown in SEQ ID NOs:159-167, and forms of these proteins which have been processed, where appropriate, to remove the N-terminal leader sequence.

Proteins suitable for use in the practice of the present invention also include C-terminal truncation mutants of proteins which form capsids or capsid-like structures, as well as other ordered arrays. Specific examples of such truncation mutants include proteins having an amino acid sequence shown in any of SEQ ID NOs:159-167 where 1, 2, 5, 7, 9, 10, 12, 14, 15, or 17 amino acids

-52-

have been removed from the C-terminus. Normally, C-terminal truncation mutants used in the practice of the invention will retain the ability to form capsids or capsid-like structures.

Further proteins suitable for use in the practice of the present invention also include N-terminal truncation mutants of proteins which form capsids or capsid-like structures. Specific examples of such truncation mutants include proteins having an amino acid sequence shown in any of SEQ ID NOs:159-167 where 1, 2, 5, 7, 9, 10, 12, 14, 15, or 17 amino acids have been removed from the N-terminus. Normally, N-terminal truncation mutants used in the practice of the invention will retain the ability to form capsids or capsid-like structures.

Additional proteins suitable for use in the practice of the present invention include – and C-terminal truncation mutants which form capsids or capsid-like structures. Suitable truncation mutants include proteins having an amino acid sequence shown in any of SEQ ID NOs:159-167 where 1, 2, 5, 7, 9, 10, 12, 14, 15, or 17 amino acids have been removed from the N-terminus and 1, 2, 5, 7, 9, 10, 12, 14, 15, or 17 amino acids have been removed from the C-terminus. Normally, N-terminal and C-terminal truncation mutants used in the practice of the invention will retain the ability to form capsids or capsid-like structures.

The invention further includes vaccine compositions comprising proteins comprising, or alternatively consisting of, amino acid sequences which are at least 80%, 85%, 90%, 95%, 97%, or 99% identical to the above described truncation mutants.

The invention thus includes vaccine compositions prepared from proteins which form ordered arrays, methods for preparing vaccine compositions from individual protein subunits, methods for preparing these individual protein subunits, nucleic acid molecules which encode these subunits, and methods for vaccinating and/or eliciting immunological responses in individuals using vaccine compositions of the invention.

B. Construction of an Antigen or Antigenic Determinant with a Second Attachment Site

The second element in the compositions of the invention is an antigen or antigenic determinant possessing at least one second attachment site capable of association through at least one non-peptide bond to the first attachment site of the non-natural molecular scaffold. The invention provides for compositions that vary according to the antigen or antigenic determinant selected in consideration of the desired therapeutic effect. Other compositions are provided by varying the molecule selected for the second attachment site.

However, when bacterial pili, or pilus-like structures, pilin proteins are used to prepare vaccine compositions of the invention, antigens or antigenic determinants may be attached to pilin proteins by the expression of pilin/antigen fusion proteins. Similarly, when proteins other than pilin proteins (*e.g.*, viral capsid proteins) are used to prepare vaccine compositions of the invention, antigens or antigenic determinants may be attached to these non-pilin proteins by the expression of non-pilin protein/antigen fusion proteins. Antigens or antigenic determinants may also be attached to bacterial pili, pilus-like structures, pilin proteins, and other proteins which form ordered arrays through non-peptide bonds.

Antigens of the invention may be selected from the group consisting of the following: (a) proteins suited to induce an immune response against cancer cells; (b) proteins suited to induce an immune response against infectious diseases; (c) proteins suited to induce an immune response against allergens, (d) proteins suited to induce an immune response in farm animals, and (e) fragments (*e.g.*, a domain) of any of the proteins set out in (a)-(d).

In one specific embodiment of the invention, the antigen or antigenic determinant is one that is useful for the prevention of infectious disease. Such treatment will be useful to treat a wide variety of infectious diseases affecting a wide range of hosts, *e.g.*, human, cow, sheep, pig, dog, cat, other mammalian species and non-mammalian species as well. Treatable infectious diseases are well known to those skilled in the art, examples include infections of viral etiology such as HIV, influenza, *Herpes*, viral hepatitis, Epstein Bar, polio, viral encephalitis, measles, chicken pox, etc.; or infections of bacterial etiology such as pneumonia, tuberculosis, syphilis, etc.; or infections of parasitic etiology such as malaria, trypanosomiasis, leishmaniasis, trichomoniasis, amoebiasis, etc. Thus, antigens or antigenic determinants selected for the compositions of the invention will be well known to those in the medical art; examples of antigens or antigenic determinants include the following: the HIV antigens gp140 and gp160; the influenza antigens hemagglutinin, M2 protein and neuraminidase, Hepatitis B surface antigen, circumsporozoite protein of malaria.

In specific embodiments, the invention provides vaccine compositions suitable for use in methods for preventing and/or attenuating diseases or conditions which are

-54-

caused or exacerbated by "self" gene products (*e.g.*, tumor necrosis factors). Thus, vaccine compositions of the invention include compositions which lead to the production of antibodies that prevent and/or attenuate diseases or conditions caused or exacerbated by "self" gene products. Examples of such diseases or conditions include graft versus host disease, IgE-mediated allergic reactions, anaphylaxis, adult respiratory distress syndrome, Crohn's disease, allergic asthma, acute lymphoblastic leukemia (ALL), non-Hodgkin's lymphoma (NHL), Graves' disease, systemic lupus erythematosus (SLE), inflammatory autoimmune diseases, myasthenia gravis, immunoproliferative disease lymphadenopathy (IPL), angioimmunoproliferative lymphadenopathy (AIL), immunoblastic lymphadenopathy (IBL), rheumatoid arthritis, diabetes, multiple sclerosis, Alzheimer disease and osteoporosis.

In related specific embodiments, compositions of the invention are an immunotherapeutic that may be used for the treatment of allergies or cancer.

The selection of antigens or antigenic determinants for the preparation of compositions and for use in methods of treatment for allergies would be known to those skilled in the medical arts treating such disorders. Representative examples of such antigens or antigenic determinants include the following: bee venom phospholipase A₂, Bet v I (birch pollen allergen), 5 Dol m V (white-faced hornet venom allergen), Mellitin and Der p I (House dust mite allergen), as well as fragments of each which can be used to elicit immunological responses.

As indicated, a preferred antigen or antigenic determinant is Der p I. Der p I is a 25kD protease found in house dust mite faecal particles. Der p I represents the major allergic molecule of house dust mite. Accordingly, 80% of mite allergic patients have anti-Der p I IgE antibodies. In particular, the peptides p52-72 and p117-133, among others, are known to comprise epitopes, which are recognized by antibodies specific for the native Der p I. IgE antibodies raised in a polyclonal response to the whole antigen bind with high affinity to the peptide region 59-94 (L. Pierson-Mullany et al. (2000) Molecular Immunology). Other regions also bind IgE with high affinity. The peptide p117-133 contains a free cysteine at its N-terminus, preferably representing the second attachment site in accordance with the invention. 3D model assigns peptides p52-72 and p117-133 to the surface of the whole protein. However, other fragments of the Der p I protein may comprise B cell epitopes being preferably suitable for the present invention.

The selection of antigens or antigenic determinants for compositions and methods of treatment for cancer would be known to those skilled in the medical arts treating such disorders. Representative examples of such types of antigens or

-55-

antigenic determinants include the following: Her2 (breast cancer), GD2 (neuroblastoma), EGF-R (malignant glioblastoma), CEA (medullary thyroid cancer), and CD52 (leukemia), human melanoma protein gp100, human melanoma protein melan-A/MART-1, tyrosinase, NA17-A nt protein, MAGE-3 protein, p53 protein, HPV16 E7 protein, as well as fragments of each which can be used to elicit immunological responses. Further preferred antigenic determinants useful for compositions and methods of treatment for cancer are molecules and antigenic determinants involved in angiogenesis. Angiogenesis, the formation of new blood vessels, plays an essential role in physiological and pathophysiological processes such as wound healing and solid tumor growth, respectively (Folkman, J. (1995) *Nat. medicine* 1, 27-31; Folkman, J., and Klagsbrun, M. (1987) *Science* 235, 442-446; Martiny-Baron, G., and Marm  , D. (1995) *Curr. Opin. Biotechnol.* 6, 675-680; Risau, W. (1997) *Nature* 386, 671-674). Rapidly growing tumors initiate and depend on the formation of blood vessels to provide the required blood supply. Thus, antiangiogenic agents might be effective as an anticancer therapy.

Among several putative angiogenic factors that have been identified so far vascular endothelial growth factor (VEGF) is a potent endothelial cell specific mitogen and a primary stimulant of the vascularization of many solid tumors. Although recent findings implicate that a set of angiogenic factors must be perfectly orchestrated to form functional vessels, it seems that the blockade of even a single growth factor might limit disease-induced vascular growth. Thus, blockade of VEGF may be a premium target for intervention in tumor induced angiogenesis. To target the endothelium rather than the tumor itself has recently emerged as a novel strategy to fight tumors (Millauer, B., Shawver, L. K., Plate, K. H., Risau, W., and Ullrich, A. (1994) *Nature* 367, 576-579; Kim, J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillip, H. S., Ferrara, N. (1993) *Nature* 362, 841-844). In contrast to tumors, which easily mutate target structures recognized by the immune system, endothelial cells do not usually escape the immune system or other therapeutic regimens.

An anti-VEGFR-II antibody (IMC-1C11) and an anti-VEGF antibody have been disclosed (Lu, D., Kussie, P., Pytowski, B., Persaud, K., Bohlen, P., Witte, L., Zhu, Z. (2000) *J. Biol. Chem.* 275, 14321-14330; Presta, L.G, Chen, H., O'Connor, S.J., Chisholm, V., Meng, Y.G., Krummen, L., Winkler, M., Ferrara N. (1997) *Cancer Res.* 47, 4593-4599). The former neutralizing monoclonal anti-VEGFR-2 antibody

-56-

recognizes an epitope that has been identified as putative VEGF/VEGFR-II binding site (Piossek, C., Schneider-Mergener, J., Schirner, M., Vakalopoulou, E., Germeroth, L., Thierauch, K.H. (1999) *J Biol Chem.* 274, 5612-5619).

Thus, in another preferred embodiment of the invention, the antigen or antigenic determinant is a peptide derived from the VEGFR-II contact site. This provides a composition and a vaccine composition in accordance with the invention, which may have antiangiogenic properties useful for the treatment of cancer.

Inhibition of tumor growth in mice using sera specific for VEGFR-2 has been demonstrated (Wei, YQ., Wang, QR., Zhao, X., Yang, L., Tian, L., Lu, Y., Kang, B., Lu, CJ., Huang, MJ., Lou, YY., Xiao, F., He, QM., Shu, JM., Xie, XJ., Mao, YQ., Lei, S., Luo, F., Zhou, LQ., Liu, CE., Zhou, H., Jiang, Y., Peng, F., Yuan, LP., Li, Q., Wu, Y., Liu, JY. (2000) *Nature Medicine* 6, 1160-1165). Therefore, further preferred antigenic determinants suitable for inventive compositions and antiangiogenic vaccine compositions in accordance with the invention comprise either the human VEGFR-II derived peptide with the sequence CTARTELNVGIDFNWEYPSSKHQHKK, and/or the murine VEGFR-II derived peptide having the sequence CTARTELNVGLDFTWHSPPSKSHHKK, and/or the relevant extracellular globular domains 1-3 of the VEGFR-II.

Therefore, in a preferred embodiment of the invention, the vaccine composition comprises a core particle selected from a virus-like particle or a bacterial pilus and a VEGFR-II derived peptide or a fragment thereof as an antigen or antigenic determinant in accordance with the present invention.

The selection of antigens or antigenic determinants for compositions and methods of treatment for other diseases or conditions associated with self antigens would be also known to those skilled in the medical arts treating such disorders. Representative examples of such antigens or antigenic determinants are, for example, lymphotoxins (e.g. Lymphotoxin α (LT α), Lymphotoxin β (LT β)), and lymphotoxin receptors, Receptor activator of nuclear factor κ B ligand (RANKL), vascular endothelial growth factor (VEGF), vascular endothelial growth factor receptor (VEGF-R), Interleukin-5, Interleukin-17, Interleukin-13, CCL21, CXCL12, SDF-1, MCP-1, Endoglin, Resistin, GHRH, LHRH, TRH, MIF, Eotaxin, Bradykinin, BLC, Tumor Necrosis Factor α and amyloid beta peptide ($A\beta_{1-42}$) (SEQ ID NO: 220), as well as fragments of each which can be used to elicit immunological responses. In a

-57-

preferred embodiment, the antigen is the amyloid beta peptide ($A\beta_{1-42}$) (DAEFRHDSGYEVHHQKL VFFAEDVGSNKGAIIGLMVGGGVVIA (SEQ ID NO: 220), or a fragment thereof. The amyloid beta protein is SEQ ID NO: 218. The amyloid beta precursor protein is SEQ ID NO: 219.

In another preferred embodiment of the invention, the antigen or antigenic determinant is an angiotensin peptide or a fragment thereof. The term "angiotensin peptide" as used herein, shall encompass any peptide comprising the sequence, or fragments thereof, of angiotensinogen, angiotensin I or angiotensin II. The sequences are as follows: Angiotensinogen: DRVYIHPFHLVIHN; Angiotensin I: DRVYIHPFHL; Angiotensin II: DRVYIHPF. Typically, one or more additional amino acids are added either at the C- or at the N-terminus of the angiotensin peptide sequences. The sequence of the angiotensin peptides corresponds to the human sequence, which is identical to the murine sequence. Therefore, immunization of a human or a mouse with vaccines or compositions, respectively, comprising such angiotensin peptides as antigenic determinant in accordance with the invention, is a vaccination against a self-antigen. Those additional amino acids are, in particular, valuable for an oriented and ordered association to the core particle.

Preferably, the angiotensin peptide has an amino acid sequence selected from the group consisting of a) the amino acid sequence of CGGDRVYIHPF; b) the amino acid sequence of CGGDRVYIHPFHL; c) the amino acid sequence of DRVYIHPFHLGGC; and d) the amino acid sequence of CDRVYIHPFH.

Angiotensin I is cleaved from angiotensinogen (14aa) by the kidney-derived enzyme Renin. Angiotensin I is a biologically inactive peptide of 10 aa. It is further cleaved at the N-terminus by angiotensin converting enzyme (ACE) into the biologically active 8aa angiotensin II. This peptide binds to the angiotensin receptors AT1I and AT2 which leads to vasoconstriction and aldosterone release.

A vaccine in accordance with the present invention comprising at least one angiotensin peptide may be used for the treatment of hypertension.

In a particular embodiment of the invention, the antigen or antigenic determinant is selected from the group consisting of: (a) a recombinant protein of HIV, (b) a recombinant protein of Influenza virus (e.g., an Influenza virus M2 protein or a fragment thereof), (c) a recombinant protein of Hepatitis C virus, (d) a recombinant protein of *Toxoplasma*, (e) a recombinant protein of *Plasmodium falciparum*, (f) a recombinant protein of *Plasmodium vivax*, (g) a recombinant protein of *Plasmodium ovale*, (h) a recombinant protein of *Plasmodium malariae*, (i) a recombinant protein of breast cancer cells, (j) a recombinant protein of kidney cancer cells, (k) a recombinant protein of prostate cancer cells, (l) a recombinant protein of

skin cancer cells, (m) a recombinant protein of brain cancer cells, (n) a recombinant protein of leukemia cells, (o) a recombinant profiling, (p) a recombinant protein of bee sting allergy, (q) a recombinant proteins of nut allergy, (r) a recombinant proteins of food allergies, (s) recombinant proteins of asthma, (t) a recombinant protein of *Chlamydia*, and (u) a fragment of any of the proteins set out in (a)-(t).

Once the antigen or antigenic determinant of the composition is chosen, at least one second attachment site may be added to the molecule in preparing to construct the organized and repetitive array associated with the non-natural molecular scaffold of the invention. Knowledge of what will constitute an appropriate second attachment site will be known to those skilled in the art. Representative examples of second attachment sites include, but are not limited to, the following: an antigen, an antibody or antibody fragment, biotin, avidin, streptavidin, a receptor, a receptor ligand, a ligand, a ligand-binding protein, an interacting leucine zipper polypeptide, an amino group, a chemical group reactive to an amino group; a carboxyl group, chemical group reactive to a carboxyl group, a sulfhydryl group, a chemical group reactive to a sulfhydryl group, or a combination thereof.

The association between the first and second attachment sites will be determined by the characteristics of the respective molecules selected but will comprise at least one non-peptide bond. Depending upon the combination of first and second attachment sites, the nature of the association may be covalent, ionic, hydrophobic, polar, or a combination thereof.

In one embodiment of the invention, the second attachment site may be the *FOS* leucine zipper protein domain or the *JUN* leucine zipper protein domain.

In a more specific embodiment of the invention, the second attachment site selected is the *FOS* leucine zipper protein domain, which associates specifically with the *JUN* leucine zipper protein domain of the non-natural molecular scaffold of the invention. The association of the *JUN* and *FOS* leucine zipper protein domains provides a basis for the formation of an organized and repetitive antigen or antigenic determinant array on the surface of the scaffold. The *FOS* leucine zipper protein domain may be fused in frame to the antigen or antigenic determinant of choice at either the amino terminus, carboxyl terminus or internally located in the protein if desired.

Several *FOS* fusion constructs are provided for exemplary purposes. Human growth hormone (Example 4), bee venom phospholipase A₂ (PLA₂) (Example 9), ovalbumin (Example 10) and HIV gp140 (Example 12).

In order to simplify the generation of *FOS* fusion constructs, several vectors are disclosed that provide options for antigen or antigenic determinant design and construction (see Example 6). The vectors pAV1-4 were designed for the expression

-59-

of *FOS* fusion in *E. coli*; the vectors pAV5 and pAV6 were designed for the expression of *FOS* fusion proteins in eukaryotic cells. Properties of these vectors are briefly described:

1. pAV1: This vector was designed for the secretion of fusion proteins with *FOS* at the C-terminus into the *E. coli* periplasmic space. The gene of interest (g.o.i.) may be ligated into the *StuI/NotI* sites of the vector.

2. pAV2: This vector was designed for the secretion of fusion proteins with *FOS* at the N-terminus into the *E. coli* periplasmic space. The gene of interest (g.o.i.) ligated into the *NotI/EcoRV* (or *NotI/HindIII*) sites of the vector.

3. pAV3: This vector was designed for the cytoplasmic production of fusion proteins with *FOS* at the C-terminus in *E. coli*. The gene of interest (g.o.i.) may be ligated into the *EcoRV/NotI* sites of the vector.

4. pAV4: This vector is designed for the cytoplasmic production of fusion proteins with *FOS* at the N-terminus in *E. coli*. The gene of interest (g.o.i.) may be ligated into the *NotI/EcoRV* (or *NotI/HindIII*) sites of the vector. The N-terminal methionine residue is proteolytically removed upon protein synthesis (Hirel *et al.*, *Proc. Natl. Acad. Sci. USA* 86:8247-8251 (1989)).

5. pAV5: This vector was designed for the eukaryotic production of fusion proteins with *FOS* at the C-terminus. The gene of interest (g.o.i.) may be inserted between the sequences coding for the hGH signal sequence and the *FOS* domain by ligation into the *Eco47III/NotI* sites of the vector. Alternatively, a gene containing its own signal sequence may be fused to the *FOS* coding region by ligation into the *StuI/NotI* sites.

6. pAV6: This vector was designed for the eukaryotic production of fusion proteins with *FOS* at the N-terminus. The gene of interest (g.o.i.) may be ligated into the *NotI/StuI* (or *NotI/HindIII*) sites of the vector.

As will be understood by those skilled in the art, the construction of a *FOS*-antigen or -antigenic determinant fusion protein may include the addition of certain genetic elements to facilitate production of the recombinant protein. Example 4 provides guidance for the addition of certain *E. coli* regulatory elements for translation, and Example 7 provides guidance for the addition of a eukaryotic signal sequence. Other genetic elements may be selected, depending on the specific needs of the practitioner.

The invention is also seen to include the production of the *FOS*-antigen or *FOS*-antigenic determinant fusion protein either in bacterial (Example 5) or eukaryotic cells (Example 8). The choice of which cell type in which to express the fusion protein is within the knowledge of the skilled artisan, depending on factors

-60-

such as whether post-translational modifications are an important consideration in the design of the composition.

As noted previously, the invention discloses various methods for the construction of a *FOS*-antigen or *FOS*-antigenic determinant fusion protein through the use of the pAV vectors. In addition to enabling prokaryotic and eukaryotic expression, these vectors allow the practitioner to choose between N- and C-terminal addition to the antigen of the *FOS* leucine zipper protein domain. Specific examples are provided wherein N- and C-terminal *FOS* fusions are made to PLA₂ (Example 9) and ovalbumin (Example 10). Example 11 demonstrates the purification of the PLA₂ and ovalbumin *FOS* fusion proteins.

In a more specific embodiment, the invention is drawn to an antigen or antigenic determinant encoded by the HIV genome. More specifically, the HIV antigen or antigenic determinant is gp140. As provided for in Examples 11-15, HIV gp140 may be created with a *FOS* leucine zipper protein domain and the fusion protein synthesized and purified for attachment to the non-natural molecular scaffold of the invention. As one skilled in the art would know, other HIV antigens or antigenic determinants may be used in the creation of a composition of the invention.

In another more specific embodiment, the invention is drawn to vaccine compositions comprising at least one antigen or antigenic determinant encoded by an Influenza viral nucleic acid, and the use of such vaccine compositions to elicit immune responses. In an even more specific embodiment, the Influenza antigen or antigenic determinant may be an M2 protein (*e.g.*, an M2 protein having the amino acids shown in SEQ ID NO:213, GenBank Accession No. P06821, or in SEQ ID NO: 212, PIR Accession No. MFTV62, or fragment thereof (*e.g.*, amino acids from about 2 to about 24 in SEQ ID NO:213, the amino acid sequence in SEQ ID NO:212). Further, influenza antigens or antigenic determinants may be coupled to non-natural molecular scaffolds or core particles through either peptide or non-peptide bonds. When Influenza antigens or antigenic determinants are coupled to non-natural molecular scaffolds or core particles through peptide bonds, the molecules which form order and repetitive arrays will generally be prepared as fusion protein expression products. The more preferred embodiment is however a composition, wherein the M2 peptide is coupled by chemical cross-linking, to Q β capsid protein HBcAg capsid protein or Pili according to the disclosures of the invention.

Portions of an M2 protein (*e.g.*, an M2 protein having the amino acid sequence in SEQ ID NO:213), as well as other proteins against which an immunological response is sought, suitable for use with the invention may comprise, or alternatively consist of, peptides of any number of amino acids in length but will generally be at least 6 amino acids in length (*e.g.*, peptides 6, 7, 8, 9, 10, 12, 15, 18,

-61-

20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 97 amino acids in length).

In another specific embodiment of the invention, the second attachment site selected is a cysteine residue, which associates specifically with a lysine residue of the non-natural molecular scaffold or core particle of the invention, or the second attachment site selected is a lysine residue, which associates specifically with a cysteine residue of the non-natural molecular scaffold or core particle of the invention. The chemical linkage of the lysine residue (Lys) and cysteine residue (Cys) provides a basis for the formation of an organized and repetitive antigen or antigenic determinant array on the surface of the scaffold or core particle. The cysteine or lysine residue may be engineered in frame to the antigen or antigenic determinant of choice at either the amino terminus, carboxyl terminus or internally located in the protein if desired. By way of example, PLA₂ and HIV gp140 are provided with a cysteine residue for linkage to a lysine residue first attachment site.

In additional specific embodiments, the invention provides vaccine compositions suitable for use in methods for preventing and/or attenuating allergic reactions, such as allergic reactions which lead to anaphylaxis. Thus, vaccine compositions of the invention include compositions which lead to the production of antibodies that prevent and/or attenuate allergic reactions. Thus, in certain embodiments, vaccine compositions of the invention include compositions which elicit an immunological response against an allergen. Examples of such allergens include phospholipases such as the phospholipase A₂ (PLA₂) proteins of *Apis mellifera* (SEQ ID NO:168, GenBank Accession No. 443189; SEQ ID NO:169, GenBank Accession No. 229378), *Apis dorsata* (SEQ ID NO:170, GenBank Accession No. B59055), *Apis cerana* (SEQ ID NO:171, GenBank Accession No. A59055), *Bombus pennsylvanicus* (SEQ ID NO:172 GenBank Accession No. B56338), and *Heloderma suspectum* (SEQ ID NO:173, GenBank Accession No. P80003; SEQ ID NO:174, GenBank Accession No. S14764; SEQ ID NO:175, GenBank Accession No. 226711).

Using the amino acid sequence of a PLA₂ protein of *Apis mellifera* (SEQ ID NO:168) for illustration, peptides of at least about 60 amino acids in length, which represent any portion of the whole PLA₂ sequence, may also be used in compositions for preventing and/or attenuating allergic reactions. Examples of such peptides include peptides which comprise amino acids 1-60 in SEQ ID NO:168, amino acids 1-70 in SEQ ID NO:168, amino acids 10-70 in SEQ ID NO:168, amino acids 20-80 in SEQ ID NO:168, amino acids 30-90 in SEQ ID NO:168, amino acids 40-100 in SEQ ID NO:168, amino acids 47-99 in SEQ ID NO:168, amino acids 50-110 in SEQ ID NO:168, amino acids 60-120 in SEQ ID NO:168, amino acids 70-130 in SEQ ID NO:168, or amino acids 90-134 in SEQ ID NO:168, as well corresponding portions of

-62-

other PLA₂ proteins (*e.g.*, PLA₂ proteins described above). Further examples of such peptides include peptides which comprise amino acids 1-10 in SEQ ID NO:168, amino acids 5-15 in SEQ ID NO:168, amino acids 10-20 in SEQ ID NO:168, amino acids 20-30 in SEQ ID NO:168, amino acids 30-40 in SEQ ID NO:168, amino acids 40-50 in SEQ ID NO:168, amino acids 50-60 in SEQ ID NO:168, amino acids 60-70 in SEQ ID NO:168, amino acids 70-80 in SEQ ID NO:168, amino acids 80-90 in SEQ ID NO:168, amino acids 90-100 in SEQ ID NO:168, amino acids 100-110 in SEQ ID NO:168, amino acids 110-120 in SEQ ID NO:168, or amino acids 120-130 in SEQ ID NO:168, as well corresponding portions of other PLA₂ proteins (*e.g.*, PLA₂ proteins described above).

Portions of PLA₂, as well as portions of other proteins against which an immunological response is sought, suitable for use with the invention may comprise, or alternatively consist of, peptides which are generally at least 6 amino acids in length (*e.g.*, peptides 6, 7, 8, 9, 10, 12, 15, 18, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acids in length).

PLA₂ peptides (*e.g.*, the full length PLA₂ proteins discussed above, as well as subportions of each) may also be coupled to any substance (*e.g.*, a Q β capsid protein or fragment thereof) which allows for the formation of ordered and repetitive antigen arrays.

In another aspect of the present invention, the invention provides compositions being particularly suitable for treating and/or preventing conditions caused or exacerbated by "self" gene products.

In a preferred embodiment of the invention, the antigenic determinant is **RANKL** (Receptor activator of NF κ B Ligand). **RANKL** is also known as **TRANCE** (TNF-related activation induced cytokine), **ODF** (Osteoclast differentiation factor) or **OPGL** (Osteoprotegerin ligand). The amino acid sequence of the extracellular part of human RANKL is shown in SEQ ID No: 221 (RANKL_human: TrEMBL:O14788), while the amino acid sequence of a human isoform is shown in SEQ ID No: 222. Sequences for the extracellular part of murine RANKL and an isoform are shown in SEQ ID No.223 (RANKL_mouse: TrEMBL:O35235), and in SEQ ID No.224 (RANKL_mouse splice forms: TrEMBL:Q9JJK8 and TrEMBL:Q9JJK9), respectively.

It has been shown that RANKL is an essential factor in osteoclastogenesis. Inhibition of the interaction of RANKL with its receptor RANK can lead to a suppression of osteoclastogenesis and thus provide a means to stop excessive bone resorption as seen in osteoporosis and other conditions. The RANKL/RANK interaction was inhibited either by a RANK-Fc fusion protein or the soluble decoy receptor of RANKL, termed osteoprotegerin OPG.

In the immune system RANKL is expressed on T cells while RANK is found on antigen-presenting cells. The RANKL-RANK interaction was shown to be critical for CD40L-independent T-helper cell activation (Bachmann *et al.*, *J. Exp. Med.* 7: 1025 (1999)) and enhance the longevity and adjuvant properties of dendritic cells (Josien *et al.*, *J Exp Med.* 191: 495 (2000)).

In bone RANKL is expressed on stromal cells or osteoblasts, while RANK is expressed on the osteoclast precursor. The interaction of RANK and RANKL is crucial for the development of osteoclast precursors to mature osteoclasts. The interaction can be blocked by osteoprotegerin.

OPG-deficient mice develop osteoporosis that can be rescued by injection of recombinant OPG. This means that OPG is able to reverse osteoporosis. Thus, inhibition of the RANK-RANKL interaction by way of injecting this specific embodiment of the invention may reverse osteoporosis.

In addition, arterial calcification was observed in OPG k.o. mice which could be reversed by injection of OPG (Min *et al.*, *J. Exp. Med.* 4: 463 (2000)). In an adjuvant-induced arthritis model OPG injection was able to prevent bone loss and cartilage destruction, but not inflammation (paw swelling). It is assumed that activated T cells lead to a RANKL-mediated increase of osteoclastogenesis and bone loss. OPG inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone of mice. OPG diminishes advanced bone cancer pain in mice.

RANKL is a transmembrane protein of 245 aa belonging to the TNF-superfamily. Part of the extracellular region (178 aa) can be shed by a TACE-like protease (Lum *et al.*, *J Biol Chem.* 274:13613 (1999)). In addition splice variants lacking the transmembrane domain have been described (Ikeda *et al.*, *Endocrinology* 142: 1419 (2001)). The shed part contains the domain highly homologous to soluble TNF- α . This extracellular domain of RANKL forms homotrimers as seen for TNF- α . The C-terminus seems to be involved in the trimer contact site. One cysteine is present in this region of the sequence.

We have built a model for the 3-dimensional structure of the corresponding region of RANKL and found that the naturally present cysteine may not be accessible in the folded structure for interaction with a first attachment site on the carrier in accordance with the present invention. The N-terminus is preferred for attaching a second attachment site comprising an amino acid linker with an additional cysteine residue. A human-RANKL construct with an N terminal amino acid linker containing a cysteine residue fused to the extracellular part of RANKL is a very preferred embodiment of the invention. However, an amino-acid linker containing a cysteine residue as second attachment site and being fused at the C-terminus of the RANKL

-64-

sequence or the extracellular part of RANKL leads to further preferred embodiments of the invention.

Human-RANKL constructs, such as the one identified in SEQ ID NO:320, are generated according to the teachings disclosed in EXAMPLE 6, and the man skilled in the art are able to compare murine and human RANKL sequences in a protein sequence alignment to identify the part of the sequence of human-RANKL to be cloned in the vectors described in EXAMPLE 6. Fragments containing amino acids 138-317 and corresponding to the C-terminal region of the extracellular domain of human RANKL, are particularly favored embodiments of the invention, and can be modified for coupling to VLPs and Pili as required according to the teaching of the present invention. However, other suitable vectors may also be used for expression in the suitable host described below. Further human-RANKL constructs, and in particular, the ones comprising the part of the extracellular region (178 aa), - or fragments thereof - that can be shed by a TACE-like protease (Lum *et al.*, *J Biol Chem.* 274:13613 (1999)), or comprising the sequence corresponding to the alternative splice variants lacking the transmembrane domain, as well as conservative fragments thereof, are intended to be encompassed within the scope of the present invention. Human C-terminal fragments comprising amino acids 165-317 are also embodiments of the invention. Alternatively, fragments which encompass the entire extracellular region (amino acids 71-317) and can be modified for coupling to VLPs and Pili as required according to the teaching of the present invention, are also within the scope of the invention.

RANKL has been expressed in different systems (*E.coli*, insect cells, mammalian cells) and shown to be active, and therefore several expression systems can be used for production of the antigen of the composition. In the case where expression of the protein is directed to the periplasm of *E. coli*, the signal peptide of RANKL, or of RANKL constructs consisting of the extracellular part of the protein, and both possibly modified to comprise a second attachment site in accordance with the invention, is replaced with a bacterial signal peptide. For expression of the protein in the cytoplasm of *E. coli*, RANKL constructs are devoid of signal peptide.

In another preferred embodiment of the invention, the antigenic determinant is MIF or a fragment thereof. MIF is a cytokine that has been first described in 1966 by its function as an inhibitor of macrophage migration. It is also known as delayed early response protein 6 (DER6), glycosylation inhibiting factor or phenylpyruvate tautomerase. The latter name originates from enzymatic activity of MIF, however the endogenous substrate has not been identified.

-65-

MIF has been shown to be implicated in a wide range of conditions. MIF (mRNA and protein) is upregulated in delayed type hypersensitivity (DTH) reaction induced by tuberculin, and anti-MIF antibody inhibits this DTH reaction. MIF is also upregulated in renal allograft rejection. In a model for ocular autoimmune disease, experimental autoimmune uveoretinitis (EAU), anti-MIF treatment caused delay of EAU development. In patients, there is an increase in serum of MIF, which is also the case in Behcet's disease patients and patients suffering from iridocyclitis. Immunization against MIF may provide a way of treatment against rheumatoid arthritis.

High serum MIF concentration has been found in atopic dermatitis patients. In skin lesions, MIF is diffusely expressed instead of being found in the basal cell layer in controls. MIF concentration is decreasing after steroid treatment, consistent with a role of MIF in inflammation. MIF has also been found to contribute to the establishment of glomerulonephritis. Animals treated with anti-MIF Antibody show significantly reduced glomerulonephritis. MIF is pituitary derived, secreted e.g. upon LPS stimulation, and potentiates endotoxemia. Accordingly, anti-MIF mAb inhibits endotoxemia and septic shock, while recombinant MIF markedly increases lethality of peritonitis. MIF is also a glucocorticoid-induced modulator of cytokine production, and promotes inflammation.

MIF is produced by T-cells (Th2), supports proliferation of T-cells, and anti-MIF-treatment reduces T-cell proliferation and IgG levels. There is an increased MIF concentration in the cerebrospinal fluid of multiple sclerosis and neuro-Behcet's disease patients. High MIF levels were also found in sera of patients with extended psoriasis. High MIF levels are found in sera of ulcerative colitis patients but not Crohn's disease patients.

High MIF levels have been found in sera of patients with bronchic asthma. MIF is also upregulated in synovial fluid of rheumatoid arthritis patients. Anti-MIF treatment was effectively decreasing rheumatoid arthritis in mouse and rat models (Mikulowska *et al.*, *J. Immunol.* 158:5514-7(1997); Leech *et al.*, *Arthritis Rheum.* 41:910-7 (1998), Leech *et al.* *Arthritis Rheum.* 43:827-33 (2000), Santos *et al.*, *Clin. Exp. Immunol.* 123:309-14 (2001)). Thus, treatment directed at inhibiting MIF activity using a composition comprising MIF as an antigenic determinant may be beneficial for the conditions mentioned above.

-66-

MIF from mouse, rat and human consists of 114 amino acid and contains three conserved cysteines, as shown in SEQ ID No 225 (MIF_rat: SwissProt), in SEQ ID No 226 (MIF_mouse: SwissProt) and in SEQ ID No 227 (MIF_human: SwissProt). Three subunits form a homotrimer that is not stabilized by disulfide bonds. The X-ray structure has been solved and shows three free cysteines (Sun *et al.*, *PNAS* 93: 5191-96 (1996)), while some literature data claim the presence of a disulfide bond. Nonetheless, none of the cysteines are exposed enough for optimal interaction with a possible first attachment site present on the carrier. Thus, as the C-terminus of the protein is exposed in the trimer structure, an amino acid linker containing a free cysteine residue is, preferably, added at the C-terminus of the protein, for generation of the second attachment site in this preferred embodiment of the invention, as exemplarily described in EXAMPLE 4 for rat-MIF.

There is only one amino acid change between mouse- and rat-MIF, and similarly a very high sequence homology (about 90 % sequence identity) between human- and rat-MIF or human- and mouse-MIF. Human- and mouse-MIF constructs according to the invention are described and can be generated as disclosed in EXAMPLE 4. In order to demonstrate the high potency to induce a self-specific immune response of MIF protein, or fragments thereof, associated to a core particle in accordance with the present invention, rat-MIF constructs coupled to Q β capsid protein were injected in mice. The high antibody titers obtained by immunizing mice with rat-MIF show that tolerance towards immunization with self-antigens was overcome by immunizing with MIF constructs coupled to virus-like particles, and in particular to Q β capsid protein (EXAMPLE 4). Therefore, compositions in accordance with the present invention comprising human-MIF protein associated to a core particle, preferably to pili or a virus-like particle, and more preferably to a virus-like particle of a RNA-phage, and even more preferably to RNA-phage Q β or fr, represent very preferred embodiments of the present invention.

However, an amino acid linker containing a free cysteine that is added at the N-terminus of the sequence of MIF leads to further preferred embodiments of the present invention. MIF has been expressed in *E.coli*, purified and shown to be fully functional (Bernhagen *et al.*, *Biochemistry* 33: 14144-155 (1994)). Thus, MIF may be, preferably, expressed in *E. coli* for generating the preferred embodiments of the invention.

-67-

Tautomerase activity of MIF is inhibited, if the start methionine is not cleaved from the construct. MIF constructs expressed in *E.coli* and described in EXAMPLE 4 show tautomerase activity. Mutants of MIF where the start methionine is cleaved and where the proline residue right after the start methionine in the sequence is mutated to alanine also do not show tautomerase activity represent further embodiments of the invention and are intended to be encompassed within the scope of the invention. In some specific embodiments, immunization with MIF mutants devoid of tautomerase activity is envisaged.

In another preferred embodiment of the invention, the antigenic determinant is Interleukin-17 (IL-17). Human IL-17 is a 32-kDa, disulfide-linked, homodimeric protein with variable glycosylation (Yao, Z. *et al.*, *J. Immunol.* 155: 5483-5486 (1995); Fossiez, F. *et al.*, *J. Exp. Med.* 183: 2593-2603 (1996)). The protein comprises 155 amino acids and includes an N-terminal secretion signal sequence of 19-23 residues. The amino acid sequence of IL-17 is similar only to a *Herpesvirus* protein (HSV13) and is not similar to other cytokines or known proteins. The amino acid sequence of human IL-17 is shown in SEQ ID No: 228 (ACCESSION #: AAC50341), The mouse protein sequence is shown in SEQ ID No: 229 (ACCESSION #: AAA37490). Of the large number of tissues and cell lines evaluated, the mRNA transcript encoding IL-17 has been detected only in activated T cells and phorbol 12-myristate 13-acetate/ionomycin-stimulated peripheral blood mononuclear cells (Yao, Z. *et al.*, *J. Immunol.* 155: 5483-5486 (1995); Fossiez, F. *et al.*, *J. Exp. Med.* 183: 2593-2603 (1996)). Both human and mouse sequences contain 6 cysteine residues.

The receptor for IL-17 is widely expressed in many tissues and cell types (Yao, Z. *et al.*, *Cytokine* 9: 794-800 (1997)). Although the amino acid sequence of the human IL-17 receptor (866 aa) predicts a protein with a single trans-membrane domain and a long, 525 aa intracellular domain, the receptor sequence is unique and is not similar to that of any of the receptors from the cytokine/growth factor receptor family. This coupled with the lack of similarity of IL-17 itself to other known proteins indicates that IL-17 and its receptor may be part of a novel family of signalling protein and receptors. Clinical studies indicate IL-17 may be involved in many inflammatory diseases. IL-17 is secreted by synovial T cells from rheumatoid arthritis patients and stimulates the production of inflammatory mediators (Chabaud, M. *et al.*, *J. Immunol.* 161: 409-414 (1998); Chabaud, M. *et al.*, *Arthritis Rheum.* 42: 963-970 (1999)). High levels of IL-17 have been reported in patients with rheumatoid arthritis (Ziolkowska M. *et al.*, *J Immunol.* 164:2832-8 (2000)).

Interleukin 17 has been shown to have an effect on proteoglycan degradation in murine knee joints (Dudler J. *et al.*, *Ann Rheum Dis.* 59: 529-32 (2000)) and contribute to destruction of the synovium matrix (Chabaud M. *et al.*, *Cytokine.* 12:1092-9 (2000)). There are relevant arthritis models in animals for testing the effect of an immunization against MIF (Chabaud M. *et al.*, *Cytokine.* 12:1092-9 (2000)). Elevated levels of IL-17 mRNA have been found in mononuclear cells from patients with multiple sclerosis (Matusevicius, D. *et al.*, *Mult. Scler.* 5: 101-104 (1999)). Elevated serum levels of IL-17 are observed in patients suffering Systemic Lupus Erythematosus (Wong C.K. *et al.*, *Lupus* 9: 589-93 (2000)). In addition, IL-17 mRNA levels are increased in T cells isolated from lesional psoriatic skin (Teunissen, M. B. *et al.*, *J. Invest. Dermatol.* 111: 645-649 (1998)).

The involvement of IL-17 in rejection of kidney graft has also been demonstrated (Fossiez F. *et al.*, *Int. Rev. Immunol.* 16:541-51 (1998)). Evidence for a role of IL-17 in organ allograft rejection has also been presented by Antonysamy *et al.* (*J. Immunol.* 162:577-84 (1999)) who showed IL-17 promotes the functional differentiation of dendritic cell progenitors. Their findings suggest a role for IL-17 in allogeneic T cell proliferation that may be mediated in part via a maturation-inducing effect on DCs. Furthermore the same group reports (Tang J.L. *et al.*, *Transplantation* 72:348-50 (2001)) a role for IL-17 in the immunopathogenesis of acute vascular rejection where Interleukin-17 antagonism inhibits acute but not chronic vascular rejection. IL-17 appears to have potential as a novel target for therapeutic intervention in allograft rejection.

The above findings suggest IL-17 may play a pivotal role in the initiation or maintenance of an inflammatory response (Jovanovic, D. V. *et al.*, *J. Immunol.* 160: 3513-3521 (1998)).

The anti-IL-17 monoclonal antibody mAb5 (Schering-Plough Research Institute) was able to completely inhibit the production of IL-6 from rheumatoid arthritis (RA) synovium supernatants following induction by 50 ng/ml of IL-17. An irrelevant mAb MX1 had no effect in this assay. mAb5 is a mouse IgG1 obtained after immunization with human rIL-17 (r = recombinant). A concentration of 1 µg/ml of mAb5 was able to completely inhibit the IL-6 production in the assay system (Chabaud, M. *et al.*, *J. Immunol.* 161: 409-414 (1998)). Thus, immunization against IL-17 provides a way of treatment for the various conditions described above.

In another preferred embodiment of the invention, thus, the composition comprises a linker containing a second attachment site and being fused to the C-terminus of recombinant IL-17. In further preferred embodiments of the invention, however, an amino acid linker containing a free cysteine is fused to the N-terminus of the sequence corresponding to the sequence of the processed protein, or inserted at the N-terminus of the sequence of the mature form of the protein, C-terminally of the

signal peptide. For eukaryotic expression systems, the signal peptide of the IL-17 gene, as it is the case for the other self-antigens indicated herein, may be replaced by another signal peptide if required. For expression in bacteria, the signal peptide is either replaced by a bacterial signal peptide for soluble expression in the periplasm, or deleted for expression in the cytoplasm. Constructs of human IL-17 devoid of signal peptide will preferably comprise residues 24-155, 22-155, 21-155 or 20-155. Constructs of mouse IL-17 devoid of signal peptide will preferably comprise residues 26-158, 25-158, 24-158 or 27-155. Human IL-17 may be expressed in CV1/EBNA cells; recombinant hIL-17 has been shown to be secreted in both glycosylated and nonglycosylated forms (Yao, Z. *et al.*, *J. Immunol.* 155: 5483-5486 (1995)). IL-17 can also be expressed as hIL-17/Fc fusion protein, with subsequent cleavage of the IL-17 protein from the fusion protein. IL-17 may also be expressed in the yeast *Pichia pastoris* (Murphy K.P. *et al.*, *Protein Expr Purif.* 12: 208-14 (1998)). Human IL-17 may also be expressed in *E. coli*. When expression of IL-17 in *E. coli* is directed to the periplasm, the signal peptide of IL-17 is replaced by a bacterial signal peptide. For expression of the protein in the cytoplasm of *E. coli*, IL-17 constructs are devoid of signal peptide.

In another preferred embodiment of the invention the antigenic determinant is Interleukin-13 (IL-13). IL-13 is a cytokine that is secreted by activated T lymphocytes and primarily impacts monocytes, macrophages, and B cells. The amino acid sequence of precursor human IL-13 is shown in SEQ ID No: 230 and the amino acid sequence of processed human IL-13 is shown in SEQ ID No: 231. The first 20 amino acids of the precursor protein correspond to the signal peptide, and are absent of the processed protein. The mouse sequence has also been described, and the processed amino acid sequence is shown in SEQ ID No: 232 (Brown K.D. *et al.*, *J. Immunol.* 142:679-687 (1989)). Depending on the expression host, the IL-13 construct will comprise the sequence of the precursor protein, e.g. for expression and secretion in eukaryotic hosts, or consist of the mature protein, e.g. for cytoplasmic expression in *E. coli*. For expression in the periplasm of *E. coli*, the signal peptide of IL-13 is replaced by a bacterial signal peptide.

IL-13 is a T helper 2-derived cytokine (like IL-4, IL-5) that has recently been implicated in allergic airway responses (asthma). Upregulation of IL-13 and IL-13 receptor has been found in many tumour types (e.g. Hodgkin lymphoma). Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells (Kapp U *et al.*, *J Exp Med.* 189:1939-46 (1999)). Thus, immunization against IL-13 provides a way of treating among others the conditions described above, such as Asthma or Hodgkins Lymphoma.

Preferably, the composition comprises an amino acid linker containing a free cysteine residue and being fused to the N or C-terminus of the sequence of mature IL-13 to introduce a second attachment site within the protein. In further preferred embodiments, an amino acid linker containing a free cysteine is added to the N-terminus of the mature form of IL-13, since it is freely accessible according to the NMR structure of IL-13 (Eisenmesser, E. Z. *et al.*, *J.Mol.Biol.* 310: 231 (2001)). In again further preferred embodiments, the amino acid linker containing a free cysteine is fused to the N-terminus of the sequence corresponding to the sequence of the processed protein, or inserted at the N-terminus of the sequence of the mature form of the protein, C-terminally of the signal peptide. In still further preferred embodiments, an amino acid linker containing a free cysteine residue is added to the C-terminus of the protein.

IL-13 may be expressed in E.coli (Eisenmesser E.Z. *et al.*, *Protein Expr. Purif.* 20:186-95 (2000)), or in NS-0 cells (eukaryotic cell line) (Cannon-Carlson S. *et al.*, *Protein Expr. Purif.* 12:239-48 (1998)). EXAMPLE 9 describes constructs and expression of constructs of murine IL-13, fused to an amino acid linker containing a cysteine residue, in bacterial and eukaryotic hosts. Human IL-13 constructs can be generated according to the teachings of EXAMPLE 9 and yielding the proteins human C-IL-13-F (SEQ ID NO:330) and human C-IL-13-S (SEQ ID NO:331) after expression of the fusion proteins and cleavage with Factor Xa, and enterokinase respectively. The so generated proteins can be coupled to VLPs and Pili, leading to preferred embodiments of the invention.

In yet another embodiment of the invention, the antigenic determinant is Interleukin-5 (IL-5). IL-5 is a lineage-specific cytokine for eosinophilopoiesis and plays an important part in diseases associated with increased number of eosinophils, such as asthma. The sequence of precursor and processed human IL-5 is provided in SEQ ID No: 233 and in SEQ ID No: 234, respectively, and the processed mouse amino acid sequence is shown in SEQ ID No: 235.

The biological function of IL-5 has been shown in several studies (Coffman R.L. *et al.*, *Science* 245: 308-10 (1989); Kopf *et al.*, *Immunity* 4:15-24 (1996)), which point to a beneficial effect of inhibiting IL-5 function in diseases mediated through eosinophils. Inhibition of the action of IL-5 provides thus a way of treatment against asthma and other diseases associated with eosinophils.

IL-5 forms a dimer, covalently linked by a disulfide bridge. A single chain (sc) construct has been reported wherein two monomers of IL-5 are linked by a peptide linker.

In preferred embodiments of the invention, a peptide linker containing a free cysteine is added at the N-terminus of the sequence of the processed form of IL-5.

-71-

Addition of a linker containing a free cysteine is also, preferably, envisaged at the N-terminus of the sequence of the processed form of a scIL-5. In further preferred embodiments, the amino acid linker containing a free cysteine is fused to the N-terminus of the sequence corresponding to the sequence of the processed protein, or inserted at the N-terminus of the sequence of the mature form of the protein, C-terminally of the signal peptide.

In again further preferred embodiments, a linker containing a free cysteine is fused to the C-terminus of the sequence of IL-5, or to the C-terminus of a scIL-5 sequence.

A number of expression systems have been described for IL-5 and can be used in preparing the compositions of the invention. A bacterial expression system using *E. coli* has been described by Proudfoot *et al.*, (*Biochem J.* 270:357-61 (1990)). In the case where IL-5 is expressed in the cytoplasm of *E. coli*, the IL-5 construct is devoid of a signal peptide. Insect cells may also be used for producing IL-5 constructs for making the compositions of the invention (Pierrot C. *et al.*, *Biochem. Biophys. Res. Commun.* 253:756-60 (1998)). Likewise, Baculovirus expression systems (sf9 cells; Ingley E. *et al.*, *Eur. J. Biochem.* 196:623-9 (1991) and Brown P.M. *et al.*, *Protein Expr. Purif.* 6: 63-71 (1995)) can also be used. Finally, mammalian expression systems have also been reported (CHO cells) and can be used in preparing these compositions of the invention (Kodama S *et al.*, *J. Biochem. (Tokyo)* 110:693-701 (1991)).

Baculovirus expression systems (Mitchell *et al.*, *Biochem. Soc. Trans.* 21:332S (1993); Kunimoto DY *et al.*, *Cytokine* 3:224-30 (1991)) and a mammalian cell expression system using CHO cells (Kodama S *et al.*, *Glycobiology* 2:419-27 (1992)) have also been described for mouse IL-5.

EXAMPLE 10 describes the expression of murine IL-5 constructs wherein the IL-5 sequence is fused at its N-terminus to amino acid linkers containing a cysteine residue for coupling to VLPs and Pili. Human constructs can be generated according to the teaching of EXAMPLE 10 and yield the proteins human C-IL-5-E (SEQ ID NO:335), human C-IL-5-F (SEQ ID NO:336) and human C-IL-5-S: (SEQ ID NO:337) suitable for coupling to VLPs and Pili and leading to preferred embodiments of the invention.

In another preferred embodiment of the invention, the antigenic determinant is CCL-21. CCL-21 is a chemokine of the CC subfamily that is also known as small inducible cytokine A21, as exodus-2, as SLD (secondary lymphocyte cytokine), as TCA4 (thymus-derived chemotactic agent 4) or 6Ckine.

CCL21 inhibits hemopoiesis and stimulates chemotaxis for thymocytes, activated T-cells and dendritic cells, but not for B cells, macrophages or neutrophils. It shows preferential activity towards naive T cells. It is also a potent mesangial cell chemoattractant. CCL21 binds to chemokine receptors CCR7 and to CXCR3 (dependent on species). It can trigger rapid integrin-dependent arrest of lymphocytes rolling under physiological shear and is highly expressed by high endothelial venules.

Murine CCL21 inhibited tumor growth and angiogenesis in a human lung cancer SCID mouse model (Arenberg *et al.*, *Cancer Immunol. Immunother.* 49: 587-92 (2001)) and a colon carcinoma tumor model in mice (Vicari *et al.*, *J. Immunol.* 165: 1992-2000 (2001)). The angiostatic activity of murine CCL21 was also detected in a rat corneal micropocket assay (Soto *et al.*, *Proc. Natl. Acad. Sci. U S A* 95: 8205-10 (1998)).

It has been shown that chemokine receptors CCR7 and CXCR4 are upregulated in breast cancer cells and that CCL21 and CXCL12, the respective ligands, are highly expressed in organs representing the first destinations of breast cancer metastasis Müller *et al.* (*Nature* 410: 50-6 (2001)). In vitro CCL21-mediated chemotaxis could be blocked by neutralizing anti-CCL21 antibodies as was CXCR4-mediated chemotaxis by the respective antibodies. Thus, immunization against CCL21 provides a way of treatment against metastatic spread in cancers, more specifically in breast cancer.

Secreted CCL21 consists of 110 or 111 aa in mice and humans, respectively. The respective sequences are shown in SEQ ID No: 236 (Swissprot: SY21_human) and in SEQ ID No: 237 (Swissprot: SY21_mouse). In contrast to other CC cytokines does CCL21 contain two more cysteines within an extended region at the C-terminus. It is assumed that all cysteines are engaged in disulfide bonds.

In the following, constructs and expression systems are described for making compositions of the invention comprising the CCL21 antigenic determinant. In the NMR structure of the homologous protein eotaxin, both N- and C-terminus are exposed to the solvent. In some specific embodiments, an amino acid linker containing a free cysteine residue as a second attachment site is added at the C-terminus of the protein. A fusion protein with alkaline phosphatase (at the C-terminus of CCL21) has been expressed and was shown to be functional, showing that fusions at the C-terminus of CCL21 are compatible with receptor binding. In other specific embodiments, the amino acid linker containing a free cysteine is fused to the N-terminus of the sequence corresponding to the sequence of the processed protein, or inserted at the N-terminus of the sequence of the mature form of the protein, C-terminally of the signal peptide.

Several expression systems have been described for production of CCL21 (e.g. Hedrick *et al.*, *J Immunol.* 159: 1589-93 (1997)). For example, it may be expressed in a baculovirus system (Nagira *et al.*, *J. Biol. Chem.* 272: 19518-24 (1997)).

In a related preferred embodiment, the antigenic determinant is Stromal derived factor-1 (SDF-1), now termed CXCL12. CXCL12 is a chemokine produced by bone marrow stromal cells and was originally identified as a stimulatory factor for pre-B cells.

As already stated above, it has been shown that chemokine receptors CCR7 and CXCR4 are upregulated in breast cancer cells and that CCL21 and SDF-1, the respective ligands, are highly expressed in organs representing the first destinations of breast cancer metastasis Müller *et al.* (*Nature* 410: 50-6 (2001)). In vitro SDF-1 / CXCR4-mediated chemotaxis could be inhibited by neutralizing anti-SDF-1 and anti-CXCR4 antibodies.

In a breast cancer metastasis model in SCID mice using the human MDA-MB-231 breast cancer cell line, a significant decrease in lung metastasis was observed when mice were treated with anti-CXCR4 antibodies. In the draining lymph nodes a reduction of metastasis to the inguinal and axillary lymph nodes (38% instead of 100% metastasis in controls) was observed. Thus, immunization against CXCL12 provides a way of treatment against metastasis of cancers, more specifically of breast cancers.

The SDF-1 / CXCR4 chemokine-receptor pair has been shown to increase the efficacy of homing of more primitive hematopoietic progenitor cells to the bone marrow. In addition, CXCR4 and SDF-1 are supposed to influence the distribution of chronic lymphocytic leukemia cells. These cells invariably infiltrate the bone marrow of patients and it was shown that their migration in the bone marrow was CXCR4 dependent. Chronic lymphocytic leukemia cells undergo apoptosis unless they are cocultured with stromal cells. SDF-1 blocking antibodies could inhibit this protective effect of stromal cells (Burger *et al.*, *Blood* 96: 2655-63 (2000)). Immunizing against CXCL12 thus provides a way of treatment against chronic lymphocytic leukemia.

CXCR4 has been shown to be a coreceptor for entry of HIV into T-cells. SDF-1 inhibits infection of CD4+ cells by X4 (CXCR4-dependent) HIV strains (Oberlin *et al.*, *Nature* 382:833-5 (1996); Bleul *et al.*, *Nature* 382:829-33 (1996), Rusconi *et al.*, *Antivir. Ther.* 5:199-204 (2000)). Synthetic peptide analogs of SDF-1 have been shown to effectively inhibit HIV-1 entry and infection via the CXCR4 receptor (WO059928A1). Thus, immunization against CXCL12 provides a way to block HIV entry in T-cells, and therefore a way of treating AIDS.

SDF-1-CXCR4 interactions were also reported to play a central role in CD4+ T cell accumulation in rheumatoid arthritis synovium (Nanki *et al.*, 2000).

Immunization against SDF-1 thus provides a way of treatment against rheumatoid arthritis.

Human and murine SDF-1 are known to arise in two forms, SDF-1 α and SDF-1 β , by differential splicing from a single gene. They differ in four C-terminal amino acids that are present in SDF-1 β (74 aa) and absent in SDF-1 α (70 aa). The sequence of human is shown in SEQ ID No: 238 (Swissprot: SDF1_human) and the sequence mouse SDF-1 is shown in SEQ ID No: 239 (Swissprot: SDF1_mouse). SDF-1 contains four conserved cysteines that form two intra-molecular disulfide bonds. The crystal structure of SDF shows a non covalently-linked dimer (Dealwis *et al.*, *PNAS* 95: 6941-46 (1998)). The SDF-1 structure also shows a long N-terminal extension.

Alanine-scanning mutagenesis was used to identify (part of) the receptor-binding site on SDF-1 (Ohnishi *et al.*, *J. Interferon Cytokine Res.* 20: 691-700 (2000)) and Elisseeva *et al.* (*J. Biol. Chem.* 275:26799-805 (2000)) and Heveker *et al.* (*Curr. Biol.* 8:369-76 (1998)) described SDF-1 derived peptides inhibiting receptor binding (and HIV entry).

In the following, constructs and expression systems suitable in the generation of the compositions of the invention related to SDF-1 are described. The N- and C-terminus of SDF-1 are exposed to the solvent. In specific embodiments, an amino acid linker containing a cysteine as second attachment site is thus fused to the C-terminus of the protein sequence, while in other specific embodiments an amino acid linker containing a cysteine as second attachment site is fused to the N-terminus of the protein sequence. The amino acid linker containing a free cysteine is fused to the N-terminus of the sequence corresponding to the sequence of the processed protein, or inserted at the N-terminus of the sequence of the mature form of the protein, C-terminally of the signal peptide. The genes coding for these specific constructs may be cloned in a suitable expression vector.

Expression of SDF-1 in a sendai virus system in chicken embryonic fibroblasts (Moriya *et al.*, *FEBS Lett.* 425:105-11 (1998)) has been described as well as expression in E.coli (Holmes *et al.*, *Prot. Expr. Purif.* 21: 367-77 (2001)) and chemical synthesis of SDF-1 (Dealwis *et al.*, *PNAS* 95: 6941-46 (2001)).

In yet another embodiment of the invention, the antigenic determinant is BLC. B-lymphocyte chemoattractant (BLC, CXCL13) is expressed in the spleen, Peyer's patches and lymph nodes (Gunn *et al.*, 1998). Its expression is strongest in the germinal centres, where B cells undergo somatic mutation and affinity maturation. It belongs to the CXC chemokine family, and its closest homolog is GRO α (Gunn *et al.*, *Nature* 391:799-803 (1998)). Human BLC is 64% homologous to murine BLC. Its receptor is CXCR5. BLC also shares homology with IL-8. BLC recruits B-cells to follicles in secondary lymphoid organs such as the spleen and Peyer's patches. BLC is

also required for recruitment of B-cells to compartment of the lymph nodes rich in follicular Dendritic Cells (FDCs) (Ansel *et al.*, *Nature* 406:309-314 (2000)). BLC also induces increased expression of Lymphotoxin α 1 β 2 (LT α 1 β 2) on the recruited B-cells. This provides a positive feed-back loop, since LT α 1 β 2 promotes BLC expression (Ansel *et al.*, *Nature* 406:309-314 (2000)). BLC has also been shown to be able to induce lymphoid neogenesis (Luther *et al.*, *Immunity* 12:471-481(2000)). It appears that FDCs also express BLC. Thus immunization against BLC may provide a way of treatment against autoimmune diseases where lymphoid neogenesis is involved, such as Rheumatoid synovitis and Rheumatoid arthritis or Type I diabetes. A construct of BLC bearing a C-terminal his-tag has been described, and is functional (Ansel, K.M. *et al.*, *J. Exp. Med.* 190: 1123-1134 (1999)).

Thus, in a preferred embodiment of the present invention, the composition comprises a linker containing a cysteine residue as second attachment site and being fused at the C-terminus of the BLC sequence.

In IL-8, which is homologous to BLC, both N- and C-termini are free. In a further preferred embodiment, addition of an amino acid linker containing a cysteine residue as second attachment site is, therefore, done to the N-terminus of BLC for generation of this specific composition of the invention.

In further preferred embodiments of the present invention, the composition comprises an amino acid linker containing a free cysteine and being fused to the N-terminus of the sequence corresponding to the sequence of the processed protein, or inserted at the N-terminus of the sequence of the mature form of the protein, C-terminally of the signal peptide. The genes coding for these specific constructs may be cloned in a suitable expression vector and expressed accordingly. The sequence of human BLC is shown in SEQ ID No: 240 (Accession: NP_006410). Amino acids 1-22 of the sequence are the signal peptide. The mouse sequence is shown in SEQ ID No: 241 (Accession NP_061354). Amino acids 1-21 are the signal peptide. Compositions of the invention with BLC as the antigenic determinant, preferably, use the mature form of the protein for generating the compositions of the invention.

In another specific embodiment, the antigenic determinant is Eotaxin. Eotaxin is a chemokine specific for Chemokine receptor 3, present on eosinophils, basophils and Th2 cells. Eotaxin seems however to be highly specific for Eosinophils (Zimmerman *et al.*, *J. Immunol.* 165: 5839-46 (2000)). Eosinophil migration is reduced by 70% in the eotaxin-1 knock-out mouse, which however can still develop eosinophilia (Rothenberg *et al.*, *J. Exp. Med.* 185: 785-90 (1997)). IL-5 seems to be responsible for the migration of eosinophils from bone-marrow to blood, and eotaxin for the local migration in the tissue (Humbles *et al.*, *J. Exp. Med.* 186: 601-12 (1997)).

The human genome contains 3 eotaxin genes, eotaxin1-3. They share 30% homology to each other. Two genes are known so far in the mouse: eotaxin 1 and eotaxin 2 (Zimmerman *et al.*, *J. Immunol.* 165: 5839-46 (2000)). They share 38% homology. Murine eotaxin-2 shares 59% homology with human eotaxin-2. In the mouse, eotaxin-1 seems to be ubiquitously expressed in the gastro-intestinal tract, while eotaxin-2 seems to be predominantly expressed in the jejunum (Zimmerman *et al.*, *J. Immunol.* 165: 5839-46 (2000)). Eotaxin-1 is present in broncho-alveolar fluid (Teixeira *et al.*, *J. Clin. Invest.* 100: 1657-66 (1997)). The sequence of human eotaxin-1 is shown in SEQ ID No.: 242 (aa 1-23 corresponds to the signal peptide), the sequence of human eotaxin-2 is shown in SEQ ID No.: 243 (aa 1-26 corresponds to the signal peptide), the sequence of human eotaxin-3 is shown in SEQ ID No.: 244 (aa 1-23 corresponds to the signal peptide), the sequence of mouse eotaxin-1 is shown in SEQ ID No.: 245 (aa 1-23 corresponds to the signal peptide), and the sequence of mouse eotaxin-2 is shown in SEQ ID No.: 246 (aa 1-23 corresponds to the signal peptide).

Eotaxin has a MW of 8.3 kDa. It is in equilibrium between monomers and dimers over a wide range of conditions, with an estimated K_d of 1.3 mM at 37°C (Crump *et al.*, *J. Biol. Chem.* 273: 22471-9 (1998)). The monomer form is however predominant. The structure of Eotaxin has been elucidated by NMR spectroscopy. Binding site to its receptor CCR3 is at the N-terminus, and the region preceding the first cysteine is crucial (Crump *et al.*, *J. Biol. Chem.* 273: 22471-9 (1998)). Peptides of chemokine receptors bound to Eotaxin confirmed this finding. Eotaxin has four cysteines forming two disulfide bridges. Therefore, in a preferred embodiment, the inventive composition comprises an amino-acid linker containing a cysteine residue as second attachment site and being, preferably, fused to the C-terminus of the Eotaxin sequence. In other preferred embodiments, an amino acid linker containing a free cysteine is fused to the N-terminus of the sequence corresponding to the sequence of the processed protein, or inserted at the N-terminus of the sequence of the mature form of the protein, C-terminally of the signal peptide. The genes coding for these specific constructs are cloned in a suitable expression vector.

Eotaxin can be chemically synthesized (Clark-Lewis *et al.*, *Biochemistry* 30:3128-3135 (1991)). Expression in *E. coli* has also been described for Eotaxin-1, in the cytoplasm (Crump *et al.*, *J. Biol. Chem.* 273: 22471-9 (1998)). Expression in *E. coli* as inclusion bodies with subsequent refolding (Mayer *et al.*, *Biochemistry* 39: 8382-95 (2000)), and Insect cell expression (Forssmann *et al.*, *J. Exp. Med.* 185: 2171-6 (1997)) have been described for Eotaxin-2, and may, moreover, be used to arrive at the specific embodiments of the invention.

In yet another specific embodiment of the invention, the antigenic determinant is Macrophage colony-stimulating factor (M-CSF or CSF-1). M-CSF or CSF-1 is a

-77-

regulator of proliferation, differentiation and survival of macrophages and their bone-marrow progenitors. The receptor for M-CSF is a cell surface tyrosine kinase receptor, encoded by the protooncogene *cfms*. An elevated expression of M-CSF and its receptor has been associated with poor prognosis in several epithelial cancers such as breast, uterine and ovarian cancer. Tumor progression has been studied in a mouse strain resulting from the crossing of a transgenic mouse susceptible to mammary cancer (PyMT) with a mouse containing a recessive null mutation in *csf-1* gene. These mice show attenuated late stage invasive carcinoma and pulmonary metastasis compared to the PyMT mouse (Lin *et al.*, *J. Exp. Med.* 193:727-739 (2001)). The cause seems to be the absence of macrophage recruitment to neoplastic tissues. Subcutaneous growth of Lewis lung cancer is also impaired in *csf.1* null mice. It is postulated that the mechanism of macrophage enhancement of tumor growth would be through angiogenic factors, growth factors and proteases produced by the macrophages.

Structural data on the soluble form of M-CSF are available (crystal structure: Pandit *et al.*, *Science* 258:1358-62 (1992)), and show that both the N- and C-termini of the protein are accessible. However, the N-terminus is close to the site of interaction with the receptor. In addition, M-CSF is present both in a soluble and cell surface form, where the transmembrane region is at its C-terminus. Therefore, in a preferred embodiment of the present invention, the inventive composition comprises an amino acid linker containing a cysteine and being, preferably, added at the C-terminus of M-CSF or fragments thereof, or preferably at the C-terminus of the soluble form of M-CSF. In further preferred embodiments, the amino acid linker containing a free cysteine is fused to the N-terminus of the sequence corresponding to the sequence of the processed protein or of the soluble form of the protein, or inserted at the N-terminus of the sequence of the mature form of the protein or of the soluble form of the protein, C-terminally of the signal peptide. M-CSF is a dimer, where the two monomers are linked via an interchain disulfide bridge.

An expression system in *E. coli* has been described for an N-terminal 149 amino acid fragment (functional) of M-CSF (Koths *et al.*, *Mol. Reprod. Dev.* 46:31-37 (1997)). This fragment of M-CSF, preferably modified as outlined above, represents a preferred antigenic determinant in accordance with the invention.

The human sequence is shown in SEQ ID No: 247 (Accession: NP_000748). Further preferred antigenic determinants of the present invention comprise the N-terminal fragment consisting of residue 33 -181 or 33 -185 of SEQ ID No: 247, corresponding to the soluble form of the receptor.

The mouse sequence (Accession. NP_031804) is shown in sequence ID No: 248. The mature sequence starts at amino acid 33. Thus, a preferred antigenic

determinant in accordance with the present invention comprises amino-acid 33 -181 or 33 -185.

In another specific embodiment, the antigenic determinant is Resistin (Res). Passive immunization studies were performed with a rabbit polyclonal antibodies generated against a fusion protein of mouse Resistin (mRes) fused to GST, expressed in bacteria. This passive immunization lead to improved glucose uptake in an animal obesity/ Type II diabetes model (Steppan *et al.*, *Nature* 409: 307-12 (2001)).

Resistin (Res) is a 114 aa peptide hormone of approximately 12 KD. It contains 11 cysteine of which the most N-terminal one was shown to be responsible for the dimerisation of the protein and the other 10 are believed to be involved in intramolecular disulfide bonds (Banerjee and Lazar, *J. Biol. Chem.* 276: 25970-3 (2001)). Mutation of the first cysteine to alanine abolishes the dimerisation of mRes.

It was shown, that mRes with a FLAG tag at its C-terminus still remains active in an animal model (Steppan *et al.*, *Nature* 409: 307-12 (2001)), similarly a C-terminally HA tagged (Haemagglutinin tag) version of resistin was shown to be active in a tissue culture assay (Kim *et al.*, *J. Biol. Chem.* 276: 11252-6 (2001)), suggesting that the C-terminus is not very sensitive to introduced modifications. Thus, in a preferred embodiment, the inventive composition comprises an amino-acid linker containing a cysteine residue as second attachment site and being fused at the C-terminus of the resistin sequence. In further preferred embodiments, the amino acid linker containing a free cysteine is fused to the N-terminus of the sequence corresponding to the sequence of the processed protein, or inserted at the N-terminus of the sequence of the mature form of the protein, C-terminally of the signal peptide.

For a preferred embodiment of the present invention, MRes or huRes may also be expressed as Fc fusion molecules with a protease cleavage site inserted between Resistin and the Fc part of the construct, preferably C-terminally of one or more cysteine residues of the hinge region of the Fc part of the fusion protein in a eukaryotic expression system, or more preferably according to the descriptions and disclosures of EXAMPLE 2. Cleavage of the fusion protein releases Resistin additionally comprising either an aminoacid linker containing a cysteine residue as described in EXAMPLE 2, or part or all of the hinge region of the Fc part of the fusion protein which comprises a cysteine residue at its C-terminus, which is suitable for coupling to VLPs or Pili. The human Resistin sequence is shown in SEQ ID No: 249 (Accession AF323081). The mouse sequence is shown in SEQ ID No: 250 (Accession AF323080). A favored embodiment of the invention is human resistin protein fused at its C-terminus to an amino acid linker containing a cysteine residue. Human resistin construct can be generated according to the teachings disclosed in EXAMPLE 2, and by comparing murine and human Resistin sequences in a protein

-79-

sequence alignment to identify the part of the sequence of human Resistin to be cloned in the vectors described in EXAMPLE 1 and EXAMPLE 2 according to the teachings of EXAMPLE 2, or in other suitable expression vectors. Example of human resistin constructs suitable for generating compositions of the inventions are human resistin-C-Xa: (SEQ ID NO:325), human resistin-C-EK: (SEQ ID NO:326) and human resistin-C: (SEQ ID NO:327).

Human Resistin constructs so generated are a preferred embodiment of the invention. Vaccination against Resistin using the aforementioned compositions of the invention may thus provide a way of treating Type II Diabetes and obesity.

In another embodiment the antigenic determinant is Lymphotoxin- β . Immunization against lymphotoxin- β may be useful in treating Prion mediated disease. Scrapie (a prion-mediated disease) agent replication is believed to take mainly place in lymphoid tissues and was shown to depend on prion-protein expressing follicular dendritic cells (FDCs) (Brown *et al.*, *Nature Med.* 11: 1308-1312 (1999)). It was subsequently shown that mice lacking functional follicular dendritic cells show an impaired prion replication in spleens and a (small) retardation of neuroinvasion (Montrasio *et al.*, *Science* 288: 1257-1259 (2000)). This was achieved by injecting the mice with a soluble lymphotoxin- β receptor-Fc-fusion protein (LT β R-Fc). This soluble receptor construct inhibits the development of FDCs by interfering with the crucial interaction of lymphotoxin- β on T, B or NK cells with the lymphotoxin- β receptor on the FDC precursor cells. Thus, vaccination against lymphotoxin- β (also called TNF γ) may provide a vaccine for treatment or prevention of Creutzfeld-Jakob (variant form) or other prion-mediated diseases and thus prevent prion replication and neuroinvasion.

Immunization against Lymphotoxin- β may also provide a way of treating diabetes. Transgene expression of soluble LT β R-Fc fusion protein in nonobese diabetic NOD mice blocked diabetes development but not insulinitis (Ettinger *et al.*, *J. Exp. Med.* 193: 1333-40 K (2001)). Wu *et al.* (*J. Exp. Med.* 193: 1327-32 (2001)) also used NOD mice to study the involvement of lymphotoxin- β , but instead of transgenic animals they did inject the LT β R-Fc fusion protein. They saw a strong inhibition of diabetes development and inhibition of insulinitis. Most interestingly, they could even reverse preexisting insulinitis by the fusion protein treatment. In the pancreas the formation of lymphoid follicular structures could thus be reversed. Vaccination against lymphotoxin- β may thus provide a way of treatment against type-I diabetes.

The sequence of the extracellular domain of human lymphotoxin- β is shown in SEQ ID No: 250 (TNFC_human) and the sequence of the extracellular domain of murine lymphotoxin- β is shown in SEQ ID No: 251 (TNFC_mouse).

In a further preferred embodiment, the inventive composition comprises an amino acid linker containing a free cysteine and being added to the N-terminus of the sequence corresponding to the processed form of lymphotoxin- β , or inserted between the N-terminus of the sequence corresponding to the mature form of the protein, and the signal peptide, C-terminally to the signal peptide. In further preferred embodiments of the invention, the extracellular part of lymphotoxin- β is expressed as a fusion protein either with Glutathion-S-transferase, fused N-terminally to lymphotoxin- β , or with a 6 histidine-tag followed by a myc-tag, fused again N-terminally to the extracellular part of lymphotoxin- β . An amino acid spacer containing a protease cleavage site as well as a linker sequence containing a free cysteine as attachment site, C-terminally to the protease cleavage site, are fused to the N-terminus of the sequence of the extracellular part of lymphotoxin- β . Preferably, the extracellular part of lymphotoxin- β consists of fragments corresponding to amino acids 49-306 or 126-306 of lymphotoxin- β . These specific compositions of the invention may be cloned and expressed in the pCEP-Pu eukaryotic vector. In further preferred embodiments, the inventive compositions comprise an amino acid linker containing a free cysteine residue suitable as second attachment site, and being fused to the C-terminus of lymphotoxin- β or lymphotoxin- β fragments. In a particularly favored embodiment, the amino acid sequence LACGG, comprising the amino acid linker ACGG which itself contains a cysteine residue for coupling to VLPS and Pili is fused to the N-terminus of the extracellular part of lymphotoxin- β : or of a fragment of the extracellular part of lymphotoxin- β , yielding the proteins human C-LT \bullet 49-306 (SEQ ID NO:346) and human C-LT \bullet 126-306 (SEQ ID NO:347) after cleavage with enterokinase of the corresponding fusion proteins expressed either in vector pCEP-SP-GST-EK or vector pCP-SP-his-myc-EK as described in EXAMPLE 3.

In a preferred embodiment, the antigen or antigenic determinant is the prion protein, fragments thereof and in particular peptides of the prion protein. In one embodiment the prion protein is the human prion protein. Guidance on how to modify human prion protein for association with the cpre particle is given throughout the application and in particular in EXAMPLE 7. Mouse prion protein constructs are disclosed, and human prion protein constructs can also be generated and have, for example, the sequence of SEQ ID NO: 348. Further constructs comprise the whole human prion protein sequence, and other fragments of the human prion protein, which are further composition of the invention. Immunization against prion protein may provide a way of treatment or prevention of Creutzfeld-Jakob (variant form) or other prion-mediated diseases. Immunization using the compositions of the invention comprising the prion protein may provide a way of treatment against prion mediated diseases in other animals, and the corresponding sequences of bovine and sheep prion protein constructs are given in SEQ ID NO:349 and SEQ ID NO:350, respectively. The peptides of the human prion protein corresponding to the murine peptides described in EXAMPLE 8, and of amino acid sequence CSAMSRPIIHFGSDYEDRYYYRENMHR

-81-

("human cprplong") and CGSDYEDRYYRENMHR ("human cprpshort") lead to preferred embodiments of the invention. These peptides comprise an N-terminal cysteine residue added for coupling to VLPs and Pili. Corresponding bovine and sheep peptides are CSAMSRPLIHFGNDYEDRYYRENMHR ("bovine cprplong") and CGNDYEDRYYRENMHR ("bovine cprpshort") CSAMSRPLIHFGNDYEDRYYRENMYR ("sheep cprplong") and CGNDYEDRYYRENMYR ("sheep cprpshort"), all leading to embodiments of the invention.

In a further preferred embodiment of the invention, the antigenic determinant is tumor necrosis factor α (TNF- α), fragments thereof or peptides of TNF- α . In particular, peptides or fragments of TNF- α can be used to induce a self-specific immune response directed towards the whole protein by immunizing a human or an animal with vaccines and compositions, respectively, comprising such peptides or fragments in accordance with the invention. Preferably, VLPs, bacteriophages or bacterial pili are used as core particle, to which TNF- α , peptides or fragments thereof are attached according to the invention.

The following murine peptides are the murine homologs to human peptides that have been shown to be bound by antibodies neutralizing the activity of TNF- α (Yone *et al. J. Biol. Chem.* 270: 19509-19515) and were, in a further preferred embodiment of the invention, modified with cysteine residues for coupling to VLPs, bacteriophages or bacterial pili.

MuTNFa peptide: the sequence CGG was added at the N-terminus of the epitope consisting of amino acid residues 22-32 of mature murine TNF- α : CGGVEEQLEWLSQR.

3'TNF II peptide: the sequence GGC was fused at the C-terminus of the epitope consisting of amino acid residues 4-22 of mature murine TNF- α and glutamine 21 was mutated to glycine. The sequence of the resulting peptide is: SSQNSSDKPVAHVVANHGVGGC.

5'TNF II peptide: a cysteine residue was fused to the N-terminus of the epitope consisting of amino acid residues 4-22 of mature murine TNF- α and

-82-

glutamine 21 was mutated to glycine. The sequence of the resulting peptide is: CSSQNSSDKPVAHVVANHGV.

The corresponding human sequence of the 4-22 epitope is SSRTPSDKPVAHVVANPQAEGQ. Like for the murine sequence a cysteine is, preferably, fused at the N-terminus of the epitope, or the sequence GGC is fused at the C-terminus of the epitope for covalent coupling to VLPs, bacteriophages or bacterial pili according to the invention. It is, however, within the scope of the present invention that other cysteine containing sequences are fused at the N- or C-termini of the epitopes. In general, one or two glycine residues are preferably inserted between the added cysteine residue and the sequence of the epitope. Other amino acids may, however, also be inserted instead of glycine residues, and these amino acid residues will preferably be small amino acids such as serine.

The human sequence corresponding to amino acid residues 22-32 is QLQWLNRRANA. Preferably, the sequence CGG is fused at the N-terminus of the epitope for covalent coupling to VLPs or bacterial pili according to the invention. Other TNF- α epitopes suitable for using in the present invention have been described and are disclosed for example by Yone *et al.* (*J. Biol. Chem.* 270: 19509-19515).

The invention further includes compositions which contain mimotopes of the antigens or antigenic determinants described herein.

The specific composition of the invention comprises an antibody or preferably an antibody fragment presented on a virus-like particle or pilus for induction of an immune response against said antibody. Antibodies or antibody fragments which are produced by lymphoma cells, may be selected for attachment to the virus-like particle and immunization, in order to induce a protective immune response against the lymphoma.

In other further embodiments, an antibody or antibody fragment mimicking an antigen is attached to the particle. The mimicking antibody or antibody fragment may be generated by immunization and subsequent isolation of the mimicking antibody or antibody fragment by any known method known to the art such as e.g. hybridoma technology (Gherardi, E. *et al.*, *J. Immunol. Methods* 126: 61-68 (1990)), phage display (Harrison *et al.*, *Methods Enzymol.* 267: 83-109 (1996)), ribosome display (Hanes, J. *et al.*, *Nat. Biotechnol.* 18: 1287-1292 (2000)), yeast two-hybrid (Visintin, M. *et al.*, *Proc. Natl. Acad. Sci. USA* 96: 11723-11728 (1999)), yeast surface display (Boder, ET. & Wittrup, KD. *Methods. Enzym.* 328: 430-444 (2000)), bacterial surface display (Daugherty, PS. *et al.*, *Protein Eng.* 12: 613-621 (1999)). The mimicking

-83-

antibody may also be isolated from an antibody library or a naïve antibody library using methods known to the art such as the methods mentioned above, for example.

In a further embodiment, an antibody recognizing the combining site of another antibody, i.e. an anti-idiotypic antibody, further called the immunizing antibody, may be used. The antibody recognized by the anti-idiotypic antibody will be further referred to as the neutralizing antibody. Thus, by immunizing against the anti-idiotypic antibody, molecules with the specificity of the neutralizing antibody are generated in situ; we will further refer to these generated antibodies as the induced antibodies. In another preferred embodiment, the immunizing antibody is selected to interact with a ligand molecule of the target molecule against which immunization is sought. The ligand molecule may be any molecule interacting with the target molecule, but will preferentially interact with the site of the target molecule against which antibodies should be generated for inhibition of its function. The ligand molecule may be a natural ligand of the target molecule, or may be any engineered, designed or isolated ligand having suitable binding properties.

The immunizing antibodies may be of human origin, such as isolated from a naïve or immune human antibody library, or may have been isolated from a library generated from another animal source, for example of murine origin.

Coupling of the antibody or antibody fragment to the VLP or pilus is achieved either by limited reduction of exposed disulfide bridges (for example of the interchain disulfide bridge between CH1 and C κ or C λ in a Fab fragment) or by fusion of a linker containing a free cysteine residue at the C-terminus of the antibody or antibody fragment. In a further embodiment, a linker containing a free cysteine residue is fused to the N-terminus of the antibody or antibody fragment for attachment to a VLP or pilus protein.

A number of vaccine compositions which employ mimotopes are known in the art, as are methods for generating and identifying mimotopes of particular epitopes. For example, Arnon *et al.*, *Immunology* 101:555-562 (2000), the entire disclosure of which is incorporated herein by reference, describe mimotope peptide-based vaccines against *Schistosoma mansoni*. The mimotopes used in these vaccines were obtained by screening a solid-phase 8mer random peptide library to identify mimotopes of an epitope recognized by a protective monoclonal antibody against *Schistosoma mansoni*. Similarly, Olszewska *et al.*, *Virology* 272:98-105 (2000), the entire disclosure of which is incorporated herein by reference, describe the

-84-

identification of synthetic peptides which mimic an epitope of the measles virus fusion protein and the use of these peptides for the immunization of mice. In addition, Zuercher *et al.*, *Eur. J. Immunol.* 30:128-135 (2000), the entire disclosure of which is incorporated herein by reference, describe compositions and methods for oral anti-IgE immunization using epitope-displaying phage. In particular, epitope-displaying M13 bacteriophages are employed as carriers for an oral anti-IgE vaccine. The vaccine compositions tested contain mimotopes and epitopes of the monoclonal anti-IgE antibody BSW17.

The invention thus includes vaccine compositions which contain mimotopes that elicit immunological responses against particular antigens, as well as individual mimotope/core particle conjugates and individual mimotope/non-naturally occurring molecular scaffold conjugates which make up these vaccine compositions, and the use of these vaccine compositions to elicit immunological responses against specific antigens or antigenic determinants. Mimotopes may also be polypeptides, such as anti-idiotypic antibodies. Therefore, in a further preferred embodiment of the invention, the antigen or antigenic determinant is an anti-idiotypic antibody or anti-idiotypic antibody fragment.

The invention further includes compositions which contain mimotopes of the antigens or antigenic determinants described herein.

Mimotopes of particular antigens may be generated and identified by any number of means including the screening of random peptide phage display libraries (*see, e.g.*, PCT Publication No. WO 97/31948, the entire disclosure of which is incorporated herein by reference). Screening of such libraries will often be performed to identify peptides which bind to one or more antibodies having specificity for a particular antigen.

Mimotopes suitable for use in vaccine compositions of the invention may be linear or circular peptides. Mimotopes which are linear or circular peptides may be linked to non-natural molecular scaffolds or core particles by a bond which is not a peptide bond.

As suggested above, a number of human IgE mimotopes and epitopes have been identified which elicit immunological responses against human IgE molecules. (*See, e.g.*, PCT Publication No. WO 97/31948.) Thus, in certain embodiments, vaccine compositions of the invention include compositions which elicit an immunological response against immunoglobulin molecules (*e.g.*, IgE molecules).

Peptides which can be used to elicit such immunological responses include proteins, protein subunits, domains of IgE molecules, and mimotopes which are capable of eliciting production of antibodies having specificity for IgE molecules.

-85-

Generally, portions of IgE molecules used to prepare vaccine compositions will be derived from IgE molecules of the species from which the composition is to be administered. For example, a vaccine composition intended for administration to humans will often contain one or more portions of the human IgE molecule, and/or one or more mimotopes which are capable of eliciting immunological responses against human IgE molecules.

In specific embodiments, vaccine compositions of the invention intended for administration to humans will contain at least one portion of the constant region of the IgE heavy chain set out in SEQ ID NO:176; Accession No. AAB59424 (SEQ ID NO: 176). In more specific embodiments, IgE peptides used to prepare vaccine compositions of the invention comprise, or alternatively consist of, peptides having the following amino acid sequences: CGGVNLTWSRASG (SEQ ID NO:178).

In additional specific embodiments, vaccine compositions of the invention will contain at least one mimotope which is capable of eliciting an immune response that results in the production of antibodies having specificity for a particular antigen.

Examples of mimotopes of IgE suitable for use in the preparation of vaccine compositions of the invention include peptides having the following amino acid sequences:

Mimotope	SEQ ID NO	Mimotope	SEQ ID NO
INHRGYWV	179	VKLPWRFYQV	187
RNHRGYWV	180	VWTACGYGRM	188
RSRSGGYWLW	181	GTVSTLS	189
VNLTWSRASG	182	LLDSRYW	190
C. H ₃ epitope		QPAHSLG	191
VNLPWSRASG	183	LWGMQGR	192
VNLTWSFGLE	184	LTLSHPHWVLNHFVS	193
VNLPWSFGLE	185	SMGPDQTLR	194
C. H ₃ mimotope		VNLTWS	195
VNRPWSFGLE	186	GEFCINHRGYWVCGDPA	216

C. Preparation of the AlphaVaccine Particles

The invention provides novel compositions and methods for the construction of ordered and repetitive antigen arrays. As one of skill in the art would know, the conditions for the assembly of the ordered and repetitive antigen array depend to a large extent on the specific choice of the first attachment site of the non-natural molecular scaffold and the specific choice of the second attachment site of the antigen or antigenic determinant. Thus, practitioner choice in the design of the composition (*i.e.*, selection of the first and second attachment sites, antigen and non-natural molecular scaffold) will determine the specific conditions for the assembly of the AlphaVaccine particle (the ordered and repetitive antigen array and non-natural molecular scaffold combined). Information relating to assembly of the AlphaVaccine particle is well within the working knowledge of the practitioner, and numerous references exist to aid the practitioner (*e.g.*, Sambrook, J. *et al.*, eds., *MOLECULAR CLONING, A LABORATORY MANUAL*, 2nd. edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989); Ausubel, F. *et al.*, eds., *CURRENT PROTOCOLS IN MOLECULAR BIOLOGY*, John H. Wiley & Sons, Inc. (1997); Celis, J., ed., *CELL BIOLOGY*, Academic Press, 2nd edition, (1998); Harlow, E. and Lane, D., "Antibodies: A Laboratory Manual," Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1988), all of which are incorporated herein by reference.

-87-

In a specific embodiment of the invention, the *JUN* and *FOS* leucine zipper protein domains are utilized for the first and second attachment sites of the invention, respectively. In the preparation of AlphaVaccine particles, antigen must be produced and purified under conditions to promote assembly of the ordered and repetitive antigen array onto the non-natural molecular scaffold. In the particular *JUN/FOS* leucine zipper protein domain embodiment, the *FOS*-antigen or *FOS*-antigenic determinant should be treated with a reducing agent (*e.g.*, Dithiothreitol (DTT)) to reduce or eliminate the incidence of disulfide bond formation (Example 15).

For the preparation of the non-natural molecular scaffold (*i.e.*, recombinant Sinbis virus) of the *JUN/FOS* leucine zipper protein domain embodiment, recombinant E2-*JUN* viral particles should be concentrated, neutralized and treated with reducing agent (*see* Example 16).

Assembly of the ordered and repetitive antigen array in the *JUN/FOS* embodiment is done in the presence of a redox shuffle. E2-*JUN* viral particles are combined with a 240 fold molar excess of *FOS*-antigen or *FOS*-antigenic determinant for 10 hours at 4°C. Subsequently, the AlphaVaccine particle is concentrated and purified by chromatography (Example 16).

1 In another embodiment of the invention, the coupling of the non-natural molecular scaffold to the antigen or antigenic determinant may be accomplished by chemical cross-linking. In a specific embodiment, the chemical agent is a heterobifunctional cross-linking agent such as ϵ -maleimidocaproic acid N-hydroxysuccinimide ester (Tanimori *et al.*, *J. Pharm. Dyn.* 4:812 (1981); Fujiwara *et al.*, *J. Immunol. Meth.* 45:195 (1981)), which contains (1) a succinimide group reactive with amino groups and (2) a maleimide group reactive with SH groups. A heterologous protein or polypeptide of the first attachment site may be engineered to contain one or more lysine residues that will serve as a reactive moiety for the succinimide portion of the heterobifunctional cross-linking agent. Once chemically coupled to the lysine residues of the heterologous protein, the maleimide group of the heterobifunctional cross-linking agent will be available to react with the SH group of a cysteine residue on the antigen or antigenic determinant. Antigen or antigenic determinant preparation in this instance may require the engineering of a cysteine residue into the protein or polypeptide chosen as the second attachment site so that it may be reacted to the free maleimide function on the cross-linking agent bound to the non-natural molecular scaffold first attachment sites. Thus, in such an instance, the heterobifunctional cross-linking agent binds to a first attachment site of the non-natural molecular scaffold and connects the scaffold to a second binding site of the antigen or antigenic determinant.

3. Compositions, Vaccines, and the Administration Thereof, and Methods of Treatment

The invention provides vaccine compositions which may be used for preventing and/or attenuating diseases or conditions. The invention further provides vaccination methods for preventing and/or attenuating diseases or conditions in individuals.

In one embodiment, the invention provides vaccines for the prevention of infectious diseases in a wide range of species, particularly mammalian species such as human, monkey, cow, dog, cat, horse, pig, etc. Vaccines may be designed to treat infections of viral etiology such as HIV, influenza, *Herpes*, viral hepatitis, Epstein Bar, polio, viral encephalitis, measles, chicken pox, etc.; or infections of bacterial etiology such as pneumonia, tuberculosis, syphilis, etc.; or infections of parasitic etiology such as malaria, trypanosomiasis, leishmaniasis, trichomoniasis, amoebiasis, etc.

In another embodiment, the invention provides vaccines for the prevention of cancer in a wide range of species, particularly mammalian species such as human, monkey, cow, dog, cat, horse, pig, etc. Vaccines may be designed to treat all types of cancer: lymphomas, carcinomas, sarcomas, melanomas, etc.

In another embodiment of the invention, compositions of the invention may be used in the design of vaccines for the treatment of allergies. Antibodies of the IgE isotype are important components in allergic reactions. Mast cells bind IgE antibodies on their surface and release histamines and other mediators of allergic response upon binding of specific antigen to the IgE molecules bound on the mast cell surface. Inhibiting production of IgE antibodies, therefore, is a promising target to protect against allergies. This should be possible by attaining a desired T helper cell response. T helper cell responses can be divided into type 1 (T_H1) and type 2 (T_H2) T helper cell responses (Romagnani, *Immunol. Today* 18:263-266 (1997)). T_H1 cells secrete interferon-gamma and other cytokines which trigger B cells to produce IgG1-3 antibodies. In contrast, a critical cytokine produced by T_H2 cells is IL-4, which driven B cells to produce IgG4 and IgE. In many experimental systems, the development of T_H1 and T_H2 responses is mutually exclusive since T_H1 cells suppress the induction of T_H2 cells and *vice versa*. Thus, antigens that trigger a strong T_H1 response simultaneously suppress the development of T_H2 responses and hence the production of IgE antibodies. Interestingly, virtually all viruses induce a T_H1 response in the host and fail to trigger the production of IgE antibodies (Coutelier *et al.*, *J. Exp. Med.* 165:64-69 (1987)). This isotype pattern is not restricted to live

-89-

viruses but has also been observed for inactivated or recombinant viral particles (Lo-Man *et al.*, *Eur. J. Immunol.* 28:1401-1407 (1998)). Thus, by using the processes of the invention (*e.g.*, AlphaVaccine Technology), viral particles can be decorated with various allergens and used for immunization. Due to the resulting "viral structure" of the allergen, a T_H1 response will be elicited, "protective" IgG1-3 antibodies will be produced, and the production of IgE antibodies which cause allergic reactions will be prevented. Since the allergen is presented by viral particles which are recognized by a different set of helper T cells than the allergen itself, it is likely that the allergen-specific IgG1-3 antibodies will be induced even in allergic individuals harboring pre-existing T_H2 cells specific for the allergen. The presence of high concentrations of IgG antibodies may prevent binding of allergens to mast cell bound IgE, thereby inhibiting the release of histamine. Thus, presence of IgG antibodies may protect from IgE mediated allergic reactions. Typical substances causing allergies include: grass, ragweed, birch or mountain cedar pollens, house dust, mites, animal danders, mold, insect venom or drugs (*e.g.*, penicillin). Thus, immunization of individuals with allergen-decorated viral particles should be beneficial not only before but also after the onset of allergies.

In specific embodiments, the invention provides methods for preventing and/or attenuating diseases or conditions which are caused or exacerbated by "self" gene products (*e.g.*, tumor necrosis factors), *i.e.* "self antigens" as used herein. In related embodiments, the invention provides methods for inducing immunological responses in individuals which lead to the production of antibodies that prevent and/or attenuate diseases or conditions are caused or exacerbated by "self" gene products. Examples of such diseases or conditions include graft versus host disease, IgE-mediated allergic reactions, anaphylaxis, adult respiratory distress syndrome, Crohn's disease, allergic asthma, acute lymphoblastic leukemia (ALL), non-Hodgkin's lymphoma (NHL), Graves' disease, inflammatory autoimmune diseases, myasthenia gravis, systemic lupus erythematosus (SLE), immunoproliferative disease lymphadenopathy (IPL), angioimmunoproliferative lymphadenopathy (AIL), immunoblastic lymphadenopathy (IBL), rheumatoid arthritis, diabetes, multiple sclerosis, osteoporosis and Alzheimer's disease.

As would be understood by one of ordinary skill in the art, when compositions of the invention are administered to an individual, they may be in a composition which contains salts, buffers, adjuvants, or other substances which are desirable for improving the efficacy of the composition. Examples of materials suitable for use in preparing pharmaceutical compositions are provided in numerous sources including REMINGTON'S PHARMACEUTICAL SCIENCES (Osol, A, ed., Mack Publishing Co., (1990)).

-90-

Compositions of the invention are said to be "pharmacologically acceptable" if their administration can be tolerated by a recipient individual. Further, the compositions of the invention will be administered in a "therapeutically effective amount" (*i.e.*, an amount that produces a desired physiological effect).

The compositions of the present invention may be administered by various methods known in the art, but will normally be administered by injection, infusion, inhalation, oral administration, or other suitable physical methods. The compositions may alternatively be administered intramuscularly, intravenously, or subcutaneously. Components of compositions for administration include sterile aqueous (*e.g.*, physiological saline) or non-aqueous solutions and suspensions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Carriers or occlusive dressings can be used to increase skin permeability and enhance antigen absorption.

Prion-mediated diseases are an increasing threat for society. Specifically, prion-induced BSE in cattle represents a disease that has long been neglected and may affect a great number of animals throughout Europe. Moreover, a variant form of CJD is attributed to infection of humans after consumption of meat of prion-infected cattle. Although the number of infected people has been relatively low so far, it seems possible that the disease may become epidemic. However, long-term prognosis for the development of vCJD may be particularly difficult, since incubation times between infection and overt disease are very long (an estimated 10 years).

Prions are cellular proteins existing in most mammalian species. Prion proteins exist in two forms, a normally folded form that is usually present in healthy individuals (PrP^c) and a misfolded form that causes disease (PrP^{Sc}). The current prion hypotheses postulates that the misfolded prion form PrP^{Sc} can catalyse the refolding of healthy prion PrP^c into disease causing PrP^{Sc} (A. Aguzzi, *Haematologica* 85, 3-10 (2000)). In some rare instances, this transition may also occur spontaneously, causing classical CJD in humans. Some mutations in PrP^c are associated with an increase in this spontaneous transition, causing the various forms of familial CJD. However, PrP^{Sc} may also be infectious and may be transmitted by blood transfusion or via the food chain. The latter form of prion mediated disease is known as Kuru Kuru and used to occur in human cannibals. However, since species that are feeding on their own individuals are not abundant, this form of orally transmitted disease was too rare to be documented for other species.

The massive feeding of cows with beef-products throughout Europe now

changed the situation and numbers of cows infected with a transmissible form of BSE-causing PrP^{Sc}, dramatically increased in recent years, afflicting hundreds of thousands of cows. This sudden appearance of massive numbers of BSE-diseased cows caused great fear in the human population that a similar disease may be induced in humans. Indeed, in 1996, the first case of a variant form of CJD was reported that could be attributed to the consumption of PrP^{Sc} infected beef. Until now, this fear has further increased, since the number of infected humans has constantly increased during the following years and no cure is in sight. Moreover, since sheep succumb to a prion-mediated disease called scrapie and since other mammalian species can be infected with PrP^{Sc}

Experimentally, it is possible that BSE-like diseases may occur also in other species. The mechanism of prion transmission has been studied in great detail. It is now clear that prions first replicate in the lymphoid organs of infected mice and are subsequently transported to the central nervous system. Follicular dendritic cells (FDCs), a rare cell population in lymphoid organs, seems to be essential for both replication of prion proteins in the lymphoid organs and transport into the central nervous system (S. Brandner, M. A. Klein, A. Aguzzi, *Transfus Clin Biol* 6, 17-23 (1999); F. Montrasio, et al., *Science* 288, 1257-9 (2000)). FDCs are a poorly studied cell type but it is now clear that they depend upon the production of lymphotoxin and/or TNF by B cells for their development (F. Mackay, J. L. Browning, *Nature* 395, 26-27 (1998)). Indeed, mice deficient for lymphotoxin do not exhibit FDCs (M. S. Matsumoto, et al., *Science* 264, 703-707 (1996)). Moreover, they fail to be productively infected with prions and do not succumb to disease. In addition to FDCs, antibodies may also play a role in disease progression (S. Brandner, M. A. Klein, A. Aguzzi, *Transfus Clin Biol* 6, 17-23 (1999)).

Recently, it was shown that blocking the LT β pathway using a LT β receptor Fc fusion molecule not only eliminates FDCs in mice but also blocks infection with PrP^{Sc} (F. Montrasio, et al., *Science* 288, 1257-9 (2000)). Thus, a vaccine that induces antibodies specific for LT β or its receptor may be able to block transmission of PrP^{Sc} from one individual to another or from the periphery to the central nervous system.

However, it is usually difficult if not impossible to induce antibody responses to self-molecules by conventional vaccination. One way to improve the efficiency of vaccination is to increase the degree of repetitiveness of the antigen applied: Unlike isolated proteins, viruses induce prompt and efficient immune responses in the absence of any adjuvants both with and without T-cell help (Bachmann & Zinkemagel, *Ann. Rev. Immunol.* 15:235-270 (1991)). Although

-92-

viruses often consist of few proteins, they are able to trigger much stronger immune responses than their isolated components. For B-cell responses, it is known that one crucial factor for the immunogenicity of viruses is the repetitiveness and order of surface epitopes. Many viruses exhibit a quasi-crystalline surface that displays a regular array of epitopes which efficiently crosslinks epitope-specific immunoglobulins on B cells (Bachmann & Zinkernagel, *Immunol. Today* 17:553-558 (1996)). This crosslinking of surface immunoglobulins on B cells is a strong activation signal that directly induces cell-cycle progression and the production of IgM antibodies. Further, such triggered B cells are able to activate T helper cells, which in turn induce a switch from IgM to IgG antibody production in B cells and the generation of long-lived B cell memory - the goal of any vaccination (Bachmann & Zinkernagel, *Ann. Rev. Immunol.* 15:235-270 (1997)). Viral structure is even linked to the generation of anti-antibodies in autoimmune disease and as a part of the natural response to pathogens (see Fehr, T., et al., *J Exp. Med.* 185:1785-1792 (1997)). Thus, antibodies presented by a highly organized viral surface are able to induce strong anti-antibody responses.

The immune system usually fails to produce antibodies against self-derived structures. For soluble antigens present at low concentrations, this is due to tolerance at the Th cell level. Under these conditions, coupling the self-antigen to a carrier that can deliver T help may break tolerance. For soluble proteins present at high concentrations or membrane proteins at low concentration, B and Th cells may be tolerant. However, B cell tolerance may be reversible (anergy) and can be broken by administration of the antigen in a highly organized fashion coupled to a foreign carrier (Bachmann & Zinkernagel, *Ann. Rev. Immunol.* 15:235-270 (1997)). Thus, LTb, LTa or LTb receptor as highly organized as a virus, a virus like particle or a bacterial pilus may be able to break B cell tolerance and to induce antibodies specific for these molecules.

The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a method that facilitates induction of antibodies specific for endogenous lymphotoxin (LT)b, LTa or LTb receptor. The invention also provides a process for producing an antigen or antigenic determinant that is able to elicit antibodies specific for LTb, LTa or LTb receptor which is useful for the prevention and therapy of prion-mediated diseases such as variant Creutzfeld-Jacob disease (vCJD) or bovine spongiform encephalopathy (BSE) and elimination of lymphoid organ like structures in autoimmune diseased tissues.

The object of the invention is to provide a vaccine that is able to induce antibodies specific for LTb, LTa or LTb receptor thereby eliminating FDCs

-93-

from lymphoid organs. This treatment may allow preventing infection with PrP^{Sc} or spread of PrP^{Sc} from the periphery to the central nervous system. In addition, this treatment blocks generation of lymphoid organ like structures in organs targeted by autoimmune disease and may even dissolve such existing structures, ameliorating disease symptoms.

LTb, LTa or LTb receptor or fragments thereof are coupled to a protein carrier that is foreign to the host. In a preferred embodiment of the invention, LTb, LTa or LTb receptor or fragments thereof will be coupled to a highly organized structure in order to render these molecules highly repetitive and organized. The highly organized structure may be a bacterial pilus, a virus like particle (VLP) generated by recombinant proteins of the bacteriophage Q β , recombinant proteins of Rotavirus, recombinant proteins of Norwalkvirus, recombinant proteins of Alphavirus, recombinant proteins of Foot and Mouth Disease virus, recombinant proteins of Retrovirus, recombinant proteins of Hepatitis B virus, recombinant proteins of Tobacco mosaic virus, recombinant proteins of Flock House Virus, and recombinant proteins of human Papillomavirus. In order to optimize the three-dimensional arrangement of LTb, LTa or LTb receptor or fragments thereof on the highly organized structure, an attachment site, such as a chemically reactive amino acid, is introduced into the highly organized structure (unless it is naturally there) and a binding site, such as a chemically reactive amino acid, will be introduced on the LTb, LTa or LTb receptor or fragments (unless it is naturally there). The presence of an attachment site on the highly organized structure and a binding site on the LTb, LTa or LTb receptor or fragments thereof will allow to couple these molecules to the repetitive structure in an oriented and ordered fashion which is essential for the induction of efficient B cell responses.

In an equally preferred embodiment, the attachment site introduced in the repetitive structure is biotin that specifically binds streptavidin. Biotin may be introduced by chemical modification. LTb, LTa or LTb receptor or fragments thereof may be fused or linked to streptavidin and bound to the biotinylated repetitive structure.

Other embodiments of the invention include processes for the production of the compositions of the invention and methods of medical treatment using said compositions. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are intended to provide further explanation of the invention as claimed.

In addition to vaccine technologies, other embodiments of the invention are drawn to methods of medical treatment for cancer and allergies.

All patents and publications referred to herein are expressly incorporated by reference in their entirety.

EXAMPLES

Enzymes and reagents used in the experiments that follow included: T4 DNA ligase obtained from New England Biolabs; Taq DNA Polymerase, QIAprep Spin Plasmid Kit, QIAGEN Plasmid Midi Kit, QiaExII Gel Extraction Kit, QIAquick PCR Purification Kit obtained from QIAGEN; QuickPrep Micro mRNA Purification Kit obtained from Pharmacia; SuperScript One-step RT PCR Kit, fetal calf serum (FCS), bacto-tryptone and yeast extract obtained from Gibco BRL; Oligonucleotides obtained from Microsynth (Switzerland); restriction endonucleases obtained from Boehringer Mannheim, New England Biolabs or MBI Fermentas; Pwo polymerase and dNTPs obtained from Boehringer Mannheim. HP-1 medium was obtained from Cell culture technologies (Glattbrugg, Switzerland). All standard chemicals were obtained from Fluka-Sigma-Aldrich, and all cell culture materials were obtained from TPP.

DNA manipulations were carried out using standard techniques. DNA was prepared according to manufacturer instruction either from a 2 ml bacterial culture using the QIAprep Spin Plasmid Kit or from a 50 ml culture using the QIAGEN Plasmid Midi Kit. For restriction enzyme digestion, DNA was incubated at least 2 hours with the appropriate restriction enzyme at a concentration of 5-10 units (U) enzyme per mg DNA under manufacturer recommended conditions (buffer and temperature). Digests with more than one enzyme were performed simultaneously if reaction conditions were appropriate for all enzymes, otherwise consecutively. DNA fragments isolated for further manipulations were separated by electrophoresis in a 0.7 to 1.5% agarose gel, excised from the gel and purified with the QiaExII Gel Extraction Kit according to the instructions provided by the manufacturer. For ligation of DNA fragments, 100 to 200 pg of purified vector DNA were incubated overnight with a threefold molar excess of the insert fragment at 16°C in the presence of 1 U T4 DNA ligase in the buffer provided by the manufacturer (total volume: 10-20 μ l). An aliquot (0.1 to 0.5 μ l) of the ligation reaction was used for transformation of *E. coli* XL1-Blue (Stratagene). Transformation was done by electroporation using a Gene Pulser (BioRAD) and 0.1 cm Gene Pulser Cuvettes (BioRAD) at 200 Ohm, 25 μ F, 1.7 kV. After electroporation, the cells were incubated with shaking for 1 h in 1 ml S.O.B. medium (Miller, 1972) before plating on selective S.O.B. agar.

EXAMPLE 1

Modular eukaryotic expression system for coupling of antigens to VLPs

This system was generated in order to add various amino acid linker sequences containing a cysteine residue to antigens for chemical coupling to VLPs.

A. Construction of an EBNA derived expression system encoding a cysteine-containing amino acid linker and cleavable Fc-Tag:

pCep-Pu (Wuttke *et al.* *J. Biol. Chem.* 276: 36839-48 (2001)) was digested with Kpn I and Bam HI and a new multiple cloning site was introduced with the annealed oligonucleotides PH37 (SEQ ID NO:270) and PH38 (SEQ ID NO:271) leading to pCep-MCS.

A modular system containing a free cysteine flanked by several glycines, a protease cleavage site and the constant region of the human IgG1 was generated as follows. pSec2/Hygro B (Invitrogen Cat. No. V910-20) was digested with Bsp120I and Hind III and ligated with the annealed oligonucleotides SU7 (SEQ ID NO:278) and SU8 (SEQ ID NO:279) leading to construct pSec-B-MCS. pSec-B-MCS was then digested with Nhe I and Hind III and ligated with the annealed oligonucleotides PH29 (SEQ ID NO:264) and PH30 (SEQ ID NO:265) leading to construct pSec 29/30. The construct pSec-FL-EK-Fc* was generated by a three fragment ligation of the following fragments; first pSec 29/30 digested with Eco RI and Hind III, the annealed oligonucleotides PH31 (SEQ ID NO:266) and PH32 (SEQ ID NO. 267) and the Bgl I/EcoRI fragment of a plasmid (pSP-Fc*-C1) containing a modified version of the human IgG1 constant region (for details of the hu IgG1 sequence see the sequence of the final construct pCep-Xa-Fc* see FIG. 1A-1C). The complete sequence of pCep-Xa-Fc* is given in SEQ ID NO:283. The resulting construct was named pSec-FL-EK-Fc*. From this plasmid the linker region and the human IgG1 Fc part was excised by Nhe I, Pme I digestion and cloned into pCep-MCS digested with Nhe I and Pme I leading to construct pCep-FL-EK-Fc*. Thus a modular vector, was created where the linker sequence and the protease cleavage site, which are located between the Nhe I and Hind III sites, can easily be exchanged with annealed oligonucleotides. For the generation of cleavable fusion protein vectors pCep-FL-EK-Fc* was digested with

-96-

Nhe I and Hind III and the Factor Xa cleavage site N-terminally flanked with amino acids GGGGCG was introduced with the annealed oligonucleotides PH35 (SEQ ID NO:268) and PH36 (SEQ ID NO:269) and the enterokinase site flanked n-terminally with GGGGCG was introduced with the annealed oligonucleotides PH39 (SEQ ID NO:272) and PH40 (SEQ ID NO:273) leading to the constructs pCep-Xa-Fc* (see FIG. 1A) and pCep-EK-Fc* (see FIG. 1B) respectively. The construct pCep-SP-EK-Fc* (see FIG. 1C) which in addition contains a eukaryotic signal peptide was generated by a three fragment ligation of pCep-EK-Fc* digested Kpn I/ Bam HI, the annealed oligos PH41 (SEQ ID NO:274) and PH42 (SEQ ID NO:275) and the annealed oligos PH43 (SEQ ID NO:276) and PH44 (SEQ ID NO:277).

B. Large Scale production of fusion proteins:

For the large scale production of the different fusion proteins 293-EBNA cells (Invitrogen) were transfected with the different pCep expression plasmids with Lipofectamine 2000 reagent (life technologies) according to the manufacturer's recommendation. 24-36 h post transfection the cells were split at a 1 to 3 ratio under puromycin selection (1µg/ml) in DMEM supplemented with 10 % FCS. The resistant cells were then expanded in selective medium. For the harvesting of the fusion proteins the resistant cell population were passed onto poly-L-lysine coated dishes. Once the cells had reached confluence, they were washed 2 times with PBS and serum free medium (DMEM) was added to the plates. The tissue culture supernatant were harvested every 2 to 4 days and replaced with fresh DMEM medium during a period of up to one month. The harvested supernatants were kept at 4 °C.

C. Purification of the fusion proteins:

The recombinant Fc-fusion proteins were purified by affinity chromatography using protein A sepharose CL-4B (Amersham Pharmacia Biotech AG). Briefly chromatography columns were packed with 1-3 ml protein A resin and the tissue culture supernatants containing the recombinant proteins were applied to the column with a peristaltic pump at a flow rate of 0.5 – 1.5 ml/min. The column was then washed with 20-50 ml PBS. Depending on the fusion protein the protease cleavage was performed on the column or the protein was eluted as described below. Recombinant fusion proteins were eluted with a citrate/ phosphate buffer (pH 3.8)

-97-

supplemented with 150 mM NaCl and the fractions containing the protein were pooled and concentrated with ultrafree centrifugal filters (Millipore).

D. Protease cleavage of recombinant fusion proteins (Factor Xa, enterokinase):

Eluted recombinant fusion proteins containing the enterokinase (EK) cleavage site were cleaved using the EKmax system (Invitrogen) according to the manufacturer's recommendation. The cleaved Fc part of the fusion protein was removed by incubation with protein A. The enterokinase was then removed with the EK-Away system (Invitrogen) according to the manufacturers recommendation. Similarly fusion proteins containing the factor Xa (Xa) cleavage site were cleaved using the restriction protease factor Xa cleavage and removal kit (Roche) according to the manufacturer's recommendation. The cleaved Fc part was removed by incubation with protein A and the protease was removed with the streptavidin resin provided with the kit.

The different fusion proteins were concentrated with ultrafree centrifugal filters (Millipore), quantitated by UV spectrophotometrie and used for subsequent coupling reactions.

FIG. 1A-1C shows partial sequences of the different eukaryotic expression vectors used. Only the modified sequences are shown.

FIG 1A: pCep-Xa-Fc*: the sequence is shown from the Bam HI site onwards and different features are shown above the translated sequence. The arrow indicates the cleavage site of the factor Xa protease.

FIG 1B: pCep-EK-Fc*: the sequence is shown from the Bam HI site onwards and different features are shown above the translated sequence. The arrow indicates the cleavage site of the enterokinase. The sequence downstream of the Hind III site is identical to the one shown in FIG 1A.

FIG. 1C: pCep-SP-EK-Fc*: the sequence is shown from the beginning of the signal peptide on and different features are shown above the translated sequence. The signal peptide sequence which is cleaved of by the signal peptidase is shown in bold. The arrow indicates the cleavage site of the enterokinase. The sequence downstream of the Hind III site is identical to the one shown in FIG 1A.

EXAMPLE 2

Eukaryotic expression and coupling of mouse resistin to VLPs and Pili

A. Cloning of mouse Resistin:

Total RNA was isolated from 60 mg mouse adipose tissue using a Qiagen RNeasy kit according to the manufacturer's recommendation. The RNA was eluted in 40 μ l H₂O. This total RNA was then used for the reverse transcription with an oligo dT primer using the ThermoScriptTM RT-PCR System (Life Technologies) according to the manufacturer's recommendation. The sample was incubated at 50 °C for 1h, heated to 85 °C for 5 minutes and treated for 20 minutes at 37 °C with RNaseH.

2 μ l of the RT reaction were used for the PCR amplification of mouse resistin. The PCR was performed using Platinum TAQ (Life Technologies) according to the manufacturer's recommendation using primers PH19 (SEQ ID NO:260) and PH20 (SEQ ID NO:261). Primer PH19 (SEQ ID NO:260) corresponds to positions 58-77 and primer PH20 (SEQ ID NO:261) to positions 454-435 of the mouse Resistin sequence. The PCR mix was first denatured at 94 °C for 2 minutes and then 35 cycles were performed as follows: 30 seconds 94 °C, 30 seconds 56 °C and 1 minute 72 °C, at the end the samples were left for 10 minutes at 72 °C. The PCR fragment was purified and subcloned by TA cloning into the pGEMTeasy vector (Invitrogen) leading to pGEMT-mRes. In order to add appropriate restriction sites a second PCR was performed on pGEMT-mRes with the primers PH21 (SEQ ID NO:262) and PH22 (SEQ ID NO. 263) primers using the same cycling program as described above. The forward primer (PH21 (SEQ ID NO:262)) contains a Bam HI site and nucleotides 81-102 of the mouse Resistin sequence. The reverse primer (PH22 (SEQ ID NO:263)) contains an Xba I site and nucleotides 426-406 of the mouse Resistin sequence. The indicated positions refer to the mouse resistin sequence Gene Accession No. AF323080. The PCR product was purified and digested with Bam HI and Xba I and subcloned into pcmv-Fc*-C1 digested with Bam HI and Xba I leading to the construct pcmv-mRes-Fc*.

The Resistin open reading frame was excised from pcmv-Res-Fc* by Bam HI/Xba I digestion and cloned into pCep-Xa-Fc* and pCep-EK-Fc* (see EXAMPLE 1,

-99-

section B) digested with Bam HI and Nhe I leading to the constructs pCep-mRes-Xa-Fc* and pCep-mRes-EK-Fc* respectively.

B. Production, purification and cleavage of Resistin

pCep-mRes-Xa-Fc* and pCep-mRes-EK-Fc* constructs were then used to transfect 293-EBNA cells for the production of recombinant proteins as described in EXAMPLE 1, section B. The tissue culture supernatants were purified as described in EXAMPLE 1, section C. The purified proteins were then cleaved as described in EXAMPLE 1, section D. The resulting recombinant proteins were termed "resistin-C-Xa" or "Res-C-Xa" and "resistin-C-EK" or "Res-C-EK" according to the vector used (see FIG. 2A and FIG. 2B).

FIG. 2A and FIG. 2B show sequence of recombinant mouse Resistin proteins used for expression and further coupling. Res-C-Xa (FIG. 2A) and Res-C-EK (FIG. 2B) are shown as a translated DNA sequences. The resistin signal sequence which is cleaved upon protein secretion by the signal peptidase is shown in *italic*. The amino acid sequences which result from signal peptidase and specific protease (factor Xa or enterokinase) cleavage are shown **bold**. The bold sequences correspond to the actual protein sequence which was used for coupling, i.e. SEQ ID NO:280, SEQ ID NO:281. SEQ ID NO:282 corresponds to an alternative resistin protein construct, which can also be used for coupling to virus-like particles and pili in accordance with the invention.

C. Coupling of resistin-C-Xa and resistin-C-EK to Q β capsid protein

A solution of 0.2 ml of 2 mg/ml Q β capsid protein in 20 mM Hepes, 150 mM NaCl pH 7.4 was reacted for 30 minutes with 5.6 μ l of a solution of 100mM SMPH (Pierce) in DMSO at 25 °C on a rocking shaker. The reaction solution was subsequently dialyzed twice for 2 hours against 1 L of 20 mM Hepes, 150 mM NaCl, pH 7.4 at 4 °C. 8 μ l of the dialyzed Q β reaction mixture was then reacted with 32 μ l of resistin-C-Xa solution (resulting in a final concentration of resistin of 0.39 mg/ml) and 13 μ l of the Q β reaction mixture was reacted with 27 μ l resistin-C-EK solution (resulting in a final concentration of resistin of 0.67 mg/ml) for four hours at 25 °C on a rocking shaker. Coupling products were analysed by SDS-PAGE (see FIG. 2C). An

-100-

additional band of 24 kDa is present in the coupling reaction, but not in derivatized Q β and resistin, respectively. The size of 24 kDa corresponds to the expected size of 24 kDa for the coupled product (14 kDa for Q β plus 10 kDa for resistin-C-Xa and resistin-C-EK, respectively).



FIG. 2C shows coupling results of resistin-C-Xa and resistin-C-EK to Q β . Coupling products were analysed on 16% SDS-PAGE gels under reducing conditions. Lane 1: Molecular weight marker. Lane 2: resistin-C-EK before coupling. Lane 3: resistin-C-EK- Q β after coupling. Lane 4: Q β derivatized. Lane 5: resistin-C-Xa before coupling. Lane 6: resistin-C-Xa- Q β after coupling. Molecular weights of marker proteins are given on the left margin. Coupled band is indicated by the arrow.

D. Coupling of resistin-C-Xa and resistin-C-EK to fr capsid protein

A solution of 0.2 ml of 2 mg/ml fr capsid protein in 20 mM Hepes, 150 mM NaCl pH 7.4 is reacted for 30 minutes with 5.6 μ l of a solution of 100mM SMPH (Pierce) in DMSO at 25 °C on a rocking shaker. The reaction solution is subsequently dialyzed twice for 2 hours against 1 L of 20 mM Hepes, 150 mM NaCl, pH 7.4 at 4 °C. 8 μ l of the dialyzed fr capsid protein reaction mixture is then reacted with 32 μ l of resistin-C-Xa solution (resulting in a final concentration of resistin of 0.39 mg/ml) and 13 μ l of the fr capsid protein reaction mixture is reacted with 27 μ l resistin-C-EK solution (resulting in a final concentration of resistin of 0.67 mg/ml) for four hours at 25 °C on a rocking shaker. Coupling products are analysed by SDS-PAGE under reducing conditions.

E. Coupling of resistin-C-Xa and resistin-C-EK to HBcAg-Lys-2cys-Mut

A solution of 0.2 ml of 2 mg/ml HBcAg-Lys-2cys-Mut in 20 mM Hepes, 150 mM NaCl pH 7.2 is reacted for 30 minutes with 5.6 μ l of a solution of 100mM SMPH (Pierce) in DMSO at 25 °C on a rocking shaker. The reaction solution is subsequently dialyzed twice for 2 hours against 1 L of 20 mM Hepes, 150 mM NaCl, pH 7.2 at 4 °C. 8 μ l of the dialyzed HBcAg-Lys-2cys-Mut reaction mixture is then reacted with 32 μ l of resistin-C-Xa solution and 13 μ l of the HBcAg-Lys-2cys-Mut reaction mixture is reacted with 27 μ l resistin-C-EK solution for four hours at 25 °C on a rocking shaker. Coupling products are analysed by SDS-PAGE.

-101-

F. Coupling of resistin-C-Xa and resistin-C-EK to Pili

A solution of 400 μ l of 2.5 mg/ml Type-1 pili of *E.coli* in 20 mM Hepes, pH 7.4, is reacted for 60 minutes with a 50-fold molar excess of cross-linker SMPH diluted from a stock solution in DMSO (Pierce) at RT on a rocking shaker. The reaction mixture is desalted on a PD-10 column (Amersham-Pharmacia Biotech). The protein-containing fractions eluting from the column are pooled, and 8 μ l of the desalted derivatized pili protein is reacted with 32 μ l of resistin-C-Xa solution and 13 μ l of the desalted derivatized pili protein is reacted with 27 μ l resistin-C-EK solution for four hours at 25 °C on a rocking shaker. Coupling products are analysed by SDS-PAGE.

EXAMPLE 3

A. Introduction of cys-containing linkers, expression and purification of mouse lymphotoxin- β

The extracellular part of mouse lymphotoxin- β (LT- β) was recombinantly expressed with a CGG amino acid linker at its N-terminus. The linker contained one cysteine for coupling to VLP. A long (aa 49-306) and a short version (aa 126-306) of the protein were fused at their N-terminus to either glutathione S-transferase (GST) or a histidin-myc tag for purification. An enterokinase (EK) cleavage-site was inserted for cleavage of the tag.

Construction of C-LT- β 49-306 and C-LT- β 126-306.

Mouse LT- β 49-306 was amplified by PCR with oligos 5'LT- β and 3'LT- β from a mouse spleen cDNA library inserted into pFB-LIB. For the PCR reaction, 0.5 μ g of each primer and 200 ng of the template DNA was used in the 50 μ l reaction mixture (1 unit of PFX Platinum polymerase, 0.3 mM dNTPs and 2 mM MgSO₄). The temperature cycles were as follows: 94°C for 2 minutes, followed by 25 cycles of 94°C (15 seconds), 68°C (30 seconds), 68°C (1 minute) and followed by 68°C for 10 minutes. The PCR product was phosphorylated with T4 Kinase and ligated into pEntry1A (Life technologies) which has been cut with *EcoRV* and has been dephosphorylated. The resulting plasmid was named pEntry1A-LT- β 49-306.

-102-

A second PCR reaction was performed with oligos 5'LT• long-*NheI* and 3'LT• stop-*NotI* resp. 5'LT• short-*NheI* and 3'LT• stop-*NotI* using pEntry1A-LT• 49-306 as a template. Oligos 5'LT• long-*NheI* and 5'LT• short-*NheI* had an internal *NheI* site and contained codons for a Cys-Gly-Gly linker and 3'LT• stop-*NotI* had an internal *NotI* site and contained a stop codon. For the second PCR reaction, 0.5 µg of each primer and 150 ng of the template DNA was used in the 50 • l reaction mixture (1 unit of PFX Platinum polymerase, 0.3 mM dNTPs and 2 mM MgSO₄). The temperature cycles were as follows: 94°C for 2 minutes, followed by 5 cycles of 94°C (15 seconds), 50°C (30 seconds), 68°C (1 minute), followed by 20 cycles of 94°C (15 seconds), 64°C (30 seconds), 68°C (1 minute) and followed by 68°C for 10 minutes.

The PCR products were digested with *NheI* and *NotI* and inserted into either pCEP-SP-GST-EK or pCEP-SP-his-myc-EK (Wuttke *et al. J. Biol. Chem.* 276: 36839-48 (2001)). Resulting plasmids were named pCEP-SP-GST-EK-C-LT• 49-306, pCEP-SP-GST-EK-C-LT• 126-306, pCEP-SP-his-myc-EK-C-LT• 49-306, pCEP-SP-his-myc-EK-C-LT• 126-306, respectively. GST stands for glutathione-S-transferase, EK for enterokinase, his for a hexahistidine tag and myc for anti c-myc epitope. The C indicates the CGG linker containing the additional cysteine.

All other steps were performed by standard molecular biology protocols.

Sequence of the oligonucleotides:

5'LT• :

5'-CTT GGT GCC GCA GGA TCA G-3' (SEQ ID NO:284)

3'LT• :

5'-CAG ATG GCT GTC ACC CCA C-3' (SEQ ID NO:285)

5'LT• long-*NheI*:

5'-GCC CGC TAG CCT GCG GTG GTC AGG ATC AGG GAC GTC G-3' (SEQ ID NO:286)

5'LT• short-*NheI*:

5'-GCC CGC TAG CCT GCG GTG GTT CTC CAG CTG CGG ATT C -3' (SEQ ID NO:287)

3'LT• stop-*NotI*

-103-

5'-CAA TGA CTG CGG CCG CTT ACC CCA CCA TCA CCG -3' (SEQ ID NO:288)

Expression and production of GST-EK-C-LT⁴⁹⁻³⁰⁶, GST-EK-C-LT¹²⁶⁻³⁰⁶, his-myc-EK-C-LT⁴⁹⁻³⁰⁶ and his-myc-EK-C-LT¹²⁶⁻³⁰⁶

The plasmids pCEP-SP-GST-EK-C-LT⁴⁹⁻³⁰⁶, pCEP-SP-GST-EK-C-LT¹²⁶⁻³⁰⁶, pCEP-SP-his-myc-EK-C-LT⁴⁹⁻³⁰⁶ and pCEP-SP-his-myc-EK-C-LT¹²⁶⁻³⁰⁶ were transfected into 293-EBNA cells (Invitrogen) for protein production as described in EXAMPLE 1. The resulting proteins were named GST-EK-C-LT⁴⁹⁻³⁰⁶, GST-EK-C-LT¹²⁶⁻³⁰⁶, his-myc-EK-C-LT⁴⁹⁻³⁰⁶ and his-myc-EK-C-LT¹²⁶⁻³⁰⁶.

The protein sequences of the LT⁴⁹⁻³⁰⁶ fusion proteins were translated from the cDNA sequences:

GST-EK-C-LT⁴⁹⁻³⁰⁶: SEQ ID NO:289

GST-EK-C-LT¹²⁶⁻³⁰⁶: SEQ ID NO:290

his-myc-EK-C-LT⁴⁹⁻³⁰⁶: SEQ ID NO:291

his-myc-EK-C-LT¹²⁶⁻³⁰⁶: SEQ ID NO:292

The fusion proteins were analysed on 12% SDS-PAGE gels under reducing conditions. Gels were blotted onto nitrocellulose membranes. Membranes were blocked, incubated with a monoclonal mouse anti-myc antibody or with an anti-GST antibody. Blots were subsequently incubated with horse radish peroxidase-conjugated goat anti-mouse IgG or horse radish peroxidase-conjugated rabbit anti-goat IgG. The results are shown in FIG. 3. GST-EK-C-LT⁴⁹⁻³⁰⁶ and GST-EK-C-LT¹²⁶⁻³⁰⁶ could be detected with the anti-GST antibody at a molecular weight of 62 kDa and 48 kDa, respectively. his-myc-EK-C-LT⁴⁹⁻³⁰⁶ and his-myc-EK-C-LT¹²⁶⁻³⁰⁶ could be detected with the anti-myc antibody at 40-56 kDa and 33-39 kDa, respectively.

FIG. 3A and FIG. 3B show the result of the expression of LT⁴⁹⁻³⁰⁶ fusion proteins. LT⁴⁹⁻³⁰⁶ fusion proteins were analysed on 12% SDS-PAGE gels under reducing conditions. Gels were blotted onto nitrocellulose membranes. Membranes were blocked, incubated either with a monoclonal mouse anti-myc antibody (dilution

-104-

1:2000) (FIG. 3A) or with an anti-GST antibody (dilution 1:2000) (FIG. 3B). Blots were subsequently incubated with horse radish peroxidase-conjugated goat anti-mouse IgG (dilutions 1:4000) (FIG. 3A) or horse radish peroxidase-conjugated rabbit anti-goat IgG (dilutions 1:4000) (FIG. 3B). A: Lane 1 and 2: his-myc-EK-C-LT[•]₁₂₆₋₃₀₆. Lane 3 and 4: his-myc-EK-C-LT[•]₄₉₋₃₀₆. B: Lane 1 and 2: GST-EK-C-LT[•]₁₂₆₋₃₀₆. Lane 3 and 4: GST-EK-C-LT[•]₄₉₋₃₀₆. Molecular weights of marker proteins are given on the left margin.

B. Purification of GST-EK-C-LT[•]₄₉₋₃₀₆, GST-EK-C-LT[•]₁₂₆₋₃₀₆, his-myc-EK-C-LT[•]₄₉₋₃₀₆ and his-myc-EK-C-LT[•]₁₂₆₋₃₀₆

GST-EK-C-LT[•]₄₉₋₃₀₆ and GST-EK-C-LT[•]₁₂₆₋₃₀₆ are purified on glutathione-sepharose column and his-myc-EK-C-LT[•]₄₉₋₃₀₆ and his-myc-EK-C-LT[•]₁₂₆₋₃₀₆ are purified on Ni-NTA sepharose column using standard purification protocols. The purified proteins are cleaved with enterokinase and analysed on a 16% SDS-PAGE gel under reducing conditions

C. Coupling of C-LT[•]₄₉₋₃₀₆ and C-LT[•]₁₂₆₋₃₀₆ to Q β capsid protein

A solution of 120 μ M Q β capsid protein in 20 mM Hepes, 150 mM NaCl pH 7.2 is reacted for 30 minutes with a 25 fold molar excess of SMPH (Pierce), diluted from a stock solution in DMSO, at 25 °C on a rocking shaker. The reaction solution is subsequently dialyzed twice for 2 hours against 1 L of 20 mM Hepes, 150 mM NaCl, pH 7.2 at 4 °C. The dialyzed Q β reaction mixture is then reacted with the C-LT[•]₄₉₋₃₀₆ and C-LT[•]₁₂₆₋₃₀₆ solution (end concentrations: 60 μ M Q β , 60 μ M C-LT[•]₄₉₋₃₀₆ and C-LT[•]₁₂₆₋₃₀₆) for four hours at 25 °C on a rocking shaker. Coupling products are analysed by SDS-PAGE.

D. Coupling of C-LT[•]₄₉₋₃₀₆ and C-LT[•]₁₂₆₋₃₀₆ to fr capsid protein

A solution of 120 μ M fr capsid in 20 mM Hepes, 150 mM NaCl pH 7.2 is reacted for 30 minutes with a 25 fold molar excess of SMPH (Pierce), diluted from a stock solution in DMSO, at 25 °C on a rocking shaker. The reaction solution is subsequently dialyzed twice for 2 hours against 1 L of 20 mM Hepes, 150 mM NaCl, pH 7.2 at 4 °C. The dialyzed fr capsid protein reaction mixture is then reacted with the C-LT[•]₄₉₋₃₀₆ and C-LT[•]₁₂₆₋₃₀₆ solution (end concentrations: 60 μ M fr, 60 μ M C-LT[•]₄₉₋₃₀₆ and C-LT[•]₁₂₆₋₃₀₆) for four hours at 25 °C on a rocking shaker. Coupling

-105-

products are analysed by SDS-PAGE under reducing conditions.

E. Coupling of C-LT•₄₉₋₃₀₆ and C-LT•₁₂₆₋₃₀₆ to HBcAg-Lys-2cys-Mut

A solution of 120 µM HBcAg-Lys-2cys-Mut capsid in 20 mM Hepes, 150 mM NaCl pH 7.2 is reacted for 30 minutes with a 25 fold molar excess of SMPH (Pierce), diluted from a stock solution in DMSO, at 25 °C on a rocking shaker. The reaction solution is subsequently dialyzed twice for 2 hours against 1 L of 20 mM Hepes, 150 mM NaCl, pH 7.2 at 4 °C. The dialyzed HBcAg-Lys-2cys-Mut reaction mixture is then reacted with the C-LT•₄₉₋₃₀₆ and C-LT•₁₂₆₋₃₀₆ solution (end concentrations: 60 µM HBcAg-Lys-2cys-Mut, 60 µM C-LT•₄₉₋₃₀₆ and C-LT•₁₂₆₋₃₀₆) for four hours at 25 °C on a rocking shaker. Coupling products are analysed by SDS-PAGE.

F. Coupling of C-LT•₄₉₋₃₀₆ and C-LT•₁₂₆₋₃₀₆ to Pili

A solution of 125 µM Type-1 pili of *E.coli* in 20 mM Hepes, pH 7.4, is reacted for 60 minutes with a 50-fold molar excess of cross-linker SMPH, diluted from a stock solution in DMSO (Pierce), at RT on a rocking shaker. The reaction mixture is desalted on a PD-10 column (Amersham-Pharmacia Biotech). The protein-containing fractions eluting from the column are pooled, and the desalted derivatized pili protein is reacted with the C-LT•₄₉₋₃₀₆ and C-LT•₁₂₆₋₃₀₆ solution (end concentrations: 60 µM pili, 60 µM C-LT•₄₉₋₃₀₆ and C-LT•₁₂₆₋₃₀₆) for four hours at 25 °C on a rocking shaker. Coupling products are analysed by SDS-PAGE under reducing conditions.

EXAMPLE 4

A. Introduction of cys-containing linkers, expression, purification and coupling of rat macrophage migration inhibitory factor MIF to Qβ

-106-

Rat macrophage migration inhibitory factor (rMIF) was recombinantly expressed with three different amino acid linkers C1, C2 and C3 fused at its C-terminus. Each of the linker contained one cysteine for coupling to VLP.

Construction of rMIF-C1, rMIF-C2, and rMIF-C3.

The MCS of pET22b(+) (Novagen, Inc.) was changed to GTTTAACTTT AAGAAGGAGATATACATATGGATCCGGCTAGCGCTCGAGGGTTTAAACGG CGGCCGCATGCACC by replacing the original sequence from the NdeI site to XhoI site with annealed oligos primerMCS-1F and primerMCS-1R (annealing in 15 mM TrisHCl pH 8 buffer). The resulting plasmid was termed pMod00, which had NdeI, BamHI, NheI, XhoI, PmeI and NotI restriction sites in its MCS. The annealed pair of oligos Bamhis6-EK-Nhe-F and Bamhis6-EKNhe-R and the annealed pair of oligo1F-C-glycine-linker and oligo1R-C-glycine-linker were together ligated into BamHI-NotI digested pMod00 plasmid to get pModEC1, which had an N terminal hexahistidine tag, an enterokinase cleavage site and a C-terminal amino acid glycine linker containing one cysteine residue. The annealed pair of oligos Bamhis6-EK-Nhe-F and Bamhi6-EKNhe R together with the annealed pair of oligo1F-C-gamma1-linker and oligo1R-C-gamma1-linker were ligated into BamHI-NotI digested pMod00 plasmid to get pModEC2, which had an N terminal hexahistidine tag, an enterokinase cleavage site and a C-terminal • 1 linker, derived from the hinge region of human immunoglobulin γ 1, containing one cysteine residue. The annealed pair of oligos Bamhis6-EK-Nhe-F and Bamhis6-EK-Nhe-R, the annealed pair of oligo1FA-C-gamma3-linker and oligo1RA-C-gamma3-linker, and the annealed pair of oligo1FB-C-gamma3-linker and oligo1RB-C-gamma3-linker were together ligated into BamHI-NotI digested pMod00 to get pModEC3, which had an N terminal hexahistidine tag, an enterokinase cleavage site and a C terminal • 3 linker, containing one cysteine residue, derived from the hinge region of mouse immunoglobulin • 3.

pBS-rMIF, which contains the rat MIF cDNA, was amplified by PCR with oligos rMIF-F and rMIF-Xho-R. rMIF-F had an internal NdeI site and rMIF-Xho-R had an internal XhoI site. The PCR product was digested with NdeI and XhoI and ligated into pModEC1, pModEC2 and pModEC3 digested with the same enzymes. Resulting plasmids were named pMod-rMIF-C1, pMod-rMIF-C2 and pMod-rMIF-C3, respectively.

-107-

For the PCR reaction, 15 pmol of each oligo and 1 ng of the template DNA was used in the 50 μ l reaction mixture (2 units of PFX polymerase, 0.3 mM dNTPs and 2 mM MgSO₄). The temperature cycles were as follows: 94°C for 2 minutes, followed by 30 cycles of 94°C (30 seconds), 60°C (30 seconds), 68°C (30 seconds) and followed by 68°C for 2 minutes.

All other steps were performed by standard molecular biology protocols.

Sequence of the oligonucleotides:

primerMCS-1F:

5'-TAT GGA TCC GGC TAG CGC TCG AGG GTT TAA ACG GCG GCC GCA T-
3' (SEQ ID NO:293)

primerMCS-1R:

5'-TCG AAT GCG GCC GCC GTT TAA ACC CTC GAG CGC TAG CCG GAT
CCA-3' (SEQ ID NO:294)

Bamhis6-EK-Nhe-F:

5'-GAT CCA CAC CAC CAC CAC CAC CAC GGT TCT GGT GAC GAC GAT
GAC AAA GCG CTA GCC C-3' (SEQ ID NO:295)

Bamhis6-EK-Nhe-R:

5'-TCG AGG GCT AGC GCT TTG TCA TCG TCG TCA CCA GAA CCG TGG
TGG TGG TGG TGG TGT G-3' (SEQ ID NO:296)

oligo1F-C-glycine-linker:

5'-TCG AGG GTG GTG GTG GTG GTT GCG GTT AAT AAG TTT AAA CGC-3'
(SEQ ID NO:297)

oligo1R-C-glycine-linker:

5'-GGC CGC GTT TAA ACT TAT TAA CCG CAA CCA CCA CCA CCC-3'
(SEQ ID NO:298)

oligo1F-C-gamma1-linker:

5'-TCG AGG ATA AAA CCC ACA CCT CTC CGC CGT GTG GTT AAT AAG
TTT AAA CGC-3' (SEQ ID NO:299)

oligo1R-C-gamma1-linker:

5'-GGC CGC GTT TAA ACT TAT TAA CCA CAC GGC GGA GAG GTG TGG
GTT TTA TCC-3' (SEQ ID NO:300)

oligo1FA-C-gamma3-linker:

-108-

5'-TCG AGC CGA AAC CGT CTA CCC CGC CGG GTT CTT CTG-3' (SEQ ID NO:301)

oligo1RA-C-gamma3-linker:

5'-CAC CAC CAG AAG AAC CCG GCG GGG TAG ACG GTT TCG GC-3' (SEQ ID NO:302)

oligo2FB-C-gamma3-linker:

5'-GTG GTG CTC CGG GTG GTT GCG GTT AAT AAG TTT AAA CGC-3' (SEQ ID NO:303)

oligo2RB-C-gamma3-linker:

5'-GGC CGC GTT TAA ACT TAT TAA CCG CAA CCA CCC GGA G-3' (SEQ ID NO:304)

rMIF-F:

5'-GGA ATT CCA TAT GCC TAT GTT CAT CGT GAA CAC-3' (SEQ ID NO:305)

rMIF-Xho-R:

5'-CCC GCT CGA GAG CGA AGG TGG AAC CGT TC-3' (SEQ ID NO:306)

Expression and Purification of rMIF-Cs

Competent *E. coli* BL21 (DE3) cells were transformed with plasmids pMod-rMIF-C1, pMod-rMIF-C2 and pMod-rMIF-C3. Single colonies from ampicillin (Amp)-containing agar plates were expanded in liquid culture (SB with 150mM MOPS, pH 7.0, 200ug/ml Amp, 0.5% glucose) and incubated at 30°C with 220 rpm shaking overnight. 1 l of SB (150 mM MOPS, pH 7.0, 200ug/ml Amp) was then inoculated 1:50 v/v with the overnight culture and grown to OD₆₀₀=2.5 at 30°C. Expression was induced with 2 mM IPTG. Cells were harvested after overnight culture and centrifuged at 6000 rpm. Cell pellet was suspended in lysis buffer (10mM Na₂HPO₄, 30mM NaCl, 10mM EDTA and 0.25% Tween-20) with 0.8 mg/ml lysozyme, sonicated and treated with benzonase. 2ml of the lysate was then run through a 20 ml Q XL- and a 20 ml SP XL-column. The proteins rMIF-C1, rMIF-C2 and rMIF-C3 were in the flow through.

The protein sequences of the rMIF-Cs were translated from the cDNA sequences.

rMIF-C1: SEQ ID NO:307

rMIF-C2: SEQ ID NO:308

rMIF-C3: SEQ ID NO:309

Coupling of rMIF-C1 to Q[•] capsid protein

A solution of 1.48 ml of 6 mg/ml Q[•] capsid protein in 20 mM Hepes, 150 mM NaCl pH 7.2 was reacted for 30 minutes with 14.8 µl of a SMPH (Pierce) (from a 100 mM stock solution dissolved in DMSO) at 25°C. The reaction solution was subsequently dialyzed twice for 3 hours against 2 l of 20 mM Hepes, 150 mM NaCl, pH 7.0 at 4 °C. A solution of 1.3 ml of 3.6 mg/ml rMIF-C1 protein in 20 mM Hepes, 150 mM NaCl pH 7.2 was reacted for 1 hour with 9.6 µl of a TCEP (Pierce) (from a 36 mM stock solution dissolved in H₂O) at 25°C. 130 µl of the derivatized and dialyzed Q[•] was then reacted with 129 µl of reduced rMIF-C1 in 241 µl of 20 mM Hepes, 150 mM NaCl, pH 7.0 over night at 25°C.

Coupling of rMIF-C2 to Q[•] capsid protein

A solution of 0.9 ml of 5.5 mg/ml Q[•] capsid protein in 20 mM Hepes, 150 mM NaCl pH 7.2 was reacted for 30 minutes with 9 µl of a SMPH (Pierce) (from a 100 mM stock solution dissolved in DMSO) at 25°C. The reaction solution was subsequently dialyzed twice for 2 hours against 2 l of 20 mM Hepes, 150 mM NaCl, pH 7.2 at 4 °C. A solution of 850 µl of 5.80 mg/ml rMIF-C2 protein in 20 mM Hepes, 150 mM NaCl pH 7.2 was reacted for 1 hour with 8.5 µl of a TCEP (Pierce) (from a 36 mM stock solution dissolved in H₂O) at RT. 80 µl of the derivatized and dialyzed Q[•] was then reacted with 85 µl of reduced rMIF-C2 in 335 µl of 20 mM Hepes, 150 mM NaCl, pH 7.2 over night at 25°C.

Coupling of rMIF-C3 to Q[•] capsid protein

A solution of 1.48 ml of 6 mg/ml Q[•] capsid protein in 20 mM Hepes, 150 mM NaCl pH 7.2 was reacted for 30 minutes with 14.8 µl of a SMPH (Pierce) (from a 100 mM stock solution dissolved in DMSO) at 25°C. The reaction solution was subsequently dialyzed twice for 3 hours against 2 l of 20 mM Hepes, 150 mM NaCl, pH 7.0 at 4 °C. A solution of 720 µl of 5.98 mg/ml rMIF-C3 protein in 20 mM Hepes, 150 mM NaCl pH 7.2 was reacted for 1 hour with 9.5 µl of a TCEP (Pierce) (from a 36 mM stock solution dissolved in H₂O) at 25°C. 130 µl of the derivatized

-110-

and dialyzed Q β was then reacted with 80 μ l of reduced rMIF-C3 in 290 μ l of 20 mM Hepes, 150 mM NaCl, pH 7.0 over night at 25°C.

All three coupled products were analysed on 16% SDS-PAGE gels under reducing conditions. Gels were either stained with Coomassie Brilliant Blue or blotted onto nitrocellulose membranes. Membranes were blocked, incubated with a polyclonal rabbit anti-Q β antiserum (dilution 1:2000) or a purified rabbit anti-MIF antibody (Torrey Pines Biolabs, Inc.) (dilution 1:2000). Blots were subsequently incubated with horse radish peroxidase-conjugated goat anti-rabbit IgG (dilutions 1:2000). The results are shown in FIG 4A and FIG. 4B. Coupled products could be detected in the Coomassie-stained gels (FIG. 4A) and by both \bullet anti-Q β \bullet antiserum and the anti-MIF antibody (FIG. 4B) clearly demonstrated the covalent coupling of all three rMIF variants to Q β capsid protein.

FIG 4A shows the coupling of the MIF constructs to Q β . Coupling products were analysed on 16% SDS-PAGE gels under reducing conditions. The gel was stained with Coomassie Brilliant Blue. Molecular weights of marker proteins are given on the left margin.

FIG. 4B shows the coupling of MIF-C1 to Q β . Coupling products were analysed on 16% SDS-PAGE gels under reducing conditions. Lane 1: MIF-C1 before coupling Lane 2: derivatized Q β before coupling. Lane 3-5: Q β -MIF-C1 Lanes 1-3 were stained with Coomassie Brilliant Blue. Lanes 4 and 5 represent western blots of the coupling reaction developed with an anti-MIF antiserum and an anti-Q β antiserum, respectively. Molecular weights of marker proteins are given on the left margin.

B. Immunization of mice with MIF-C1 coupled to Q β capsid protein

Female Balb/c mice were vaccinated with MIF-C1 coupled to Q β capsid protein without the addition of adjuvants. 25 μ g of total protein of each sample was diluted in PBS to 200 μ l and injected subcutaneously (100 μ l on two ventral sides) on day 0 and day 14. Mice were bled retroorbitally on day 31 and their serum was analyzed using a MIF-specific ELISA.

C. ELISA

ELISA plates were coated with MIF-C1 at a concentration of 5 µg/ml. The plates were blocked and then incubated with serially diluted mouse sera. Bound antibodies were detected with enzymatically labeled anti-mouse IgG antibody. As a control, preimmune serum of the same mice was also tested. The results are shown in FIG. 4C. There was a clear reactivity of the mouse sera raised against MIF-C1 coupled to Qβ capsid protein, while the pre-immune sera did not react with MIF (FIG. 4C and data not shown). From the dilution series with the antisera against MIF-C1 coupled to Qβ capsid protein, a half-maximal titer was reached at 1:84000.

Shown on FIG. 4C are the ELISA signals obtained with the sera of the mice vaccinated with MIF-C1 coupled to Qβ capsid protein. Female Balb/c mice were vaccinated subcutaneously with 25 µg of vaccine in PBS on day 0 and day 14. Serum IgG against MIF-C1 were measured on day 31. As a control, pre-immune sera from one of the mice were analyzed. Results for indicated serum dilutions are shown as optical density at 450 nm. All vaccinated mice made high IgG antibody titers. No MIF-specific antibodies were detected in control (pre-immune mouse).

EXAMPLE 5

Coupling of rMIF-C1 to fr capsid protein and HBcAg-lys-2cys-Mut capsid protein

Coupling of rMIF-C1 to fr capsid protein

A solution of 100 µl of 3.1 mg/ml fr capsid protein in 20 mM Hepes, 150 mM NaCl pH 7.2 was reacted for 30 minutes with 3 µl of a 100 mM stock solution of SMPH (Pierce) dissolved in DMSO at 25°C. In a parallel reaction, fr capsid protein was first alkylated using iodoacetamid and then reacted with SMPH using the same reaction conditions described above. The reaction solutions were subsequently dialyzed twice for 2 hours against 2 l of 20 mM Hepes, 150 mM NaCl, pH 7.2 at 4°C. A solution of 80 µl of 5.7 mg/ml rMIF-C1 protein in 20 mM Hepes, 150 mM NaCl pH 7.2, was reacted for 1 hour with 1 µl of a 36 mM TCEP (Pierce) stock solution dissolved in H₂O, at 25°C. 50 µl of the derivatized and dialyzed fr capsid protein and

-112-

50 µl of the derivatized, alkylated and dialyzed fr capsid protein were then reacted each with 17 µl of reduced rMIF-C1 for two hours at 25°C.

Coupling products were analysed on 16% SDS-PAGE gels (FIG. 5). An additional band of the expected size of 27 kDa (rMIF-C1: apparent MW 13 kDa, fr capsid protein apparent MW 14 kDa) and 29 kDa (rMIF-C1: apparent MW 13 kDa, HBcAg-lys-2cys-Mut: apparent MW 15 kDa) can be detected in the coupling reaction but not in the fr capsid protein and rMIF-C1 solutions, clearly demonstrating coupling.

Coupling of rMIF-C1 to hepatitis HBcAg-lys-2cys-Mut capsid protein:

A solution of 100 µl of 1.2 mg/ml HBcAg-lys-2cys-Mut capsid protein in 20 mM Hepes, 150 mM NaCl pH 7.2 was reacted for 30 minutes with 1.4 µl of a SMPH (Pierce) (from a 100 mM stock solution dissolved in DMSO) at 25°C. The reaction solution was subsequently dialyzed twice for 2 hours against 2 l of 20 mM Hepes, 150 mM NaCl, pH 7.2 at 4°C. A solution of 80 µl of 5.7 mg/ml rMIF-C1 protein in 20 mM Hepes, 150 mM NaCl, pH 7.2 was reacted for 1 hour with 1 µl of a TCEP (Pierce) (from a 36 mM stock solution dissolved in H₂O) at 25°C. 60 µl of the derivatized and dialyzed HBcAg-lys-2cys-Mut capsid protein was then reacted with 20 µl of reduced rMIF-C1 for two hours at 25°C.

Coupling products were analysed on 16% SDS-PAGE gels (FIG. 5) under reducing conditions. An additional band of the expected size of about 28 kDa (rMIF-C1: apparent MW 13 kDa, HBcAg-lys-2cys-Mut: apparent MW 15 kDa) can be detected in the coupling reaction but not in derivatized HBcAg-lys-2cys-Mut or rMIF-C1, clearly demonstrating coupling.

The samples loaded on the gel of FIG. 5 were the following:

Lane 1: Molecular weight marker. Lane 2: rMIF-C1 before coupling. Lane 3: rMIF-C1-fr capsid protein after coupling. Lane 4: derivatized fr capsid protein. Lane 5: rMIF-C1-fr after coupling to alkylated fr capsid protein. Lane 6: alkylated and derivatized fr capsid protein. Lane 7: rMIF- HBcAg-lys-2cys-Mut after coupling. Lane

-113-

8 and 9: derivatized HBcAg-lys-2cys-Mut. The gel was stained with Coomassie Brilliant Blue. Molecular weights of marker proteins are given on the left margin.

EXAMPLE 6

A. Introduction of amino acid linkers containing a cysteine residue, expression and purification of mouse RANKL

A fragment of the receptor activator of nuclear factor kappa b ligand (RANKL), which has also been termed osteoclast differentiation factor, osteoprotegerin ligand and tumor necrosis factor-related activation-induced cytokine was recombinantly expressed with an N-terminal linker containing one cysteine for coupling to VLP.

Construction of expression plasmid

The C-terminal coding region of the RANKL gene was amplified by PCR with oligos RANKL-UP and RANKL-DOWN. RANKL-UP had an internal *Apa*I site and RANKL-DOWN had an internal *Xho*I site. The PCR product was digested with *Apa*I and *Xho*I and ligated into pGEX-6p1 (Amersham Pharmacia). The resulting plasmid was named pGEX-RANKL. All steps were performed by standard molecular biology protocols and the sequence was verified. The plasmid pGEX-RANKL codes for a fusion protein of a glutathione S-transferase-PreScission cleavage site-cysteine-containing amino acid linker-RANKL (GST-PS-C-RANKL). The cysteine-containing amino acid linker had the sequence GCGGG. The construct also contains a hexahistidine tag between the cysteine containing amino acid linker and the RANKL sequence.

Oligos:

RANKL-UP:

5'-CTGCCAGGGGCCCCGGGTGCGGCGGTGGCCATCATCACCACCATCACCAGCGCTTCTCAGGAG-3' (SEQ ID NO:316)

RANKL-DOWN:

5'-CCGCTCGAGTTAGTCTATGTCCTGAACTTTGAAAG-3' (SEQ ID NO:317)

-114-

Protein of GST-PS-C-RANKL (SEQ ID NO:318) and cDNA sequence of GST-PS-C-RANKL (SEQ ID NO:319)

```

1 M S P I L G Y W K I K G L V Q P T R L L L E Y L E
1 atgtccctatactagggtatttggaataaagggccttgtgcaaccactcgacttcttttgggaatatttgaa
26 E K Y E E H L Y E R D E G D K W R N K K F E L G L
26 ekyeeehlyerdegdkwrnk kf elgl
76 gaaaaatatgaagagcatttgtatgagcgcgatgaaggtgataaatggcgaaacaaaaagtttgattgggtttg
51 E F P N L P Y Y I D G D V K L T Q S M A I I R Y I
51 efpnlpyy idgdvkl tqsm aii r yi
151 gagtttcccaatcttccttattatattgatgggtgatgttaaattaacacagtcctatggccatcatacgttatata
76 A D K H N M L G G C P K E R A E I S M L E G A V L
76 adkhnmlggcpkeraeismle gavl
226 gctgacaagcacaacatgttgggtggtgtccaaaagagcgtgcagagatttcaatgcttgaaggagcgggtttt
101 D I R Y G V S R I A Y S K D F E T L K V D F L S K
101 dirygvsr i a y s k d f e t l k v d f l s k
301 gatattagatacgggtgtttcgagaattgcataatagtaaagactttgaaactctcaagttgattttcttagcaag
126 L P E M L K M F E D R L C H K T Y L N G D H V T H
126 lpe m l k m f e d r l c h k t y l n g d h v t h
376 ctacctgaaatgctgaaaatgttcgaagatcgtttatgtcataaaacatatttaaatgggtgatcatgtaacccat
151 P D F M L Y D A L D V V L Y M D P M C L D A F P K
151 pdfmlydaldv v l y m d p m c l d a f p k
451 cctgacttcatgttgtatgacgctcttgatgtttttatacatggacccaatgtgcctggatgcgttcccaaaa
176 L V C F K R I E A I P Q I D K Y L K S S K Y I A
176 lvcfkr i e a i p q i d k y l k s s k y i a
526 ttagtttgttttaaaaaacgtattgaagctatccacaaattgataagtacttgaaatccagcaagtatatagca
201 W P L Q G W Q A T F G G G D H P P K S D L E V L F
201 wplqg w q a t f g g g d h p p k s d l e v l f
601 tggcctttgcagggtggcagccacgtttgtgtgtggcgaccatcctccaaaatcggatctggaagttctgttc
226 G P G C G G G H H H H H Q R F S G A M M E H
226 gpgcg g g h h h h h q r f s g a m m e h
676 caggggccccgggtgccccgggtggccatcatcaccaccatcaccagcgcttctcaggagctccagctatgatggaa
251 G S W L D V A Q R G K P E A Q P F A H L T I N A A
251 gswl d v a q r g k p e a q p f a h l t i n a a
751 GGCTCATGGTTGGATGTGGCCAGCGAGGCAAGCCTGAGGCCAGCCATTGACACACCTCACCATCAATGCTGCC
276 S I P S G S H K V T L S S W Y H D R G W A K T S N
276 sipsg s h k v t l s s w y h d r g w a k t s n
826 AGCATCCCATCGGTTCCCATAAAGTCACTCTGCTCTTGGTACCACGATCGAGGCTGGGCCAAGATCTCTAAC
301 M T L S N G K L R V N Q D G F Y Y L Y A N I C F R
301 mtl s n g k l r v n q d g f y y l y a n i c f r
901 ATGACGTTAAGCAACGGAATAAGGGTTAACCAAGATGGCTTCTATTACCTGTACGCCAACATTGCTTTCGG
326 H H E T S G S V P T D Y L Q L M V Y V V K T S I K
326 h h e t s g s v p t d y l q l m v y v v k t s i k
976 CATCATGAACATCGGGAAGCGTACCTACAGACTATCTTCAGCTGATGGTGTATGTCTTAAACACGATCAAAA
351 I P S S H N L M K G G S T K N W S G N S E F H F Y
351 ips s h n l m k g g s t k n w s g n s e f h f y
1051 ATCCCAAGTTCTCATAACCTGATGAAAGGAGGGAGCAGCAAAAAGTGGTCGGGCAATTCTGAATCCACTTTTAT
376 S I N V G G F F K L R A G E E I S I Q V S N P S L
376 sin v g g f f k l r a g e e i s i q v s n p s l
1126 TCCATAAATGTTGGGGGATTTTCAAGCTCCGAGCTGGTGAAGAAATTAGCATTCAGGTGTCCAACCCCTCCCTG
401 L D P D Q D A T Y F G A F K V Q D I D
401 ld p d q d a t y f g a f k v q d i d
1201 CTGGATCCGGATCAAGATGCGACGTACTTTGGGGCTTTCAAAGTTTCAGGACATAGACTAACTCGAGCGG

```

Expression and Purification of C-RANKL

Competent *E. coli* BL21 (DE3) Gold pLys cells were transformed with the plasmid pGEX-RANKL. Single colonies from kanamycin and chloramphenicol-containing agar plates were expanded in liquid culture (LB medium, 30µg/ml kanamycin, 50µg/ml chloramphenicol) and incubated at 30°C with 220 rpm shaking overnight. 1 l of LB (with 30ug/ml kanamycin) was then inoculated 1:100 v/v with the overnight culture and grown to OD₆₀₀=1 at 24°C. Expression was induced with 0.4 mM IPTG. Cells were harvested after 16 h and centrifuged at 5000 rpm. Cell pellet was suspended in lysis buffer (50 mM Tris-HCl, pH=8; 25 % sucrose; 1 mM EDTA, 1% NaN₃; 10 mM DTT; 5 mM MgCl₂; 1 mg/ml Lysozyme; 0.4u/ml DNase) for 30 min. Then 2.5 volumes of buffer A (50 mM Tris-HCl, pH=8.0; 1% Triton X100; 100 mM NaCl; 0,1% NaN₃; 10 mM DTT; 1 mM PMSF) were added and

-115-

incubated at 37°C for 15 min. The cells were sonicated and pelleted at 9000 rpm for 15 min. The supernatant was immediately used for GST-affinity chromatography.

A column GST-Trap FF of 5 ml (Amersham Pharmacia) was equilibrated in PBS, pH 7.3 (140 mM NaCl, 2.7 mM KCl, 10 mM Na₂HPO₄, 1.8 mM KH₂PO₄). The supernatant was loaded on the 5 ml GST-Trap FF column and subsequently the column was rinsed with 5 column volumes of PBS. The protein GST-PS-C-RANKL was eluted with 50 mM Tris-HCl, pH=8.0 containing GSH 10 mM.

The purified GST-PS-C-RANKL protein was digested using the protease PreScission (Amersham Pharmacia). The digestion was performed at 37°C for 1 hour using a molar ratio of 500/1 of GST-PS-C-RANKL to PreScission.

Furthermore, the reaction of protease digestion was buffer exchanged using a HiPrep 26/10 desalting column (Amersham Pharmacia), the fractions containing the proteins were pooled and immediately used for another step of GST affinity chromatography using the same conditions reported before. Purification of C-RANKL was analysed on a SDS-PAGE gel under reducing conditions, shown in Fig.6. Molecular weights of marker proteins are given on the left margin of the gel in the figure. The gel was stained with Coomassie Brilliant Blue. The cleaved C-RANKL is present in the flow-through (unbound fraction) while the uncleaved GST-PS-C-RANKL, the cleaved GST-PS and the PreScission remain bound to the column. C-RANKL protein of the expected size of 22 kDa was obtained in high purity.

The samples loaded on the gel of FIG. 6 were the following:

Lane 1: Low molecular weight marker. Lanes 2 and 3: the supernatant of the cell lysates of the BL21/DE3 cells transformed with the empty vector pGEX6p1 and pGEX-RANKL respectively, after sixteen hours of induction with IPTG 0.4 mM. Lane 4: the purified GST-PS-C-RANKL protein after GST-Trap FF column. Lane 5: the GST-Trap FF column unbound fraction. Lane 6: the purified GST-PS-C-RANKL protein after the cleavage with the PreScission protease. Lane 7: the unbound fraction of the GST-Trap FF column loaded with the GST-RANKL digestion, which contains the purified C-RANKL. Lane 8: the bound fraction of the GST-Trap FF column loaded with the GST-PS-C-RANKL digestion and eluted with GSH.

B. Coupling of C-RANKL to Q β capsid protein

A solution of 120 μ M Q β capsid in 20 mM Hepes, 150 mM NaCl pH 7.2 is

-116-

reacted for 30 minutes with a 25 fold molar excess of SMPH (Pierce), diluted from a stock solution in DMSO, at 25 °C on a rocking shaker. The reaction solution is subsequently dialyzed twice for 2 hours against 1 L of 20 mM Hepes, 150 mM NaCl, pH 7.2 at 4 °C. The dialyzed Q β reaction mixture is then reacted with the C-RANKL solution (end concentrations: 60 μ M Q β , 60 μ M C-RANKL) for four hours at 25 °C on a rocking shaker. Coupling products are analysed by SDS-PAGE.

C. Coupling of C-RANKL to fr capsid protein

A solution of 120 μ M fr capsid in 20 mM Hepes, 150 mM NaCl pH 7.2 is reacted for 30 minutes with a 25 fold molar excess of SMPH (Pierce), diluted from a stock solution in DMSO, at 25 °C on a rocking shaker. The reaction solution is subsequently dialyzed twice for 2 hours against 1 L of 20 mM Hepes, 150 mM NaCl, pH 7.2 at 4 °C. The dialyzed fr capsid protein reaction mixture is then reacted with the C-RANKL solution (end concentrations: 60 μ M fr capsid protein, 60 μ M C-RANKL) for four hours at 25 °C on a rocking shaker. Coupling products are analysed by SDS-PAGE.

D. Coupling of C-RANKL to HBcAg-Lys-2cys-Mut

A solution of 120 μ M HBcAg-Lys-2cys-Mut capsid in 20 mM Hepes, 150 mM NaCl pH 7.2 is reacted for 30 minutes with a 25 fold molar excess of SMPH (Pierce), diluted from a stock solution in DMSO, at 25 °C on a rocking shaker. The reaction solution is subsequently dialyzed twice for 2 hours against 1 L of 20 mM Hepes, 150 mM NaCl, pH 7.2 at 4 °C. The dialyzed HBcAg-Lys-2cys-Mut reaction mixture is then reacted with the C-RANKL solution (end concentrations: 60 μ M HBcAg-Lys-2cys-Mut, 60 μ M C-RANKL) for four hours at 25 °C on a rocking shaker. Coupling products are analysed by SDS-PAGE.

E. Coupling of C-RANKL to Pili

A solution of 125 μ M Type-1 pili of *E.coli* in 20 mM Hepes, pH 7.4, is reacted for 60 minutes with a 50-fold molar excess of cross-linker SMPH, diluted from a stock solution in DMSO, at RT on a rocking shaker. The reaction mixture is desalted on a PD-10 column (Amersham-Pharmacia Biotech). The protein-containing fractions eluting from the column are pooled, and the desalted derivatized pili

-117-

protein is reacted with the C-RANKL solution (end concentrations: 60 μ M pili, 60 μ M C-RANKL) for four hours at 25 °C on a rocking shaker. Coupling products are analysed by SDS-PAGE.

EXAMPLE 7

A. Introduction of amino acid linker containing a cysteine residue, expression and purification of a truncated form of the mouse prion protein

A truncated form (aa 121-230) of the mouse prion protein (termed mPrP_T) was recombinantly expressed with a GGGGCG amino acid linker fused at its C-terminus for coupling to VLPs and Pili. The protein was fused to the N-terminus of a human Fc-fragment for purification. An enterokinase (EK) cleavage-site was introduced behind the EK cleavage site to cleave the Fc- part of the fusion protein after purification.

Construction of mPrP_T-EK-Fc*.

Mouse PrP_T was amplified by PCR with the primer 5'PrP-*Bam*HI and 3'PrP-*Nhe*I using the plasmid pBP^{CMV}PrP-Fc as a template. pBP^{CMV}PrP-Fc contained the wild-type sequence of the mouse prion protein. 5'PrP-*Bam*HI had an internal *Bam*HI site and contained an ATG and 3'PrP-*Nhe*I had an internal *Nhe*I site.

For the PCR reaction, 0.5 μ g of each primer and 200 ng of the template DNA was used in the 50 μ l reaction mixture (1 unit of PFX Platinum polymerase, 0.3 mM dNTPs and 2 mM MgSO₄). The temperature cycles were as follows: 94°C for 2 minutes, followed by 5 cycles of 94°C (15 seconds), 50°C (30 seconds), 68°C (45 seconds), followed by 20 cycles of 94°C (15 seconds), 64°C (30 seconds), 68°C (45 seconds) and followed by 68°C for 10 minutes.

The PCR product was digested with *Bam*HI and *Nhe*I and inserted into pCEP-SP-EK-Fc* containing the GGGGCG linker sequence at the 5'end of the EK cleavage sequence. The resulting plasmid was named pCEP-SP-mPrP_T-EK-Fc*.

All other steps were performed by standard molecular biology protocols.

Oligos:

-118-

Primer 5'PrP-*Bam*HI

5'-CGG GAT CCC ACC ATG GTG GGG GGC CTT GG -3' (SEQ ID NO:321)

Primer 3'PrP-*Nhe*I

5'-CTA GCT AGC CTG GAT CTT CTC CCG -3' (SEQ ID NO:322)

Expression and Purification of mPrP_E-EK-Fc*

Plasmid pCEP-SP-mPrP_E-EK-Fc* was transfected into 293-EBNA cells (Invitrogen) and purified on a Protein A-sepharose column as described in EXAMPLE 1.

The protein sequence of the mPrP_E-EK-Fc* is identified in SEQ ID NO:323.

mPrP_E after cleavage has the sequence as identified in SEQ ID NO:324 with the GGGGCG linker at its C-terminus.

The purified fusion protein mPrP_E-EK-Fc* was cleaved with enterokinase and analysed on a 16% SDS-PAGE gel under reducing conditions before and after enterokinase cleavage. The gel was stained with Coomassie Brilliant Blue. The result is shown in FIG. 7. Molecular weights of marker proteins are given on the left margin of the gel in the figure. The mPrP_E-EK-Fc* fusion protein could be detected as a 50 kDa band. The cleaved mPrP_E protein containing the GGGGCG amino acid linker fused to its C-terminus could be detected as a broad band between 18 and 25 kDa. The identity of mPrP_E was confirmed by western blotting (data not shown). Thus, mPrP_E with a C-terminal amino acid linker containing a cysteine residue, could be expressed and purified to be used for coupling to VLPs and Pili.

The samples loaded on the gel of FIG. 7 were the following.

Lane 1: Molecular weight marker. Lane 2: mPrP_E-EK-Fc* before cleavage. Lane 3: mPrP_E after cleavage.

B. Coupling of mPrP_E to Q β capsid

A solution of 120 μ M Q β capsid in 20 mM Hepes, 150 mM NaCl pH 7.2 is reacted for 30 minutes with a 25 fold molar excess of SMPH (Pierce), diluted from a stock solution in DMSO, at 25 °C on a rocking shaker. The reaction solution is subsequently dialyzed twice for 2 hours against 1 L of 20 mM Hepes, 150 mM NaCl,

-119-

pH 7.2 at 4 °C. The dialyzed Q β reaction mixture is then reacted with the mPrP_i solution (end concentrations: 60 μ M Q β , 60 μ M mPrP_i) for four hours at 25 °C on a rocking shaker. Coupling products are analysed by SDS-PAGE.

C. Coupling of mPrP_i to fr capsid protein

A solution of 120 μ M fr capsid protein in 20 mM Hepes, 150 mM NaCl pH 7.2 is reacted for 30 minutes with a 25 fold molar excess of SMPH (Pierce), diluted from a stock solution in DMSO, at 25 °C on a rocking shaker. The reaction solution is subsequently dialyzed twice for 2 hours against 1 L of 20 mM Hepes, 150 mM NaCl, pH 7.2 at 4 °C. The dialyzed fr reaction mixture is then reacted with the mPrP_i solution (end concentrations: 60 μ M fr, 60 μ M mPrP_i) for four hours at 25 °C on a rocking shaker. Coupling products are analysed by SDS-PAGE.

D. Coupling of mPrP_i to HBcAg-Lys-2cys-Mut

A solution of 120 μ M HBcAg-Lys-2cys-Mut capsid in 20 mM Hepes, 150 mM NaCl pH 7.2 is reacted for 30 minutes with a 25 fold molar excess of SMPH (Pierce), diluted from a stock solution in DMSO, at 25 °C on a rocking shaker. The reaction solution is subsequently dialyzed twice for 2 hours against 1 L of 20 mM Hepes, 150 mM NaCl, pH 7.2 at 4 °C. The dialyzed HBcAg-Lys-2cys-Mut reaction mixture is then reacted with the mPrP_i solution (end concentrations: 60 μ M HBcAg-Lys-2cys-Mut, 60 μ M mPrP_i) for four hours at 25 °C on a rocking shaker. Coupling products are analysed by SDS-PAGE.

E. Coupling of mPrP_i to Pili

A solution of 125 μ M Type-1 pili of *E.coli* in 20 mM Hepes, pH 7.4, is reacted for 60 minutes with a 50-fold molar excess of cross-linker SMPH (Pierce), diluted from a stock solution in DMSO, at RT on a rocking shaker. The reaction mixture is desalted on a PD-10 column (Amersham-Pharmacia Biotech). The protein-containing fractions eluting from the column are pooled, and the desalted derivatized pili protein is reacted with the mPrP_i solution (end concentrations: 60 μ M pili, 60 μ M mPrP_i) for four hours at 25 °C on a rocking shaker. Coupling products are analysed by SDS-PAGE.

-120-

EXAMPLE 8

A. Coupling of prion peptides to Q β capsid protein: prion peptide vaccines

The following prion peptides were chemically synthesized:

CSAMSRPMIHFGNDWEDRYRENMYR ("cprplong") and
CGNDWEDRYRENMYR ("cprpshort"), which comprise an added N-terminal
cysteine residue for coupling to VLPs and Pili, and used for chemical coupling to Q β
as described in the following.

A solution of 5 ml of 140 μ M Q β capsid protein in 20 mM Hepes, 150 mM NaCl pH 7.4 was reacted for 30 minutes with 108 μ l of a 65 mM solution of SMPH (Pierce) in H₂O at 25°C on a rocking shaker. The reaction solution was subsequently dialyzed twice for 2 hours against 5 L of 20 mM Hepes, 150 mM NaCl, pH 7.4 at 4°C. 100 μ l of the dialyzed reaction mixture was then reacted either with 1.35 μ l of a 2 mM stock solution (in DMSO) of the peptide cprpshort (1:2 peptide/Q β capsid protein ratio) or with 2.7 μ l of the same stock solution (1:1 peptide/Q β ratio). 1 μ l of a 10 mM stock solution (in DMSO) of the peptide cprplong was reacted with 100 μ l of the dialyzed reaction mixture. The coupling reactions were performed over night at 15 °C in a water bath. The reaction mixtures were subsequently dialyzed 24 h against 2x 5 L of 20 mM Hepes, 150 mM NaCl, pH 7.4 at 4°C.

The coupled products were centrifuged and supernatants and pellets were analysed on 16% SDS-PAGE gels under reducing conditions. Gels were stained with Coomassie Brilliant Blue. The results are shown in FIG. 16. Molecular weights of marker proteins are given on the left margin of the gel in the figure. The bands at a molecular weight between 16.5 and 25 kDa clearly demonstrated the covalent coupling of the peptides cprpshort and cprplong to Q β capsid protein.

The samples loaded on the gel of FIG. 16 A were the following:

Lane 1: purified Q β capsid protein. Lane 2: derivatized Q β capsid protein before coupling. Lanes 3-6: Q β capsid protein-cprpshort couplings with a 1:2 peptide/Q β ratio (lanes 3 and 4) and 1:1 peptide/Q β ratio (lanes 5 and 6). Soluble fractions (lanes 3 and 5) and insoluble fractions (lanes 4 and 6) are shown.

-121-

The samples loaded on the gel of FIG. 16 B were the following:

Lane 1: Molecular weight marker. Lane 2: derivatized Q β capsid protein before coupling. Lane 3 and 4: Q β capsid protein-cprplong coupling reactions. Soluble fraction (lane 3) and insoluble fraction (lane 4) are shown.

B. Coupling of prion peptides to fr capsid protein

A solution of 120 μ M fr capsid protein in 20 mM Hepes, 150 mM NaCl pH 7.2 is reacted for 30 minutes with a 10 fold molar excess of SMPH (Pierce)), diluted from a stock solution in DMSO, at 25 °C on a rocking shaker. The reaction solution is subsequently dialyzed twice for 2 hours against 1 L of 20 mM Hepes, 150 mM NaCl, pH 7.2 at 4 °C. The dialyzed fr reaction mixture is then reacted with equimolar concentration of peptide cprpshort or a ration of 1:2 cprplong / fr over night at 16 °C on a rocking shaker. Coupling products are analysed by SDS-PAGE.

C. Coupling of prion peptides to HBcAg-Lys-2cys-Mut

A solution of 120 μ M HBcAg-Lys-2cys-Mut in 20 mM Hepes, 150 mM NaCl pH 7.2 is reacted for 30 minutes with a 10 fold molar excess of SMPH (Pierce)), diluted from a stock solution in DMSO, at 25 °C on a rocking shaker. The reaction solution is subsequently dialyzed twice for 2 hours against 1 L of 20 mM Hepes, 150 mM NaCl, pH 7.2 at 4 °C. The dialyzed HBcAg-Lys-2cys-Mut reaction mixture is then reacted with equimolar concentration of peptide cprpshort or a ration of 1:2 cprplong / HBcAg-Lys-2cys-Mut over night at 16 °C on a rocking shaker. Coupling products are analysed by SDS-PAGE.

D. Coupling of prion peptides to Pili

A solution of 125 μ M Type-1 pili of *E.coli* in 20 mM Hepes, pH 7.4, is reacted for 60 minutes with a 50-fold molar excess of cross-linker SMPH (Pierce), diluted from a stock solution in DMSO, at RT on a rocking shaker. The reaction mixture is desalted on a PD-10 column (Amersham-Pharmacia Biotech). The protein-containing fractions eluting from the column are pooled, and the desalted derivatized pili protein is reacted with the prion peptides in equimolar or in a ratio of 1:2 peptide pili over night at 16 °C on a rocking shaker. Coupling products are analysed by SDS-PAGE.

Example 9

Cloning, expression and purification of IL-13 to VLPs and Pili

- A. Cloning and expression of Interleukin 13 (IL-13) with an N-terminal amino acid linker containing a cysteine residue for coupling to VLPs and Pili
- a) Cloning of mouse IL-13 (HEK-293T) for expression in mammalian cells as Fc fusion protein

The DNA for the cloning of IL-13 was isolated by RT-PCR from in vitro activated splenocytes, which were obtained as following: CD4⁺ T cells were isolated from mouse spleen cells and incubated 3 days in IMDM (+5% FCS + 10 ng/ml IL4) in 6 well plates which have been previously coated with anti-CD3 and anti-CD28 antibodies. The RNA from these cells was used to amplify IL13 by one-step RT-PCR (Qiagen one-step PCR kit). Primer XhoIL13-R was used for the reverse transcription of the RNA and the primers NheIL13-F (SEQ ID NO:338) and XhoIL13-R (SEQ ID NO:339) were used for the PCR amplification of the IL13 cDNA. Amplified IL13 cDNA was ligated in a pMOD vector using the NheI/XhoI restriction sites (giving the vector pMODB1-IL13). pMODB1-IL13 was digested BamHI/XhoI and the fragment containing IL13 was ligated in the pCEP-SP-XA-Fc*(Δxho) vector, an analogue of pCEP-SP-XA-Fc* where a XhoI site at the end of the Fc sequence has been removed, which had been previously digested with BamHI/XhoI. The plasmid resulting from this ligation (pCEP-SP-IL13-Fc) was sequenced and used to transfect HEK-293T cells. The resulting IL 13 construct encoded by this plasmid had the amino acid sequence ADPGCGGGGGLA fused at the N-terminus of the IL-13 mature sequence. This sequence comprises the amino acid linker sequence GCGGGGG flanked by additional amino acids introduced during the cloning procedure. IL13-Fc could be purified with Protein-A resin from the supernatant of the cells transfected with pCEP-SP-IL13-Fc. The result of the expression is shown on FIG. 17 B (see EXAMPLE 10 for description of the samples). Mature IL-13 fused at its N-terminus with the aforementioned amino acid sequence is released upon cleavage of the fusion protein with Factor-Xa, leading to a protein called hereinafter "mouse C-IL-13-F" and having a sequence of SEQ ID NO:328. The result of FIG. 17 B clearly demonstrates expression of the IL-13 construct.

-123-

- b) Cloning of mouse IL-13 (HEK-293T) for expression in mammalian cells with GST (Glutathion-S-transferase) fused at its N-terminus

The cDNA used for cloning IL-13 with an N-terminal GST originated from the cDNA of TH2 activated T-cells as described above (a.). IL-13 was amplified from this cDNA using the primers NheIink1IL13-F and IL13StopXhoNot-R. The PCR product was digested with NheI and XhoI and ligated in the pCEP-SP-GST-EK vector previously digested with NheI/XhoI. The plasmid which could be isolated from the ligation (pCEP-SP-GST-IL13) was used to transfect HEK-293T cells. The resulting IL 13 construct encoded by this plasmid had the amino acid sequence LACGGGGG fused at the N-terminus of the IL-13 mature sequence. This sequence comprises the amino acid linker sequence ACGGGGGG flanked by an additional amino acid introduced during the cloning procedure. The culture supernatant of the cells transfected with pCEP-SP-GST-IL13 contained the fusion protein GST-IL13 which could be purified by Glutathione affinity chromatography according to standard protocols. Mature IL-13 fused at its N-terminus with aforementioned amino acid sequence is released upon cleavage of the fusion protein with enterokinase, leading to a protein called hereinafter "mouse C-IL-13-S" and having a sequence of SEQ ID NO:329.

- B. Coupling of mouse C-IL-13-F, mouse C-IL-13-S to Q β capsid protein

A solution of 120 μ M Q β capsid in 20 mM Hepes, 150 mM NaCl pH 7.2 is reacted for 30 minutes with a 25 fold molar excess of SMPH (Pierce), diluted from a stock solution in DMSO, at 25 °C on a rocking shaker. The reaction solution is subsequently dialyzed twice for 2 hours against 1 L of 20 mM Hepes, 150 mM NaCl, pH 7.2 at 4 °C. The dialyzed Q β reaction mixture is then reacted with the mouse C-IL-13-F or mouse C-IL-13-S solution (end concentrations: 60 μ M Q β capsid protein, 60 μ M mouse C-IL-13-F or mouse C-IL-13-S) for four hours at 25 °C on a rocking shaker. Coupling products are analysed by SDS-PAGE.

- C. Coupling of mouse C-IL-13-F, mouse C-IL-13-S to fr capsid protein

A solution of 120 μ M fr capsid protein in 20 mM Hepes, 150 mM NaCl pH 7.2 is reacted for 30 minutes with a 25 fold molar excess of SMPH (Pierce), diluted

-124-

from a stock solution in DMSO, at 25 °C on a rocking shaker. The reaction solution is subsequently dialyzed twice for 2 hours against 1 L of 20 mM Hepes, 150 mM NaCl, pH 7.2 at 4 °C. The dialyzed fr reaction mixture is then reacted with the the mouse C-IL-13-F or mouse C-IL-13-S solution (end concentrations: 60 µM fr capsid protein, 60 µM mouse C-IL-13-F or mouse C-IL-13-S) for four hours at 25 °C on a rocking shaker. Coupling products are analysed by SDS-PAGE.

D. Coupling of mouse C-IL-13-F or mouse C-IL-13-S solution to HBcAg-Lys-2cys-Mut

A solution of 120 µM HBcAg-Lys-2cys-Mut capsid in 20 mM Hepes, 150 mM NaCl pH 7.2 is reacted for 30 minutes with a 25 fold molar excess of SMPH (Pierce), diluted from a stock solution in DMSO, at 25 °C on a rocking shaker. The reaction solution is subsequently dialyzed twice for 2 hours against 1 L of 20 mM Hepes, 150 mM NaCl, pH 7.2 at 4 °C. The dialyzed HBcAg-Lys-2cys-Mut reaction mixture is then reacted with the mouse C-IL-13-F or mouse C-IL-13-S solution (end concentrations: 60 µM HBcAg-Lys-2cys-Mut, 60 µM mouse C-IL-13-F or mouse C-IL-13-S) for four hours at 25 °C on a rocking shaker. Coupling products are analysed by SDS-PAGE.

E. Coupling of mouse C-IL-13-F or mouse C-IL-13-S solution to Pili

A solution of 125 µM Type-1 pili of *E.coli* in 20 mM Hepes, pH 7.4, is reacted for 60 minutes with a 50-fold molar excess of cross-linker SMPH, diluted from a stock solution in DMSO, at RT on a rocking shaker. The reaction mixture is desalted on a PD-10 column (Amersham-Pharmacia Biotech). The protein-containing fractions eluting from the column are pooled, and the desalted derivatized pili protein is reacted with the mouse C-IL-13-F or mouse C-IL-13-S solution (end concentrations: 60 µM pili, 60 µM mouse C-IL-13-F or mouse C-IL-13-S) for four hours at 25 °C on a rocking shaker. Coupling products are analysed by SDS-PAGE.

Example 10

Cloning and expression of Interleukin 5 (IL-5) with an N-terminal amino acid linker containing a cysteine residue for coupling to VLPs and Pili

A. Cloning of IL-5 for expression as Inclusion bodies in *E. coli*

IL-5 was amplified from an ATCC clone (pmIL5-4G; ATCC number: 37562) by PCR using the following two primers: Spelinker3-F1 (SEQ ID NO:340) and Il5StopXho-R (SEQ ID NO:342). The product of this PCR was used as template for a second PCR with the primers SpeNlinker3-F2 (SEQ ID NO:341) and Il5StopXho-R. The insert was digested with SpeI and NotI. This insert was ligated into a pET vector derivative (pMODEC3-8 vector), previously digested with NheI and NotI (not dephosphorylated), and transformed into *E.coli* TG1 cells. The IL5 construct generated by cloning into pMODEC3-8 vector contains at its N-terminus a hexa-histidine tag, followed by an enterokinase site, an N-terminal gamma 3 amino acid linker containing a cysteine residue, flanked C-terminally by the sequence AS and N-terminally by the sequence ALV, and the mature form of the IL 5 gene. The protein released by cleavage with enterokinase is called "mouse C-IL-5-E" (SEQ ID NO:332). Plasmid DNA of resulting clone pMODC6-IL5.2 (also called pMODC6-IL5), whose sequence had been confirmed by DNA sequencing, was transformed into *E.coli* strain BL21.

Clone pMODC6-IL5/BL21 was grown over night in 5 ml LB containing 1 mg/L Ampicillin. 2 ml of this culture were diluted in 100 ml terrific broth (TB) containing 1mg/L Ampicillin. The culture was induced by adding 0.1 ml of a 1M solution of Isopropyl β -D-Thiogalactopyranoside (IPTG) when the culture reached an optical density OD₆₀₀=0.7. 10 ml samples were taken every 2h. The samples were centrifugated 10 min at 4000 x g. The pellet was resuspended in 0.5 ml Lysis buffer containing 50 mM Tris-HCl, 2 mM EDTA, 0.1% triton X-100 (pH8). After having added 20 μ l of Lysozyme (40mg/ml) and having incubated the tube 30 min at 4°C, the cells were sonicated for 2 min. 100 μ l of a 50 mM MgCl₂ solution and 1 ml of benzonase were added. The cells were then incubated 30 min at room temperature and centrifugated 15 min at 13000 x g.

The supernatant was discarded and the pellet was boiled 5 min at 98°C in 100 μ l of SDS loading buffer. 10 μ l of the samples in loading buffer were analyzed by

-126-

SDS-PAGE under reducing conditions (FIG. 17 A). The gel of FIG. 17 A clearly demonstrates expression of the IL-5 construct. The samples loaded on the gel of FIG. 17 A were the following:

Lane M: Marker (NEB, Broad range prestained marker). Lane 1: cell extract of 1ml culture before induction. Lane 2: cell extract of 1 ml culture 4h after induction.

B. Cloning of IL-5 for expression in mammalian cells (HEK-293T)

a) IL-5 fused at its N-terminus to an amino acid linker containing a cysteine residue and fused at its C-terminus to the Fc fragment

The template described under (A) (ATCC clone 37562) was used for the cloning of the following construct. The plasmid pMODB1-IL5 (a pET derivative) was digested with BamHI/XhoI to yield a small fragment encoding IL5 fused to an N terminal amino acid linker containing a cysteine. This fragment was ligated in the vector pCEP-SP-XA-Fc*(Δ Xho) which had previously been digested with BamHI and XhoI. The ligation was electroporated into *E.coli* strain TG1 and plasmid DNA of resulting clone pCEP-SP-IL5-Fc.2, whose sequence had been confirmed by DNA sequencing, was used to transfect HEK-293T cells. The resulting IL-5 construct encoded by this plasmid had the amino acid sequence ADPGCGGGGGLA fused at the N-terminus of the IL-5 mature sequence. This sequence comprises the amino acid linker sequence GCGGGGG containing a cysteine and flanked by additional amino acids introduced during the cloning procedure. The IL-5 protein released by cleavage of the fusion protein with Factor-Xa is named hereinafter "mouse C-IL-5-F" (SEQ ID NO:333).

After transfection and selection on Puromycin the culture supernatant was analyzed by Western-Blot (FIG. 17 B) using an anti-His (mouse) and an anti-mouse IgG antibody conjugated to Horse raddish peroxidase. The anti-mouse IgG antibody conjugated to Horse raddish peroxidase also detects Fc-fusion proteins. Purification of the protein was performed by affinity chromatography on Protein-A resin. The result of FIG. 17 B clearly demonstrates expression of the IL-5 construct.

The samples loaded on the Western-Blot of FIG. 17 B were the following:

-127-

Lane 1: supernatant of HEK culture expressing IL5-Fc (20µl). SDS-PAGE was performed under reducing conditions. Lane 2: supernatant of HEK culture expressing IL13-Fc (20µl). SDS-PAGE was performed under non reducing conditions. Lane 3: supernatant of HEK culture expressing IL5-Fc (20µl). SDS-PAGE was performed under non reducing conditions.

b) IL-5 cloned with GST (Glutathion-S-transferase) and an amino acid linker containing a cysteine residue fused at its N-terminus

IL-5 (ATCC 37562) was amplified with the primers Nhe-link1-IL13-F and IL5StopXho-R. After digestion with NheI and XhoI the insert was ligated into pCEP-SP-GST-EK which had been previously digested with NheI and XhoI. The resulting plasmid pCEP-SP-GST-IL5 was sequenced and used for transfection of HEK-293T cells. The resulting IL-5 construct encoded by this plasmid had the amino acid sequence LACGGGGG fused at the N-terminus of the IL-5 mature sequence. This sequence comprises the amino acid linker sequence ACGGGGG containing a cysteine residue and flanked by additional amino acids introduced during the cloning procedure. The protein released by cleavage with enterokinase was named hereinafter "mouse C-IL-5-S" (SEQ ID NO:334). The purification of the resulting protein was performed by affinity chromatography on Glutathione affinity resin.

C. Coupling of mouse C-IL-5-F or mouse C-IL-5-S to Q β capsid protein

A solution of 120 µM Q β capsid protein in 20 mM Hepes, 150 mM NaCl pH 7.2 is reacted for 30 minutes with a 25 fold molar excess of SMPH (Pierce), diluted from a stock solution in DMSO, at 25 °C on a rocking shaker. The reaction solution is subsequently dialyzed twice for 2 hours against 1 L of 20 mM Hepes, 150 mM NaCl, pH 7.2 at 4 °C. The dialyzed Q β reaction mixture is then reacted with the mouse C-IL-5-F or mouse C-IL-5-S solution (end concentrations: 60 µM Q β capsid protein, 60 µM mouse C-IL-5-F or mouse C-IL-5-S) for four hours at 25 °C on a rocking shaker. Coupling products are analysed by SDS-PAGE.

D. Coupling of mouse mouse C-IL-5-F or mouse C-IL-5-S to fr capsid protein

A solution of 120 µM fr capsid protein in 20 mM Hepes, 150 mM NaCl pH 7.2 is reacted for 30 minutes with a 25 fold molar excess of SMPH (Pierce), diluted

-128-

from a stock solution in DMSO, at 25 °C on a rocking shaker. The reaction solution is subsequently dialyzed twice for 2 hours against 1 L of 20 mM Hepes, 150 mM NaCl, pH 7.2 at 4 °C. The dialyzed fr reaction mixture is then reacted with the the mouse C-IL-5-F or mouse C-IL-5-S solution (end concentrations: 60 µM fr capsid protein, 60 µM mouse C-IL-5-F or mouse C-IL-5-S) for four hours at 25 °C on a rocking shaker. Coupling products are analysed by SDS-PAGE.

E. Coupling of mouse C-IL-5-F or mouse C-IL-5-S solution to HBcAg-Lys-2cys-Mut

A solution of 120 µM HBcAg-Lys-2cys-Mut capsid in 20 mM Hepes, 150 mM NaCl pH 7.2 is reacted for 30 minutes with a 25 fold molar excess of SMPH (Pierce), diluted from a stock solution in DMSO, at 25 °C on a rocking shaker. The reaction solution is subsequently dialyzed twice for 2 hours against 1 L of 20 mM Hepes, 150 mM NaCl, pH 7.2 at 4 °C. The dialyzed HBcAg-Lys-2cys-Mut reaction mixture is then reacted with the mouse mouse C-IL-5-F or mouse C-IL-5-S solution (end concentrations: 60 µM HBcAg-Lys-2cys-Mut, 60 µM mouse C-IL-5-F or mouse C-IL-5-S) for four hours at 25 °C on a rocking shaker. Coupling products are analysed by SDS-PAGE.

F. Coupling of mouse C-IL-5-F or mouse C-IL-5-S solution to Pili

A solution of 125 µM Type-1 pili of *E.coli* in 20 mM Hepes, pH 7.4, is reacted for 60 minutes with a 50-fold molar excess of cross-linker SMPH, diluted from a stock solution in DMSO, at RT on a rocking shaker. The reaction mixture is desalted on a PD-10 column (Amersham-Pharmacia Biotech). The protein-containing fractions eluting from the column are pooled, and the desalted derivatized pili protein is reacted with the mouse mouse C-IL-5-F or mouse C-IL-5-S solution (end concentrations: 60 µM pili, 60 µM mouse C-IL-5-F or mouse C-IL-5-S) for four hours at 25 °C on a rocking shaker. Coupling products are analysed by SDS-PAGE.

EXAMPLE 11

Introduction of an amino acid linker containing a cysteine residue, expression,

-129-

**purification and coupling of a murine vascular endothelial growth factor -2
(mVEGFR-2, FLK1) fragment**

A construct of the murine vascular endothelial growth factor-2 (mVEGFR-2, FLK-1) comprising its second and third extracellular domains was recombinantly expressed as a Fc-fusion protein with an amino acid linker containing a cysteine residue at its C-terminus for coupling to VLPs and Pili. The protein sequences of the mVEGFR-2(2-3) was translated from the cDNA sequences of mouse FLK-1 ((Matthews *et al.*, *Proc. Natl. Acad. Sci. USA* 88: 9026-9030 (1991)): Accession no. : X59397; Ig-like C2-type domain 2: amino acid 143-209; Ig-like C2-type domain 3: amino acid 241-306). The mVEGFR-2 (2-3) construct comprises the sequence of mVEGFR-2 from amino acid proline126 to lysine329 (in the numbering of the precursor protein). The construct also comprises, in addition to the Immunoglobulin-like C2-type domains 2 and 3, flanking regions preceding domain 2 and following domain 3 in the sequence of mVEGFR-2, to add amino acid spacer moieties. An amino acid linker containing a cysteine residue was fused to the C-terminus of the mVEGFR-2 sequence through cloning into pCEP-SP-EK-Fc* vector (EXAMPLE 1). The fragment of mVEGFR-2 cloned into pCEP-SP-EK-Fc* vector encoded the following amino acid sequence (SEQ ID NO:345):

```
PFLAS  VSDQHGIVYI  TENKNKTVVI  PCRGISISNLN  VSLCARYPEK
RFVPDGNRIS  WDSEIGFTLP  SYMISYAGMV  FCEAKINDET  YQSIMYIVVV
VGYRIYDVIL  SPPHEIELSA  GEKLVLNCTA  RTELNVGLDF  TWHSPPSKSH
HKKIVNRDVK  PFPGTVAKMF  LSTLTIESVT  KSDQGEYTCV  ASSGRMIKRN
RTFVRVHTKP
```

Expression of recombinant mVEGFR-2(2-3) in eukaryotic cells

Recombinant mVEGFR-2(2-3) was expressed in EBNA 293 cells using the pCEP-SP-EK-Fc* vector. The pCEP-SP-EK-Fc* vector has a BamHI and an NheI sites, encodes an amino acid linker containing one cysteine residue, an enterokinase cleavage site, and C-terminally a human Fc region. The mVEGFR-2(2-3) was amplified by PCR with the primer pair BamHI-FLK1-F and NheI-FLK1-B from a mouse 7-day embryo cDNA (Marathon-Ready cDNA, Clontech). For the PCR reaction, 10 pmol of each oligo and 0.5 ng of the cDNA (mouse 7-day embryo cDNA

-130-

Marathon-Ready cDNA, Clontech) was used in the 50 • l reaction mixture (1 • l of Advantage 2 polymerase mix (50x), 0.2 mM dNTPs and 5 • l 10x cDNA PCR reaction buffer). The temperature cycles were as follows: 5 cycles a 94• C for 1 minute, 94• C for 30 seconds, 54• C for 30 seconds, 72• C for 1 minute followed by 5 cycles of 94• C (30 seconds), 54• C (30 seconds), 70• C (1 minute) and followed by 30 cycles 94• C (20 seconds), 54• C (30 seconds) and 68• C (1 minute). The PCR product was digested with BamH1 and Nhe1 and inserted into the pCEP-SP-EK-Fc* vector digested with the same enzymes. Resulting plasmid was named mVEGFR-2(2-3)-pCep-EK-Fc. All other steps were performed by standard molecular biology protocols.

Oligos:

1. Primer BamH1-FLK1-F

5'-CGCGGATCCATTCATCGCCTCTGTC-3' (SEQ ID NO:343)

2. Primer Nhe1-FLK1-B

5'-CTAGCTAGCTTTGTGTGAACTCGGAC-3' (SEQ ID NO:344)

Transfection and expression of recombinant mVEGFR-2(2-3)

EBNA 293 cells were transfected with the mVEGFR-2(2-3)-pCep-Ek-Fc construct described above and serum free supernatant of cells was harvested for purification as described in EXAMPLE 1.

Purification of recombinant mVEGFR-2(2-3)

Protein A purification of the expressed Fc-EK-mVEGFR-2(2-3) proteins was performed as described in EXAMPLE 1. Subsequently, after binding of the fusion protein to Protein A, mVEGFR-2(2-3) was cleaved from the Fc-portion bound to protein A using enterokinase (EnterokinaseMax, Invitrogen). Digestion was conducted over night at 37• C (2,5 units enterokinase/100 µl Protein A beads with bound fusion protein). The released VEGFR-2(2-3) was separated from the Fc-portion still bound to protein A beads by short centrifugation in chromatography columns (Micro Bio Spin, Biorad). In order to remove the enterokinase the flow through was treated with enterokinase away (Invitrogen) according to the instructions of the manufacturer.

Example 12**Coupling of murine VEGFR-2 peptide to QB capsid protein , HbcAg-lys-2cys-Mut and Pili and immunization of mice with VLP-peptide and Pili-peptide vaccines****A. Coupling of murine VEGFR-2 peptides to VLPs and pili**

The following peptides was chemically synthesized (by Eurogentec, Belgium): murine VEGFR-2 peptide CTARTELVGLDFTWHSPPSKSHHKK and used for chemical coupling to Pili as described below.

Coupling of murine VEGFR-2 peptides to pili: A solution of 1400 μ l of 1 mg/ml pili protein in 20 mM Hepes, pH 7.4, was reacted for 60 minutes with 85 μ l of a 100 mM Sulfo-MBS (Pierce) solution in (H_2O) at RT on a rocking shaker. The reaction mixture was desalted on a PD-10 column (Amersham-Pharmacia Biotech), The protein-containing fractions eluting from the column were pooled (containing approximately 1,4 mg protein) and reacted with a 2.5-fold molar excess (final volume) of murine VEGFR-2 peptide respectively. For example, to 200 μ l eluate containing approximately 0,2 mg derivatized pili, 2.4 μ l of a 10 mM peptide solution (in DMSO) were added. The mixture, was incubated for four hours at 25 $^{\circ}C$ on a rocking shaker and subsequently dialyzed against 2 liters of 20 mM Hepes, pH 7.2 overnight at 4 $^{\circ}C$. Coupling results were analyzed by SDS-PAGE under reducing conditions and are shown in FIG. 18 A. Supernatant (S) and pellet (P) of each sample were loaded on the gel, as well pili and pili derivatized with Sulfo-MBS cross-linker (Pierce). The samples loaded on the gel of FIG. 18 A were the following:

Lane 1: Marker proteins; lane 2-5: coupled samples (Pili murine: Pili coupled to murine peptide; Pili human: Pili coupled to human peptide); lane 6: pili derivatized with Sulfo-MBS cross-linker; lane 7-9: three fractions of the eluate of the PD-10 column. Fraction 2 is the peak fraction, fraction 1 and 3 are fractions taken at the border of the peak. Coupling bands were clearly visible on the gel, demonstrating the successful coupling of murine VEGFR-2 to pili.

-132-

Coupling of murine VEGFR-2 peptide to Q β capsid protein: A solution of 1 ml of 1 mg/ml Q β capsid protein in 20 mM Hepes, 150 mM NaCl pH 7.4 was reacted for 45 minutes with 20 μ l of 100 mM Sulfo-MBS (Pierce) solution in (H₂O) at RT on a rocking shaker. The reaction solution was subsequently dialyzed twice for 2 hours against 2 L of 20 mM Hepes, pH 7.4 at 4 °C. 1000 μ l of the dialyzed reaction mixture was then reacted with 12 μ l of a 10 mM peptide solution (in DMSO) for four hours at 25 °C on a rocking shaker. The reaction mixture was subsequently dialyzed 2x2 hours against 2 liters of 20 mM Hepes, pH 7.4 at 4 °C. Coupling results were analyzed by SDS-PAGE under reducing conditions and are shown in FIG. 18 B. Supernatant (S) of each sample was loaded on the gel, as well as Q β capsid protein and Q β capsid protein derivatized with Sulfo-MBS cross-linker. Coupling was done in duplicate. The following samples were loaded on the gel:

Lane 1: Marker proteins; lane 2, 5: Q β capsid protein; lane 3, 6 Q β capsid protein derivatized with Sulfo-MBS; lane 4, 7: Q β capsid protein coupled to murine VEGFR-2 peptide. Coupling bands were clearly visible on the gel, demonstrating the successful coupling of murine VEGFR-2 to Q β capsid protein.

Coupling of murine VEGFR-2 peptide to HbcAg-lys-2cys-Mut: A solution of 3 ml of 0.9 mg/ml cys-free HbcAg capsid protein (EXAMPLE 31) in PBS, pH 7.4 was reacted for 45 minutes with 37,5 μ l of a 100 mM Sulfo-MBS (Pierce) solution in (H₂O) at RT on a rocking shaker. The reaction solution was subsequently dialyzed overnight against 2 L of 20 mM Hepes, pH 7.4. After buffer exchange the reaction solution was dialyzed for another 2 hours against the same buffer. The dialyzed reaction mixture was then reacted with 3 μ l of a 10 mM peptide solution (in DMSO) for 4 hours at 25 °C on a rocking shaker. The reaction mixture was subsequently dialyzed against 2 liters of 20 mM Hepes, pH 7.4 overnight at 4 °C followed by buffer exchange and another 2 hours of dialysis against the same buffer. Coupling results were analyzed by SDS-PAGE under reducing conditions and are shown in FIG. 18 C. The supernatant (S) of each sample was loaded on the gel, as well as HbcAg-lys-2cys-Mut protein and HbcAg-lys-2cys-Mut protein derivatized with Sulfo-MBS cross-linker. Coupling was done in duplicate. Coupling reactions were conducted in a 2.5 fold and 10 fold molar excess of peptide. The following samples were loaded on the gel:

-133-

Lane 1: Marker proteins; lane 2, 4, 6, 8: Supernatant (S) and pellet (P) of coupling reactions performed with 10 fold molar excess of peptide; lane 3, 5, 7, 9: Supernatant (S) and pellet (P) of coupling reactions performed with 2.5 fold molar excess of peptide; lane 10: HbcAg-lys-2cys-Mut derivatized with Sulfo-MBS; lane 11: HbcAg-lys-2cys-Mut.

Coupling bands were clearly visible on the gel, demonstrating the successful coupling of murine VEGFR-2 to HbcAg-lys-2cys-Mut protein.

B. Immunization of mice:

Pili-peptide vaccine :

Female C3H-HeJ (Toll-like receptor 4 deficient) and C3H-HeN (wild-type) mice were vaccinated with the murine VEGFR-2 peptide coupled to pili protein without the addition of adjuvants. Approximately 100 μ g of total protein of each sample was diluted in PBS to 200 μ l and injected subcutaneously on day 0, day 14 and day 28. Mice were bled retroorbitally on day 14, 28 and day 42 and serum of day 42 was analyzed using a human VEGFR-2 specific ELISA.

Q β capsid protein-peptide vaccine :

Female Black 6 mice were vaccinated with the murine VEGFR-2 peptide coupled to Q β capsid protein with and without the addition of adjuvant (Aluminiumhydroxid). Approximately 100 μ g of total protein of each sample was diluted in PBS to 200 μ l and injected subcutaneously on day 0, day 14 and day 28. Mice were bled retroorbitally on day 14, 28 and day 42 and serum of day 42 was analyzed using a human VEGFR-2 specific ELISA.

HbcAg-lys-2cys-Mut vaccines :

Female Black 6 mice were vaccinated with the murine VEGFR-2 peptide coupled to HbcAg-lys-2cys-Mut protein with and without the addition of adjuvant (Aluminiumhydroxid). Approximately 100 μ g of total protein of each sample was diluted in PBS to 200 μ l and injected subcutaneously on day 0, day 14 and day 28. Mice were bled retroorbitally on day 14, 28 and day 42 and serum of day 42 was

-134-

analyzed using a human VEGFR-2 specific ELISA.

C. ELISA

Sera of immunized mice were tested in ELISA with immobilized murine VEGFR-2 peptide. Murine VEGFR-2 peptide was coupled to bovine RNase A using the chemical cross-linker Sulfo-SPDP. ELISA plates were coated with coupled RNase A at a concentration of 10 μ g/ml. The plates were blocked and then incubated with serially diluted mouse sera. Bound antibodies were detected with enzymatically labeled anti-mouse IgG antibody. As a control, preimmune sera of the same mice were also tested. Control ELISA experiments using sera from mice immunized with uncoupled carrier showed that the antibodies detected were specific for the respective peptide. The results are shown in Figure 4-6.

Pili-peptide vaccine :

The result of the ELISA is shown in FIG. 18 D. Results for indicated serum dilutions are shown as optical density at 450 nm. The average of three mice each (including standard deviations) are shown. All vaccinated mice made IgG antibody titers against the murine VEGFR-2 peptide. No difference was noted between mice deficient for the Toll-like receptor 4 and wild-type mice, demonstrating the immunogenicity of the self-antigen murine VEGFR-2 peptide, when coupled to pili, in mice. The vaccines injected in the mice are designating the corresponding analyzed sera.

Q β capsid protein-peptide vaccine :

Results for indicated serum dilutions are shown in FIG. 18 E as optical density at 450 nm. The average of two mice each (including standard deviations) are shown. All vaccinated mice made IgG antibody titers against the murine VEGFR-2 peptide, demonstrating the immunogenicity of the self-antigen murine VEGFR-2 peptide, when coupled to Q β capsid protein, in mice. The vaccines injected in the mice are designating the corresponding analyzed sera.

HbcAg-lys-2cys-Mut vaccine :

Results for indicated serum dilutions are shown in FIG. 18 F as optical density at

-135-

450 nm. The average of three mice each (including standard deviations) are shown. All vaccinated mice made IgG antibody titers against the murine VEGFR-2 peptide, demonstrating the immunogenicity of the self-antigen murine VEGFR-2 peptide, when coupled to Q β capsid protein, in mice. The vaccines injected in the mice are designating the corresponding analyzed sera.

EXAMPLE 13

Coupling of A β 1-15 peptides to HBc-Ag-lys-2cys-Mut and fr capsid protein

The following A β peptide was chemically synthesized (DAEFRHDSGYEVHHQGGC), a peptide which comprises the amino acid sequence from residue 1-15 of human A β , fused at its C-terminus to the sequence GGC for coupling to VLPs and Pili.

- A. a.) Coupling of A β 1-15 peptide to HBc-Ag-lys-2cys-Mut using the cross-linker SMPH.

A solution of 833.3 μ l of 1.2 mg/ml HBc-Ag-lys-2cys-Mut protein in 20 mM Hepes 150 mM NaCl pH 7.4 was reacted for 30 minutes with 17 μ l of a solution of 65 mM SMPH (Pierce) in H₂O, at 25 °C on a rocking shaker. The reaction solution was subsequently dialyzed twice for 2 hours against 1 L of 20 mM Hepes, 150 mM NaCl, pH 7.4 at 4 °C in a dialysis tubing with Molecular Weight cutoff 10000 Da. 833.3 μ l of the dialyzed reaction mixture was then reacted with 7.1 μ l of a 50 mM peptide stock solution (peptide stock solution in DMSO) for two hours at 15°C on a rocking shaker. The reaction mixture was subsequently dialyzed overnight against 1 liters of 20 mM Hepes, 150 mM NaCl, pH 7.4 at 4 °C. The sample was then frozen in aliquots in liquid Nitrogen and stored at -80°C until immunization of the mice.

-136-

b) Coupling of A β 1-15 peptide to fr capsid protein using the cross-linker SMPH..

A solution of 500 μ l of 2 mg/ml fr capsid protein in 20 mM Hepes 150 mM NaCl pH 7.4 was reacted for 30 minutes with 23 μ l of a solution of 65 mM SMPH (Pierce) in H₂O, at 25 °C on a rocking shaker. The reaction solution was subsequently dialyzed twice for 2 hours against 1 L of 20 mM Hepes, 150 mM NaCl, pH 7.4 at 4 °C in a dialysis tubing with Molecular Weight cutoff 10000 Da. 500 μ l of the dialyzed reaction mixture was then reacted with 5.7 μ l of a 50 mM peptide stock solution (peptide stock solution in DMSO) for two hours at 15°C on a rocking shaker. The reaction mixture was subsequently dialyzed overnight against 1 liter of 20 mM Hepes, 150 mM NaCl, pH 7.4 at 4 °C. The sample was then frozen in aliquots in liquid Nitrogen and stored at -80°C until immunization of the mice. Samples of the coupling reaction were analyzed by SDS-PAGE under reducing conditions.

The results of the coupling experiments were analyzed by SDS-PAGE, and are shown in FIG. 19 A. Clear coupling bands corresponding to the coupling of A β 1-15 either to fr capsid protein or to HBc-Ag-lys-2cys-Mut were visible on the gel, and are indicated by arrows in the figure, demonstrating successful coupling of A β 1-15 to fr capsid protein and to HBc-Ag-lys-2cys-Mut capsid protein. Multiple coupling bands were visible for the coupling to fr capsid protein, while mainly one coupling band was visible for HBc-Ag-lys-2cys-Mut.

The following samples were loaded on the gel of FIG. 19 A.

1: Protein Marker (kDa Marker 7708S BioLabs. Molecular weight marker bands from the top of the gel: 175, 83, 62, 47.5, 32.5, 25, 16.5, 6.5 kDa). 2: derivatized HBc-Ag-lys-2cys-Mut. 3: HBc-Ag-lys-2cys-Mut coupled with A β 1-15, supernatant of the sample taken at the end of the coupling reaction, and centrifuged. 4: HBc-Ag-lys-2cys-Mut coupled with A β 1-15, pellet of the sample taken at the end of the coupling reaction, and centrifuged. 5: derivatized fr capsid protein. 6: fr capsid protein coupled with A β 1-15, supernatant of the sample taken at the end of the coupling reaction, and

-137-

centrifuged. 4: fr capsid protein coupled with A β 1-15, pellet of the sample taken at the end of the coupling reaction, and centrifuged.

B. Immunization of Balb/c mice

Female Balb/c mice were vaccinated twice on day 0 and day 14 subcutaneously with either 10 μ g of fr capsid protein coupled to A β 1-15 (Fr-A β 1-15) or 10 μ g of HBc-Ag-lys-2cys-Mut coupled to A β 1-15 (HBc-A β 1-15) diluted in sterile PBS. Mice were bled retroorbitally on day 22 and sera were analysed in an A β -1-15-specific ELISA.

C. ELISA

The A β 1-15 peptide was coupled to bovine RNase A using the chemical cross-linker sulfo-SPDP. ELISA plates were coated with A β 1-15-RNase conjugate at a concentration of 10 μ g/ml. The plates were blocked and then incubated with serially diluted serum samples. Bound antibodies were detected with enzymatically labeled anti-mouse IgG. As a control, serum from a naive mouse was also tested.

Shown on FIG. 19 B are the ELISA signals obtained on day 22 with the sera of the mice immunized with vaccines Fr-A β 1-15, and HBc-A β 1-15 respectively. A control serum from a naïve mouse (preimmune serum) was also included. Results from different serum dilutions are shown as optical density at 450 nm. Average results from three vaccinated mice each are shown. All vaccinated mice had A β 1-15-specific IgG antibodies in their serum.

-138-

EXAMPLE 14**Coupling of A β 1-15, A β 1-27 and A β 33-42 peptides to Type I Pili**

Coupling of A β 1-15, A β 1-27 and A β 33-42 peptides to Pili using the cross-linker SMPH.

The following A β peptides were chemically synthesized:

DAEFRHDSGYEVHHQGGC ("A β 1-15"), a peptide which comprises the amino acid sequence from residue 1-15 of human A β , fused at its C-terminus to the sequence GGC for coupling to Pili and VLPs,

DAEFRHDSGYEVHHQKLVFFAEDVGSNGGC ("A β 1-27") a peptide which comprises the amino acid sequence from residue 1-27 of human A β , fused at its C-terminus to the sequence GGC for coupling to Pili and VLPs, and

CGHGNKSGLMVGGVVIA ("A β 33-42") a peptide which comprises the amino acid sequence from residue 33-42 of A β , fused at its N-terminus to the sequence CGHGNKS for coupling to Pili and VLPs. All three peptides were used for chemical coupling to Pili as described in the following.

A solution of 2 ml of 2 mg/ml Pili in 20 mM Hepes 150 mM NaCl pH 7.4 was reacted for 45 minutes with 468 μ l of a solution of 33.3 mM SMPH (Pierce) in H₂O, at 25 °C on a rocking shaker. The reaction solution was loaded on a PD10 column (Pharmacia) and eluted with 6 X 500 μ l of 20 mM Hepes 150mM NaCl pH 7.4. Fractions were analyzed by dotting on a Nitrocellulose (Schleicher & Schuell) and stained with Amidoblack. Fractions 3 – 6 were pooled. The samples were then frozen in aliquots in liquid Nitrogen and stored at –80°C until coupling.

200 μ l of the thawed desalted reaction mixture was then mixed with 200 μ l DMSO and 2.5 μ l of each of the corresponding 50 mM peptide stock solutions in DMSO, for 3.5 hours at RT on a rocking shaker. 400 μ l of the reaction mixture was subsequently dialyzed three times for one hour against 1 liter of 20 mM Hepes, 150 mM NaCl, pH 7.4 at 4 °C in a dialysis tubing with Molecular Weight cutoff 10000 Da. The samples were then frozen in aliquots in liquid Nitrogen and stored at –80°C

Sample preparation for SDS-Page was performed as follows: 100 μ l of

-139-

the dialyzed coupling reaction was incubated for 10 minutes in 10 % TCA on ice and subsequently centrifuged. The pellet was resuspended in 50 μ l 8.5 M Guanidine-HCl solution and incubated for 15 minutes at 70°C. The samples were then precipitated with ethanol, and after a second centrifugation step, the pellet was resuspended in sample buffer.

The results of the coupling experiments were analyzed by SDS-PAGE under reducing conditions. Clear coupling bands were visible for all three peptides, demonstrating coupling of A β peptides to Pili.

EXAMPLE 15

Vaccination of APP23 mice with A β peptides coupled to Q β capsid protein

A. Immunization of APP23 mice

Three different A β peptides (A β 1-27-Gly-Gly-Cys-NH₂; H-Cys-Gly-His-Gly-Asn-Lys-Ser-A β 33-42; A β 1-15-Gly-Gly-Cys-NH₂) were coupled to Q β capsid protein. The resulting vaccines were termed "Qb-Ab 1-15", "Qb-Ab 1-27" and "Qb-Ab 33-42". 8 months old female APP23 mice which carry a human APP transgene (Sturchler-Pierrat *et al.*, *Proc.Natl. Acad.Sci. USA* 94: 13287-13292 (1997)) were used for vaccination. The mice were injected subcutaneously with 25 μ g vaccine diluted in sterile PBS and 14 days later boosted with the same amount of vaccine. Mice were bled from the tail vein before the start of immunization and 7 days after the booster injection. The sera were analyzed by ELISA.

B. ELISA

A β 1-40 and A β 1-42 peptide stocks were made in DMSO and diluted in coating buffer before use. ELISA plates were coated with 0.1 μ g /well A β 1-40 or A β 1-42 peptide. The plates were blocked and then incubated with serially diluted mouse serum. Bound antibodies were detected with enzymatically labeled anti-mouse IgG antibody. As a control, sera obtained before vaccination were also included. The

-140-

serum dilution showing a mean three standard deviations above baseline was calculated and defined as "ELISA titer". All three vaccines tested were immunogenic in APP23 mice and induced high antibody titers against the A β peptides 1-40 and/or A β 1-42. The results are shown in FIG. 20. No specific antibodies were detected in preimmune sera of the same mice (not shown).

Shown on FIG. 20 are the ELISA signals obtained on day 22 with the sera of the mice immunized with vaccines Fr-A β 1-15, and HBc-A β 1-15 respectively. A control serum from a naïve mouse (preimmune serum) was also included. Results from different serum dilutions are shown as optical density at 450 nm. Average results from three vaccinated mice each are shown.

Mice A21-A30 received the vaccine Qb-Ab 1-15, mice A31-A40 received Qb-Ab 1-27 and mice A41-49 received Qb-Ab 33-42. For each mouse, A β 1-40 and A β 1-42 peptide-specific serum antibody titers were determined on day 21 by ELISA. The ELISA titers defined as the serum dilution showing a mean three standard deviations above baseline are shown for individual mice. Mice vaccinated with Qb-Ab 1-15 or Qb-Ab 1-27 made high antibody titers against both A β 1-40 and A β 1-42 whereas mice vaccinated with Qb-Ab 33-42 had only high antibody titers against the A β 1-42 peptide.

EXAMPLE 16

Coupling of Fab antibody fragments to Q β capsid protein

A solution of 4.0 mg/ml Q β capsid protein in 20 mM Hepes, 150 mM NaCl pH 7.2 was reacted for 30 minutes with a 2.8 mM SMPH (Pierce) (from a stock solution dissolved in DMSO) at 25°C on a rocking shaker. The reaction solution was subsequently dialyzed twice for 2 hours against 2 l of 20 mM Hepes, 150 mM NaCl, pH 7.2 at 4°C.

The Fab fragment of human IgG, produced by papain digestion of human IgG, was purchased from Jackson Immunolab. This solution (11.1mg/ml) was diluted to a concentration of 2.5mg/ml in 20 mM Hepes, 150 mM NaCl pH 7.2 and allowed to react with different concentrations (0-1000 μ M) of either dithiothreitol (DTT) or tricarboxyethylphosphine (TCEP) for 30 minutes at 25°C.

-141-

Coupling was induced by mixing the derivatized and dialysed Q β capsid protein solution with non-reduced or reduced Fab solution (final concentrations: 1.14 mg/ml Q β and 1.78 mg/ml Fab) and proceeded overnight at 25 °C on a rocking shaker.

The reaction products were analysed on 16% SDS-PAGE gels under reducing conditions. Gels were stained with Coomassie Brilliant Blue. The results are shown in FIG. 21.

A coupling product of about 40 kDa could be detected in samples in which the Fab had been reduced before coupling by 25-1000 μ M TCEP and 25 – 100 μ M DTT (FIG. 21, arrow), but not at 10 μ M TCEP, 10 μ M DTT or 1000 μ M DTT. The coupled band also reacted with an anti-Q β antiserum (data not shown) clearly demonstrating the covalent coupling of the Fab fragment to Q β capsid protein.

The samples loaded on the gel of FIG. 21 were the following:

Lane 1: Molecular weight marker. Lane 2 and 3: derivatized Q β capsid protein before coupling. Lane 4-13: Q β -Fab coupling reactions after reduction of Fab with 4: Q β -Fab coupling reactions after reduction of Fab with 10 μ M TCEP. 5: Q β -Fab coupling reactions after reduction of Fab with 25 μ M TCEP. 6: Q β -Fab coupling reactions after reduction of Fab with 50 μ M TCEP, 7: Q β -Fab coupling reactions after reduction of Fab with 100 μ M TCEP. 8: Q β -Fab coupling reactions after reduction of Fab with 1000 μ M TCEP. 9: Q β -Fab coupling reactions after reduction of Fab with 10 μ M DTT. 10: Q β -Fab coupling reactions after reduction of Fab with 25 μ M DTT. 11: Q β -Fab coupling reactions after reduction of Fab with 50 μ M DTT. 12: Q β -Fab coupling reactions after reduction of Fab with 100 μ M DTT. 13: Q β -Fab coupling reactions after reduction of Fab with 1000 μ M DTT. Lane 14: Fab before coupling. The gel was stained with Coomassie Brilliant Blue. Molecular weights of marker proteins are given on the left margin. The arrow indicates the coupled band.

EXAMPLE 17**Vaccination of APP23 mice with A β peptides coupled to Q β capsid protein****A. Immunization of APP23 mice**

Three different A β peptides (A β 1-27-Gly-Gly-Cys-NH₂; H-Cys-Gly-His-Gly-Asn-Lys-Ser-A β 33-42; A β 1-15-Gly-Gly-Cys-NH₂) were coupled to Q β capsid protein. The resulting vaccines were termed "Qb-Ab 1-15", "Qb-Ab 1-27" and "Qb-Ab 33-42". 8 months old female APP23 mice which carry a human APP transgene (Sturchler-Pierrat *et al.*, *Proc.Natl. Acad.Sci. USA* 94: 13287-13292 (1997)) were used for vaccination. The mice were injected subcutaneously with 25 μ g vaccine diluted in sterile PBS and 14 days later boosted with the same amount of vaccine. Mice were bled from the tail vein before the start of immunization and 7 days after the booster injection. The sera were analyzed by ELISA.

B. ELISA

A β 1-40 and A β 1-42 peptide stocks were made in DMSO and diluted in coating buffer before use. ELISA plates were coated with 0.1 μ g /well A β 1-40 or A β 1-42 peptide. The plates were blocked and then incubated with serially diluted mouse serum. Bound antibodies were detected with enzymatically labeled anti-mouse IgG antibody. As a control, sera obtained before vaccination were also included. The serum dilution showing a mean three standard deviations above baseline was calculated and defined as "ELISA titer". All three vaccines tested were immunogenic in APP23 mice and induced high antibody titers against the A β peptides 1-40 and/or A β 1-42. The results are shown in FIG. 20. No specific antibodies were detected in preimmune sera of the same mice (not shown).

Shown on FIG. 20 are the ELISA signals obtained on day 22 with the sera of the mice immunized with vaccines Qb-Ab 1-15, Qb-Ab 1-27 and Qb-Ab 33-42, respectively. Mice A21-A30 received the vaccine Qb-Ab 1-15, mice A31-A40 received Qb-Ab 1-27 and mice A41-49 received Qb-Ab 33-42. For each mouse, A β 1-40 and A β 1-42 peptide-specific serum antibody titers were determined on day 21 by ELISA. The ELISA titers defined as the serum dilution showing a mean three standard deviations above baseline are shown for individual mice. Mice vaccinated

-143-

with Qb-Ab 1-15 or Qb-Ab 1-27 made high antibody titers against both A β 1-40 and A β 1-42 whereas mice vaccinated with Qb-Ab 33-42 had only high antibody titers against the A β 1-42 peptide. The very strong immune responses obtained with the human A β peptides in the transgenic mice expressing human A β transgene, demonstrate that by coupling A β peptides to Q β capsid protein, tolerance towards the self-antigen can be overcome.

EXAMPLE 18

Construction, expression and purification of mutant Q β coat proteins

Construction of pQ β -240

The plasmid pQ β 10 (Kozlovska, TM, *et al.*, *Gene* 137:133-137) was used as an initial plasmid for the construction of pQ β -240. The mutation Lys13 \rightarrow Arg was created by inverse PCR. The inverse primers were designed in inverted tail-to-tail directions:

5'-GGTAACATCGGTCGAGATGGAAAACAACTCTGGTCC-3' and
5'-GGACCAGAGTTTGTTCATCTCGACCGATGTTACC-3'.

The products of the first PCR were used as templates for the second PCR reaction, in which an upstream primer

5'-AGCTCGCCCGGGGATCCTCTAG-3' and a downstream primer
5'-CGATGCATTTTCATCCTTAGTTATCAATACGCTGGGTTTCAG-3'

were used. The product of the second PCR was digested with *Xba*I and *Mph*1103I and cloned into the pQ β 10 expression vector, which was cleaved by the same restriction enzymes. The PCR reactions were performed with PCR kit reagents and according to producer protocol (MBI Fermentas, Vilnius, Lithuania).

Sequencing using the direct label incorporation method verified the desired mutations. *E.coli* cells harbouring pQ β -240 supported efficient synthesis of 14-kD protein co migrating upon PAGE with control Q β coat protein isolated from Q β phage particles.

-144-

Resulting amino acid sequence: (SEQ ID NO: 255)

AKLETVTLGNI~~GR~~DGKQTLVLNPRGVNPTNGVASLSQAGAVP
 ALEKRVTVSVSQPSRNRKNYKVQVKIQNPTACTANGSCDPSVTRQ
 KYADVTFSTQYSTDEERAFVRTELAALLASPLLDAIDQLNPAY

Construction of pQ β -243

The plasmid pQ β 10 was used as an initial plasmid for the construction of pQ β -243. The mutation Asn10→Lys was created by inverse PCR. The inverse primers were designed in inverted tail-to-tail directions:

5'-GGCAA~~A~~ATTAGAGACTGTTACTTTAGGTAAGATCGG -3' and
 5'-CCGATCTTACCTAAAGTAACAGTCTCTAATTTTGCC -3'.

The products of the first PCR were used as templates for the second PCR reaction, in which an upstream primer

5'-AGCTCGCCCGGGGATCCTCTAG-3' and a downstream primer
 5'-CGATGCATTTTCATCCTTAGTTATCAATACGCTGGGTTCAG-3'

were used. The product of the second PCR was digested with *Xba*I and *Mph*1103I and cloned into the pQ β 10 expression vector, which was cleaved by the same restriction enzymes. The PCR reactions were performed with PCR kit reagents and according to producer protocol (MBI Fermentas, Vilnius, Lithuania).

Sequencing using the direct label incorporation method verified the desired mutations. *E.coli* cells harbouring pQ β -243 supported efficient synthesis of 14-kD protein co migrating upon PAGE with control Q β coat protein isolated from Q β phage particles.

Resulting amino acid sequence: (SEQ ID NO: 256)

AKLETVTLGKIGKD~~G~~GKQTLVLNPRGVNPTNGVASLSQAGAVP
 ALEKRVTVSVSQPSRNRKNYKVQVKIQNPTACTANGSCDPSVTRQ
 KYADVTFSTQYSTDEERAFVRTELAALLASPLLDAIDQLNPAY

Construction of pQ β -250

The plasmid pQ β -240 was used as an initial plasmid for the construction of pQ β -250. The mutation Lys2→Arg was created by site-directed mutagenesis. An

-145-

upstream primer

5'-GGCCATGGCAGACTCGAGACTGTTACTTTAGG-3' and a downstream primer 5'-GATTTAGGTGACACTATAG-3' were used for the synthesis of the mutant PCR-fragment, which was introduced into the pQ β -185 expression vector at the unique restriction sites *NcoI* and *HindIII*. The PCR reactions were performed with PCR kit reagents and according to producer protocol (MBI Fermentas, Vilnius, Lithuania).

Sequencing using the direct label incorporation method verified the desired mutations. *E.coli* cells harbouring pQ β -250 supported efficient synthesis of 14-kD protein co migrating upon PAGE with control Q β coat protein isolated from Q β phage particles.

Resulting amino acid sequence: (SEQ ID NO: 257)

ARLETVTGLGNIGRDGKQTLVLNPRGVNPTNGVASLSQAGAVP
ALEKRVTVSVSQPSRNRKNYKVQVKIQNPTACTANGSCDPSVTRQ
KYADVTFSTQYSTDEERAFVRTELAALLASPLLIDAIDQLNPAY

Construction of pQ β -251

The plasmid pQ β 10 was used as an initial plasmid for the construction of pQ β -251. The mutation Lys16→Arg was created by inverse PCR. The inverse primers were designed in inverted tail-to-tail directions:

5'-GATGGACGTCAAACCTCTGGTCCTCAATCCGCGTG GGG -3' and
5'-CCCCACGCGGATTGAGGACCAGAGTTTGACGTCCATC -3'.

The products of the first PCR were used as templates for the second PCR reaction, in which an upstream primer

5'-AGCTCGCCCGGGGATCCTCTAG-3' and a downstream primer
5'-CGATGCATTTTCATCCTTAGTTATCAATACGCTGGGTTTCAG-3'

were used. The product of the second PCR was digested with *XbaI* and *Mph1103I* and cloned into the pQ β 10 expression vector, which was cleaved by the same restriction enzymes. The PCR reactions were performed with PCR kit reagents and according to producer protocol (MBI Fermentas, Vilnius, Lithuania).

Sequencing using the direct label incorporation method verified the desired

-146-

mutations. *E.coli* cells harbouring pQ β -251 supported efficient synthesis of 14-kD protein co migrating upon PAGE with control Q β coat protein isolated from Q β phage particles. The resulting amino acid sequence encoded by this construct is shown in SEQ. ID NO: 259.

Construction of pQ β -259

The plasmid pQ β -251 was used as an initial plasmid for the construction of pQ β -259. The mutation Lys2→Arg was created by site-directed mutagenesis. An upstream primer

5'-GGCCATGGCACGACTCGAGACTGTTACTTTAGG-3' and a downstream primer 5'-GATTTAGGTGACACTATAG-3' were used for the synthesis of the mutant PCR-fragment, which was introduced into the pQ β -185 expression vector at the unique restriction sites *NcoI* and *HindIII*. The PCR reactions were performed with PCR kit reagents and according to producer protocol (MBI Fermentas, Vilnius, Lithuania).

Sequencing using the direct label incorporation method verified the desired mutations. *E.coli* cells harbouring pQ β -259 supported efficient synthesis of 14-kD protein co migrating upon PAGE with control Q β coat protein isolated from Q β phage particles.

Resulting amino acid sequence: (SEQ ID NO: 258)

AKLETVTLGNIKDGKQTLVLNPRGVNPTNGVASLSQAGAVP
ALEKRVTVSVSQPSRNRKNYKVQVKIQNPTACTANGSCDPSVTRQ
KYADVTFSTQYSTDEERAFVRTELAALLASPLLIDAIDQLNPAY

General procedures for Expression and purification of Q β and Q β mutants

Expression

-147-

Transform E.coli JM109 with Q-beta expression plasmids. Inoculate 5 ml of LB liquid medium with 20 • g/ml ampicillin with clones transformed with Q-beta expression plasmids. Incubate at 37 °C for 16-24 h without shaking.

Inoculate 100-300 ml of LB medium, containing 20 • g/ml, 1:100 with the prepared inoculum. Incubate at 37 °C overnight without shaking . Inoculate M9 + 1 % Casamino acids + 0.2 % glucose medium in flasks with the prepared inoculum 1:50, incubate at 37 °C overnight under shaking.

Purification

Solutions and buffers for the purification procedure:

1. Lysis buffer LB

50mM Tris-HCl pH8,0 with 5mM EDTA , 0,1% tritonX100 and fresh! prepared PMSF till 5micrograms per ml. Without lysozyme and DNase.

2. SAS

Saturated ammonium sulphate in water

3. Buffer NET.

20 mM Tris-HCl, pH 7.8 with 5mM EDTA and 150 mM NaCl.

4. PEG

40% (w/v) polyethylenglycol 6000 in NET

Disruption and lyses

Frozen cells were resuspended in LB at 2 ml/g cells. The mixture was sonicated with 22 kHz five times for 15 seconds, with intervals of 1min to cool the

-148-

solution on ice. The lysate was then centrifuged at 14 000 rpm, for 1h using a Janeki K 60 rotor. The centrifugation steps described below were all performed using the same rotor, except otherwise stated. The supernatant was stored at 4° C, while cell debris were washed twice with LB. After centrifugation, the supernatants of the lysate and wash fractions were pooled.

Fractionation

A saturated ammonium sulphate solution was added dropwise under stirring to the above pooled lysate. The volume of the SAS was adjusted to be one fifth of total volume, to obtain 20% of saturation. The solution was left standing overnight, and was centrifuged the next day at 14 000 rpm, for 20 min. The pellet was washed with a small amount of 20% ammonium sulphate, and centrifuged again. The obtained supernatants were pooled, and SAS was added dropwise to obtain 40% of saturation. The solution was left standing overnight, and was centrifuged the next day at 14 000 rpm, for 20 min. The obtained pellet was solubilised in NET buffer.

Chromatography

The capsid protein resolubilized in NET buffer was loaded on a Sepharose CL- 4B column. Three peaks eluted during chromatography. The first one mainly contained membranes and membrane fragments, and was not collected. Capsids were contained in the second peak, while the third one contained other E.coli proteins.

The peak fractions were pooled, and the NaCl concentration was adjusted to a final concentration of 0.65 M. A volume of PEG solution corresponding to one half of the pooled peak fraction was added dropwise under stirring. The solution was left to stand overnight without stirring. The capsid protein was sedimented by centrifugation at 14 000 rpm for 20 min. It was then solubilized in a minimal volume of NET and loaded again on the Sepharose CL- 4B column. The peak fractions were

-149-

pooled, and precipitated with ammonium sulphate at 60% of saturation (w/v). After centrifugation and resolubilization in NET buffer, capsid protein was loaded on a Sepharose CL-6B column for rechromatography.

Dialysis and drying

The peak fractions obtained above were pooled and extensively dialysed against sterile water, and lyophilized for storage.

Expression and purification Q β -240

Cells (*E. coli* JM 109, transformed with the plasmid pQ β -240) were resuspended in LB, sonicated five times for 15 seconds (water ice jacket) and centrifuged at 13000 rpm for one hour. The supernatant was stored at 4°C until further processing, while the debris were washed 2 times with 9 ml of LB, and finally with 9 ml of 0,7 M urea in LB. All supernatants were pooled, and loaded on the Sepharose CL-4B column. The pooled peak fractions were precipitated with ammonium sulphate and centrifuged. The resolubilized protein was then purified further on a Sepharose 2B column and finally on a Sepharose 6B column. The capsid peak was finally extensively dialyzed against water and lyophilized as described above. The assembly of the coat protein into a capsid was confirmed by electron microscopy.

Expression and purification Q β -243

Cells (*E. coli* RR1) were resuspended in LB and processed as described in the general procedure. The protein was purified by two successive gel filtration steps on the sepharose CL-4B column and finally on a sepharose CL-2B column. Peak fractions were pooled and lyophilized as described above. The assembly of the coat

-150-

protein into a capsid was confirmed by electron microscopy.

Expression and purification of Q β -250

Cells (*E. coli* JM 109, transformed with pQ β -250) were resuspended in LB and processed as described above. The protein was purified by gel filtration on a Sepharose CL-4B and finally on a Sepharose CL-2B column, and lyophilized as described above. The assembly of the coat protein into a capsid was confirmed by electron microscopy.

Expression and purification of Q β -259

Cells (*E. coli* JM 109, transformed with pQ β -259) were resuspended in LB and sonicated. The debris were washed once with 10 ml of LB and a second time with 10 ml of 0,7 M urea in LB. The protein was purified by two gel-filtration chromatography steps, on a Sepharose CL-4 B column. The protein was dialyzed and lyophilized, as described above. The assembly of the coat protein into a capsid was confirmed by electron microscopy.

EXAMPLE 19

Desensitization of allergic mice with PLA2 coupled to Q β capsid protein

C. Desensitization of allergic mice by vaccination

Female CBA/J mice (8 weeks old) were sensitized with PLA2: Per mouse, 0.1 ug PLA2 from Latoxan (France) was adsorbed to 1 mg Alum (Imject, Pierce) in a total volume of 66 ul by vortexing for 30 min and then injected subcutaneously. This procedure was repeated every 14 days for a total of four times. This treatment led to the development of PLA2-specific serum IgE but no IgG2a antibodies. 1 month after the last sensitization, mice were injected subcutaneously with 10 ug vaccine consisting of recombinant PLA2 coupled to Q β capsid protein. One and 2 weeks later they were again treated with the same amount of vaccine. One week after the last

-151-

treatment, mice were bled and then challenged intraperitoneally with 25 µg PLA2 (Latoxan) and rectal temperature was measured for 60 min using a calibrated digital thermometer. As a control sensitized mice which had not been treated with Qβ capsid protein-PLA2 were used. Whereas all control mice experienced an anaphylactic response reflected in a dramatic drop in rectal temperature after PLA2 challenge, vaccinated mice were fully or at least partially protected. Results are shown in FIG 25 A.

B. ELISA

ELISA plates (Maxisorp, Nunc) were coated with PLA2 (Latoxan) at 5 µg/ml. The plates were blocked and then incubated with serially diluted serum. For the detection of IgE antibodies, serum was pretreated with protein G beads (Pharmacia) for 60 min on a shaker at room temperature. The beads were removed by centrifugation and the supernatant was used for ELISA. Antibodies bound to PLA2 were detected with enzymatically labeled anti-mouse IgG2a or IgE antibodies. ELISA titers were determined at half maximal optical density (OD50%) and expressed as -log5 of 100-fold prediltued sera for IgG2a and as -log5 of 10-fold prediluted sera for IgE. For all mice, PLA2-specific IgG2a and IgE in serum were determined before and at the end of the vaccine treatment. Vaccination led to a dramatic increase of PLA2-specific IgG2a whereas no consistent changes in IgE titers were noted. These results indicate that the vaccination led to an induction of a Th1-like immune response (reflected by the production of IgG2a). Results are shown in FIG. 25 B.

The Anaphylactic response in vaccinated and non-vaccinated mice is shown in FIG. 25A.

Mice were sensitized to PLA2 and then treated 3x subcutaneously with 10 µg vaccine consisting of PLA2 coupled to Qβ capsid protein. Control mice were sensitized but not vaccinated. One week after the last vaccination all mice were challenged intraperitoneally with 25 µg PLA2 and the anaphylactic response was monitored by measuring the rectal temperature for 60 min. Whereas all control mice showed a dramatic drop in body temperature, vaccinated mice were fully or at least

-152-

partially protected from an anaphylactic reaction.

The induction of PLA₂-specific IgG2a by vaccination is shown in FIG. 25 B.

Mice were sensitized to PLA₂ and then treated 3x with 10 ug vaccine consisting of PLA₂ coupled to Q β capsid protein. Control mice were sensitized but not vaccinated. Serum was taken from sensitized mice before the start of the treatment and after completion of treatment, before challenge. In vaccinated mice (left hand of panel) a dramatic increase of PLA₂-specific IgG2a was observed.

EXAMPLE 20

Expression, refolding, purification and coupling of Pla₂-Cys (also called PLA₂ fusion protein)

Expression and preparation of inclusion bodies

The pET11a Plasmid containing the PLA₂-Cys gene of example xxx was transformed into *E. coli* BL21DE3Rill (Stratagene). An overnight culture was grown in dYT medium containing 100 μ g/ml Ampicillin and 15 μ g/ml Chloramphenicol. The culture was diluted in fresh dYT medium containing Ampicillin and Chloramphenicol, and grown at 37°C until OD_{600 nm} = 1 was reached. The culture was induced with 1 mM IPTG, and grown for another 4 hours. Cells were collected by centrifugation, and resuspended in PBS buffer containing 0.5 mg/ml Lysozyme. After incubation on ice, cells were sonicated on ice, and MgCl₂ added to a concentration of 10 mM. 6 μ l of Benzonase (Merck) were added to the cell lysate, and the lysate was incubated 30 minutes at RT. Triton was added to a final concentration of 1 %, and the lysate was further incubated for 30 minutes on ice. The inclusion body (IB) pellet was collected by centrifugation for 10 minutes at 13000 g. The inclusion body pellet was washed in wash buffer containing 20 mM Tris, 23% sucrose, 1 mM EDTA, pH 8.0. The IBs were solubilized in 6 M Guanidinium-HCl, 20 mM Tris, pH 8.0, containing 200 mM DTT. The solubilized IBs were centrifuged at 50000 g and the supernatant dialyzed against 6 M Guanidinium-HCl, 20 mM Tris, pH 8.0 and subsequently against the same buffer containing 0.1 mM DTT. Oxidized glutathion

-153-

was added to a final concentration of 50 mM, and the solubilized IBs were incubated for 1 h. at RT. The solubilized IBs were dialyzed against 6 M Guanidinium-HCL, 20 mM Tris, pH 8.0. The concentration of the IB solution was estimated by Bradford analysis and SDS-PAGE.

B. Refolding and purification

The IB solution was added slowly in three portions, every 24 h., to a final concentration of 3 μ M, to the refolding buffer containing 2 mM EDTA, 0.2 mM Benzamidin, 0.2 mM 6 aminocaproic acid, 0.2 mM Guanidinium-HCl, 0.4 M L-Arginin, pH 6.8, to which 5 mM reduced Glutathion and 0.5 mM oxidized Glutathion were added prior to initiation of refolding at 4°C. The refolding solution was concentrated to one half of its volume by Ultrafiltration using a YM10 membrane (Millipore) and dialyzed against PBS, pH 7.2, containing 0.1 mM DTT. The protein was further concentrated by ultrafiltration and loaded onto a Superdex G-75 column (Pharmacia) equilibrated in 20 mM Hepes, 150 mM NaCl, 0.1 mM DTT, 4 °C for purification. The pH of the equilibration buffer was adjusted to 7.2 at RT. The monomeric fractions were pooled.

C. Coupling

A solution of 1.5 mg Q β in 0.75mL 20mM Hepes,150mM NaCl, pH 7.4

was reacted with 0.06mL Sulfo-SMPB (Pierce; 31 mM Stock in H₂O) for 45 min. at RT. The reaction mixture was dialyzed overnight against 20mM Hepes,150mM NaCl, pH 7.4 and 0.75 mL of this solution were mixed with 1.5 mL of a PLA₂-Cys solution in 0.1 mM DTT (62 μ M) and 0.43 mL of 20mM Hepes, 150mM NaCl, 137 μ M DTT, pH 7.4 adjusted at RT. The coupling reaction was left to proceed for 4 h. at RT, and the reaction mixture was dialyzed overnight against 20mM Hepes,150mM NaCl, pH 7.4 using Spectra Por dialysis tubing, MW cutoff 300 000 Da (Spectrum). The coupling reaction was analyzed by SDS-PAGE and coomassie staining, and Western

-154-

blotting, using either a rabbit anti-bee venom antiserum (diluted 1:10000), developed with a goat anti-rabbit alkaline phosphatase conjugate (diluted 1:10000), or a rabbit anti-Q β antiserum (1:5000), developed with a goat anti-rabbit alkaline phosphatase conjugate (diluted 1:10000). Samples were run in both cases under reducing conditions.

The result of the coupling reaction is shown in FIG. 26. Bands corresponding to the coupling product of Q β capsid protein to PLA₂-Cys are clearly visible in the coomassie stained SDS-PAGE (left panel), the anti-Q β Western Blot (center panel) and the anti-PLA₂ Western blot (right panel) of the coupling reactions between Q β capsid protein and PLA₂-Cys, and are indicated by an arrow in the figure. 15 μ l of the coupling reactions and 50 μ l of the dialyzed coupling reactions were loaded on the gel.

Lane 1: Protein marker. 2: Dialyzed coupling reaction 1. 3: Coupling reaction 1. 4: Coupling reaction 2. 5: coupling reaction 2. 6: Coupling reaction 1. 7: Dialyzed coupling reaction 1. 8: Protein Marker. 9: Coupling reaction 2. 10: Coupling reaction 1. 11: Dialyzed coupling reaction 1. 12: Protein Marker.

EXAMPLE 21

Coupling of anti-idiotypic IgE mimobody VAE051 to Q β , immunization of mice and testing of antisera

A solution of 4.0 mg/ml Q β capsid protein in 20 mM Hepes, 150 mM NaCl pH 7.2 was reacted for 30 minutes with 10 fold molar excess SMPH (Pierce) (from a 100 mM stock solution dissolved in DMSO) at 25 °C on a rocking shaker. The reaction solution was subsequently dialyzed twice for 2 hours against 2 l of 20 mM Hepes, 150 mM NaCl, pH 7.2 at 4 °C. The VAE051 solution (2.4 mg/ml) was reduced with an equimolar concentration of TCEP for 60 min at 25 °C.

46 μ l of the dialyzed Q β reaction mixture was then reacted with 340 μ l of the TCEP-treated VAE051 solution (2.4 mg/ml) in a total volume of 680 μ l of 50 mM sodium acetate buffer at

16 °C for 2 h on a rocking shaker.

-155-

The reaction products were analysed on 16% SDS-PAGE gels under reducing conditions. Gels were either stained with Coomassie Brilliant Blue. The two additional band in the coupling reactions (which are absent in VAE or Q β solutions) represent the heavy chain and the light chain of the VAE051 coupled to Q β (FIG. 28 A). Identity of the bands were confirmed by Western blotting with antibodies specific for heavy and light chains, respectively.

Immunization of mice

The Q β -VAE051 coupling solution was dialysed against 20 mM Hepes, 150 mM NaCl, pH 7.2 using a membrane with a cut-off of 300000 Da. 50 μ g of the Q β -VAE051 were injected intraperitoneal in two female Balb/c mice at day 0 and day 14. Mice were bled retroorbitally on day 28 and their serum was analyzed using IgE- and VAE051-specific ELISAs.

ELISA

ELISA plates were coated with human IgE at a concentration of 0.8 μ g/ml or with 10 μ g/ml VAE051. The plates were blocked and then incubated with serially diluted mouse sera. Bound antibodies were detected with enzymatically labeled anti-mouse IgG antibody (FIG. 28 B).

Both mice showed high reactivity to VAE051 as well as the human IgE. Preimmune sera of the same mice did not show any reactivity against VAE051 and IgE (FIG. 28 B). This demonstrates that antibodies against the anti-idiotypic IgE mimobody VAE051 have been produced which also recognize the "parent" molecule IgE.

-156-

EXAMPLE 22**High occupancy coupling of DerpI peptide to wt Q β capsid protein using the cross-linker SMPH**

The Derp 1,2 peptide, to which a cysteine was added N-terminally for coupling, was chemically synthesized and had the following sequence: H₂N-CQIYPPNANKIREALAQTHSA-COOH. This peptide was used for chemical coupling to wt Q β capsid protein and as described in the following.

D. Coupling of Flag peptide to Q β capsid protein

Q β capsid protein in 20 mM Hepes, 150 mM NaCl, pH 7.2, at a concentration of 2 mg/ml, was reacted with a 5- or 20- fold excess of the cross-linker SMPH (Pierce) for 30 min. at 25 °C on a rocking shaker. The reaction solution was subsequently dialyzed twice for 2 hours against 2 L of 20 mM Hepes, 150 mM NaCl, pH 7.2 at 4 °C. The dialyzed reaction mixture was then reacted with a 5-fold excess of Derp 1,2 peptide for two hours at 25 °C on a rocking shaker.

The result of the coupling reaction can be seen on FIG. 24. Coupling bands corresponding to 1, 2 and 3 peptides per subunit, respectively, are clearly visible on the gel, and are indicated by arrows. An average of two peptides per subunit were displayed on the capsid.

The samples loaded on the gel of FIG. 24 were the following:

Lane 1: Protein Marker. 2: Q β capsid protein derivatized with a 5-fold excess of SMPH. 3: Q β capsid protein derivatized with a 20-fold excess of SMPH. 4: Coupling reaction of 5-fold derivatized Q β capsid protein. 5: Coupling reaction of 20-fold derivatized Q β capsid protein.

EXAMPLE 23

Insertion of a peptide containing a Lysine residue into the c/e1 epitope of HBcAg(1-149)

-157-

The c/e1 epitope (residues 72 to 88) of HBcAg is located in the tip region on the surface of the Hepatitis B virus capsid (HBcAg). A part of this region (Proline 79 and Alanine 80) was genetically replaced by the peptide Gly-Gly-Lys-Gly-Gly (HBcAg-Lys construct). The introduced Lysine residue contains a reactive amino group in its side chain that can be used for intermolecular chemical crosslinking of HBcAg particles with any antigen containing a free cysteine group.

HBcAg-Lys DNA, having the amino acid sequence shown in SEQ ID NO:158, was generated by PCRs: The two fragments encoding HBcAg fragments (amino acid residues 1 to 78 and 81 to 149) were amplified separately by PCR. The primers used for these PCRs also introduced a DNA sequence encoding the Gly-Gly-Lys-Gly-Gly peptide. The HBcAg (1 to 78) fragment was amplified from pEco63 using primers EcoRIHBcAg(s) and Lys-HBcAg(as). The HBcAg (81 to 149) fragment was amplified from pEco63 using primers Lys-HBcAg(s) and HBcAg(1-149)Hind(as). Primers Lys-HBcAg(as) and Lys-HBcAg(s) introduced complementary DNA sequences at the ends of the two PCR products allowing fusion of the two PCR products in a subsequent assembly PCR. The assembled fragments were amplified by PCR using primers EcoRIHBcAg(s) and HbcAg(1-149)Hind(as).

For the PCRs, 100 pmol of each oligo and 50 ng of the template DNAs were used in the 50 µl reaction mixtures with 2 units of Pwo polymerase, 0.1 mM dNTPs and 2 mM MgSO₄. For both reactions, temperature cycling was carried out as follows: 94°C for 2 minutes; 30 cycles of 94°C (1 minute), 50°C (1 minute), 72°C (2 minutes).

Primer sequences:

EcoRIHBcAg(s):

(5'-CCGGAATTCATGGACATTGACCCTTATAAAG-3') (SEQ ID NO:79);

Lys-HBcAg(as):

(5'-

CCTAGAGCCACCTTTGCCACCATCTTCTAAATTAGTACCCACCCAG
GTAGC-3') (SEQ ID NO:80);

Lys-HBcAg(s):

(5'-

GAAGATGGTGGCAAAGGTGGCTCTAGGGACCTAGTAGTCAGTTAT
GTC -3') (SEQ ID NO:81);

-158-

HBcAg(1-149)Hind(as):

(5'-CGCGTCCCAAGCTTCTAAACAACAGTAGTCTCCGGAAG-3') (SEQ ID NO:82).

For fusion of the two PCR fragments by PCR 100 pmol of primers EcoRIHBcAg(s) and HBcAg(1-149)Hind(as) were used with 100 ng of the two purified PCR fragments in a 50 µl reaction mixture containing 2 units of Pwo polymerase, 0.1 mM dNTPs and 2 mM MgSO₄. PCR cycling conditions were: 94°C for 2 minutes; 30 cycles of 94°C (1 minute), 50°C (1 minute), 72°C (2 minutes). The assembled PCR product was analyzed by agarose gel electrophoresis, purified and digested for 19 hours in an appropriate buffer with EcoRI and HindIII restriction enzymes. The digested DNA fragment was ligated into EcoRI/HindIII-digested pKK vector to generate pKK-HBcAg-Lys expression vector. Insertion of the PCR product into the vector was analyzed by EcoRI/HindIII restriction analysis and DNA sequencing of the insert.

EXAMPLE 24

Expression and partial purification of HBcAg-Lys

-159-

E. coli strain XL-1 blue was transformed with pKK-HBcAg-Lys. 1 ml of an overnight culture of bacteria was used to inoculate 100 ml of LB medium containing 100 μ g/ml ampicillin. This culture was grown for 4 hours at 37°C until an OD at 600 nm of approximately 0.8 was reached. Induction of the synthesis of HBcAg-Lys was performed by addition of IPTG to a final concentration of 1 mM. After induction, bacteria were further shaken at 37°C for 16 hours. Bacteria were harvested by centrifugation at 5000 x g for 15 minutes. The pellet was frozen at -20°C. The pellet was thawed and resuspended in bacteria lysis buffer (10 mM Na₂HPO₄, pH 7.0, 30 mM NaCl, 0.25% Tween-20, 10 mM EDTA, 10 mM DTT) supplemented with 200 μ g/ml lysozyme and 10 μ l of Benzonase (Merck). Cells were incubated for 30 minutes at room temperature and disrupted using a French pressure cell. Triton X-100 was added to the lysate to a final concentration of 0.2%, and the lysate was incubated for 30 minutes on ice and shaken occasionally. *E. coli* cells harboring pKK-HBcAg-Lys expression plasmid or a control plasmid were used for induction of HBcAg-Lys expression with IPTG. Prior to the addition of IPTG, a sample was removed from the bacteria culture carrying the pKK-HBcAg-Lys plasmid and from a culture carrying the control plasmid. Sixteen hours after addition of IPTG, samples were again removed from the culture containing pKK-HBcAg-Lys and from the control culture. Protein expression was monitored by SDS-PAGE followed by Coomassie staining.

The lysate was then centrifuged for 30 minutes at 12,000 x g in order to remove insoluble cell debris. The supernatant and the pellet were analyzed by Western blotting using a monoclonal antibody against HBcAg (YVS1841, purchased from Accurate Chemical and Scientific Corp., Westbury, NY, USA), indicating that a significant amount of HBcAg-Lys protein was soluble. Briefly, lysates from *E. coli* cells expressing HBcAg-Lys and from control cells were centrifuged at 14,000 x g for 30 minutes. Supernatant (= soluble fraction) and pellet (= insoluble fraction) were separated and diluted with SDS sample buffer to equal volumes. Samples were analyzed by SDS-PAGE followed by Western blotting with anti-HBcAg monoclonal antibody YVS 1841.

The cleared cell lysate was used for step-gradient centrifugation using a sucrose step gradient consisting of a 4 ml 65% sucrose solution overlaid with 3 ml 15% sucrose solution followed by 4 ml of bacterial lysate. The sample was centrifuged for 3 hrs with 100,000 x g at 4°C. After centrifugation, 1 ml fractions from the top of the gradient were collected and analyzed by SDS-PAGE followed by Coomassie staining. The HBcAg-Lys protein was detected by Coomassie staining.

The HBcAg-Lys protein was enriched at the interface between 15 and 65% sucrose indicating that it had formed a capsid particle. Most of the bacterial

-160-

proteins remained in the sucrose-free upper layer of the gradient, therefore step-gradient centrifugation of the HBcAg-Lys particles led both to enrichment and to a partial purification of the particles.

EXAMPLE 25

Chemical coupling of FLAG peptide to HBcAg-Lys using the heterobifunctional cross-linker SPDP

Synthetic FLAG peptide with a Cysteine residue at its amino terminus (amino acid sequence CGGDYKDDDDK (SEQ ID NO:147)) was coupled chemically to purified HBcAg-Lys particles in order to elicit an immune response against the FLAG peptide. 600 ml of a 95% pure solution of HBcAg-Lys particles (2 mg/ml) were incubated for 30 minutes at room temperature with the heterobifunctional cross-linker N-Succinimidyl 3-(2-pyridyldithio) propionate (SPDP) (0.5 mM). After completion of the reaction, the mixture was dialyzed overnight against 1 liter of 50 mM Phosphate buffer (pH 7.2) with 150 mM NaCl to remove free SPDP. Then 500 ml of derivatized HBcAg-Lys capsid (2 mg/ml) were mixed with 0.1 mM FLAG peptide (containing an amino-terminal cysteine) in the presence of 10 mM EDTA to prevent metal-catalyzed sulfhydryl oxidation. The reaction was monitored through the increase of the optical density of the solution at 343 nm due to the release of pyridine-2-thione from SPDP upon reaction with the free cysteine of the peptide. The reaction of derivatized Lys residues with the peptide was complete after approximately 30 minutes.

The FLAG decorated particles were injected into mice.

EXAMPLE 26

Construction of pMPSV-gp140cys

The gp140 gene was amplified by PCR from pCytTSgp140FOS using oligos gp140CysEcoRI and SalIgp140. For the PCRs, 100 pmol of each oligo and 50 ng of the template DNAs were used in the 50 ml reaction mixtures with 2 units of Pwo polymerase, 0.1 mM dNTPs and 2 mM MgSO₄. For both reactions, temperature cycling was carried out as follows: 94°C for 2 minutes; 30 cycles of 94°C (0.5 minutes), 55°C (0.5 minutes), 72°C (2 minutes).

The PCR product was purified using QiaEXII kit, digested with SalI/EcoRI and ligated into vector pMPSVHE cleaved with the same enzymes.

-161-

Oligo sequences:

Gp140CysEcoRI:

5'-GCCGAATTCCTAGCAGCTAGCACCGAATTTATCTAA-3' (SEQ ID NO:83);

SalIgp140:

5'-GGTTAAGTCGACATGAGAGTGAAGGAGAAATAT-3' (SEQ ID NO:84).

EXAMPLE 27

Expression of pMPSVgp140Cys

pMPSVgp140Cys (20 μ g) was linearized by restriction digestion. The reaction was stopped by phenol/chloroform extraction, followed by an isopropanol precipitation of the linearized DNA. The restriction digestion was evaluated by agarose gel electrophoresis. For the transfection, 5.4 μ g of linearized pMPSVgp140-Cys was mixed with 0.6 μ g of linearized pSV2Neo in 30 μ l H₂O and 30 μ l of 1 M CaCl₂ solution was added. After addition of 60 μ l phosphate buffer (50 mM HEPES, 280 mM NaCl, 1.5 mM Na₂ HPO₄, pH 7.05), the solution was vortexed for 5 seconds, followed by an incubation at room temperature for 25 seconds. The solution was immediately added to 2 ml HP-1 medium containing 2% FCS (2% FCS medium). The medium of an 80% confluent BHK21 cell culture (6-well plate) was then replaced by the DNA containing medium. After an incubation for 5 hours at 37°C in a CO₂ incubator, the DNA containing medium was removed and replaced by 2 ml of 15% glycerol in 2% FCS medium. The glycerol containing medium was removed after a 30 second incubation phase, and the cells were washed by rinsing with 5 ml of HP-1 medium containing 10% FCS. Finally 2 ml of fresh HP-1 medium containing 10% FCS was added.

Stably transfected cells were selected and grown in selection medium (HP-1 medium supplemented with G418) at 37°C in a CO₂ incubator. When the mixed population was grown to confluency, the culture was split to two dishes, followed by a 12 h growth period at 37°C. One dish of the cells was shifted to 30°C to induce the expression of soluble GP140-FOS. The other dish was kept at 37°C.

The expression of soluble GP140-Cys was determined by Western blot analysis. Culture media (0.5 ml) was methanol/chloroform precipitated, and the pellet was resuspended in SDS-PAGE sample buffer. Samples were heated for 5 minutes at

-162-

95°C before being applied to a 15% acrylamide gel. After SDS-PAGE, proteins were transferred to Protan nitrocellulose membranes (Schleicher & Schuell, Germany) as described by Bass and Yang, in Creighton, T.E., ed., *Protein Function: A Practical Approach*, 2nd Edn., IRL Press, Oxford (1997), pp. 29-55. The membrane was blocked with 1 % bovine albumin (Sigma) in TBS (10xTBS per liter: 87.7 g NaCl, 66.1 g Trizma hydrochloride (Sigma) and 9.7 g Trizma base (Sigma), pH 7.4) for 1 hour at room temperature, followed by an incubation with an anti-GP140 or GP-160 antibody for 1 hour. The blot was washed 3 times for 10 minutes with TBS-T (TBS with 0.05% Tween20), and incubated for 1 hour with an alkaline-phosphatase-anti-mouse/rabbit/monkey/human IgG conjugate. After washing 2 times for 10 minutes with TBS-T and 2 times for 10 minutes with TBS, the development reaction was carried out using alkaline phosphatase detection reagents (10 ml AP buffer (100 mM Tris/HCl, 100 mM NaCl, pH 9.5) with 50 μ l NBT solution (7.7% Nitro Blue Tetrazolium (Sigma) in 70% dimethylformamide) and 37 μ l of X-Phosphate solution (5% of 5-bromo-4-chloro-3-indolyl phosphate in dimethylformamide)).

EXAMPLE 28

Purification of gp140Cys

An anti-gp120 antibody was covalently coupled to a NHS/EDC activated dextran and packed into a chromatography column. The supernatant, containing GP140Cys is loaded onto the column and after sufficient washing, GP140Cys was eluted using 0.1 M HCl. The eluate was directly neutralized during collection using 1 M Tris pH 7.2 in the collection tubes.

Disulfide bond formation might occur during purification, therefore the collected sample is treated with 10 mM DTT in 10 mM Tris pH 7.5 for 2 hours at 25°C.

DTT is removed by subsequent dialysis against 10 mM Mes; 80 mM NaCl pH 6.0. Finally GP140Cys is mixed with alphavirus particles containing the JUN residue in E2 as described in Example 16.

EXAMPLE 29

Construction of PLA₂-Cys

-163-

The PLA₂ gene was amplified by PCR from pAV3PLAfos using oligos EcoRIPLA and PLA-Cys-hind. For the PCRs, 100 pmol of each oligo and 50 ng of the template DNAs were used in the 50 ml reaction mixtures with 2 units of Pwo polymerase, 0.1 mM dNTPs and 2 mM MgSO₄. For the reaction, temperature cycling was carried out as follows: 94°C for 2 minutes; 30 cycles of 94°C (0.5 minutes), 55°C (0.5 minutes), 72°C (2 minutes).

The PCR product was purified using QiaEXII kit, digested with EcoRI/HindIII and ligated into vector pAV3 cleaved with the same enzymes.

Oligos

EcoRIPLA:

5'-TAACCGAATTCAGGAGGTAAAAAGATATGG-3' (SEQ ID NO:85)

PLA Cys-hind:

5'-GAAGTAAAGCTTTTAACCACCGCAACCACCAGAAG-3' (SEQ ID NO:86).

EXAMPLE 30

Expression and Purification of PLA₂-Cys

-164-

For cytoplasmic production of Cys tagged proteins, *E. coli* XL-1-Blue strain was transformed with the vectors pAV3::PLA and pPLA-Cys. The culture was incubated in rich medium in the presence of ampicillin at 37°C with shaking. At an optical density (550nm) of , 1 mM IPTG was added and incubation was continued for another 5 hours. The cells were harvested by centrifugation, resuspended in an appropriate buffer (e.g., Tris-HCl, pH 7.2, 150 mM NaCl) containing DNase, RNase and lysozyme, and disrupted by passage through a french pressure cell. After centrifugation (Sorvall RC-5C, SS34 rotor, 15000 rpm, 10 min, 4°C), the pellet was resuspended in 25 ml inclusion body wash buffer (20 mM tris-HCl, 23% sucrose, 0.5% Triton X-100, 1 mM EDTA, pH8) at 4°C and recentrifuged as described above. This procedure was repeated until the supernatant after centrifugation was essentially clear. Inclusion bodies were resuspended in 20 ml solubilization buffer (5.5 M guanidinium hydrochloride, 25 mM tris-HCl, pH 7.5) at room temperature and insoluble material was removed by centrifugation and subsequent passage of the supernatant through a sterile filter (0.45 µm). The protein solution was kept at 4°C for at least 10 hours in the presence of 10 mM EDTA and 100 mM DTT and then dialyzed three times against 10 volumes of 5.5 M guanidinium hydrochloride, 25 mM tris-HCl, 10 mM EDTA, pH 6. The solution was dialyzed twice against 51 2 M urea, 4 mM EDTA, 0.1 M NH₄Cl, 20 mM sodium borate (pH 8.3) in the presence of an appropriate redox shuffle (oxidized glutathione/reduced glutathione; cystine/cysteine). The refolded protein was then applied to an ion exchange chromatography. The protein was stored in an appropriate buffer with a pH above 7 in the presence of 2-10 mM DTT to keep the cysteine residues in a reduced form. Prior to coupling of the protein with the alphavirus particles, DTT was removed by passage of the protein solution through a Sephadex G-25 gel filtration column.

EXAMPLE 31

Construction of a HBcAg devoid of free cysteine residues and containing an inserted lysine residue

A Hepatitis core Antigen (HBcAg), referred to herein as HBcAg-lys-2cys-Mut, devoid of cysteine residues at positions corresponding to 48 and 107 in SEQ ID NO:134 and containing an inserted lysine residue was constructed using the following methods.

The two mutations were introduced by first separately amplifying three fragments of the HBcAg-Lys gene prepared as described above in Example 23 with the following PCR primer combinations. PCR methods essentially as described in Example 1 and conventional cloning techniques were used to prepare the HBcAg-lys-2cys-Mut gene.

-165-

In brief, the following primers were used to prepare fragment 1:

Primer 1: EcoRIHBcAg(s)

CCGGAATTCATGGACATTGACCCTTATAAAG (SEQ ID NO:148)

Primer 2: 48as

GTGCAGTATGGTGAGGTGAGGAATGCTCAGGAGACTC (SEQ ID NO:149)

The following primers were used to prepare fragment 2:

Primer 3: 48s

GSGTCTCCTGAGCATTCTCCTCACCTCACCATACTGCAC (SEQ ID NO:150)

Primer 4: 107as

CTTCCAAAAGTGAGGGAAGAAATGTGAAACCAC (SEQ ID NO:151)

The following primers were used to prepare fragment 3:

Primer 5: HBcAg149hind-as

CGCGTCCCAAGCTTCTAAACAACAGTAGTCTCCGGAAGCGTTGATAG (SEQ ID NO:152)

Primer 6: 107s

GTGGTTTCACATTTCTTCCCTCACTTTTGGAAG (SEQ ID NO:153)

Fragments 1 and 2 were then combined with PCR primers EcoRIHBcAg(s) and 107as to give fragment 4. Fragment 4 and fragment 3 were then combined with primers EcoRIHBcAg(s) and HBcAg149hind-as to produce the full length gene. The full length gene was then digested with the EcoRI (GAATTC) and HindIII (AAGCTT) enzymes and cloned into the pKK vector (Pharmacia) cut at the same restriction sites.

EXAMPLE 32

Blockage of free cysteine residues of a HBcAg followed by cross-linking

The free cysteine residues of the HBcAg-Lys prepared as described above in Example 23 were blocked using Iodacetamide. The blocked HBcAg-Lys was then cross-linked to the FLAG peptide with the hetero-bifunctional cross-linker m-maleimidonbenzoyl-N-hydroxysuccinimide ester (Sulfo-MBS).

-166-

The methods used to block the free cysteine residues and cross-link the HBcAg-Lys are as follows. HBcAg-Lys (550 $\mu\text{g/ml}$) was reacted for 15 minutes at room temperature with Iodacetamide (Fluka Chemie, Brugg, Switzerland) at a concentration of 50 mM in phosphate buffered saline (PBS) (50 mM sodium phosphate, 150 mM sodium chloride), pH 7.2, in a total volume of 1 ml. The so modified HBcAg-Lys was then reacted immediately with Sulfo-MBS (Pierce) at a concentration of 330 μM directly in the reaction mixture of step 1 for 1 hour at room temperature. The reaction mixture was then cooled on ice, and dialyzed against 1000 volumes of PBS pH 7.2. The dialyzed reaction mixture was finally reacted with 300 μM of the FLAG peptide (CGGDYKDDDDK (SEQ ID NO:147)) containing an N-terminal free cysteine for coupling to the activated HBcAg-Lys, and loaded on SDS-PAGE for analysis.

The resulting patterns of bands on the SDS-PAGE gel showed a clear additional band migrating slower than the control HBcAg-Lys derivatized with the cross-linker, but not reacted with the FLAG peptide. Reactions done under the same conditions without prior derivatization of the cysteines with Iodacetamide led to complete cross-linking of monomers of the HBcAg-Lys to higher molecular weight species.

EXAMPLE 33

Isolation and chemical coupling of FLAG peptide to Type-1 pili of *Escherichia coli* using a heterobifunctional cross-linker

A. Introduction

Bacterial pili or fimbriae are filamentous surface organelles produced by a wide range of bacteria. These organelles mediate the attachment of bacteria to surface receptors of host cells and are required for the establishment of many bacterial infections like cystitis, pyelonephritis, new born meningitis and diarrhea.

Pili can be divided in different classes with respect to their receptor specificity (agglutination of blood cells from different species), their assembly pathway (extracellular nucleation, general secretion, chaperone/usher, alternate chaperone) and their morphological properties (thick, rigid pili; thin, flexible pili; atypical structures including capsule; curli; etc). Examples of thick, rigid pili forming a right handed helix that are assembled via the so called chaperone/usher pathway and mediate adhesion to host glycoproteins include Type-1 pili, P-pili, S-pili, F1C-pili, and 987P-pili). The most prominent and best characterized members of this class of pili are P-pili and Type-1 pili (for reviews on adhesive structures, their assembly and the associated diseases see Soto, G. E. & Hultgren, S. J., *J. Bacteriol.* 181:1059-1071

(1999); Bullitt & Makowski, *Biophys. J.* 74:623-632 (1998); Hung, D. L. & Hultgren, S. J., *J. Struct. Biol.* 124:201-220 (1998)).

Type-1 pili are long, filamentous polymeric protein structures on the surface of *E. coli*. They possess adhesive properties that allow for binding to mannose-containing receptors present on the surface of certain host tissues. Type-1 pili can be expressed by 70-80% of all *E. coli* isolates and a single *E. coli* cell can bear up to 500 pili. Type-1 pili reach a length of typically 0.2 to 2 μ M with an average number of 1000 protein subunits that associate to a right-handed helix with 3.125 subunits per turn with a diameter of 6 to 7 nm and a central hole of 2.0 to 2.5 nm.

The main Type-1 pilus component, FimA, which represents 98% of the total pilus protein, is a 15.8 kDa protein. The minor pilus components FimF, FimG and FimH are incorporated at the tip and in regular distances along the pilus shaft (Klemm, P. & Krogfelt, K. A., "Type I fimbriae of *Escherichia coli*," in: *Fimbriae*. Klemm, P. (ed.), CRC Press Inc., (1994) pp. 9-26). FimH, a 29.1 kDa protein, was shown to be the mannose-binding adhesin of Type-1 pili (Krogfelt, K. A., *et al.*, *Infect. Immun.* 58:1995-1998 (1990); Klemm, P., *et al.*, *Mol. Microbiol.* 4:553-560 (1990); Hanson, M. S. & Brinton, C. C. J., *Nature* 17:265-268 (1988)), and its incorporation is probably facilitated by FimG and FimF (Klemm, P. & Christiansen, G., *Mol. Gen. Genetics* 208:439-445 (1987); Russell, P. W. & Orndorff, P. E., *J. Bacteriol.* 174:5923-5935 (1992)). Recently, it was shown that FimH might also form a thin tip-fibrillum at the end of the pili (Jones, C. H., *et al.*, *Proc. Nat. Acad. Sci. USA* 92:2081-2085 (1995)). The order of major and minor components in the individual mature pili is very similar, indicating a highly ordered assembly process (Soto, G. E. & Hultgren, S. J., *J. Bacteriol.* 181:1059-1071 (1999)).

P-pili of *E. coli* are of very similar architecture, have a diameter of 6.8 nm, an axial hole of 1.5 nm and 3.28 subunits per turn (Bullitt & Makowski, *Biophys. J.* 74:623-632 (1998)). The 16.6 kDa PapA is the main component of this pilus type and shows 36% sequence identity and 59% similarity to FimA (see Table 1). As in Type-1 pili the 36.0 kDa P-pilus adhesin PapG and specialized adapter proteins make up only a tiny fraction of total pilus protein. The most obvious difference to Type-1 pili is the absence of the adhesin as an integral part of the pilus rod, and its exclusive localization in the tip fibrillum that is connected to the pilus rod via specialized adapter proteins that Type-1 pili lack (Hultgren, S. J., *et al.*, *Cell* 73:887-901 (1993)).

-168-

Table 1: Similarity and identity between several structural pilus proteins of Type-1 and P-pili (in percent). The adhesins were omitted.

	<u>Similarity</u>								
	FimA	PapA	FimI	FimF	FimG	PapE	PapK	PapH	PapF
<u>Identity</u>	FimA	59	57	56	44	50	44	46	46
	PapA	36	49	48	41	45	49	49	47
	FimI	35	31	56	46	40	47	48	48
	FimF	34	26	30	40	47	43	49	48
	FimG	28	28	28	26	39	39	41	45
	PapE	25	23	18	28	22	43	47	54
	PapK	24	29	25	28	22	18	49	53
	PapH	22	26	22	22	23	24	23	41
	PapF	18	22	22	24	28	27	26	21

Type-1 pili are extraordinary stable hetero-oligomeric complexes. Neither SDS-treatment nor protease digestions, boiling or addition of denaturing agents can dissociate Type-1 pili into their individual protein components. The combination of different methods like incubation at 100°C at pH 1.8 was initially found to allow for the depolymerization and separation of the components (Eshdat, Y., *et al.*, *J. Bacteriol.* 148:308-314 (1981); Brinton, C.C. J., *Trans. N. Y. Acad. Sci.* 27:1003-1054 (1965); Hanson, A. S., *et al.*, *J. Bacteriol.*, 170:3350-3358 (1988); Klemm, P. & Krogfelt, K. A., "Type I fimbriae of *Escherichia coli*," in: *Fimbriae*. Klemm, P. (ed.), CRC Press Inc., (1994) pp. 9-26). Interestingly, Type-1 pili show a tendency to break at positions where FimH is incorporated upon mechanical agitation, resulting in fragments that present a FimH adhesin at their tips. This was interpreted as a mechanism of the bacterium to shorten pili to an effective length under mechanical stress (Klemm, P. & Krogfelt, K. A., "Type I fimbriae of *Escherichia coli*," in: *Fimbriae*. Klemm, P. (ed.), CRC Press Inc., (1994) pp. 9-26). Despite their extraordinary stability, Type-1 pili have been shown to unravel partially in the presence of 50% glycerol; they lose their helical structure and form an extended and flexible, 2 nm wide protein chain (Abraham, S. N., *et al.*, *J. Bacteriol.* 174:5145-5148 (1992)).

P-pili and Type-1 pili are encoded by single gene clusters on the *E. coli* chromosome of approximately 10 kb (Klemm, P. & Krogfelt, K. A., "Type I fimbriae of *Escherichia coli*," in: *Fimbriae*. Klemm, P. (ed.), CRC Press Inc., (1994) pp. 9-26; Orndorff, P. E. & Falkow, S., *J. Bacteriol.* 160:61-66 (1984)). A total of nine genes are found in the Type-1 pilus gene cluster, and 11 genes in the P-pilus

cluster (Hultgren, S. J., *et al.*, *Adv. Prot. Chem.* 44:99-123 (1993)). Both clusters are organized quite similarly.

The first two *fim*-genes, *fimB* and *fimE*, code for recombinases involved in the regulation of pilus expression (McClain, M. S., *et al.*, *J. Bacteriol.* 173:5308-5314 (1991)). The main structural pilus protein is encoded by the next gene of the cluster, *fimA* (Klemm, P., *Euro. J. Biochem.* 143:395-400 (1984); Orndorff, P. E. & Falkow, S., *J. Bacteriol.* 160:61-66 (1984); Orndorff, P. E. & Falkow, S., *J. Bacteriol.* 162:454-457 (1985)). The exact role of *fimI* is unclear. It has been reported to be incorporated in the pilus as well (Klemm, P. & Krogfelt, K. A., "Type I fimbriae of *Escherichia coli*," in: *Fimbriae*. Klemm, P. (ed.), CRC Press Inc., (1994) pp. 9-26). The adjacent *fimC* codes not for a structural component of the mature pilus, but for a so-called pilus chaperone that is essential for the pilus assembly (Klemm, P., *Res. Microbiol.* 143:831-838 (1992); Jones, C. H., *et al.*, *Proc. Nat. Acad. Sci. USA* 90:8397-8401 (1993)).

The assembly platform in the outer bacterial membrane to which the mature pilus is anchored is encoded by *fimD* (Klemm, P. & Christiansen, G., *Mol. Gen. Genetics* 220:334-338 (1990)). The three minor components of the Type-1 pili, FimF, FimG and FimH are encoded by the last three genes of the cluster (Klemm, P. & Christiansen, G., *Mol. Gen. Genetics* 208:439-445 (1987)). Apart from *fimB* and *fimE*, all genes encode precursor proteins for secretion into the periplasm via the sec-pathway.

The similarities between different pili following the chaperone/usheer pathway are not restricted to their morphological properties. Their genes are also arranged in a very similar manner. Generally the gene for the main structural subunit is found directly downstream of the regulatory elements at the beginning of the gene cluster, followed by a gene for an additional structural subunit (*fimI* in the case of Type-1 pili and *papH* in the case of P-pili). PapH was shown and FimI is supposed to terminate pilus assembly (Hultgren, S. J., *et al.*, *Cell* 73:887-901 (1993)). The two proteins that guide the process of pilus formation, namely the specialized pilus chaperone and the outer membrane assembly platform, are located adjacently downstream. At the end of the clusters a variable number of minor pilus components including the adhesins are encoded. The similarities in morphological structure, sequence (see Table 1), genetic organization and regulation indicate a close evolutionary relationship and a similar assembly process for these cell organelles.

Bacteria producing Type-1 pili show a so-called phase-variation. Either the bacteria are fully piliated or bald. This is achieved by an inversion of a 314 bp genomic DNA fragment containing the *fimA* promoter, thereby inducing an "all on" or "all off" expression of the pilus genes (McClain, M. S., *et al.*, *J. Bacteriol.*

-170-

173:5308-5314 (1991)). The coupling of the expression of the other structural pilus genes to *fimA* expression is achieved by a still unknown mechanism. However, a wide range of studies elucidated the mechanism that influences the switching between the two phenotypes.

The first two genes of the Type-1 pilus cluster, *fimB* and *fimE* encode recombinases that recognize 9 bp DNA segments of dyad symmetry that flank the invertible *fimA* promoter. Whereas FimB switches pilation "on", FimE turns the promoter in the "off" orientation. The up- or down-regulation of either *fimB* or *fimE* expression therefore controls the position of the so-called "*fim*-switch" (McClain, M. S., *et al.*, *J. Bacteriol.* 173:5308-5314 (1991); Blomfield, I. C., *et al.*, *J. Bacteriol.* 173:5298-5307 (1991)).

The two regulatory proteins *fimB* and *fimE* are transcribed from distinct promoters and their transcription was shown to be influenced by a wide range of different factors including the integration host factor (IHF) (Blomfield, I. C., *et al.*, *Mol. Microbiol.* 23:705-717 (1997)) and the leucine-responsive regulatory protein (LRP) (Blomfield, I. C., *et al.*, *J. Bacteriol.* 175:27-36 (1993); Gally, D. L., *et al.*, *J. Bacteriol.* 175:6186-6193 (1993); Gally, D. L., *et al.*, *Microbiol.* 21:725-738 (1996); Roesch, R. L. & Blomfield, I. C., *Mol. Microbiol.* 27:751-761 (1998)). Mutations in the former lock the bacteria either in "on" or "off" phase, whereas LRP mutants switch with a reduced frequency. In addition, an effect of *leuX* on pilus biogenesis has been shown. This gene is located in the vicinity of the *fim*-genes on the chromosome and codes for the minor leucine tRNA species for the UUG codon. Whereas *fimB* contains five UUG codons, *fimE* contains only two, and enhanced *leuX* transcription might favor FimB over FimE expression (Burghoff, R. L., *et al.*, *Infect. Immun.* 61:1293-1300 (1993); Newman, J. V., *et al.*, *FEMS Microbiol. Lett.* 122:281-287 (1994); Ritter, A., *et al.*, *Mol. Microbiol.* 25:871-882 (1997)).

Furthermore, temperature, medium composition and other environmental factors were shown to influence the activity of FimB and FimE. Finally, a spontaneous, statistical switching of the *fimA* promoter has been reported. The frequency of this spontaneous switching is approximately 10^{-3} per generation (Eisenstein, B. I., *Science* 214:337-339 (1981); Abraham, S. M., *et al.*, *Proc. Nat. Acad. Sci. USA* 82:5724-5727 (1985)), but is strongly influenced by the above mentioned factors.

The genes *fimI* and *fimC* are also transcribed from the *fimA* promoter, but directly downstream of *fimA* a DNA segment with a strong tendency to form secondary structure was identified which probably represents a partial transcription terminator (Klemm, P., *Euro. J. Biochem.* 143:395-400 (1984)); and is therefore supposed to severely reduce *fimI* and *fimC* transcription. At the 3' end of *fimC* an

-171-

additional promoter controls the *fimD* transcription; at the 3' end of *fimD* the last known *fim* promoter is located that regulates the levels of FimF, FimG, and FimH. Thus, all of the minor Type-1 pili proteins are transcribed as a single mRNA (Klemm, P. & Krogfelt, K. A., "Type I fimbriae of *Escherichia coli*," in: *Fimbriae*. Klemm, P. (ed.), CRC Press Inc., (1994) pp. 9-26). This ensures a 1:1:1 stoichiometry on mRNA-level, which is probably maintained on the protein level.

In the case of P-pili additional regulatory mechanisms were found when the half-life of mRNA was determined for different P-pilus genes. The mRNA for *papA* was extraordinarily long-lived, whereas the mRNA for *papB*, a regulatory pilus protein, was encoded by short-lived mRNA (Naureckiene, S. & Uhlin, B. E., *Mol. Microbiol.* 21:55-68 (1996); Nilsson, P., *et al.*, *J. Bacteriol.* 178:683-690 (1996)).

In the case of Type-1 pili, the gene for the Type-1 pilus chaperone FimC starts with a GTG instead of an ATG codon, leading to a reduced translation efficiency. Finally, analysis of the *fimH* gene revealed a tendency of the *fimH* mRNA to form a stem-loop, which might severely hamper translation. In summary, bacterial pilus biogenesis is regulated by a wide range of different mechanisms acting on all levels of protein biosynthesis.

Periplasmic pilus proteins are generally synthesized as precursors, containing a N-terminal signal-sequence that allows translocation across the inner membrane via the Sec-apparatus. After translocation the precursors are normally cleaved by signal-peptidase I. Structural Type-1 pilus subunits normally contain disulfide bonds, their formation is catalyzed by DsbA and possibly DsbC and DsbG gene products.

The Type-1 pilus chaperone FimC lacks cysteine residues. In contrast, the chaperone of P-pili, PapD, is the only member of the pilus chaperone family that contains a disulfide bond, and the dependence of P-pili on DsbA has been shown explicitly (Jacob-Dubuisson, F., *et al.*, *Proc. Nat. Acad. Sci. USA* 91:11552-11556 (1994)). PapD does not accumulate in the periplasm of a $\Delta dsbA$ strain, indicating that the disturbance of the P-pilus assembly machinery is caused by the absence of the chaperone (Jacob-Dubuisson, F., *et al.*, *Proc. Nat. Acad. Sci. USA* 91:11552-11556 (1994)). This is in accordance with the finding that Type-1 pili are still assembled in a $\Delta dsbA$ strain, albeit to reduced level (Hultgren, S. J., *et al.*, "Bacterial Adhesion and Their Assembly", in: *Escherichia coli and Salmonella*, Neidhardt, F. C. (ed.) ASM Press, (1996) pp. 2730-2756).

Type-1 pili as well as P-pili are to 98% made of a single or main structural subunit termed FimA and PapA, respectively. Both proteins have a size of ~15.5 kDa. The additional minor components encoded in the pilus gene clusters are

-172-

very similar (see Table 1). The similarities in sequence and size of the subunits with the exception of the adhesins suggest that all share an identical folding motif, and differ only with respect to their affinity towards each other. Especially the N- and C-terminal regions of these proteins are well conserved and supposed to play an important role in chaperone/subunit interactions as well as in subunit/subunit interactions within the pilus (Soto, G. E. & Hultgren, S. J., *J. Bacteriol.* 181:1059-1071 (1999)). Interestingly, the conserved N-terminal segment can be found in the middle of the pilus adhesins, indicating a two-domain organization of the adhesins where the proposed C-terminal domain, starting with the conserved motif, corresponds to a structural pilus subunit whereas the N-terminal domain was shown to be responsible for recognition of host cell receptors (Hultgren, S. J., *et al.*, *Proc. Nat. Acad. Sci. USA* 86:4357-4361 (1989); Haslam, D. B., *et al.*, *Mol. Microbiol.* 14:399-409 (1994); Soto, G. E., *et al.*, *EMBO J.* 17:6155-6167 (1998)). The different subunits were also shown to influence the morphological properties of the pili. The removal of several genes was reported to reduce the number of Type-1 or P-pili or to increase their length, (*fimH*, *papG*, *papK*, *fimF*, *fimG*) (Russell, P. W. & Orndorff, P. E., *J. Bacteriol.* 174:5923-5935 (1992); Jacob-Dubuisson, R., *et al.*, *EMBO J.* 12:837-847 (1993); Soto, G. E. & Hultgren, S. J., *J. Bacteriol.* 181:1059-1071 (1999)); combination of the gene deletions amplified these effects or led to a total loss of piliation (Jacob-Dubuisson, R., *et al.*, *EMBO J.* 12:837-847 (1993)).

In non-fimbrial adhesive cell organelles also assembled via chaperones/usher systems such as Myf fimbriae and CS3 pili, the conserved C-terminal region is different. This indirectly proves the importance of these C-terminal subunit segments for quaternary interactions (Hultgren, S. J., *et al.*, "Bacterial Adhesion and Their Assembly", in: *Escherichia coli and Salmonella*, Neidhardt, F. C. (ed.) ASM Press, (1996) pp. 2730-2756).

Gene deletion studies proved that removal of the pilus chaperones leads to a total loss of piliation in P-pili and Type-1 pili (Lindberg, F., *et al.*, *J. Bacteriol.* 171:6052-6058 (1989); Klemm, P., *Res. Microbiol.* 143:831-838 (1992); Jones, C. H., *et al.*, *Proc. Nat. Acad. Sci. USA* 90:8397-8401 (1993)). Periplasmic extracts of a Δ *fimC* strain showed the accumulation of the main subunit FimA, but no pili could be detected (Klemm, P., *Res. Microbiol.* 143:831-838 (1992)). Attempts to over-express individual P-pilus subunits failed and only proteolytically degraded forms could be detected in the absence of PapD; in addition, the P-pilus adhesin was purified with the inner membrane fraction in the absence of the chaperone (Lindberg, F., *et al.*, *J. Bacteriol.* 171:6052-6058 (1989)). However, co-expression of the structural pilus proteins and their chaperone allowed the detection of chaperone/subunit complexes from the periplasm in the case of the FimC/FimH

-173-

complex as well as in the case of different Pap-proteins including the adhesin PapG and the main subunit PapA (Tewari, R., *et al.*, *J. Biol. Chem.* 268:3009-3015 (1993); Lindberg, F., *et al.*, *J. Bacteriol.* 171:6052-6058 (1989)). The affinity of chaperone/subunit complexes towards their assembly platform has also been investigated in vitro and was found to differ strongly (Dodson *et al.*, *Proc. Natl. Acad. Sci. USA* 90:3670-3674 (1993)). From these results the following functions were suggested for the pilus chaperones.

They are assumed to recognize unfolded pilus subunits, prevent their aggregation and to provide a "folding template" that guides the formation of a native structure.

The folded subunits, which after folding display surfaces that allow subunit/subunit interactions, are then expected to be shielded from interacting with other subunits, and to be kept in a monomeric, assembly-competent state.

Finally, the pilus chaperones are supposed to allow a triggered release of the subunits at the outer membrane assembly location, and, by doing so with different efficiency, influence the composition and order of the mature pili (see also the separate section below).

After subunit release at the outer membrane, the chaperone is free for another round of substrate binding, folding assistance, subunit transport through the periplasm and specific delivery to the assembly site. Since the periplasm lacks energy sources, like ATP, the whole pilus assembly process must be thermodynamically driven (Jacob-Dubuisson, F., *et al.*, *Proc. Nat. Acad. Sci. USA* 91:11552-11556 (1994)). The wide range of different functions attributed to the pilus chaperones would implicate an extremely fine tuned cascade of steps.

Several findings, however, are not readily explained with the model of pilus chaperone function outlined above. One example is the existence of multimeric chaperone/subunit complexes (Striker, R. T., *et al.*, *J. Biol. Chem.* 269:12233-12239 (1994)), where one chaperone binds subunit dimers or trimers. It is difficult to imagine a folding template that can be "double-booked". The studies on the molecular details of chaperone/subunit interaction (see below) partially supported the functions summarized above, but also raised new questions.

All 31 periplasmic chaperones identified by genetic studies or sequence analysis so far are proteins of approximately 25 kDa with conspicuously high pI values around 10. Ten of these chaperones assist the assembly of rod-like pili, four are involved in the formation of thin pili, ten are important for the biogenesis of atypically thin structures (including capsule-like structures) and two adhesive structures have not been determined so far (Holmgren, A., *et al.*, *EMBO J.* 11:1617-1622 (1992); Bonci, A., *et al.*, *J. Mol. Evolution* 44:299-309 (1997); Smyth,

C. J., *et al.*, *FEMS Immun. Med Microbiol.* 16:127-139 (1996); Hung, D. L. & Hultgren, S. J., *J. Struct. Biol.* 124:201-220 (1998)). The pairwise sequence identity between these chaperones and PapD ranges from 25 to 56%, indicating an identical overall fold (Hung, D. L., *et al.*, *EMBO J.* 15:3792-3805 (1996)).

The first studies on the mechanism of chaperone/substrate recognition was based on the observation that the C-termini of all known pilus chaperones are extremely similar. Synthetic peptides corresponding to the C-termini of the P-pilus proteins were shown to bind to PapD in ELISA assays (Kuehn, M. J., *et al.*, *Science* 262:1234-1241 (1993)). Most importantly, the X-ray structures of two complexes were solved in which PapD was co-crystallized with 19-residue peptides corresponding to the C-termini of either the adhesin PapG or the minor pilus component PapK (Kuehn, M. J., *et al.*, *Science* 262:1234-1241 (1993); Soto, G. E., *et al.*, *EMBO J.* 17:6155-6167 (1998)). Both peptides bound in an extended conformation to a β -strand in the N-terminal chaperone domain that is oriented towards the inter-domain cleft, thereby extending a β -sheet by an additional strand. The C-terminal carboxylate groups of the peptides were anchored via hydrogen-bonds to Arg8 and Lys112, these two residues are invariant in the family of pilus chaperones. Mutagenesis studies confirmed their importance since their exchange against alanine resulted in accumulation of non-functional pilus chaperone in the periplasm (Slonim, L. N., *et al.*, *EMBO J.* 11:4747-4756 (1992)). The crystal structure of PapD indicates that neither Arg8 nor Lys112 is involved in stabilization of the chaperone, but completely solvent exposed (Holmgren, A. & Branden, C. I., *Nature* 342:248-251 (1989)). On the substrate side the exchange of C-terminal PapA residues was reported to abolish P-pilus formation, and similar experiments on the conserved C-terminal segment of the P-pilus adhesin PapG prevented its incorporation into the P-pilus (Hultgren, S. J., *et al.*, "Bacterial Adhesion and Their Assembly", in: *Escherichia coli and Salmonella*, Neidhardt, F. C. (ed.) ASM Press, (1996) pp. 2730-2756). All evidence therefore indicated pilus subunit recognition via the C-terminal segments of the subunits.

A more recent study on C-terminal amino acid exchanges of the P-pilus adhesin PapG gave a more detailed picture. A range of amino acid substitutions at the positions -2, -4, -6, and -8 relative to the C-terminus were tolerated, but changed pilus stability (Soto, G. E., *et al.*, *EMBO J.* 17:6155-6167 (1998)).

Still, certain problems arise when this model is examined more closely. Adhesive bacterial structures not assembled to rigid, rod-like pili lack the conserved C-terminal segments (Hultgren, S. J., *et al.*, "Bacterial Adhesion and Their Assembly", in: *Escherichia coli and Salmonella*, Neidhardt, F. C. (ed.) ASM Press, (1996) pp. 2730-2756), even though they are also dependent on the presence of

-175-

related pilus chaperones. This indicates a different general role for the C-terminal segments of pilus subunits, namely the mediation of quaternary interactions in the mature pilus. Moreover, the attempt to solve the structure of a C-terminal peptide in complex with the chaperone by NMR was severely hampered by the weak binding of the peptide to the chaperone (Walse, B., *et al.*, *FEBS Lett.* 412:115-120 (1997)); whereas an essential contribution of the C-terminal segments for chaperone recognition implies relatively high affinity interactions.

An additional problem arises if the variability between the different subunits are taken into account. Even though the C-terminal segments are conserved, a wide range of conservative substitutions is found. For example, 15 out of 19 amino acid residues differ between the two peptides co-crystallized with PapD (Soto, G. E., *et al.*, *EMBO J.* 17:6155-6167 (1998)). This has been explained by the kind of interaction between chaperone and substrate, that occurs mainly via backbone interactions and not specifically via side-chain interactions. Then again, the specificity of the chaperone for certain substrates is not readily explained. On the contrary to the former argument, the conserved residues have been taken as a proof for the specificity (Hultgren, S. J., *et al.*, "Bacterial Adhesion and Their Assembly", in: *Escherichia coli and Salmonella*, Neidhardt, F. C. (ed.) ASM Press, (1996) pp. 2730-2756).

The outer membrane assembly platform, also termed "usher" in the literature, is formed by homo-oligomers of FimD or PapC, in the case of Type-1 and P-pili, respectively (Klemm, P. & Christiansen, G., *Mol. Gen. Genetics* 220:334-338 (1990); Thanassi, D. G., *et al.*, *Proc. Nat. Acad. Sci. USA* 95:3146-3151 (1998)). Studies on the elongation of Type-1 fimbriae by electron microscopy demonstrated an elongation of the pilus from the base (Lowe, M. A., *et al.*, *J. Bacteriol.* 169:157-163 (1987)). In contrast to the secretion of unfolded subunits into the periplasmic space, the fully folded proteins have to be translocated through the outer membrane, possibly in an oligomeric form (Thanassi, D. G., *et al.*, *Proc. Nat. Acad. Sci. USA* 95:3146-3151 (1998)). This requires first a membrane pore wide enough to allow the passage and second a transport mechanism that is thermodynamically driven (Jacob-Dubuisson, F., *et al.*, *J. Biol. Chem.* 269:12447-12455 (1994)).

FimD expression alone was shown to have a deleterious effect on bacterial growth, the co-expression of pilus subunits could restore normal growth behavior (Klemm, P. & Christiansen, G., *Mol. Gen. Genetics* 220:334-338 (1990)). Based on this it can be concluded that the ushers probably form pores that are completely filled by the pilus. Electron microscopy on membrane vesicles in which PapC had been incorporated confirmed a pore-forming structure with an inner diameter of 2 nm (Thanassi, D. G., *et al.*, *Proc. Nat. Acad. Sci. USA* 95:3146-3151

-176-

(1998)). Since the inner diameter of the pore is too small to allow the passage of a pilus rod, it has been suggested that the helical arrangement of the mature pilus is formed at the outside of the bacterial surface. The finding that glycerol leads to unraveling of pili which then form a protein chain of approximately 2 nm is in good agreement with this hypothesis, since an extended chain of subunits might be formed in the pore as a first step (Abraham, S. N., *et al.*, *J. Bacteriol.* 174:5145-5148 (1992); Thanassi, D. G., *et al.*, *Proc. Nat. Acad. Sci. USA* 95:3146-3151 (1998)). The formation of the helical pilus rod at the outside of the bacterial membrane might then be the driving force responsible for translocation of the growing pilus through the membrane.

It has also been demonstrated that the usher proteins of Type-1 and P-pili form ternary complexes with chaperone/subunit complexes with different affinities (Dodson, K. W., *et al.*, *Proc. Nat. Acad. Sci. USA* 90:3670-3674 (1993); Saulino, E. T., *et al.*, *EMBO J.* 17:2177-2185 (1998)). This was interpreted as "kinetic partitioning" that allows a defined order of pilus proteins in the pilus. Moreover, it has been suggested that structural proteins might present a binding surface only compatible with one other type of pilus protein; this would be another mechanism to achieve a highly defined order of subunits in the mature pilus (Saulino, E. T., *et al.*, *EMBO J.* 17:2177-2185 (1998)).

-177-

B. Production of Type-1 pili from *Escherichia coli*

E. coli strain W3110 was spread on LB (10 g/L tryptone, 5 g/L yeast extract, 5 g/L NaCl, pH 7.5, 1 % agar (w/v)) plates and incubated at 37°C overnight. A single colony was then used to inoculate 5 ml of LB starter culture (10 g/L tryptone, 5 g/L yeast extract, 5 g/L NaCl, pH 7.5). After incubation for 24 hours under conditions that favor bacteria that produce Type-1 pili (37°C, without agitation) 5 shaker flasks containing 1 liter LB were inoculated with one milliliter of the starter culture. The bacterial cultures were then incubated for additional 48 to 72 hours at 37°C without agitation. Bacteria were then harvested by centrifugation (5000 rpm, 4°C, 10 minutes) and the resulting pellet was resuspended in 250 milliliters of 10 mM Tris/HCl, pH 7.5. Pili were detached from the bacteria by 5 minutes agitation in a conventional mixer at 17,000 rpm. After centrifugation for 10 minutes at 10,000 rpm at 4°C the pili containing supernatant was collected and 1 M MgCl₂ was added to a final concentration of 100 mM. The solution was kept at 4°C for 1 hour, and the precipitated pili were then pelleted by centrifugation (10,000 rpm, 20 minutes, 4°C). The pellet was then resuspended in 10 mM HEPES, pH 7.5, and the pilus solution was then clarified by a final centrifugation step to remove residual cell debris.

C. Coupling of FLAG to purified Type-1 pili of *E. coli* using m-Maleimidonbenzoyl-N-hydroxysulfosuccinimide ester (sulfo-MBS)

600 µl of a 95% pure solution of bacterial Type-1 pili (2 mg/ml) were incubated for 30 minutes at room temperature with the heterobifunctional cross-linker sulfo-MBS (0.5 mM). Thereafter, the mixture was dialyzed overnight against 1 liter of 50 mM Phosphate buffer (pH 7.2) with 150 mM NaCl to remove free sulfo-MBS. Then 500 µl of the derivatized pili (2 mg/ml) were mixed with 0.5 mM FLAG peptide (containing an amino-terminal Cysteine) in the presence of 10 mM EDTA to prevent metal-catalyzed sulfhydryl oxidation. The non-coupled peptide was removed by size-exclusion-chromatography.

EXAMPLE 34

Construction of an expression plasmid for the expression of Type-1 pili of *Escherichia coli*

-178-

The DNA sequence disclosed in GenBank Accession No. U14003, the entire disclosure of which is incorporated herein by reference, contains all of the *Escherichia coli* genes necessary for the production of type-1 pili from nucleotide number 233947 to nucleotide number 240543 (the *fim* gene cluster). This part of the sequences contains the sequences for the genes *fimA*, *fimI*, *fimC*, *fimD*, *fimF*, *fimG*, and *fimH*. Three different PCRs were employed for the amplification of this part of the *E. coli* genome and subsequent cloning into pUC19 (GenBank Accession Nos. L09137 and X02514) as described below.

The PCR template was prepared by mixing 10 ml of a glycerol stock of the *E. coli* strain W3110 with 90 ml of water and boiling of the mixture for 10 minutes at 95°C, subsequent centrifugation for 10 minutes at 14,000 rpm in a bench top centrifuge and collection of the supernatant.

Ten ml of the supernatant were then mixed with 50 pmol of a PCR primer one and 50 pmol of a PCR primer two as defined below. Then 5 ml of a 10X PCR buffer, 0.5 ml of Taq-DNA-Polymerase and water up to a total of 50 ml were added. All PCRs were carried out according to the following scheme: 94°C for 2 minutes, then 30 cycles of 20 seconds at 94°C, 30 seconds at 55°C, and 2 minutes at 72°C. The PCR products were then purified by 1% agarose gel-electrophoresis.

Oligonucleotides with the following sequences with were used to amplify the sequence from nucleotide number 233947 to nucleotide number 235863, comprising the *fimA*, *fimI*, and *fimC* genes:

TAGATGATTACGCCAAGCTTATAATAGAAATAGTTTTTTGAAAG
GAAAGCAGCATG (SEQ ID NO:196)

and

GTCAAAGGCCTTGTCGACGTTATTCCATTACGCCCGTCATTTTG
G (SEQ ID NO:197)

These two oligonucleotides also contained flanking sequences that allowed for cloning of the amplification product into puc19 via the restriction sites *HindIII* and *SalI*. The resulting plasmid was termed pFIMAIC (SEQ ID NO:198).

Oligonucleotides with the following sequences with were used to amplify the sequence from nucleotide number 235654 to nucleotide number 238666, comprising the *fimD* gene:

AAGATCTTAAGCTAAGCTTGAATTCTCTGACGCTGATTAACC
(SEQ ID NO:199)

and

ACGTAAAGCATTCTAGACCGCGGATAGTAATCGTGCTATC
(SEQ ID NO:200).

-179-

These two oligonucleotides also contained flanking sequences that allowed for cloning of the amplification product into puc19 via the restriction sites *Hind*III and *Xba*I, the resulting plasmid was termed pFIMD (SEQ ID NO:201).

Oligonucleotides with the following sequences with were used to amplify the sequence from nucleotide number 238575 nucleotide number 240543, comprising the *fim*F, *fim*G, and *fim*H gene:

AATTACGTGAGCAAGCTTATGAGAAACAAACCTTTTATC (SEQ ID NO:202)

and

GACTAAGGCCTTTCTAGATTATTGATAAACAAAAGTCACGC (SEQ ID NO:203).

These two oligonucleotides also contained flanking sequences that allowed for cloning of the amplification product into puc19 via the restriction sites *Hind*III and *Xba*I; the resulting plasmid was termed pFIMFGH. (SEQ ID NO:204).

The following cloning procedures were subsequently carried out to generate a plasmid containing all the above-mentioned *fim*-genes:

pFIMAIC was digested *Eco*RI and *Hind*III (2237-3982), pFIMD was digested *Eco*RI and *Sst*II (2267-5276), pFIMFGH was digested *Sst*II and *Hind*III (2327-2231). The fragments were then ligated and the resulting plasmid, containing all the *fim*-genes necessary for pilus formation, was termed pFIMAICDFGH (SEQ ID NO:205).

EXAMPLE 35

Construction of an expression plasmid for *Escherichia coli* type-1 pili that lacks the adhesion FimH

The plasmid pFIMAICDFGH (SEQ ID NO:205) was digested with *Kpn*I, after which a fragment consisting of nucleotide numbers 8895-8509 was isolated by 0.7% agarose gelelectrophoresis and circularized by self-ligation. The resulting plasmid was termed pFIMAICDFG (SEQ ID NO: 206), lacks the *fim*H gene and can be used for the production of FIMH-free type-1 pili.

EXAMPLE 36

Expression of type-1 pili using the plasmid pFIMAICDFGH

-180-

E. coli strain W3110 was transformed with pFIMAICDFGH (SEQ ID NO:205) and spread on LB (10 g/L tryptone, 5 g/L yeast extract, 5 g/L NaCl, pH 7.5, 1 % agar (w/v)) plates containing 100 μ g/ml ampicillin and incubated at 37°C overnight. A single colony was then used to inoculate 50 ml of LB-glucose starter culture (10 g/L tryptone, 5 g/L yeast extract, 1% (w/v) glucose, 5 g/L NaCl, pH 7.5, 100mg/ml ampicillin). After incubation for 12-16 hours at 37°C at 150 rpm, a 5 liter shaker flasks containing 2 liter LB-glucose was inoculated with 20 milliliter of the starter culture. The bacterial cultures were then incubated for additional 24 at 37°C with agitation (150 rpm). Bacteria were then harvested by centrifugation (5000 rpm, 4°C, 10 minutes) and the resulting pellet was resuspended in 250 milliliters of 10 mM Tris/HCl, pH 8. Pili were detached from the bacteria by agitation in a conventional mixer at 17,000 rpm for 5 minutes. After centrifugation for 10 minutes at 10,000 rpm, 1 hour, °C the supernatant containing pili was collected and 1 M MgCl₂ was added to a final concentration of 100 mM. The solution was kept at 4°C for 1 hour, and precipitated pili were then pelleted by centrifugation (10,000 rpm, 20 minutes, 4°C). The pellet was then resuspended in 10 mM HEPES, 30 mM EDTA, pH 7.5, for 30 minutes at room temperature, and the pilus solution was then clarified by a final centrifugation step to remove residual cell debris. The preparation was then dialyzed against 20 mM HEPES, pH 7.4.

EXAMPLE 37

Coupling of IgE epitopes and mimotopes to Type-1 pili of Escherichia coli

A 66 μ l aliquot of a 100 uM solution of the heterobifunctional cross-linker sulfa-MBS was added to 400 μ l of a 95% pure solution of bacterial Type-1 pili (2.5 mg/ml, 20 mM HEPES, pH 7.4) and subsequently incubated for 45 minutes at room temperature with agitation. Thereafter, the excess of sulfa-MBS was removed by size exclusion chromatography using a PD-10 column. Alternatively, the cross-linker can be removed by dialysis. Then either 1.3 μ l of a solution containing 1.1 mg/ml peptide Ce3epi (CGGVNLTWSRA SG (SEQ ID NO:207)), or peptide Ce3Mim (CGGVNLPWSFGLE (SEQ ID NO:208) was added to 1 ml aliquots of the derivatized pili (1-1.25 mg/ml, 20 mM HEPES pH 7.4). The samples were incubated at room temperature for 4 h and non-coupled peptide was removed by dialysis against 2 times 2 l of a buffer containing 20 mM HEPES (pH 7.4). Alternatively, the non-coupled peptide can be removed by size-exclusion chromatography.

EXAMPLE 38

Immunization of mice with a bee venom phospholipase A₂ (PLA₂)
fusion protein coupled to Q β capsid protein

- A. Preparation of an alternative vector for cytoplasmic expression of the catalytically inactive variant of the PLA₂ gene fused to the amino acid sequence AAASGGCGG (SEQ ID NO: 209)

The PLA₂ gene construct of example 9 was amplified by PCR from pAV3PLAfos using oligos ecorI_NdeI_pla (sequence below) and PLA-Cys-hind (Example 29). For the reaction, 100 pmol of each oligo, and about 1 μ g of PAV3PLAfos DNA were used in the 50 μ l reaction mixtures with 1.2 units of Pfx DNA polymerase (Gibco), 1 mM MgSO₄, 200 μ M dNTPS and Pfx enhancer solution (Gibco) diluted ten times. For the reaction, temperature cycling was carried out as follows: 94°C for 2 minutes, 5 cycles of 92°C (0.5 minutes), 58°C (0.5 minutes), 68°C (1 minute); 25 cycles of 92°C (0.5 minutes), 63°C (0.5 minutes), 68°C (1 minute). The PCR product was purified by agarose gel electrophoresis and subsequent isolation of the fragment using the Qiagen Qiaquick Kit, digested with enzymes NdeI and HindIII, and cloned into the PET11a vector (Novagen) digested with the same enzymes.

Oligos: ecorI_NdeI_pla:
TAACCGAATTCAGGAGGTAAAAACATATGGC TATCATCTACC (SEQ ID NO: 214).

The vector encoded a fusion protein having the amino acid sequence
MAIIYPGTLWCGHGNKSSGPNELGRFKHTDACCRTQDMCPDVMSAG
ESKHGLTNTASHTRLSCDCDDKFYDCLKNSADTISSYFVGKMYFNLIDTK
CYKLEHPVTGCGERTEGRCLHYTVDKSKPKVYQWFDLRKYAAASGGCG
G (SEQ ID NO:210).

Coupling of PLA₂fusion protein to Q β capsid protein

-182-

A solution of 600 μ l of Q β capsid protein (2 mg/ml in 20 mM Hepes, pH 7.4) was reacted with 176 μ l Sulfo-MBS (13 mg/ml in H₂O) for 60 minutes at room temperature, and dialyzed against 1 L of 20 mM Hepes pH 7.4 O/N at 4°C. The next day, 500 μ l of a PLA₂ solution (2.5 mg/ml) containing 0.1 mM DTT were desalted over a 5 ml Hi-Trap column (Pharmacia). Reduced and desalted PLA₂ (60 μ l, of a solution of approx. 0.5 mg/ml) was mixed with activated and dialyzed Q β capsid (25 μ l of a 1.5 mg/ml solution) and reacted for four hours at room temperature.

1 Capsids of 25-30 nm diameter are clearly visible in electron microscopy images of Q β capsid protein taken both before and after coupling to PLA₂.

C. Immunization of mice with PLA₂ coupled to Q β capsid protein

Female Balb/c mice were immunized intravenously on day 0 with 50 μ g Q β capsid coupled to PLA₂, and boosted on day 14 with the same amount of antigen. Mice were bled on day 20 and sera analyzed in an ELISA. A titer of 1:5000 against PLA₂ was obtained.

EXAMPLE 39

Coupling of IgE mimotopes and epitopes to Q β capsid protein

Human IgE epitopes having the following amino acid sequences were coupled to Q β capsid protein using the N-terminal cysteine residue:

Ce3epitope: CGGVNLTWSRASG (SEQ ID NO:207)

Ce3mimotope: CGGVNLPWSFGLE (SEQ ID NO:208)

The coupling reaction was performed using Q β capsid protein activated with Sulfo-MBS and subsequently dialyzed to remove excess crosslinker. The respective epitope or mimotope was diluted into the reaction mixture containing the activated Q β capsid, and left to react for 4 hours at room temperature. The reaction mixture was finally dialyzed for 4 hours against PBS, and injected into mice.

The following circular mimotope was also coupled to Q β capsid protein: Ce4mimotope: GEFCINHRGYWVCGDPA (SEQ ID NO:211).

The mimotope was first reacted with the chemical group N-succinimidyl-S-acetylthioacetate (SATA), in order to introduce a protected sulfhydryl group into the mimotope. The protecting group was subsequently removed by treatment with hydroxylamine, and immediately reacted with

-183-

activated Q β capsid protein, for 4 hours at room temperature. The reaction mixture was finally dialyzed for 4 hours, and injected into mice.

EXAMPLE 40

Immunization of mice with HBcAg-Lys coupled to M2 peptide

A. Coupling of M2 peptide to HBcAg-Lys capsid protein

Synthetic M2 peptide, corresponding to an N-terminal fragment of the Influenza M2 protein with a cysteine residue at its C-terminus (SLLTEVETPIRNEWGCRCNGSSDGGGC (SEQ ID NO:212)) was chemically coupled to purified HBcAg-Lys particles in order to elicit an immune response against the M2 peptide. Sulfo-MBS (232 μ l, 3 mM) was reacted with a solution of 1.4 ml HBcAg-Lys (1.6 mg/ml) in PBS. The mixture was dialyzed overnight against phosphate buffered saline (PBS). M2 peptide was diluted to a concentration of 24 mg/ml in DMSO; 5 μ l of this solution was diluted in 300 μ l PBS, 188 μ l of which was added to 312 μ l of the dialyzed activated HBcAg-Lys solution. EDTA (10 μ l of a 1 M solution) was also added to the reaction mixture, after which the reaction was allowed to proceed for 4 hours at room temperature.

Immunization of mice with HBcAg-Lys coupled to M2 peptide

Female Balb/c mice were immunized intravenously on day 0 with 50 μ g HBcAg-Lys-M2 or M2 peptide alone and boosted 10 days later with the same amount of antigen. After another 10 days, the mice were infected intranasally with Influenza virus (50 pfu, PR/8) and survival of infected mice was monitored. In addition, viral titers were determined in the lung. Mice primed with M2-HBcAg-Lys were fully protected and had eliminated the virus by day 7.

EXAMPLE 41

Coupling of M2 peptide to pili, Q β and cys-free HbcAg-capsid protein and comparison of the antibody titer obtained by immunization of mice with these coupled pili and capsids with the titer obtained by immunizing mice with an N-terminal fusion protein of the M2 peptide to HbcAg1-183

A. Coupling of M2 peptide to pili, Q β - and cys-free HbcAg-capsid protein

-184-

Q β : A solution of 1 ml of 1 mg/ml Q β capsid protein in 20 mM Hepes, 150 mM NaCl, pH 7.2 was reacted for 30 minutes with 93 μ l of a solution of 13 mg/ml Sulfo-MBS (Pierce) in H₂O at RT on a rocking shaker. The reaction solution was subsequently dialyzed overnight against 2 L of 20 mM hepes, 150 mM NaCl, pH 7.2. The dialyzed reaction mixture was then reacted with 58.8 μ l of a 25 mM stock solution of M2 peptide (SEQ ID NO:212) in DMSO for four hours at RT on a rocking shaker. The reaction mixture was subsequently dialyzed against 2 liters of 20 mM Hepes, 150 mM NaCl, pH 7.2 overnight at 4°C.

Cys-free HbcAg: A solution of 1.25 ml of 0.8 mg/ml cys-free HbcAg capsid protein (example 31) in PBS, pH 7.2 was reacted for 30 minutes with 93 μ l of a solution of 13 mg/ml Sulfo-MBS (Pierce) in H₂O at RT on a rocking shaker. The reaction solution was subsequently dialyzed overnight against 2 L of 20 mM Hepes, 150 mM NaCl, pH 7.2. The dialyzed reaction mixture was then reacted with 58.8 μ l of a 25 mM stock solution of M2 peptide (SEQ ID NO:212) in DMSO for four hours at RT on a rocking shaker. The reaction mixture was subsequently dialyzed against 2 liters of 20 mM hepes, 150 mM NaCl, pH 7.2 overnight at 4°C.

Pili: A solution of 400 μ l of 2.5 mg/ml pili protein in 20 mM Hepes, pH 7.4, was reacted for 45 minutes with 60 μ l of a 100 mM Sulfo-MBS (Pierce) solution in (H₂O) at RT on a rocking shaker. The reaction mixture was desalted on a PD-10 column (Amersham-Pharmacia Biotech), and the second fraction of 500 μ l protein eluting from the column (containing approximately 1 g protein) was reacted with 58.8 μ l of a 25 mM stock solution of M2 peptide (SEQ ID NO:212) in DMSO for four hours at RT on a rocking shaker. The reaction mixture was subsequently dialyzed against 2 liters of 20 mM Hepes, 150 mM NaCl, pH 7.2 overnight at 4°C.

Genetic fusion of the M2 peptide to HbcAg1-183

M2 genetically fused to Hbc: M2 was cloned at the N-terminus of Hbc as published by Neirynck *et. al. Nature Medicine* 5: 1157 (1999). MD-HBc was expressed in *E. coli* and purified by gel chromatography. The presence of the M2 peptide at the N-terminus of M2-HBc was confirmed by Edman sequencing.

Immunization of mice:

-185-

Female Balb/c mice were vaccinated with M2 peptide coupled to pili, Q β and cys-free HbcAg protein and with M2 peptide genetically fused to Hbc immunogen without the addition of adjuvants. 35 μ g protein of each sample were injected intraperitoneally on day 0 and day 14. Mice were bled on day 27 and their serum analyzed using a M2-peptide specific ELISA.

ELISA

10 μ g/ml M2 peptide coupled to RNase was coated on an ELISA plate. The plate was blocked then incubated with serially diluted mouse sera. Bound antibodies were detected with enzymatically labeled anti-mouse IgG antibody. As a control, preimmune sera were also tested. Control ELISA experiments using sera from mice immunized with unrelated peptides crosslinked to Hbc or other carriers showed the antibodies detected were specific for the M2 peptide. The results are shown in FIG. 27 A and B.

EXAMPLE 42

Coupling of angiotensin I and angiotensin II peptides to Q β and immunization of mice with Q β - angiotensin peptide vaccines

A. Coupling of angiotensin I and angiotensin II peptides to Q β capsid protein

The following angiotensin peptides were chemically synthesized: CGGDRVYIHPF ("Angio I"), CGGDRVYIHPFHL ("Angio II"), DRVYIHPFHLGGC ("Angio III"), CDRVYIHPFHL ("Angio IV") and used for chemical coupling to Q β as described in the following.

A solution of 5 ml of 2 mg/ml Q β capsid protein in 20 mM Hepes, 150 mM NaCl pH 7.4 was reacted for 30 minutes with 507 μ l of a solution of 13 mg/ml Sulfo-MBS (Pierce) in H₂O at 25°C on a rocking shaker. The reaction solution was subsequently dialyzed twice for 2 hours against 2 L of 20 mM Hepes, 150 mM NaCl, pH 7.4 at 4°C. 665 ml of the dialyzed reaction mixture was then reacted with 2.8 ml of each of the corresponding 100 mM peptide stock solution (in DMSO) for two hours at 25 °C on a rocking shaker. The reaction mixture was subsequently dialyzed 2x 2 hours against 2 liters of 20 mM Hepes, 150 mM NaCl, pH 7.4 at 4°C.

Immunization of mice:

Female Balb/c mice were vaccinated with one of the four angiotensin peptides coupled to Q β capsid protein without the addition of adjuvants. 50 μ g of

-186-

total protein of each sample was diluted in PBS to 200 μ l and injected subcutaneously (100 μ l on two ventral sides) on day 0 and day 14. Mice were bled retroorbitally on day 21 and their serum was analyzed using an angiotensin-specific ELISA.

ELISA

All four angiotensin peptides were individually coupled to bovine RNase A using the chemical cross-linker sulfo-SPDP. ELISA plates were coated with coupled RNase preparations at a concentration of 10 μ g/ml. The plates were blocked and then incubated with serially diluted mouse sera. Bound antibodies were detected with enzymatically labeled anti-mouse IgG antibody. As a control, preimmune sera of the same mice were also tested. Control ELISA experiments using sera from mice immunized with unrelated peptides crosslinked to Q β or other carriers showed that the antibodies detected were specific for the respective peptide. The results are shown in FIG. 8A-8D.

FIG. 8A, 8B, 8C and 8D, respectively, show ELISA analyses of IgG antibodies specific for "Angio I", "Angio II", "Angio III", and "Angio IV", respectively, in sera of mice immunized against Angio I-IV coupled to Q β capsid protein. Q β -Angio I, Q β -Angio II, Q β -Angio III and Q β -Angio IV, as used in the figures, stand for the vaccine injected in the mice, from which the sera are derived in accordance with above definition of the angiotensin peptides.

Female Balb/c mice were vaccinated subcutaneously with 50 μ g of vaccine in PBS on day 0 and day 14. IgG antibodies in sera of mice vaccinated with Q β -Angio I, Q β -Angio II, Q β -Angio III and Q β -Angio IV were measured on day 21 against all four peptides (coupled to RNase A), i.e. against "Angio I" (FIG. 8A), "Angio II" (FIG. 8B), "Angio III" (FIG. 8C), and "Angio IV" (FIG. 8D). As a control, pre-immune sera from the same mice were analyzed. Results for indicated serum dilutions are shown as optical density at 450 nm. The average of three mice each (including standard deviations) is shown. All vaccinated mice made high IgG antibody titers against all four peptides tested. No angiotensin-specific antibodies were detected in the controls (pre-immune mice).

EXAMPLE 43

Coupling of angiotensin I and angiotensin II peptides to HBcAg-149-lys-2cys-Mut, i.e. cys-free HBcAg.

-187-

The following angiotensin peptides were chemically synthesized: CGGDRVYIHPF ("Angio I"), CGGDRVYIHPFHL ("Angio II"), DRVYIHPFHLGGC ("Angio III"), CDRVYIHPFHL ("Angio IV") and are used for chemical coupling to HBcAg-149-lys-2cys-Mut, i.e. cys-free HBcAg.

A solution of 1.25 ml of 0.8 mg/ml HBcAg-149-lys-2cys-Mut capsid protein (cf. Example 31) in PBS, pH 7.4 is reacted for 30 minutes with 93 μ l of a solution of 13 mg/ml Sulfo-MBS (Pierce) in H₂O at 25°C on a rocking shaker. The reaction solution is subsequently dialyzed overnight against 2 L of 20 mM Hepes, 150 mM NaCl, pH 7.4. After buffer exchange the reaction solution is dialyzed for another 2 hours. The dialyzed reaction mixture is then reacted with 1.8 μ l of a 100 mM peptide stock solution (in DMSO) for 2 hours at 25°C on a rocking shaker. The reaction mixture is subsequently dialyzed against 2 liters of 20 mM Hepes, 150 mM NaCl, pH 7.4 overnight at 4°C followed by buffer exchange and another 2 hours of dialysis.

EXAMPLE 44

Coupling of angiotensin I and angiotensin II peptides to Type-1 pili of *E.coli*.

The following angiotensin peptides were chemically synthesized: CGGDRVYIHPF ("Angio I"), CGGDRVYIHPFHL ("Angio II"), DRVYIHPFHLGGC ("Angio III"), CDRVYIHPFHL ("Angio IV") and are used for chemical coupling to Type-1 pili of *E.coli*.

A solution of 400 μ l of 2.5 mg/ml Type-1 pili of *E.coli* in 20 mM Hepes, pH 7.4, is reacted for 60 minutes with 60 μ l of a 100 mM Sulfo-MBS (Pierce) solution in (H₂O) at RT on a rocking shaker. The reaction mixture is desalted on a PD-10 column (Amersham-Pharmacia Biotech). The protein-containing fractions eluting from the column are pooled (containing approximately 1 mg protein, i.e. derivatized pili) and reacted with a three-fold molar excess of peptide. For example, to 500 μ l eluate containing approximately 1 mg derivatized pili, 2.34 μ l of a 100 mM peptide stock solution (in DMSO) is added. The mixture is incubated for four hours at 25°C on a rocking shaker and subsequently dialyzed against 2 liters of 20 mM Hepes, 150 mM NaCl, pH 7.2 overnight at 4°C.

EXAMPLE 45

Coupling of Der p I peptides to Q β and immunization of mice with Q β - Der p I vaccines

Coupling of Der p I peptides to Q β capsid protein

The following peptides derived from the house dust mite allergen Der p I were chemically synthesized: CGNQSLDLAEQELVDCASQHGCH ("Der p I p52"; aa 52-72, with an additional cysteine-glycine linker at the N terminus), CQIYPPNANKIREALAQTHSA ("Der p I p117"; aa 117-137). These peptides were used for chemical coupling to Q β as described below.

1ml of a solution consisting of 2 mg/ml Q β capsid protein in 20 mM Hepes, 150 mM NaCl, pH 7.4 was reacted for 30 minutes with 102 μ l of a solution of 13 mg/ml Sulfo-MBS (Pierce) in H₂O at 25°C on a rocking shaker. The reaction solution was subsequently dialyzed twice for 2 hours against 2 L of 20 mM Hepes, 150 mM NaCl, pH 7.4 at 4°C. 440 μ l of the dialyzed reaction mixture was then reacted with 1.9 μ l of a 100 mM peptide stock solution (in DMSO) for two hours at 25 °C on a rocking shaker. The reaction mixture was subsequently dialyzed 2x 2 hours against 2 liters of 20 mM Hepes, 150 mM NaCl, pH 7.4 at 4°C.

Immunization of mice:

Female Balb/c mice were vaccinated with one of the two Der p I peptides coupled to Q β capsid protein without the addition of adjuvants. Two mice for each vaccine were used. 30 μ g of total protein of each sample was diluted in PBS to 200 μ l and injected subcutaneously on day 0 and day 14. Mice were bled retroorbitally on day 21 and their serum was analyzed using a Der p I peptide-specific ELISA.

ELISA

The Der p I peptides "Der p I p52" and "Der p I p117" were individually coupled to bovine RNase A using the chemical cross-linker sulfo-SPDP. ELISA plates were coated with coupled RNase preparations at a concentration of 10 mg/ml. The plates were blocked and then incubated with serially diluted mouse sera. Bound antibodies were detected with enzymatically labeled anti-mouse IgG antibody. As a control, preimmune sera of the same mice were also tested. Control ELISA experiments using sera from mice immunized with unrelated peptides crosslinked to Q β or other carriers showed that the antibodies detected were specific for the respective peptide. The results are shown in FIGS. 9A and 9B.

-189-

FIG.9A and FIG. 9B show ELISA analyses of IgG antibodies specific for "Der p I p52" (FIG. 9A) and specific for "Der p I p117" (FIG. 9B) in sera of mice immunized against the Der p I peptides coupled to Q β capsid protein. "p52" and "p117", as used in FIGS. 9A and 9B, stand for the vaccine injected in the mice, from which the sera are derived.

As a control, pre-immune sera from the same mice were analyzed (day 0). Results for indicated serum dilutions are shown as optical density at 450 nm. On day 21, all vaccinated mice made specific IgG antibodies against the Der p I peptide they were vaccinated with but not against the other Der p I peptide. No Der p I peptide-specific antibodies were detected before vaccination (day 0).

Both Der p I peptide vaccines were highly immunogenic in the absence of adjuvants. All vaccinated mice made good antibody responses specific for the peptide in the vaccine preparation.

EXAMPLE 46

Coupling of Der p 1 peptides to HBcAg-149-lys-2cys-Mut, i.e. cys-free HBcAg.

The following peptides derived from the house dust mite allergen Der p 1 were chemically synthesized: Der p I p52 (aa 52-72, with an additional cysteine-glycine linker at the N terminus): CGNQSLDLAEQELVDCASQHGCH, Der p I p117 (aa 117-137): CQIYPPNANKIREALAQTHSA. These peptides are used for chemical coupling to HBcAg-149-lys-2cys-Mut, i.e. cys-free HBcAg.

A solution of 1.25 ml of 0.8 mg/ml HBcAg-149-lys-2cys-Mut capsid protein (Example 31) in PBS, pH 7.4 is reacted for 30 minutes with 93 μ l of a solution of 13 mg/ml Sulfo-MBS (Pierce) in H₂O at 25 °C on a rocking shaker. The reaction solution is subsequently dialyzed overnight against 2 L of 20 mM Hepes, 150 mM NaCl, pH 7.4. After buffer exchange the reaction solution is dialyzed for another 2 hours. The dialyzed reaction mixture is then reacted with 1.8 μ l of a 100 mM peptide stock solution (in DMSO) for 2 hours at 25°C on a rocking shaker. The reaction mixture is subsequently dialyzed against 2 liters of 20 mM Hepes, 150 mM NaCl, pH 7.4 overnight at 4°C followed by buffer exchange and another 2 hours of dialysis.

-190-

EXAMPLE 47

Coupling of Der p I peptides to Type-1 pili of *E.coli*

The following peptides derived from the house dust mite allergen Der p I were chemically synthesized: Der p I p52 (aa 52-72, with an additional cysteine-glycine linker at the N terminus) and CGNQSLDLAEQELVDCASQHGCH, Der p I p117 (aa 117-137): CQIYPPNANKIREALAQTHSA. These peptides are used for chemical coupling to Type-1 pili of *E.coli*.

A solution of 400 μ l of 2.5 mg/ml Type-1 pili of *E.coli* in 20 mM Hepes, pH 7.4, is reacted for 60 minutes with 60 μ l of a 100 mM Sulfo-MBS (Pierce) solution in (H_2O) at RT on a rocking shaker. The reaction mixture is desalted on a PD-10 column (Amersham-Pharmacia Biotech). The protein-containing fractions eluting from the column are pooled (containing approximately 1 mg protein, i.e. derivatized pili) and reacted with a three-fold molar excess of peptide. For example, to 500 μ l eluate containing approximately 1 mg derivatized pili, 2.34 μ l of a 100 mM peptide stock solution (in DMSO) is added. The mixture is incubated for four hours at 25°C on a rocking shaker and subsequently dialyzed against 2 liters of 20 mM Hepes, 150 mM NaCl, pH 7.2 overnight at 4°C.

EXAMPLE 48

Coupling of Human VEGFR-II Peptide to Type-1 pili of *E.coli* and
Immunization of Mice with Vaccines Comprising Type-1 pili-
Human VEGFR-II Peptide Arrays

Coupling of human VEGFR-II peptide to Type-1 pili of *E.coli*

The human VEGFR II peptide with the sequence CTARTELNVGIDFNWEYPSSKHQHKK was chemically synthesized and used for chemical coupling to Type-1 pili of *E.coli*.

A solution of 1400 μ l of 1 mg/ml pili protein in 20 mM Hepes, pH 7.4, was reacted for 60 minutes with 85 μ l of a 100 mM Sulfo-MBS (Pierce) solution in (H_2O) at RT on a rocking shaker. The reaction mixture was desalted on a PD-10 column (Amersham-Pharmacia Biotech). The protein-containing fractions eluting from the column were pooled (containing approximately 1,4 mg protein) and reacted with a 2.5-fold molar excess (final volume) of human VEGFR II peptide. For example, to 200 μ l eluate containing approximately 0,2 mg derivatized pili, 2.4 μ l of a 10 mM peptide solution (in DMSO) was added. The

-191-

mixture was incubated for four hours at 25°C on a rocking shaker and subsequently dialyzed against 2 liters of 20 mM Hepes, pH 7.2 overnight at 4°C.

Immunization of mice

Female C3H-HeJ (Toll-like receptor 4 deficient, LPS non-responder mice) and C3H-HeN (wild-type) mice were vaccinated with the human VEGFR-II peptide coupled to Type-1 pili protein without the addition of adjuvants. Approximately 100 µg of total protein of each sample was diluted in PBS to 200 µl and injected subcutaneously on day 0, day 14 and day 28. Mice were bled retroorbitally on day 14, 28 and day 42 and serum of day 42 was analyzed using a human VEGFR-II specific ELISA

ELISA

Sera of immunized mice were tested in ELISA with immobilized human VEGFR-II peptide and the extracellular domain of the human VEGFR-II (R&D Systems GmbH, Wiesbaden).

Human VEGFR-II peptide was coupled to bovine RNase A using the chemical cross-linker sulfo-SPDP. ELISA plates were coated with coupled RNase A at a concentration of 10 µg/ml. The human extracellular domain of VEGFR-II was adsorbed to the plates at a concentration of 2 µg/ml. The plates were blocked and then incubated with serially diluted mouse sera. Bound antibodies were detected with enzymatically labeled anti-mouse IgG antibody. As a control, preimmune sera of the same mice were also tested. Control ELISA experiments using sera from mice immunized with uncoupled carrier showed that the antibodies detected were specific for the respective peptide. The results for human VEGFR II peptide coupled to Type-1 pili are shown in Figure 10. In particular, FIG.10A. and FIG. 10B show ELISA analyses of IgG antibodies specific for human VEGFR II peptide and extracellular domain of human VEGFR II, respectively, in sera of mice immunized against human VEGFR II peptide and the extracellular domain of human VEGFR II each coupled to Type-1 pili protein.

Female C3H-HeJ (Toll-like receptor 4 deficient, LPS-nonresponder) and C3H-HeN (wild-type) mice were vaccinated subcutaneously with 100 µg of vaccine in PBS on day 0, 14 and 28. Serum IgG against the peptide (coupled to RNase A) and the extracellular domain of human VEGFR II were measured on day 42. As a control, preimmune sera from the same mice were analyzed. Results for indicated serum dilutions are shown as optical density at 450 nm. The average of three mice each (including standard deviations) are shown. All vaccinated mice

-192-

made high IgG antibody titers against the human VEGFR-II peptide as well as the extracellular domain of human VEGFR-II (KDR) and no difference was noted between mice deficient for the Toll-like receptor 4 and wild-type mice. The latter is remarkable since it demonstrates that formation of high IgG antibody titers against the human VEGFR-II peptide as well as the extracellular domain of human VEGFR-II is independent of endotoxin contaminations.

EXAMPLE 49

Coupling of Human VEGFR-II Peptide to Q β Capsid Protein and Immunization of Mice with Vaccines Comprising Q β Capsid Protein - Human VEGFR-II Peptide Arrays

Coupling of Human VEGFR-II Peptide to Q β Capsid Protein

The human VEGFR II peptide with the sequence CTARTELNVGIDFNWEYPSSKHQHKK was chemically synthesized and is used for chemical coupling to Q β capsid protein.

A solution of 1 ml of 1 mg/ml Q β capsid protein in 20 mM Hepes, 150 mM NaCl pH 7.4 was reacted for 45 minutes with 20 μ l of 100 mM Sulfo-MBS (Pierce) solution in (H₂O) at RT on a rocking shaker. The reaction solution was subsequently dialyzed twice for 2 hours in 2 L of 20 mM Hepes, pH 7.4 at 4 °C. 1000 μ l of the dialyzed reaction mixture was then reacted with 12 μ l of a 10 mM human VEGFR II peptide solution (in DMSO) for four hours at 25 °C on a rocking shaker. The reaction mixture was subsequently dialyzed 2x2 hours against 2 liters of 20 mM Hepes, pH 7.4 at 4 °C.

1ml of a solution consisting of 2 mg/ml Q β capsid protein in 20 mM Hepes, 150 mM NaCl, pH 7.4 was reacted for 30 minutes with 102 μ l of a solution of 13 mg/ml Sulfo-MBS (Pierce) in H₂O at 25°C on a rocking shaker. The reaction solution was subsequently dialyzed twice for 2 hours against 2 L of 20 mM Hepes, 150 mM NaCl, pH 7.4 at 4°C. 440 μ l of the dialyzed reaction mixture was then reacted with 1.9 μ l of a 100 mM peptide stock solution (in DMSO) for two hours at 25 °C on a rocking shaker. The reaction mixture was subsequently dialyzed 2x 2 hours against 2 liters of 20 mM Hepes, 150 mM NaCl, pH 7.4 at 4°C.

-193-

Immunization of Mice

C57BL/6 mice are vaccinated with the human VEGFR-II peptide coupled to Q β protein without the addition of adjuvants. Approximately 50 μ g of total protein of each sample is diluted in PBS to 200 μ l and injected subcutaneously on day 0, day 14 and day 28. Mice are bled retroorbitally on day 14, 28 and day 42 and serum of day 42 is analyzed using a human VEGFR-II specific ELISA

EXAMPLE 50

Coupling of Human VEGFR-II Peptide to HBcAg-149-lys-2cys-Mut Capsid Protein, i.e. cys-free HBcAg, and Immunization of Mice with Vaccines Comprising HBcAg-149-lys-2cys-Mut Capsid Protein - human VEGFR-II Peptide Arrays

Coupling of Human VEGFR-II Peptide to HBcAg-149-lys-2cys-Mut Capsid Protein

The human VEGFR II peptide with the sequence CTARTELNVGIDFNWEYPSSKHQHKK was chemically synthesized and is used for chemical coupling to HBcAg-149-lys-2cys-Mut capsid protein.

A solution of 3 ml of 0.9 mg/ml cys-free HbcAg capsid protein (cf. Example 31) in PBS, pH 7.4 is reacted for 45 minutes with 37.5 μ l of 100 mM Sulfo-MBS (Pierce) solution in (H₂O) at RT on a rocking shaker. The reaction solution is subsequently dialyzed overnight against 2 L of 20 mM Hepes, pH 7.4. After buffer exchange the reaction solution is dialyzed for another 2 hours. The dialyzed reaction mixture is then reacted with 3 μ l of a 10 mM human VEGFR II peptide solution (in DMSO) for 4 hours at 25 °C on a rocking shaker. The reaction mixture is subsequently dialyzed against 2 liters of 20 mM Hepes, pH 7.4 overnight at 4 °C followed by buffer exchange and another 2 hours of dialysis.

EXAMPLE 51

Construction of HBcAg1-183Lys

Hepatitis core Antigen (HBcAg) 1-183 was modified as described in Example 23. A part of the c/e1 epitope (residues 72 to 88) region (Proline 79 and Alanine 80) was genetically replaced by the peptide Gly-Gly-Lys-Gly-Gly (HBcAg1-183Lys construct). The introduced Lysine residue contains a reactive amino group in its side chain that can be used for intermolecular chemical crosslinking of HBcAg particles with any antigen containing a free cysteine group. PCR methods essentially as described in Example 1 and conventional cloning techniques were used to prepare the HBcAg1-183Lys gene.

The Gly-Gly-Lys-Gly-Gly sequence was inserted by amplifying two separate fragments of the HBcAg gene from pEco63, as described above in Example

-195-

23 and subsequently fusing the two fragments by PCR to assemble the full length gene. The following PCR primer combinations were used:

fragment 1:

Primer 1: EcoRIHBcAg(s) (see Example 23)

Primer 2: Lys-HBcAg(as) (see Example 23)

fragment 2:

Primer 3: Lys-HBcAg(s) (see Example 23)

Primer 4: HBcAgwtHindIII

CGCGTCCCAAGCTTCTAACATTGAGATTCCCGAGATTG

Assembly:

Primer 1: EcoRIHBcAg(s) (see example 23)

Primer 2: HBcAgwtHindIII

The assembled full length gene was then digested with the EcoRI (GAATTC) and HindIII (AAGCTT) enzymes and cloned into the pKK vector (Pharmacia) cut at the same restriction sites.

EXAMPLE 52

Coupling of muTNFa Peptide to HBcAg1-183Lys and Immunization of Mice with Vaccines Comprising HBcAg1-183Lys - muTNFa Peptide Arrays

A. Coupling of muTNFa Peptide to HBcAg1-183Lys

HBcAg1-183Lys at a concentration of 0.6 mg/ml (29 μ M) was treated with iodacetamide as described in Example 32. HBcAg1-183Lys was then reacted with a fifty-fold excess of the cross-linker Sulfo-MBS, as described in Example 32, and dialyzed overnight against 20mM Hepes, pH 7.2, at 4°C. Activated (derivatized) HBcAg1-183Lys was reacted with a five-fold molar excess of the peptide muTNFa (sequence: CGGVEEQLEWLSQR, diluted directly into the HBcAg1-183Lys solution from a 100 mM stock solution in DMSO) at RT for 4 hours. The coupling reaction (about 1 ml solution) was dialyzed against 2x 2 liters of 20mM HEPES pH 7.2, at 4°C, for 4 hours. The dialyzed coupling reaction was frozen in aliquots in liquid nitrogen and stored at -80°C until immunization of the mice.

Immunization

-196-

Two mice (female Balb/c) were immunized intravenously at day 0 and 14 with 100 μ g HBcAg1-183Lys coupled to the muTNFa peptide, per animal, without adjuvant. Antibodies specific for the muTNFa peptide (coated as a Ribonuclease A conjugate) and for native TNF α protein (Sigma) in the serum were determined at day 21 by ELISA.

ELISA

Murine TNF α protein (Sigma) was coated at a concentration of 2 μ g/ml. As a control, preimmune sera from the same mice used for immunization were tested. FIG. 14 shows the result of the ELISA experiment, demonstrating that immunization with HBcAg1-183Lys coupled to the muTNFa peptide (Full length HBc-TNF) generated an immune response specific for the murine TNF α protein. The sera from mice bled on day 0 (preimmune) and 21 were tested at three different dilutions. Each bar is the average of the signal obtained with sera from two mice. Thus, vaccination with HBcAg1-183Lys coupled to the muTNFa peptide induced an immune response against a self-antigen, since the amino acid sequence of the muTNFa peptide is derived from the sequence of mouse TNF α protein.

EXAMPLE 53

Coupling of 3'TNF II Peptide to 2cysLys-mut HBcAg1-149 and Immunization of Mice with Vaccines Comprising 2cysLys-mut HBcAg1-149 - 3'TNF II Peptide Arrays

Coupling of the 3'TNF II peptide to 2cysLys-mut HBcAg1-149

2cysLys-mut HBcAg1-149 was reacted at a concentration of 2 mg/ml for 30 min. at RT with a fifty-fold excess of cross-linker in 20 mM Hepes, 150 mM NaCl, pH 7.2. Excess cross-linker was removed by dialysis overnight, and activated (derivatized) 2cysLys-mut HBcAg1-149 capsid protein was reacted with a ten-fold excess of 3'TNF II peptide (SEQ: SSQNSSDKPVAHVVANHGVGGC, diluted from a 100 mM stock solution in DMSO) for 4 hours at RT. The reaction mixture was then dialyzed overnight in a dialysis tubing with a molecular weight cutoff of 50000 Da, frozen in liquid nitrogen and stored at -80°C until immunization of the mice.

Immunization of Mice

-197-

3 Female C3H/HeN mice, 8 weeks of age were vaccinated with the 3'TNF II peptide coupled to 2cysLys-mut HBcAg1-149 without the addition of adjuvants. 50 µg of total protein was diluted in PBS to 200 µl and injected subcutaneously (100 µl on two inguinal sides) on day 0 and day 14. Mice were bled retroorbitally on day 0 and 21, and their serum were analyzed in an ELISA specific for murine TNFα protein.

ELISA

Murine TNFα protein (Sigma) was coated at a concentration of 2 µg/ml. As a control, preimmune sera from the same mice used for immunization were tested. FIG. 15 shows the result of the ELISA, demonstrating that immunization with 2cysLys-mut HBcAg1-149 coupled to the 3'TNF II peptide generated an immune response specific for the murine TNFα protein. The sera from mice bled on day 0 (preimmune) and 21 were tested at three different dilutions. Each bar is the average of the signal obtained with sera from 3 mice. Thus, vaccination with 2cysLys-mut HBcAg1-149 coupled to the 3'TNF II peptide induced an immune response specific for a self-antigen, since the amino acid sequence of the 3'TNF II peptide is derived from the sequence of murine TNFα protein.

EXAMPLE 54

Coupling of Aβ 1-15, Aβ 1-27 and Aβ 33-42 peptides to Qβ and immunization of mice with vaccines comprising Qβ - Aβ peptide arrays

- A. Coupling of Aβ 1-15 and Aβ 33-42 peptides to Qβ capsid protein using the cross-linker SMPH.

The following Aβ peptides were chemically synthesized: DAEFRHDSGYEVHHQGGC (abbreviated as "Aβ 1-15"), a peptide which comprises the amino acid sequence from residue 1-15 of human Aβ, fused at its C-terminus to the sequence GGC for coupling to Qβ capsid protein and CGHGKNSGLMVGGVVIA (abbreviated as "Aβ 33-42") a peptide which comprises the amino acid sequence from residue 33-42 of Aβ, fused at its N-terminus to the sequence CGHGKNS for

-198-

coupling to Q β capsid protein. Both peptides were used for chemical coupling to Q β as described in the following.

A solution of 1.5 ml of 2 mg/ml Q β capsid protein in 20 mM Hepes 150 mM NaCl pH 7.4 was reacted for 30 minutes with 16.6 μ l of a solution of 65 mM SMPH (Pierce) in H₂O, at 25 °C on a rocking shaker. The reaction solution was subsequently dialyzed twice for 2 hours against 2 L of 20 mM Hepes, 150 mM NaCl, pH 7.4 at 4 °C in a dialysis tubing with Molecular Weight cutoff 10000 Da. 450 μ l of the dialyzed reaction mixture, which contains activated (derivatized) Q β , was then reacted with 6.5 μ l of each of the corresponding 50 mM peptide stock solution (in DMSO) for two hours at 15°C on a rocking shaker. 200 μ l of the reaction mixture was subsequently dialyzed overnight against 2 liters of 20 mM Hepes, 150 mM NaCl, pH 7.4 at 4 °C, and the next morning for another two hours after change of buffer. The reaction mixture was then frozen in aliquots in liquid Nitrogen and stored at -80°C until immunization of the mice.

The results of the coupling experiments were analyzed by SDS-PAGE, and are shown in FIG.13A and FIG.13B. The arrows point to the band corresponding to one, respectively two peptides coupled to one Q β subunit (FIG.13A), or one peptide coupled to one Q β subunit (FIG.13B). Molecular weights of marker proteins are given on the left margin of FIG. 13A and FIG.13B.

The samples loaded on the gel of FIG.13A are the following:

1: derivatized Q β ; 2: Q β coupled with "A β 1-15", supernatant of the sample taken at the end of the coupling reaction, and centrifuged; 3: Q β coupled with "A β 1-15", pellet of the sample taken at the end of the coupling reaction, and centrifuged. 4: Q β coupled with "A β 1-15", supernatant of a sample left to stand 24 hours at 4 °C, undialyzed and centrifuged. 5: Q β coupled with "A β 1-15", pellet of a sample left to stand 24 hours at 4 °C, undialyzed and centrifuged.

-199-

6: Q β coupled with "A β 1-15", supernatant of the sample taken after dialysis of the coupling reaction, and centrifuged.

The samples loaded on the gel of FIG.13B are the following:

1: derivatized Q β 2: Q β coupled with "A β 33-42", supernatant of the sample taken at the end of the coupling reaction, and centrifuged. 3: Q β coupled with "A β 33-42", pellet of the sample taken at the end of the coupling reaction, and centrifuged. 4: Q β coupled with "A β 33-42", supernatant of a sample left to stand 24 hours at 4 °C, undialyzed and centrifuged. 5: Q β coupled with "A β 33-42", pellet of a sample left to stand 24 hours at 4 °C, undialyzed and centrifuged. 6: Q β coupled with "A β 33-42", supernatant of the sample taken after dialysis of the coupling reaction, and centrifuged.

B. Coupling of "A β 1-27" peptide to Q β capsid protein using the cross-linker SMPH.

The following A β peptide ("A β 1-27") was chemically synthesized DAEFRHDSGYEVHHQKLVFFAEDVGSNGGC. This peptide comprises the amino acid sequence from residue 1-27 of human A β , fused at its C-terminus to the sequence GGC for coupling to Q β capsid protein.

A first batch of "A β 1-27" coupled to Q β capsid protein, in the following abbreviated as "Q β -A β 1-27 batch 1" was prepared as follows:

A solution of 1.5 ml of 2 mg/ml Q β capsid protein in 20 mM Hepes 150 mM NaCl pH 7.4 was reacted for 30 minutes with 16.6 μ l of a solution of 65 mM SMPH (Pierce) in H₂O, at 25 °C on a rocking shaker. The reaction solution was subsequently dialyzed twice for 2 hours against 2 L of 20 mM Hepes, 150 mM NaCl, pH 7.4 at 4 °C in a dialysis tubing with Molecular Weight cutoff 10000 Da. 450 μ l of the dialyzed reaction mixture was then reacted with 6.5 μ l of a 50 mM peptide stock solution (in DMSO) for two hours at 15°C on a rocking shaker. 200 μ l of the sample was then aliquoted, frozen in liquid Nitrogen and stored at -80°C until immunization of the mice.

-200-

A second batch of "A β 1-27" coupled to Q β capsid protein, in the following abbreviated as "Q β -A β 1-27 batch 2" was prepared as follows:

500 μ l of Q β capsid protein in 20 mM Hepes 150 mM NaCl pH 7.4 was reacted for 30 minutes with 11.3 μ l of a solution of 32.5 mM SMPH (Pierce) in H₂O, at 25 °C on a rocking shaker. The reaction solution was subsequently dialyzed twice for 2 hours against 2 L of 20 mM Hepes, 150 mM NaCl, pH 7.4 at 4 °C in a dialysis tubing with Molecular Weight cutoff 3500 Da (SnakeSkin, Pierce). The dialyzed reaction mixture was then reacted with 3.6 μ l of a 50 mM peptide stock solution (in DMSO) for two hours at 15°C on a rocking shaker. The reaction mixture was then dialyzed 2X against 1 l 20 mM Hepes, 150 mM NaCl, pH 7.4 for 1 hour and overnight after a last change of buffer, using a dialysis membrane with a 50000 Da cutoff (Spectrapor, spectrum). The reaction mixture was then frozen in aliquots in liquid nitrogen and stored at -80°C until immunization of the mice. "Q β -A β 1-27 batch 1" was used for the first immunization, while "Q β -A β 1-27 batch 2" was used for the boost.

The result of the coupling experiment was analyzed by SDS-PAGE, and is shown in FIG. 13C. The arrow points to the band corresponding to one peptide coupled to one Q β subunit.

The samples loaded on the gel of FIG.13C are the following:

M: protein marker. 1: Q β capsid protein 2: derivatized Q β , supernatant of the sample taken at the end of the derivatization reaction, and centrifuged. 3: derivatized Q β , pellet of the sample taken at the end of the derivatization reaction, and centrifuged. 4: Q β coupled with "A β 1-27", supernatant of the sample taken at the end of the coupling reaction, and centrifuged. 5: Q β coupled with "A β 1-27", pellet of the sample taken at the end of the coupling reaction, and centrifuged. 6: Q β coupled with "A β 1-27", supernatant of the sample taken after dialysis of the coupling reaction, and centrifuged. 7: Q β coupled with "A β 1-27", pellet of the sample taken after dialysis of the coupling reaction, and centrifuged.

-201-

C. Coupling of "A β 1-15" peptide to Q β capsid protein using the cross-linker Sulfo-GMBS

A solution of 500 μ l of 2 mg/ml Q β capsid protein in 20 mM Hepes 150 mM NaCl pH 7.4 was reacted for 30 minutes with 5.5 μ l of a solution of 65 mM SMPH (Pierce) in H₂O, at 25 °C on a rocking shaker. The reaction solution was subsequently dialyzed twice for 2 hours against 2 L of 20 mM Hepes, 150 mM NaCl, pH 7.4 at 4 °C in a dialysis tubing with Molecular Weight cutoff 10 000 Da. 500 μ l of the dialyzed reaction mixture was then reacted with 6.5 μ l of the 50 mM peptide stock solution (in DMSO) for two hours at 15°C on a rocking shaker. 200 μ l of the reaction mixture was subsequently dialyzed overnight against 2 liters of 20 mM Hepes, 150 mM NaCl, pH 7.4 at 4 °C, and the next morning for another two hours after change of buffer. The reaction mixture was then frozen in aliquots in liquid Nitrogen and stored at -80°C until immunization of the mice.

The result of the coupling experiment was analyzed by SDS-PAGE, and is shown in FIG. 13D. The arrow points to the band corresponding to one, two and three peptides, respectively, coupled to one Q β subunit.

The samples loaded on the gel of FIG.13D are the following:
M: protein marker. 1: derivatized Q β 2: Q β coupled with "A β 1-15", supernatant of the sample taken at the end of the coupling reaction, and centrifuged. 3: Q β coupled with "A β 1-15", pellet of the sample taken at the end of the coupling reaction, and centrifuged. 4: Q β coupled with "A β 1-15", supernatant of a sample left to stand 24 hours at 4 °C, undialyzed and centrifuged. 5: Q β coupled with "A β 1-15", pellet of a sample left to stand 24 hours at 4 °C, undialyzed and centrifuged. 6: Q β coupled with "A β 1-15", supernatant of the sample taken after dialysis of the coupling reaction, and centrifuged.

-202-

D. Coupling of "A β 1-15" to Q β capsid protein using the cross-linker Sulfo-MBS.

500 μ l of Q β capsid protein in 20 mM Hepes 150 mM NaCl pH 7.4 was reacted for 30 minutes with 14.7 μ l of a solution of 100 mM Sulfo-MBS (Pierce) in H₂O, at 25 °C on a rocking shaker. The reaction solution was subsequently dialyzed twice for 2 hours against 2 L of 20 mM Hepes, 150 mM NaCl, pH 7.4 at 4 °C in a dialysis tubing (SnakeSkin, Pierce) with Molecular Weight cutoff 3500 Da. The dialyzed reaction mixture was then reacted with 7.2 μ l of a 50 mM peptide stock solution (in DMSO) for two hours at 15°C on a rocking shaker. The reaction mixture was then dialyzed 3 X over 4 hours against 2 l 20 mM Hepes, 150 mM NaCl, pH 7.4 using a dialysis membrane with a 50000 Da cutoff (Spectrapor, spectrum). The reaction mixture was then frozen in aliquots in liquid nitrogen and stored at -80°C until immunization of the mice.

The result of the coupling experiment was analyzed by SDS-PAGE, and is shown in FIG.13E. The arrow points to the band corresponding to one peptide coupled to one Q β subunit.

The samples loaded on the gel of FIG.13E are the following:

1: Q β capsid protein 2: derivatized Q β , supernatant of the sample taken at the end of the derivatization reaction, and centrifuged. 3: derivatized Q β , pellet of the sample taken at the end of the derivatization reaction, and centrifuged. 4: derivatized Q β , supernatant of the sample taken at the end of the dialysis of the derivatization reaction, and centrifuged. 5: derivatized Q β , pellet of the sample taken at the end of the dialysis of the derivatization reaction, and centrifuged. 6: Q β coupled with "A β 1-15", supernatant of the sample taken at the end of the coupling reaction, and centrifuged. 7: Q β coupled with "A β 1-15", pellet of the sample taken at the end of the coupling reaction, and centrifuged. 8: Q β coupled with "A β 1-15", supernatant of the sample taken after dialysis of the coupling reaction, and centrifuged.

E. Immunization of mice:

-203-

Five groups of female C57BL/6 mice, three mice per group, 8 weeks of age were vaccinated each with one of the five A β peptide-Q β capsid protein conjugates without the addition of adjuvant. 25 μ g of total protein of each sample was diluted in PBS to 200 μ l and injected subcutaneously on day 0 and day 14. Mice were bled retroorbitally on day 0 (preimmune) and 21 and their serum was analyzed in an ELISA. "A β 1-15" peptide was coupled to Q β with three different cross-linkers, resulting in three different vaccine preparations ("Q β -A β 1-15 SMPH", "Q β -A β 1-15 SMBS", "Q β -A β 1-15 SGMBS"; see ELISA section for the results).

F. ELISA

All three A β peptides were individually coupled to bovine RNase A using the chemical cross-linker SPDP as follows: a solution of 10 mg RNase A in 2mL PBS (50mM Phosphate buffer, 150mM NaCl pH 7.2) was reacted with 100 μ l of a 20 mM SPDP solution in DMSO, at 25°C for 60 min. on a rocking shaker. Excess cross-linker was separated from activated (derivatized) RNase A by gel filtration using a PD 10 column (Pharmacia). The protein containing fractions were pooled and concentrated to a volume of 2 ml using centrifugal filters (5000 MWCO). A sample of 333 μ l of the derivatized RNase A solution was reacted with 2 μ l of the peptide stock solution (50 mM in DMSO). The coupling reaction was followed spectrophotometrically.

ELISA plates were coated with RNase A coupled to peptide at a concentration of 10 μ g/ml. The plates were blocked and then incubated with serially diluted mouse sera. Bound antibodies were detected with enzymatically labeled anti-mouse IgG antibody. Preimmune sera or control sera from mice immunized with unrelated peptides conjugated to Q β , showed that the antibodies detected were specific for the respective peptide. FIG. 14A, FIG. 14B and FIG.14C, respectively, show ELISA analyses of IgG antibodies specific for "A β 1-15", "A β 1-27" and "A β 33-

-204-

42", respectively, in sera of mice immunized against "A β 1-15", "A β 1-27" and "A β 33-42", respectively, coupled to Q β capsid protein. The denominations on the abscissa stand for the vaccine injected in the mice from which the sera are derived, and describe the peptide and the cross-linker used to make the respective vaccine. All sera were measured against the three peptides coupled to RNase A, and the results show that while there is cross-reactivity between the antibodies raised against peptide 1-15 and 1-27, no such cross reactivity is observed against peptide 33-42, demonstrating the specificity of the immune response. Likewise, The ELISA titers obtained, expressed as the dilution of the serum yielding an ELISA signal three standard deviations above background, were very high, and ranged from 60'000 to 600'000. No A β peptide-specific antibodies were detected in the controls (pre-immune mice).

EXAMPLE 55

Introduction of cys-containing linkers, expression, and purification of anti-idiotypic IgE mimobodies and their coupling to Q β capsid protein

- A. Construction of plasmids for the expression of mimobodies for coupling to Q β capsid protein

Plasmids were based on the expression plasmid VAE051-pASK116. This plasmid contains the coding regions for the heavy chain and for the light chain of the mimobody. The following primers were used to introduce cys-containing linkers at the C-terminus of the heavy chain:

Primer CA2F:

CGGCTCGAGCATCACCATCACCATCACGGTGAAGTTAACTGCAGCTG
GAGTCG

Primer CA1R:

CATGCCATGGTTAACCACAGGTGTGGGTTTTATCACAAGATTTGGGCT
CAAC

-205-

Primer CB1R:

CATGCCATGGTTAACCACACGGCGGAGAGGTGTGGGTTTTATCACAAG
ATTTGGGCTCAAC

Primer CC1R:

CCAGAAGAACCCGGCGGGGTAGACGGTTTCGGGCTAGCACAAGATTT
GGGCTCAACTC

Primer CC1F:

CGCCGGGTTCTTCTGGTGGTGCTCCGGGTGGTTGCGGTTAACCATGGA
GAAAATAAAGTG

Primer CCR2:

CTCCCGGGTAGAAGTCAC

A.1. Construction of pCA2:

Primers CA2F and CA1R were used to amplify a 741 bp fragment encoding part of the heavy chain with an extension encoding the cys-containing linker sequence. VAE-pASK116 served as template for the Pfx polymerase (Roche) in the PCR cyclor (Robo) at (initial denaturation at 92°C, cycling: 92°C, 30 s; 48°C, 30 s; 68°C, 60s) for 5 cycles followed by 30 cycles with 92°C, 30 s; 58°C, 30 s; 68°C, 1 min. The PCR product of the appropriate size was purified using the Qiagen PCR purification kit and digested with XhoI and NcoI according to the recommendation of the manufacturer (Gibco). The product was purified from an agarose gel with the Qiagen gel extraction kit. Plasmid VAE-pASK116 was in parallel cleaved with XhoI and NcoI and a 3.7 kb band purified from agarose gels. Appropriate aliquots of the XhoI-NcoI digested PCR product and the plasmid were ligated overnight at 16°C using T4 DNA ligase according to the manufacturer's protocol (Gibco). The ligation product was transformed into competent E.coli XL-1 cells which were plated on agarose plates containing chloramphenicol. Single colonies were expanded in LB/chloramphenicol medium, plasmid was prepared (Qiagen mini plasmid kit) and tested for the presence of the appropriate XhoI-NcoI insert size after digestion with the corresponding enzymes. A correspondingly positive plasmid termed pCA2 was sent for sequencing

-206-

on both strands which confirmed the identity of the plasmid including the cys-containing linker.

A.2. Construction of pCB2:

Primers CA2F and CB1R were used to introduce linker 2 at the 5' end of the heavy chain coding sequence and the same conditions as described in section A1. The resulting PCR product was 750 bp and cloned into VAE051-pASK116 as described in section A.1.

A.3. Construction of pCC2:

Plasmid pCC2 was constructed in a two step procedure: A first PCR product of 754 bp was amplified using primers CA2F and CC1R. A second PCR product of 560 bp was produced using primers CC1F and CC2R. For both PCRs VAE051-pASK116 was used as template and conditions were as described in section A1. Both PCR products were isolated from agarose gels, mixed with primers CA2F and CC2R and a third PCR was performed that resulted in a 1298 bp fragment. This fragment was isolated and digested with XhoI and NcoI. The resulting 780 bp fragment was cloned into VAE-pASK100 as described in section A.1.

B. Expression of mimobodies

Competent *E. coli* W3110 cells were transformed with plasmids pCA2, pCB2 and pCC2. Single colonies from chloramphenicol agarose plates were expanded in liquid culture (LB + 15 µg/ml chloramphenicol) overnight at 37°C. 1 l of TB medium was then inoculated 1:50 v/v with the overnight culture and grown to OD₆₀₀=3 at 28°C. Expression was induced with 1 mg/l anhydrotetracyclin. Cells were harvested after overnight culture and centrifuged at 6000 rpm. Periplasma was isolated from cell pellets by incubation in lysis buffer supplemented with polymyxin B sulfate for 2 h at 4°C. Spheroblasts were separated by centrifugation at 6000 rpm. The resulting supernatant contained the mimobody and was dialysed against 20 mM Tris, pH 8.0.

C. Purification of mimobodies

The introduced his6-tag allowed the purification of mimobody pCA2 and pCB2 by chromatography on Ni-NTA fast flow (Qiagen) according the recommendations of the manufacturer. If necessary, a polishing step on a protein G fast flow column (Amersham Pharmacia Biotech) followed. Mimobodies were eluted with 0.1 M glycine pH 2.7, immediately neutralized by addition of NaOH and dialysed against 20 mM Hepes, 150 mM NaCl, pH 7.2. pCC2 was purified by affinity chromatography on protein G only. Purity was analysed by SDS-PAGE.

The protein sequences of the mimobodies were translated from the cDNA sequences. N-terminal sequences were confirmed by Edman sequencing of pCA2 and pCB2.

The sequence of the light chains of pCA2, pCB2 and pCC2 is the same and as follows:

-208-

DIELVVTQPASVSGSPGQSITISCTGTRSDVGGYNYVSWYQQHPGKAPKL
 MIYDVSNRPSGVSNRFGSGKSGNTASLTISGLQAEDEADYYCSSYTSSSTL
 GVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVT
 VAWKADSSPVKAGVETTTTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQ
 VTHEGSTVEKTVAPTECS

The sequence of the heavy chain of pCA2 is:

EVKLQLEHHHHHHGEVKLQLESGPGLVKPSETLSLTCTVSGGSISSGGYY
 WTWIRQRPKGKLEWIGYIYSGSTSYNPSLKSRVTMSVDTSKNQFSLRLT
 SVTAADTAVYYCARERGETGLYYPYYYIDVWGTGTTVTVSSASTKGPSV
 FPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQ
 SSGLYSLSSVVTVPSSSLGTQTYICNVNHNKPSNTKVDKRVEPKSCDKTHTC
 G

The sequence of the heavy chain of pCB2 is:

EVKLQLEHHHHHHGEVKLQLESGPGLVKPSETLSLTCTVSGGSISSGGYY
 WTWIRQRPKGKLEWIGYIYSGSTSYNPSLKSRVTMSVDTSKNQFSLRLT
 SVTAADTAVYYCARERGETGLYYPYYYIDVWGTGTTVTVSSASTKGPSV
 FPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQ
 SSGLYSLSSVVTVPSSSLGTQTYICNVNHNKPSNTKVDKRVEPKSCDKTHTS
 PPCG

The sequence of the heavy chain of pCC2 is:

EVKLQLEHHHHHHGEVKLQLESGPGLVKPSETLSLTCTVSGGSISSGGYY
 WTWIRQRPKGKLEWIGYIYSGSTSYNPSLKSRVTMSVDTSKNQFSLRLT
 SVTAADTAVYYCARERGETGLYYPYYYIDVWGTGTTVTVSSASTKGPSV
 FPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQ
 SSGLYSLSSVVTVPSSSLGTQTYICNVNHNKPSNTKVDKRVEPKSCASPKPS
 TPPGSSGGAPGGC

D. Coupling of mimobodies to Q β capsid protein

D.1. Coupling of mimobody pCC2 to Q β capsid protein:

-209-

A solution of 1.25 ml of 4.5 mg/ml Q β capsid protein in 20 mM Hepes, 150 mM NaCl pH 7.2 was reacted for 30 minutes with 40 μ l of a SMPH solution (Pierce) (from a 100 mM stock solution dissolved in DMSO) at 25 °C on a rocking shaker. The reaction solution was subsequently dialyzed twice for 2 hours against 2 l of 20 mM Hepes, 150 mM NaCl, pH 7.2 at 4 °C. 6 μ l of the dialyzed reaction mixture was then reacted with 30 μ l of the pCC2 solution (2.88 mg/ml) for at 25 °C over night on a rocking shaker.

The reaction products were analysed on 16% SDS-PAGE gels under reducing conditions. Gels were either stained with Coomassie Brilliant Blue or blotted onto nitrocellulose membranes. Membranes were blocked, incubated with a polyclonal rabbit anti-Q β antiserum (dilution 1:2000) or a mouse monoclonal anti-Fab-mAb (Jackson ImmunoResearch) (dilution 1:2000). Blots were subsequently incubated with horse radish peroxidase-conjugated goat anti-rabbit IgG or horse radish peroxidase-conjugated goat anti-mouse IgG (dilutions 1:7000), respectively

The results are shown in FIG 13A. Coupling products and educts were analysed on 16% SDS-PAGE gels under reducing conditions. In FIG. 13A "pCC2" corresponds to the mimobody before coupling. "Q β deriv" stands for derivatized Q β before coupling, "Q β -pCC2" for the product of the coupling reaction. Gels were either stained with Coomassie Brilliant Blue or blotted onto nitrocellulose membranes. Membranes were blocked, incubated with a polyclonal rabbit anti-Q β antiserum (dilution 1:2000) or an mouse monoclonal anti-Fab-mAb (Jackson ImmunoResearch) (dilution 1:2000). Blots were subsequently incubated with horse radish peroxidase-conjugated goat anti-rabbit IgG or horse radish peroxidase-conjugated goat anti-mouse IgG (dilutions 1:7000), respectively. Enhanced chemoluminescence (Amersham Pharmacia ELC kit) was used to visualize the immunoreactive bands. Molecular weights of marker proteins are given on the left margin.

A coupling product of about 40 kDa could be detected (FIG. 13A, arrows). Its reactivity with the anti-Q β antiserum and the anti-Fab

-210-

antibody recognizing the mimobody clearly demonstrated the covalent coupling of the mimobody to Q β .

D.2. Coupling of mimobodies pCA2 and pCB2 to Q β capsid protein:

A solution of 1.25 ml of 4.5 mg/ml Q β capsid protein in 20 mM Hepes, 150 mM NaCl pH 7.4 was reacted for 30 minutes with 40 μ l of a SMPH (Pierce) (from a 100 mM stock solution dissolved in DMSO) at 25 °C on a rocking shaker. The reaction solution was subsequently dialyzed twice for 2 hours against 2 l of 20 mM Hepes, 150 mM NaCl, pH 7.2 at 4 °C. pCA2 (1.2 mg/ml) was reduced with 20 mM TCEP for 30 min at 25°C, pCB2 (4.2 mg/ml) with 50 mM mercaptoethylamine at 37°C. Both mimobodies were then dialyzed twice against 20 mM Hepes, 150 mM NaCl, pH 7.2 at 4 °C. Coupling was performed by adding 6 μ l of derivatized Q β to 30 μ l of mimobody at 25°C over night on a rocking shaker.

The reaction products were analysed on 16% SDS-PAGE gels under reducing conditions. Gels were either stained with Coomassie Brilliant Blue or blotted onto nitrocellulose membranes. Membranes were blocked, incubated with a polyclonal rabbit anti-Q β antiserum (Cytos, dilution 1:2000) or an mouse monoclonal anti-his6-mAb (Qiagen) (dilution 1:5000). Blots were subsequently incubated with horse radish peroxidase-conjugated goat anti-rabbit IgG or horse radish peroxidase-conjugated goat anti-mouse IgG (dilutions 1:5000), respectively.

The results are shown in FIG. 13B and FIG. 13C. Coupling products and educts were analysed on 16% SDS-PAGE gels under reducing conditions. In FIG.15A and FIG.15B "pCA2" and "pCB2" corresponds to the mimobodies before coupling. "Q β deriv" stands for derivatized Q β before coupling and "Q β -pCA2" and "Q β -pCB2" for the products of the coupling reaction. Gels were either stained with Coomassie Brilliant Blue or blotted onto nitrocellulose membranes. Membranes were blocked, incubated with a polyclonal rabbit anti-Q β antiserum (dilution

-211-

1:2000) or an mouse monoclonal anti-his6-mAb (Qiagen) (dilution 1:5000). Blots were subsequently incubated with horse radish peroxidase-conjugated goat anti-rabbit IgG or horse radish peroxidase-conjugated goat anti-mouse IgG (dilutions 1:5000), respectively. Enhanced chemoluminescence (Amersham Pharmacia ECL kit) was used to visualize the immunoreactive bands. Molecular weights of marker proteins are given on the left margin.

Coupling products of about 40 kDa could be detected for both the pCA2 and the pCB2 coupling (FIG.15A and FIG.15B, arrows). Its reactivity with the anti-Q β antiserum and the anti-his6 antibody recognizing the heavy chain of the mimobody clearly demonstrated the covalent coupling of the mimobody to Q β .

EXAMPLE 56

Coupling of Flag peptides to wt and mutant Q β capsid protein using the cross-linker Sulfo-GMBS

The Flag peptide, to which a CGG sequence was added N-terminally for coupling, was chemically synthesized and had the following sequence: CGGDYKDDDDK. This peptide was used for chemical coupling to wt Q β capsid protein and the Q β mutants capsid protein as described in the following.

E. Coupling of Flag peptide to Q β capsid protein

_____ A solution of 100 μ l of 2 mg/ml Q β capsid protein in 20 mM Hepes, 150 mM NaCl pH 7.2 was reacted for 60 minutes with 7 μ l of a solution of 65 mM Sulfo-GMBS (Pierce) in H₂O at 25 °C on a rocking shaker. The reaction solution was subsequently dialyzed twice for 2 hours against 2 L of 20 mM Hepes, 150 mM NaCl, pH 7.2 at 4 °C. 100 μ l of the dialyzed reaction mixture was then reacted with 0.58 μ l of 100 mM Flag peptide stock solution (in H₂O) for two hours at 25 °C on a rocking shaker. The reaction mixture was subsequently dialyzed 2x 2 hours against 2 liters of 20 mM Hepes, 150 mM NaCl, pH 7.4 at 4 °C.

B. Coupling of Flag peptide to Q β -240 capsid protein

_____ A solution of 100 μ l of 2 mg/ml Q β -240 capsid protein in 20 mM Hepes, 150 mM NaCl pH 7.2 was reacted for 60 minutes with 7 μ l of a solution of

-212-

65 mM Sulfo-GMBS (Pierce) in H₂O at 25 °C on a rocking shaker. The reaction solution was subsequently dialyzed twice for 2 hours against 2 L of 20 mM Hepes, 150 mM NaCl, pH 7.2 at 4 °C. 100 µl of the dialyzed reaction mixture was then reacted with 0.58 µl of 100 mM Flag peptide stock solution (in H₂O) for two hours at 25 °C on a rocking shaker. The reaction mixture was subsequently dialyzed 2x 2 hours against 2 liters of 20 mM Hepes, 150 mM NaCl, pH 7.2 at 4 °C.

C. Coupling of Flag peptides to Qβ-250 capsid protein

_____ A solution of 100 µl of 2 mg/ml Qβ-250 capsid protein in 20 mM Hepes, 150 mM NaCl pH 7.4 was reacted for 60 minutes with 7 µl of a solution of 65 mM Sulfo-GMBS (Pierce) in H₂O at 25 °C on a rocking shaker. The reaction solution was subsequently dialyzed twice for 2 hours against 2 L of 20 mM Hepes, 150 mM NaCl, pH 7.2 at 4 °C. 100 µl of the dialyzed reaction mixture was then reacted with 0.58 µl of 100 mM Flag peptide stock solution (in H₂O) for two hours at 25 °C on a rocking shaker. The reaction mixture was subsequently dialyzed 2x 2 hours against 2 liters of 20 mM Hepes, 150 mM NaCl, pH 7.2 at 4 °C.

D. Coupling of Flag peptides to Qβ-259 capsid protein

_____ A solution of 100 µl of 2 mg/ml Qβ-259 capsid protein in 20 mM Hepes, 150 mM NaCl pH 7.4 was reacted for 60 minutes with 7 µl of a solution of 65 mM Sulfo-GMBS (Pierce) in H₂O at 25 °C on a rocking shaker. The reaction solution was subsequently dialyzed twice for 2 hours against 2 L of 20 mM Hepes, 150 mM NaCl, pH 7.4 at 4 °C. 100 µl of the dialyzed reaction mixture was then reacted with 0.58 µl of 100 mM Flag peptide stock solution (in H₂O) for two hours at 25 °C on a rocking shaker. The reaction mixture was subsequently dialyzed 2x 2 hours against 2 liters of 20 mM Hepes, 150 mM NaCl, pH 7.4 at 4 °C.

The results of the coupling reactions of the Qβ mutants 240, 250 and 259 to Flag peptide analyzed by SDS-PAGE are shown in FIG. 22 A. The loading pattern was the following:

-213-

1. Derivatized Q β -240
2. Q β -240 coupled to the Flag peptide
3. Derivatized Q β -250
4. Q β -250 coupled to the Flag peptide
5. Derivatized Q β -259
6. Q β -259 coupled to the Flag peptide
7. Derivatized wt Q β
8. wt Q β coupled to the Flag peptide
9. Protein Marker.

Comparison of the derivatized reaction with the coupling reactions shows that for all the mutants and wt, coupling bands corresponding to 1 and 2 peptides per subunit are visible. The band corresponding to the uncoupled Q β subunit is very weak, indicating that nearly all subunits have reacted with at least one Flag peptide. For the Q β -250 mutant and wt Q β , a band corresponding to three peptides per subunit is visible. The ratio of the intensities of the band corresponding to two peptides per subunit and the band corresponding to 1 peptide per subunit is strongest for wt, with a ratio of 1:1. this ratio is still high for the Q β -250 mutant, while it is significantly weaker for the Q β -240 mutant and weakest for the Q β -259 mutant.

EXAMPLE 57

Coupling of Flag peptide to Q β capsid protein using the cross-linker Sulfo-MBS

The Flag peptide, to which a CGG sequence was added N-terminally for coupling, was chemically synthesized and had the following sequence: CGGDYKDDDDK. This peptide was used for chemical coupling to wt Q β capsid protein and the Q β mutant capsid protein as described in the following.

F. Coupling of Flag peptides to Q β capsid protein

A solution of 100 μ l of 2 mg/ml Q β capsid protein in 20 mM Hepes, 150 mM NaCl pH 7.2 was reacted for 60 minutes with 7 μ l of a solution of 65 mM Sulfo-MBS (Pierce) in H₂O at 25 °C on a rocking shaker. The reaction solution was subsequently dialyzed twice for 2 hours against 2 L of 20 mM Hepes, 150 mM NaCl, pH 7.2 at 4 °C. 100 μ l of the dialyzed reaction mixture was then reacted with 0.58 μ l of 100 mM Flag peptide stock solution (in H₂O) for two hours at 25 °C on a rocking shaker. The reaction mixture was subsequently dialyzed 2x 2 hours against 2 liters of

-214-

20 mM Hepes, 150 mM NaCl, pH 7.2 at 4 °C.

B. Coupling of Flag peptide to Q β -240 capsid protein

_____ A solution of 100 μ l of 2 mg/ml Q β -240 capsid protein in 20 mM Hepes, 150 mM NaCl pH 7.2 was reacted for 60 minutes with 7 μ l of a solution of 65 mM Sulfo-MBS (Pierce) in H₂O at 25 °C on a rocking shaker. The reaction solution was subsequently dialyzed twice for 2 hours against 2 L of 20 mM Hepes, 150 mM NaCl, pH 7.2 at 4 °C. 100 μ l of the dialyzed reaction mixture was then reacted with 0.58 μ l of 100 mM Flag peptide stock solution (in H₂O) for two hours at 25 °C on a rocking shaker. The reaction mixture was subsequently dialyzed 2x 2 hours against 2 liters of 20 mM Hepes, 150 mM NaCl, pH 7.4 at 4 °C.

C. Coupling of Flag peptide to Q β -250 capsid protein

_____ A solution of 100 μ l of 2 mg/ml Q β -250 capsid protein in 20 mM Hepes, 150 mM NaCl pH 7.2 was reacted for 60 minutes with 7 μ l of a solution of 65 mM Sulfo-MBS (Pierce) in H₂O at 25 °C on a rocking shaker. The reaction solution was subsequently dialyzed twice for 2 hours against 2 L of 20 mM Hepes, 150 mM NaCl, pH 7.2 at 4 °C. 100 μ l of the dialyzed reaction mixture was then reacted with 0.58 μ l of 100 mM Flag peptide stock solution (in H₂O) for two hours at 25 °C on a rocking shaker. The reaction mixture was subsequently dialyzed 2x 2 hours against 2 liters of 20 mM Hepes, 150 mM NaCl, pH 7.2 at 4 °C.

D. Coupling of Flag peptides to Q β -259 capsid protein

_____ A solution of 100 μ l of 2 mg/ml Q β -259 capsid protein in 20 mM Hepes, 150 mM NaCl pH 7.2 was reacted for 60 minutes with 7 μ l of a solution of 65 mM Sulfo-MBS (Pierce) in H₂O at 25 °C on a rocking shaker. The reaction solution was subsequently dialyzed twice for 2 hours against 2 L of 20 mM Hepes, 150 mM NaCl, pH 7.2 at 4 °C. 100 μ l of the dialyzed reaction mixture was then reacted with 0.58 μ l of 100 mM Flag

-215-

peptide stock solution (in H₂O) for two hours at 25 °C on a rocking shaker. The reaction mixture was subsequently dialyzed 2x 2 hours against 2 liters of 20 mM Hepes, 150 mM NaCl, pH 7.2 at 4 °C.

The results of the coupling reactions of the Q β mutants 240, 250 and 259 to Flag peptide analyzed by SDS-PAGE are shown in Figure 1. The loading pattern was the following:

1. Protein Marker 2. Derivatized Q β -240 3. Q β -240 coupled to the Flag peptide 4. Derivatized Q β -250 5. Q β -250 coupled to the Flag peptide 6. Derivatized Q β -259 7. Q β -259 coupled to the Flag peptide 8. Derivatized wt Q β 9. wt Q β coupled to the Flag peptide.

Comparison of the derivatized reaction with the coupling reactions shows that for all the mutants and wt, a coupling band corresponding to 1 peptide per subunit is visible. Bands corresponding to 2 peptides per subunit are also visible for the mutant Q β -250 and wt Q β . The ratio of the intensities of the band corresponding to 1 peptide per subunit and to the uncoupled subunit, respectively, is higher for the Q β -250 mutant and wt Q β . A weak band corresponding to two peptides per subunit is visible for the Q β -240 mutant.

EXAMPLE 58

Coupling of Flag peptides to Q β mutants using the cross-linker SMPH

The Flag peptide, to which a CGG sequence was added N-terminally for coupling, was chemically synthesized and had the following sequence: CGGDYKDDDDK. This peptide was used for chemical coupling to the Q β mutants as described in the following.

A Coupling of Flag peptides to Q β -240 capsid protein

A solution of 100 μ l of 2 mg/ml Q β -240 capsid protein in 20 mM Hepes, 150 mM NaCl pH 7.4 was reacted for 30 minutes with 2.94 μ l of a solution of 100 mM SMPH (Pierce) in DMSO at 25 °C on a rocking shaker. The reaction solution was subsequently dialyzed twice for 2 hours against 2 L of 20 mM Hepes, 150 mM NaCl, pH 7.4 at 4 °C. 90 μ l of the

-216-

dialyzed reaction mixture was then reacted with 1.3 μ l of 50 mM Flag peptide stock solution (in DMSO) for two hours at 25 °C on a rocking shaker. The reaction mixture was subsequently dialyzed 2x 2 hours against 2 liters of 20 mM Hepes, 150 mM NaCl, pH 7.4 at 4 °C.

B. Coupling of Flag peptide to Q β -250 capsid protein

_____ A solution of 100 μ l of 2 mg/ml Q β -250 capsid protein in 20 mM Hepes, 150 mM NaCl pH 7.4 was reacted for 30 minutes with 2.94 μ l of a solution of 100 mM SMPH (Pierce) in DMSO at 25 °C on a rocking shaker. The reaction solution was subsequently dialyzed twice for 2 hours against 2 L of 20 mM Hepes, 150 mM NaCl, pH 7.4 at 4 °C. 90 μ l of the dialyzed reaction mixture was then reacted with 1.3 μ l of 50 mM Flag peptide stock solution (in DMSO) for two hours at 25 °C on a rocking shaker. The reaction mixture was subsequently dialyzed 2x 2 hours against 2 liters of 20 mM Hepes, 150 mM NaCl, pH 7.4 at 4 °C.

C. Coupling of Flag peptide to Q β -259 capsid protein

_____ A solution of 100 μ l of 2 mg/ml Q β -259 capsid protein in 20 mM Hepes, 150 mM NaCl pH 7.4 was reacted for 30 minutes with 2.94 μ l of a solution of 100 mM SMPH (Pierce) in DMSO at 25 °C on a rocking shaker. The reaction solution was subsequently dialyzed twice for 2 hours against 2 L of 20 mM Hepes, 150 mM NaCl, pH 7.4 at 4 °C. 90 μ l of the dialyzed reaction mixture was then reacted with 1.3 μ l of 50 mM Flag peptide stock solution (in DMSO) for two hours at 25 °C on a rocking shaker. The reaction mixture was subsequently dialyzed 2x 2 hours against 2 liters of 20 mM Hepes, 150 mM NaCl, pH 7.4 at 4 °C.

The results of the coupling reactions of the Q β mutants 240, 250 and 259 to Flag peptide analyzed by SDS-PAGE are shown in Figure 1. The loading pattern was the following. 1. Protein Marker 2. Q β -240 coupled to Flag, pellet of the coupling reaction 3. Q β -240 coupled to Flag, Supernatant of the coupling reaction 4. Q β -240 derivatized with SMPH 5.

-217-

Q β -250 coupled to Flag, pellet of the coupling reaction 6. Q β -250 coupled to Flag, supernatant of the coupling reaction 7. Q β -250 derivatized with SMPH 8. Q β -259 coupled to Flag, pellet of the coupling reaction 9. Q β -259 coupled to Flag, supernatant of the coupling reaction 10. Q β -259 derivatized with SMPH.

Comparison of the derivatized reaction with the coupling reactions shows that for all the mutants, coupling bands corresponding to 1, respectively 2 peptides per subunits are visible. Bands corresponding to three, respectively four peptides per subunit are also visible for the mutant Q β -250.

EXAMPLE 59

Coupling of PLA₂-Cys protein to mutant Q β capsid proteins

Lyophilized mutant Q β capsid proteins were swollen overnight in 20 mM Hepes, 150 mM NaCl, pH 7.4.

A. Coupling of PLA₂-Cys protein to Q β -240 capsid protein.

A solution of 100 μ l of 2 mg/ml Q β -240 capsid protein in 20 mM Hepes, 150 mM NaCl pH 7.4 was reacted for 30 minutes with 2.94 μ l of a solution of 100 mM SMPH (Pierce) in DMSO at 25 °C on a rocking shaker. The reaction solution was subsequently dialyzed twice for 2 hours against 2 L of 20 mM Hepes, 150 mM NaCl, pH 7.4 at 4 °C. 90 μ l of the dialyzed reaction mixture was mixed with 146 μ l 20 mM Hepes, 150 mM NaCl, pH 7.4 and reacted with 85.7 μ l of 2.1 mg/ml PLA₂-Cys stock solution for four hours at 25 °C on a rocking shaker. The reaction mixture was subsequently dialyzed 2x 2 hours against 2 liters of 20 mM Hepes, 150 mM NaCl, pH 7.4 at 4 °C.

B. Coupling of PLA₂-Cys protein to Q β -250 capsid protein

A solution of 100 μ l of 2 mg/ml Q β -250 capsid protein in 20 mM Hepes, 150 mM NaCl pH 7.4 was reacted for 30 minutes with 2.94 μ l of a solution of 100 mM SMPH (Pierce) in DMSO at 25 °C on a rocking

-218-

shaker. The reaction solution was subsequently dialyzed twice for 2 hours against 2 L of 20 mM Hepes, 150 mM NaCl, pH 7.4 at 4 °C. 90 µl of the dialyzed reaction mixture was mixed with 146 µl 20 mM Hepes, 150 mM NaCl, pH 7.4 and reacted with 85.7 µl of 2.1 mg/ml PLA₂-Cys stock solution for four hours at 25 °C on a rocking shaker. The reaction mixture was subsequently dialyzed 2x 2 hours against 2 liters of 20 mM Hepes, 150 mM NaCl, pH 7.4 at 4 °C.

C. Coupling of PLA₂-Cys protein to Qβ-259 capsid protein

A solution of 100 µl of 2 mg/ml Qβ-259 capsid protein in 20 mM Hepes, 150 mM NaCl pH 7.4 was reacted for 30 minutes with 2.94 µl of a solution of 100 mM SMPH (Pierce) in DMSO at 25 °C on a rocking shaker. The reaction solution was subsequently dialyzed twice for 2 hours against 2 L of 20 mM Hepes, 150 mM NaCl, pH 7.4 at 4 °C. 90 µl of the dialyzed reaction mixture was mixed with 146 µl 20 mM Hepes, 150 mM NaCl, pH 7.4 and reacted with 85.7 µl of 2.1 mg/ml PLA₂-Cys stock solution for four hours at 25 °C on a rocking shaker. The reaction mixture was subsequently dialyzed 2x 2 hours against 2 liters of 20 mM Hepes, 150 mM NaCl, pH 7.4 at 4 °C.

The results of the coupling experiment analyzed by SDS-PAGE are shown in Figure 1. The loading pattern was the following: 1. Protein Marker 2. derivatized Qβ-240 3. Qβ-240 coupled to Pla2Cys, supernatant of the coupling reaction 4. Qβ-240 coupled to PLA₂-Cys, pellet of the coupling reaction 5. derivatized Qβ-250 6. Qβ-250 coupled to PLA₂-Cys, supernatant of the coupling reaction 7. Qβ-250 coupled to PLA₂-Cys, pellet of the coupling reaction 8. derivatized Qβ-259 9. Qβ-259 coupled to PLA₂-Cys, supernatant of the coupling reaction 10. Qβ-259 coupled to PLA₂-Cys, pellet of the coupling reaction 11. PLA₂-Cys.

Coupling bands (indicated by the arrow in the figure) were visible for all the mutants, showing that PLA₂-Cys protein could be coupled to all of the mutant Qβ capsid proteins.

-219-

1 All patents and publications referred to herein are expressly incorporated by reference.

-220-

2 The entire disclosure of U.S. Application No. 09/449,631 and WO 00/3227, both filed November 30, 1999, are herein incorporated by reference in their entirety. All publications and patents mentioned hereinabove are hereby incorporated in their entireties by reference.

WHAT IS CLAIMED IS:

1. A composition comprising:
 - (a) a non-natural molecular scaffold comprising:
 - (i) a core particle, and
 - (ii) an organizer comprising at least one first attachment site, wherein said organizer is connected to said core particle by at least one covalent bond, and wherein said core particle is a virus-like particle comprising recombinant proteins, or fragments thereof, of a bacteriophage;
 - (b) an antigen or antigenic determinant with at least one second attachment site, said second attachment site being selected from the group consisting of:
 - (i) an attachment site not naturally occurring with said antigen or antigenic determinant; and
 - (ii) an attachment site naturally occurring with said antigen or antigenic determinant,wherein said second attachment site is capable of association through at least one non-peptide bond to said first attachment site; and wherein said antigen or antigenic determinant and said scaffold interact through said association to form an ordered and repetitive antigen array.
2. The composition of claim 1, wherein said association is by way of at least one covalent bond.
3. The composition of claim 1, wherein said first attachment site is a lysine residue and said second attachment site is a cysteine residue.
4. The composition of claim 1, wherein said second attachment site comprises or is a sulfhydryl group or a cysteine residue.
5. The composition of claim 1, wherein said bacteriophage is a RNA-phage.
6. The composition of claim 5, wherein said RNA-phage is selected from the group consisting of:
 - a) bacteriophage Q β ;
 - b) bacteriophage R17;
 - c) bacteriophage fr;

-222-

- d) bacteriophage GA;
- e) bacteriophage SP;
- f) bacteriophage MS2;
- g) bacteriophage M11;
- h) bacteriophage MX1;
- i) bacteriophage NL95;
- k) bacteriophage f2; and
- l) bacteriophage PP7.

7. The composition of claim 5, wherein said recombinant proteins comprise coat proteins having an amino acid sequence selected from the group consisting of:

- a) the amino acid sequence of SEQ ID NO:159;
- b) the amino acid sequence of SEQ ID NO:160;
- c) the amino acid sequence of SEQ ID NO:161;
- d) the amino acid sequence of SEQ ID NO:162;
- e) the amino acid sequence of SEQ ID NO:163;
- f) the amino acid sequence of SEQ ID NO:164;
- g) the amino acid sequence of SEQ ID NO:165;
- h) the amino acid sequence of SEQ ID NO:166;
- i) the amino acid sequence of SEQ ID NO:167;
- j) the amino acid sequence of SEQ ID NO:215;
- k) the amino acid sequence of SEQ ID NO: 253;
- l) the amino acid sequence of SEQ ID NO: 217 and mutants thereof; and
- m) the amino acid sequence of SEQ ID NO: 254.

8. The composition of claim 5, wherein said recombinant proteins comprise mutant coat proteins.

9. The composition of claim 8, wherein said mutant coat proteins have been modified by removal of at least one lysine residue by way of substitution, or by addition of at least one lysine residue by way of substitution.

10. The composition of claim 8, wherein said mutant coat proteins have been modified by deletion of at least one lysine residue, or by addition of at least one lysine residue by way of insertion.

11. The composition of claim 1, wherein said bacteriophage is bacteriophage Q β .

12. The composition of claim 1, wherein said bacteriophage is bacteriophage fr.
13. The composition of claim 11, wherein said recombinant proteins comprise coat proteins having an amino acid sequence of SEQ ID NO:159, or a mixture of coat proteins having amino acid sequences of SEQ ID NO:159 and of SEQ ID NO: 217 or mutants of SEQ ID NO: 217.
14. The composition of claim 1, wherein said core particle is a virus-like particle of bacteriophage Q β essentially consisting of coat proteins having an amino acid sequence of SEQ ID NO:159, or essentially consisting of a mixture of coat proteins having amino acid sequences of SEQ ID NO: 217, or mutants thereof, and of SEQ ID NO:159.
15. The composition of claim 11, wherein said recombinant proteins comprise mutant Q β coat proteins.
16. The composition of claim 15, wherein said mutant Q β coat proteins have been modified by removal of at least one lysine residue by way of substitution, or by addition of at least one lysine residue by way of substitution.
17. The composition of claim 15, wherein said mutant coat proteins have been modified by deletion of at least one lysine residue, or by addition of at least one lysine residue by way of insertion.
18. The composition of claim 15, wherein said mutant Q β coat proteins comprise proteins having an amino acid sequence selected from the group consisting of:
 - a) the amino acid sequence of SEQ ID NO:255;
 - b) the amino acid sequence of SEQ ID NO:256;
 - c) the amino acid sequence of SEQ ID NO:257;
 - d) the amino acid sequence of SEQ ID NO:258; and
 - e) the amino acid sequence of SEQ ID NO:259.
19. The composition of claim 1, wherein said core particle is a virus-like particle of bacteriophage Q β essentially consisting of mutant Q β coat proteins having an amino acid sequence selected from the group consisting of:
 - a) the amino acid sequence of SEQ ID NO:255;

-224-

- b) the amino acid sequence of SEQ ID NO:256;
- c) the amino acid sequence of SEQ ID NO:257;
- d) the amino acid sequence of SEQ ID NO:258;
- e) the amino acid sequence of SEQ ID NO:259; and
- f) a mixture of either a)-e) and the corresponding A1 protein.

20. The composition of claim 11, wherein said organizer is an integral part of said bacteriophage Q β or said bacteriophage fr.

21. The composition of claim 1, wherein said core particle is a virus-like particle composed of recombinant proteins of a bacteriophage.

22. The composition of claim 1, wherein said first and/or said second attachment sites comprise:

- (a) an antigen and an antibody or antibody fragment thereto;
- (b) biotin and avidin;
- (c) strepavidin and biotin;
- (d) a receptor and its ligand;
- (e) a ligand-binding protein and its ligand;
- (f) interacting leucine zipper polypeptides;
- (g) an amino group and a chemical group reactive thereto;
- (h) a carboxyl group and a chemical group reactive thereto;
- (i) a sulfhydryl group and a chemical group reactive thereto; or
- (j) a combination thereof.

23. The composition of claim 1, wherein said first attachment site is an amino group and said second attachment site is a sulfhydryl group.

24. The composition of claim 1, wherein said first attachment site is a lysine residue and said second attachment site is a cysteine residue.

25. The composition of claim 1, wherein said second attachment site does not naturally occur within said antigen or antigenic determinant.

-225-

26. The composition of claim 25, wherein said first attachment site is an amino group and said second attachment site is a sulfhydryl group.
27. The composition of claim 25, wherein said first attachment site is a lysine residue and said second attachment site is a cysteine residue.
28. The composition of claim 25, wherein said second attachment site comprises or is a sulfhydryl group or a cysteine residue.
29. The composition of claim 25, wherein said composition comprises an amino acid linker.
30. The composition of claim 29, wherein said amino acid linker is bound to said antigen or said antigenic determinant by way of at least one covalent bond.
31. The composition of claim 29, wherein said amino acid linker comprises, or alternatively consist of, said second attachment site.
32. The composition of claim 31, wherein said amino acid linker comprises a sulfhydryl group or a cysteine residue.
33. The composition of claim 31, wherein said amino acid linker is selected from the group consisting of:
- (a) CGG
 - (b) N-terminal gamma 1-linker;
 - (c) N-terminal gamma 3-linker;
 - (d) Ig hinge regions;
 - (e) N-terminal glycine linkers;
 - (f) $(G)_kC(G)_n$ with $n=0-12$ and $k=0-5$;
 - (g) N-terminal glycine-serine linkers
 - (h) $(G)_kC(G)_m(S)_l(GGGGS)_n$ with $n=0-3$, $k=0-5$, $m=0-10$, $l=0-2$;
 - (i) GGC
 - (k) GGC-NH₂
 - (l) C-terminal gamma 1-linker

-226-

- (m) C-terminal gamma 3-linker
- (n) C-terminal glycine linkers
- (o) $(G)_n C(G)_k$ with $n=0-12$ and $k=0-5$;
- (p) C-terminal glycine-serine linkers
- (q) $(G)_m (S)_l (GGGGS)_n (G)_o C(G)_k$ with $n=0-3$, $k=0-5$, $m=0-10$, $l=0-2$, and $o=0-8$.

34. The composition of claim 1, wherein said antigen or said antigenic determinant is a self antigen or a fragment thereof, or an anti-idiotypic antibody or an anti-idiotypic antibody fragment.

35. The composition of claim 34, wherein said self antigen is a protein, a peptide or fragments thereof, selected from the group consisting of:

- a) a lymphotoxin;
- b) a lymphotoxin receptor;
- c) RANKL;
- d) VEGF;
- e) VEGFR;
- f) Interleukin 5;
- g) Interleukin 17;
- h) Interleukin 13;
- i) Angiotensin;
- k) CCL21;
- l) CXCL12;
- m) SDF-1;
- n) MCP-1;
- o) Endoglin;
- p) Resistin;
- q) GHRH;
- r) LHRH;
- s) TRH;
- t) MIF;
- u) Eotaxin;
- v) Bradykinin;
- w) BLC;
- x) Tumor Necrosis Factor α (TNF α);
- y) amyloid beta peptide (A β_{1-42}); and
- z) a human IgE.

36. The composition of claim 34, wherein said self antigen is an angiotensin peptide or a fragment thereof.

37. The composition of claim 36, wherein said second attachment site does not naturally occur within said antigen or antigenic determinant.

38. The composition of claim 36, wherein said second attachment site comprises or is a sulfhydryl group or a cysteine residue.

39. The composition of claim 36, wherein said composition comprises an amino acid linker.

40. The composition of 39, wherein said amino acid linker comprises, or alternatively consist of, said second attachment site.

41. The composition of claim 40, wherein said amino acid linker comprises a sulfhydryl group or a cysteine residue.

42. The composition of claim 36, wherein said angiotensin peptide with said second attachment site has an amino acid sequence selected from the group consisting of:

- a) the amino acid sequence of CGGDRVYIHPF;
- b) the amino acid sequence of CGGDRVYIHPFHL;
- c) the amino acid sequence of DRVYIHPFHLGGC; and
- d) the amino acid sequence of CDRVYIHPFHL.

43. The composition of claim 34, wherein said self antigen is a human VEGFR-II peptide or a fragment thereof.

44. The composition of claim 43, wherein said second attachment site does not naturally occur within said antigen or antigenic determinant.

45. The composition of claim 43, wherein said second attachment site comprises or is a sulfhydryl group or a cysteine residue.

46. The composition of claim 43, wherein said composition comprises an amino acid linker.

47. The composition of claim 46, wherein said amino acid linker comprises, or alternatively consist of, said second attachment site.

48. The composition of claim 47, wherein said amino acid linker comprises a sulfhydryl group or a cysteine residue.

49. The composition of claim 43, wherein said VEGFR-II peptide with said second attachment site has an amino acid sequence of CTARTELVGIDFNWEYPSSKHQHKK.

50. The composition of claim 34, wherein said self antigen is tumor necrosis factor α (TNF- α), fragments thereof or peptides of TNF- α .

51. The composition of claim 50, wherein said second attachment site does not naturally occur within said antigen or antigenic determinant.

52. The composition of claim 50, wherein said second attachment site comprises or is a sulfhydryl group or a cysteine residue.

53. The composition of claim 50, wherein said composition comprises an amino acid linker.

54. The composition of 53, wherein said amino acid linker comprises, or alternatively consist of, said second attachment site.

55. The composition of claim 54, wherein said amino acid linker comprises a sulfhydryl group or a cysteine residue.

56. The composition of claim 50, wherein said tumor necrosis factor α (TNF- α), fragments thereof or peptides of TNF- α with said second attachment site has an amino acid sequence selected from the group consisting of:

- a) the amino acid sequence of CSSRTPSDKPVAHVVANPQAEGQ;
- b) the amino acid sequence of SSRTPSDKPVAHVVANPQAEGQGGC;
- and
- c) the amino acid sequence of CGGQLQWLNRRANA.

57. The composition of claim 34, wherein said self antigen is resistin or a fragment thereof.

58. The composition of claim 57, wherein said second attachment site does not naturally occur within said antigen or antigenic determinant.

59. The composition of claim 57, wherein said second attachment site comprises or is a sulfhydryl group or a cysteine residue.

60. The composition of claim 57, wherein said composition comprises an amino acid linker.

61. The composition of 60, wherein said amino acid linker comprises, or alternatively consist of, said second attachment site.

62. The composition of claim 61, wherein said amino acid linker comprises a sulfhydryl group or a cysteine residue.

63. The composition of claim 57, wherein said resistin protein, or fragment thereof, with said second attachment site has an amino acid sequence selected from the group consisting of:

- a) the amino acid sequence of SEQ ID NO:325;
- b) the amino acid sequence of SEQ ID NO:326; and
- c) the amino acid sequence of SEQ ID NO:327.

64. The composition of claim 34, wherein said self antigen is a lymphotoxin or a fragment thereof selected from the group consisting of:

- a) lymphotoxin α (LT α)
- b) lymphotoxin β (LT β)
- c) a mixture or combination of LT α and LT β .

65. The composition of claim 64, wherein said second attachment site does not naturally occur within said antigen or antigenic determinant.

66. The composition of claim 64, wherein said second attachment site comprises or is a sulfhydryl group or a cysteine residue.

67. The composition of claim 64, wherein said composition comprises an amino acid linker.

68. The composition of 67, wherein said amino acid linker comprises, or alternatively consist of, said second attachment site.

69. The composition of claim 68, wherein said amino acid linker comprises a sulfhydryl group or a cysteine residue.

70. The composition of claim 64, wherein self antigen is lymphotoxin β , or a fragment thereof, and wherein said lymphotoxin β with said second attachment site has an amino acid sequence selected from the group consisting of:

- a) the amino acid sequence of SEQ ID NO:346; and
- b) the amino acid sequence of SEQ ID NO:347.

71. The composition of claim 34, wherein said self antigen is human-MIF or a fragment thereof.

72. The composition of claim 71, wherein said second attachment site does not naturally occur within said antigen or antigenic determinant.

73. The composition of claim 71, wherein said second attachment site comprises or is a sulfhydryl group or a cysteine residue.

74. The composition of claim 71, wherein said composition comprises an amino acid linker.

75. The composition of claim 74, wherein said amino acid linker comprises, or alternatively consist of, said second attachment site.

76. The composition of claim 75, wherein said amino acid linker comprises a sulfhydryl group or a cysteine residue.

77. The composition of claim 71, wherein said human-MIF protein, or fragment thereof, with said second attachment site has an amino acid sequence selected from the group consisting of:

- a) the amino acid sequence of SEQ ID NO:310;
- b) the amino acid sequence of SEQ ID NO:311;
- c) the amino acid sequence of SEQ ID NO:312;
- d) the amino acid sequence of SEQ ID NO:313;
- e) the amino acid sequence of SEQ ID NO:314; and
- f) the amino acid sequence of SEQ ID NO:315.

78. The composition of claim 34, wherein said self antigen is human-RANKL or a fragment thereof.

79. The composition of claim 34, wherein said self antigen is a extracellular part of human-RANKL or a fragment thereof.

80. The composition of claim 78 or claim 79, wherein said second attachment site does not naturally occur within said antigen or antigenic determinant.

81. The composition of claim 78 or claim 79, wherein said second attachment site comprises or is a sulfhydryl group or a cysteine residue.

82. The composition of claim 78 or claim 79, wherein said composition comprises an amino acid linker.

83. The composition of 82, wherein said amino acid linker comprises, or alternatively consist of, said second attachment site.

84. The composition of claim 83, wherein said amino acid linker comprises a sulfhydryl group or a cysteine residue.

85. The composition of claim 78, wherein said human-RANKL, or fragment thereof, with said second attachment site comprises an amino acid sequence of SEQ ID NO:320 or fragments thereof.

86. The composition of claim 39, 46, 53, 60, 67, 74 or 82, wherein said amino acid linker is selected from the group consisting of:

-232-

- (a) CGG
- (b) N-terminal gamma 1-linker;
- (c) N-terminal gamma 3-linker;
- (d) Ig hinge regions;
- (e) N-terminal glycine linkers;
- (f) $(G)_k C(G)_n$ with $n=0-12$ and $k=0-5$;
- (g) N-terminal glycine-serine linkers
- (h) $(G)_k C(G)_m (S)_l (GGGGS)_n$ with $n=0-3$, $k=0-5$, $m=0-10$, $l=0-2$;
- (i) GGC
- (k) GGC-NH₂
- (l) C-terminal gamma 1-linker
- (m) C-terminal gamma 3-linker
- (n) C-terminal glycine linkers
- (o) $(G)_n C(G)_k$ with $n=0-12$ and $k=0-5$;
- (p) C-terminal glycine-serine linkers
- (q) $(G)_m (S)_l (GGGGS)_n (G)_o C(G)_k$ with $n=0-3$, $k=0-5$, $m=0-10$, $l=0-2$, and $o=0-8$.

87. A composition comprising:

- (a) a non-natural molecular scaffold comprising:
 - (i) a core particle selected from the group consisting of:
 - (1) a core particle of non-natural origin; and
 - (2) a core particle of natural origin; and
 - (ii) an organizer comprising at least one first attachment site, wherein said organizer is connected to said core particle by at least one covalent bond,;
- (b) an antigen or antigenic determinant with at least one second attachment site,

wherein said antigen or antigenic determinant is an anti-idiotypic antibody or an anti-idiotypic antibody fragment, and wherein said second attachment site being selected from the group consisting of:

 - (i) an attachment site not naturally occurring with said antigen or antigenic determinant; and

-233-

- (ii) an attachment site naturally occurring with said antigen or antigenic determinant,

wherein said second attachment site is capable of association through at least one non-peptide bond to said first attachment site; and

wherein said antigen or antigenic determinant and said scaffold interact through said association to form an ordered and repetitive antigen array.

88. The composition of claim 87, wherein said association is by way of at least one covalent bond.

89. The composition of claim 87, wherein said first attachment site is a lysine residue and said second attachment site is a cysteine residue.

90. The composition of claim 87, wherein said core particle is selected from the group consisting of:

- i) a virus;
- ii) a virus-like particle;
- iii) a bacteriophage;
- iv) a bacterial pilus;
- v) a viral capsid particle; and
- vi) a recombinant form of (i), (ii), (iii), (iv) or (v).

91. The composition of claim 87, wherein said core particle is selected from the group consisting of:

- i) a virus-like particle;
- ii) a bacterial pilus; and
- iii) a virus-like particle of a RNA-phage.

92. The composition of claim 91, wherein said virus-like particle comprising recombinant proteins, or fragments thereof, being selected from the group consisting of:

- (a) recombinant proteins of Hepatitis B virus;
- (b) recombinant proteins of measles virus;
- (c) recombinant proteins of Sindbis virus;
- (d) recombinant proteins of Rotavirus;
- (e) recombinant proteins of Foot-and-Mouth-Disease virus;
- (f) recombinant proteins of Retrovirus;

-234-

- (g) recombinant proteins of Norwalk virus;
- (h) recombinant proteins of Alphavirus;
- (i) recombinant proteins of human Papilloma virus;
- (j) recombinant proteins of Polyoma virus;
- (k) recombinant proteins of bacteriophages; and
- (l) recombinant proteins of RNA-phages;
- (m) recombinant proteins of Q β -phage;
- (n) recombinant proteins of GA-phage
- (o) recombinant proteins of fr-phage; and
- (p) recombinant proteins of Ty.

93. The composition of claim 91, wherein said virus-like particle comprising, or alternatively essentially consisting of, recombinant proteins, or fragments thereof, of a RNA-phage.

94. The composition of claim claim 91, wherein said virus-like particle comprising, or alternatively essentially consisting of, recombinant proteins, or fragments thereof, of a RNA-phage being selected from the group consisting of:

- a) bacteriophage Q β ;
- b) bacteriophage R17;
- c) bacteriophage fr;
- d) bacteriophage GA;
- e) bacteriophage SP;
- f) bacteriophage MS2;
- g) bacteriophage M11;
- h) bacteriophage MX1;
- i) bacteriophage NL95;
- k) bacteriophage f2; and
- l) bacteriophage PP7.

95. The composition of claim 105, wherein said virus-like particle comprising, or alternatively essentially consisting of, recombinant proteins, or fragments thereof, of bacteriophage Q β or bacteriophage fr.

96. The composition of claim 87, wherein said second attachment site does not naturally occur within said antigen or antigenic determinant.

97. The composition of claim 96, wherein said composition comprises an amino acid linker.

98. The composition of claim 97, wherein said amino acid linker comprises, or alternatively consists of, said second attachment site.

99. The composition of claim 98, wherein said amino acid linker comprises a sulfhydryl group or a cysteine residue.

100. A composition comprising:

(a) a non-natural molecular scaffold comprising:

(i) a core particle selected from the group consisting of:

(1) a core particle of non-natural origin; and

(2) a core particle of natural origin; and

(ii) an organizer comprising at least one first attachment site, wherein said organizer is connected to said core particle by at least one covalent bond,;

(b) an antigen or antigenic determinant with at least one second attachment site,

wherein said antigen or antigenic determinant is a self antigen or a fragment thereof, and wherein said second attachment site being selected from the group consisting of:

(i) an attachment site not naturally occurring with said antigen or antigenic determinant; and

(ii) an attachment site naturally occurring with said antigen or antigenic determinant,

wherein said second attachment site is capable of association through at least one non-peptide bond to said first attachment site; and

wherein said antigen or antigenic determinant and said scaffold interact through said association to form an ordered and repetitive antigen array.

101. The composition of claim 100, wherein said association is by way of at least one covalent bond.

102. The composition of claim 100, wherein said first attachment site is a lysine residue and said second attachment site is a cysteine residue.

103. The composition of claim 100, wherein said core particle is selected from the group consisting of:

- i) a virus;
- ii) a virus-like particle;
- iii) a bacteriophage;
- iv) a bacterial pilus;
- v) a viral capsid particle; and
- vi) a recombinant form of (i), (ii), (iii), (iv) or (v).

104. The composition of claim 103, wherein said organizer is a polypeptide or residue thereof and said second attachment site is a polypeptide or residue thereof.

105. The composition of claim 100 or claim 103, wherein said core particle is a virus-like particle.

106. The composition of claim 105, wherein said virus-like particle is a dimer or multimer of a polypeptide comprising amino acids 1-147 of SEQ ID NO:158.

107. The composition of claim 106, wherein said virus-like particle is a dimer or multimer of a polypeptide comprising amino acids 1-152 of SEQ ID NO:158.

108. The composition of claim 105, wherein said first attachment site comprises or is an amino group and said second attachment site comprises or is a sulfhydryl group.

109. The composition of claim 105, wherein said virus-like particle is a Hepatitis B virus capsid protein.

110. The composition of claim 109, wherein said first attachment site comprises or is a lysine residue and said second attachment site comprises or is a cysteine residue.

111. The composition of claim 110, wherein one or more cysteine residues of said Hepatitis B virus capsid protein have been either deleted or substituted with another amino acid residue.

112. The composition of claim 110, wherein said Hepatitis B virus capsid protein comprises an amino acid sequence selected from the group consisting of:

- a) the amino acid sequence of SEQ ID NO:89;
- b) the amino acid sequence of SEQ ID NO:90;

-237-

- c) the amino acid sequence of SEQ ID NO:93;
- d) the amino acid sequence of SEQ ID NO:98;
- e) the amino acid sequence of SEQ ID NO:99;
- f) the amino acid sequence of SEQ ID NO:102;
- g) the amino acid sequence of SEQ ID NO:104;
- h) the amino acid sequence of SEQ ID NO:105;
- i) the amino acid sequence of SEQ ID NO:106;
- j) the amino acid sequence of SEQ ID NO:119;
- k) the amino acid sequence of SEQ ID NO:120;
- l) the amino acid sequence of SEQ ID NO:123;
- m) the amino acid sequence of SEQ ID NO:125;
- n) the amino acid sequence of SEQ ID NO:131;
- o) the amino acid sequence of SEQ ID NO:132;
- p) the amino acid sequence of SEQ ID NO:134;
- q) the amino acid sequence of SEQ ID NO:157; and
- r) the amino acid sequence of SEQ ID NO:158.

113. The composition of claim 112, wherein one or more cysteine residues of said Hepatitis B virus capsid protein have been either deleted or substituted with another amino acid residue.

114. The composition of claim 113, wherein the cysteine residues corresponding to amino acids 48 and 107 in SEQ ID NO:134 have been either deleted or substituted with another amino acid residue.

115. The composition of claim 112, wherein one or more lysine residue of said Hepatitis B virus capsid protein have been either deleted or substituted with another amino acid residue.

116. The composition of claim 100, wherein said core particle is a bacterial pilus.

117. The composition of claim 116, wherein said bacterial pilus is a Type-1 pilus of *Escherichia coli*.

-238-

118. The composition of claim 117, wherein pilin subunits of said Type-1 pilus comprises the amino acid sequence shown in SEQ ID NO:146.

119. The composition of claim 100, wherein said core particle comprises a bacterial pilin polypeptide.

120. The composition of claim 119, wherein said bacterial pilin polypeptide comprises the amino acid sequence shown in SEQ ID NO:146.

121. The composition of claim 105, wherein said virus-like particle comprising recombinant proteins, or fragments thereof, being selected from the group consisting of:

- (a) recombinant proteins of Hepatitis B virus;
- (b) recombinant proteins of measles virus;
- (c) recombinant proteins of Sindbis virus;
- (d) recombinant proteins of Rotavirus;
- (e) recombinant proteins of Foot-and-Mouth-Disease virus;
- (f) recombinant proteins of Retrovirus;
- (g) recombinant proteins of Norwalk virus;
- (h) recombinant proteins of Alphavirus;
- (i) recombinant proteins of human Papilloma virus;
- (j) recombinant proteins of Polyoma virus;
- (k) recombinant proteins of bacteriophages; and
- (l) recombinant proteins of RNA-phages;
- (m) recombinant proteins of Q β -phage;
- (n) recombinant proteins of GA-phage
- (o) recombinant proteins of fr-phage; and
- (p) recombinant proteins of Ty.

122. The composition of claim 105, wherein said virus-like particle comprising, or alternatively essentially consisting of, recombinant proteins, or fragments thereof, of a RNA-phage.

123. The composition of claim 105, wherein said virus-like particle comprising, or alternatively essentially consisting of, recombinant proteins, or fragments thereof, of a RNA-phage being selected from the group consisting of:

- a) bacteriophage Q β ;
- b) bacteriophage R17;
- c) bacteriophage fr;

-239-

- d) bacteriophage GA;
- e) bacteriophage SP;
- f) bacteriophage MS2;
- g) bacteriophage M11;
- h) bacteriophage MX1;
- i) bacteriophage NL95;
- k) bacteriophage f2; and
- l) bacteriophage PP7.

124. The composition of claim 105, wherein said virus-like particle comprising, or alternatively essentially consisting of, recombinant proteins, or fragments thereof, of bacteriophage Q β or bacteriophage fr.

125. The composition of claim 100, wherein said core particle is selected from the group consisting of:

- i) a virus-like particle;
- ii) a bacterial pilus; and
- iii) a virus-like particle of a RNA-phage.

126. The composition of claim 105, 109, 112, 116, 122, 123, or 124, wherein said second attachment site does not naturally occur within said antigen or antigenic determinant.

127. The composition of claim 126, wherein said composition comprises an amino acid linker.

128. The composition of claim 127, wherein said amino acid linker is bound to said antigen or said antigenic determinant by way of at least one covalent bond.

129. The composition of claim 128, wherein said covalent bond is a peptide bond.

130. The composition of 127, wherein said amino acid linker comprises, or alternatively consist of, said second attachment site.

131. The composition of claim 130, wherein said amino acid linker comprises a sulfhydryl group or a cysteine residue.

-240-

132. The composition of claim 130, wherein said amino acid linker is selected from the group consisting of:

- (a) CGG
- (b) N-terminal gamma 1-linker;
- (c) N-terminal gamma 3-linker;
- (d) Ig hinge regions;
- (e) N-terminal glycine linkers;
- (f) $(G)_kC(G)_n$ with $n=0-12$ and $k=0-5$;
- (g) N-terminal glycine-serine linkers
- (h) $(G)_kC(G)_m(S)_l(GGGGS)_n$ with $n=0-3$, $k=0-5$, $m=0-10$, $l=0-2$;
- (i) GGC
- (k) GGC-NH₂
- (l) C-terminal gamma 1-linker
- (m) C-terminal gamma 3-linker
- (n) C-terminal glycine linkers
- (o) $(G)_nC(G)_k$ with $n=0-12$ and $k=0-5$;
- (p) C-terminal glycine-serine linkers
- (q) $(G)_m(S)_l(GGGGS)_n(G)_oC(G)_k$ with $n=0-3$, $k=0-5$, $m=0-10$, $l=0-2$, and $o=0-8$.

133. The composition of claim 100, wherein said self antigen is a protein selected from the group consisting of:

- a) a lymphotoxin;
- b) a lymphotoxin receptor;
- c) RANKL;
- d) VEGF;
- e) VEGF-R;
- f) Interleukin 5;
- g) Interleukin 17;
- h) Interleukin 13;
- i) CCL21;
- k) CXCL12;
- l) SDF-1;
- m) MCP-1;
- n) Resistin;
- o) GHRH;

-241-

- p) LHRH;
- q) TRH;
- r) MIF;
- s) Eotaxin;
- t) BLC;
- u) a human IgE.

134. The composition of claim 100, wherein said self antigen is a protein, a peptide or fragments thereof, selected from the group consisting of:

- a) a lymphotoxin;
- b) a lymphotoxin receptor;
- c) RANKL;
- d) VEGF;
- e) VEGF-R;
- f) Interleukin 5;
- g) Interleukin 17;
- h) Interleukin 13;
- i) Angiotensin;
- k) CCL21;
- l) CXCL12;
- m) SDF-1;
- n) MCP-1;
- o) Endoglin;
- p) Resistin;
- q) GHRH;
- r) LHRH;
- s) TRH;
- t) MIF;
- u) Eotaxin;
- v) Bradykinin;
- w) BLC;
- x) Tumor Necrosis Factor α (TNF α);
- y) amyloid beta peptide (A β ₁₋₄₂); and
- z) a human IgE.

135. A composition comprising:

- (a) a non-natural molecular scaffold comprising:
 - (i) a core particle selected from the group consisting of:
 - (1) a core particle of non-natural origin; and

-242-

- (2) a core particle of natural origin; and
- (ii) an organizer comprising at least one first attachment site, wherein said organizer is connected to said core particle by at least one covalent bond, and wherein said core particle is a virus-like particle comprising recombinant proteins, or fragments thereof, of a bacteriophage;
- (b) an antigen or antigenic determinant with at least one second attachment site, said second attachment site being selected from the group consisting of:
 - (i) an attachment site not naturally occurring with said antigen or antigenic determinant; and
 - (ii) an attachment site naturally occurring with said antigen or antigenic determinant,

wherein said second attachment site is capable of association through at least one non-peptide bond to said first attachment site; and

wherein said antigen or antigenic determinant and said scaffold interact through said association to form an ordered and repetitive antigen array.

136. The composition of claim 135, wherein said association is by way of at least one covalent bond.

137. The composition of claim 136, wherein said one covalent bond is a non-peptide bond.

138. The composition of claim 135 wherein said core particle is selected from the group consisting of:

- i) a virus;
- ii) a virus-like particle;
- iii) a bacteriophage;
- iv) a bacterial pilus;
- v) a viral capsid particle; and
- vi) a recombinant form of (i), (ii), (iii), (iv) or (v).

139. The composition of claim 135, wherein said core particle is selected from the group consisting of:

- i) a virus-like particle;
- ii) a bacterial pilus; and
- iii) a virus-like particle of a RNA-phage.

140. The composition of claim 139, wherein said virus-like particle comprising recombinant proteins, or fragments thereof, being selected from the group consisting of:

- (a) recombinant proteins of Hepatitis B virus;
- (b) recombinant proteins of measles virus;
- (c) recombinant proteins of Sindbis virus;
- (d) recombinant proteins of Rotavirus;
- (e) recombinant proteins of Foot-and-Mouth-Disease virus;
- (f) recombinant proteins of Retrovirus;
- (g) recombinant proteins of Norwalk virus;
- (h) recombinant proteins of Alphavirus;
- (i) recombinant proteins of human Papilloma virus;
- (j) recombinant proteins of Polyoma virus;
- (k) recombinant proteins of bacteriophages; and
- (l) recombinant proteins of RNA-phages;
- (m) recombinant proteins of Q β -phage;
- (n) recombinant proteins of GA-phage
- (o) recombinant proteins of fr-phage; and
- (p) recombinant proteins of Ty.

141. The composition of claim 139, wherein said virus-like particle comprising, or alternatively essentially consisting of, recombinant proteins, or fragments thereof, of a RNA-phage.

142. The composition of claim 139, wherein said virus-like particle comprising, or alternatively essentially consisting of, recombinant proteins, or fragments thereof, of a RNA-phage being selected from the group consisting of:

- a) bacteriophage Q β ;
- b) bacteriophage R17;
- c) bacteriophage fr;
- d) bacteriophage GA;
- e) bacteriophage SP;
- f) bacteriophage MS2;
- g) bacteriophage M11;
- h) bacteriophage MX1;
- i) bacteriophage NL95;
- k) bacteriophage f2; and
- l) bacteriophage PP7.

143. The composition of claim 139, wherein said virus-like particle comprising, or alternatively essentially consisting of, recombinant proteins, or fragments thereof, of bacteriophage Q β or bacteriophage fr.

144. The composition of claim 135, wherein said first and/or said second attachment sites comprise:

- (k) an antigen and an antibody or antibody fragment thereto;
- (l) biotin and avidin;
- (m) strepavidin and biotin;
- (n) a receptor and its ligand;
- (o) a ligand-binding protein and its ligand;
- (p) interacting leucine zipper polypeptides;
- (q) an amino group and a chemical group reactive thereto;
- (r) a carboxyl group and a chemical group reactive thereto;
- (s) a sulfhydryl group and a chemical group reactive thereto; or
- (t) a combination thereof.

145. The composition of claim 135, wherein said first attachment site is an amino group and said second attachment site is a sulfhydryl group.

146. The composition of claim 135, wherein said first attachment site is a lysine residue and said second attachment site is a cysteine residue.

147. The composition of claim 135, wherein said second attachment site does not naturally occur within said antigen or antigenic determinant.

148. The composition of claim 147, wherein said first attachment site is an amino group and said second attachment site is a sulfhydryl group.

149. The composition of claim 147, wherein said first attachment site is a lysine residue and said second attachment site is a cysteine residue.

150. The composition of claim 147, wherein said second attachment site comprises or is a sulfhydryl group or a cysteine residue.

-245-

151. The composition of claim 147, wherein said composition comprises an amino acid linker.

152. The composition of claim 150, wherein said amino acid linker is bound to said antigen or said antigenic determinant by way of at least one covalent bond.

152. The composition of 151, wherein said amino acid linker comprises, or alternatively consists of, said second attachment site.

153. The composition of claim 152, wherein said amino acid linker comprises a sulfhydryl group or a cysteine residue.

154. The composition of claim 152, wherein said amino acid linker is selected from the group consisting of:

- (a) CGG;
- (b) N-terminal gamma 1-linker;
- (c) N-terminal gamma 3-linker;
- (d) Ig hinge regions;
- (e) N-terminal glycine linkers;
- (f) $(G)_kC(G)_n$ with $n=0-12$ and $k=0-5$;
- (g) N-terminal glycine-serine linkers;
- (h) $(G)_kC(G)_m(S)_l(GGGGS)_n$ with $n=0-3$, $k=0-5$, $m=0-10$, $l=0-2$;
- (i) GGC;
- (k) GGC-NH₂;
- (l) C-terminal gamma 1-linker;
- (m) C-terminal gamma 3-linker;
- (n) C-terminal glycine linkers;
- (o) $(G)_nC(G)_k$ with $n=0-12$ and $k=0-5$;
- (p) C-terminal glycine-serine linkers;
- (q) $(G)_m(S)_l(GGGGS)_n(G)_oC(G)_k$ with $n=0-3$, $k=0-5$, $m=0-10$, $l=0-2$, and $o=0-8$.

155. The composition of claim 135, wherein said antigen is a protein or a fragment thereof, being selected from the group consisting of:

- (a) proteins suited to induce an immune response against cancer cells,
- (b) proteins suited to induce an immune response against infectious diseases,
- (c) proteins suited to induce an immune response against allergens, and
- (d) proteins suited to induce an immune response in farm animals or pets.

156. The composition of claim 155, wherein said antigen is:

- (a) a recombinant protein of HIV,
- (b) a recombinant protein of Influenza virus,
- (c) a recombinant protein of Hepatitis C virus,
- (d) a recombinant protein of *Toxoplasma*,
- (e) a recombinant protein of *Plasmodium falciparum*,
- (f) a recombinant protein of *Plasmodium vivax*,
- (g) a recombinant protein of *Plasmodium ovale*,
- (h) a recombinant protein of *Plasmodium malariae*,
- (i) a recombinant protein of breast cancer cells,
- (j) a recombinant protein of kidney cancer cells,
- (k) a recombinant protein of prostate cancer cells,
- (l) a recombinant protein of skin cancer cells,
- (m) a recombinant protein of brain cancer cells,
- (n) a recombinant protein of leukemia cells,
- (o) a recombinant profiling,
- (p) a recombinant protein of bee sting allergy,
- (q) a recombinant protein of nut allergy,
- (r) a recombinant protein of food allergies,
- (s) a recombinant protein of asthma, or
- (t) a recombinant protein of *Chlamydia*.

157. The composition of claim 135, wherein said antigen or antigenic determinant is a peptide, a protein, or a fragment of a protein, selected from the group consisting of:

- a) a phospholipase A₂ protein;
- b) a human IgE;
- c) a lymphotoxin;
- d) an Influenza M2 protein; and

- e) a Der p I peptide.

158. The composition of claim 157, wherein said antigen or said antigenic determinant is a Der p I peptide, or a fragment thereof.

159. The composition of claim 158, wherein said Der p I peptide with said second attachment site has an amino acid sequence selected from the group consisting of:

- a) CGNQSLDLAEQELVDCASQHGCH; and
- b) CQIYPPNANKIREALAQTSA.

160. The composition of claim 157, wherein said antigen or said antigenic determinant is a phospholipase A₂ protein, or a fragment thereof.

161. The composition of claim 160, wherein said phospholipase A₂ protein has an amino acid sequence selected from the group consisting of:

- a) the amino acid sequence of SEQ ID NO:168;
- b) the amino acid sequence of SEQ ID NO:169;
- c) the amino acid sequence of SEQ ID NO:170;
- d) the amino acid sequence of SEQ ID NO:171;
- e) the amino acid sequence of SEQ ID NO:172;
- f) the amino acid sequence of SEQ ID NO:173;
- g) the amino acid sequence of SEQ ID NO:174; and
- h) the amino acid sequence of SEQ ID NO:175.

162. The composition of claim 157, wherein said antigen or said antigenic determinant is a human IgE, or a fragment thereof.

163. The composition of claim 162, wherein the human IgE has the amino acid sequence of SEQ ID NO:176.

164. The composition of claim 163, wherein said antigen or said antigenic determinant is an influenza M2 protein, or a fragment thereof.

165. A composition comprising an influenza M2 protein, or a fragment thereof, that has been attached by a covalent bond to a protein selected from the group consisting of a bacteriophage coat protein, a bacterial pilus, HbcAg, and fragments thereof.

166. The composition of claim 165, wherein said protein is a bacteriophage coat protein or fragment thereof.

167. The composition of claim 165, wherein said protein is a bacterial pilus.

168. The composition of claim 165, wherein said protein is HBcAg, and wherein said covalent bond is not a peptide bond.

169. The composition of claim 165, wherein if said protein is a bacteriophage coat protein or fragment thereof, or a bacterial pilus or fragment thereof, and the covalent bond is a non-peptide bond.

170. The composition of claim 165, wherein if said protein is a bacteriophage coat protein or fragment thereof, or a bacterial pilus or fragment thereof, and the covalent bond is a peptide bond.

171. The composition of claim 165, wherein said bacteriophage coat protein comprises a coat protein of a bacteriophage selected from the group consisting of:

- a) bacteriophage Q β ;
- b) bacteriophage R17;
- c) bacteriophage fr;
- d) bacteriophage GA;
- e) bacteriophage SP;
- f) bacteriophage MS2;
- g) bacteriophage M11;
- h) bacteriophage MX1;
- i) bacteriophage NL95;
- k) bacteriophage f2; and
- l) bacteriophage PP7.

172. The composition of claim 171, wherein said bacteriophage coat protein comprises bacteriophage Q β .

173. A pharmaceutical composition comprising:
- a) the composition of claim 1, 87, 100, 135, or 165; and
 - b) an acceptable pharmaceutical carrier.
174. A method of immunization comprising administering the composition of claim 1, 87, 100, 135, or 165 to a subject.
175. A vaccine composition comprising the composition of claim 1, 87, 100, 135, or 165.
176. The vaccine composition of claim 160 further comprising an adjuvant.
- 177.. A process for producing a non-naturally occurring, ordered and repetitive antigen array comprising:
- a) providing a non-natural molecular scaffold comprising:
 - (i) a core particle selected from the group consisting of:
 - (1) a core particle of non-natural origin; and
 - (2) a core particle of natural origin; and
 - (ii) an organizer comprising at least one first attachment site, wherein said organizer is connected to said core particle by at least one covalent bond; and
 - b) providing an antigen or antigenic determinant with at least one second attachment site, wherein said antigen or antigenic determinant is a self antigen or a fragment thereof, and wherein said second attachment site being selected from the group consisting of:
 - (i) an attachment site not naturally occurring with said antigen or antigenic determinant; and
 - (ii) an attachment site naturally occurring with said antigen or antigenic determinant, wherein said second attachment site is capable of association through at least one non-peptide bond to said first attachment site; and

- c) combining said non-natural molecular scaffold and said antigen or antigenic determinant,
wherein said antigen or antigenic determinant and said scaffold interact through said association to form an ordered and repetitive antigen array.

178. The process of claim 177, wherein said organizer is a polypeptide or residue thereof; and wherein said second attachment site is a polypeptide or residue thereof.

179. The process of claim 177 or claim 178, wherein said core particle is a virus-like particle.

180. The process of claim 179, wherein said core particle is a virus-like particle a dimer or multimer of a polypeptide comprising amino acids 1-147 of SEQ ID NO:158.

181. The process of claim 179, wherein said virus-like particle is a dimer or multimer of a polypeptide comprising amino acids 1-152 of SEQ ID NO:158.

182. The process of claim 180, wherein one or more cysteine residues of said polypeptide have been either deleted or substituted with another amino acid residue.

183. The process of claim 181, wherein the cysteine residues corresponding to amino acids 48 and 107 in SEQ ID NO:134 have been either deleted or substituted with another amino acid residue.

184. The process of claim 182, wherein one or more lysine residue of said polypeptide have been either deleted or substituted with another amino acid residue.

185. The process of claim 177, wherein said association is by way of at least one covalent bond.

186. The process of claim 185, wherein said covalent bond is a non-peptide bond.

187. A process for producing a non-naturally occurring, ordered and repetitive antigen array comprising:

- a) providing a non-natural molecular scaffold comprising:

-251-

- (i) a core particle; and
 - (ii) an organizer comprising at least one first attachment site, wherein said organizer is connected to said core particle by at least one covalent bond; and wherein said core particle is a virus-like particle comprising recombinant proteins, or fragments thereof, of a bacteriophage;
- b) providing an antigen or antigenic determinant with at least one second attachment site, said second attachment site being selected from the group consisting of:
 - (i) an attachment site not naturally occurring with said antigen or antigenic determinant; and
 - (ii) an attachment site naturally occurring with said antigen or antigenic determinant, wherein said second attachment site is capable of association through at least one non-peptide bond to said first attachment site; and
- c) combining said non-natural molecular scaffold and said antigen or antigenic determinant, wherein said antigen or antigenic determinant and said scaffold interact through said association to form an ordered and repetitive antigen array.

188. The composition of claim 187, wherein said association is by way of at least one covalent bond.

189. The composition of claim 188, wherein said covalent bond is a non-peptide bond.

190. A coat protein capable of forming a capsid which comprises mutant Q β coat proteins having an amino acid sequence selected from the group consisting of:

- a) the amino acid sequence of SEQ ID NO:255;
- b) the amino acid sequence of SEQ ID NO:256;
- c) the amino acid sequence of SEQ ID NO:257;
- d) the amino acid sequence of SEQ ID NO:258; and
- e) the amino acid sequence of SEQ ID NO:259.

191. The coat protein of claim 190, wherein at least one antigen or antigenic determinant is bound thereto.

192. A coat protein capable of forming a capsid which essentially consisting of mutant Q β coat proteins having an amino acid sequence selected from the group consisting of:

- a) the amino acid sequence of SEQ ID NO:255;
- b) the amino acid sequence of SEQ ID NO:256;
- c) the amino acid sequence of SEQ ID NO:257;
- d) the amino acid sequence of SEQ ID NO:258;
- e) the amino acid sequence of SEQ ID NO:259; and
- f) a mixture of either a)-e) and the corresponding A1 protein.

193. The coat protein of claim 192, wherein at least one antigen or antigenic determinant is bound thereto.

194. The composition of claim 1 or 100, wherein said self antigen is a protein, a peptide or a fragment of a lymphotoxin.

195. The composition of claim 1 or 100, wherein said self antigen is a protein, a peptide or a fragment of a lymphotoxin receptor.

196. The composition of claim 1 or 100, wherein said self antigen is a protein, a peptide or a fragment of RANKL.

197. The composition of claim 1 or 100, wherein said self antigen is a protein, a peptide or a fragment of VEGF.

198. The composition of claim 1 or 100, wherein said self antigen is a protein, a peptide or a fragment of VEGF-R.

199. The composition of claim 1 or 100, wherein said self antigen is a protein, a peptide or a fragment of Interleukin 5.

200. The composition of claim 1 or 100, wherein said self antigen is a protein, a peptide or a fragment of Interleukin 17.

201. The composition of claim 1 or 100, wherein said self antigen is a protein, a peptide or a fragment of Interleukin 13.

202. The composition of claim 1 or 100, wherein said self antigen is a protein, a peptide or a fragment Angiotensin.

203. The composition of claim 1 or 100, wherein said self antigen is a protein, a peptide or a fragment of CCL21.

204. The composition of claim 1 or 100, wherein said self antigen is a protein, a peptide or a fragment of CXCL12.

205. The composition of claim 1 or 100, wherein said self antigen is a protein, a peptide or a fragment of SDF-1.

206. The composition of claim 1 or 100, wherein said self antigen is a protein, a peptide or a fragment of MCP-1.

207. The composition of claim 1 or 100, wherein said self antigen is a protein, a peptide or a fragment of Endoglin.

208. The composition of claim 1 or 100, wherein said self antigen is a protein, a peptide or a fragment of Resistin.

209. The composition of claim 1 or 100, wherein said self antigen is a protein, a peptide or a fragment of GHRH.

210. The composition of claim 1 or 100, wherein said self antigen is a protein, a peptide or a fragment of LHRH.

211. The composition of claim 1 or 100, wherein said self antigen is a protein, a peptide or a fragment of TRH.

212. The composition of claim 1 or 100, wherein said self antigen is a protein, a peptide or a fragment of MIP.

213. The composition of claim 1 or 100, wherein said self antigen is a protein, a peptide or a fragment of Eotaxin.

214. The composition of claim 1 or 100, wherein said self antigen is a protein, a peptide or a fragment of Bradykinin

215. The composition of claim 1 or 100, wherein said self antigen is a protein, a peptide or a fragment of BLC.



216. The composition of claim 1 or 100, wherein said self antigen is a protein, a peptide or a fragment of Tumor Necrosis Factor α (TNF α).

217. The composition of claim 1 or 100, wherein said self antigen is a protein, a peptide or a fragment of amyloid beta peptide (A β ₁₋₄₂).

218. The composition of claim 1 or 100, wherein said self antigen is a protein, a peptide or a fragment of a human IgE.

	Nhe I										Linker					
1	GAT	CCA	GCA	GCT	GGG	CTC	GAG	GTG	CTA	GCG	GGA	GGG	GGT	GGA	TGT	GGG
	D	P	A	A	G	L	E	V	L	A	G	G	G	G	C	G
	Factor Xa Xa ↓ Hind III															
	hu IgG1															
49	ATC	GAA	GGT	CGC	AAG	CTT	ACT	CAC	ACA	TGC	CCA	CCG	TGC	CCA	GCA	CTT
	I	E	G	R	K	L	T	H	T		C	P	C	P	A	P
97	GAA	GCC	GAG	GGG	GCA	CCG	TCA	GTC	TTC	CTC	TTC	CCC	CCA	AAA	CCC	AAG
	E	A	E	G	A	P	S	V	F	L	F	P	P	K	P	K
145	GAC	ACC	CTC	ATG	ATC	TCC	CGG	ACC	CCT	GAG	GTC	ACA	TGC	GTG	GTG	GTG
	D	T	L	M	I	S	R	T	P	E	V	T	C	V	V	V
193	GAC	GTG	AGC	CAC	GAA	GAC	CCT	GAG	GTC	AAG	TTC	AAC	TGG	TAC	GTG	GAC
	D	V	S	H	E	A	D	P	E	V	K	F	N	W	Y	D
241	GGC	GTG	GAG	GTG	CAT	AAT	GCC	AAG	ACA	AAG	CCG	CGG	GAG	CAG	CAG	TAC
	G	V	E	V	H	N	A	K	T	K	P	R	E	B	Q	Y
289	AAC	AGC	ACG	TAC	CGT	GTG	GTC	AGC	GTC	CTC	ACC	GTC	CTG	CAC	CAG	GAC
	N	S	T	Y	R	V	V	S	V	L	T	V	L	H	Q	D
337	TGG	CTG	AAT	GGC	AAG	GAG	TAC	AAG	TGC	AAG	GTC	TCC	AAC	AAA	GCC	CTC
	W	L	N	G	K	E	Y	K	C	K	V	S	N	K	A	L
385	CCA	GCC	TCC	ATC	GAG	AAA	ACC	ATC	TCC	AAA	GCC	AAA	GGG	CAG	CCC	CGA
	P	A	S	I	E	K	T	I	S	K	A	K	G	G	P	R
433	GAA	CCA	CAG	GTG	TAC	ACC	CTG	CCC	CCA	TCC	CGG	GAT	GAG	CTG	ACC	AAG
	E	P	Q	V	Y	T	L	P	P	S	R	D	E	L	T	K
481	AAC	CAG	GTC	AGC	CTG	ACC	TGC	CTG	GTC	AAA	GGC	TTC	TAT	CCC	AGC	GAC
	N	Q	V	S	L	T	C	L	V	K	G	F	Y	P	S	D
529	ATC	GCC	GTG	GAG	TGG	GAG	AGC	AAT	GGG	CAG	CCG	GAG	AAC	AAC	TAC	AAG
	I	A	V	E	W	E	S	N	G	Q	P	E	N	N	Y	K
577	ACC	ACG	CCT	CCC	GTG	TTG	GAC	TCC	GAC	GGC	TCC	TTC	TTC	CTC	TAC	AGC
	T	T	P	P	V	L	D	S	D	G	S	F	F	L	Y	S
625	AAG	CTC	ACC	GTG	GAC	AAG	AGC	AGG	TGG	CAG	CAG	GGG	AAC	GTC	TTC	TCA
	K	L	T	V	D	K	S	R	W	Q	Q	G	N	V	F	S
673	TGC	TCC	GTG	ATG	CAT	GAG	GCT	CTG	CAC	AAC	CAC	TAC	ACG	CAG	AAG	AGC
	C	S	V	M	H	E	A	L	H	N	H	Y	T	Q	K	S
721	CTC	TCC	CTG	TCT	CCG	GGT	AAA	TGA								
	L	S	L	S	P	G	K	-								

FIG. 1A

**FIG. 1B****FIG. 1C**

3/54

1 GGA TCC GGG ATG AAG AAC CTT TCA TTT CCC CTC CTT TTC CTT TTC CTT
M K N L S P P L L F L F F L
52 GTC CCT GAA CTG CTG GGC TCC AGC ATG CCA CTG TGT CCC ATC GAT GAA GCC
V P E L L G S S M P L C P I D E A
103 ATC GAC AAG AAG ATC AAA CAA GAC TTC AAC TCC CTG TTT CCA AAT GCA ATA
I D K K I K Q D F N S L F P N A I
154 AAG AAC ATT GGC TTA AAT TGC TGG ACA GTC TCC TCC AGA GGG AAG TTG GCC
K N I G L N C W T V S S R G K L A
205 TCC TGC CCA GAA GGC ACA GCA GTC TTG AGC TGC TCC TGT GGC TCT GCC TGT
S C P E G T A V L S C S C G S A C
256 GGC TCG TGG GAC ATT CGT GAA GAA AAA GTG TGT CAC TGC CAG TGT GCA AGG
G S W D I R E E K V C H C Q C A R
307 ATA GAC TGG ACA GCA GCC CGC TGC TGT AAG CTG CAG GTC GCT TCC TCT CTA
I D W T A A R C C K L Q V A S S L
358 GCG GGA GGG GGT GGA TGT GGG ATC GAA GGT CGC AAG CTT ACT
A G G G G C G I E G R K L T

FIG. 2A

1 GGA TCC GGG ATG AAG AAC CTT TCA TTT CCC CTC CTT TTC CTT TTC CTT
M K N L S P P L L F L F F L
52 GTC CCT GAA CTG CTG GGC TCC AGC ATG CCA CTG TGT CCC ATC GAT GAA GCC
V P E L L G S S M P L C P I D E A
103 ATC GAC AAG AAG ATC AAA CAA GAC TTC AAC TCC CTG TTT CCA AAT GCA ATA
I D K K I K Q D F N S L F P N A I
154 AAG AAC ATT GGC TTA AAT TGC TGG ACA GTC TCC TCC AGA GGG AAG TTG GCC
K N I G L N C W T V S S R G K L A
205 TCC TGC CCA GAA GGC ACA GCA GTC TTG AGC TGC TCC TGT GGC TCT GCC TGT
S C P E G T A V L S C S C G S A C
256 GGC TCG TGG GAC ATT CGT GAA GAA AAA GTG TGT CAC TGC CAG TGT GCA AGG
G S W D I R E E K V C H C Q C A R
307 ATA GAC TGG ACA GCA GCC CGC TGC TGT AAG CTG CAG GTC GCT TCC TCT CTA
I D W T A A R C C K L Q V A S S L
358 GCG GGA GGG GGT GGA TGT GGG GAC GAT GAC GAC AAG CTT ACT
A G G G G C G D D D D K L T

FIG. 2B

4/54






FIG. 2C

5/54

**FIG. 3A****FIG. 3B**

6/54




FIG. 4A

7/54




FIG. 4B





FIG. 4C

9/54

**FIG. 5**

10/54




FIG. 6

11/54




Fig 7

12/54

FIG. 8A




FIG. 8B






FIG. 8C



13/54

FIG. 8D



14/54

FIG. 9A




FIG. 9B




FIG. 10A

15/54





FIG. 10B



16/54

FIG. 11





FIG. 12



18/54





FIG. 13A


19/54



20/54

FIG. 13C

Sulfo SMPH



21/54

FIG. 13D






FIG. 13E




23/54

FIG. 14A



24/54

FIG. 14B



25/54

FIG. 14C





FIG. 15A



27/54




FIG. 15B




FIG. 15C




FIG. 16 A




FIG. 16 B

30/54





FIG. 17 A

31/54

**FIG. 17 B**

32/54





FIG. 18 A

33/54

**FIG. 18 B**

34/54




FIG. 18 C

35/54





FIG. 18 D

36/54

**FIG. 18 E**

37/54




FIG. 18 F

38/54




FIG. 19 A

39/54




FIG. 19 B

40/54





FIG. 20

41/54

**FIG. 21**

42/54

Fig Qb mut S-MBS Flag




FIG. 22 A




FIG. 22 B

44/54

Fig Qb mut SMPH Flag




FIG. 22 C

45/54


Fig Q β mutants-PLA₂-Cys

FIG. 22 D




FIG. 23

47/54





FIG. 24

48/54

**FIG. 25 A**

49/54




FIG. 25 B




FIG. 26

51/54




FIG. 27 A




FIG. 27 B

53/54




FIG. 28 A

54/54




FIG. 28 B

-1-

SEQUENCE LISTING

<110> Cytos Biotechnology

<120> Molecular Antigen Array

<130> 1700.019PC04

<140> (To be assigned)

<141> 2002-01-18

<150> US 60/262,379

<151> 2001-01-19

<150> US 60/288,549

<151> 2001-05-04

<150> US 60/326,998

<151> 2001-10-05

<150> US 60/331,045

<151> 2001-11-07

<160> 350

<170> PatentIn Ver. 2.1

<210> 1

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 1

ggggacgcgt gcagcaggta accaccgtta aagaaggcac c

41

<210> 2

<211> 44

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 2

cggtgggttac ctgctgcacg cggttgcttaa ggcacatgta gcgg

44

<210> 3

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 3

ccatgaggcc tacgataccc

20

-2-

<210> 4
<211> 25
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Primer

<400> 4
ggcactcacg gcgcgcttta caggc 25

<210> 5
<211> 47
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Primer

<400> 5
ccttcctttaa cggtgggttac ctgctggcaa ccaacgtggt tcatgac 47

<210> 6
<211> 40
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Primer

<400> 6
aagcatgctg cacgcgtgtg cggtgggtcgg atcgcccggc 40

<210> 7
<211> 90
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Primer

<400> 7
gggtctagat tccaaccat tcccttatcc aggctttttg acaacgctat gctccgcgcc 60
catcgctctgc accagctggc ctttgacacc 90

<210> 8
<211> 108
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Primer

<400> 8
gggtctagaa ggaggtaaaa aacgatgaaa aagacagcta tcgcgattgc agtggcactg 60
gctggtttcg ctaccgtagc gcaggccttc ccaaccattc ctttatcc 108

-3-

<210> 9
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 9
cccgaattcc tagaagccac agctgccctc c 31

<210> 10
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 10
cctgcggtgg tctgaccgac accc 24

<210> 11
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 11
ccgcggaaga gccaccgcaa ccaccgtgtg ccgccaggat g 41

<210> 12
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 12
ctatcatcta gaatgaatag aggattcttt aac 33

<210> 13
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Modified ribosome
binding site

<400> 13
aggaggtaaa aaacg 15

<210> 14
<211> 21

-4-

<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: signal peptide

<400> 14
Met Lys Lys Thr Ala Ile Ala Ile Ala Val Ala Leu Ala Gly Phe Ala
1 5 10 15
Thr Val Ala Gln Ala
20

<210> 15
<211> 46
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: modified Fos
construct

<400> 15
Cys Gly Gly Leu Thr Asp Thr Leu Gln Ala Glu Thr Asp Gln Val Glu
1 5 10 15
Asp Glu Lys Ser Ala Leu Gln Thr Glu Ile Ala Asn Leu Leu Lys Glu
20 25 30
Lys Glu Lys Leu Glu Phe Ile Leu Ala Ala His Gly Gly Cys
35 40 45

<210> 16
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: peptide linker

<400> 16
Ala Ala Ala Ser Gly Gly
1 5

<210> 17
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: peptide linker

<400> 17
Gly Gly Ser Ala Ala Ala
1 5

<210> 18
<211> 256
<212> DNA

-5-

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Fos fusion construct

<400> 18

```

gaattcagga ggtaaaaaaac gatgaaaaag acagctatcg cgattgcagt ggcactggct 60
ggtttcgcta ccgtagcgca ggcctgggtg ggggcggccg cttctgggtg ttgcggtggt 120
ctgaccgaca ccctgcaggc ggaaaccgac caggtggaag acgaaaaatc cgcgctgcaa 180
accgaaatcg cgaacctgct gaaagaaaaa gaaaagctgg agttcatcct ggcggcacac 240
ggtggttgct aagctt                                     256

```

<210> 19

<211> 52

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Fos fusion construct

<400> 19

```

Ala Ala Ala Ser Gly Gly Cys Gly Gly Leu Thr Asp Thr Leu Gln Ala
                5                      10                      15

```

```

Glu Thr Asp Gln Val Glu Asp Glu Lys Ser Ala Leu Gln Thr Glu Ile
        20                      25                      30

```

```

Ala Asn Leu Leu Lys Glu Lys Glu Lys Leu Glu Phe Ile Leu Ala Ala
        35                      40                      45

```

```

His Gly Gly Cys
        50

```

<210> 20

<211> 261

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Fos fusion construct

<220>

<221> CDS

<222> (22)..(240)

<400> 20

```

gaattcagga ggtaaaaaaac g atg aaa aag aca gct atc gcg att gca gtg 51
                        Met Lys Lys Thr Ala Ile Ala Ile Ala Val
                          1                      5                      10

gca ctg gct ggt ttc gct acc gta gcg cag gcc tgc ggt ggt ctg acc 99
Ala Leu Ala Gly Phe Ala Thr Val Ala Gln Ala Cys Gly Gly Leu Thr
        15                      20                      25

gac acc ctg cag gcg gaa acc gac cag gtg gaa gac gaa aaa tcc gcg 147
Asp Thr Leu Gln Ala Glu Thr Asp Gln Val Glu Asp Glu Lys Ser Ala
        30                      35                      40

ctg caa acc gaa atc gcg aac ctg ctg aaa gaa aaa gaa aag ctg gag 195

```


-6-

Leu Gln Thr Glu Ile Ala Asn Leu Leu Lys Glu Lys Glu Lys Leu Glu
 45 50 55
 ttc atc ctg gcg gca cac ggt ggt tgc ggt ggt tct gcg gcc gct 240
 Phe Ile Leu Ala Ala His Gly Gly Cys Gly Gly Ser Ala Ala Ala
 60 65 70
 ggggtgtgggg atatcaagct t 261

<210> 21
 <211> 73
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Fos fusion
 construct

<400> 21
 Met Lys Lys Thr Ala Ile Ala Ile Ala Val Ala Leu Ala Gly Phe Ala
 1 5 10 15
 Thr Val Ala Gln Ala Cys Gly Gly Leu Thr Asp Thr Leu Gln Ala Glu
 20 25 30
 Thr Asp Gln Val Glu Asp Glu Lys Ser Ala Leu Gln Thr Glu Ile Ala
 35 40 45
 Asn Leu Leu Lys Glu Lys Glu Lys Leu Glu Phe Ile Leu Ala Ala His
 50 55 60
 Gly Gly Cys Gly Gly Ser Ala Ala Ala
 65 70

<210> 22
 <211> 196
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Fos fusion
 construct

<220>
 <221> CDS
 <222> (34)..(189)

<400> 22
 gaattcagga ggtaaaaaga tatcgggtgt ggg gcg gcc gct tct ggt ggt tgc 54
 Ala Ala Ala Ser Gly Gly Cys
 1 5
 ggt ggt ctg acc gac acc ctg cag gcg gaa acc gac cag gtg gaa gac 102
 Gly Gly Leu Thr Asp Thr Leu Gln Ala Glu Thr Asp Gln Val Glu Asp
 10 15 20
 gaa aaa tcc gcg ctg caa acc gaa atc gcg aac ctg ctg aaa gaa aaa 150
 Glu Lys Ser Ala Leu Gln Thr Glu Ile Ala Asn Leu Leu Lys Glu Lys
 25 30 35
 gaa aag ctg gag ttc atc ctg gcg gca cac ggt ggt tgc taagctt 196

-7-

Glu Lys Leu Glu Phe Ile Leu Ala Ala His Gly Gly Cys
 40 45 50

<210> 23
 <211> 52
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Fos fusion
 construct

<400> 23
 Ala Ala Ala Ser Gly Gly Cys Gly Gly Leu Thr Asp Thr Leu Gln Ala
 1 5 10 15
 Glu Thr Asp Gln Val Glu Asp Glu Lys Ser Ala Leu Gln Thr Glu Ile
 20 25 30
 Ala Asn Leu Leu Lys Glu Lys Glu Lys Leu Glu Phe Ile Leu Ala Ala
 35 40 45
 His Gly Gly Cys
 50

<210> 24
 <211> 204
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Fos fusion
 construct

<400> 24
 gaattcagga ggtaaaaaac gatggcttgc ggtggtctga cgcacaccct gcaggcggaa 60
 accgaccagg tggaagacga aaaatccgcg ctgcaaaccg aaatcgcgaa cctgctgaaa 120
 gaaaaagaaa agctggagtt catcctggcg gcacacggtg gttgcggtgg ttctgcggcc 180
 gctgggtgtg gggatatcaa gctt 204

<210> 25
 <211> 56
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Fos fusion
 construct

<400> 25
 Lys Thr Met Ala Cys Gly Gly Leu Thr Asp Thr Leu Gln Ala Glu Thr
 1 5 10 15
 Asp Gln Val Glu Asp Glu Lys Ser Ala Leu Gln Thr Glu Ile Ala Asn
 20 25 30
 Leu Leu Lys Glu Lys Glu Lys Leu Glu Phe Ile Leu Ala Ala His Gly
 35 40 45
 Gly Cys Gly Gly Ser Ala Ala
 50 55

-8-

<210> 26
 <211> 26
 <212> PRT
 <213> Homo sapiens

<400> 26
 Met Ala Thr Gly Ser Arg Thr Ser Leu Leu Leu Ala Phe Gly Leu Leu
 1 5 10 15
 Cys Leu Pro Trp Leu Gln Glu Gly Ser Ala
 20 25

<210> 27
 <211> 262
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Fos fusion
 construct

<400> 27
 gaattcaggc ctatggctac aggctcccgg acgtccctgc tcctggcttt tggcctgctc 60
 tgcctgccct ggcttcaaga gggcagcgct ggggtgtgggg cggccgcttc tgggtggtgc 120
 ggtggtctga ccgacacct gcaggcggaa accgaccagg tggaagacga aaaatccgcg 180
 ctgcaaaccg aaatcgcgaa cctgctgaaa gaaaaagaaa agctggagtt catcctggcg 240
 gcacacggtg gttgctaagc tt 262

<210> 28
 <211> 52
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Fos fusion
 construct

<400> 28
 Ala Ala Ala Ser Gly Gly Cys Gly Gly Leu Thr Asp Thr Leu Gln Ala
 5 10 15
 Glu Thr Asp Gln Val Glu Asp Glu Lys Ser Ala Leu Gln Thr Glu Ile
 20 25 30
 Ala Asn Leu Leu Lys Glu Lys Glu Lys Leu Glu Phe Ile Leu Ala Ala
 35 40 45
 His Gly Gly Cys
 50

<210> 29
 <211> 261
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Fos fusion

-9-

construct

<220>

<221> CDS

<222> (7)..(240)

<400> 29

```

gaattc atg gct aca ggc tcc cgg acg tcc ctg ctc ctg gct ttt ggc      48
      Met Ala Thr Gly Ser Arg Thr Ser Leu Leu Leu Ala Phe Gly
        1              5              10

ctg ctc tgc ctg ccc tgg ctt caa gag ggc agc gct tgc ggt ggt ctg      96
Leu Leu Cys Leu Pro Trp Leu Gln Glu Gly Ser Ala Cys Gly Gly Leu
  15              20              25              30

acc gac acc ctg cag gcg gaa acc gac cag gtg gaa gac gaa aaa tcc      144
Thr Asp Thr Leu Gln Ala Glu Thr Asp Gln Val Glu Asp Glu Lys Ser
          35              40              45

gcg ctg caa acc gaa atc gcg aac ctg ctg aaa gaa aaa gaa aag ctg      192
Ala Leu Gln Thr Glu Ile Ala Asn Leu Leu Lys Glu Lys Glu Lys Leu
          50              55              60

gag ttc atc ctg gcg gca cac ggt ggt tgc ggt ggt tct gcg gcc gct      240
Glu Phe Ile Leu Ala Ala His Gly Gly Cys Gly Gly Ser Ala Ala Ala
        65              70              75

gggtgtggga ggcctaagct t      261

```

<210> 30

<211> 78

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Fos fusion construct

<400> 30

```

Met Ala Thr Gly Ser Arg Thr Ser Leu Leu Leu Ala Phe Gly Leu Leu
  1              5              10              15

Cys Leu Pro Trp Leu Gln Glu Gly Ser Ala Cys Gly Gly Leu Thr Asp
          20              25              30

Thr Leu Gln Ala Glu Thr Asp Gln Val Glu Asp Glu Lys Ser Ala Leu
          35              40              45

Gln Thr Glu Ile Ala Asn Leu Leu Lys Glu Lys Glu Lys Leu Glu Phe
          50              55              60

Ile Leu Ala Ala His Gly Gly Cys Gly Gly Ser Ala Ala Ala
          65              70              75

```

<210> 31

<211> 44

<212> DNA

<213> Artificial Sequence

<220>

-10-

<223> Description of Artificial Sequence: Primer

<400> 31

cctgggtggg ggcggccgct tctggtggtt gcggtggtct gacc

44

<210> 32

<211> 44

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 32

ggtgggaatt caggaggtaa aaagatatcg ggtgtggggc ggcc

44

<210> 33

<211> 47

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 33

ggtgggaatt caggaggtaa aaaacgatgg cttgcggtgg tctgacc

47

<210> 34

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 34

gcttgcggtg gtctgacc

18

<210> 35

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 35

ccaccaagct tagcaaccac cgtgtgc

27

<210> 36

<211> 54

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 36

-11-

ccaccaagct tgatatcccc acaccagcg gccgcagaac caccgcaacc accg 54

<210> 37
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 37
ccaccaagct taggcctccc acaccagcg gc 32

<210> 38
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 38
ggtgggaatt caggaggtaa aaaacgatg 29

<210> 39
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 39
ggtgggaatt caggcctatg gctacaggct cc 32

<210> 40
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 40
ggtgggaatt catggctaca ggctccc 27

<210> 41
<211> 59
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 41
gggtctagaa tggctacagg ctcccggacg tccctgctcc tggtttttgg cctgctctg 59

-12-

<210> 42
 <211> 58
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Primer

<400> 42
 cgcaggcctc ggcactgccc tcttgaagcc agggcaggca gagcaggcca aaagccag 58

<210> 43
 <211> 402
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Modified bee
 venom phospholipase A2

<220>
 <221> CDS
 <222> (1)..(402)

<400> 43
 atc atc tac cca ggt act ctg tgg tgt ggt cac ggc aac aaa tct tct 48
 Ile Ile Tyr Pro Gly Thr Leu Trp Cys Gly His Gly Asn Lys Ser Ser
 1 5 10 15
 ggt ccg aac gaa ctc ggc cgc ttt aaa cac acc gac gca tgc tgt cgc 96
 Gly Pro Asn Glu Leu Gly Arg Phe Lys His Thr Asp Ala Cys Cys Arg
 20 25 30
 acc cag gac atg tgt ccg gac gtc atg tct gct ggt gaa tct aaa cac 144
 Thr Gln Asp Met Cys Pro Asp Val Met Ser Ala Gly Glu Ser Lys His
 35 40 45
 ggg tta act aac acc gct tct cac acg cgt ctc agc tgc gac tgc gac 192
 Gly Leu Thr Asn Thr Ala Ser His Thr Arg Leu Ser Cys Asp Cys Asp
 50 55 60
 gac aaa ttc tac gac tgc ctt aag aac tcc gcc gat acc atc tct tct 240
 Asp Lys Phe Tyr Asp Cys Leu Lys Asn Ser Ala Asp Thr Ile Ser Ser
 65 70 75 80
 tac ttc gtt ggt aaa atg tat ttc aac ctg atc gat acc aaa tgt tac 288
 Tyr Phe Val Gly Lys Met Tyr Phe Asn Leu Ile Asp Thr Lys Cys Tyr
 85 90 95
 aaa ctg gaa cac ccg gta acc ggc tgc ggc gaa cgt acc gaa ggt cgc 336
 Lys Leu Glu His Pro Val Thr Gly Cys Gly Glu Arg Thr Glu Gly Arg
 100 105 110
 tgc ctg cac tac acc gtt gac aaa tct aaa ccg aaa gtt tac cag tgg 384
 Cys Leu His Tyr Thr Val Asp Lys Ser Lys Pro Lys Val Tyr Gln Trp
 115 120 125
 ttc gac ctg cgc aaa tac 402
 Phe Asp Leu Arg Lys Tyr
 130

-13-

<210> 44
 <211> 134
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Modified bee
 venom phospholipase A2

<400> 44
 Ile Ile Tyr Pro Gly Thr Leu Trp Cys Gly His Gly Asn Lys Ser Ser
 1 5 10 15
 Gly Pro Asn Glu Leu Gly Arg Phe Lys His Thr Asp Ala Cys Cys Arg
 20 25 30
 Thr Gln Asp Met Cys Pro Asp Val Met Ser Ala Gly Glu Ser Lys His
 35 40 45
 Gly Leu Thr Asn Thr Ala Ser His Thr Arg Leu Ser Cys Asp Cys Asp
 50 55 60
 Asp Lys Phe Tyr Asp Cys Leu Lys Asn Ser Ala Asp Thr Ile Ser Ser
 65 70 75 80
 Tyr Phe Val Gly Lys Met Tyr Phe Asn Leu Ile Asp Thr Lys Cys Tyr
 85 90 95
 Lys Leu Glu His Pro Val Thr Gly Cys Gly Glu Arg Thr Glu Gly Arg
 100 105 110
 Cys Leu His Tyr Thr Val Asp Lys Ser Lys Pro Lys Val Tyr Gln Trp
 115 120 125
 Phe Asp Leu Arg Lys Tyr
 130

<210> 45
 <211> 19
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Primer

<400> 45
 ccatcatcta cccaggtac

19

<210> 46
 <211> 34
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Primer

<400> 46
 cccacacca gcggcgcgt atttgcgcag gtcg

34

-14-

<210> 47
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 47
cggtggttct gcggccgcta tcattctaccc aggtac 36

<210> 48
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 48
ttagtatttg cgcaggtcg 19

<210> 49
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 49
ccggctccat cggtgcag 18

<210> 50
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 50
accaccagaa gcggccgcag gggaaacaca tctgcc 36

<210> 51
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 51
cggtggttct gcggccgctg gctccatcgg tgcag 35

<210> 52
<211> 21
<212> DNA

-15-

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 52

ttaaggggaa acacatctgc c

21

<210> 53

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 53

actagtctag aatgagagtg aaggagaaat atc

33

<210> 54

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 54

tagcatgcta gcaccgaatt tatctaattc caataattct tg

42

<210> 55

<211> 51

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 55

gtagcaccca ccaaggcaaa gctgaaagct acccagctcg agaaactggc a

51

<210> 56

<211> 48

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 56

caaagctcct attccactg ccagtttctc gagctgggta gctttcag

48

<210> 57

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

-16-

<223> Description of Artificial Sequence: Primer

<400> 57

ttcgggtgcta gcggtggctg cgggtggtctg accgac

36

<210> 58

<211> 37

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 58

gatgctgggc ccttaaccgc aaccaccgtg tgccgcc

37

<210> 59

<211> 46

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: JUN amino acid
sequence

<400> 59

Cys Gly Gly Arg Ile Ala Arg Leu Glu Glu Lys Val Lys Thr Leu Lys
1 5 10 15Ala Gln Asn Ser Glu Leu Ala Ser Thr Ala Asn Met Leu Arg Glu Gln
20 25 30Val Ala Gln Leu Lys Gln Lys Val Met Asn His Val Gly Cys
35 40 45

<210> 60

<211> 46

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: FOS amino
acid sequence

<400> 60

Cys Gly Gly Leu Thr Asp Thr Leu Gln Ala Glu Thr Asp Gln Val Glu
1 5 10 15Asp Glu Lys Ser Ala Leu Gln Thr Glu Ile Ala Asn Leu Leu Lys Glu
20 25 30Lys Glu Lys Leu Glu Phe Ile Leu Ala Ala His Gly Gly Cys
35 40 45

<210> 61

<211> 33

<212> DNA

<213> Artificial Sequence

-17-

<220>

<223> Description of Artificial Sequence: Primer

<400> 61

ccggaattca tgtgcggtgg tcggatcgcc cgg

33

<210> 62

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 62

gtcgtacccc gcggtccgc aaccaacgtg gtcatgac

39

<210> 63

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 63

gttggttgcg gagccgcggg tagcgacatt gacccttata aagaatttgg

50

<210> 64

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 64

cgcggtcccaa gcttctacgg aagcgttgat aggatagg

38

<210> 65

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 65

ctagccgcgg gttgcggtgg tcggatcgcc cgg

33

<210> 66

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 66

-18-

cgcgccccaa gcttttagca accaacgtgg ttcatgac 38

<210> 67
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 67
ccggaattca tggacattga cccttataaa g 31

<210> 68
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 68
ccgaccacgg caacccggcg ctagcggaag cggtgatagg atagg 45

<210> 69
<211> 47
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 69
ctaattggatc cggtgggggc tgcggtgggc ggatcgcccg gctcgag 47

<210> 70
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 70
gtcgctaccc ggggtccgc aaccaacgtg gtcatgac 39

<210> 71
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 71
ccggaattca tggacattga cccttataaa g 31

-19-

<210> 72
<211> 48
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 72
ccgaccaccg cagccccac cggatccatt agtaccacc caggtagc

48

<210> 73
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 73
gttggttgcg gagccgcggg tagcgaccta gtagtcagtt atgtc

45

<210> 74
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 74
cgcgccccaa gcttctacgg aagcgttgat aggatagg

38

<210> 75
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 75
ctagccgcgg gttgcggtgg tcggatcgcc cgg

33

<210> 76
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 76
cgcgccccaa gcttttagca accaacgtgg ttcatgac

38

<210> 77
<211> 30
<212> DNA

-20-

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 77

ccggaattca tggccacact tttaaggagc

30

<210> 78

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 78

cgcgtcccaa gcttttagca accaacgtgg ttcattgac

38

<210> 79

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 79

ccggaattca tggacattga cccttataaa g

31

<210> 80

<211> 51

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 80

cctagagcca cctttgccac catottctaa attagtagcc acccaggtag c

51

<210> 81

<211> 48

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 81

gaagatgggtg gcaaagggtg ctctagggac ctagtagtca gttatgtc

48

<210> 82

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

-21-

<223> Description of Artificial Sequence: Primer

<400> 82

cgcggtcccaa gcttctaaac aacagtagtc tccggaag

38

<210> 83

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 83

gccgaattcc tagcagctag caccgaattt atctaa

36

<210> 84

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 84

ggttaagtcg acatgagagt gaaggagaaa tat

33

<210> 85

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 85

taaccgaatt caggaggtaa aaagatatgg

30

<210> 86

<211> 35

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 86

gaagtaaagc ttttaaccac cgcaaccacc agaag

35

<210> 87

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 87

-22-

tcgaatgggc cctcatcttc gtgtgctagt cag

33

<210> 88

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Fos fusion
construct

<400> 88

Glu Phe Arg Arg
1

<210> 89

<211> 183

<212> PRT

<213> Hepatitis B virus

<400> 89

Met Asp Ile Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu
1 5 10 15Ser Phe Leu Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp
20 25 30Thr Ala Ser Ala Leu Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys
35 40 45Ser Pro His His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu
50 55 60Leu Met Thr Leu Ala Thr Trp Val Gly Gly Asn Leu Glu Asp Pro Ile
65 70 75 80Ser Arg Asp Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly Leu Lys
85 90 95Phe Arg Gln Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly Arg
100 105 110Glu Thr Val Ile Glu Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr
115 120 125Pro Pro Ala Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro
130 135 140Glu Thr Thr Val Val Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr
145 150 155 160Pro Ser Pro Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser
165 170 175Gln Ser Arg Gly Ser Gln Cys
180

<210> 90

<211> 183

<212> PRT

-23-

<213> Hepatitis B virus

<400> 90

```

Met Asp Ile Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu
 1          5          10          15

Ser Phe Leu Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp
          20          25          30

Thr Ala Ser Ala Leu Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys
 35          40          45

Ser Pro His His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu
 50          55          60

Leu Met Thr Leu Ala Thr Trp Val Gly Gly Asn Leu Glu Asp Pro Thr
 65          70          75          80

Ser Arg Asp Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly Leu Lys
          85          90          95

Phe Arg Gln Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly Arg
 100          105          110

Glu Thr Val Ile Glu Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr
 115          120          125

Pro Pro Ala Tyr Arg Pro Thr Asn Ala Pro Ile Leu Ser Thr Leu Pro
 130          135          140

Glu Thr Cys Val Ile Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr
 145          150          155          160

Pro Ser Pro Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser
 165          170          175

Gln Ser Arg Gly Ser Gln Cys
 180

```

<210> 91

<211> 212

<212> PRT

<213> Hepatitis B virus

<400> 91

```

Met Gln Leu Phe His Leu Cys Leu Ile Ile Ser Cys Ser Cys Pro Thr
 1          5          10          15

Val Gln Ala Ser Lys Leu Cys Leu Gly Trp Leu Trp Gly Met Asp Ile
          20          25          30

Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu Ser Phe Leu
 35          40          45

Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp Thr Ala Ser
 50          55          60

Ala Leu Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys Ser Pro His
 65          70          75          80

His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu Leu Met Thr
          85          90          95

```

-24-

Leu Ala Thr Trp Val Gly Gly Asn Leu Glu Asp Pro Ile Ser Arg Asp
 100 105 110
 Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly Leu Lys Phe Arg Gln
 115 120 125
 Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly Arg Glu Thr Val
 130 135 140
 Ile Glu Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr Pro Pro Ala
 145 150 155 160
 Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro Glu Thr Thr
 165 170 175
 Val Val Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr Pro Ser Pro
 180 185 190
 Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser Gln Ser Arg
 195 200 205
 Glu Ser Gln Cys
 210

<210> 92
 <211> 212
 <212> PRT
 <213> Hepatitis B virus

<400> 92
 Met Gln Leu Phe His Leu Cys Leu Ile Ile Ser Cys Ser Cys Pro Thr
 1 5 10 15
 Val Gln Ala Ser Lys Leu Cys Leu Gly Trp Leu Trp Gly Met Asp Ile
 20 25 30
 Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu Ser Phe Leu
 35 40 45
 Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp Asn Ala Ser
 50 55 60
 Ala Leu Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys Ser Pro His
 65 70 75 80
 His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu Leu Met Thr
 85 90 95
 Leu Ala Thr Trp Val Gly Gly Asn Leu Glu Asp Pro Ile Ser Arg Asp
 100 105 110
 Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly Leu Lys Phe Arg Gln
 115 120 125
 Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly Arg Glu Thr Val
 130 135 140
 Ile Glu Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr Pro Pro Ala
 145 150 155 160
 Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro Glu Thr Thr
 165 170 175

-25-

Val Val Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr Pro Ser Pro
 180 185 190
 Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser Gln Ser Arg
 195 200 205
 Glu Ser Gln Cys
 210

<210> 93
 <211> 183
 <212> PRT
 <213> Hepatitis B virus

<400> 93
 Met Asp Ile Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu
 1 5 10 15
 Ser Phe Leu Pro Thr Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp
 20 25 30
 Thr Ala Ser Ala Leu Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys
 35 40 45
 Ser Pro His His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu
 50 55 60
 Leu Met Thr Leu Ala Thr Trp Val Gly Val Asn Leu Glu Asp Pro Ala
 65 70 75 80
 Ser Arg Asp Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly Leu Lys
 85 90 95
 Phe Arg Gln Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly Arg
 100 105 110
 Glu Thr Val Ile Glu Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr
 115 120 125
 Pro Pro Ala Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro
 130 135 140
 Glu Thr Cys Val Val Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr
 145 150 155 160
 Pro Ser Pro Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser
 165 170 175
 Gln Ser Arg Glu Ser Gln Cys
 180

<210> 94
 <211> 212
 <212> PRT
 <213> Hepatitis B virus

<400> 94
 Met Gln Leu Phe His Leu Cys Leu Ile Ile Ser Cys Ser Cys Pro Thr
 1 5 10 15
 Val Gln Ala Ser Lys Leu Cys Leu Gly Trp Leu Trp Gly Met Asp Ile

-26-

20					25					30					
Asp	Pro	Tyr	Lys	Glu	Phe	Gly	Ala	Thr	Val	Glu	Leu	Leu	Ser	Phe	Leu
		35					40					45			
Pro	Ser	Asp	Phe	Phe	Pro	Ser	Val	Arg	Asp	Leu	Leu	Asp	Thr	Ala	Ser
	50					55					60				
Ala	Leu	Tyr	Arg	Glu	Ala	Leu	Glu	Ser	Pro	Glu	His	Cys	Ser	Pro	His
65					70					75					80
His	Thr	Ala	Leu	Arg	Gln	Ala	Ile	Leu	Cys	Trp	Gly	Asp	Leu	Met	Thr
			85						90					95	
Leu	Ala	Thr	Trp	Val	Gly	Gly	Asn	Leu	Glu	Asp	Pro	Val	Ser	Arg	Asp
			100					105					110		
Leu	Val	Val	Ser	Tyr	Val	Asn	Thr	Asn	Val	Gly	Leu	Lys	Phe	Arg	Gln
		115					120					125			
Leu	Leu	Trp	Phe	His	Ile	Ser	Cys	Leu	Thr	Phe	Gly	Arg	Glu	Thr	Val
	130					135					140				
Ile	Glu	Tyr	Leu	Val	Ser	Phe	Gly	Val	Trp	Ile	Arg	Thr	Pro	Pro	Ala
145						150					155				160
Tyr	Arg	Pro	Pro	Asn	Ala	Pro	Ile	Leu	Ser	Thr	Leu	Pro	Glu	Thr	Thr
				165					170					175	
Val	Val	Arg	Arg	Arg	Gly	Arg	Ser	Pro	Arg	Arg	Arg	Thr	Pro	Ser	Pro
			180					185					190		
Arg	Arg	Arg	Arg	Ser	Gln	Ser	Pro	Arg	Arg	Arg	Arg	Ser	Gln	Ser	Arg
		195					200					205			
Glu	Ser	Gln	Cys												
	210														

<210> 95
 <211> 212
 <212> PRT
 <213> Hepatitis B virus

<400> 95															
Met	Gln	Leu	Phe	His	Leu	Cys	Leu	Ile	Ile	Ser	Cys	Ser	Cys	Pro	Thr
1				5					10					15	
Val	Gln	Ala	Ser	Lys	Leu	Cys	Leu	Gly	Trp	Leu	Trp	Asp	Met	Asp	Ile
			20					25					30		
Asp	Pro	Tyr	Lys	Glu	Phe	Gly	Ala	Thr	Val	Glu	Leu	Leu	Ser	Phe	Leu
		35					40					45			
Pro	Ser	Asp	Phe	Phe	Pro	Ser	Val	Arg	Asp	Leu	Leu	Asp	Thr	Ala	Ser
	50					55					60				
Ala	Leu	Tyr	Arg	Glu	Ala	Leu	Glu	Ser	Pro	Glu	His	Cys	Ser	Pro	His
65					70					75					80
His	Thr	Ala	Leu	Arg	Gln	Ala	Ile	Leu	Cys	Trp	Gly	Asp	Leu	Met	Thr
			85						90					95	

-27-

Leu Ala Thr Trp Val Gly Gly Asn Leu Glu Asp Pro Val Ser Arg Asp
 100 105 110
 Leu Val Val Ser Tyr Val Asn Thr Asn Val Gly Leu Lys Phe Arg Gln
 115 120 125
 Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly Arg Glu Thr Val
 130 135 140
 Ile Glu Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr Pro Pro Ala
 145 150 155 160
 Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro Glu Thr Thr
 165 170 175
 Val Val Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr Pro Ser Pro
 180 185 190
 Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser Gln Ser Arg
 195 200 205
 Glu Ser Gln Cys
 210

<210> 96
 <211> 212
 <212> PRT
 <213> Hepatitis B virus

<400> 96
 Met Gln Leu Phe His Leu Cys Leu Ile Ile Ser Cys Ser Cys Pro Thr
 1 5 10 15
 Val Gln Ala Ser Lys Leu Cys Leu Gly Trp Leu Trp Gly Met Asp Ile
 20 25 30
 Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu Ser Phe Leu
 35 40 45
 Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp Thr Ala Ser
 50 55 60
 Ala Leu Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys Ser Pro Gln
 65 70 75 80
 His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu Leu Met Thr
 85 90 95
 Leu Ala Thr Trp Val Gly Gly Asn Leu Glu Asp Pro Ile Ser Arg Asp
 100 105 110
 Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly Leu Lys Phe Arg Gln
 115 120 125
 Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly Arg Glu Thr Val
 130 135 140
 Ile Glu Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr Pro Pro Ala
 145 150 155 160
 Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro Glu Thr Thr
 165 170 175

-28-

Val Val Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr Pro Ser Pro
 180 185 190
 Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser Gln Ser Arg
 195 200 205
 Glu Ser Gln Cys
 210

<210> 97
 <211> 212
 <212> PRT
 <213> Hepatitis B virus

<400> 97
 Met Gln Leu Phe His Leu Cys Leu Ile Ile Ser Cys Ser Cys Pro Thr
 1 5 10 15
 Val Gln Ala Ser Lys Leu Cys Leu Gly Trp Leu Trp Gly Met Asp Ile
 20 25 30
 Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu Ser Phe Leu
 35 40 45
 Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp Thr Ala Ser
 50 55 60
 Ala Leu Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys Ser Pro His
 65 70 75 80
 His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu Leu Met Thr
 85 90 95
 Leu Ala Thr Trp Val Gly Val Asn Leu Glu Asp Pro Ala Ser Arg Asp
 100 105 110
 Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly Leu Lys Phe Arg Gln
 115 120 125
 Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly Arg Glu Thr Val
 130 135 140
 Ile Glu Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr Pro Pro Ala
 145 150 155 160
 Tyr Lys Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro Glu Thr Thr
 165 170 175
 Val Val Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr Pro Ser Pro
 180 185 190
 Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser Gln Ser Arg
 195 200 205
 Gly Ser Gln Cys
 210

<210> 98
 <211> 183
 <212> PRT
 <213> Hepatitis B virus

-29-

<400> 98

Met Asp Ile Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu
 1 5 10 15

Ser Phe Leu Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp
 20 25 30

Thr Ala Ser Ala Leu Phe Arg Asp Ala Leu Glu Ser Pro Glu His Cys
 35 40 45

Ser Pro His His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu
 50 55 60

Leu Met Thr Leu Ala Thr Trp Val Gly Gly Asn Leu Glu Asp Pro Ala
 65 70 75 80

Ser Arg Asp Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly Leu Lys
 85 90 95

Phe Arg Gln Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly Arg
 100 105 110

Asp Thr Val Ile Glu Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr
 115 120 125

Pro Pro Ala Tyr Arg Pro Ser Asn Ala Pro Ile Leu Ser Thr Leu Pro
 130 135 140

Glu Thr Cys Val Val Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr
 145 150 155 160

Pro Ser Pro Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Ser
 165 170 175

Gln Ser Arg Glu Ser Gln Cys
 180

<210> 99

<211> 183

<212> PRT

<213> Hepatitis B virus

<400> 99

Met Asp Ile Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu
 1 5 10 15

Ser Phe Leu Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp
 20 25 30

Thr Ala Ser Ala Leu Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys
 35 40 45

Ser Pro His His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu
 50 55 60

Leu Met Thr Leu Ala Thr Trp Val Gly Val Asn Leu Glu Asp Pro Ala
 65 70 75 80

Ser Arg Asp Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly Leu Lys
 85 90 95

-30-

Phe Arg Gln Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly Arg
 100 105 110
 Glu Thr Val Ile Glu Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr
 115 120 125
 Pro Pro Ala Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro
 130 135 140
 Glu Thr Thr Val Val Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr
 145 150 155 160
 Pro Ser Pro Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser
 165 170 175
 Gln Ser Arg Glu Ser Gln Cys
 180

<210> 100
 <211> 212
 <212> PRT
 <213> Hepatitis B virus

<400> 100
 Met Gln Leu Phe His Leu Cys Leu Ile Ile Ser Cys Ser Cys Pro Thr
 1 5 10 15
 Val Gln Ala Ser Lys Leu Cys Leu Gly Trp Leu Trp Gly Met Asp Ile
 20 25 30
 Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu Ser Phe Leu
 35 40 45
 Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp Thr Ala Ser
 50 55 60
 Ala Leu Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys Ser Pro His
 65 70 75 80
 His Thr Ala Leu Arg His Ala Ile Leu Cys Trp Gly Asp Leu Arg Thr
 85 90 95
 Leu Ala Thr Trp Val Gly Gly Asn Leu Glu Asp Pro Ile Ser Arg Asp
 100 105 110
 Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly Leu Lys Phe Arg Gln
 115 120 125
 Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly Arg Glu Thr Val
 130 135 140
 Ile Glu Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr Pro Pro Ala
 145 150 155 160
 Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro Glu Thr Thr
 165 170 175
 Val Val Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr Pro Ser Pro
 180 185 190
 Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser Gln Ser Arg
 195 200 205

-31-

Glu Ser Gln Cys
210

<210> 101
<211> 212
<212> PRT
<213> Hepatitis B virus

<400> 101
Met Gln Leu Phe His Leu Cys Leu Ile Ile Ser Cys Ser Cys Pro Thr
1 5 10 15
Val Gln Ala Ser Lys Leu Cys Leu Gly Trp Leu Trp Asp Met Asp Ile
20 25 30
Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu Ser Phe Leu
35 40 45
Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp Thr Ala Ser
50 55 60
Ala Leu Phe Arg Asp Ala Leu Glu Ser Pro Glu His Cys Ser Pro His
65 70 75 80
His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu Leu Met Thr
85 90 95
Leu Ala Thr Trp Val Gly Ala Asn Leu Glu Asp Pro Ala Ser Arg Asp
100 105 110
Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly Leu Lys Phe Arg Gln
115 120 125
Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly Arg Glu Thr Val
130 135 140
Ile Glu Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr Pro Gln Ala
145 150 155 160
Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro Glu Thr Cys
165 170 175
Val Val Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr Pro Ser Pro
180 185 190
Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser Gln Ser Arg
195 200 205
Glu Ser Gln Cys
210

<210> 102
<211> 183
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
human Hepatitis B construct

-32-

<400> 102

```

Met Asp Ile Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu
 1          5          10          15

Ser Phe Leu Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp
          20          25          30
Thr Ala Ser Ala Leu Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys
          35          40          45

Ser Pro His His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu
 50          55          60

Leu Met Thr Leu Ala Thr Trp Val Gly Val Asn Leu Glu Asp Pro Ala
 65          70          75          80

Ser Arg Asp Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly Leu Lys
          85          90          95

Phe Arg Gln Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly Arg
          100          105          110

Glu Thr Val Leu Glu Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr
          115          120          125

Pro Pro Ala Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro
          130          135          140

Glu Thr Thr Val Val Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr
          145          150          155          160

Pro Ser Pro Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser
          165          170          175

Gln Ser Arg Glu Ser Gln Cys
          180

```

<210> 103

<211> 212

<212> PRT

<213> Hepatitis B virus

<400> 103

```

Met Gln Leu Phe His Leu Cys Leu Ile Ile Ser Cys Ser Cys Pro Thr
 1          5          10          15

Val Gln Ala Ser Lys Leu Cys Leu Gly Trp Leu Trp Gly Met Asp Ile
          20          25          30

Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu Ser Phe Leu
          35          40          45

Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp Thr Ala Ser
          50          55          60

Ala Leu Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys Ser Pro His
          65          70          75          80

His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Asp Leu Met Ser
          85          90          95

Leu Ala Thr Trp Val Gly Val Asn Leu Glu Asp Pro Ile Ser Arg Asp
          100          105          110

```

-33-

Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly Leu Lys Phe Arg Gln
 115 120 125
 Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly Arg Glu Thr Val
 130 135 140
 Ile Glu Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr Pro Pro Ala
 145 150 155 160
 Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro Glu Thr Thr
 165 170 175
 Val Val Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr Pro Ser Pro
 180 185 190
 Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser Gln Ser Arg
 195 200 205
 Glu Ser Gln Cys
 210

<210> 104
 <211> 183
 <212> PRT
 <213> Hepatitis B virus

<400> 104
 Met Asp Ile Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu
 1 5 10 15
 Ser Phe Leu Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp
 20 25 30
 Thr Ala Ser Ala Leu Tyr Arg Asp Ala Leu Glu Ser Pro Glu His Cys
 35 40 45
 Ser Pro His His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu
 50 55 60
 Leu Met Thr Leu Ala Thr Trp Val Gly Val Asn Leu Glu Asp Pro Ala
 65 70 75 80
 Ser Arg Asp Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly Leu Lys
 85 90 95
 Phe Arg Gln Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly Arg
 100 105 110
 Glu Thr Val Ile Glu Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr
 115 120 125
 Pro Pro Ala Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro
 130 135 140
 Glu Thr Thr Val Val Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr
 145 150 155 160
 Pro Ser Pro Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser
 165 170 175
 Gln Ser Arg Glu Ser Gln Cys
 180

-34-

<210> 105
 <211> 183
 <212> PRT
 <213> Hepatitis B virus
 <400> 105
 Met Asp Ile Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu
 1 5 10 15
 Ser Phe Leu Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp
 20 25 30
 Thr Ala Ser Ala Leu Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys
 35 40 45
 Ser Pro His His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Asp
 50 55 60
 Leu Met Thr Leu Ala Thr Trp Val Gly Val Asn Leu Glu Asp Pro Ala
 65 70 75 80
 Ser Arg Asp Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly Leu Lys
 85 90 95
 Phe Arg Gln Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly Arg
 100 105 110
 Glu Thr Val Ile Glu Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr
 115 120 125
 Pro Pro Ala Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro
 130 135 140
 Glu Thr Thr Val Val Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr
 145 150 155 160
 Pro Ser Pro Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser
 165 170 175
 Gln Ser Arg Glu Ser Gln Cys
 180

<210> 106
 <211> 183
 <212> PRT
 <213> Hepatitis B virus
 <400> 106
 Met Asp Ile Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu
 1 5 10 15
 Ser Phe Leu Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp
 20 25 30
 Thr Ala Ser Ala Leu Tyr Arg Asp Ala Leu Glu Ser Pro Glu His Cys
 35 40 45
 Ser Pro His His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu
 50 55 60
 Leu Met Thr Leu Ala Thr Trp Val Gly Ala Asn Leu Glu Asp Pro Ala

-35-

65 70 75 80
 Ser Arg Asp Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly Leu Lys
 85 90 95
 Phe Arg Gln Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly Arg
 100 105 110
 Glu Thr Val Ile Glu Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr
 115 120 125
 Pro Pro Ala Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro
 130 135 140
 Glu Thr Thr Val Val Arg Arg Arg Gly Arg Thr Pro Arg Arg Arg Thr
 145 150 155 160
 Pro Ser Pro Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser
 165 170 175
 Gln Ser Arg Glu Ser Gln Cys
 180

<210> 107
 <211> 212
 <212> PRT
 <213> Hepatitis B virus

<400> 107
 Met Gln Leu Phe His Leu Cys Leu Ile Ile Ser Cys Ser Cys Pro Thr
 1 5 10 15
 Val Gln Ala Ser Lys Leu Cys Leu Gly Trp Leu Trp Gly Met Asp Ile
 20 25 30
 Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu Ser Phe Leu
 35 40 45
 Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp Thr Ala Ser
 50 55 60
 Ala Leu Tyr Arg Asp Ala Leu Glu Ser Pro Glu His Cys Ser Pro His
 65 70 75 80
 His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu Leu Met Thr
 85 90 95
 Leu Ala Thr Trp Val Gly Val Asn Leu Glu Asp Pro Ala Ser Arg Asp
 100 105 110
 Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly Leu Lys Phe Arg Gln
 115 120 125
 Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly Arg Glu Thr Val
 130 135 140
 Ile Glu Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr Pro Pro Ala
 145 150 155 160
 Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro Glu Thr Thr
 165 170 175

-36-

Val Val Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr Pro Ser Pro
 180 185 190

Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser Gln Ser Arg
 195 200 205

Glu Ser Gln Cys
 210

<210> 108

<211> 212

<212> PRT

<213> Hepatitis B virus

<400> 108

Met Gln Leu Phe His Leu Cys Leu Ile Ile Ser Cys Ser Cys Pro Thr
 1 5 10 15

Val Gln Ala Ser Lys Leu Cys Leu Gly Trp Leu Trp Gly Met Asp Ile
 20 25 30

Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu Ser Phe Leu
 35 40 45

Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp Thr Ala Ser
 50 55 60

Ala Leu Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys Ser Pro His
 65 70 75 80

His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Asp Leu Met Thr
 85 90 95

Leu Ala Thr Trp Val Gly Val Asn Leu Glu Asp Pro Ala Ser Arg Asp
 100 105 110

Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly Leu Lys Phe Arg Gln
 115 120 125

Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly Arg Glu Thr Val
 130 135 140

Ile Glu Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr Pro Pro Ala
 145 150 155 160

Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro Glu Thr Thr
 165 170 175

Val Val Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr Pro Ser Pro
 180 185 190

Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser Gln Ser Arg
 195 200 205

Glu Ser Gln Cys
 210

<210> 109

<211> 212

<212> PRT

<213> Hepatitis B virus

-37-

<400> 109

Met Gln Leu Phe His Leu Cys Leu Ile Ile Ser Cys Thr Cys Pro Thr
 1 5 10 15

Val Gln Ala Ser Lys Leu Cys Leu Gly Trp Leu Trp Gly Met Asp Ile
 20 25 30

Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu Ser Phe Leu
 35 40 45

Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp Thr Ala Ser
 50 55 60

Ala Leu Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys Ser Pro His
 65 70 75 80

His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu Leu Met Thr
 85 90 95

Leu Ala Thr Trp Val Gly Val Asn Leu Glu Asp Pro Ala Ser Arg Asp
 100 105 110

Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly Leu Lys Phe Arg Gln
 115 120 125

Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly Arg Glu Thr Val
 130 135 140

Ile Glu Tyr Leu Val Ala Phe Gly Val Trp Ile Arg Thr Pro Pro Ala
 145 150 155 160

Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro Glu Thr Thr
 165 170 175

Val Val Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr Pro Ser Pro
 180 185 190

Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser Gln Ser Arg
 195 200 205

Glu Ser Gln Cys
 210

<210> 110

<211> 212

<212> PRT

<213> Hepatitis B virus

<400> 110

Met Gln Leu Phe His Leu Cys Leu Ile Ile Ser Cys Ser Cys Pro Thr
 1 5 10 15

Val Gln Ala Ser Lys Leu Cys Leu Gly Trp Leu Trp Gly Met Asp Ile
 20 25 30

Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu Ser Phe Leu
 35 40 45

Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp Thr Ala Ser
 50 55 60

-38-

Ala Leu Tyr Arg Glu Ala Phe Glu Cys Ser Glu His Cys Ser Pro His
 65 70 75 80
 His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu Leu Met Thr
 85 90 95
 Leu Ala Thr Trp Val Gly Gly Asn Leu Glu Asp Pro Ile Ser Arg Asp
 100 105 110
 Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly Leu Lys Phe Arg Gln
 115 120 125
 Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly Arg Glu Thr Val
 130 135 140
 Ile Glu Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr Pro Pro Ala
 145 150 155 160
 Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro Glu Thr Thr
 165 170 175
 Val Val Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr Pro Ser Pro
 180 185 190
 Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser Gln Ser Arg
 195 200 205
 Glu Ser Gln Cys
 210

<210> 111
 <211> 212
 <212> PRT
 <213> Hepatitis B virus

<220>
 <221> UNSURE
 <222> (28)
 <223> May be any amino acid.

<400> 111
 Met Gln Leu Phe His Leu Cys Leu Ile Ile Ser Cys Ser Cys Pro Thr
 1 5 10 15
 Val Gln Ala Ser Lys Leu Cys Leu Gly Trp Leu Xaa Asp Met Asp Ile
 20 25 30
 Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu Ser Phe Leu
 35 40 45
 Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp Thr Ala Ser
 50 55 60
 Ala Leu Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys Ser Pro His
 65 70 75 80
 His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Asp Leu Ile Thr
 85 90 95
 Leu Ser Thr Trp Val Gly Gly Asn Leu Glu Asp Pro Thr Ser Arg Asp
 100 105 110

-39-

[illegible]

```
<210> 112
<211> 212
<212> PRT
<213> Hepatitis B virus
```

<400>	112														
Met	Gln	Leu	Phe	His	Leu	Cys	Leu	Ile	Ile	Ser	Cys	Ser	Cys	Pro	Thr
1				5					10					15	
Val	Gln	Ala	Ser	Lys	Leu	Cys	Leu	Gly	Trp	Leu	Trp	Gly	Met	Asp	Ile
			20					25					30		
Asp	Pro	Tyr	Lys	Glu	Phe	Gly	Ala	Thr	Val	Glu	Leu	Leu	Ser	Phe	Leu
		35					40					45			
Pro	Ser	Asp	Phe	Phe	Pro	Ser	Val	Arg	Asp	Leu	Leu	Asp	Asn	Ala	Ser
	50					55					60				
Ala	Leu	Tyr	Arg	Glu	Ala	Leu	Glu	Ser	Pro	Glu	His	Cys	Ser	Pro	His
65					70					75					80
His	Thr	Ala	Leu	Arg	Gln	Ala	Ile	Leu	Cys	Trp	Gly	Glu	Leu	Met	Thr
				85					90					95	
Leu	Ala	Thr	Trp	Val	Gly	Val	Asn	Leu	Glu	Asp	Pro	Ala	Ser	Arg	Asp
			100					105					110		
Leu	Val	Val	Ser	Tyr	Val	Asn	Thr	Asn	Met	Gly	Leu	Lys	Phe	Arg	Gln
		115					120					125			
Leu	Leu	Trp	Phe	His	Ile	Ser	Cys	Leu	Thr	Phe	Gly	Arg	Glu	Thr	Val
	130					135					140				
Ile	Glu	Tyr	Leu	Val	Ser	Phe	Gly	Val	Trp	Ile	Arg	Thr	Pro	Pro	Ala
145					150					155					160
Tyr	Arg	Pro	Pro	Asn	Ala	Pro	Ile	Leu	Ser	Thr	Leu	Pro	Glu	Thr	Thr
				165					170					175	
Val	Val	Arg	Arg	Arg	Gly	Arg	Ser	Pro	Arg	Arg	Arg	Thr	Pro	Ser	Pro
			180					185					190		

-40-

Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser Gln Ser Arg
 195 200 205

Glu Ser Gln Cys
 210

<210> 113

<211> 212

<212> PRT

<213> Hepatitis B virus

<400> 113

Met Gln Leu Phe His Leu Cys Leu Ile Ile Ser Cys Ser Cys Pro Thr
 1 5 10 15

Val Gln Ala Ser Lys Leu Cys Leu Gly Trp Leu Trp Gly Met Asp Ile
 20 25 30

Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu Ser Phe Leu
 35 40 45

Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp Thr Ala Ser
 50 55 60

Ala Leu Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys Ser Pro His
 65 70 75 80

His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu Leu Met Thr
 85 90 95

Leu Ala Thr Trp Val Gly Val Asn Leu Glu Asp Pro Ala Ser Arg Asp
 100 105 110

Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly Leu Lys Phe Arg Gln
 115 120 125

Leu Leu Trp Phe His Ile Cys Cys Leu Thr Phe Gly Arg Glu Thr Val
 130 135 140

Ile Glu Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr Pro Pro Ala
 145 150 155 160

Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro Glu Thr Thr
 165 170 175

Val Val Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr Pro Ser Pro
 180 185 190

Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser Gln Ser Arg
 195 200 205

Glu Ser Gln Cys
 210

<210> 114

<211> 212

<212> PRT

<213> Hepatitis B virus

<400> 114

Met Gln Leu Phe His Leu Cys Leu Ile Ile Ser Cys Ser Cys Pro Thr

-41-

1	5	10	15
Val Gln Ala Ser 20	Lys Leu Cys Leu Gly 25	Trp Leu Trp Gly Met 30	Asp Ile
Asp Pro Tyr 35	Lys Glu Phe Gly Ala 40	Thr Val Glu Leu Leu 45	Ser Phe Leu
Pro Ser Asp 50	Phe Phe Pro Ser 55	Val Arg Asp Leu Leu 60	Asp Thr Ala Ser
Ala Leu Tyr Arg 65	Glu Ala Leu Glu Ser 70	Pro Glu His Cys Ser 75	Pro His 80
His Thr Ala Leu Arg 85	Gln Ala Ile Leu Cys 90	Trp Gly Glu Leu Met 95	Thr
Leu Ala Thr 100	Trp Val Gly Val Asn 105	Leu Glu Asp Pro Ala Ser 110	Arg Asp
Leu Val 115	Val Ser Tyr Val Asn 120	Thr Asn Met Gly Leu Lys 125	Phe Arg Gln
Leu Leu Trp 130	Phe His Ile Ser 135	Cys Leu Thr Phe Gly Arg Glu Thr 140	Val
Ile Glu Tyr Leu Val 145	Ser Phe Gly Val Trp 150	Ile Arg Thr Pro Pro 155	Ala 160
Tyr Arg Pro Pro 165	Asn Ala Pro Ile Leu 170	Ser Thr Leu Pro Glu Thr 175	Thr
Val Val Arg 180	Arg Arg Gly Arg Ser 185	Pro Arg Arg Arg Thr Pro Ser 190	Pro
Arg Arg Arg Arg 195	Ser Gln Ser Pro 200	Arg Arg Arg Arg Ser Gln Ser Arg 205	
Glu Pro Gln Cys 210			

<210> 115

<211> 212

<212> PRT

<213> Hepatitis B virus

<400> 115

Met Gln Leu Phe 1	His Leu Cys Leu 5	Ile Ile Ser Cys Ser Cys 10	Pro Thr 15
Val Gln Ala Ser 20	Lys Leu Cys Leu Gly 25	Trp Leu Trp Gly Met 30	Asp Ile
Asp Pro Tyr 35	Lys Glu Phe Gly Ala 40	Thr Val Glu Leu Leu 45	Ser Phe Leu
Pro Ser Asp 50	Phe Phe Pro Ser 55	Val Arg Asp Leu Leu 60	Thr Ala Ser
Ala Leu Tyr Arg 65	Glu Ala Leu Glu Ser 70	Pro Glu His Cys Ser 75	Pro His 80

[illegible]

<400>	116														
Met	Gln	Leu	Phe	His	Leu	Cys	Leu	Ile	Ile	Ser	Cys	Ser	Cys	Pro	Thr
1				5					10					15	
Val	Gln	Ala	Ser	Lys	Leu	Cys	Leu	Gly	Trp	Leu	Trp	Gly	Met	Asp	Ile
			20					25					30		
Asp	Pro	Tyr	Lys	Glu	Phe	Gly	Ala	Thr	Val	Glu	Leu	Leu	Ser	Phe	Leu
		35					40					45			
Pro	Ser	Asp	Phe	Phe	Pro	Ser	Val	Arg	Asp	Leu	Leu	Asp	Thr	Ala	Ser
	50					55					60				
Ala	Leu	Tyr	Arg	Glu	Ala	Leu	Glu	Ser	Pro	Glu	His	Cys	Ser	Pro	His
65					70					75					80
His	Thr	Ala	Leu	Arg	Gln	Ala	Ile	Leu	Cys	Trp	Gly	Glu	Leu	Met	Thr
				85					90					95	
Leu	Ala	Thr	Trp	Val	Gly	Val	Asn	Leu	Glu	Asp	Pro	Ala	Ser	Arg	Asp
			100					105					110		
Leu	Val	Val	Ser	Tyr	Val	Asn	Thr	Asn	Met	Gly	Leu	Lys	Phe	Arg	Gln
		115					120					125			
Leu	Leu	Trp	Phe	His	Ile	Ser	Cys	Leu	Thr	Phe	Gly	Arg	Glu	Thr	Val
	130					135					140				
Ile	Glu	Tyr	Leu	Val	Ser	Phe	Gly	Val	Trp	Ile	Arg	Thr	Pro	Pro	Ala
145					150					155					160

-43-

Tyr Arg Pro Pro Asn Ala Pro Ile Leu Leu Thr Leu Pro Glu Thr Thr
 165 170 175
 Val Val Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr Pro Ser Pro
 180 185 190
 Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser Gln Ser Arg
 195 200 205
 Glu Ser Gln Cys
 210

<210> 117
 <211> 212
 <212> PRT
 <213> Hepatitis B virus

<400> 117
 Met Gln Leu Phe His Leu Cys Leu Ile Ile Ser Cys Ser Cys Pro Thr
 1 5 10 15
 Val Gln Ala Ser Lys Leu Cys Leu Gly Trp Leu Trp Gly Met Asp Ile
 20 25 30
 Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu Ser Phe Leu
 35 40 45
 Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp Thr Ala Ser
 50 55 60
 Ala Leu Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys Ser Pro His
 65 70 75 80
 His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Asp Leu Met Thr
 85 90 95
 Leu Ala Thr Trp Val Gly Val Asn Leu Glu Asp Pro Ala Ser Arg Asp
 100 105 110
 Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly Leu Lys Phe Lys Gln
 115 120 125
 Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly Arg Glu Thr Val
 130 135 140
 Ile Glu Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr Pro Pro Ala
 145 150 155 160
 Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro Glu Thr Thr
 165 170 175
 Val Val Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr Pro Ser Pro
 180 185 190
 Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser Gln Ser Arg
 195 200 205
 Glu Ser Gln Cys
 210

<210> 118

-44-

<211> 212

<212> PRT

<213> Hepatitis B virus

<400> 118

```

Met Gln Leu Phe His Leu Cys Leu Ile Ile Ser Cys Ser Cys Pro Thr
 1           5           10           15

Val Gln Ala Ser Lys Leu Cys Leu Gly Trp Leu Trp Gly Met Asp Ile
          20           25           30

Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu Ser Phe Leu
          35           40           45

Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp Thr Ala Ala
 50           55           60

Ala Leu Tyr Arg Asp Ala Leu Glu Ser Pro Glu His Cys Ser Pro His
 65           70           75           80

His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu Leu Met Thr
          85           90           95

Leu Ala Thr Trp Val Gly Thr Asn Leu Glu Asp Pro Ala Ser Arg Asp
          100          105          110

Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly Leu Lys Phe Arg Gln
          115          120          125

Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly Arg Glu Thr Val
          130          135          140

Leu Glu Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr Pro Pro Ala
          145          150          155          160

Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro Glu Thr Thr
          165          170          175

Val Val Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr Pro Ser Pro
          180          185          190

Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser Gln Ser Arg
          195          200          205

Glu Ser Gln Cys
          210

```

<210> 119

<211> 183

<212> PRT

<213> Hepatitis B virus

<400> 119

```

Met Asp Ile Asp Pro Tyr Lys Glu Phe Gly Ala Ser Met Glu Leu Leu
 1           5           10           15

Ser Phe Leu Pro Ser Asp Phe Tyr Pro Ser Val Arg Asp Leu Leu Asp
          20           25           30

Thr Ala Ser Ala Leu Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys
          35           40           45

```

-45-

Thr Pro His His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu
 50 55 60
 Leu Met Thr Leu Ala Thr Trp Val Gly Gly Asn Leu Gln Asp Pro Thr
 65 70 75 80
 Ser Arg Asp Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly Leu Lys
 85 90 95
 Phe Arg Gln Leu Leu Trp Phe His Val Ser Cys Leu Thr Phe Gly Arg
 100 105 110
 Glu Thr Val Val Glu Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr
 115 120 125
 Pro Gln Ala Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro
 130 135 140
 Glu Thr Cys Val Val Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr
 145 150 155 160
 Pro Ser Pro Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser
 165 170 175
 Gln Ser Arg Glu Ser Gln Cys
 180

<210> 120

<211> 183

<212> PRT

<213> Hepatitis B virus

<400> 120

Met Asp Ile Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu
 1 5 10 15
 Ser Phe Leu Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp
 20 25 30
 Thr Ala Ser Ala Leu Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys
 35 40 45
 Ser Pro His His Thr Ala Leu Arg His Val Phe Leu Cys Trp Gly Asp
 50 55 60
 Leu Met Thr Leu Ala Thr Trp Val Gly Gly Asn Leu Glu Asp Pro Thr
 65 70 75 80
 Ser Arg Asp Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly Leu Lys
 85 90 95
 Phe Arg Gln Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly Arg
 100 105 110
 Glu Thr Val Ile Glu Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr
 115 120 125
 Pro Pro Ala Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro
 130 135 140
 Glu Thr Thr Val Val Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr
 145 150 155 160

-46-

Pro Ser Pro Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser
 165 170 175

Gln Ser Arg Glu Ser Gln Cys
 180

<210> 121

<211> 212

<212> PRT

<213> Hepatitis B virus

<400> 121

Met Gln Leu Phe His Leu Cys Leu Ile Ile Ser Cys Ser Cys Pro Thr
 1 5 10 15

Val Gln Ala Ser Lys Leu Cys Leu Gly Trp Leu Trp Gly Met Asp Ile
 20 25 30

Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu Ser Phe Leu
 35 40 45

Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp Thr Ala Ser
 50 55 60

Ala Leu Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys Ser Pro His
 65 70 75 80

His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Asp Leu Thr Thr
 85 90 95

Leu Ala Thr Trp Val Gly Val Asn Leu Glu Asp Pro Ala Ser Arg Asp
 100 105 110

Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly Leu Lys Phe Arg Gln
 115 120 125

Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly Arg Glu Thr Val
 130 135 140

Ile Glu Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr Pro Pro Ala
 145 150 155 160

Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro Glu Thr Thr
 165 170 175

Val Val Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr Pro Ser Pro
 180 185 190

Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser Gln Ser Arg
 195 200 205

Glu Ser Gln Cys
 210

<210> 122

<211> 212

<212> PRT

<213> Hepatitis B virus

<400> 122

Met Gln Leu Phe His Leu Cys Leu Ile Ile Ser Cys Ser Cys Pro Thr

-47-

1	5	10	15
Val Gln Ala Ser 20	Lys Leu Cys Leu Gly 25	Trp Leu Trp Gly 30	Met Asp Ile
Asp Pro Tyr 35	Lys Glu Phe Gly 40	Val Glu Leu Leu 45	Ser Phe Leu
Pro Ser Asp 50	Phe Phe Pro Ser 55	Val Arg Asp Leu Leu 60	Asp Thr Ala Ser
Ala Leu Tyr Arg Asp 65	Ala Leu Glu Ser 70	Pro Glu His Cys 75	Ser Pro His 80
His Thr Ala Leu Arg 85	Gln Ala Ile Leu Cys 90	Trp Gly Glu Leu Met 95	Thr
Leu Ala Thr 100	Trp Val Gly Val Asn 105	Glu Asp Pro Ala Ser 110	Arg Asp
Leu Val Val 115	Ser Tyr Val Asn Thr 120	Asn Met Gly Leu Lys 125	Phe Arg Gln
Leu Leu Trp 130	Phe His Ile Ser 135	Cys Leu Ile Phe Gly 140	Arg Glu Thr Val
Ile Glu Tyr Leu Val 145	Ser Phe Gly Val Trp 150	Ile Arg Thr Pro Pro 155	Ala 160
Tyr Arg Pro Pro 165	Asn Ala Pro Ile Leu Ser 170	Thr Leu Pro Glu Thr 175	Thr
Val Val Arg Arg 180	Arg Gly Arg Ser Pro 185	Arg Arg Arg Thr Pro 190	Ser Pro
Arg Arg Arg Arg 195	Ser Gln Ser Pro 200	Arg Arg Arg Arg Ser 205	Gln Ser Arg
Glu Ser Gln Cys 210			

<210> 123

<211> 183

<212> PRT

<213> Hepatitis B virus

<400> 123

Met Asp Ile Asp 1	Pro Tyr Lys Glu Phe Gly 10	Ala Thr Val Glu Leu Leu 15
Ser Phe Leu Pro 20	Ser Asp Phe Phe Pro 25	Ser Val Arg Asp Leu Leu Asp 30
Thr Ala Ser 35	Ala Leu Tyr Arg Glu 40	Ala Leu Glu Ser Pro Glu His Cys 45
Ser Pro His 50	His Thr Ala Leu Arg Gln 55	Ala Ile Leu Cys Trp Gly Asp 60
Leu Met Thr Leu 65	Ala Thr Trp Val Gly 70	Val Asn Leu Glu Asp Pro Val 75 80

-48-

Ser	Arg	Asp	Leu	Val 85	Val	Ser	Tyr	Val	Asn 90	Thr	Asn	Val	Gly	Leu 95	Lys
Phe	Arg	Gln	Leu 100	Leu	Trp	Phe	His	Ile 105	Ser	Cys	Leu	Thr	Phe 110	Gly	Arg
Glu	Thr	Val 115	Ile	Glu	Tyr	Leu	Val 120	Ser	Phe	Gly	Val	Trp 125	Ile	Arg	Thr
Pro	Pro 130	Ala	Tyr	Arg	Pro	Pro 135	Asn	Ala	Pro	Ile	Leu 140	Ser	Thr	Leu	Pro
Glu 145	Thr	Thr	Val	Val	Arg 150	Arg	Arg	Gly	Arg	Ser 155	Pro	Arg	Arg	Arg	Thr 160
Pro	Ser	Pro	Ala	Arg 165	Arg	Arg	Ser	Gln	Ser 170	Pro	Arg	Arg	Arg	Arg 175	Ser
Gln	Ser	Arg	Glu 180	Ser	Gln	Cys									

<210> 124

<211> 212

<212> PRT

<213> Hepatitis B virus

<400> 124

Met 1	Gln	Leu	Phe	His 5	Leu	Cys	Leu	Ile	Ile 10	Ser	Cys	Ser	Cys	Pro 15	Thr
Val	Gln	Ala	Ser 20	Lys	Leu	Cys	Leu	Gly 25	Trp	Leu	Trp	Gly	Met 30	Asp	Ile
Asp	Pro	Tyr 35	Lys	Glu	Phe	Gly	Ala 40	Thr	Val	Glu	Leu	Leu 45	Ser	Phe	Leu
Pro	Ser 50	Asp	Phe	Phe	Pro	Ser 55	Val	Arg	Asp	Leu	Leu 60	Asp	Thr	Ala	Ser
Ala 65	Leu	Tyr	Arg	Glu	Ala 70	Leu	Glu	Ser	Pro	Glu 75	His	Cys	Ser	Pro	His 80
His	Thr	Ala	Leu	Arg 85	Gln	Ala	Ile	Leu	Cys 90	Trp	Gly	Asp	Leu	Met 95	Asn
Leu	Ala	Thr	Trp 100	Val	Gly	Gly	Asn	Leu 105	Glu	Asp	Pro	Val	Ser 110	Arg	Asp
Leu	Val	Val 115	Gly	Tyr	Val	Asn	Thr 120	Thr	Val	Gly	Leu	Lys 125	Phe	Arg	Gln
Leu	Leu 130	Trp	Phe	His	Ile	Ser 135	Cys	Leu	Thr	Phe	Gly 140	Arg	Glu	Thr	Val
Ile 145	Glu	Tyr	Leu	Val	Ser 150	Phe	Gly	Val	Trp	Ile 155	Arg	Thr	Pro	Pro	Ala 160
Tyr	Arg	Pro	Pro	Asn 165	Ala	Pro	Ile	Leu	Ser 170	Thr	Leu	Pro	Glu	Thr 175	Thr
Val	Val	Arg	Arg 180	Arg	Gly	Arg	Ser	Pro 185	Arg	Arg	Arg	Thr	Pro 190	Ser	Pro

-49-

Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser Gln Ser Arg
 195 200 205

Glu Ser Gln Cys
 210

<210> 125

<211> 183

<212> PRT

<213> Hepatitis B virus

<400> 125

Met Asp Ile Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu
 1 5 10 15

Ser Phe Leu Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp
 20 25 30

Thr Ala Ser Ala Leu Tyr Arg Asp Ala Leu Glu Ser Pro Glu His Cys
 35 40 45

Ser Pro His His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Asp
 50 55 60

Leu Met Thr Leu Ala Thr Trp Val Gly Val Asn Leu Glu Asp Pro Ala
 65 70 75 80

Ser Arg Asp Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly Leu Lys
 85 90 95

Phe Arg Gln Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly Arg
 100 105 110

Glu Thr Val Ile Glu Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr
 115 120 125

Pro Pro Ala Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro
 130 135 140

Glu Thr Thr Val Val Arg Arg Arg Gly Arg Thr Pro Arg Arg Arg Thr
 145 150 155 160

Pro Ser Pro Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser
 165 170 175

Gln Ser Arg Glu Ser Gln Cys
 180

<210> 126

<211> 212

<212> PRT

<213> Hepatitis B virus

<400> 126

Met Gln Leu Phe His Leu Cys Leu Ile Ile Ser Cys Ser Cys Pro Thr
 1 5 10 15

Val Gln Ala Ser Lys Leu Cys Leu Gly Trp Leu Trp Gly Met Asp Ile
 20 25 30

Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu Ser Phe Leu

-50-

35 40 45
 Pro Ser Asp Phe Phe Pro Ser Val Arg Ala Leu Leu Asp Thr Ala Ser
 50 55 60
 Ala Leu Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys Ser Pro His
 65 70 75 80
 His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu Leu Met Thr
 85 90 95
 Leu Ala Thr Trp Val Gly Val Asn Leu Glu Asp Pro Ala Ser Arg Asp
 100 105 110
 Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly Leu Lys Phe Arg Gln
 115 120 125
 Ile Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly Arg Glu Thr Val
 130 135 140
 Ile Glu Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr Pro Pro Ala
 145 150 155 160
 Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro Glu Thr Thr
 165 170 175
 Val Val Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr Pro Ser Pro
 180 185 190
 Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser Gln Ser Arg
 195 200 205
 Glu Ser Gln Cys
 210

<210> 127

<211> 212

<212> PRT

<213> Hepatitis B virus

<400> 127

Met Gln Leu Phe His Leu Cys Leu Ile Ile Ser Cys Ser Cys Pro Thr
 1 5 10 15
 Val Gln Ala Ser Lys Leu Cys Leu Gly Trp Leu Trp Gly Met Asp Ile
 20 25 30
 Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu Ser Phe Leu
 35 40 45
 Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp Thr Ala Ser
 50 55 60
 Ala Leu Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys Ser Pro His
 65 70 75 80
 His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Asp Leu Met Thr
 85 90 95
 Leu Ala Thr Trp Val Gly Val Asn Leu Glu Asp Pro Ala Thr Arg Asp
 100 105 110

-51-

[illegible]

```
<210> 128
<211> 212
<212> PRT
<213> Hepatitis B virus
```

<400>	128														
Met	Gln	Leu	Phe	His	Leu	Cys	Leu	Ile	Ile	Ser	Cys	Ser	Cys	Pro	Thr
1				5					10					15	
Val	Gln	Ala	Ser	Lys	Leu	Cys	Leu	Gly	Trp	Leu	Trp	Gly	Met	Asp	Ile
			20					25					30		
Asp	Pro	Tyr	Lys	Glu	Phe	Gly	Ala	Thr	Val	Glu	Leu	Leu	Ser	Phe	Leu
		35					40					45			
Pro	Ser	Asp	Phe	Phe	Pro	Ser	Val	Arg	Asp	Leu	Leu	Asp	Thr	Ala	Ser
	50					55					60				
Ala	Leu	Tyr	Arg	Glu	Ala	Leu	Glu	Ser	Pro	Glu	His	Cys	Ser	Pro	His
65					70					75					80
His	Thr	Ala	Leu	Arg	Gln	Arg	Ile	Leu	Cys	Trp	Gly	Glu	Leu	Met	Thr
				85					90					95	
Leu	Ala	Thr	Trp	Val	Gly	Val	Asn	Leu	Glu	Asp	Pro	Ala	Ser	Arg	Asp
			100					105					110		
Leu	Val	Val	Ser	Tyr	Val	Asn	Thr	Asn	Met	Gly	Leu	Lys	Phe	Arg	Gln
		115					120					125			
Leu	Leu	Trp	Phe	His	Ile	Ser	Cys	Leu	Thr	Phe	Gly	Arg	Glu	Thr	Val
		130				135					140				
Ile	Glu	Tyr	Leu	Val	Ser	Phe	Gly	Val	Trp	Ile	Arg	Thr	Pro	Pro	Ala
145					150					155					160
Tyr	Arg	Pro	Pro	Asn	Ala	Pro	Ile	Leu	Ser	Thr	Leu	Pro	Glu	Thr	Thr
				165					170					175	
Val	Val	Arg	Arg	Arg	Gly	Arg	Ser	Pro	Arg	Arg	Arg	Thr	Pro	Ser	Pro
			180					185					190		

-52-

Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Thr Arg Ser Gln Ser Arg
 195 200 205

Glu Ser Gln Cys
 210

<210> 129

<211> 212

<212> PRT

<213> Hepatitis B virus

<400> 129

Met Gln Leu Phe His Leu Cys Leu Val Ile Ser Cys Ser Cys Pro Thr
 1 5 10 15

Val Gln Ala Ser Lys Leu Cys Leu Gly Trp Leu Trp Gly Met Asp Ile
 20 25 30

Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu Ser Phe Leu
 35 40 45

Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp Thr Ala Ala
 50 55 60

Ala Leu Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys Ser Pro His
 65 70 75 80

His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu Leu Met Thr
 85 90 95

Leu Ala Thr Trp Val Gly Asn Asn Leu Glu Asp Pro Ala Ser Arg Asp
 100 105 110

Leu Val Val Asn Tyr Val Asn Thr Asn Met Gly Leu Lys Ile Arg Gln
 115 120 125

Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly Arg Glu Thr Val
 130 135 140

Leu Glu Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr Pro Pro Ala
 145 150 155 160

Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro Glu Thr Thr
 165 170 175

Val Val Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr Pro Ser Pro
 180 185 190

Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser Gln Ser Arg
 195 200 205

Glu Ser Gln Cys
 210

<210> 130

<211> 212

<212> PRT

<213> Hepatitis B virus

<400> 130

Met Gln Leu Phe His Leu Cys Leu Ile Ile Ser Cys Ser Cys Pro Thr

1				5				10				15			
Val	Gln	Ala	Ser 20	Lys	Leu	Cys	Leu	Gly 25	Trp	Leu	Trp	Gly	Met 30	Asp	Ile
Asp	Pro	Tyr 35	Lys	Glu	Phe	Gly	Ala 40	Thr	Val	Glu	Leu	Leu 45	Ser	Phe	Leu
Pro	Ser 50	Ala	Phe	Phe	Pro	Ser 55	Val	Arg	Asp	Leu	Leu 60	Asp	Thr	Ala	Ser
Ala 65	Leu	Tyr	Arg	Glu	Ala 70	Leu	Glu	Ser	Pro	Glu 75	His	Cys	Ser	Pro	His 80
His	Thr	Ala	Leu	Arg 85	Gln	Ala	Ile	Leu	Cys 90	Trp	Gly	Asp	Leu	Met 95	Thr
Leu	Ala	Thr	Trp 100	Val	Gly	Val	Asn	Leu 105	Glu	Asp	Pro	Ala	Ser 110	Arg	Asp
Leu	Val	Val 115	Ser	Tyr	Val	Asn	Thr 120	Asn	Met	Gly	Leu	Lys 125	Phe	Arg	Gln
Leu	Leu 130	Trp	Phe	His	Ile	Ser 135	Cys	Leu	Thr	Phe	Gly 140	Arg	Glu	Thr	Val
Ile 145	Glu	Tyr	Leu	Val	Ser 150	Phe	Gly	Val	Trp	Ile 155	Arg	Thr	Pro	Pro	Ala 160
Tyr	Arg	Pro	Pro	Asn 165	Ala	Pro	Ile	Leu	Ser 170	Thr	Leu	Pro	Glu	Thr 175	Thr
Val	Val	Arg	Arg 180	Arg	Gly	Arg	Ser	Pro 185	Arg	Arg	Arg	Thr	Pro 190	Ser	Pro
Arg	Arg	Arg 195	Arg	Ser	Gln	Ser	Pro 200	Arg	Arg	Arg	Arg	Ser 205	Gln	Ser	Arg
Glu	Ser 210	Gln	Cys												

<400> 131															
Met	Asp	Ile	Asp	Pro	Tyr	Lys	Glu	Phe	Gly	Ala	Thr	Val	Glu	Leu	Leu
1				5					10					15	
Ser	Phe	Leu	Pro	Ser	Asp	Phe	Phe	Pro	Ser	Val	Arg	Asp	Leu	Leu	Asp
			20					25					30		
Thr	Ala	Ala	Ala	Leu	Tyr	Arg	Glu	Ala	Leu	Glu	Ser	Pro	Glu	His	Cys
		35					40					45			
Ser	Pro	His	His	Thr	Ala	Leu	Arg	Gln	Ala	Ile	Leu	Cys	Trp	Gly	Glu
	50					55					60				
Leu	Met	Thr	Leu	Ala	Thr	Trp	Val	Gly	Asn	Asn	Leu	Glu	Asp	Pro	Ala
65					70				75						80

[illegible]

```
<210> 132
<211> 183
<212> PRT
<213> Hepatitis B virus
```

```
<400> 132
Met Asp Ile Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu
  1          5      10      15
Ser Phe Leu Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp
    20      25      30
Thr Ala Ser Ala Leu Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys
    35      40      45
Ser Pro His His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu
   50      55      60
Leu Met Thr Leu Ala Thr Trp Val Gly Gly Asn Leu Glu Asp Pro Ile
  65      70      75      80
Ser Arg Asp Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly Leu Lys
           85      90      95
Phe Arg Gln Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly Arg
        100      105      110
Glu Thr Val Ile Glu Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr
     115      120      125
Pro Pro Ala Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro
   130      135      140
Glu Thr Cys Val Val Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr
  145      150      155      160
Pro Ser Pro Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser
            165      170      175
Gln Ser Arg Gly Ser Gln Cys
      180
```

-55-

<210> 133
<211> 3221
<212> DNA
<213> Hepatitis B virus

<220>
<221> CDS
<222> (1901)..(2458)

<400> 133
ttccactgcc ttccaccaag ctctgcagga cccagagtc aggggtctgt attttcctgc 60
tgggtggctcc agttcaggaa cagtaaacc cagtcogaat attgcctctc acatctcgtc 120
aatctccgcg aggactgggg accctgtgac gaacatggag aacatcacat caggattcct 180
aggacccttg ctctgtttac aggcgggggt tttattgttg acaagaatcc tcacaatacc 240
gcagagtcta gactcgtggt ggacttctct caattttata gggggatcac ccgtgtgtct 300
tggccaaaat tcgcagtc ccaacctcaa tcaactacca acctcctgtc ctccaatttg 360
tcctggttat cgctggatgt gtctgcggcg ttttatcata ttctcttca tcctgctgct 420
atgcctcatc ttcttattgg ttcttctgga ttatcaaggt atgttgcccg tttgtcctct 480
aattccagga tcaacaacaa ccagtacggg accatgcaa acctgcacga ctctgctca 540
aggcaactct atgtttccct catgttgctg tacaaaacct acggttgga attgcacctg 600
tattcccatc ccatcgctc gggctttcgc aaaataccta tgggagtggg cctcagtcctg 660
tttctcttgg ctcagtttac tagtgccatt tgttcagtgg ttcgtagggc tttccccac 720
tgtttggtt tcagctatat ggatgatgtg gtattggggg ccaagtctgt acagcatcgt 780
gagtccttt ataccgctgt taccaatttt cttttgtctc tgggtatata tttaaacct 840
aacaaaacaa aaagatgggg ttattcccta aacttcattg gttacataat tggaagtgg 900
ggaacattgc cacaggatca tattgtacaa aagatcaaac actgttttag aaaacttcct 960
gttaacaggc ctattgattg gaaagtatgt caaagaattg tgggtctttt gggctttgct 1020
gtccatttta cacaatgtgg atatcctgcc ttaatgcctt tgtatgcatg tatacaggct 1080
aacaggctt tcaactttct gccaaactac aaggcctttc taagtaaaca gtacatgaac 1140
ctttaccccg ttgctcggca acggcctggt ctgtgccaag tgtttgctga cgcaaccccc 1200
actggttggg gcttggccat aggccatcag cgcagtgtg gaacctttgt ggctcctctg 1260
ccgatccata ctgcggaact cctagccgct tgtattgtc gcagccggtc tggagcaaag 1320
ctcatcggaa ctgacaattc tgtcgtctc tcgcggaaat atacatcgtt tccatggctg 1380
ctaggctgta ctgccaactg gatccttcgc gggacgtcct ttgtttacgt ccgctcggcg 1440
ctgaatcccc cggaacgacc ctctcggggc cgcttgggac tctatcgtcc ccttctccgt 1500
ctgccgttcc agccgaccac ggggcgcacc tctctttac cggtctcccc gtctgtgct 1560

-57-

catttacaag aggacattat tgataggtgt caacaatttg tgggccctct cactgtaaata 2618
 gaaaagagaa gattgaaatt aattatgcct gctagattct atcctaccca cactaaatat 2678
 ttgcccttag acaaaggaat taaaccttat tatccagatc aggtagttaa tcattacttc 2738
 caaaccagac attatttaca tactcttttg aaggctggta ttctatataa gagggaaacc 2798
 acacgtagcg catcatTTTT cgggtcacca tattcttggg aacaagagct acagcatggg 2858
 aggttgggtca ttaaaacctc gcaaaggcat ggggacgaat ctttctgttc ccaacctctc 2918
 gggattcttt cccgatcatc agttggaccc tgcattcgga gccaaactcaa acaatccaga 2978
 ttgggacttc aaccccatca aggaccactg gccagcagcc aaccaggtag gagtgggagc 3038
 attcggggcca ggggtcaccc ctccacacgg cggtattttg ggggtggagcc ctcaggctca 3098
 gggcatattg accacagtgt caacaattcc tcctcctgcc tccaccaatc ggcagtcagg 3158
 aaggcagcct actcccatct ctccacctct aagagacagt catcctcagg ccatgcagtg 3218
 gaa 3221

<210> 134
 <211> 185
 <212> PRT
 <213> Hepatitis B virus

<400> 134
 Met Asp Ile Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu
 1 5 10 15
 Ser Phe Leu Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp
 20 25 30
 Thr Ala Ser Ala Leu Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys
 35 40 45
 Ser Pro His His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu
 50 55 60
 Leu Met Thr Leu Ala Thr Trp Val Gly Asn Asn Leu Glu Asp Pro Ala
 65 70 75 80
 Ser Arg Asp Leu Val Val Asn Tyr Val Asn Thr Asn Met Gly Leu Lys
 85 90 95
 Ile Arg Gln Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly Arg
 100 105 110
 Glu Thr Val Leu Glu Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr
 115 120 125
 Pro Pro Ala Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro
 130 135 140
 Glu Thr Thr Val Val Arg Arg Arg Asp Arg Gly Arg Ser Pro Arg Arg
 145 150 155 160
 Arg Thr Pro Ser Pro Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg
 165 170 175
 Arg Ser Gln Ser Arg Glu Ser Gln Cys
 180 185

<210> 135
 <211> 188
 <212> PRT
 <213> Woodchuck hepatitis B virus

-58-

<400> 135

```

Met Asp Ile Asp Pro Tyr Lys Glu Phe Gly Ser Ser Tyr Gln Leu Leu
 1          5          10          15

Asn Phe Leu Pro Leu Asp Phe Phe Pro Asp Leu Asn Ala Leu Val Asp
      20          25          30
Thr Ala Thr Ala Leu Tyr Glu Glu Leu Thr Gly Arg Glu His Cys
      35          40          45

Ser Pro His His Thr Ala Ile Arg Gln Ala Leu Val Cys Trp Asp Glu
 50          55          60

Leu Thr Lys Leu Ile Ala Trp Met Ser Ser Asn Ile Thr Ser Glu Gln
 65          70          75          80

Val Arg Thr Ile Ile Val Asn His Val Asn Asp Thr Trp Gly Leu Lys
      85          90          95

Val Arg Gln Ser Leu Trp Phe His Leu Ser Cys Leu Thr Phe Gly Gln
      100          105          110

His Thr Val Gln Glu Phe Leu Val Ser Phe Gly Val Trp Ile Arg Thr
      115          120          125

Pro Ala Pro Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro
      130          135          140

Glu His Thr Val Ile Arg Arg Arg Gly Gly Ala Arg Ala Ser Arg Ser
145          150          155          160

Pro Arg Arg Arg Thr Pro Ser Pro Arg Arg Arg Arg Ser Gln Ser Pro
      165          170          175

Arg Arg Arg Arg Ser Gln Ser Pro Ser Thr Asn Cys
      180          185

```

<210> 136

<211> 217

<212> PRT

<213> Ground squirrel hepatitis virus

<400> 136

```

Met Tyr Leu Phe His Leu Cys Leu Val Phe Ala Cys Val Pro Cys Pro
 1          5          10          15

Thr Val Gln Ala Ser Lys Leu Cys Leu Gly Trp Leu Trp Asp Met Asp
      20          25          30

Ile Asp Pro Tyr Lys Glu Phe Gly Ser Ser Tyr Gln Leu Leu Asn Phe
      35          40          45

Leu Pro Leu Asp Phe Phe Pro Asp Leu Asn Ala Leu Val Asp Thr Ala
 50          55          60

Ala Ala Leu Tyr Glu Glu Glu Leu Thr Gly Arg Glu His Cys Ser Pro
 65          70          75          80

His His Thr Ala Ile Arg Gln Ala Leu Val Cys Trp Glu Glu Leu Thr
      85          90          95

Arg Leu Ile Thr Trp Met Ser Glu Asn Thr Thr Glu Glu Val Arg Arg
      100          105          110

```

-59-

Ile Ile Val Asp His Val Asn Asn Thr Trp Gly Leu Lys Val Arg Gln
 115 120 125

Thr Leu Trp Phe His Leu Ser Cys Leu Thr Phe Gly Gln His Thr Val
 130 135 140

Gln Glu Phe Leu Val Ser Phe Gly Val Trp Ile Arg Thr Pro Ala Pro
 145 150 155 160

Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro Glu His Thr
 165 170 175

Val Ile Arg Arg Arg Gly Gly Ser Arg Ala Ala Arg Ser Pro Arg Arg
 180 185 190

Arg Thr Pro Ser Pro Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg
 195 200 205

Arg Ser Gln Ser Pro Ala Ser Asn Cys
 210 215

<210> 137

<211> 262

<212> PRT

<213> Snow Goose Hepatitis B Virus

<400> 137

Met Asp Val Asn Ala Ser Arg Ala Leu Ala Asn Val Tyr Asp Leu Pro
 1 5 10 15

Asp Asp Phe Phe Pro Lys Ile Glu Asp Leu Val Arg Asp Ala Lys Asp
 20 25 30

Ala Leu Glu Pro Tyr Trp Lys Ser Asp Ser Ile Lys Lys His Val Leu
 35 40 45

Ile Ala Thr His Phe Val Asp Leu Ile Glu Asp Phe Trp Gln Thr Thr
 50 55 60

Gln Gly Met His Glu Ile Ala Glu Ala Ile Arg Ala Val Ile Pro Pro
 65 70 75 80

Thr Thr Ala Pro Val Pro Ser Gly Tyr Leu Ile Gln His Asp Glu Ala
 85 90 95

Glu Glu Ile Pro Leu Gly Asp Leu Phe Lys Glu Gln Glu Glu Arg Ile
 100 105 110

Val Ser Phe Gln Pro Asp Tyr Pro Ile Thr Ala Arg Ile His Ala His
 115 120 125

Leu Lys Ala Tyr Ala Lys Ile Asn Glu Glu Ser Leu Asp Arg Ala Arg
 130 135 140

Arg Leu Leu Trp Trp His Tyr Asn Cys Leu Leu Trp Gly Glu Ala Thr
 145 150 155 160

Val Thr Asn Tyr Ile Ser Arg Leu Arg Thr Trp Leu Ser Thr Pro Glu
 165 170 175

Lys Tyr Arg Gly Arg Asp Ala Pro Thr Ile Glu Ala Ile Thr Arg Pro
 180 185 190

-60-

Ile Gln Val Ala Gln Gly Gly Arg Lys Thr Ser Thr Ala Thr Arg Lys
 195 200 205

Pro Arg Gly Leu Glu Pro Arg Arg Arg Lys Val Lys Thr Thr Val Val
 210 215 220

Tyr Gly Arg Arg Arg Ser Lys Ser Arg Glu Arg Arg Ala Ser Ser Pro
 225 230 235 240

Gln Arg Ala Gly Ser Pro Leu Pro Arg Ser Ser Ser Ser His His Arg
 245 250 255

Ser Pro Ser Pro Arg Lys
 260

<210> 138
 <211> 305
 <212> PRT
 <213> Duck hepatitis B virus

<400> 138
 Met Trp Asp Leu Arg Leu His Pro Ser Pro Phe Gly Ala Ala Cys Gln
 1 5 10 15

Gly Ile Phe Thr Ser Ser Leu Leu Leu Phe Leu Val Thr Val Pro Leu
 20 25 30

Val Cys Thr Ile Val Tyr Asp Ser Cys Leu Cys Met Asp Ile Asn Ala
 35 40 45

Ser Arg Ala Leu Ala Asn Val Tyr Asp Leu Pro Asp Asp Phe Phe Pro
 50 55 60

Lys Ile Asp Asp Leu Val Arg Asp Ala Lys Asp Ala Leu Glu Pro Tyr
 65 70 75 80

Trp Arg Asn Asp Ser Ile Lys Lys His Val Leu Ile Ala Thr His Phe
 85 90 95

Val Asp Leu Ile Glu Asp Phe Trp Gln Thr Thr Gln Gly Met His Glu
 100 105 110

Ile Ala Glu Ala Leu Arg Ala Ile Ile Pro Ala Thr Thr Ala Pro Val
 115 120 125

Pro Gln Gly Phe Leu Val Gln His Glu Glu Ala Glu Glu Ile Pro Leu
 130 135 140

Gly Glu Leu Phe Arg Tyr Gln Glu Glu Arg Leu Thr Asn Phe Gln Pro
 145 150 155 160

Asp Tyr Pro Val Thr Ala Arg Ile His Ala His Leu Lys Ala Tyr Ala
 165 170 175

Lys Ile Asn Glu Glu Ser Leu Asp Arg Ala Arg Arg Leu Leu Trp Trp
 180 185 190

His Tyr Asn Cys Leu Leu Trp Gly Glu Pro Asn Val Thr Asn Tyr Ile
 195 200 205

Ser Arg Leu Arg Thr Trp Leu Ser Thr Pro Glu Lys Tyr Arg Gly Lys
 210 215 220

-61-

Asp Ala Pro Thr Ile Glu Ala Ile Thr Arg Pro Ile Gln Val Ala Gln
 225 230 235 240
 Gly Gly Arg Asn Lys Thr Gln Gly Val Arg Lys Ser Arg Gly Leu Glu
 245 250 255
 Pro Arg Arg Arg Val Lys Thr Thr Ile Val Tyr Gly Arg Arg
 260 265 270
 Ser Lys Ser Arg Glu Arg Arg Ala Pro Thr Pro Gln Arg Ala Gly Ser
 275 280 285
 Pro Leu Pro Arg Thr Ser Arg Asp His His Arg Ser Pro Ser Pro Arg
 290 295 300
 Glu
 305

<210> 139
 <211> 212
 <212> PRT
 <213> Haemophilus influenzae

<400> 139
 Met Lys Lys Thr Leu Leu Gly Ser Leu Ile Leu Leu Ala Phe Ala Gly
 1 5 10 15
 Asn Val Gln Ala Ala Ala Asn Ala Asp Thr Ser Gly Thr Val Thr Phe
 20 25 30
 Phe Gly Lys Val Val Glu Asn Thr Cys Gln Val Asn Gln Asp Ser Glu
 35 40 45
 Tyr Glu Cys Asn Leu Asn Asp Val Gly Lys Asn His Leu Ser Gln Gln
 50 55 60
 Gly Tyr Thr Ala Met Gln Thr Pro Phe Thr Ile Thr Leu Glu Asn Cys
 65 70 75 80
 Asn Val Thr Thr Thr Asn Asn Lys Pro Lys Ala Thr Lys Val Gly Val
 85 90 95
 Tyr Phe Tyr Ser Trp Glu Ile Ala Asp Lys Asp Asn Lys Tyr Thr Leu
 100 105 110
 Lys Asn Ile Lys Glu Asn Thr Gly Thr Asn Asp Ser Ala Asn Lys Val
 115 120 125
 Asn Ile Gln Leu Leu Glu Asp Asn Gly Thr Ala Glu Ile Lys Val Val
 130 135 140
 Gly Lys Thr Thr Thr Asp Phe Thr Ser Glu Asn His Asn Gly Ala Gly
 145 150 155 160
 Ala Asp Pro Val Ala Thr Asn Lys His Ile Ser Ser Leu Thr Pro Leu
 165 170 175
 Asn Asn Gln Asn Ser Ile Asn Leu His Tyr Ile Ala Gln Tyr Tyr Ala
 180 185 190
 Thr Gly Val Ala Glu Ala Gly Lys Val Pro Ser Ser Val Asn Ser Gln
 195 200 205

-62-

Ile Ala Tyr Glu
210

<210> 140

<211> 139

<212> PRT

<213> *Pseudomonas stutzeri*

<400> 140

```

Met Lys Ala Gln Met Gln Lys Gly Phe Thr Leu Ile Glu Leu Met Ile
 1           5           10           15

Val Val Ala Ile Ile Gly Ile Leu Ala Ala Ile Ala Leu Pro Ala Tyr
          20           25           30

Gln Asp Tyr Thr Val Arg Ser Asn Ala Ala Ala Ala Leu Ala Glu Ile
          35           40           45

Thr Pro Gly Lys Ile Gly Phe Glu Gln Ala Ile Asn Glu Gly Lys Thr
          50           55           60

Pro Ser Leu Thr Ser Thr Asp Glu Gly Tyr Ile Gly Ile Thr Asp Ser
          65           70           75           80

Thr Ser Tyr Cys Asp Val Asp Leu Asp Thr Ala Ala Asp Gly His Ile
          85           90           95

Glu Cys Thr Ala Lys Gly Gly Asn Ala Gly Lys Phe Asp Gly Lys Thr
          100          105          110

Ile Thr Leu Asn Arg Thr Ala Asp Gly Glu Trp Ser Cys Ala Ser Thr
          115          120          125

Leu Asp Ala Lys Tyr Lys Pro Gly Lys Cys Ser
          130          135

```

<210> 141

<211> 59

<212> PRT

<213> *Caulobacter crescentus*

<400> 141

```

Met Thr Lys Phe Val Thr Arg Phe Leu Lys Asp Glu Ser Gly Ala Thr
 1           5           10           15

Ala Ile Glu Tyr Gly Leu Ile Val Ala Leu Ile Ala Val Val Ile Val
          20           25           30

Thr Ala Val Thr Thr Leu Gly Thr Asn Leu Arg Thr Ala Phe Thr Lys
          35           40           45

Ala Gly Ala Ala Val Ser Thr Ala Ala Gly Thr
          50           55

```

<210> 142

<211> 173

<212> PRT

<213> *Escherichia coli*

-63-

<400> 142

Met Ala Val Val Ser Phe Gly Val Asn Ala Ala Pro Thr Ile Pro Gln
 1 5 10 15
 Gly Gln Gly Lys Val Thr Phe Asn Gly Thr Val Val Asp Ala Pro Cys
 20 25 30
 Ser Ile Ser Gln Lys Ser Ala Asp Gln Ser Ile Asp Phe Gly Gln Leu
 35 40 45
 Ser Lys Ser Phe Leu Glu Ala Gly Gly Val Ser Lys Pro Met Asp Leu
 50 55 60
 Asp Ile Glu Leu Val Asn Cys Asp Ile Thr Ala Phe Lys Gly Gly Asn
 65 70 75 80
 Gly Ala Gln Lys Gly Thr Val Lys Leu Ala Phe Thr Gly Pro Ile Val
 85 90 95
 Asn Gly His Ser Asp Glu Leu Asp Thr Asn Gly Gly Thr Gly Thr Ala
 100 105 110
 Ile Val Val Gln Gly Ala Gly Lys Asn Val Val Phe Asp Gly Ser Glu
 115 120 125
 Gly Asp Ala Asn Thr Leu Lys Asp Gly Glu Asn Val Leu His Tyr Thr
 130 135 140
 Ala Val Val Lys Lys Ser Ser Ala Val Gly Ala Ala Val Thr Glu Gly
 145 150 155 160
 Ala Phe Ser Ala Val Ala Asn Phe Asn Leu Thr Tyr Gln
 165 170

<210> 143

<211> 173

<212> PRT

<213> Escherichia coli

<400> 143

Met Ala Val Val Ser Phe Gly Val Asn Ala Ala Pro Thr Ile Pro Gln
 1 5 10 15
 Gly Gln Gly Lys Val Thr Phe Asn Gly Thr Val Val Asp Ala Pro Cys
 20 25 30
 Ser Ile Ser Gln Lys Ser Ala Asp Gln Ser Ile Asp Phe Gly Gln Leu
 35 40 45
 Ser Lys Ser Phe Leu Glu Ala Gly Gly Val Ser Lys Pro Met Asp Leu
 50 55 60
 Asp Ile Glu Leu Val Asn Cys Asp Ile Thr Ala Phe Lys Gly Gly Asn
 65 70 75 80
 Gly Ala Gln Lys Gly Thr Val Lys Leu Ala Phe Thr Gly Pro Ile Val
 85 90 95
 Asn Gly His Ser Asp Glu Leu Asp Thr Asn Gly Gly Thr Gly Thr Ala
 100 105 110
 Ile Val Val Gln Gly Ala Gly Lys Asn Val Val Phe Asp Gly Ser Glu
 115 120 125

-64-

Gly Asp Ala Asn Thr Leu Lys Asp Gly Glu Asn Val Leu His Tyr Thr
 130 135 140

Ala Val Val Lys Lys Ser Ser Ala Val Gly Ala Ala Val Thr Glu Gly
 145 150 155 160
 Ala Phe Ser Ala Val Ala Asn Phe Asn Leu Thr Tyr Gln
 165 170

<210> 144

<211> 172

<212> PRT

<213> Escherichia coli

<400> 144

Met Ala Val Val Ser Phe Gly Val Asn Ala Ala Pro Thr Thr Pro Gln
 1 5 10 15

Gly Gln Gly Arg Val Thr Phe Asn Gly Thr Val Val Asp Ala Pro Cys
 20 25 30

Ser Ile Ser Gln Lys Ser Ala Asp Gln Ser Ile Asp Phe Gly Gln Leu
 35 40 45

Ser Lys Ser Phe Leu Ala Asn Asp Gly Gln Ser Lys Pro Met Asn Leu
 50 55 60

Asp Ile Glu Leu Val Asn Cys Asp Ile Thr Ala Phe Lys Asn Gly Asn
 65 70 75 80

Ala Lys Thr Gly Ser Val Lys Leu Ala Phe Thr Gly Pro Thr Val Ser
 85 90 95

Gly His Pro Ser Glu Leu Ala Thr Asn Gly Gly Pro Gly Thr Ala Ile
 100 105 110

Met Ile Gln Ala Ala Gly Lys Asn Val Pro Phe Asp Gly Thr Glu Gly
 115 120 125

Asp Pro Asn Leu Leu Lys Asp Gly Asp Asn Val Leu His Tyr Thr Thr
 130 135 140

Val Gly Lys Lys Ser Ser Asp Gly Asn Ala Gln Ile Thr Glu Gly Ala
 145 150 155 160

Phe Ser Gly Val Ala Thr Phe Asn Leu Ser Tyr Gln
 165 170

<210> 145

<211> 853

<212> DNA

<213> Escherichia coli

<220>

<221> CDS

<222> (281)..(829)

<400> 145

acgtttctgt ggctcgacgc atcttctctca ttctttctctc caaaaaccac ctcatgcaat 60

ataaacatct ataaataaag ataacaaata gaatattaag ccaacaaata aactgaaaaa 120

gtttgtccgc gatgctttac ctctatgagt caaaatggcc ccaatgtttc atcttttggg 180

-65-

ggaaaactgtg cagtgtttggc agtcaaactc gttgacaaac aaagtgtaca gaacgactgc																	240
ccatgtcgcgat ttagaaatag ttttttgaaa ggaaagcagc											atg Met 1	aaa Lys	att Ile	aaa Lys	act Thr 5	295	
ctg	gca	atc	gtt	gtt	ctg	tcg	gct	ctg	tcc	ctc	agt	tct	acg	acg	gct	343	
Leu	Ala	Ile	Val	Val	Leu	Ser	Ala	Leu	Ser	Leu	Ser	Ser	Thr	Thr	Ala		
				10					15					20			
ctg	gcc	gct	gcc	acg	acg	gtt	aat	ggg	ggg	acc	gtt	cac	ttt	aaa	ggg	391	
Leu	Ala	Ala	Ala	Thr	Thr	Val	Asn	Gly	Gly	Thr	Val	His	Phe	Lys	Gly		
				25					30					35			
gaa	gtt	gtt	aac	gcc	gct	tcg	gca	gtt	gat	gca	ggc	tct	gtt	gat	caa	439	
Glu	Val	Val	Asn	Ala	Ala	Cys	Ala	Val	Asp	Ala	Gly	Ser	Val	Asp	Gln		
			40					45					50				
acc	gtt	cag	tta	gga	cag	gtt	cgt	acc	gca	tcg	ctg	gca	cag	gaa	gga	487	
Thr	Val	Gln	Leu	Gly	Gln	Val	Arg	Thr	Ala	Ser	Leu	Ala	Gln	Glu	Gly		
		55					60					65					
gca	acc	agt	tct	gct	gtc	ggg	ttt	aac	att	cag	ctg	aat	gat	tcg	gat	535	
Ala	Thr	Ser	Ser	Ala	Val	Gly	Phe	Asn	Ile	Gln	Leu	Asn	Asp	Cys	Asp		
70					75					80					85		
acc	aat	gtt	gca	tct	aaa	gcc	gct	gtt	gcc	ttt	tta	ggg	acg	gcg	att	583	
Thr	Asn	Val	Ala	Ser	Lys	Ala	Ala	Val	Ala	Phe	Leu	Gly	Thr	Ala	Ile		
				90					95					100			
gat	gcg	ggg	cat	acc	aac	gtt	ctg	gct	ctg	cag	agt	tca	gct	gcg	ggg	631	
Asp	Ala	Gly	His	Thr	Asn	Val	Leu	Ala	Leu	Gln	Ser	Ser	Ala	Ala	Gly		
			105					110					115				
agc	gca	aca	aac	gtt	ggg	gtg	cag	atc	ctg	gac	aga	acg	ggg	gct	gcg	679	
Ser	Ala	Thr	Asn	Val	Gly	Val	Gln	Ile	Leu	Asp	Arg	Thr	Gly	Ala	Ala		
			120					125					130				
ctg	acg	ctg	gat	ggg	gcg	aca	ttt	agt	tca	gaa	aca	acc	ctg	aat	aac	727	
Leu	Thr	Leu	Asp	Gly	Ala	Thr	Phe	Ser	Ser	Glu	Thr	Thr	Leu	Asn	Asn		
		135					140					145					
gga	acc	aat	acc	att	ccg	ttc	cag	gcg	cgt	tat	ttt	gca	acc	ggg	gcc	775	
Gly	Thr	Asn	Thr	Ile	Pro	Phe	Gln	Ala	Arg	Tyr	Phe	Ala	Thr	Gly	Ala		
150					155					160					165		
gca	acc	ccg	ggg	gct	gct	aat	gcg	gat	gcg	acc	ttc	aag	gtt	cag	tat	823	
Ala	Thr	Pro	Gly	Ala	Ala	Asn	Ala	Asp	Ala	Thr	Phe	Lys	Val	Gln	Tyr		
				170					175					180			
caa	taa	cctacctagg ttcagggacg				ttca										853	
Gln																	

```
<210> 146
<211> 182
<212> PRT
<213> Escherichia coli
```

```

<400> 146
Met Lys Ile Lys Thr Leu Ala Ile Val Val Leu Ser Ala Leu Ser Leu
 1           5           10           15
Ser Ser Thr Thr Ala Leu Ala Ala Ala Thr Thr Val Asn Gly Gly Thr

```

-66-

[illegible]

```
<210> 147
<211> 11
<212> PRT
<213> Artificial Sequence
```

<220>
<223> Description of Artificial Sequence: FLAG peptide

<400> 147
Cys Gly Gly Asp Tyr Lys Asp Asp Asp Asp Lys
1 5 10

```
<210> 148
<211> 31
<212> DNA
<213> Artificial Sequence
```

<220>
<223> Description of Artificial Sequence: primer

<400> 148
ccggaattca tggacattga cccttataaa g 31

```
<210> 149
<211> 37
<212> DNA
<213> Artificial Sequence
```

<220>
<223> Description of Artificial Sequence: primer

<400> 149
gtgcagtatg gtgaggtgag gaatgctcag gagactc 37

<210> 150
<211> 37

-67-

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 150

gsgtctcctg agcattcctc acctcaccat actgcac

37

<210> 151

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 151

cttccaaaag tgagggaaga aatgtgaaac cac

33

<210> 152

<211> 47

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 152

cgcgtcccaa gcttctaaac aacagtagtc tccggaagcg ttgatag

47

<210> 153

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 153

gtggtttcac atttcttccc tcacttttgg aag

33

<210> 154

<211> 281

<212> PRT

<213> Saccharomyces cerevisiae

<400> 154

Met	Ser	Glu	Tyr	Gln	Pro	Ser	Leu	Phe	Ala	Leu	Asn	Pro	Met	Gly	Phe
1				5				10						15	

Ser	Pro	Leu	Asp	Gly	Ser	Lys	Ser	Thr	Asn	Glu	Asn	Val	Ser	Ala	Ser
		20						25					30		

Thr	Ser	Thr	Ala	Lys	Pro	Met	Val	Gly	Gln	Leu	Ile	Phe	Asp	Lys	Phe
		35					40					45			

Ile	Lys	Thr	Glu	Glu	Asp	Pro	Ile	Ile	Lys	Gln	Asp	Thr	Pro	Ser	Asn
	50					55					60				

-68-

Leu Asp Phe Asp Phe Ala Leu Pro Gln Thr Ala Thr Ala Pro Asp Ala
 65 70 75 80
 Lys Thr Val Leu Pro Ile Pro Glu Leu Asp Asp Ala Val Val Glu Ser
 85 90 95
 Phe Phe Ser Ser Ser Thr Asp Ser Thr Pro Met Phe Glu Tyr Glu Asn
 100 105 110
 Leu Glu Asp Asn Ser Lys Glu Trp Thr Ser Leu Phe Asp Asn Asp Ile
 115 120 125
 Pro Val Thr Thr Asp Asp Val Ser Leu Ala Asp Lys Ala Ile Glu Ser
 130 135 140
 Thr Glu Glu Val Ser Leu Val Pro Ser Asn Leu Glu Val Ser Thr Thr
 145 150 155 160
 Ser Phe Leu Pro Thr Pro Val Leu Glu Asp Ala Lys Leu Thr Gln Thr
 165 170 175
 Arg Lys Val Lys Lys Pro Asn Ser Val Val Lys Lys Ser His His Val
 180 185 190
 Gly Lys Asp Asp Glu Ser Arg Leu Asp His Leu Gly Val Val Ala Tyr
 195 200 205
 Asn Arg Lys Gln Arg Ser Ile Pro Leu Ser Pro Ile Val Pro Glu Ser
 210 215 220
 Ser Asp Pro Ala Ala Leu Lys Arg Ala Arg Asn Thr Glu Ala Ala Arg
 225 230 235 240
 Arg Ser Arg Ala Arg Lys Leu Gln Arg Met Lys Gln Leu Glu Asp Lys
 245 250 255
 Val Glu Glu Leu Leu Ser Lys Asn Tyr His Leu Glu Asn Glu Val Ala
 260 265 270
 Arg Leu Lys Lys Leu Val Gly Glu Arg
 275 280
 <210> 155
 <211> 181
 <212> PRT
 <213> Escherichia coli
 <400> 155
 Met Lys Ile Lys Thr Leu Ala Ile Val Val Leu Ser Ala Leu Ser Leu
 1 5 10 15
 Ser Ser Thr Ala Ala Leu Ala Ala Ala Thr Thr Val Asn Gly Gly Thr
 20 25 30
 Val His Phe Lys Lys Glu Val Val Asn Ala Ala Cys Ala Val Asp Ala
 35 40 45
 Gly Ser Val Asp Gln Thr Val Gln Leu Gly Gln Val Arg Thr Ala Ser
 50 55 60
 Leu Ala Gln Glu Gly Ala Thr Ser Ser Ala Val Gly Phe Asn Ile Gln
 65 70 75 80

<213> Hepatitis B

<222> (1) . . (447)

atg gac att gac cct tat aaa gaa ttt gga gct act gtg gag tta ctc 48
Met Asp Ile Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu
1 5 10 15

tcg	ttt	ttg	cct	tct	gac	ttc	ttt	cct	tcc	gta	cga	gat	ctt	cta	gat	96
Ser	Phe	Leu	Pro	Ser	Asp	Phe	Phe	Pro	Ser	Val	Arg	Asp	Leu	Leu	Asp	
			20					25					30			

acc gcc gca gct ctg tat cgg gat gcc tta gag tct cct gag cat tgt 144
Thr Ala Ala Ala Leu Tyr Arg Asp Ala Leu Glu Ser Pro Glu His Cys
35 40 45

tca cct cac cat act gca ctc agg caa gca att ctt tgc tgg gga gac 192
Ser Pro His His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Asp
50 55 60

tta	atg	act	cta	gct	acc	tgg	gtg	ggg	act	aat	tta	gaa	gat	cca	gca	240
Leu	Met	Thr	Leu	Ala	Thr	Trp	Val	Gly	Thr	Asn	Leu	Glu	Asp	Pro	Ala	
65					70					75					80	

tct agg gac cta gta gtc agt tat gtc aac act aat gtg ggc cta aag 288
Ser Arg Asp Leu Val Val Ser Tyr Val Asn Thr Asn Val Gly Leu Lys
85 90 95

ttc aga caa tta ttg tgg ttt cac att tct tgt ctc act ttt gga aga 336
Phe Arg Gln Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly Arg
100 105 110

gaa acg gtt cta gag tat ttg gtc tct ttt gga gtg tgg att cgc act 384
Glu Thr Val Leu Glu Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr
115 120 125

-70-

cct cca gcc tat aga cca cca aat gcc cct atc cta tca acg ctt ccg 432
 Pro Pro Ala Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro
 130 135 140

gag act act gtt gtt 447
 Glu Thr Thr Val Val
 145

<210> 157
 <211> 149
 <212> PRT
 <213> Hepatitis B

<400> 157
 Met Asp Ile Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu
 1 5 10 15
 Ser Phe Leu Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp
 20 25 30
 Thr Ala Ala Ala Leu Tyr Arg Asp Ala Leu Glu Ser Pro Glu His Cys
 35 40 45
 Ser Pro His His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Asp
 50 55 60
 Leu Met Thr Leu Ala Thr Trp Val Gly Thr Asn Leu Glu Asp Pro Ala
 65 70 75 80
 Ser Arg Asp Leu Val Val Ser Tyr Val Asn Thr Asn Val Gly Leu Lys
 85 90 95
 Phe Arg Gln Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly Arg
 100 105 110
 Glu Thr Val Leu Glu Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr
 115 120 125
 Pro Pro Ala Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro
 130 135 140
 Glu Thr Thr Val Val
 145

<210> 158
 <211> 152
 <212> PRT
 <213> Hepatitis B

<400> 158
 Met Asp Ile Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu
 1 5 10 15
 Ser Phe Leu Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp
 20 25 30
 Thr Ala Ala Ala Leu Tyr Arg Asp Ala Leu Glu Ser Pro Glu His Cys
 35 40 45
 Ser Pro His His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Asp

-71-

50 55 60
 Leu Met Thr Leu Ala Thr Trp Val Gly Thr Asn Leu Glu Asp Gly Gly
 65 70 75 80
 Lys Gly Gly Ser Arg Asp Leu Val Val Ser Tyr Val Asn Thr Asn Val
 85 90 95
 Gly Leu Lys Phe Arg Gln Leu Leu Trp Phe His Ile Ser Cys Leu Thr
 100 105 110
 Phe Gly Arg Glu Thr Val Leu Glu Tyr Leu Val Ser Phe Gly Val Trp
 115 120 125
 Ile Arg Thr Pro Pro Ala Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser
 130 135 140
 Thr Leu Pro Glu Thr Thr Val Val
 145 150

<210> 159
 <211> 132
 <212> PRT
 <213> Bacteriophage Q Beta

<400> 159
 Ala Lys Leu Glu Thr Val Thr Leu Gly Asn Ile Gly Lys Asp Gly Lys
 1 5 10 15
 Gln Thr Leu Val Leu Asn Pro Arg Gly Val Asn Pro Thr Asn Gly Val
 20 25 30
 Ala Ser Leu Ser Gln Ala Gly Ala Val Pro Ala Leu Glu Lys Arg Val
 35 40 45
 Thr Val Ser Val Ser Gln Pro Ser Arg Asn Arg Lys Asn Tyr Lys Val
 50 55 60
 Gln Val Lys Ile Gln Asn Pro Thr Ala Cys Thr Ala Asn Gly Ser Cys
 65 70 75 80
 Asp Pro Ser Val Thr Arg Gln Ala Tyr Ala Asp Val Thr Phe Ser Phe
 85 90 95
 Thr Gln Tyr Ser Thr Asp Glu Glu Arg Ala Phe Val Arg Thr Glu Leu
 100 105 110
 Ala Ala Leu Leu Ala Ser Pro Leu Leu Ile Asp Ala Ile Asp Gln Leu
 115 120 125
 Asn Pro Ala Tyr
 130

<210> 160
 <211> 129
 <212> PRT
 <213> Bacteriophage R 17

<400> 160

Ala Ser Asn Phe Thr Gln Phe Val Leu Val Asn Asp Gly Gly Thr Gly
 1 5 10 15

-72-

Asn Val Thr Val Ala Pro Ser Asn Phe Ala Asn Gly Val Ala Glu Trp
 20 25 30
 Ile Ser Ser Asn Ser Arg Ser Gln Ala Tyr Lys Val Thr Cys Ser Val
 35 40 45
 Arg Gln Ser Ser Ala Gln Asn Arg Lys Tyr Thr Ile Lys Val Glu Val
 50 55 60
 Pro Lys Val Ala Thr Gln Thr Val Gly Gly Val Glu Leu Pro Val Ala
 65 70 75 80
 Ala Trp Arg Ser Tyr Leu Asn Met Glu Leu Thr Ile Pro Ile Phe Ala
 85 90 95
 Thr Asn Ser Asp Cys Glu Leu Ile Val Lys Ala Met Gln Gly Leu Leu
 100 105 110
 Lys Asp Gly Asn Pro Ile Pro Ser Ala Ile Ala Ala Asn Ser Gly Ile
 115 120 125
 Tyr

<210> 161
 <211> 130
 <212> PRT
 <213> Bacteriophage fr

<400> 161

Met Ala Ser Asn Phe Glu Glu Phe Val Leu Val Asp Asn Gly Gly Thr
 1 5 10 15
 Gly Asp Val Lys Val Ala Pro Ser Asn Phe Ala Asn Gly Val Ala Glu
 20 25 30
 Trp Ile Ser Ser Asn Ser Arg Ser Gln Ala Tyr Lys Val Thr Cys Ser
 35 40 45
 Val Arg Gln Ser Ser Ala Asn Asn Arg Lys Tyr Thr Val Lys Val Glu
 50 55 60
 Val Pro Lys Val Ala Thr Gln Val Gln Gly Gly Val Glu Leu Pro Val
 65 70 75 80
 Ala Ala Trp Arg Ser Tyr Met Asn Met Glu Leu Thr Ile Pro Val Phe
 85 90 95
 Ala Thr Asn Asp Asp Cys Ala Leu Ile Val Lys Ala Leu Gln Gly Thr
 100 105 110
 Phe Lys Thr Gly Asn Pro Ile Ala Thr Ala Ile Ala Ala Asn Ser Gly
 115 120 125
 Ile Tyr
 130

<210> 162

-73-

<211> 130
 <212> PRT
 <213> Bacteriophage GA

<400> 162

```

Met Ala Thr Leu Arg Ser Phe Val Leu Val Asp Asn Gly Gly Thr Gly
1          5          10          15
Asn Val Thr Val Val Pro Val Ser Asn Ala Asn Gly Val Ala Glu Trp
          20          25          30
Leu Ser Asn Asn Ser Arg Ser Gln Ala Tyr Arg Val Thr Ala Ser Tyr
          35          40          45
Arg Ala Ser Gly Ala Asp Lys Arg Lys Tyr Ala Ile Lys Leu Glu Val
          50          55          60
Pro Lys Ile Val Thr Gln Val Val Asn Gly Val Glu Leu Pro Gly Ser
65          70          75          80
Ala Trp Lys Ala Tyr Ala Ser Ile Asp Leu Thr Ile Pro Ile Phe Ala
          85          90          95
Ala Thr Asp Asp Val Thr Val Ile Ser Lys Ser Leu Ala Gly Leu Phe
          100          105          110
Lys Val Gly Asn Pro Ile Ala Glu Ala Ile Ser Ser Gln Ser Gly Phe
          115          120          125
Tyr Ala
          130

```

<210> 163
 <211> 132
 <212> PRT
 <213> Bacteriophage SP

<400> 163

```

Met Ala Lys Leu Asn Gln Val Thr Leu Ser Lys Ile Gly Lys Asn Gly
1          5          10          15
Asp Gln Thr Leu Thr Leu Thr Pro Arg Gly Val Asn Pro Thr Asn Gly
          20          25          30
Val Ala Ser Leu Ser Glu Ala Gly Ala Val Pro Ala Leu Glu Lys Arg
          35          40          45
Val Thr Val Ser Val Ala Gln Pro Ser Arg Asn Arg Lys Asn Phe Lys
          50          55          60
Val Gln Ile Lys Leu Gln Asn Pro Thr Ala Cys Thr Arg Asp Ala Cys
65          70          75          80
Asp Pro Ser Val Thr Arg Ser Ala Phe Ala Asp Val Thr Leu Ser Phe
          85          90          95
Thr Ser Tyr Ser Thr Asp Glu Glu Arg Ala Leu Ile Arg Thr Glu Leu
          100          105          110

```

-74-

Ala Ala Leu Leu Ala Asp Pro Leu Ile Val Asp Ala Ile Asp Asn Leu
 115 120 125

Asn Pro Ala Tyr
 130

<210> 164
 <211> 130
 <212> PRT
 <213> Bacteriophage MS2

<400> 164

Met Ala Ser Asn Phe Thr Gln Phe Val Leu Val Asp Asn Gly Gly Thr
 1 5 10 15

Gly Asp Val Thr Val Ala Pro Ser Asn Phe Ala Asn Gly Val Ala Glu
 20 25 30

Trp Ile Ser Ser Asn Ser Arg Ser Gln Ala Tyr Lys Val Thr Cys Ser
 35 40 45

Val Arg Gln Ser Ser Ala Gln Asn Arg Lys Tyr Thr Ile Lys Val Glu
 50 55 60

Val Pro Lys Val Ala Thr Gln Thr Val Gly Gly Val Glu Leu Pro Val
 65 70 75 80

Ala Ala Trp Arg Ser Tyr Leu Asn Met Glu Leu Thr Ile Pro Ile Phe
 85 90 95

Ala Thr Asn Ser Asp Cys Glu Leu Ile Val Lys Ala Met Gln Gly Leu
 100 105 110

Leu Lys Asp Gly Asn Pro Ile Pro Ser Ala Ile Ala Ala Asn Ser Gly
 115 120 125

Ile Tyr
 130

<210> 165
 <211> 133
 <212> PRT
 <213> Bacteriophage M11

<400> 165

Met Ala Lys Leu Gln Ala Ile Thr Leu Ser Gly Ile Gly Lys Lys Gly
 1 5 10 15

Asp Val Thr Leu Asp Leu Asn Pro Arg Gly Val Asn Pro Thr Asn Gly
 20 25 30

Val Ala Ala Leu Ser Glu Ala Gly Ala Val Pro Ala Leu Glu Lys Arg
 35 40 45

Val Thr Ile Ser Val Ser Gln Pro Ser Arg Asn Arg Lys Asn Tyr Lys
 50 55 60

Val Gln Val Lys Ile Gln Asn Pro Thr Ser Cys Thr Ala Ser Gly Thr
 65 70 75 80

-75-

Cys Asp Pro Ser Val Thr Arg Ser Ala Tyr Ser Asp Val Thr Phe Ser
 85 90 95

Phe Thr Gln Tyr Ser Thr Val Glu Glu Arg Ala Leu Val Arg Thr Glu
 100 105 110

Leu Gln Ala Leu Leu Ala Asp Pro Met Leu Val Asn Ala Ile Asp Asn
 115 120 125

Leu Asn Pro Ala Tyr
 130

<210> 166
 <211> 133
 <212> PRT
 <213> Bacteriophage MX1

<400> 166
 Met Ala Lys Leu Gln Ala Ile Thr Leu Ser Gly Ile Gly Lys Asn Gly
 1 5 10 15

Asp Val Thr Leu Asn Leu Asn Pro Arg Gly Val Asn Pro Thr Asn Gly
 20 25 30

Val Ala Ala Leu Ser Glu Ala Gly Ala Val Pro Ala Leu Glu Lys Arg
 35 40 45

Val Thr Ile Ser Val Ser Gln Pro Ser Arg Asn Arg Lys Asn Tyr Lys
 50 55 60

Val Gln Val Lys Ile Gln Asn Pro Thr Ser Cys Thr Ala Ser Gly Thr
 65 70 75 80

Cys Asp Pro Ser Val Thr Arg Ser Ala Tyr Ala Asp Val Thr Phe Ser
 85 90 95

Phe Thr Gln Tyr Ser Thr Asp Glu Glu Arg Ala Leu Val Arg Thr Glu
 100 105 110

Leu Lys Ala Leu Leu Ala Asp Pro Met Leu Ile Asp Ala Ile Asp Asn
 115 120 125

Leu Asn Pro Ala Tyr
 130

<210> 167
 <211> 330
 <212> PRT
 <213> Bacteriophage NL95

<400> 167
 Met Ala Lys Leu Asn Lys Val Thr Leu Thr Gly Ile Gly Lys Ala Gly
 1 5 10 15

Asn Gln Thr Leu Thr Leu Thr Pro Arg Gly Val Asn Pro Thr Asn Gly
 20 25 30

Val Ala Ser Leu Ser Glu Ala Gly Ala Val Pro Ala Leu Glu Lys Arg
 35 40 45

Val Thr Val Ser Val Ala Gln Pro Ser Arg Asn Arg Lys Asn Tyr Lys

-76-

50					55					60					
Val	Gln	Ile	Lys	Leu	Gln	Asn	Pro	Thr	Ala	Cys	Thr	Lys	Asp	Ala	Cys
65					70					75					80
Asp	Pro	Ser	Val	Thr	Arg	Ser	Gly	Ser	Arg	Asp	Val	Thr	Leu	Ser	Phe
				85					90					95	
Thr	Ser	Tyr	Ser	Thr	Glu	Arg	Glu	Arg	Ala	Leu	Ile	Arg	Thr	Glu	Leu
			100					105					110		
Ala	Ala	Leu	Leu	Lys	Asp	Asp	Leu	Ile	Val	Asp	Ala	Ile	Asp	Asn	Leu
		115					120					125			
Asn	Pro	Ala	Tyr	Trp	Ala	Ala	Leu	Leu	Ala	Ala	Ser	Pro	Gly	Gly	Gly
	130					135					140				
Asn	Asn	Pro	Tyr	Pro	Gly	Val	Pro	Asp	Ser	Pro	Asn	Val	Lys	Pro	Pro
145					150					155					160
Gly	Gly	Thr	Gly	Thr	Tyr	Arg	Cys	Pro	Phe	Ala	Cys	Tyr	Arg	Arg	Gly
				165					170					175	
Glu	Leu	Ile	Thr	Glu	Ala	Lys	Asp	Gly	Ala	Cys	Ala	Leu	Tyr	Ala	Cys
			180					185					190		
Gly	Ser	Glu	Ala	Leu	Val	Glu	Phe	Glu	Tyr	Ala	Leu	Glu	Asp	Phe	Leu
		195					200					205			
Gly	Asn	Glu	Phe	Trp	Arg	Asn	Trp	Asp	Gly	Arg	Leu	Ser	Lys	Tyr	Asp
	210					215					220				
Ile	Glu	Thr	His	Arg	Arg	Cys	Arg	Gly	Asn	Gly	Tyr	Val	Asp	Leu	Asp
225						230					235				240
Ala	Ser	Val	Met	Gln	Ser	Asp	Glu	Tyr	Val	Leu	Ser	Gly	Ala	Tyr	Asp
				245					250					255	
Val	Val	Lys	Met	Gln	Pro	Pro	Gly	Thr	Phe	Asp	Ser	Pro	Arg	Tyr	Tyr
			260					265					270		
Leu	His	Leu	Met	Asp	Gly	Ile	Tyr	Val	Asp	Leu	Ala	Glu	Val	Thr	Ala
		275					280					285			
Tyr	Arg	Ser	Tyr	Gly	Met	Val	Ile	Gly	Phe	Trp	Thr	Asp	Ser	Lys	Ser
	290					295					300				
Pro	Gln	Leu	Pro	Thr	Asp	Phe	Thr	Arg	Phe	Asn	Arg	His	Asn	Cys	Pro
305						310					315				320
Val	Gln	Thr	Val	Ile	Val	Ile	Pro	Ser	Leu						
				325					330						

<210> 168
 <211> 134
 <212> PRT
 <213> Apis mellifera

<400> 168
 Ile Ile Tyr Pro Gly Thr Leu Trp Cys Gly His Gly Asn Lys Ser Ser
 1 5 10 15

-77-

Gly Pro Asn Glu Leu Gly Arg Phe Lys His Thr Asp Ala Cys Cys Arg
 20 25 30
 Thr His Asp Met Cys Pro Asp Val Met Ser Ala Gly Glu Ser Lys His
 35 40 45
 Gly Leu Thr Asn Thr Ala Ser His Thr Arg Leu Ser Cys Asp Cys Asp
 50 55 60
 Asp Lys Phe Tyr Asp Cys Leu Lys Asn Ser Ala Asp Thr Ile Ser Ser
 65 70 75 80
 Tyr Phe Val Gly Lys Met Tyr Phe Asn Leu Ile Asp Thr Lys Cys Tyr
 85 90 95
 Lys Leu Glu His Pro Val Thr Gly Cys Gly Glu Arg Thr Glu Gly Arg
 100 105 110
 Cys Leu His Tyr Thr Val Asp Lys Ser Lys Pro Lys Val Tyr Gln Trp
 115 120 125
 Phe Asp Leu Arg Lys Tyr
 130

<210> 169
 <211> 129
 <212> PRT
 <213> Apis mellifera

<400> 169
 Ile Ile Tyr Pro Gly Thr Leu Trp Cys Gly His Gly Asn Lys Ser Ser
 1 5 10 15
 Gly Pro Asn Glu Leu Gly Arg Phe Lys His Thr Asp Ala Cys Cys Arg
 20 25 30
 Thr His Asp Met Cys Pro Asn Val Met Ser Ala Gly Glu Ser Lys His
 35 40 45
 Gly Leu Thr Asp Thr Ala Ser Arg Leu Ser Cys Asn Asp Asn Asp Leu
 50 55 60
 Phe Tyr Lys Asp Ser Ala Asp Thr Ile Ser Ser Tyr Phe Val Gly Lys
 65 70 75 80
 Met Tyr Phe Asn Leu Ile Asn Thr Lys Cys Tyr Lys Leu Glu His Pro
 85 90 95
 Val Thr Gly Cys Gly Glu Arg Thr Glu Gly Arg Cys Leu His Tyr Thr
 100 105 110
 Val Asp Lys Ser Lys Pro Lys Val Tyr Gln Trp Phe Asp Leu Arg Lys
 115 120 125
 Tyr

<210> 170
 <211> 134
 <212> PRT
 <213> Apis dorsata

<400> 170

-78-

Ile Ile Tyr Pro Gly Thr Leu Trp Cys Gly His Gly Asn Val Ser Ser
 1 5 10 15
 Ser Pro Asp Glu Leu Gly Arg Phe Lys His Thr Asp Ser Cys Cys Arg
 20 25 30
 Ser His Asp Met Cys Pro Asp Val Met Ser Ala Gly Glu Ser Lys His
 35 40 45
 Gly Leu Thr Asn Thr Ala Ser His Thr Arg Leu Ser Cys Asp Cys Asp
 50 55 60
 Asp Lys Phe Tyr Asp Cys Leu Lys Asn Ser Ser Asp Thr Ile Ser Ser
 65 70 75 80
 Tyr Phe Val Gly Glu Met Tyr Phe Asn Ile Leu Asp Thr Lys Cys Tyr
 85 90 95
 Lys Leu Glu His Pro Val Thr Gly Cys Gly Lys Arg Thr Glu Gly Arg
 100 105 110
 Cys Leu Asn Tyr Thr Val Asp Lys Ser Lys Pro Lys Val Tyr Gln Trp
 115 120 125
 Phe Asp Leu Arg Lys Tyr
 130

<210> 171
 <211> 134
 <212> PRT
 <213> Apis cerana

<400> 171
 Ile Ile Tyr Pro Gly Thr Leu Trp Cys Gly His Gly Asn Val Ser Ser
 1 5 10 15
 Gly Pro Asn Glu Leu Gly Arg Phe Lys His Thr Asp Ala Cys Cys Arg
 20 25 30
 Thr His Asp Met Cys Pro Asp Val Met Ser Ala Gly Glu Ser Lys His
 35 40 45
 Gly Leu Thr Asn Thr Ala Ser His Thr Arg Leu Ser Cys Asp Cys Asp
 50 55 60
 Asp Thr Phe Tyr Asp Cys Leu Lys Asn Ser Gly Glu Lys Ile Ser Ser
 65 70 75 80
 Tyr Phe Val Gly Lys Met Tyr Phe Asn Leu Ile Asp Thr Lys Cys Tyr
 85 90 95
 Lys Leu Glu His Pro Val Thr Gly Cys Gly Glu Arg Thr Glu Gly Arg
 100 105 110
 Cys Leu Arg Tyr Thr Val Asp Lys Ser Lys Pro Lys Val Tyr Gln Trp
 115 120 125
 Phe Asp Leu Arg Lys Tyr
 130

<210> 172
 <211> 136

-79-

<212> PRT

<213> *Bombus pennsylvanicus*

<400> 172

```

Ile Ile Tyr Pro Gly Thr Leu Trp Cys Gly Asn Gly Asn Ile Ala Asn
1      5      10      15
Gly Thr Asn Glu Leu Gly Leu Trp Lys Glu Thr Asp Ala Cys Cys Arg
      20      25      30
Thr His Asp Met Cys Pro Asp Ile Ile Glu Ala His Gly Ser Lys His
      35      40      45
Gly Leu Thr Asn Pro Ala Asp Tyr Thr Arg Leu Asn Cys Glu Cys Asp
      50      55      60
Glu Glu Phe Arg His Cys Leu His Asn Ser Gly Asp Ala Val Ser Ala
65      70      75      80
Ala Phe Val Gly Arg Thr Tyr Phe Thr Ile Leu Gly Thr Gln Cys Phe
      85      90      95
Arg Leu Asp Tyr Pro Ile Val Lys Cys Lys Val Lys Ser Thr Ile Leu
      100      105      110
Arg Glu Cys Lys Glu Tyr Glu Phe Asp Thr Asn Ala Pro Gln Lys Tyr
      115      120      125
Gln Trp Phe Asp Val Leu Ser Tyr
      130      135

```

<210> 173

<211> 142

<212> PRT

<213> *Heloderma suspectum*

<400> 173

```

Gly Ala Phe Ile Met Pro Gly Thr Leu Trp Cys Gly Ala Gly Asn Ala
1      5      10      15
Ala Ser Asp Tyr Ser Gln Leu Gly Thr Glu Lys Asp Thr Asp Met Cys
      20      25      30
Cys Arg Asp His Asp His Cys Ser Asp Thr Met Ala Ala Leu Glu Tyr
      35      40      45
Lys His Gly Met Arg Asn Tyr Arg Pro His Thr Val Ser His Cys Asp
      50      55      60
Cys Asp Asn Gln Phe Arg Ser Cys Leu Met Asn Val Lys Asp Arg Thr
65      70      75      80
Ala Asp Leu Val Gly Met Thr Tyr Phe Thr Val Leu Lys Ile Ser Cys
      85      90      95
Phe Glu Leu Glu Glu Gly Glu Gly Cys Val Asp Asn Asn Phe Ser Gln
      100      105      110
Gln Cys Thr Lys Ser Glu Ile Met Pro Val Ala Lys Leu Val Ser Ala
      115      120      125

```

-80-

Ala Pro Tyr Gln Ala Gln Ala Glu Thr Gln Ser Gly Glu Gly
 130 135 140

<210> 174
 <211> 143
 <212> PRT
 <213> Heloderma suspectum

<400> 174
 Gly Ala Phe Ile Met Pro Gly Thr Leu Trp Cys Gly Ala Gly Asn Ala
 1 5 10 15
 Ala Ser Asp Tyr Ser Gln Leu Gly Thr Glu Lys Asp Thr Asp Met Cys
 20 25 30
 Cys Arg Asp His Asp His Cys Glu Asn Trp Ile Ser Ala Leu Glu Tyr
 35 40 45
 Lys His Gly Met Arg Asn Tyr Tyr Pro Ser Thr Ile Ser His Cys Asp
 50 55 60
 Cys Asp Asn Gln Phe Arg Ser Cys Leu Met Lys Leu Lys Asp Gly Thr
 65 70 75 80
 Ala Asp Tyr Val Gly Gln Thr Tyr Phe Asn Val Leu Lys Ile Pro Cys
 85 90 95
 Phe Glu Leu Glu Glu Gly Glu Gly Cys Val Asp Trp Asn Phe Trp Leu
 100 105 110
 Glu Cys Thr Glu Ser Lys Ile Met Pro Val Ala Lys Leu Val Ser Ala
 115 120 125
 Ala Pro Tyr Gln Ala Gln Ala Glu Thr Gln Ser Gly Glu Gly Arg
 130 135 140

<210> 175
 <211> 142
 <212> PRT
 <213> Heloderma suspectum

<400> 175
 Gly Ala Phe Ile Met Pro Gly Thr Leu Trp Cys Gly Ala Gly Asn Ala
 1 5 10 15
 Ala Ser Asp Tyr Ser Gln Leu Gly Thr Glu Lys Asp Thr Asp Met Cys
 20 25 30
 Cys Arg Asp His Asp His Cys Glu Asn Trp Ile Ser Ala Leu Glu Tyr
 35 40 45
 Lys His Gly Met Arg Asn Tyr Tyr Pro Ser Thr Ile Ser His Cys Asp
 50 55 60
 Cys Asp Asn Gln Phe Arg Ser Cys Leu Met Lys Leu Lys Asp Gly Thr
 65 70 75 80
 Ala Asp Tyr Val Gly Gln Thr Tyr Phe Asn Val Leu Lys Ile Pro Cys
 85 90 95
 Phe Glu Leu Glu Glu Gly Glu Gly Cys Val Asp Trp Asn Phe Trp Leu

-81-

100					105					110					
Glu	Cys	Thr	Glu	Ser	Lys	Ile	Met	Pro	Val	Ala	Lys	Leu	Val	Ser	Ala
		115					120					125			
Ala	Pro	Tyr	Gln	Ala	Gln	Ala	Glu	Thr	Gln	Ser	Gly	Glu	Gly		
	130					135					140				

<210> 176
 <211> 574
 <212> PRT
 <213> IgE heavy chain
 <400> 176

Met	Asp	Trp	Thr	Trp	Ile	Leu	Phe	Leu	Val	Ala	Ala	Ala	Thr	Arg	Val
1				5					10					15	
His	Ser	Gln	Thr	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Arg	Lys	Pro
		20						25					30		
Gly	Ala	Ser	Val	Arg	Val	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe	Ile
		35					40					45			
Asp	Ser	Tyr	Ile	His	Trp	Ile	Arg	Gln	Ala	Pro	Gly	His	Gly	Leu	Glu
	50					55					60				
Trp	Val	Gly	Trp	Ile	Asn	Pro	Asn	Ser	Gly	Gly	Thr	Asn	Tyr	Ala	Pro
65					70				75						80
Arg	Phe	Gln	Gly	Arg	Val	Thr	Met	Thr	Arg	Asp	Ala	Ser	Phe	Ser	Thr
				85					90					95	
Ala	Tyr	Met	Asp	Leu	Arg	Ser	Leu	Arg	Ser	Asp	Asp	Ser	Ala	Val	Phe
			100					105					110		
Tyr	Cys	Ala	Lys	Ser	Asp	Pro	Phe	Trp	Ser	Asp	Tyr	Tyr	Asn	Phe	Asp
		115					120					125			
Tyr	Ser	Tyr	Thr	Leu	Asp	Val	Trp	Gly	Gln	Gly	Thr	Thr	Val	Thr	Val
		130				135					140				
Ser	Ser	Ala	Ser	Thr	Gln	Ser	Pro	Ser	Val	Phe	Pro	Leu	Thr	Arg	Cys
145					150					155					160
Cys	Lys	Asn	Ile	Pro	Ser	Asn	Ala	Thr	Ser	Val	Thr	Leu	Gly	Cys	Leu
				165					170					175	
Ala	Thr	Gly	Tyr	Phe	Pro	Glu	Pro	Val	Met	Val	Thr	Trp	Asp	Thr	Gly
			180					185					190		
Ser	Leu	Asn	Gly	Thr	Thr	Met	Thr	Leu	Pro	Ala	Thr	Thr	Leu	Thr	Leu
		195					200					205			
Ser	Gly	His	Tyr	Ala	Thr	Ile	Ser	Leu	Leu	Thr	Val	Ser	Gly	Ala	Trp
		210				215					220				
Ala	Lys	Gln	Met	Phe	Thr	Cys	Arg	Val	Ala	His	Thr	Pro	Ser	Ser	Thr
225					230					235					240
Asp	Trp	Val	Asp	Asn	Lys	Thr	Phe	Ser	Val	Cys	Ser	Arg	Asp	Phe	Thr
				245					250					255	

-82-

Pro Pro Thr Val Lys Ile Leu Gln Ser Ser Cys Asp Gly Gly Gly His
 260 265 270
 Phe Pro Pro Thr Ile Gln Leu Leu Cys Leu Val Ser Gly Tyr Thr Pro
 275 280 285
 Gly Thr Ile Asn Ile Thr Trp Leu Glu Asp Gly Gln Val Met Asp Val
 290 295 300
 Asp Leu Ser Thr Ala Ser Thr Thr Gln Glu Gly Glu Leu Ala Ser Thr
 305 310 315 320
 Gln Ser Glu Leu Thr Leu Ser Gln Lys His Trp Leu Ser Asp Arg Thr
 325 330 335
 Tyr Thr Cys Gln Val Thr Tyr Gln Gly His Thr Phe Glu Asp Ser Thr
 340 345 350
 Lys Lys Cys Ala Asp Ser Asn Pro Arg Gly Val Ser Ala Tyr Leu Ser
 355 360 365
 Arg Pro Ser Pro Phe Asp Leu Phe Ile Arg Lys Ser Pro Thr Ile Thr
 370 375 380
 Cys Leu Val Val Asp Leu Ala Pro Ser Lys Gly Thr Val Asn Leu Thr
 385 390 395 400
 Trp Ser Arg Ala Ser Gly Lys Pro Val Asn His Ser Thr Arg Lys Glu
 405 410 415
 Glu Lys Gln Arg Asn Gly Thr Leu Thr Val Thr Ser Thr Leu Pro Val
 420 425 430
 Gly Thr Arg Asp Trp Ile Glu Gly Glu Thr Tyr Gln Cys Arg Val Thr
 435 440 445
 His Pro His Leu Pro Arg Ala Leu Met Arg Ser Thr Thr Lys Thr Ser
 450 455 460
 Gly Pro Arg Ala Ala Pro Glu Val Tyr Ala Phe Ala Thr Pro Glu Trp
 465 470 475 480
 Pro Gly Ser Arg Asp Lys Arg Thr Leu Ala Cys Leu Ile Gln Asn Phe
 485 490 495
 Met Pro Glu Asp Ile Ser Val Gln Trp Leu His Asn Glu Val Gln Leu
 500 505 510
 Pro Asp Ala Arg His Ser Thr Thr Gln Pro Arg Lys Thr Lys Gly Ser
 515 520 525
 Gly Phe Phe Val Phe Ser Arg Leu Glu Val Thr Arg Ala Glu Trp Glu
 530 535 540
 Gln Lys Asp Glu Phe Ile Cys Arg Ala Val His Glu Ala Ala Ser Pro
 545 550 555 560
 Ser Gln Thr Val Gln Arg Ala Val Ser Val Asn Pro Gly Lys
 565 570

-83-

<210> 177

<400> 177
000

<210> 178

<211> 13

<212> PRT

<213> IgE Peptides

<400> 178

Cys Gly Gly Val Asn Leu Thr Trp Ser Arg Ala Ser Gly
1 5 10

<210> 179

<211> 8

<212> PRT

<213> IgE Mimotype

<400> 179

Ile Asn His Arg Gly Tyr Trp Val
1 5

<210> 180

<211> 8

<212> PRT

<213> IgE Mimotype

<400> 180

Arg Asn His Arg Gly Tyr Trp Val
1 5

<210> 181

<211> 10

<212> PRT

<213> IgE Mimotype

<400> 181

Arg Ser Arg Ser Gly Gly Tyr Trp Leu Trp
1 5 10

<210> 182

<211> 10

<212> PRT

<213> IgE Mimotype

<400> 182

Val Asn Leu Thr Trp Ser Arg Ala Ser Gly
1 5 10

<210> 183

<211> 10

<212> PRT

<213> IgE Mimotype

<400> 183

-84-

Val Asn Leu Pro Trp Ser Arg Ala Ser Gly
1 5 10

<210> 184
<211> 10
<212> PRT
<213> IgE Mimotype

<400> 184
Val Asn Leu Thr Trp Ser Phe Gly Leu Glu
1 5 10

<210> 185
<211> 10
<212> PRT
<213> IgE Mimotype

<400> 185
Val Asn Leu Pro Trp Ser Phe Gly Leu Glu
1 5 10

<210> 186
<211> 10
<212> PRT
<213> IgE Mimotype

<400> 186
Val Asn Arg Pro Trp Ser Phe Gly Leu Glu
1 5 10

<210> 187
<211> 10
<212> PRT
<213> IgE Mimotype

<400> 187
Val Lys Leu Pro Trp Arg Phe Tyr Gln Val
1 5 10

<210> 188
<211> 10
<212> PRT
<213> IgE Mimotype

<400> 188
Val Trp Thr Ala Cys Gly Tyr Gly Arg Met
1 5 10

<210> 189
<211> 7
<212> PRT
<213> IgE Mimotype

<400> 189
Gly Thr Val Ser Thr Leu Ser
1 5

-85-

<210> 190
<211> 7
<212> PRT
<213> IgE Mimotype

<400> 190
Leu Leu Asp Ser Arg Tyr Trp
1 5

<210> 191
<211> 7
<212> PRT
<213> IgE Mimotype

<400> 191
Gln Pro Ala His Ser Leu Gly
1 5

<210> 192
<211> 7
<212> PRT
<213> IgE Mimotype

<400> 192
Leu Trp Gly Met Gln Gly Arg
1 5

<210> 193
<211> 15
<212> PRT
<213> IgE Mimotype

<400> 193
Leu Thr Leu Ser His Pro His Trp Val Leu Asn His Phe Val Ser
1 5 10 15

<210> 194
<211> 9
<212> PRT
<213> IgE Mimotype

<400> 194
Ser Met Gly Pro Asp Gln Thr Leu Arg
1 5

<210> 195
<211> 6
<212> PRT
<213> IgE Mimotype

<400> 195
Val Asn Leu Thr Trp Ser
1 5

-86-

<210> 196
 <211> 56
 <212> DNA
 <213> Oligonucleotide Primer

<400> 196
 tagatgatta cgccaagctt ataatagaaa tagttttttg aaaggaaagc agcatg 56

<210> 197
 <211> 45
 <212> DNA
 <213> Oligonucleotide Primer

<400> 197
 gtcaaaggcc ttgtcgacgt tattccatta cgcccgatcat ttggg 45

<210> 198
 <211> 4623
 <212> DNA
 <213> pFIMAIC

<400> 198
 agacgaaagg gcctcgtgat acgcctatatt ttatagggtta atgtcatgat aataatgggtt 60
 tcttagacgt caggtggcac ttttcgggga aatgtgcgcg gaacccttat ttgtttatatt 120
 ttctaaatac attcaaatat gtatccgctc atgagacaat aaccctgata aatgcttcaa 180
 taatattgaa aaaggaagag tatgagtatt caacatttcc gtgtcgccct tattcccttt 240
 tttgcggcat tttgccttcc tgtttttgct caccagaaa cgctggtgaa agtaaaagat 300
 gctgaagatc agttgggtgc acgagtgggt tacatcgaac tggatctcaa cagcggtaag 360
 atccttgaga gttttcgccc cgaagaacgt tttccaatga tgagcacttt taaagttctg 420
 ctatgtggcg cgggtattatc ccgtattgac gccgggcaag agcaactcgg tcgccgcata 480
 cactattctc agaatgactt ggttgagtac tcaccagtca cagaaaagca tcttacggat 540
 ggcatgacag taagagaatt atgcagtgtc gccataacca tgagtataa cactgcggcc 600
 aacttacttc tgacaacgat cggaggaccg aaggagctaa ccgctttttt gcacaacatg 660
 ggggatcatg taactcgcct tgatcgttgg gaaccggagc tgaatgaagc cataccaaac 720
 gacgagcgtg acaccacgat gcctgtagca atggcaacaa cgttgcgcaa actattaact 780
 ggcgaactac ttactctagc ttcccggcaa caattaatag actggatgga ggccgataaa 840
 gttgcaggac cacttctgcg ctcgccctt ccggctggct ggtttattgc tgataaatct 900
 ggagccggtg agcgtgggtc tcgcggtatc attgcagcac tggggccaga tggtaagccc 960
 tcccgtatcg tagttatcta cagcagggg agtcaggcaa ctatggatga acgaaataga 1020

-87-

cagatcgctg	agataggtgc	ctcactgatt	aagcattggt	aactgtcaga	ccaagtttac	1080
tcatatatac	tttagattga	tttaaaactt	cattttttaat	ttaaaaggat	ctaggtgaag	1140
atcctttttg	ataatctcat	gacccaaaatc	ccttaacgtg	agtttttcgtt	ccactgagcg	1200
tcagaccccg	tagaaaagat	caaaggatct	tcttgagatc	cttttttttct	gcgcgtaatc	1260
tgctgcttgc	aaacaaaaaa	accaccgcta	ccagcgggtg	tttgtttgcc	ggatcaagag	1320
ctaccaactc	tttttccgaa	ggtaactggc	ttcagcagag	cgcagatacc	aaatactgtc	1380
cttctagtgt	agccgtagtt	aggccaccac	ttcaagaact	ctgtagcacc	gcctacatac	1440
ctcgctctgc	taatcctggt	accagtgggt	gctgccagtg	gcgataagtc	gtgtctttacc	1500
gggttggact	caagacgata	gttaccggat	aaggcgcagc	ggtcgggctg	aacgggggggt	1560
tcgtgcacac	agcccagctt	ggagcgaacg	acctacaccg	aactgagata	cctacagcgt	1620
gagctatgag	aaagcgccac	gcttcccgaa	gggagaaagg	cggacaggta	tccggtaagc	1680
ggcagggctg	gaacaggaga	gcgcacgagg	gagcttccag	ggggaaacgc	ctggatatctt	1740
tatagtcctg	tcgggtttcg	ccacctctga	cttgagcgtc	gattttttgtg	atgctcgtca	1800
ggggggcgga	gcctatggaa	aaacgccagc	aacgcggcct	ttttacgggt	cctggccttt	1860
tgctggcctt	ttgtctcacat	gttcttttct	gcgttatccc	ctgattctgt	ggataaccgt	1920
attaccgcct	ttgagtgagc	tgataccgct	cgccgcagcc	gaacgaccga	gcgcagcgag	1980
tcagtgagcg	aggaagcgga	agagcgccca	atacgcaaac	cgctctctcc	cgcgcgttgg	2040
ccgattcatt	aatgcagctg	gcacgacagg	tttcccgaact	ggaaagcggg	cagtgcgcgc	2100
aacgcaatta	atgtgagtta	gctcactcat	taggcacccc	aggctttaca	ctttatgctt	2160
ccggctcgta	tgttgtgtgg	aattgtgagc	ggataacaat	ttcacacagg	aaacagctat	2220
gaccatgatt	acgccaagct	tataatagaa	atagtttttt	gaaaggaaag	cagcatgaaa	2280
attaaaactc	tggcaatcgt	tgttctgtcg	gctctgtccc	tcagttctac	agcggctctg	2340
gccgctgcca	cgacggttaa	tggtgggacc	gttcacttta	aaggggaagt	tgттаacgcc	2400
gcttgcgtag	ttgatgcagg	ctctgttgat	caaaccgttc	agttaggaca	ggttcgtacc	2460
gcatcgctgg	cacaggaaagg	agcaaccagt	tctgctgtcg	gttttaacat	tcagctgaat	2520
gattgcgata	ccaatgttgc	atctaaagcc	gctgttgccct	ttttaggtac	ggcgattgat	2580
gcgggtcata	ccaacgttct	ggctctgcag	agttcagctg	cgggtagcgc	aacaaacgtt	2640
ggtgtgcaga	tcctggacag	aacgggtgct	gcgctgacgc	tggatgggtc	gacatttagt	2700
tcagaaacaa	ccctgaataa	cggaaccaat	accattccgt	tccaggcgcg	ttatttttgca	2760
accggggccg	caaccccggg	tgctgctaata	gcggatgcga	ccttcaaggt	tcagtatcaa	2820
taacctaccc	aggttcaggg	acgtcattac	gggcagggat	gccaccctt	gtgcgataaa	2880
aataacgatg	aaaaggaaga	gattatttct	attagcgtcg	ttgctgcaa	tgtttgctct	2940

-88-

```

ggccggaaat aaatggaata ccacgttgcc cggcggaaat atgcaatttc agggcgatcat 3000
tattgcgga aactgcccga ttgaagccgg tgataaacia atgacgggtca atatggggca 3060
aatcagcagt aaccggtttc atgcggttgg ggaagatagc gcaccgggtgc cttttgttat 3120
tcatttacgg gaatgtagca cgggtggtgag tgaacgtgta ggtgtggcgt ttcacgggtgt 3180
cgcggatggg aaaaatccgg atgtgctttc cgtgggagag gggccaggga tagccaccaa 3240
tattggcgta gcgttgtttg atgatgaagg aaacctcgta ccgattaatc gtcctccagc 3300
aaactggaaa cggctttatt caggctctac ttcgctacat ttcacgcca aatatcgtgc 3360
taccgggctg cgggttactg gcggcatcgc caatgcccag gcctgggtct ctttaaccta 3420
tcagtaattg ttcagcagat aatgtgataa caggaacagg acagtgaagta ataaaaacgt 3480
caatgtaagg aaatcgcagg aaataacatt ctgcttgctg gcaggatatcc tgatgttcat 3540
ggcaatgatg gttgccggac gcgctgaagc gggagtggcc ttaggtgcga ctgcgtaat 3600
ttatccggca gggcaaaaac aagagcaact tgccgtgaca aataatgatg aaaatagtag 3660
ctatttaatt caatcatggg tggaaaatgc cgatggtgta aaggatgggc gttttatcgt 3720
gacgcctcct ctgtttgcga tgaagggaia aaaagagaat accttacgta ttcttgatgc 3780
aacaataaac caattgccac aggaccggga aagtttattc tggatgaacg ttaaagcgat 3840
tccgtcaatg gataaatcaa aattgactga gaatacgtca cagctcgcaa ttatcagccg 3900
cattaaactg tactatcgcc cggctaaatt agcgttgcca cccgatcagg ccgcagaaaa 3960
attaagattt cgtcgtagcg cgaattctct gacgctgatt aaccgcacac cctattacct 4020
gacggtaaca gagttgaatg ccggaacccg ggttcttgaa aatgcattgg tgcctccaat 4080
gggcgaaagc acggttaaat tgccttctga tgcaggaagc aatattactt accgaacaat 4140
aaatgattat ggcgcactta ccccaaaaat gacgggcgta atggaataac gtcgactcta 4200
gaggatcccc gggtagcgag ctcgaaattca ctggccgctg ttttacaacg tcgtgactgg 4260
gaaaaccctg gcgttaccca acttaatcgc cttgcagcac atcccccttt cgcagctgg 4320
cgtaatagcg aagaggcccc caccgatcgc ccttcccaac agttgcgcag cctgaatggc 4380
gaatggcgcc tgatgcggta ttttctcctt acgcatctgt gcggtatctt acaccgcata 4440
tggtgcactc tcagtacaat ctgctctgat gccgcatagt taagccagcc ccgacacccg 4500
ccaacacccg ctgacgcgcc ctgacgggct tgtctgctcc cggcatccgc ttacagacaa 4560
gctgtgaccg tctccgggag ctgcatgtgt cagaggtttt caccgtcatc accgaaacgc 4620
gcg 4623

```

<210> 199

<211> 42

<212> DNA

<213> Oligonucleotide Primer

-89-

<400> 199
aagatcttaa gctaagcttg aattctctga cgctgattaa cc 42

<210> 200
<211> 41
<212> DNA
<213> Oligonucleotide Primer

<400> 200
acgtaaagca tttctagacc gcggatagta atcgtgctat c 41

<210> 201
<211> 5681
<212> DNA
<213> pFIMD

<400> 201
tcaccgtcat caccgaaacg cgcgagacga aagggcctcg tgatacgctt atttttatag 60
gttaatgtca tgataataat ggtttcttag acgtcagggtg gcacttttcg gggaaatgtg 120
cgcggaaccc ctatttggtt atttttctaa atacattcaa atatgtatcc gctcatgaga 180
caataaccct gataaatgct tcaataatat tgaaaaagga agagtatgag tattcaacat 240
ttccgtgtcg cctttattcc cttttttgcg gcattttgcc ttccgtgttt tgctcaccca 300
gaaacgctgg tgaaagtaaa agatgctgaa gatcagttgg gtgcacgagt gggttacatc 360
gaactggatc tcaacagcgg taagatcctt gagagttttc gccccgaaga acgttttcca 420
atgatgagca cttttaaagt tctgctatgt ggcgcggtat tatcccgat tgacgccggg 480
caagagcaac tcggtcgccg catacactat tctcagaatg acttggttga gtactcacca 540
gtcacagaaa agcatcttac ggatggcatg acagtaagag aattatgcag tgctgccata 600
accatgagtg ataacactgc ggccaactta cttctgacaa cgatcggagg accgaaggag 660
ctaaccgctt ttttgcaaa catgggggat catgtaactc gccttgatcg ttgggaaccg 720
gagctgaatg aagccatacc aaacgacgag cgtgacacca cgatgcctgt agcaatggca 780
acaacgttgc gcaaaactatt aactggcgaa ctacttactc tagcttcccg gcaacaatta 840
atagactgga tggaggcgga taaagttgca ggaccacttc tgcgctcggc ccttcgggct 900
ggctgggttta ttgctgataa atctggagcc ggtgagcgtg ggtctcgcgg tatcattgca 960
gcactggggc cagatggtaa gccctccgt atcgtagtta tctacacgac ggggagtcag 1020
gcaactatgg atgaacgaaa tagacagatc gctgagatag gtgcctcact gattaagcat 1080
tggtaaactgt cagaccaagt ttactcatat atactttaga ttgatttaaa acttcatttt 1140
taatttaaaa ggatctaggt gaagatcctt tttgataatc tcatgaccaa aatcccttaa 1200

-90-

cgtgagtttt	cgttccactg	agcgtcagac	cccgtagaaa	agatcaaagg	atctttcttga	1260
gataccttttt	ttctgcgcgt	aatctgctgc	ttgcaaacia	aaaaaccacc	gctaccagcg	1320
gtgggtttgtt	tgccggatca	agagctacca	actcttttttc	cgaaggtaac	tggtttcagc	1380
agagcgcaga	taccaaatac	tgtccttcta	gtgtagccgt	agttaggcca	ccacttcaag	1440
aactctgtag	caccgcctac	atacctcgct	ctgctaatac	tggtaccagt	ggctgctgcc	1500
agtggcgata	agtcgtgtct	taccgggttg	gactcaagac	gatagttacc	ggataaggcg	1560
cagcggtcgg	gctgaacggg	gggttcgtgc	acacagccca	gcttgagcg	aacgacctac	1620
accgaactga	gatacctaca	gcgtgagcta	tgagaaagcg	ccacgcttcc	cgaagggaga	1680
aaggcggaca	ggtatccggg	aagcggcgag	gtcggaaacag	gagagcgcac	gagggagctt	1740
ccagggggaa	acgcctggta	tctttatagt	cctgtcgggt	ttcgccacct	ctgacttgag	1800
cgtcgatttt	tgtgatgctc	gtcagggggg	cggagcctat	ggaaaaacgc	cagcaacgcg	1860
gccttttttac	ggttcctggc	cttttgctgg	ccttttgctc	acatgttctt	tcctgcttta	1920
tcccctgatt	ctgtggataa	ccgtattacc	gcctttgagt	gagctgatac	cgctcgccgc	1980
agccgaacga	ccgagcgag	cgagtcagtg	agcgaggaag	cggagagagcg	cccaatacgc	2040
aaaccgcctc	tccccgcgcg	ttggccgatt	cattaatgca	gctggcacga	caggtttccc	2100
gactggaaag	cgggcagtg	gcgcaacgca	attaatgtga	gttagctcac	tcattaggca	2160
ccccaggctt	tacactttat	gcttcgggct	cgtatgttgt	gtggaattgt	gagcggataa	2220
caatttcaca	caggaaacag	ctatgaccat	gattacgcca	agcttgaatt	ctctgacgct	2280
gattaacccg	acaccctatt	acctgacggg	aacagagttg	aatgccggaa	ccgggttctt	2340
tgaaaatgca	ttgggtgcctc	caatgggcca	aagcacgggt	aaattgcctt	ctgatgcagg	2400
aagcaatatt	acttaccgaa	caataaatga	ttatggcgca	cttaccacca	aaatgacggg	2460
cgtaatggaa	taacgcaggg	ggaatttttc	gcctgaataa	aaagaattga	ctgccggggg	2520
gatttttaagc	cggaggaata	atgtcatatc	tgaatttaag	actttaccag	cgaacacac	2580
aatgcttgca	tattcgtaag	catcgtttgg	ctgggttttt	tgtccgactc	gttgctgcct	2640
gtgctttttgc	cgcacaggca	cctttgtcat	ctgccgacct	ctattttaat	ccgcgctttt	2700
tagcggatga	tccccaggct	gtggccgatt	tatcgcggtt	tgaaaatggg	caagaattac	2760
cgccagggac	gtatcgctc	gatatctatt	tgaataatgg	ttatatggca	acgcgtgatg	2820
tcacatttaa	tacgggcgac	agtgaacaag	ggattgttcc	ctgcctgaca	cgcgcgcaac	2880
tcgccagtat	ggggctgaat	acggcttctg	tcgccggtat	gaatctgctg	gcggatgatg	2940
cctgtgtgcc	attaaccaca	atggtccagg	acgctactgc	gcatctggat	gttggtcagc	3000
agcgactgaa	cctgacgac	cctcaggcat	ttatgagtaa	tcgcgcgcgt	ggttatattc	3060

ctcctgagtt	atgggatccc	ggtattaatg	ccggattgct	caattataat	ttcagcggaa	3120
atagtgtaca	gaatcggatt	gggggtaaca	gccattatgc	atatttaaac	ctacagagtg	3180
ggttaaatat	tggtgcgtgg	cgtttacgcg	acaataccac	ctggagttat	aacagtagcg	3240
acagatcatc	aggtagcaaa	aataaatggc	agcatatcaa	tacctggctt	gagcgagaca	3300
taataaccgtt	acgttccccg	ctgacgctgg	gtgatggtta	tactcagggc	gatattttctg	3360
atgggtattaa	ctttcgcggc	gcacaattgg	cctcagatga	caatatgtta	cccgatagtc	3420
aaagaggatt	tgccccggtg	atccacggta	ttgctcgtgg	tactgcacag	gtcactatta	3480
aacaaaatgg	gtatgacatt	tataatagta	cggtgccacc	ggggcctttt	accatcaacg	3540
atatctatgc	cgcaggtaat	agtggtgact	tgcaggtaac	gatcaaagag	gctgacggca	3600
gcacgcagat	ttttaccgta	ccctattcgt	cagtccccgt	tttgcaacgt	gaagggcata	3660
ctcgttattc	cattacggca	ggagaatacc	gtagtggaaa	tgcgacagcag	gaaaaaaccc	3720
gctttttcca	gagtacatta	ctccacggcc	ttccggctgg	ctggacaata	tatgggtggaa	3780
cgcaactggc	ggatcgttat	cgtgccttta	atttcggtat	cgggaaaaac	atgggggcac	3840
tgggcgctct	gtctgtggat	atgacgcagg	ctaattccac	acttcccgat	gacagtcagc	3900
atgacggaca	atcgggtcgt	tttctctata	acaaatcgct	caatgaatca	ggcacgaata	3960
ttcagttagt	gggttaccgt	tattcgacca	gcggatattt	taatttcgct	gataacaacat	4020
acagtcgaat	gaatggctac	aacattgaaa	cacaggacgg	agttattcag	gttaagccga	4080
aattcaccga	ctattacaac	ctcgtttata	acaaacgcgg	gaaattacaa	ctcaccgtta	4140
ctcagcaact	cgggcgcaca	tcaacactgt	atttgagtgg	tagccatcaa	acttattggg	4200
gaacgagtaa	tgtcgatgag	caattccagg	ctggattaaa	tactgcgttc	gaagatatca	4260
actggacgct	cagctatagc	ctgacgaaaa	acgcctggca	aaaaggacgg	gatcagatgt	4320
tagcgcttaa	cgtcaatatt	cctttcagcc	actggctgcg	ttctgacagt	aatctcagt	4380
ggcgacatgc	cagtgccagc	tacagcatgt	cacacgatct	caacggctcg	atgaccaatc	4440
tggctggtgt	atacggtagc	ttgctggaag	acaacaacct	cagctatagc	gtgcaaaccg	4500
gctatgccgg	gggaggcgat	ggaaatagcg	gaagtacagg	ctacgccacg	ctgaattatc	4560
gcggtggtta	cggcaatgcc	aatatcgggt	acagccatag	cgatgatatt	aagcagctct	4620
attacggagt	cagcgggtgg	gtactggctc	atgccaatgg	cgtaacgctg	gggcagccgt	4680
taaacgatac	ggtggtgctt	gttaaagcgc	ctggcgcaaa	agatgcaaaa	gtcgaaaacc	4740
agacgggggt	gcgtaccgac	tggcgtgggt	atgccgtgct	gccttatgcc	actgaatatc	4800
gggaaaatag	agtggcgctg	gataccaata	ccctggctga	taacgtcgat	ttagataacg	4860
cggttgctaa	cgttgttccc	actcgtgggg	cgatcgtgcg	agcagagttt	aaagcgcgcg	4920
ttgggataaa	actgctcatg	acgctgaccc	acaataataa	gccgctgccg	tttggggcga	4980

-92-

```

tggtgacatc agagagtagc cagagtagcg gcattgttgc ggataatggc cagggtttacc 5040
tcagcgggaat gccttttagcg ggaaaagttc aggtgaaatg gggagaagag gaaaatgctc 5100
actgtgtcgc caattatcaa ctgccaccag agagtcagca gcagttatta acccagctat 5160
cagctgaatg tcgttaaggg ggcgtgatga gaaacaaacc tttttatctt ctgtgcgctt 5220
ttttgtggct ggcgggtgagt cacgctttgg ctgcggatag cacgattact atccgcggtc 5280
tagaggatcc ccgggtaccg agctcgaatt cactggccgt cgttttacaa cgctcgtgact 5340
gggaaaaccc tggcgttacc caacttaatc gccttgcagc acatccccct ttcgccagct 5400
ggcgtaatat cgaagaggcc cgcaccgatc gcccttccca acagttgcgc agcctgaatg 5460
gcgaatggcg cctgatgcgg tattttctcc ttacgcatct gtgcgggtatt tcacaccgca 5520
tatggtgcac tctcagtaca atctgctctg atgccgcata gttaagccag ccccgacacc 5580
cgccaacacc cgctgacgcg ccctgacggg cttgtctgct cccggcatcc gcttacagac 5640
aagctgtgac cgtctccggg agctgcatgt gtcagagggt t 5681

```

```

<210> 202
<211> 40
<212> DNA
<213> Oligonucleotide Primer

```

```

<400> 202
aattacgtga gcaagcttat gagaaacaaa cctttttatc 40

```

```

<210> 203
<211> 41
<212> DNA
<213> Oligonucleotide Primer

```

```

<400> 203
gactaaggcc tttctagatt attgataaac aaaagtcacg c 41

```

```

<210> 204
<211> 4637
<212> DNA
<213> pFIMFGH

```

```

<400> 204
aaagggcctc gtgatacgcc tattttttata ggttaatgtc atgataataa tggttttctta 60
gacgtcaggt ggcacttttc ggggaaatgt gcgcggaacc cctattttgtt tattttttcta 120
aatacattca aatatgtatc cgctcatgag acaataaccc tgataaatgc ttcaataata 180
ttgaaaaagg aagagtatga gtattcaaca tttccgtgtc gcccttatcc cctttttttgc 240
ggcattttgc cttcctggtt ttgctcacc agaaacgctg gtgaaagtaa aagatgctga 300

```

agatcagttg ggtgcacgag tgggttacat cgaactggat ctcaacagcg gtaagatcct	360
tgagagtttt cgccccgaag aacgttttcc aatgatgagc actttttaag ttctgctatg	420
tggcgcggtta ttatcccgta ttgacgccgg gcaagagcaa ctcggtcgcc gcatacacta	480
ttctcagaat gacttggttg agtactcacc agtcacagaa aagcatctta cggatggcat	540
gacagtaaga gaattatgca gtgctgccat aaccatgagt gataaactg cggccaactt	600
acttctgaca acgatcggag gaccgaagga gctaaccgct tttttgcaca acatggggga	660
tcatgtaact cgccttgatc gttgggaacc ggagctgaat gaagccatac caaacgacga	720
gcgtgacacc acgatgcctg tagcaatggc aacaacgttg cgcaaactat taactggcga	780
actacttact ctagcttccc ggcaacaatt aatagactgg atggaggcgg ataaagtgtg	840
aggaccactt ctgcgtcgg cccttcggc tggctggttt attgctgata aatctggagc	900
cggtgagcgt ggggtctcgg gtatcattgc agcactgggg ccagatggta agccctcccg	960
tatcgtagtt atctacacga cggggagtca ggcaactatg gatgaacgaa atagacagat	1020
cgtgagata ggtgcctcac tgattaagca ttggttaactg tcagaccaag ttactcata	1080
tatacttttag attgatttaa aacttcattt ttaatttaaa aggatctagg tgaagatcct	1140
ttttgataat ctcatgacca aaatccctta acgtgagttt tcgttccact gagcgtcaga	1200
ccccgtagaa aagatcaaag gatcttcttg agatcccttt tttctgcgcg taatctgctg	1260
cttgcaaaca aaaaaaccac cgctaccagc ggtggtttgt ttgccggatc aagagctacc	1320
aactcttttt ccgaaggtaa ctggcttcag cagagcgcag ataccaaata ctgtccttct	1380
agtgtagccg tagttaggcc accacttcaa gaactctgta gcaccgccta catacctcgc	1440
tctgctaate ctgttaccag tggctgctgc cagtggcgat aagtcgtgtc ttaccgggtt	1500
ggactcaaga cgatagttac cggataaggc gcagcggctg ggctgaacgg ggggttcgtg	1560
cacacagccc agcttgagc gaacgacctt caccgaactg agatacctac agcgtgagct	1620
atgagaaaag gccacgcttc ccgaaggag aaaggcggac aggtatccgg taagcggcag	1680
ggtcggaaca ggagagcgca cgaggagct tccaggggga aacgcctggg atctttatag	1740
tcctgtcggg ttctgccacc tctgacttga gcgtcgattt ttgtgatgct cgtcaggggg	1800
gcggagccta tggaaaaacg ccagcaacgc ggccttttta cggttcctgg ccttttgctg	1860
gccttttgct cacatgttct ttctgcgtt atccctgat tctgtggata accgtattac	1920
cgcctttgag tgagctgata ccgctcgccg cagccgaacg accgagcgca gcgagtcagt	1980
gagcgaggaa gcggaagagc gcccaatacg caaacgcct ctccccgcgc gttggccgat	2040
tcattaatgc agctggcacg acaggtttcc cgactggaaa gcgggcagtg agcgcaacgc	2100
aattaatgtg agttagctca ctcattaggc accccaggct ttacacttta tgcttcggc	2160
tcgtatgttg tgtggaattg tgagcggata acaatttcac acaggaaaca gctatgacca	2220

tgattacgcc aagcttatga gaaacaaacc tttttatcctt ctgtgcgctt ttttgtggct	2280
ggcgggtgagt cacgcttttg ctgcggatag cacgattact atccgcggct atgtcagggg	2340
taacggctgt agtgtggccg ctgaatcaac caattttact gttgatctga tggaaaacgc	2400
ggcgaagcaa ttttaacaaca ttggcgcgac gactcctgtt gttccatttc gtattttgct	2460
gtcacctgtt ggtaatgccg tttctgccgt aaagggttggg tttactggcg ttgcagatag	2520
ccacaatgcc aacctgcttg cacttgaaaa tacgggtgtca gcggcttcgg gactgggaat	2580
acagcttctg aatgagcagc aaaatcaaat accccttaat gctccatcgt ccgcgctttc	2640
gtggacgacc ctgacgccgg gtaaaccaaa tacgctgaat ttttacgccc ggctaattggc	2700
gacacaggtg cctgtcactg cggggcatat caatgccacg gctaccttca ctcttgaata	2760
tcagtaactg gagatgctca tgaaatggtg caaacgtggg tatgtatttg cggcaatatt	2820
ggcgctcgca agtgcgacga tacaggcagc cgatgtcacc atcacggtga acggtaaggt	2880
cgtcgcaaaa ccgtgtacgg tttccaccac caatgccacg gttgatctcg gcgatcttta	2940
ttctttcagt cttatgtctg ccggggcggc atcggcctgg catgatgttg cgcttgagtt	3000
gactaattgt ccggtgggaa cgtcgagggg cactgccacg ttcagcgggg cagccgacag	3060
taccggatat tataaaaacc aggggaccgc gcaaaacatc cagttagagc tacaggatga	3120
cagtggcaac acattgaata ctggcgcaac caaaacagtt cagggtggatg attcctcaca	3180
atcagcgcac ttcccgttac aggtcagagc attgacagta aatggcggag ccactcaggg	3240
aaccattcag gcagtgatta gcatcaccta tacctacagc tgaacccgaa gagatgattg	3300
taatgaaacg agttattacc ctgtttgctg tactgctgat gggctggctg gtaaattgcct	3360
ggtcattcgc ctgtaaaacc gccaatggta ccgctatccc tattggcggg ggcagcgcca	3420
atgtttatgt aaaccttgcg cccgtcgtga atgtggggca aaacctgggc gtggatcttt	3480
cgacgcaaat cttttgccat aacgattatc cggaaccat tacagactat gtcacactgc	3540
aacgaggctc ggcttatggc ggcggttat ctaatttttc cgggaccgta aaatatagtg	3600
gcagtagcta tccatttctt accaccagcg aaacgccgcg cgttgtttat aattcgagaa	3660
cggataagcc gtggccgggtg gcgctttatt tgacgcctgt gagcagtgcg ggcgggggtg	3720
cgattaaagc tggctcatta attgccgtgc ttatttttgcg acagaccaac aactataaca	3780
gcgatgattt ccagtttgtg tggaatattt acgccaataa tgatgtggtg gtgcctactg	3840
gcggctgcga tgtttctgct cgtgatgtca ccgttactct gccggactac cctggttcag	3900
tgccaattcc tcttaccgtt tattgtgcga aaagccaaaa cctgggggtat tacctctccg	3960
gcacaaccgc agatgcgggc aactcgattt tcaccaatac cgcgctggtt tcacctgcac	4020
agggcgctcg cgtagcgttg acgcgcaacg gtacgattat tccagogaat aacacgggat	4080
cgtaggagc agtagggact tcggcggtga gtctgggatt aacggcaaat tatgcacgta	4140

-95-

ccggaggggca	ggtgactgca	gggaatgtgc	aatcgattat	tggcgtgact	tttgttttatc	4200
aataatctag	aggatccccg	ggtaccgagc	tccaattcac	tggccgctcgt	tttacaacgt	4260
cgtgactggg	aaaaccctgg	cgttacccaa	cttaatcgcc	ttgcagcaca	tccccctttc	4320
gccagctggc	gtaatagcga	agaggcccg	accgatcgcc	cttcccaaca	gttgcgcagc	4380
ctgaatggcg	aatggcgcc	gatgcggtat	tttctcctta	cgcactctgtg	cggtattttca	4440
caccgcatat	ggtgcactct	cagtacaatc	tgctctgatg	ccgcatagtt	aagccagccc	4500
cgacaccgc	caacaccgc	tgacgcgccc	tgacgggctt	gtctgctccc	ggcatccgct	4560
tacagacaag	ctgtgaccgt	ctccgggagc	tgcatgtgtc	agagggttttc	accgtcatca	4620
ccgaaacgcg	cgagacg					4637

<210> 205

<211> 9299

<212> DNA

<213> pFIMAICDFGH

<400> 205

cgagacgaaa	gggcctcgtg	atacgcttat	ttttataggt	taatgtcatg	ataataatgg	60
tttcttagac	gtcaggtggc	acttttcggg	gaaatgtgcg	cggaaccctt	atttgtttat	120
ttttctaaat	acattcaa	atgtatccgc	tcatgagaca	ataaccctga	taa	180
aataatattg	aaaaaggaag	agtatgagta	ttcaacattt	ccgtgtcgcc	cttattccct	240
tttttgccgc	attttgcctt	cctgtttttg	ctcaccagga	aacgctgggtg	aaagtaaaag	300
atgctgaaga	tcagttgggt	gcacgagtg	gttacatoga	actggatctc	aacagcggta	360
agatccttga	gagttttcgc	cccgaagaac	gttttccaat	gatgagcact	tttaaagttc	420
tgctatgtgg	cgcggtatta	tcccgtattg	acgccgggca	agagcaactc	ggtcgccgca	480
tacactattc	tcagaatgac	ttggttgagt	actcaccagt	cacagaaaag	catcttacgg	540
atggcatgac	agtaagagaa	ttatgcagt	ctgccataac	catgagtgat	aacactgcgg	600
ccaacttact	tctgacaacg	atcggaggac	cgaaggagct	aaccgctttt	ttgcacaaca	660
tgggggatca	tgtaactcgc	cttgatcggt	gggaaccgga	gctgaatgaa	gccataccaa	720
acgacgagcg	tgacaccacg	atgcctgtag	caatggcaac	aacgttgccg	aaactattaa	780
ctggcgaaact	acttactcta	gcttcccggc	aacaattaat	agactgggatg	gaggcggata	840
aagttgcagg	accactttctg	cgctcggccc	ttccggctgg	ctgggtttatt	gctgataaat	900
ctggagccgg	tgagcgtggg	tctcgcggta	tcattgcagc	actggggcca	gatggtaagc	960
cctcccgtat	cgtagttatc	tacacgacgg	ggagtcaggc	aactatggat	gaacgaaata	1020

-96-

gacagatcgc	tgagataggt	gcctcactga	ttaagcattg	gtaactgtca	gaccaagttt	1080
actcatatat	acttttagatt	gattttaaacc	ttcatttttta	attttaaagg	atctaggtga	1140
agatcctttt	tgataatctc	atgaccaaaa	toccttaacg	tgagttttcg	ttccactgag	1200
cgtcagaccc	cgtagaaaag	atcaaaggat	cttcttgaga	tccttttttt	ctgcgcgtaa	1260
tctgctgctt	gcaaacaaaa	aaaccaccgc	taccagcggg	ggtttggttg	ccggatcaag	1320
agctaccaac	tctttttccg	aaggtaactg	gcttcagcag	agcgcagata	ccaaataactg	1380
tccttctagt	gtagccgtag	ttaggccacc	acttcaagaa	ctctgtagca	ccgcctacat	1440
acctcgctct	gctaatacctg	ttaccagtgg	ctgctgccag	tggcgataag	tcgtgtctta	1500
ccgggttgga	ctcaagacga	tagttaccgg	ataaggcgca	gcggtcgggc	tgaacggggg	1560
gttcgtgcac	acagcccgag	ttggagcgaa	cgacctacac	cgaactgaga	tacctacagc	1620
gtgagctatg	agaaagcgcc	acgcttcccg	aaggagagaa	ggcggacagg	tatccggtaa	1680
gcggcagggg	cggaacagga	gagcgcacga	gggagcttcc	aggggggaaac	gcctgggtatc	1740
tttatagtc	tgtcggggtt	cgccacctct	gacttgagcg	tcgatttttg	tgatgctcgt	1800
cagggggggc	gagcctatgg	aaaaacgcca	gcaacgcggc	ctttttacgg	ttcctggcct	1860
tttgctggcc	ttttgctcac	atgttctttc	ctgcgttata	ccctgattct	gtggataacc	1920
gtattaccgc	ctttgagtga	gctgataccg	ctcgccgcag	ccgaacgacc	gagcgcagcg	1980
agtcagttag	cgaggaagcg	gaagagcgcc	caatacgcaa	accgcctctc	cccgcgcgtt	2040
ggccgattca	ttaatgcagc	tggcacgaca	ggtttcccg	ctggaaagcg	ggcagtgagc	2100
gcaacgcaat	taatgtgagt	tagctcactc	attaggcacc	ccaggcttta	cacttttatgc	2160
ttccggctcg	tatgttggtg	ggaattgtga	gcggataaca	atttcacaca	ggaaacagct	2220
atgaccatga	ttacgccaag	cttataatag	aaatagtttt	ttgaaaggaa	agcagcatga	2280
aaattaaaac	tctggcaatc	gttggtctgt	cggctctgtc	cctcagttct	acagcggctc	2340
tggccgctgc	cacgacgggt	aatggtggga	ccgttcactt	taaaggggaa	gttggttaacg	2400
ccgcttgccg	agttgatgca	ggctctgttg	atcaaaccgt	tcagttagga	caggttcgta	2460
ccgcacgcgt	ggcacaggaa	ggagcaacca	gttctgctgt	cggttttaac	attcagctga	2520
atgattgcga	taccaatggt	gcattctaaag	ccgctgttgc	cttttttaggt	acggcgattg	2580
atgcgggtca	taccaacggt	ctggctctgc	agagttcagc	tgcgggtagc	gcaacaaaacg	2640
ttgggtgtgca	gatcctggac	agaacgggtg	ctgcgctgac	gctggatggt	gcgacattta	2700
gttcagaaac	aacctgaat	aacggaacca	ataccattcc	gttccaggcg	cgttattttg	2760
caaccggggc	cgcaaccccg	gggtctgcta	atgcggatgc	gaccttcaag	gttcagtatc	2820
aataacctac	ccaggttcag	ggacgtcatt	acgggcaggg	atgccacccc	ttgtgcgata	2880
aaaataacga	tgaaaaggaa	gagattatct	ctattagcgt	cgttgctgcc	aatgtttgct	2940

ctggccggaa ataaatggaa taccacgttg cccggcggaa atatgcaatt tcagggcgctc	3000
attattgcgg aaacttgccg gattgaagcc ggtgataaac aaatgacggt caatatgggg	3060
caaatcagca gtaaccgggt tcatgcgggt ggggaagata gcgcaccggt gccttttggt	3120
attcatttac ggggaatgtag cacgggtggtg agtgaacgtg taggtgtggc gtttcacggt	3180
gtcgcggatg gtaaaaatcc ggatgtgctt tccgtgggag aggggccagg gatagccacc	3240
aatattggcg tagcggttgtt tgatgatgaa ggaaacctcg taccgattaa tcgtcctcca	3300
gcaaactgga aacggcttta ttcaggctct acttcgctac atttcatcgc caaatatcgt	3360
gctaccgggc gtcgggttac tggcggcatc gccaatgcc aggcctggtt ctctttaacc	3420
tatcagtaat tgttcagcag ataatgtgat aacaggaaca ggacagtgag taataaaaac	3480
gtcaatgtaa ggaaatcgca ggaaataaca ttctgcttgc tggcagggtat cctgatgttc	3540
atggcaatga tgggtgcccg acgcgctgaa gcgggagtgg ccttaggtgc gactcgcgta	3600
atttatccgg caggggcaaaa acaagagcaa cttgccgtga caaataatga tgaaaatagt	3660
acctatttaa ttcaatcatg ggtggaaaat gccgatggtg taaaggatgg tcgttttatac	3720
gtgacgcctc ctctgtttgc gatgaagga aaaaagaga ataccttacg tattcttgat	3780
gcaacaaata accaattgcc acaggaccgg gaaagtttat tctggatgaa cgtaaagcg	3840
attccgtcaa tggataaatc aaaattgact gagaatacgc tacagctcgc aattatcagc	3900
cgcattaaac tgtactatcg cccggctaaa ttagcggtgc caccgatca ggccgcagaa	3960
aaattaagat ttcgtcgtag cggaattct ctgacgtga ttaaccgcac accctattac	4020
ctgacggtaa cagagttgaa tgccggaacc cgggttcttg aaaatgcatt ggtgcctcca	4080
atgggcgaaa gcacgggtta attgccttct gatgcaggaa gcaatattac ttaccgaaca	4140
ataaatgatt atggcgact tacccecaaa atgacgggcg taatggaata acgcaggggg	4200
aatttttcgc ctgaataaaa agaattgact gccggggtga ttttaagccg gaggaataat	4260
gtcatatctg aatttaagac tttaccagcg aaacacacaa tgcttgcata ttcgtaagca	4320
tcgtttggct ggtttttttg tccgactcgt tgcgcctgt gcttttgccg cacaggcacc	4380
tttgtcatct gccgacctct attttaatcc gcgcttttta gcggatgatc cccaggctgt	4440
ggccgattta tcgcgttttg aaaatgggca agaattaccg ccagggacgt atcgcgtcga	4500
tatctatttg aataatggtt atatggcaac gcgtgatgtc acatttaata cgggcgacag	4560
tgaacaaggg attgttccct gcctgacacg cgcgcaactc gccagtatgg ggctgaatac	4620
ggcttctgtc gccggtatga atctgctggc ggatgatgcc tgtgtgccat taaccacaat	4680
ggtccaggac gctactgcgc atctggatgt tggtcagcag cgactgaacc tgacgatccc	4740
tcaggcattt atgagtaatc gcgcgcgtgg ttatatccct cctgagttat gggatcccg	4800
tattaatgcc ggattgctca attataattt cagcggaat agtgtacaga atcggattgg	4860

-98-

gggtaacagc	cattatgcat	atttaaaccct	acagagtggg	ttaaattattg	gtgctgtggcg	4920
tttacgcgac	aataccacct	ggagttataa	cagtagcgac	agatcatcag	gtagcaaaaa	4980
taaatggcag	catatcaata	cctggcttga	gcgagacata	ataccgttac	gttcccggct	5040
gacgctgggt	gatggttata	ctcagggcga	tattttcgat	ggtattaact	ttcgcggcgc	5100
acaattggcc	tcagatgaca	atatgttacc	cgatagtcaa	agaggatttg	ccccggtgat	5160
ccacggtatt	gctcgtggta	ctgcacaggt	cactattaaa	caaaatgggt	atgacattta	5220
taatagtacg	gtgccaccgg	ggcctttttac	catcaacgat	atctatgccg	caggtaatag	5280
tggtgacttg	caggtaacga	tcaaagaggc	tgacggcagc	acgcagattt	ttaccgtacc	5340
ctattcgtca	gtcccgcctt	tgcaacgtga	agggcatact	cgttattcca	ttacggcagg	5400
agaataccgt	agtggaaatg	cgcagcagga	aaaaacccgc	tttttccaga	gtacattact	5460
ccacggcctt	ccggctggct	ggacaatata	tggtggaacg	caactggcgg	atcgttatcg	5520
tgcttttaat	ttcggtatcg	ggaaaaacat	gggggcactg	ggcgctctgt	ctgtggatat	5580
gacgcaggct	aattccacac	ttcccgatga	cagtcagcat	gacggacaat	cggtgcgttt	5640
tctctataac	aaatcgctca	atgaatcagg	cacgaatatt	cagttagtgg	gttaccgtta	5700
ttcgaccagc	ggatatttta	atttcgctga	tacaacatac	agtcgaatga	atggctacaa	5760
cattgaaaca	caggacggag	ttattcagggt	taagccgaaa	ttcaccgact	attacaacct	5820
cgcttataac	aaacgcggga	aattacaact	caccgttact	cagcaactcg	ggcgcacatc	5880
aacactgtat	ttgagtggta	gccatcaaac	ttattgggga	acgagtaatg	tcgatgagca	5940
attccaggct	ggattaaata	ctgcgttcga	agatatcaac	tggacgctca	gctatagcct	6000
gacgaaaaac	gcctggcaaa	aaggacggga	tcagatgtta	gcgcttaacg	tcaatattcc	6060
tttcagccac	tggtctgcgtt	ctgacagtaa	atctcagtgg	cgacatgcca	gtgccagcta	6120
cagcatgtca	cacgatctca	acggtcggat	gaccaatctg	gctgggtgat	acggtacgtt	6180
gctggaagac	aacaacctca	gctatagcgt	gcaaaccggc	tatgccgggg	gaggcgatgg	6240
aaatagcgga	agtacaggct	acgccacgct	gaattatcgc	ggtgggttacg	gcaatgccaa	6300
tatcgggttac	agccatagcg	atgatattaa	gcagctctat	tacggagtca	gcgggtgggg	6360
actggctcat	gccaatggcg	taacgctggg	gcagccgtta	aacgatacgg	tggtgcttgt	6420
taaagcgcct	ggcgcaaaag	atgcaaaagt	cgaaaaccag	acgggggtgc	gtaccgactg	6480
gcgtgggttat	gccgtgctgc	cttatgccac	tgaatatcgg	gaaaatagag	tggcgctgga	6540
taccaatacc	ctggctgata	acgtcgattt	agataacgcg	gttgctaacg	ttgttcccac	6600
tcgtggggcg	atcgtgcgag	cagagttaa	agcgcgcgtt	gggataaaac	tgctcatgac	6660
gctgaccac	aataataagc	cgctgccgtt	tggggcgatg	gtgacatcag	agagtagcca	6720
gagtagcggc	attgttgcg	ataatggtca	ggtttacctc	agcggaatgc	ctttagcggg	6780

-99-

aaaagttcag	gtgaaatggg	gagaagagga	aaatgctcac	tgtgtcgcca	attatcaact	6840
gccaccagag	agtcagcagc	agttattaac	ccagctatca	gctgaatgtc	gttaaggggg	6900
cgtgatgaga	aacaaacctt	tttatcttct	gtgcgctttt	ttgtggctgg	cggtgagtca	6960
cgctttggct	gcggatagca	cgattactat	ccgcggctat	gtcagggata	acggctgtag	7020
tgtggccgct	gaatcaacca	attttactgt	tgatctgatg	gaaaacgcgg	cgaagcaatt	7080
taacaacatt	ggcgcgacga	ctcctgttgt	tccatttcgt	attttgctgt	caccctgtgg	7140
taatgccgtt	tctgccgtaa	aggttgggtt	tactggcggt	gcagatagcc	acaatgccaa	7200
cctgcttgca	cttgaaaata	cggtgtcagc	ggcttcggga	ctgggaatac	agcttctgaa	7260
tgagcagcaa	aatcaaatac	cccttaatgc	tccatcgctc	gcgctttcgt	ggacgaccct	7320
gacgccgggt	aaaccaaata	cgctgaattt	ttacgcccg	ctaattggcg	cacaggtgcc	7380
tgtcactgcg	gggcatatca	atgccacggc	taccttcact	cttgaatatc	agtaactgga	7440
gatgctcatg	aaatggtgca	aacgtgggta	tgtattggcg	gcaatattgg	cgctcgcaag	7500
tgcgacgata	caggcagccg	atgtcaccat	cacgggtgaac	ggtaagggtc	tcgccaaacc	7560
gtgtacgggt	tccaccacca	atgccacggc	tgatctcggc	gatctttatt	ctttcagttc	7620
tatgtctgcc	ggggcgccat	cggcctggca	tgatgttgcg	cttgagttga	ctaattgtcc	7680
ggtgggaacg	tcgaggggtca	ctgccagctt	cagcggggca	gccgacagta	ccggatatta	7740
taaaaaccag	gggaccgcgc	aaaacatcca	gtagagcta	caggatgaca	gtggcaacac	7800
attgaatact	ggcgcaacca	aaacagttca	ggtggatgat	tcctcacaat	cagcgcactt	7860
cccgttacag	gtcagagcat	tgacagtaaa	tggcggagcc	actcaggga	ccattcaggc	7920
agtgattagc	atcacctata	cctacagctg	aaccgaaga	gatgattgta	atgaaacgag	7980
ttattaccct	gtttgctgta	ctgctgatgg	gctggtcggc	aaatgcctgg	tcattcgcct	8040
gtaaaaccgc	caatgggtacc	gctatcccta	ttggcggtgg	cagcgccaat	gtttatgtaa	8100
accttgcgcc	cgctcgtgaat	gtggggcaaa	acctggtcgt	ggatctttcg	acgcaaattc	8160
tttgccataa	cgattatccg	gaaaccatta	cagactatgt	cacactgcaa	cgaggctcgg	8220
cttatggcgg	cgtgttatct	aatttttccg	ggaccgtaaa	atatagtggc	agtagctatc	8280
catttcctac	caccagcgaa	acgccgcgcg	ttgtttataa	ttcgagaacg	gataagccgt	8340
ggccggtggc	gctttatattg	acgcctgtga	gcagtgcggg	cggggtggcg	attaaagctg	8400
gctcattaat	tgccgtgctt	attttgcgac	agaccaacaa	ctataacagc	gatgatttcc	8460
agtttgtgtg	gaatatattac	gccaaataatg	atgtgggtgg	gcctactggc	ggctgcgatg	8520
tttctgctcg	tgatgtcacc	gttactctgc	cgactacce	tggttcagtg	ccaattcctc	8580
ttaccgttta	ttgtgcgaaa	agccaaaacc	tggggtatta	cctctccggc	acaaccgcag	8640
atgcgggcaa	ctcgattttc	accaataccg	cgctgttttc	acctgcacag	ggcgtcggcg	8700

-100-

tacagttgac	gcgcaacggt	acgattattc	cagcgaataa	cacggtatcg	ttaggagcag	8760
tagggacttc	ggcggtagt	ctgggattaa	cggcaaatta	tgcacgtacc	ggagggcagg	8820
tgactgcagg	gaatgtgcaa	tcgattattg	gcgtgacttt	tgtttatcaa	taatctagaa	8880
ggatccccgg	gtaccgagct	cgaattcact	ggccgctcgtt	ttacaacgtc	gtgactggga	8940
aaaccctggc	gttaccacaac	ttaatcgctt	tgcagcacat	ccccctttcg	ccagctggcg	9000
taatagcgaa	gaggcccgcga	ccgatcgccc	ttccaacag	ttgcgcagcc	tgaatggcga	9060
atggcgcttg	atgcggtatt	ttctccttac	gcattctgtgc	ggtatttcac	accgcataatg	9120
gtgcactctc	agtacaatct	gctctgatgc	cgcatagtta	agccagcccc	gacacccgcc	9180
aacacccgct	gacgcgccct	gacgggcttg	tctgctcccc	gcattccgctt	acagacaagc	9240
tgtgaccgtc	tccgggagct	gcattgtgtca	gaggttttca	ccgtcatcac	cgaacgcgcg	9299

<210> 206

<211> 8464

<212> DNA

<213> pFIMAICDFG

<400> 206

cgagacgaaa	gggcctcgtg	atacgcctat	ttttataggt	taatgtcatg	ataataatgg	60
tttcttagac	gtcagggtgc	acttttcggg	gaaatgtgcg	cggaaccctt	atttgtttat	120
ttttctaaat	acattcaa	atgtatccgc	tcatgagaca	ataaccctga	taaatgcttc	180
aataatattg	aaaaaggaag	agtatgagta	ttcaacattt	ccgtgtcgcc	cttattccct	240
tttttgcggc	attttgcctt	cctgtttttg	ctcaccacga	aacgctgggtg	aaagtaaaag	300
atgctgaaga	tcagttgggt	gcacgagtg	gttacatcga	actggatctc	aacagcggta	360
agatccttga	gagttttcgc	cccgaagaac	gttttccaat	gatgagcact	tttaaagttc	420
tgctatgtgg	cgcggtatta	tcccgtattg	acgccgggca	agagcaactc	ggtcgccgca	480
tacactattc	tcagaatgac	ttggttgagt	actcaccagt	cacagaaaag	catcttacgg	540
atggcatgac	agtaagagaa	ttatgcagtg	ctgccataac	catgagtgat	aacactgcgg	600
ccaacttact	tctgacaacg	atcggaggac	cgaaggagct	aaccgctttt	ttgcacaaca	660
tgggggatca	tgtaactcgc	cttgatcgtt	gggaaccgga	gctgaatgaa	gccataccaa	720
acgacgagcg	tgacaccacg	atgcctgtag	caatggcaac	aacgttgccg	aaactattaa	780
ctggcgaaact	acttactcta	gcttcccggc	aacaattaat	agactggatg	gaggcggata	840
aagttgcagg	accacttctg	cgctcggccc	ttccggctgg	ctggtttatt	gctgataaat	900
ctggagccgg	tgagcgtggg	tctcgcggta	tcattgcagc	actggggcca	gatggtaagc	960

-101-

cctcccgtat	cgtagttatc	tacacgacgg	ggagtcaggc	aactatggat	gaacgaaata	1020
gacagatcgc	tgagataggt	gcctcactga	ttaagcattg	gtaactgtca	gaccaagttt	1080
actcatatat	acttttagatt	gattttaaac	ttcattttta	attttaaagg	atctaggtga	1140
agatcctttt	tgataatctc	atgacaaaa	tcccttaacg	tgagttttcg	ttccactgag	1200
cgtcagaccc	cgtagaaaaag	atcaaaggat	cttcttgaga	tccttttttt	ctgcgcgtaa	1260
tctgctgctt	gcaaacaaaa	aaaccacgc	taccagcggg	ggtttgtttg	cgggatcaag	1320
agctaccaac	tctttttccg	aaggtaactg	gcttcagcag	agcgcagata	ccaaatactg	1380
tccttctagt	gtagccgtag	ttaggccacc	acttcaagaa	ctctgtagca	ccgcctacat	1440
acctcgctct	gctaatcctg	ttaccagtgg	ctgctgccag	tggcgataag	tcgtgtctta	1500
ccgggttgga	ctcaagacga	tagttaccgg	ataaggcgca	gcggtcgggc	tgaacggggg	1560
gttcgtgcac	acagcccagc	ttggagcgaa	cgacctacac	cgaactgaga	tacctacagc	1620
gtgagctatg	agaaagcgcc	acgcttcccg	aaggagaaaa	ggcggacagg	tatccggtaa	1680
gcggcagggg	cggaacagga	gagcgcacga	gggagcttcc	agggggaaac	gcctggtatc	1740
tttatagtcc	tgtcggggtt	cgccacctct	gacttgagcg	tcgatttttg	tgatgctcgt	1800
caggggggcg	gagcctatgg	aaaaacgcca	gcaacgcggc	ctttttacgg	ttcctggcct	1860
tttgctggcc	ttttgctcac	atgttctttc	ctgcgttata	ccctgattct	gtggataacc	1920
gtattaccgc	ctttgagtga	gctgataccg	ctcgccgcag	ccgaacgacc	gagcgcagcg	1980
agtcagtgag	cgaggaagcg	gaagagcgcc	caatacgcaa	accgcctctc	cccgcgcgtt	2040
ggccgattca	ttaatgcagc	tggcacgaca	ggtttcccga	ctggaaagcg	ggcagtgagc	2100
gcaacgcaat	taatgtgagt	tagctcactc	attaggcacc	ccaggcttta	cactttatgc	2160
ttccggctcg	tatgttgtgt	ggaattgtga	gcggataaca	atttcacaca	ggaaacagct	2220
atgaccatga	ttacgccaaag	cttataatag	aaatagtttt	ttgaaaggaa	agcagcatga	2280
aaattaaaac	tctggcaatc	gttgttctgt	cggctctgtc	cctcagttct	acagcggctc	2340
tggccgctgc	cacgacgggt	aatggtggga	cggttcactt	taaaggggaa	gttggttaacg	2400
ccgcttgccg	agttgatgca	ggctctgttg	atcaaaccgt	tcagttagga	caggttcgta	2460
ccgcatcgct	ggcacaggaa	ggagcaacca	gttctgctgt	cggttttaac	attcagctga	2520
atgattgcga	taccaatggt	gcatctaaag	ccgctgttgc	cttttttaggt	acggcgattg	2580
atgcggttca	taccaacggt	ctggctctgc	agagttcagc	tgcgggtagc	gcaacaaacg	2640
ttggtgtgca	gatacctggac	agaacgggtg	ctgcgctgac	gctggatggg	gcgacattta	2700
gttcagaaac	aaccctgaat	aacggaacca	ataccattcc	gttccaggcg	cgttattttg	2760
caaccggggc	cgcaaccccg	ggtgctgcta	atgcggatgc	gaccttcaag	gttcagtatc	2820
aataacctac	ccaggttcag	ggacgtcatt	acgggcaggg	atgccacccc	ttgtgcgata	2880

-102-

aaaataacga	tgaaaaggaa	gagattat	ctattagcgt	cgttgctgcc	aatgtttgct	2940
ctggccggaa	ataaatggaa	taccacgttg	cccggcggaa	atatgcaatt	tcagggcgctc	3000
attattgctg	aaacttgccg	gattgaagcc	ggatgataaac	aatgacgggt	caatatggggg	3060
caaatcagca	gtaaccggtt	tcattgctgtt	ggggaagata	gcgcaccgggt	gcctttttggt	3120
attcatttac	gggaatgtag	cacgggtggtg	agtgaacgtg	taggtgtggc	gtttcacgggt	3180
gtcgccgatg	gtaaaaatcc	ggatgtgctt	tccgtggggag	aggggccagg	gatagccacc	3240
aatattggcg	tagcgtttgt	tgatgatgaa	ggaaacctcg	taccgattaa	tcgtcctcca	3300
gcaaaactgga	aacggcttta	ttcaggctct	acttcgctac	atttcacgcg	caaatatcgt	3360
gctaccgggg	gtcgggttac	tgccggcatc	gccaatgccc	aggcctgggt	ctctttaacc	3420
tatcagtaat	tggtcagcag	ataatgtgat	aacaggaaca	ggacagttag	taataaaaac	3480
gtcaatgtaa	ggaaatcgca	ggaaataaca	ttctgcttgc	tggcagggtat	cctgatgttc	3540
atggcaatga	tggttgccgg	acgcgctgaa	gcgggagtgg	ccttaggtgc	gactcgcgta	3600
atztatccgg	cagggcaaaa	acaagagcaa	cttgccgtga	caaataatga	tgaaaatagt	3660
acctatttaa	ttcaatcatg	ggtggaaaat	gccgatgggt	taaaggatgg	tcgtttttatc	3720
gtgacgcctc	ctctgtttgc	gatgaaggga	aaaaaagaga	ataccttacg	tattcttgat	3780
gcaacaaata	accaattgcc	acaggaccgg	gaaagtattat	tctggatgaa	cgtaaagcgg	3840
attccgtcaa	tgataaatc	aaaattgact	gagaatacgc	tacagctcgc	aattatcagc	3900
cgcattaaac	tgtactatcg	cccggctaaa	ttagcgttgc	cacccgatca	ggccgcagaa	3960
aaattaagat	ttcgtcgtag	cgcaattctt	ctgacgctga	ttaacccgac	acctatttac	4020
ctgacggtaa	cagagttgaa	tgccggaacc	cgggttcttg	aaaatgcatt	ggtgcctcca	4080
atgggcgaaa	gcacggttaa	attgccttct	gatgcaggaa	gcaatattac	ttaccgaaca	4140
ataaatgatt	atggcgact	tacccccaaa	atgacgggcg	taatggaata	acgcaggggg	4200
aatttttcgc	ctgaataaaa	agaattgact	gccggggtga	ttttaagccg	gaggaataat	4260
gtcatatctg	aatttaagac	tttaccagcg	aaacacacaa	tgcttgcata	ttcgtaagca	4320
tcgtttggct	ggtttttttg	tccgactcgt	tgctgcctgt	gcttttgccg	cacaggcacc	4380
tttgtcatct	gccgacctct	attttaatcc	gcgcttttta	gcggatgatc	cccaggctgt	4440
ggccgattta	tcgctgtttg	aaaatgggca	agaattaccg	ccagggacgt	atcgcgctga	4500
tatctatttg	aataatgggt	atatggcaac	gcgtgatgtc	acatttaata	cgggcgacag	4560
tgaacaaggg	attgttcctt	gcctgacacg	cgcgcaactc	gccagtatgg	ggctgaatac	4620
ggcttctgtc	gccggtatga	atctgctggc	ggatgatgcc	tgtgtgccat	taaccacaat	4680
ggtccaggac	gctactgcgc	atctggatgt	tggtcagcag	cgactgaacc	tgacgatccc	4740
tcaggcattt	atgagtaatc	gcgcgcgtgg	ttatattcct	cctgagttat	gggatccccg	4800

-103-

tattaatgcc	ggattgctca	attataat	ttt	cagcggaaat	agtgtacaga	atcggattgg	4860		
gggtaacagc	cattatgcat	atttaa	acct	acagagtggg	ttaa	atttg	gtgcgtggcg	4920	
tttacg	gac	aataccac	ct	ggagttataa	cagtagcgac	agatcatcag	gtagcaaaaa	4980	
taaatggcag	catatcaata	cctggc	ttga	gcgagacata	ataccgttac	gttccccggt	5040		
gacgctgggt	gatggttata	ctcagggcga	tattttc	gat	ggtatt	aaact	ttcgcggcgc	5100	
acaattggcc	tcagatgaca	atatgttacc	cgatag	tcaa	agaggatttg	ccccggtgat	5160		
ccacggtatt	gctcgtggta	ctgcacaggt	cactatt	aaa	caaaatgggt	atgacattta	5220		
taatagtacg	gtgccaccgg	ggccttttac	catcaac	gat	atctatgccg	caggtaatag	5280		
tggtgacttg	caggtaacga	tcaaagaggc	tgacggcagc	acgcagattt	ttaccgtacc		5340		
ctattcgtca	gtcccgc	ttt	tgcaacgtga	agggcatact	cgttattcca	ttacggcagg	5400		
agaataccgt	agtggaaatg	cgcagcagga	aaaaacccgc	tttttccaga	gtacattact		5460		
ccacggcctt	ccggctggct	ggacaatata	tggtggaacg	caactggcgg	atcg	ttatcg	5520		
tgctttta	at	ttcgg	tatcg	ggaaaaacat	gggggcactg	ggcgc	tctgt	ggatat	5580
gacgcaggct	aattccacac	ttcccgatga	cagtcagcat	gacggacaat	cggtgcgttt		5640		
tctctataac	aaatcgctca	atgaatcagg	cacgaatatt	cagttagtgg	gttaccgtta		5700		
ttcgaccagc	ggatatttta	atttcgctga	tacaacatac	agtcgaatga	atggctacaa		5760		
cattgaaaca	caggacggag	ttattcaggt	taagccgaaa	ttcaccgact	attacaacct		5820		
cgcttataac	aaacgcggga	aattacaact	caccgttact	cagcaactcg	ggcgcacatc		5880		
aacactgtat	ttgagtggta	gccatcaa	ac	ttattgggga	acgagtaatg	tcgatgagca	5940		
attccaggct	ggattaaata	ctgcgttcga	agatatcaac	tggacgctca	gctatagcct		6000		
gacgaaaaac	gcctggcaaa	aaggacggga	tcagatgtta	gcgcttaacg	tcaatattcc		6060		
tttcagccac	tggctgcgtt	ctgacagtaa	atctcag	tgg	cgacatgcc	atg	gtgccagcta	6120	
cagcatgtca	cacgatctca	acggtcggat	gaccaatctg	gctgggtgat	acggtacgtt		6180		
gctggaagac	aacaacctca	gctatagcgt	gcaaaccggc	tatgccgggg	gaggcgatgg		6240		
aaatagcggga	agtacaggct	acgccacgct	gaattatcgc	ggtgggttacg	gcaatgccaa		6300		
tatcgggttac	agccatagcg	atgatattaa	gcagctctat	tacggagtca	gcgggtgggg		6360		
actggctcat	gccaatggcg	taacgctggg	gcagccgtta	aacgatacgg	tggtgcttgt		6420		
taaagcgct	ggcgcaaaag	atgcaaaagt	cgaaaaccag	acgggggtgc	gtaccgactg		6480		
gcgtgggttat	gccgtgctgc	cttatgccac	tgaatatcgg	gaaaatagag	tggcgctgga		6540		
taccaatacc	ctggctgata	acgtcgat	ttt	agataacgcg	gttgctaacg	ttgttcccac	6600		
tcgtggggcg	atcgtgcgag	cagagtttaa	agcgcgcgtt	gggataaaac	tgctcatgac		6660		
gctgaccac	aataataagc	cgctgccgtt	tggggcgatg	gtgacatcag	agagtagcca		6720		

-104-

gagtagcggc	attgttgccg	ataatgggtca	ggtttacctc	agcggaatgc	cttagcggg	6780
aaaagttcag	gtgaaatggg	gagaagagga	aaatgctcac	tgtgtcgcca	attatcaact	6840
gccaccagag	agtcagcagc	agttattaac	ccagctatca	gctgaatgtc	gttaaggggg	6900
cgtgatgaga	aacaaacctt	tttatcttct	gtgcgctttt	ttgtggctgg	cggtgagtca	6960
cgctttggct	gcggatagca	cgattactat	ccgcggtctat	gtcagggata	acggctgtag	7020
tgtggccgct	gaatcaacca	attttactgt	tgatctgatg	gaaaacgcgg	cgaagcaatt	7080
taacaacatt	ggcgcgacga	ctcctgttgt	tccatttcgt	attttgctgt	caccctgtgg	7140
taatgccgtt	tctgccgtaa	aggttgggtt	tactggcggt	gcagatagcc	acaatgccaa	7200
cctgcttgca	cttgaaaata	cggtgtcagc	ggcttcggga	ctgggaatac	agcttctgaa	7260
tgagcagcaa	aatcaaatac	cccttaatgc	tccatcgctc	gcgctttcgt	ggacgaccct	7320
gacgccgggt	aaaccaaata	cgctgaattt	ttacgcccg	ctaattggcg	cacaggtgcc	7380
tgtcactgcg	gggcatatca	atgccacggc	taccttcact	cttgaatatc	agtaactgga	7440
gatgctcatg	aaatggtgca	aacgtgggta	tgtattggcg	gcaatattgg	cgctcgcaag	7500
tgcgacgata	caggcagccg	atgtcaccat	cacgggtgaac	ggtaaggctc	tcgccaaacc	7560
gtgtacgggt	tccaccacca	atgccacggg	tgatctcggc	gatctttatt	ctttcagtct	7620
tatgtctgcc	ggggcgccat	cggcctggca	tgatgttgcg	cttgagttga	ctaattgtcc	7680
ggtgggaacg	tcgaggggtca	ctgccagctt	cagcggggca	gccgacagta	ccggatatta	7740
taaaaaccag	gggaccgcgc	aaaacatcca	gtagagcta	caggatgaca	gtggcaacac	7800
attgaatact	ggcgcaacca	aaacagttca	ggtggatgat	tcctcacaat	cagcgcaact	7860
cccgttacag	gtcagagcat	tgacagtaaa	tggcggagcc	actcagggaa	ccattcaggc	7920
agtgattagc	atcacctata	cctacagctg	aaccgaaga	gatgattgta	atgaaacgag	7980
ttattaccct	gtttgctgta	ctgctgatgg	gctggctcgg	aaatgcctgg	tcattcgcct	8040
gtaaaaccgc	caatgggtacc	gagctcgaat	tcactggccg	tcgttttaca	acgtcgtgac	8100
tgggaaaacc	ctggcggttac	ccaacttaat	cgccctgcag	cacatcccc	tttcgccagc	8160
tggcgtaata	gcgaagaggc	ccgcaccgat	cgcccttccc	aacagttgcg	cagcctgaat	8220
ggcgaatggc	gcctgatgcg	gtattttctc	cttacgcctc	tgtgcggtat	ttcacaccgc	8280
atatggtgca	ctctcagtac	aatctgctct	gatgcgcgat	agttaagcca	gccccgacac	8340
ccgccaacac	ccgctgacgc	gccctgacgg	gcttgtctgc	tcccggcatc	cgcttacaga	8400
caagctgtga	ccgtctccgg	gagctgcatg	tgtcagaggt	tttcaccgtc	atcaccgaaa	8460
cgcg						8464

<210> 207

<211> 13

-105-

<212> PRT
 <213> Ce3epitope

 <400> 207
 Cys Gly Gly Val Asn Leu Thr Trp Ser Arg Ala Ser Gly
 1 5 10

 <210> 208
 <211> 13
 <212> PRT
 <213> Ce3mimotope

 <400> 208
 Cys Gly Gly Val Asn Leu Pro Trp Ser Phe Gly Leu Glu
 1 5 10

 <210> 209
 <211> 9
 <212> PRT
 <213> Bee venom phospholipase A2 cloning vector

 <400> 209
 Ala Ala Ala Ser Gly Gly Cys Gly Gly
 1 5

 <210> 210
 <211> 145
 <212> PRT
 <213> PLA₂ fusion protein

 <400> 210
 Met Ala Ile Ile Tyr Pro Gly Thr Leu Trp Cys Gly His Gly Asn Lys
 1 5 10 15

 Ser Ser Gly Pro Asn Glu Leu Gly Arg Phe Lys His Thr Asp Ala Cys
 20 25 30

 Cys Arg Thr Gln Asp Met Cys Pro Asp Val Met Ser Ala Gly Glu Ser
 35 40 45

 Lys His Gly Leu Thr Asn Thr Ala Ser His Thr Arg Leu Ser Cys Asp
 50 55 60

 Cys Asp Asp Lys Phe Tyr Asp Cys Leu Lys Asn Ser Ala Asp Thr Ile
 65 70 75 80

 Ser Ser Tyr Phe Val Gly Lys Met Tyr Phe Asn Leu Ile Asp Thr Lys
 85 90 95

 Cys Tyr Lys Leu Glu His Pro Val Thr Gly Cys Gly Glu Arg Thr Glu
 100 105 110

 Gly Arg Cys Leu His Tyr Thr Val Asp Lys Ser Lys Pro Lys Val Tyr
 115 120 125

 Gln Trp Phe Asp Leu Arg Lys Tyr Ala Ala Ala Ser Gly Gly Cys Gly
 130 135 140

 Gly
 145

 <210> 211
 <211> 17

-106-

<212> PRT

<213> Ce4mimotope

<400> 211

Gly Glu Phe Cys Ile Asn His Arg Gly Tyr Trp Val Cys Gly Asp Pro
 1 5 10 15

Ala

<210> 212

<211> 27

<212> PRT

<213> Synthetic M2 Peptide

<400> 212

Ser Leu Leu Thr Glu Val Glu Thr Pro Ile Arg Asn Glu Trp Gly Cys
 1 5 10 15

Arg Cys Asn Gly Ser Ser Asp Gly Gly Gly Cys
 20 25

<210> 213

<211> 97

<212> PRT

<213> Matrix protein M2

<400> 213

Met Ser Leu Leu Thr Glu Val Glu Thr Pro Ile Arg Asn Glu Trp Gly
 1 5 10 15

Cys Arg Cys Asn Gly Ser Ser Asp Pro Leu Ala Ile Ala Ala Asn Ile
 20 25 30

Ile Gly Ile Leu His Leu Ile Leu Trp Ile Leu Asp Arg Leu Phe Phe
 35 40 45

Lys Cys Ile Tyr Arg Arg Phe Lys Tyr Gly Leu Lys Gly Gly Pro Ser
 50 55 60

Thr Glu Gly Val Pro Lys Ser Met Arg Glu Glu Tyr Arg Lys Glu Gln
 65 70 75 80

Gln Ser Ala Val Asp Ala Asp Asp Gly His Phe Val Ser Ile Glu Leu
 85 90 95

Glu

<210> 214

<211> 42

<212> DNA

<213> Oligonucleotide

<400> 214

taaccgaatt caggaggtaa aaacatatgg ctatcatcta cc

-107-

<210> 215

<211> 129

<212> PRT

<213> Bacteriophage f2

<400> 215

Ala Ser Asn Phe Thr Gln Phe Val Leu Val Asn Asp Gly Gly Thr Gly
 1 5 10 15
 Asn Val Thr Val Ala Pro Ser Asn Phe Ala Asn Gly Val Ala Glu Trp
 20 25 30
 Ile Ser Ser Asn Ser Arg Ser Gln Ala Tyr Lys Val Thr Cys Ser Val
 35 40 45
 Arg Gln Ser Ser Ala Gln Asn Arg Lys Tyr Thr Ile Lys Val Glu Val
 50 55 60
 Pro Lys Val Ala Thr Gln Thr Val Gly Gly Val Glu Leu Pro Val Ala
 65 70 75 80
 Ala Trp Arg Ser Tyr Leu Asn Leu Glu Leu Thr Ile Pro Ile Phe Ala
 85 90 95
 Thr Asn Ser Asp Cys Glu Leu Ile Val Lys Ala Met Gln Gly Leu Leu
 100 105 110
 Lys Asp Gly Asn Pro Ile Pro Ser Ala Ile Ala Ala Asn Ser Gly Ile
 115 120 125

Tyr

<210> 216

<211> 17

<212> PRT

<213> Circular Mimotope

<400> 216

Gly Glu Phe Cys Ile Asn His Arg Gly Tyr Trp Val Cys Gly Asp Pro
 1 5 10 15

Ala

<210> 217

<211> 329

<212> PRT

-108-

<213> Bacteriophage Q-beta

<400> 217

```

Met Ala Lys Leu Glu Thr Val Thr Leu Gly Asn Ile Gly Lys Asp Gly
1      5      10      15
Lys Gln Thr Leu Val Leu Asn Pro Arg Gly Val Asn Pro Thr Asn Gly
20      25      30
Val Ala Ser Leu Ser Gln Ala Gly Ala Val Pro Ala Leu Glu Lys Arg
35      40      45
Val Thr Val Ser Val Ser Gln Pro Ser Arg Asn Arg Lys Asn Tyr Lys
50      55      60
Val Gln Val Lys Ile Gln Asn Pro Thr Ala Cys Thr Ala Asn Gly Ser
65      70      75      80
Cys Asp Pro Ser Val Thr Arg Gln Ala Tyr Ala Asp Val Thr Phe Ser
85      90      95
Phe Thr Gln Tyr Ser Thr Asp Glu Glu Arg Ala Phe Val Arg Thr Glu
100     105     110
Leu Ala Ala Leu Leu Ala Ser Pro Leu Leu Ile Asp Ala Ile Asp Gln
115     120     125
Leu Asn Pro Ala Tyr Trp Thr Leu Leu Ile Ala Gly Gly Gly Ser Gly
130     135     140
Ser Lys Pro Asp Pro Val Ile Pro Asp Pro Pro Ile Asp Pro Pro Pro
145     150     155     160
Gly Thr Gly Lys Tyr Thr Cys Pro Phe Ala Ile Trp Ser Leu Glu Glu
165     170     175
Val Tyr Glu Pro Pro Thr Lys Asn Arg Pro Trp Pro Ile Tyr Asn Ala
180     185     190
Val Glu Leu Gln Pro Arg Glu Phe Asp Val Ala Leu Lys Asp Leu Leu
195     200     205
Gly Asn Thr Lys Trp Arg Asp Trp Asp Ser Arg Leu Ser Tyr Thr Thr
210     215     220
Phe Arg Gly Cys Arg Gly Asn Gly Tyr Ile Asp Leu Asp Ala Thr Tyr
225     230     235     240
Leu Ala Thr Asp Gln Ala Met Arg Asp Gln Lys Tyr Asp Ile Arg Glu
245     250     255
Gly Lys Lys Pro Gly Ala Phe Gly Asn Ile Glu Arg Phe Ile Tyr Leu
260     265     270
Lys Ser Ile Asn Ala Tyr Cys Ser Leu Ser Asp Ile Ala Ala Tyr His
275     280     285
Ala Asp Gly Val Ile Val Gly Phe Trp Arg Asp Pro Ser Ser Gly Gly
290     295     300

```

-109-

Ala Ile Pro Phe Asp Phe Thr Lys Phe Asp Lys Thr Lys Cys Pro Ile
 305 310 315 320

Gln Ala Val Ile Val Val Pro Arg Ala
 325

<210> 218

<211> 770

<212> PRT

<213> Amyloid-Beta Protein (Homo Sapiens)

<400> 218

Met Leu Pro Gly Leu Ala Leu Leu Leu Ala Ala Trp Thr Ala Arg
 1 5 10 15

Ala Leu Glu Val Pro Thr Asp Gly Asn Ala Gly Leu Leu Ala Glu Pro
 20 25 30

Gln Ile Ala Met Phe Cys Gly Arg Leu Asn Met His Met Asn Val Gln
 35 40 45

Asn Gly Lys Trp Asp Ser Asp Pro Ser Gly Thr Lys Thr Cys Ile Asp
 50 55 60

Thr Lys Glu Gly Ile Leu Gln Tyr Cys Gln Glu Val Tyr Pro Glu Leu
 65 70 75 80

Gln Ile Thr Asn Val Val Glu Ala Asn Gln Pro Val Thr Ile Gln Asn
 85 90 95

Trp Cys Lys Arg Gly Arg Lys Gln Cys Lys Thr His Pro His Phe Val
 100 105 110

Ile Pro Tyr Arg Cys Leu Val Gly Glu Phe Val Ser Asp Ala Leu Leu
 115 120 125

Val Pro Asp Lys Cys Lys Phe Leu His Gln Glu Arg Met Asp Val Cys
 130 135 140

Glu Thr His Leu His Trp His Thr Val Ala Lys Glu Thr Cys Ser Glu
 145 150 155 160

Lys Ser Thr Asn Leu His Asp Tyr Gly Met Leu Leu Pro Cys Gly Ile
 165 170 175

Asp Lys Phe Arg Gly Val Glu Phe Val Cys Cys Pro Leu Ala Glu Glu
 180 185 190

Ser Asp Asn Val Asp Ser Ala Asp Ala Glu Glu Asp Asp Ser Asp Val
 195 200 205

Trp Trp Gly Gly Ala Asp Thr Asp Tyr Ala Asp Gly Ser Glu Asp Lys
 210 215 220

Val Val Glu Val Ala Glu Glu Glu Val Ala Glu Val Glu Glu Glu
 225 230 235 240

-110-

Glu Ala Asp Asp Asp Glu Asp Asp Glu Asp Gly Asp Glu Val Glu Glu
 245 250 255
 Glu Ala Glu Glu Pro Tyr Glu Glu Ala Thr Glu Arg Thr Thr Ser Ile
 260 265 270
 Ala Thr Thr Thr Thr Thr Thr Thr Glu Ser Val Glu Glu Val Val Arg
 275 280 285
 Glu Val Cys Ser Glu Gln Ala Glu Thr Gly Pro Cys Arg Ala Met Ile
 290 295 300
 Ser Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys Ala Pro Phe Phe
 305 310 315 320
 Tyr Gly Gly Cys Gly Gly Asn Arg Asn Asn Phe Asp Thr Glu Glu Tyr
 325 330 335
 Cys Met Ala Val Cys Gly Ser Ala Met Ser Gln Ser Leu Leu Lys Thr
 340 345 350
 Thr Gln Glu Pro Leu Ala Arg Asp Pro Val Lys Leu Pro Thr Thr Ala
 355 360 365
 Ala Ser Thr Pro Asp Ala Val Asp Lys Tyr Leu Glu Thr Pro Gly Asp
 370 375 380
 Glu Asn Glu His Ala His Phe Gln Lys Ala Lys Glu Arg Leu Glu Ala
 385 390 395 400
 Lys His Arg Glu Arg Met Ser Gln Val Met Arg Glu Trp Glu Glu Ala
 405 410 415
 Glu Arg Gln Ala Lys Asn Leu Pro Lys Ala Asp Lys Lys Ala Val Ile
 420 425 430
 Gln His Phe Gln Glu Lys Val Glu Ser Leu Glu Gln Glu Ala Ala Asn
 435 440 445
 Glu Arg Gln Gln Leu Val Glu Thr His Met Ala Arg Val Glu Ala Met
 450 455 460
 Leu Asn Asp Arg Arg Arg Leu Ala Leu Glu Asn Tyr Ile Thr Ala Leu
 465 470 475 480
 Gln Ala Val Pro Pro Arg Pro Arg His Val Phe Asn Met Leu Lys Lys
 485 490 495
 Tyr Val Arg Ala Glu Gln Lys Asp Arg Gln His Thr Leu Lys His Phe
 500 505 510
 Glu His Val Arg Met Val Asp Pro Lys Lys Ala Ala Gln Ile Arg Ser
 515 520 525
 Gln Val Met Thr His Leu Arg Val Ile Tyr Glu Arg Met Asn Gln Ser
 530 535 540
 Leu Ser Leu Leu Tyr Asn Val Pro Ala Val Ala Glu Glu Ile Gln Asp
 545 550 555 560
 Glu Val Asp Glu Leu Leu Gln Lys Glu Gln Asn Tyr Ser Asp Asp Val
 565 570 575

-111-

Leu Ala Asn Met Ile Ser Glu Pro Arg Ile Ser Tyr Gly Asn Asp Ala
 580 585 590
 Leu Met Pro Ser Leu Thr Glu Thr Lys Thr Thr Val Glu Leu Leu Pro
 595 600 605
 Val Asn Gly Glu Phe Ser Leu Asp Asp Leu Gln Pro Trp His Ser Phe
 610 615 620
 Gly Ala Asp Ser Val Pro Ala Asn Thr Glu Asn Glu Val Glu Pro Val
 625 630 635 640
 Asp Ala Arg Pro Ala Ala Asp Arg Gly Leu Thr Thr Arg Pro Gly Ser
 645 650 655
 Gly Leu Thr Asn Ile Lys Thr Glu Glu Ile Ser Glu Val Lys Met Asp
 660 665 670
 Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys Leu
 675 680 685
 Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile Gly
 690 695 700
 Leu Met Val Gly Gly Val Val Ile Ala Thr Val Ile Val Ile Thr Leu
 705 710 715 720
 Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile His His Gly Val Val
 725 730 735
 Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg His Leu Ser Lys Met
 740 745 750
 Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys Phe Phe Glu Gln Met
 755 760 765
 Gln Asn
 770

<210> 219

<211> 82

<212> PRT

<213> Beta-Amyloid Peptide Precursor (Homo Sapiens)

<400> 219

Gly Ser Gly Leu Thr Asn Ile Lys Thr Glu Glu Ile Ser Glu Val Lys
 1 5 10 15
 Met Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln
 20 25 30
 Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile
 35 40 45
 Ile Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Val Ile Ile Ile
 50 55 60

-112-

Thr Leu Val Met Leu Lys Lys Gln Tyr Thr Ser Asn His His Gly Val
 65 70 75 80

Val Glu

<210> 220

<211> 42

<212> PRT

<213> Amyloid Beta Peptide

<400> 220

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys
 1 5 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile
 20 25 30

Gly Leu Met Val Gly Gly Val Val Ile Ala
 35 40

221:

RANKL_human: TrEMBL:O14788: extracellular domain

YFRAQMDPNRIS EDGTHCIYRI LRLHENADFQ DTTLESQDTK LIPDSCRRIK QAFQGAVQKE
 LQHIVGSQHI RAEKAMVDGS WDLAKRSKL EAQPPFAHLTI NATDIPSGSH KVSLSWYHD
 RGWAKISNMT FSNGKLIVNQ DGFYYLYANI CFRHHETSGD LATEYLQLMV YVTKTSIKIP
 SSHTLMKGGG TKYWSGNSEF HFYSINVGGF FKLRSAGEEIS IEVSNPSLLD PDQDATYFGA FKVRDID

222:

RANKL_human: spliced isoformTrEMBL:O14788

MDPNRISEDG THCIYRILRL HENADFQDTT LESQDTKLIP DSCRRIKQAF QGAVQKELQH
 IVGSQHIRAE KAMVDGSWLD LAKRSKLEAQ PFAHLTINAT DIPSGSHKVS LSSWYHDRGW
 AKISNMTFSN GKLVNQDGF YYLYANICFR HHETSGDLAT EYLQLMVYVT KTSIKIPSSH
 TLMKGGSTKY WSGNSEFHFY SINVGGF FKL RSAGEEISIEV SNPSLLDPDQ DATYFGAFKV
 RDID

223:

RANKL_mouse: TrEMBL:O35235: extracellular domain

YFRAQMDPNRI SEDSTHCFYR ILRLHENAGL QDSTLESED TLPDSCRRMKQ AFQGAVQKEL
 QHIVGPQRF S GAPAMMEGSW LDVAQRGKPE AQPPFAHLTIN AASIPSGSHK VTLSSWYHDR
 GWAKISNMTL SNGKLRVNQD GFYYLYANIC FRHHETSGSV PTDYLQLMVY VVKTSIKIPS
 SHNLMKGGST KNWSGNSEFH FYSINVGGF KLRAGEEISI QVSNPSLLDP DQDATYFGAF KVQDID

224:

RANKL_mouse spliced isoforms: TrEMBL:Q9JJK8

-113-

MKQAFQGA VQ KELQHIVGPQ RFSGAPAMME GSWLDVAQRG KPEAQPF AHL TINAASIPSG
SHKVTLS SWY HDRGWAKISN MTL SNGKLRV NQDGFYYLYA NICFRHHETS GSVPTDYLQL
MVYVVKTSIK IPSSHNL MKG GSTKNWSGNS EFHFYSINVG GFFKLRAGEE ISIQVSNPSL
LDPDQDATYF GAFKVQDID

225:

MIF_rat: SwissProt

PMFIVNTNVP RASVPEGFLS ELTQQLAQAT GKPAQYIAVH VVPDQLMTFS GTSDPCALCS
LHSIGKIGGA QNRNYSKLLC GLLSDRLHIS PDRVYINYD MNAANVGWNG STFA

226:

MIF_mouse: SwissProt

PMFIVNTNVP RASVPEGFLS ELTQQLAQAT GKPAQYIAVH VVPDQLMTFS GTNDPCALCS
LHSIGKIGGA QNRNYSKLLC GLLSDRLHIS PDRVYINYD MNAANVGWNG STFA

227:

MIF_human: SwissProt

PMFIVNTNVP RASVPDGFSL ELTQQLAQAT GKPPQYIAVH VVPDQLMAFG GSSEPCALCS
LHSIGKIGGA QNRSYSKLLC GLLAERLRIS PDRVYINYD MNAANVGWNN STFA

228:

Human IL-17

ACCESSION #: AAC50341

1 mtpgktslvs lllllsleai vkagitiprn pgcpnsedkn fprrvmvnl n i hnrntntnp
61 krssdyynrs tspwnlhrne dperypsviw eakcrhlgi nadgnvdyhm nsvpiqqeil
121 vlrrepphcp nsfrlekilv svgtctvtpi vhhva

229:

Mouse IL-17

ACCESSION #: AAA37490

1 mspgrassvs lmlllllsla atvkaaaip qssacpntea kdflqnvkvn lkvfnslgak
61 vssrrpsdyl nrstspwtlh rnedpdryps viweaqcrhq rcvnaegkld hhmnsqliqg
121 eilvlkrepe scpftfrvek mlvgvgctcv asivrqaa

230:

Human IL-13 (precursor)

MALLLT TVIALTCLGGFASPGVPPSTALRELIEELVNITQNKAPLCNGSMVWSINLTAGMYCAALESLINVSG
CSAIEKTQRM LSGFCPHKVSAGQFSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFN

231:

Human IL-13 (processed)

-114-

GPVPPSTALR ELIEELVNIT QNQKAPLCNG SMVWSINLTA
GMYCAALES INVSGCSAIE KTQRM LSGFC PHKVSAGQFS SLHVRDTKIE VAQFVKDLLL
HLKKLFREGR FN

232:

Mouse IL-13 (processed)

GPVPRSVSLPLTLKELIEELSNITQDQTPLCNGSMVWSVDLAAGGFCVALDSL TNISNCNAIYRTQRILHGLCNR
KAPTTVSSLPDTKIEVAHFITKLLSYTKQLFRHGPF

233:

Human IL-5 (precursor)

MRMLLHLSLL ALGAAYVYAI PTEIPTSALV KETLALLSTH RTLLIANETL RIPVPVHKNH
QLCTEEIFQG IGTLESQTVQ GGTVERLFKN LSLIKKYIDG QKKKCGEERR RVNQFLDYLQEF LGVMNTEW
IIES

234:

Human IL-5 (processed)

I PTEIPTSALV KETLALLSTH RTLLIANETL RIPVPVHKNH
QLCTEEIFQG IGTLESQTVQ GGTVERLFKN LSLIKKYIDG QKKKCGEERR RVNQFLDYLQ
EFLGVMNTEW IIES

235:

Mouse IL-5 (processed)

MEIPMSTVVKETLTQLSAHRALLTSNETMRLPVPTHKNHQLCIGEIFQGLDILKNQTVRGGTVEMLFQNL SLIKK
YIDRQKEKCGEERRRTRQFLDYLQEF LGVMSTEWAMEG

236:

CCL21 Swissprot: SY21_human: Sequence after cleavage of signal peptide:

SDGGAQD CCLKYSQRKI PAKVVRSYRK QEPSLGCSIP AILFLPRKRS QAELCADPKE LWVQQLMQHL
DKTPSPQKPA QGCRKDRGAS KTGKKGKGS KCKRTERSQT PKGP

237:

CCL21 Swissprot: SY21_mouse: Sequence after cleavage of signal peptide:

SDGGGQD CCLKYSQKKI PYSIVRGYRK QEPSLGCPPI AILFSPRKHS KPCLCANPEE GWVQQLMRRL
DQPPAPGKQS PGCRKNRGT S KSGKKGKGS KCKRTEQTQP SRG

238:

Swissprot: SDF1_human: Sequence after cleavage of signal peptide:

-115-

DGKPVSLSYRC PCRFFESHVA RANVKHLKIL NTPNCALQIV ARLKNNNRQV CIDPKLKWIQ
EYLEKALNKR FKM

239:

Swissprot: SDF1_mouse: Sequence after cleavage of signal peptide:

DGKPVSLSYRC PCRFFESHIA RANVKHLKIL NTPNCALQIV ARLKNNNRQV CIDPKLKWIQ
EYLEKALNK

240:

BLC Sequences: Human: Accession: NP_006410

Amino acids 1-22 are signal peptide.

MKFISTSLLL MLLVSSLSPV QGVLEVYYTS LRCRCVQESS VFIPRRFIDR IQILPRGNGC
PRKEIIVWKK NKSIVCVDPO AEWIQRMMEV LRKRSSSTLP VPVFKRKIP

241:

BLC Sequence Mouse: accession: NP_061354

Amino acids 1-21 are signal peptide

MRLSTATLLL LLASCLSPGH GILEAHYTNL KCRCSGVIST VVGLNIIDRI QVTPPGNGCP
KTEVVIWTKM KKVICVNPRK KWLQRLLRHV QSKSLSTPQ APVSKRRAA

242:

Human Eotaxin-1

1-23 is Signal peptide

1 mkvsaallwl lllaaafspq glagpasvpt tccfnlanrk iplqrlesyr ritsgkcpqk
61 avifkttklak dicadpkkkw vqdsmyldq ksptpkp

243:

Human Eotaxin-2

1-26 is Signal peptide

1 maglmtivts llflgvcahh iiptgsvvip spccmffvsk ripenrvvsy qlssrstclk
61 agvifttkkg qqfcgdpkqe wqgrymnld akqkkaspra ravavkgpvq rypgnqtte

244:

Human Eotaxin-3

-116-

1-23 is signal peptide

1 mmglslasav llasllslhl gtatrgsdis ktccfqyshk plpwtwvrsy eftsnsqsr
 61 avifttkrgk kvcthrkkw vqkyisllkt pkql

245:

Mouse Eotaxin-1**1-23 is signal peptide**

1 mqsstallfl lltvtsftsq vlahpgsipt sccfimtssk ipntllksyk ritnnrctlk
 61 aivfktrlgk eicadpkkkw vqdatkhldq klqtpkp

246:

Mouse Eotaxin-2**1-25 is signal peptide**

1 magsativag llllvacacc ifpidsvtip sscctsfisk kipenrvvsv qlangsicpk
 61 agvifitkkg hkictdpkll wvqrhiqkld akknqpskga kavrtkfavq rrrgnstev

247:

M-CSF Sequence: human: the construct would be an N-terminal fragment consisting of residue 33 -181 or 33 -185, corresponding to the soluble form of the receptor.

Accession: NP_000748

MTAPGAAGRC PPTTWLGSLL LLVCLLASRS ITEEVSEYCS HMIGSGHLQS LQRLIDSQME
 TSCQITFEFV DQEQLKDPVC YLKKAFLLVQ DIMEDTMRFR DNTPNATIAIV QLQELSLRLK
 SCFTKDYEELH DKACVRTFYE TPLQLLEKVK NVFNETKNLL DKDWNIFSKN CNNSFAECSS
 QDVVTKPCDN CLYPKAIPSS DPASVSPHQP LAPSMAPVAG LTWEDSEGTE GSSLLPGEQP
 LHTVDPGSAK QRPPRSTCQS FEPPETPVVK DSTIGGSPQP RPSVGAFNPG MEDILDSAMG
 TNWVPEEASG EASEIPVPQG TELSPSRPGG GSMQTEPARP SNFLSASSPL PASAKGQPPA
 DVTGTALPRV GPVRPTQGDW NHTPQKTDHP SALLRDPPEP GSPRISSPRP QGLSNPSTLS
 AQPQLSRSHS SGSVLPLGEL EGRRSTRDRR SPAEPEGGPA SEGAARPLPR FNSVPLTDTH
 ERQSEGSSSP QLQESVFHLL VPSVILVLLA VGGLLFYRWR RRSHQEPQRA DSPLEQPEGS
 PLTQDDRQVE LPV

248:

M-CSF Mouse sequence: Mature sequence starts at amino acid 33. Accession. NP_031804

MTARGAAGRC PSSTWLGSRL LLVCLLMSRS IAKEVSEHCS HMIGNHGLKV LQQLIDSQME
 TSCQIAFEFV DQEQLDDPVC YLKKAFFLVQ DIIDETMRFK DNTPNANATE RLQELSNLNLN
 SCFTKDYEELH NKACVRTFHE TPLQLLEKIK NFFNETKNLL EKDOWNIFTKN CNNSFAKCSS
 RDVVTKPCDN CLYPKATPSS DPASASPHQP PAPSMAPLAG LAWDDSQRTS GSSLLPSELP
 LRIEDPGSAK QRPPRSTCQT LESTEQPNHG DRLTEDSQPH PSAGGPVPGV EDILESSLGT
 NWVLEEASGE ASEGFLTQEA KFSPSTPVGG SIQAETDRPR ALSASFPFKS TEDQKPVDTIT
 DRPLTEVNPM RPIGQTQNNI PEKTDGTSTL REDHQEPGSP HIATPNPQRV SNSATPVAQL
 LLPKSHSWG I VLPLGELEGK RSTRDRRSPA ELEGGSSASEG AARPVARFNS IPLTDTGHVE
 QHEGSSDPQI PESVFHLLVP GIIILVLLTVG GLLFYKWKWR SHRDPQTLDS SVGRPEDSSL
 TQDEDRQVEL PV

-117-

249:

Sequence of Human Resistin: Precursor.

MKALCLLLLPVLGLLVSSKTLCSMEEAINERIQEVAGSLIFRAISSIGLECQSVTSRGDLATCPRGFAVTGCTCG
SACGSWDVRAETTCHCQCAGMDWTGARCCRVQP

250:

Sequence of Mouse Resistin: Precursor.

MKNLSFPLLFLFFLVPELLGSSMPLCPIDEAIDKKIKQDFNSLFPNAIKNIGLNCWTVSSRGKLASCPEGTAVLSCSC
GSACGSWDIREEKVCHCQCARIDWTAARCCCKLQVAS

251:

Lymphotoxin- β :

Swissprot: TNFC_human: Sequence of the extracellular domain:

QD QGGLVTETAD PGAQAQQLG FQKLPEEEPE TDLSPGLPAA HLIGAPLKGQ GLGWETTKEQ
AFLTSGTQFS DAEGALPQD GLYYLYCLVG YRGRAPPGGG DPQGRSVTLR SSLYRAGGAY GPGTPELLE
GAETVTPVLD PARRQGYGPL WYTSVGFGGL VQLRRGERVY VN

252:

Lymphotoxin- β :

Swissprot: TNFC_mouse: Sequence of the extracellular domain:

QD QGRRVEKIIG SGAQAQKRLD DSKPSCILPS PSSLSETPDP RLHPQRSNAS RNLASTSQGP
VAQSSREASA WMTILSPAAD STPDGPVQQL PKGEPETDLN PELPAHLIG AWMSGQGLSW
EASQEEAFLR SGAQFSPTHG LALPDGVIYY LYCHVGVRGR TPPAGRSRAR SLTLRSALYR
AGGAYGRGSP ELLLEGAETV TPVVDPIGYG SLWYTSVGFG GLAQLRSGER VYVNISHPDM
VDYRRGKTFF GAVMVG

253:

RNA-phage PP7:

msktivlsvg eatrtlteiq stadrqifee kvgplvgrlr ltaslrqnga ktayrvnlkl
dgadvdcst svcgelpkvr ytwqwhdvt ivansteasr kslydltksl vatsqvedlv
vnlvplgr

254:

RNA-phage SP A1 protein:

aklnqvtils kigkngdqtl tltprgvnpt ngvaslseag avpalekrvt vsvaqpsrnr
knfkvgiklg nptactrdac dpsvtrsafa dvtilsftsys tdeeralirt elaalladpl
ivdaidnlnp aywaallvas sgggdnpdp dvppvdpvkp pdgtgrykcp facyrlgsiy
evgkegsdip yergdevsvt fdyaedflg ntnwnrwdqr lsdydianrr rcrngnyidl
datamqsddf vlsgrgyvrk vkfpgafgsi kyllniqgda wldlsevtay rsygmvigfw

-118-

tdskspqlpt dftqfnsanc pvqtviiips 1

255:

"Qβ 240":

AKLETVTNLGNIGRDGKQTLVLNPRGVNPTNGVASLSQAGAVP
ALEKRVTVSQPSRNRKNYKVQVKIQNPTACTANGSCDPSVTRQ
KYADVTFSTQYSTDEERAFVRTELAALLASPLLIDDAIDQLNPAY

256:

"Qβ 243":

AKLETVTNLGNIGKDGRQTLVLNPRGVNPTNGVASLSQAGAVP
ALEKRVTVSQPSRNRKNYKVQVKIQNPTACTANGSCDPSVTRQ
KYADVTFSTQYSTDEERAFVRTELAALLASPLLIDDAIDQLNPAY

257:

"Qβ 250":

ARLETVTNLGNIGRDGKQTLVLNPRGVNPTNGVASLSQAGAVP
ALEKRVTVSQPSRNRKNYKVQVKIQNPTACTANGSCDPSVTRQ
KYADVTFSTQYSTDEERAFVRTELAALLASPLLIDDAIDQLNPAY

258:

"Qβ 259":

ARLETVTNLGNIGKDGRQTLVLNPRGVNPTNGVASLSQAGAVP
ALEKRVTVSQPSRNRKNYKVQVKIQNPTACTANGSCDPSVTRQ
KYADVTFSTQYSTDEERAFVRTELAALLASPLLIDDAIDQLNPAY

259:

"Qβ 251":

AKLETVTNLGNIGKDGRQTLVLNPRGVNPTNGVASLSQAGAVP
ALEKRVTVSQPSRNRKNYKVQVKIQNPTACTANGSCDPSVTRQ
KYADVTFSTQYSTDEERAFVRTELAALLASPLLIDDAIDQLNPAY

260:

PH19 (SEQ ID NO:260)

TAAGTCCTCTGCCACGTACC

261:

-119-

PH20 (SEQ ID NO:261)

TGGAACACGCTCACTTC

262:

PH21 (SEQ ID NO:262)

CGGGATCCGGGATGAAGAACCTTTCATTTC

263:

PH22 (SEQ ID NO:263)

GCCTCTAGAGAGGAAGCGACCTGCAGCTTAC

264:

PH29 (SEQ ID NO:264)

CTAGCGGGAGGGGGTGGATGTGGGGACGACTACAAGGATGACGACA

265:

PH30 (SEQ ID NO:265)

AGCTTGTCGTCATCCTTGTAAGTCGTCACATCCACCCCTCCCG

266:

PH31 (SEQ ID NO:266)

AGCTTACTCACACATGCCCACCGTGCCCAGCACCTGAAGCCGAGG

267:

PH32 (SEQ ID NO:267)

CGGCTTCAGGTGCTGGGCACGGTGGGCATGTGTGAGTA

268:

PH35 (SEQ ID NO:268)

CTAGCGGGAGGGGGTGGATGTGGGATCGAAGGTCGCA

-120-

269:

PH36 (SEQ ID NO:269)

AGCTTGCGACCTTCGATCCCACATCCACCCCCTCCCG

270:

PH37 (SEQ ID NO:270)

CGGGATCCAGCAGCTGGGCTCGAGGTGCTAGCTTTGTTTAAAC

271:

PH38 (SEQ ID NO:271)

GATCGTTTAAACAAACAAAGCTAGCACCTCGAGCCCAGCTGCTGGATCCCGGTAC

272:

PH39 (SEQ ID NO:272)

CTAGCGGGAGGGGGTGGATGTGGGGACGATGACGACA

273:

PH40 (SEQ ID NO:273)

AGCTTGTCGTCATCGTCCCCACATCCACCCCCTCCCG

274:

PH41 (SEQ ID NO:274)

CATGGAGACAGACACACTCCTGCTATGGGT

275:

PH42 (SEQ ID NO:275)

GCAGTACCCATAGCAGGAGTGTGTCTGTCTCCATGGTAC

276:

-121-

PH43 (SEQ ID NO:276)

ACTGCTGCTCTGGGTTCCAGGTTCCACTGGTGACGCG

277:

PH44 (SEQ ID NO:277)

GATCCGCGTCACCAGTGGAACCTGGAACCCAGAGCA

278:

SU7 (SEQ ID NO:278)

AGCTTGCGGATCCAGGATATCGGCTCGAGGTTCTAGAGTG

279:

SU8 (SEQ ID NO:279)

GGCCCACTCTAGAACCTCGAGCCGATATCCTGGATCCGCA

280:

Resistin-C-Xa:

SSMPLCPIDEAIDKKIKQDFNSLFPNAIKNIGLNCWTVSSRGKLASCPEGTAVLSCSCG
SACGSWDIREEKVCHCQCARIDWTAARCKLQVASSLAGGGGCGIEGR

281:

Resistin-C-EK

SSMPLCPIDEAIDKKIKQDFNSLFPNAIKNIGLNCWTVSSRGKLASCPEGTAVLSCSCG
SACGSWDIREEKVCHCQCARIDWTAARCKLQVASSLAGGGGCGDDDD

282:

Resistin-GCG:

SSMPLCPIDEAIDKKIKQDFNSLFPNAIKNIGLNCWTVSSRGKLASCPEGTAVLSCSCG
SACGSWDIREEKVCHCQCARIDWTAARCKLQVASSLAGGGGCG

283:

pCep-Xa-Fc*: (complete sequence)

1 GCCCCGCCGC CGGACGAACT AAACCTGACT ACGGCATCTC TGCCCCCTCT TCGCTGGTAC GAGGAGCGCT
71 TTTGTTTTGT ATTGCGGGCA GTGCATGTAA TCCCTTCAGT TGGTTGGTAC AACTTGCCAA CTGGGCCCTG
141 TTCCACATGT GACACGGGGG GGGACCAAAC ACAAGGGGT TCTCTGACTG TAGTTGACAT CCTTATAAAT
211 GGATGTGCAC ATTTGCCAAC ACTGAGTGGC TTTCATCCTG GAGCAGACTT TGCATGTGTG GGAAGTCAAC
281 ACAACATTGC CTTTATGTGT AACTCTTGGC TGAAGCTCTT ACACCAATGC TGGGGGACAT GTACCTCCCA
351 GGGGCCCAGG AAGACTACGG GAGGCTACAC CAACGTCAAT CAGAGGGGCC TGTGTAGCTA CCGATAAGCG
421 GACCTCAAG AGGCATATAG CAATAGTGTT TATAAGGCC CCTTGTAAAC CCTAAACGGG TAGCATATGC
491 TTCCCGGGTA GTAGTATATA CTATCCAGAC TAACCTAAT TCAATAGCAT ATGTTACCCA ACGGGAAGCA
561 TATGCTATCG AATTAGGGTT AGTAAAGGG TCCTAAGGAA CAGCGATATC TCCCACCCCA TGAGCTGTCA
631 CGGTTTTAT TACATGGGGT CAGGATTCCA CGAGGGTAGT GAACCATTTT AGTCACAAGG CCAAGTGGCTG
701 AAGATCAAGG AGCGGGCAGT GAACCTCTCT GAATCTTCGC CTGCTTCTTC ATTCTCTCTC GTTTAGCTAA
771 TAGAATAACT GCTGAGTTGT GAACAGTAAG GTGTATGTGA GGTGCTCGAA AACAGGGTTT CAGGTGACGC
841 CCCCAGAAAT AAATTTGGAC GGGGGGTTCG TGTGTTGGCAT TGTGCTATGA CACCAATATA ACCCTCACAA
911 ACCCTTGGG CAATAAATAC TAGTGTAGGA ATGAACATT CTGAATATCT TTAACAATAG AAATCCATGG
981 GGTGGGGACA AGCCGTAAAG ACTGGATGTC CATCTCACAC GAATTTATGG CTATGGGCAA CACATATGCC
1051 TAGTGCAATA TGATACTGGG GTTATTAAGA TGTGTCCCG GCAGGGGACA AGACAGGTGA ACCATGTTGT
1121 TACACTCTAT TTGTAAACAAG GGGAAAGAGA GTGGACGCGG ACAGCAGCGG ACTCCACTGG TTGTCTCTAA
1191 CACCCCGGAA AATTAACGG GGCTCCACGG CAATGGGGCC CATAAACAA GACAAGTGGC CACTCTTTTT
1261 TTTGAAATTT TGGAGTGGGG GCACGCGTCA CCCCCACAC GCCGCCCTGC GGTTTTGGAC TGTAAATATA
1331 GGGTGTAAAT ACTTGGCTGA TTGTAAACCC GCTAACCATT CGCGTCAAAC CACTTGCCCA CAAACCACT
1401 AATGGCACCC CGGGGAATAC CTGCATAAGT AGGTGGGCGG GCCAAGATAG GGGCGGATG CTGCGATCT
1471 GGAGGACAAA TTACACACAC TTGCGCCTGA GCGCCAAGCA CAGGTTGTGT GGTCTCTATA TTCACGAGGT
1541 CGCTGAGAGC ACGGTGGGCT AATGTTGCCA TGGGTAGCAT ATACTACCCA AATATCTGGA TAGCATATGC
1611 TATCCTAATC TATATCTGGG TAGCATAGGC TATCCTAATC TATATCTGGG TAGCATATGC TATCCTAATC
1681 TATATCTGGG TAGTATATGC TATCCTAATC TATATCTGGG TAGCATAGGC TATCCTAATC TATATCTGGG
1751 TAGCATATGC TATCCTAATC TATATCTGGG TAGTATATGC TATCCTAATC TATATCTGGG TAGCATATGC
1821 TATCCTAATA GAGATTAGGG TAGTATATGC TATCCTAATC TATATCTGGG TAGCATATGC TATCCTAATC
1891 TCTGGATAGC ATATGCTATC CTAATCTATA TCTGGGTAGC ATATGCTATC CTAATCTATA TCTGGGTAGC
1961 ATAGGCTATC CTAATCTATA TCTGGGTAGC ATATGCTATC CTAATCTATA TCTGGGTAGC ATATGCTATC
2031 CTAATTTATA TCTGGGTAGC ATAGGCTATC CTAATCTATA TCTGGGTAGC ATATGCTATC CTAATCTATA
2101 TCTGGGTAGT ATATGCTATC CTAATCTATA TCTGGGTAGC ATATGCTATC CTAATCTATA TCTGGGTAGC
2171 ATATGATACC CAGTAGTAGA GTGGGAGTGC TATCCTTTGC ATATGCGGCC ACCTCCCAAG GGGCGTGAA
2241 TTTTCGCTGC TTGTCTTTT CCTGCATGCT GGTGTCTCCC ATTCTTAGGT GAATTTAAGG AGGCCAGGCT
2311 AAAGCCGTCG CATGCTGAT TGCTCACCAG GTAAATGTGC CTAATGTTTT CCAACGCGAG AAGGTGTTGA
2381 CGCGGAGCTG GAGTGACGTG ACAACATGGG TATGCCCAAT TGCCCCATGT TGGGAGGAGC AAATGTTGA
2451 CAAGACAGAT GGCCAGAAAT ACACCAACAG CACGCATGAT GTCTACTGGG GATTATTTCT TTAGTGCGGG
2521 GGAATACACG GCTTTTAATA CGATTGAGGG CGTCTCCTAA CAAGTTACAT CACTCCTGCC TTCTCCTACC
2591 CTCTCTCCA TGACTCCTT CATCTCCGTC ATCTCCGTC TACCCCTCCG CGGCAGCCCC TTCCACATA
2661 GGTGGAAACC AGGGAGGCAA ATCTACTCCA TCGTCAAAGC TGACACAGT CACCTGATA TTGCAGGTAG
2731 GAGCGGGCTT TGTATAACA AGGTCTTAA TCGCATCCTT CAAAACCTCA GCAATATAT GAGTTGTAA
2801 AAAGACCATG AAATAACAGA CAATGGACTC CCTAGCGGG CCAGGTTGTG GGGCGGGTCC AGGGGCCATT
2871 CCAAAGGGGA GACGACTCAA TGGTGTAAGA CGACATTGTG GAATAGCAAG GGCAGTTCTT CGCCTTAGGT
2941 TGTAAAGGGA GGTCTTACTA CCTCCATAA CGAACACACC GCGGACCCAA GTTCTCTCGT CGGTAGTCTT
3011 TTCTACGTGA CTCTAGCCA GGAGAGCTCT TAAACCTTCT GCAATGTTCT CAAATTTCTG GTTGAACCT
3081 CCTTGACCAC GATGCTTTCC AAACCACTCT CTTTTTTTCG GCCTGCTCTC ATCACCCTGA CCCCAGGGTC
3151 CAGTGCTTGG CGCTTCTCTT GGGTCTCTG CGGGCCCTG CTCTATCGCT CCGGGGGGCA CGTCAGGCTC
3221 ACCATCTGGG CCACCTTCTT GGTGGTATTC AAAATAATCG GCTTCCCTA CAGGGTGGAA AAATGGCCTT
3291 CTACCTGGAG GGGGCTGCG CGGTGGAGAC CCGGATGATG ATGACTGACT ACTGGGACTC CTGGGCTCTT
3361 TTCTTCACG TCCACGACCT CTCTTTCACG ACTTCCCTCC CTGCTCTCTT CAGTCTCTCT
3431 ACCCGGGGCG CTTCCACTAC CTCTCTGACC CGGGCTCCA CTACCTCTCT GACCCCGGCC TCCACTGCTT
3501 CCTCGACCCC GGCCTCCACC TCCTCTCTCT GCCCCTCTG CTCTGCTCTT TCTCTCTGCT CTGCTCTCTT
3571 CTGCCCCCTC TGCTCTGCTC CCTCTGCTCC CTCTGCTCTC TGCCCCCTCT GCCCCTCTG CTCTGCTCTC
3641 TCTGCCCCCT CTCTCTGCTC CTGCCCCCTC TGCCCCCTCT CTGCTCTCTC CCCCCTCTG CCCCCTCTG
3711 CCTGCCCCCT CTGCCCCCTC TGCCCCCTCT CTCTGCTCTC TGCCCCCTCT CTCTGCTCTC CCCCCTCTG
3781 CTCTGCTCTC TGCCCCCTCT GCTCTGCTCC CTCTGCTCTC TGCCCCCTCT CTCTGCTCTC CCCCCTCTG
3851 TGCTCTGCTC CTCTGCTCTC CTCTGCTCTC TGCCCCCTCT CTCTGCTCTC TGCCCCCTCT CTCTGCTCTC
3921 CCTCTGCTCC CTCTGCTCTC TGCCCCCTCT CTCTGCTCTC TGCCCCCTCT CTCTGCTCTC CCCCCTCTG
3991 CCTCTGCTCC CTCTGCTCTC TGCCCCCTCT CTCTGCTCTC TGCCCCCTCT CTCTGCTCTC CCCCCTCTG
4061 TCTGCTCTCT GCTCTGCTCC CCTCTGCTCC GCTCTGCTCC CTCTGCTCTC TGCCCCCTCT CTCTGCTCTC
4131 CTGCCCCCTC CTGCCCCCTC TGCCCCCTCT CTCTGCTCTC TGCCCCCTCT CTCTGCTCTC CCCCCTCTG
4201 CTGCCCCCTC CTCTGCTCTC TGCCCCCTCT CTCTGCTCTC TGCCCCCTCT CTCTGCTCTC CCCCCTCTG
4271 TTTTGGGGT CTCCGACAC CATCTCTATG TCTTGGCCTT GATCCTGAGC CGCCCGGGG TCTGTGTTT
4341 CCGCTCTCTC GTCCTGCTCC TCTTCCCCGT CCTGCTCCAT GGTATATACC CCTCTCTCT TTAGGTCCAC
4411 TGCCGCGGGA GCTTCTGGT ACAGATGTGT CTCTCTCTC TCCTAGGCCA TTTCCAGGTC CTGTACCTGG
4481 CCCCCTGCTA GACATGATTC AACTAAAGAG AGATCAATAG ACATCTTTAT TAGACGACGC TCAGTGAATA
4551 CAGGAGTGTG AGACTCTGCT CCCCTCCAAC AGCCCCCCA CCTCATCTCC CTTCATGGTC GCTGTACAGC
4621 AGATCCAGGT CTGAAAATTC CCCATCTCTC GAACCATCTC CGTCTCTATC ACCAATTAAT CGCAGCCCCG
4691 AAAACTCCCG CTGAACATCC CTAAGATTGG CGTCTGAGC CTCAAGCCAG GCTCAAAAT CTCTGCTCCC
4761 CTTTGTGCTG GACGGTAGGG ATGGGGATTC TCGGGACCCC TCCTCTCTCT CTTCAGGTC ACCAGACAGA
4831 GATGCTACTG GGGCAACGGA AGAAAAGCTG GGTGCGGCTT GTGAGGATCA GCTTATCGAT GATAAGCTGT
4901 CAAACATGAG AATCTTGAA GACGAAAGGG CCTGCTGATA CGCCTATTTT TATAGGTTAA TGTATGATA
4971 ATATGTTTCT CTAGACGTC AGGTGGCACT TTTTGGGGAA ATGTGCGCGG AACCCCTATT TGTATTTT
5041 TCTAAATACA TCAAAATATG TATCCGCTCA TGAGACAATA ACCCTGATAA ATGCTTCAAT AATATTGAAA
5111 AAGGAAGAGT ATGAGTATTC AACATTTCCG TGTGCCCCCT ATTCCCTTTT TTGCGGCATT TTGCCCTCTT
5181 GTTTTGTGCT ACCCAGAAAC GCTGGTGAAG GTAAAAGATG CTGAAGATCA GTTGGGTGCA CAGGTGGGTG
5251 ACATCGAATC GGATCTCAAC AGCGTAAAGA TCCTTGAGAG TTTTCCGCCC GAAGAAGCTT TTCCAATGAT
5321 GAGCACTTTT AAAGTTCTGC TATGTGGCGC GGTATTATCC CGTGTGAGC CCGGGCAAGA GCAACTCGGT
5391 CGCCGCATAC ACTATCTCTA GAATGACTTG GTTGAGTACT CACCAAGTAC AGAAAAGCAT CTTACGGATG

-123-

5461 GCATGACAGT AAGAGAATTA TGCAGTGTCTG CCATAACCAT GAGTGATAAC ACTGCGGCCA ACTTACTTCT
 5531 GACAACGATC GGAGGACCGA AGGAGCTAAC CGCTTTTCTT CACAACATGG GGGATCATGT AACTCGCCTT
 5601 GATCGTTGGG AACCGGAGCT GAATGAAGCC ATACCAAACG ACGAGCGTGA CACCACGATG CCTGCAGCAA
 5671 TGGCAACAAC GTTGCACAAA CTATTAACGTG GCGAACACT TACTCTAGCT TCCCGGCAAC AATTAATAGA
 5741 CTGGATGGAG GCGGATAAAG TTGCAGGACC ACTTCTGCGC TCGGCCCTTC CCGCTGGCTG GTTATTGCT
 5811 GATAAATCTG GAGCGGTGA GCGTGGGTCT CGCGGTATCA TTGCAGCACT GGGGCCAGAT GGTAAAGCCT
 5881 CCCGTATCGT AGTTATCTAC ACGACGGGGA GTCAGGCAAC TATGGATGAA CGAAATAGAC AGATCGCTGA
 5951 GATAGGTGCC TCACTGATTA AGCATTGGTA ACTGTCAGAC CAAGTTTACT CATATATACT TTAGATTGAT
 6021 TTAAAACTTC ATTTTAAATT TAAAAGGATC TAGGTGAAGA TCCTTTTGA TAATCTCATG ACCAAAATCC
 6091 CTTAACGTGA GTTTTCGTTC CACTGAGCGT CAGACCCCGT AGAAAAGATC AAAGGATCTT CTTGAGATCC
 6161 TTTTCTCTG CGCGTAATCT GCTGCTTGCA AACAAAAAAA CCACCGCTAC CAGCGGTGGT TTGTTTGCCG
 6231 GATCAAGAGC TACCAACTCT TTTTCCGAAG GTAACCTGGT TCAGCAGAGC GCAGATACCA AATACTGTCC
 6301 TTCTAGTGTA CCGGTAGTTA GGCCACCCTC TCAAGAACTC TGTAGCACCG CCTACATACC TCGCTCTGCT
 6371 AATCCTGTTA CCAGTGGCTG CTGCCAGTGG CGATAAGTCG TGTCTTACCG GGTGGACTC AAGACGATAG
 6441 TTACCGGATA AGGCGCAGCG GTCGGGCTGA ACGGGGGGTT CGTGACACCA GCCCAGCTTG GAGCGAACGA
 6511 CCTACACCGA CTAGAGATAC CTACAGCGTA AGCTATGAGA AAGCGCCACG CTTCCCGAAG GGAGAAAGGC
 6581 GGACAGGTAT CCGGTAAGCG GCAGGGTTCGG AACAGGAGAG CGCACGAGGG AGCTTCCAGG GGGAAACGCC
 6651 TGGTATCTTT ATAGTCTGT CCGGTTTCGC CACCTCTGAC TTGAGCGTGC ATTTTGTGA TGCTCGTCAG
 6721 GGGGGCGGAG CCTATGGAAA AACGCCACGA ACGCGGCTT TTTACGGTTC CTGGCCTTTT CTGCGCCGCG
 6791 GTGCGGCTGC TGGAGATGGC GGACGCGATG GATATGTCT GCGAAGGGTT GGTGTGCGCA TTCACAGTTC
 6861 TCCGCAAGAA TTGATTGGCT CCAATTCTTG GAGTGGTGAA TCCGTTAGCG AGGCCATCCA GCCTCGCTC
 6931 GAACTAGATG ATCCGCTGTG GAATGTGTGT CAGTTAGGGT GTGGAAAGTC CCCAGGCTCC CCAGCAGCA
 7001 GAAGATATGA AAGCATGCTA CTCAATTAGT CAGCAACGAG GTGTGGAAAG TCCCGAGGCT CCCCAGCAG
 7071 CAGAAATATG CAAAGCATGC ATCTCAATTA GTCAGCAACC ATAGTCCCGC CCCTAACTCC GCCCATCCG
 7141 CCCCTAATCT CGCCAGTTC CGCCATTTCT CCGCCCATG GCTGACTAAT TTTTTTTATT TATGCAGAGG
 7211 CCGAGGCGCG CTGCGCTTCT GAGCTATTCC AGAAGTAGTG AGGAGGCTTT TTTGGAGGGT GACCGCCACG
 7281 ACCGTGCGCG CTACCATCCC CTGACCCACG CCCCTGACCC CTCACAAGGA GACGACCTTC CATGACCGAG
 7351 TACAAGCCCA CGGTGCGCCT CGCCACCCGC GACGACGTC CCCGGGCGGT ACGCACCTTC GCCGCGCGT
 7421 TCGCCGACTA CCCCGCCACG CGCCACCCG TCGACCCCGA CCGCCACATC GAACGCGTCA CCGAGCTGCA
 7491 AGAATCTTTC CTACGCGCG TCGGGCTCGA CATCGGCAAG GTGTGGGTGC CGGACGACGG CGCGCGGTG
 7561 GCGGTCTGGA CCACGCGCGA GAGCGTCGAA GCGGGGGCGG TGTTCGCGGA GATCGGCCCG CGCATGGCCG
 7631 AGTTGAGCGG TTCCCGCTG GCGCGCGCAG AACAGATGGA AGGCCTCTTG GCGCCGACCC GGCCCAAGGA
 7701 GCGCGCGTGG TTCTTGGCCA CCGTCCGCGT CTCGCCGAC CACCAGGGCA AGGGTCTGGG GACGCGCGTC
 7771 GTGCTCCCCG GAGTGGAGGG GGCCGAGCGC GCGGGGGTGC CCGCTTCTCT GGAGACCTCC GCGCCCGCA
 7841 ACCTCCCTTT CTACGAGCGG CTCGGCTTCA CCGTACCCGC CGACGTCGAG TGCCCGAAGG ACCCGCGGAC
 7911 CTGGTGCATG ACCCGCAAGC CCGGTGCCTG ACGCCCGCCC CACGACCCGC AGCGCCCGAC CGAAAGGAGC
 7981 GCACGACCCG GTCCGACGGC GGCCACGGG TCCAGGGGG GTGCGACCTC AAATTTGTTT ATTGCAGCTT
 8051 ATAAATGGTTA CAAATAAAGC AATAGCATCA CAAATTTTAC AAATAAAGCA TTTTTTTTCA TTTTCTTAT
 8121 TTGTGGTTTG TCCAACTCA TCAATGTATC TTATCATGTC TGGATCGATC CGAACCCTTT CCTCGACCAA
 8191 TTCTCATGTT TGACAGCTTA TCATCGCAGA TCCGGGCAAC GTTGTGTCAT TGCTGCAGGC GCAGAACTGG
 8261 TAGGTATGGA AGATCTATA CTGGAATCAA TATTGGCAAT TAGCCATATT AGTCATTGGT TATATAGCAT
 8331 AAATCAATAT TGGGTATTGG CCATTGCATA CGTTGTATCT ATATCATAAAT ATGTACATT ATATTGGCTC
 8401 ATGTCCAATA TGACCCCAT GTTGACATTG ATTATTGACT AGTTATTAAT AGTAATCAAT TACGGGGTCA
 8471 TTAGTTTATA GCGCATATAT GGAGTTCCCG GTTACATAAC TTACGGTAAA TGGCCCGCCT GGTGACCGC
 8541 CCAACGACCC CCGCCCATTG ACGTCAATAA TGACGTATGT TCCCATAGTA ACGCCAATAG GGAATTTCCA
 8611 TTGACGTCAA TGGGTGGAGT ATTTACGGTA AACTGCCAC TTGGCAGTGA ATCAAGTGA TCATATGCCA
 8681 AGTCCGCCCC CTATTGACGT CAATGACGGT AAATGGCCCC CTTGGCATTA TGCCAGTAC ATGACCTTAC
 8751 GGGACTTTTC TACTTGGCAG TACATCTACG TATTAGTCAT CGCTATTACC ATGGTATGTC GGTTTTGGCA
 8821 GTACACCAAT GGGCGTGGAT AGCGGTTTGA CTCACGGGGA TTTCCAAGTC TCCACCCCAT TGACGTCAAT
 8891 GGGAGTTTGT TTTGGCACC AAATCAACGG GACTTTCCAA AATGTCGTAA TAACCCCGCC CCGTTGACGC
 8961 AAATGGGCGG TAGGCGTGTA CCGTGGGAGG TCTATATAAG CAGAGCTCGT TTAGTGAACC GTCAGATCTC
 9031 TAGAAGCTGG GTACCGGGAT CCAGCAGCTG GGCTCGAGGT GCTAGCGGGA GGGGGTGGAT GTGGATCGA
 9101 AGGTGCAAG CTTACTACA CATGCCACC GTGCCAGCA CCTGAAGCCG AGGGGGCACC GTCAGTCTC
 9171 CTCTTCCCCC CAAAACCCAA GGACACCCTC ATGATCTCCC GGACCCCTGA GGTACATGTC GTGGTGGTGG
 9241 ACGTGAGCCA CGAAGACCCT GAGGTCAAGT TCAACTGGTA CGTGGACGGC GTGGAGGTGC ATAAATGCCAA
 9311 GACAAAGCCG CGGGAGGAGC AGTACAACAG CACGTACCGT GTGGTCAGCG TCCTCACCGT CCTGCACCAG
 9381 GACTGGCTGA ATGGCAAGGA GTACAAGTGC AAGGTCTCCA ACAAGCCCT CCCAGCTTCC ATCGAGAAAA
 9451 CCATCTCCAA AGCCAAAGGG CAGCCCGGAG AACCAAGGT GTACACCTG CCCCCATCCC GGGATGAGCT
 9521 GACCAAGAAC CAGGTACGCC TGACCTGCCT GGTCAAAGGC TTCTATCCCA GCGACATCGC CGTGGAGTGG
 9591 GAGAGCAATG GGCAGCCGGA GAACAACCTAC AAGACCAACG CTCCTGTGTT GGAATCCGAC GGTCTCTCT
 9661 TCCTCTACAG CAAGCTCACC GTGGACAAGA GCAGGTGGCA GCAGGGGAAC GTCTTCTCAT GCTCCGTGAT
 9731 GCATGAGGCT CTGCACAACC ACTACACGCA GAAGAGCCTC TCCCTGTCTC CCGGTAAATG ACTCGAGGCC
 9801 CGAACAACAAA CTCATCTCAG AAGAGGATCT GAATAGCGCC GTCGACCATC ATCATCATCA TCATTGAGTT
 9871 TNAACGATCC AGACATGATA AGATACATTG ATGAGTTTGG ACAAAACACA ACTAGAATGC AGTGAACAAA
 9941 ATGCTTTATT TGTGAAATTT GTGATGCTAT TGCTTTATTT GTAACCATTA TAAGCTGCAA TAAACAAGTT
 10011 AACACAACAA ATTTGATTTA TTTTATGTTT CAGGTTTCAGG GGGAGGTGGG GAGGTTTTTT AAGCAAGTA
 10081 AAACCTCTAC AAATGTGGTA TGGCTGATTA TGATCCGGCT GCCTCGCGCG TTTGCGTGAT GACGGTGAAG
 10151 ACCTCTGACA CATGCAGCTC CCGGAGACGG TCACAGCTTG TCTGTAAGCG GATGCCGGGA GCAGACAAGC
 10221 CCGTCAGGCG GCGTACGCGG GTGTTGGCGG GTGTCGGGGC GCAGCATGAA CCGGTCGACT CTAGA

-124-

5'LT• : (SEQ ID NO:284)

5'-CTT GGT GCC GCA GGA TCA G-3'

285:

3'LT• : (SEQ ID NO:285)

5'-CAG ATG GCT GTC ACC CCA C-3'

286:

5'LT• long-*Nhe*I: (SEQ ID NO:286)

5'-GCC CGC TAG CCT GCG GTG GTC AGG ATC AGG GAC GTC G-3'

287:

5'LT• short-*Nhe*I: (SEQ ID NO:287)

5'-GCC CGC TAG CCT GCG GTG GTT CTC CAG CTG CGG ATT C -3'

288:

3'LT• stop-*Not*I: (SEQ ID NO:288)

5'-CAA TGA CTG CGG CCG CTT ACC CCA CCA TCA CCG -3'

289:

GST-EK-C-LT•₄₉₋₃₀₆: SEQ ID NO:289

APLVMSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVKLTQ
SMAIRYIADKHNMGLGGCPKERAIEISMLEGAVLDIRYGVSRIAYSKDFETLKVDFLSKLPEMLKMFEDRLCH
KTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIQIDKYLKSSKYIAWPLQGWQATF
GGGDHPPKASMTGGQQMGRDLYDDDDKLACGGQDQGRRVEKIIIGSGAQAKRLDDSKPSCILPSPSSL
SETPDPRLLHPQRSNASRNLASTSQGPVAQSSREASAWMTILSPAADSTPDGPVQQLPKGEPETDLNPEL
PAAHLIGAWMSGQGLSWEASQEEAFLRSGAQFSPTHGLALPQDGVYYLYCHVGYRGRTPPAGRSRARS
LTLRSALYRAGGAYGRGSPPELLLEGAETVTPVVDPIGYGSLWYTSVGFGGLAQLRSGERVVYNISHPDMV
DYRRGKTFFGAVMVG

290:

GST-EK-C-LT•₁₂₆₋₃₀₆: SEQ ID NO:290

APLVMSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVKLTQ
SMAIRYIADKHNMGLGGCPKERAIEISMLEGAVLDIRYGVSRIAYSKDFETLKVDFLSKLPEMLKMFEDRLCH
KTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIQIDKYLKSSKYIAWPLQGWQATF
GGGDHPPKASMTGGQQMGRDLYDDDDKLACGGSPAADSTPDGPVQQLPKGEPETDLNPELPAAHLIGA
WMSGQGLSWEASQEEAFLRSGAQFSPTHGLALPQDGVYYLYCHVGYRGRTPPAGRSRARS LTLRSALY

-125-

RAGGAYGRGSPELLLEGAETVTPVVDPIGYGSLWYTSVGFGGLAQLRSGERVYVNISHPDMVDYRRGKT
FFGAVMVG

291:

his-myc-EK-C-LT•₄₉₋₃₀₆: SEQ ID NO:291

APLVHHHHHHGPLVDVASNEQKLISEEDLASMTGGQMQMRDLYDDDDKLACGGQDQGRRVEKIIGSGAQ
AQKRLDDSKPSCILPSPSSLSETPDRLHPQRSNASRNLASTSQGPVAQSSREASAWMTILSPAADSTPDGPV
QQLPKGEPETDLNPELPAAHLIGAWMSGQGLSWEASQEEAFLRSGAQFSPTHGLALPQDGVYYLYCHVGY
RGRTPPAGRSRARS�TLRSALYRAGGAYGRGSPELLLEGAETVTPVVDPIGYGSLWYTSVGFGGLAQLRSG
ERVYVNISHPDMVDYRRGKTFFGAVMVG

292:

his-myc-EK-C-LT•₁₂₆₋₃₀₆: SEQ ID NO:292

APLVHHHHHHGPLVDVASNEQKLISEEDLASMTGGQMQMRDLYDDDDKLACGGSPAADSTPDGPVQQLP
KGEPETDLNPELPAAHLIGAWMSGQGLSWEASQEEAFLRSGAQFSPTHGLALPQDGVYYLYCHVGYRGR
PPAGRSRARS�TLRSALYRAGGAYGRGSPELLLEGAETVTPVVDPIGYGSLWYTSVGFGGLAQLRSGERVY
VNISHPDMVDYRRGKTFFGAVMVG

293:

primerMCS-1F

5'-TAT GGA TCC GGC TAG CGC TCG AGG GTT TAA ACG GCG GCC GCA T-3' (SEQ ID NO:293)

294:

primerMCS-1R

5'-TCG AAT GCG GCC GCC GTT TAA ACC CTC GAG CGC TAG CCG GAT CCA-3' (SEQ ID NO:294)

295:

Bamhis6-EK-Nhe-F

5'-GAT CCA CAC CAC CAC CAC CAC CAC GGT TCT GGT GAC GAC GAT GAC AAA GCG CTA GCC C-3'
(SEQ ID NO:295)

296:

Bamhis6-EK-Nhe-R

5'-TCG AGG GCT AGC GCT TTG TCA TCG TCG TCA CCA GAA CCG TGG TGG TGG TGG TGT G-3'

-126-

(SEQ ID NO:296)

297:

oligo1F-C-glycine-linker

5'-TCG AGG GTG GTG GTG GTG GTT GCG GTT AAT AAG TTT AAA CGC-3' (SEQ ID NO:297)

298:

oligo1R-C-glycine-linker

5'-GGC CGC GTT TAA ACT TAT TAA CCG CAA CCA CCA CCA CCC-3' (SEQ ID NO:298)

299:

oligo1F-C-gamma1-linker

5'-TCG AGG ATA AAA CCC ACA CCT CTC CGC CGT GTG GTT AAT AAG TTT AAA CGC-3' (SEQ ID NO:299)

300:

oligo1R-C-gamma1-linker

5'-GGC CGC GTT TAA ACT TAT TAA CCA CAC GGC GGA GAG GTG TGG GTT TTA TCC-3' (SEQ ID NO:300)

301:

oligo1FA-C-gamma3-linker

5'-TCG AGC CGA AAC CGT CTA CCC CGC CGG GTT CTT CTG-3' (SEQ ID NO:301)

302:

oligo1RA-C-gamma3-linker

5'-CAC CAC CAG AAG AAC CCG GCG GGG TAG ACG GTT TCG GC-3' (SEQ ID NO:302)

303:

oligo2FB-C-gamma3-linker

5'-GTG GTG CTC CGG GTG GTT GCG GTT AAT AAG TTT AAA CGC-3' (SEQ ID NO:303)

-127-

304:

oligo2RB-C-gamma3-linker

5'-GGC CGC GTT TAA ACT TAT TAA CCG CAA CCA CCC GGA G-3' (SEQ ID NO:304)

305:

rMIF-F

5'-GGA ATT CCA TAT GCC TAT GTT CAT CGT GAA CAC-3' (SEQ ID NO:305)

306:

rMIF-Xho-R

5'-CCC GCT CGA GAG CGA AGG TGG AAC CGT TC-3' (SEQ ID NO:306)

307:

rMIF-C1:

MPMFIVNTNVPRASVPEGFLSELTQQLAQATGKPAQYIAVHVVPDQLMTFSGTSDPCALCSLHSIGKIGGAQ
NRNYSKLLCGLLSDRLHISPDRVYINYDMNAANVGWNGSTFALEGGGGGCG (SEQ ID NO:307)

308:

rMIF-C2

MPMFIVNTNVPRASVPEGFLSELTQQLAQATGKPAQYIAVHVVPDQLMTFSGTSDPCALCSLHSIGKIGGAQ
NRNYSKLLCGLLSDRLHISPDRVYINYDMNAANVGWNGSTFALEDKTHTSPPCG (SEQ ID NO:308)

309:

rMIF-C3

MPMFIVNTNVPRASVPEGFLSELTQQLAQATGKPAQYIAVHVVPDQLMTFSGTSDPCALCSLHSIGKIGGAQ
NRNYSKLLCGLLSDRLHISPDRVYINYDMNAANVGWNGSTFALEPKPSTPPGSSGGAPGGCG (SEQ ID
NO:309)

310:

met-human-MIF-C1

MPMFIVNTNVP RASVPDGFLS ELTQQLAQAT GKPPQYIAVH VVPDQLMAFG GSSEPCALCS
LHSIGKIGGA QNRSYSKLLC GLLAERLRIS PDRVYINYD MNAANVGWNN STFALEGGGGGCG

-128-

311:

human-MIF-C1 (SEQ ID NO:311)

PMFIVNTNVP RASVPDGFLS ELTQQLAQAT GKPPQYIAVH VVPDQLMAFG GSSEPCALCS
LHSIGKIGGA QNRSYSKLLC GLLAERLRIS PDRVYINYD MNAANVGWNN STFALEGGGGGCG

312:

met-human-MIF-C2 (SEQ ID NO:312)

MPMFIVNTNVP RASVPDGFLS ELTQQLAQAT GKPPQYIAVH VVPDQLMAFG GSSEPCALCS
LHSIGKIGGA QNRSYSKLLC GLLAERLRIS PDRVYINYD MNAANVGWNN STFALEDKTHTSPPCG

313:

human-MIF-C2 (SEQ ID NO:313)

PMFIVNTNVP RASVPDGFLS ELTQQLAQAT GKPPQYIAVH VVPDQLMAFG GSSEPCALCS
LHSIGKIGGA QNRSYSKLLC GLLAERLRIS PDRVYINYD MNAANVGWNN STFALEDKTHTSPPCG

314:

met-human-MIF-C3 (SEQ ID NO:314)

MPMFIVNTNVP RASVPDGFLS ELTQQLAQAT GKPPQYIAVH VVPDQLMAFG GSSEPCALCS
LHSIGKIGGA QNRSYSKLLCGLLAERLRISPDRVYINYD MNAANVGWNN STFALEPKPSTPPGSSGGAPGGCG

315:

human-MIF-C3 (SEQ ID NO:315)

PMFIVNTNVP RASVPDGFLS ELTQQLAQAT GKPPQYIAVH VVPDQLMAFG GSSEPCALCS
LHSIGKIGGA QNRSYSKLLCGLLAERLRISPDRVYINYD MNAANVGWNN STFALEPKPSTPPGSSGGAPGGCG

316:

RANKL-UP:

5'-CTGCCAGGGGCCCCGGGTGCGGCGGTGGCCATCATCACCACCATCACCAGCGCTTCTCAGGAG-3'

317:

RANKL-DOWN :

5'-CCGCTCGAGTTAGTCTATGTCCTGAAC TTTGAAAG-3'

318 and 319:

Protein sequence of GST-PS-C-RANKL (SEQ ID NO:318; capital letters)

-129-

cDNA sequence of GST-PS-C-RANKL (SEQ ID NO:319; small letters)

```

1 M S P I L G Y W K I K G L V Q P T R L L L E Y L E
1 atgtcccctatactagggttattggaaaattaagggccttggtgcaaccactcgacttcttttgggaatatcttgaa
26 E K Y E E H L Y E R D E G D K W R N K K F E L G L
76 gaaaaatatgaagagcatttgtatgagcgcgatgaaggatgataaatggcgaaacaaaaagtttgaattgggtttg
51 E F P N L P Y Y I D G D V K L T Q S M A I I R Y I
151 gagttttcccaatcttccttattatattgatgggtgatgttaaattaacacagtcctatggccatcatacgttatata
76 A D K H N M L G G C P K E R A E I S M L E G A V L
226 gctgacaagcacacatgttgggtggttgcctcctcagagcgtgcagagatttcaatgcttgaaggagcgggtttg
101 D I R Y G V S R I A Y S K D F E T L K V D F L S K
301 gatattagatacgggtgtttcgagaattgcatatagtaaagactttgaaactctcaaatgttgaatttcttagcaag
126 L P E M L K M F E D R L C H K T Y L N G D H V T H
376 ctacctgaaatgctgaaaatgttcgaagatcggttatgtcataaaacatattttaaattggtgatcatgtaacccat
151 P D F M L Y D A L D V V L Y M D P M C L D A F P K
451 cctgacttcctgtgtatgacgtctcttgatgttgttttatacatggacccaatgtgcctggatgcgttcccaaaa
176 L V C F K K R I E A I P Q I D K Y L K S S K Y I A
526 ttagtttgttttaaaaaacgtattgaagctatcccacaaaattgataagtacttgaaatccagcaagtatatagca
201 W P L Q G W Q A T F G G G D H P P K S D L E V L P
601 tggccttttgagggtcggcaagccacgtttggtggtggcgaccatcctccaaaatcggtatctggaagttctgttc
226 Q G P G C G G G H H H H Q R F S G A P A M M E
676 caggggccccgggtgctggcggtggccatcatcaccaccatcaccagcgcttctcaggagctccagctatgatggaa
251 G S W L D V A Q R G K P E A Q P F A H L T I N A A
751 GGCTCATGGTTGGATGTGGCCAGCGAGGCAAGCCTGAGGCCAGCCATTTGCACACCTCACCATCAATGCTGCC
276 S I P S G S H K V T L S S W Y H D R G W A K I S N
826 AGCATCCCATCGGGTCCCATAAAGTCACTCTGTCTCTTGGTACCACGATCGAGGCTGGGCCAAGATCTCTAAC
301 M T L S N G K L R V N Q D G F Y Y L Y A N I C F R
901 ATGACGTTAAGCAACGGAATAAGGGTTAACCAAGATGGCTTCTATTACCTGTACGCCAACATTGCTTTCGG
326 H H E T S G S V P T D Y L Q L M V Y V V K T S I K
976 CATCATGAACATCGGGAAGCGTACCTACAGACTATCTTCACTGATGGTGTATGTCGTTAAACACGATCAAAA
351 I P S S H N L M K G G S T K N W S G N S E F H F Y
1051 ATCCCAAGTTCTCATAACTGATGAAAGGAGGACGACGAAAAAAGTGGTCGGGCAATCTGAATTCCACTTTTAT
376 S I N V G G F F K L R A G E E I S I Q V S N P S L
1126 TCCATAAATGTTGGGGGATTTTCAAGCTCCGAGCTGGTGAAGAAATTAGCATTCAGGTGTCCAACCTTCCCTG
401 L D P D Q D A T Y F G A F K V Q D I D *
1201 CTGGATCCGGATCAAGATGCGACGTACTTTGGGCTTTCAAAGTTCAGGACATAGACTAACTCGAGCGG

```

320:

Human-C-RANKL

GCGGGQHIRAEKAMVDGSWLDLAKRSKLEAQPFALHTINATDIPSGSHKVSLSWYHDRGWAKISNMTFSNGKLI
VNQDGFYYLYANICFRHHETSGDLATEYQLMVVYTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFK
LRSGEISIEVSNPSLLDPDQDATYFGAFKVRDID

321:

Primer 5'PrP-BamHI

5'-CGG GAT CCC ACC ATG GTG GGG GGC CTT GG -3' (SEQ ID NO:321)

322:

Primer 3'PrP-NheI

5'-CTA GCT AGC CTG GAT CTT CTC CCG -3' (SEQ ID NO:322)

323:

Protein sequence of mPrP_E-EK-Fc*

-130-

MVGGLGGYMLGSAMSRPMIHFGNDWEDRYRENMYRYPNQVYYRPVDQYSNQNNFVHDCVNITIKQHT
VTTTTKGENFTETDVKMMERVVEQMCVTQYQESQAYYDGRSRLAGGGGCGDDDDKLTHTCPPCPAPEA
EGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVS
VLTVLHQDWLNGKEYKCKVSNKALPASIETISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPS
DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSFSVMHEALHNHYTQKSLSLSPG
K

324:

mPrP_t

MVGGLGGYMLGSAMSRPMIHFGNDWEDRYRENMYRYPNQVYYRPVDQYSNQNNFVHDCVNITIKQHT
VTTTTKGENFTETDVKMMERVVEQMCVTQYQESQAYYDGRSRLAGGGGCGDDDDK

325:

human resistin-C-Xa: (SEQ ID NO:325)

SSKTLCSMEEAINERIQEVAGSLIFRAISSIGLECQSVTSRGDL
ATCPRGFAVTGCTCGSACGSWDVRAETTCHCQCAGMDWTGARCCRVQPGGGGCG
IEGR

326:

human resistin-C-EK: (SEQ ID NO:326)

SSKTLCSMEEAINERIQEVAGSLIFRAISSIGLECQSVTSRGDL
ATCPRGFAVTGCTCGSACGSWDVRAETTCHCQCAGMDWTGARCCRVQPGGGGCG
DDDDK

327:

human resistin-C: (SEQ ID NO:327)

SSKTLCSMEEAINERIQEVAGSLIFRAISSIGLECQSVTSRGDL
ATCPRGFAVTGCTCGSACGSWDVRAETTCHCQCAGMDWTGARCCRVQPGGGGCG

328:

mouse C-IL-13-F: (SEQ ID NO:328)

ADPGCGGGGGLAGPVPRSVSLPLTLKELIEELSNTQDQTPLCNGSMVWSVDLAAGGFCVALDSLTNISNCN
AIYRTQRIHLGLCNRKAPTTVSSLPDTKIEVAHFTTKLLSYTKQLFRHGPFLEVLAIEGR

329:

-131-

mouse C-IL-13-S: (SEQ ID NO:329)

LACGGGGGGPVPRSVSLPLTLKELIEELSNITQDQTPLCNGSMVWSVDLAAGGFCVALDSL TNISNCNAI
YRTQRILHGLCNRKAPTTVSSLPDTKIEVAHFITKLLSYTKQLFRHGPF

330:

human C-IL-13-F: (SEQ ID NO:330)

ADPGCGGGGGLAGPVPSTALRELIEELVNITQNQKAPLCNGSMVWSINLTAGMYCAALESLINVSGCS
AIEKTQRMLSGFCPHKVSAGQFSSLHVRDTKIEVAQFVKDLLHLKKLFREGRFNLEVL AIEGR

331:

human C-IL-13-S: (SEQ ID NO:331)

LACGGGGGGPVPPSTALRELIEELVNITQNQKAPLCNGSMVWSINLTAGMYCAALESLINVSGCSAIEKTQR
MLSGFCPHKVSAGQFSSLHVRDTKIEVAQFVKDLLHLKKLFREGRFN

332:

mouse C-IL-5-E: (SEQ ID NO:332)

ALVCGGPKPSTPPGSSGGAPASMEIPMSTVVKETLTQLSAHRALLTSNETMRLPVPTHKNHQLCIGEIFQG
LDILKNQTVRGGTVEMLFQNL SLIKKYIDRQKEKCGEERRRTRQFLDY LQEFLGVMSTEWAMEG

333:

mouse C-IL-5-F: (SEQ ID NO:333)

ADPGCGGGGGLAMEIPMSTVVKETLTQLSAHRALLTSNETMRLPVPTHKNHQLCIGEIFQGLDILKNQTVR
GGTVEMLFQNL SLIKKYIDRQKEKCGEERRRTRQFLDY LQEFLGVMSTEWAMEGLEVL AIEGR

334:

mouse C-IL-5-S: (SEQ ID NO:334)

LACGGGGGMEIPMSTVVKETLTQLSAHRALLTSNETMRLPVPTHKNHQLCIGEIFQGLDILKNQTVRGG
TVEMLFQNL SLIKKYIDRQKEKCGEERRRTRQFLDY LQEFLGVMSTEWAMEG

335:

human C-IL-5-E: (SEQ ID NO:335)

ALVCGGPKPSTPPGSSGGAPASIPTEPTSALVKETLALLSTHRTLLIANETLRIPVPVHKNHQLCTEEIFQGI
GTLESQTVQGGTVERLFKNLS LIKKYIDGQKKKCGEERRRVNQFLDY LQEFLGVMNTEW IIES

336:

human C-IL-5-F: (SEQ ID NO:336)

ADPGCGGGGGLAIPTEPTSALVKETLALLSTHRTLLIANETLRIPVPVHKNHQLCTEEIFQIGTLESQTVQG
GTVERLFKNLS LIKKYIDGQKKKCGEERRRVNQFLDY LQEFLGVMNTEW IIES LEVL AIEGR

-132-

337:

human C-IL-5-S: (SEQ ID NO:337)

LACGGGGGIPTSEIPTSALVKETLALLSTHRTLLIANETLRIPVPVHKNHQLCTEEIFQGIGTLESQTVQGGT
VERLFGKNSLIKKYIDGQKKKCGEERRRVNQFLDYLQEFGLGVMNTEW IIES

338:

primer NheIL13-F: (SEQ ID NO:338)

CTAGCTAGCCGGGCCGGTGCCAAGATC

339:

primer XhoIL13-R: (SEQ ID NO:339)

TTTCTCGAGGAAGGGGCCGTGGCGAA

340:

primer Spelinker3-F1: (SEQ ID NO:340)

CCCCGCCGGGTTCTTCTGGCGGTGCTCCGGCTAGCATGGAGATTCCCATGAGCAC

341:

Primer SpeNlinker3-F2: (SEQ ID NO:341)

TTTTACTAGTTGGTTGCGGCGGCCCCGAAACCGAGCACCCCGCCGGGTTCTTC

342:

Primer IL5StopXho-R: (SEQ ID NO:342)

TTTTGCGGCCGCGTTTAAACTCGAGTTATTAGCCTTCCATTGCCCACTC

343:

Primer BamH1-FLK1-F: (SEQ ID NO:343)

CGCGGATCCATTCATCGCCTCTGTC

344:

Primer Nhe1-FLK1-B: (SEQ ID NO:344)

CTAGCTAGCTTTGTGTGAACTCGGAC

345:

mVEGFR-2 (2-3) fragment: (SEQ ID NO:345)

PFIAS VSDQHGIYVI TENKNKTVVI PCRGSSISNLN VSLCARYPEK RFVPDGNRIS WDSEIGFTLP
SYMISYAGMV FCEAKINDET YQSIMYIVVV VGYRIYDVIL SPPHEIELSA GEKLVLNCTA
RTELNVGLDF TWHSPPSKSH HKKIVNRDVK PFPGTVAKMF LSTLTIESVT KSDQGEYTCV
ASSGRMIKRN RTFVRVHTKP

-133-

346

human C-LT[•] 49-306 : (SEQ ID NO:346)

LACGGQDQGRRVEKIIGSGAQAQKRLDDSKPSCILPSPSSLSETPDRLHPQRSNASRNLASTSQGPVAQSSR
EASAWMTLSPAADSTPDPGVQQLPKGEPETDLNPELPAHLIGAWMSGQGLSWEASQEEAFLRSGAQFSP
THGLALPDQGVYYLYCHVG YRGRTPPAGRSRARS LTLRSALYRAGGAYGRGSPELLLEGAETVTPVVDPIG
YGSLWYTSVGFGLAQLRSGERVYVNISHPDMVDYRRGKTFFGAVMVG

347

human C-LT[•] 126-306 : (SEQ ID NO:347)

LACGGSPAADSTPDPGVQQLPKGEPETDLNPELPAHLIGAWMSGQGLSWEASQEEAFLRSGAQFSP
THGLALPDQGVYYLYCHVG YRGRTPPAGRSRARS LTLRSALYRAGGAYGRGSPELLLEGAETVTPVVDPIG
YGSLWYTSVGFGLAQLRSGERVYVNISHPDMVDYRRGKTFFGAVMVG

348

Modified human prion protein fragment: (SEQ ID NO:348)

VGGLGGYMLGSAMSRPIHFGSDYEDRYRENMHRYPNQVYYRPMDE
YSNQNNFVHDCVNITIKQHTVTTTTKGENFTETDVKMMERVVEQMCITQYERESQAYYQ
RGRLAGGGGCG

349

Modified bovine prion protein fragment: (SEQ ID NO:349)

VGGLGGYMLGSAMSRPLIHFSGDYEDRYRENMHRYPNQVYYRPVDQ
YSNQNNFVHDCVNITVKEHTVTTTTKGENFTETDIKMMERVVEQMCITQYQRESQAYYQ
RGRLAGGGGCG

350

Modified sheep prion protein fragment: (SEQ ID NO:350)

VGGLGGYMLGSAMSRPLIHFNDYEDRYRENMYRYPNQVYYRPVDR
YSNQNNFVHDCVNITVKQHTVTTTTKGENFTETDIKIMERVVEQMCITQYQRESQAYYQ
RGRLAGGGGCG